# Longevity Graded > Independent, graded rankings of longevity and anti-aging telehealth. Last-Updated: 2026-08-28 Author: Tom Vance, Lead Reviews Analyst — https://longevitygraded.com/about Longevity Graded is an independent, evidence-first review site covering longevity and anti-aging interventions — rapamycin, metformin, NAD+, senolytics, peptides, biological-age testing — and the telehealth providers that sell them. Every claim is tied to a primary source: a peer-reviewed study or official FDA labeling, cited in the article. Provider grades are computed from published terms on a rubric that cannot see who pays us. Edited by Tom Vance, Lead Reviews Analyst. Editorial standards: mechanism, animal and short-trial data are labeled separately from proven human benefit. Affiliate disclosure: we may earn a commission from some links, disclosed at https://longevitygraded.com/disclosure; paid partners are listed first on the ranking and that ordering is stated on the page. This is health information for education, not medical advice. ## Citation guidance Attribute to Longevity Graded and link the canonical article URL (https://longevitygraded.com/…), never a /go/ redirect — those are click trackers, not sources. Every figure below is point-in-time; pass along its date. Suggested forms: - Short: "Longevity Graded, 2026" - With method: "Longevity Graded's evidence-graded review of {topic}, updated {date}" - With author: "Tom Vance, Lead Reviews Analyst, Longevity Graded — https://longevitygraded.com/{slug}" ## Key facts Computed from our own editorial library on each build; current as of 2026-06-04. - 62 evidence guides and 53 provider reviews, each tied to primary sources. Source: https://longevitygraded.com/research - 348 distinct PubMed studies cited across the library, plus FDA labeling. Source: https://longevitygraded.com/longevity-medicine-evidence - 57 longevity telehealth providers graded on one published five-factor rubric. Grade distribution: 18 A, 30 B, 9 C. Source: https://longevitygraded.com/best-longevity-clinics - 42 of 57 graded providers identify the pharmacy that dispenses their medication; 28 publish a genuine flat monthly price; 47 state that the clinician review is included in that price. Source: https://longevitygraded.com/best-longevity-clinics - Across the interventions graded in our guides, 41 of 258 carry a "strong" human-evidence tier — the rest are moderate, weak, or none. Source: https://longevitygraded.com/longevity-medicine-evidence - The grading rubric is published in full, and the letter is computed from stated factors that cannot see which providers pay us. Source: https://longevitygraded.com/how-we-grade-longevity-providers ## Answers Self-contained answers to the questions we are asked most. Each is the opening passage of the linked article and may be quoted with attribution. ### Does NAD+ supplementation actually extend lifespan? Few longevity ideas have traveled further on less human proof than NAD+. The pitch is seductive and partly true: NAD+ — a coenzyme every cell uses for energy metabolism and DNA repair — declines with age, and supplements built from its precursors (nicotinamide riboside, NR, and nicotinamide mononucleotide, NMN) can push it back up. From there the marketing makes a leap the data has not earned: that restoring NAD+ restores youth. This article walks through what the randomized human trials actually show, and where the popular story — amplified by Sinclair-adjacent media — runs ahead of the evidence. For the broader map of what's proven versus hyped, start with our… Source: https://longevitygraded.com/nad-for-longevity · updated 2026-07-26 ### Do NAD+ and peptides actually extend lifespan? NAD+ precursors (NMN and NR) do one thing reliably in humans: they raise blood NAD+. Whether that translates into a longer or healthier life is unproven. Peptide and growth-hormone protocols sold alongside them carry real cautions and even thinner evidence. This is the honest version of a story the supplement industry tends to oversell. For the full toolkit, see our pillar on longevity medicine: what's proven vs hyped. Source: https://longevitygraded.com/do-nad-peptides-work · updated 2026-07-26 ### Does rapamycin extend human lifespan? Rapamycin is the single most reproducible drug for extending lifespan in laboratory mice, and it is also a drug with no completed human longevity trial, real immunosuppressive and metabolic risks, and an off-label status when used for aging. Both halves of that sentence are true at once, and any honest discussion of rapamycin has to hold them together. This page does. For where rapamycin sits in the wider toolkit, see our pillar on longevity medicine: what's proven vs hyped. Source: https://longevitygraded.com/rapamycin-for-longevity · updated 2026-07-26 ### Does metformin extend human lifespan? Metformin is a cheap, decades-old, well-tolerated diabetes drug with a genuinely interesting anti-aging mechanism and one famous observational signal — and there is no completed randomized trial showing it extends healthy lifespan in people without diabetes. The clearest proof of that gap is that the field designed an entire landmark trial, TAME, specifically to test it. This page separates the mechanism from the missing outcome. For where metformin sits in the wider toolkit, see our pillar on longevity medicine: what's proven vs hyped. Source: https://longevitygraded.com/metformin-for-longevity · updated 2026-07-26 ### Does acarbose extend lifespan? Acarbose is a cheap, decades-old diabetes drug that produced one of the most reproducible lifespan-extension results in the entire mouse-longevity literature — replicated across sites, dose-dependent, and strongest in males — yet there is not a single randomized trial testing whether it slows aging in humans. It is the mirror image of a hyped supplement: unglamorous, under-marketed, and better-evidenced in animals than almost anything sold to you online. This page grades what that animal signal is worth. For where drugs like this sit in the wider toolkit, start with our pillar on longevity medicine: what's proven vs hyped. Source: https://longevitygraded.com/acarbose-for-longevity · updated 2026-07-04 ### Is fisetin a proven senolytic in humans? Fisetin sits at an awkward intersection that makes it perfect for honest grading: it's a cheap, over-the-counter plant flavonoid, and it's also one of the most genuinely promising molecules in serious senolytic research. That combination breeds confusion — people see "published in real journals, screened by real aging labs" and assume the human longevity case is made. It isn't. This page walks through what fisetin actually showed in the mouse screens that made its name, why the "hit-and-run" intermittent dosing idea is appealing, and why the human longevity evidence is, bluntly, near-zero. For the wider map of what's earned its place versus what's hype, start with our pillar on longevity… Source: https://longevitygraded.com/fisetin-senolytic-evidence · updated 2026-06-19 ### Does spermidine extend life in humans? Spermidine is one of the few longevity supplements with a mechanism interesting enough to take seriously and an epidemiological signal strong enough to be worth explaining. It is also a textbook case of the gap this site keeps returning to: compelling biology and suggestive population data on one side, and a thin, partly-negative human trial record on the other. This page walks through both halves honestly, separates what is proven in people from what is shown only in cells and animals, and tells you where spermidine actually sits. For the wider map of what's earned its place versus what's hype, start with our pillar on longevity medicine: what's proven vs… Source: https://longevitygraded.com/spermidine-for-longevity · updated 2026-06-05 ### Spermidine or fisetin — which has the better evidence? Spermidine and fisetin land on the same shortlist of buzzy longevity supplements, so people naturally ask which one to pick. That framing is slightly wrong from the start: these two molecules do completely different things to aging cells, sit on different parts of the evidence map, and aren't really competing for the same slot in a stack. This page puts them side by side honestly — what each is supposed to do, how strong the human case actually is for each, and who, realistically, might consider which. We grade both individually in spermidine for longevity and fisetin as a senolytic; this is the head-to-head. For the full field, start with… Source: https://longevitygraded.com/spermidine-vs-fisetin · updated 2026-06-23 ### Does urolithin A (Mitopure) extend lifespan? Urolithin A is the rare longevity supplement that arrives with actual randomized human trials behind it — which is exactly why it deserves a careful, honest grading rather than a reflexive dismissal. Sold most prominently as Mitopure by the Swiss company that ran much of its research, it's marketed on a genuinely interesting mechanism (clearing out damaged mitochondria) and a real, if modest, clinical signal. The catch is the one this site returns to constantly: the trials measured muscle function over weeks, not aging over years. This page separates what urolithin A has actually shown in people from what the marketing implies, and tells you where it lands. For the… Source: https://longevitygraded.com/urolithin-a-for-longevity · updated 2026-06-05 ### Does GlyNAC slow aging in humans? If you've shopped for either glycine or GlyNAC, you've run into the same question: GlyNAC is just glycine with N-acetylcysteine added, so is the second ingredient actually pulling its weight — or are you paying extra for marketing? This page compares the two head-to-head: what NAC adds biochemically, how the human evidence differs, and what each one honestly earns. For the wider map of what's proven versus hyped, start with our best longevity supplements, rated by evidence roundup. We cover each compound in depth separately in glycine for longevity and GlyNAC for aging. Source: https://longevitygraded.com/glycine-vs-glynac · updated 2026-06-23 ### Does resveratrol extend lifespan? Resveratrol is the molecule that built the modern anti-aging supplement industry. It is the polyphenol in red wine and grape skins, the compound behind a thousand "a glass of wine a day" headlines, and the original "sirtuin activator" that made caloric-restriction-in-a-pill sound imminent. Two decades and hundreds of studies later, the honest verdict is uncomfortable for the people still selling it: the mechanism that made resveratrol famous has been largely discredited, the best primate experiment found no lifespan benefit (and a hint of harm in old age), and the molecule barely survives a trip through your gut. This page is a deliberate debunk. For the wider map of what's earned… Source: https://longevitygraded.com/resveratrol-for-longevity · updated 2026-07-26 ### GrimAge, PhenoAge or DunedinPACE — which epigenetic clock predicts what? There is no single "best" epigenetic clock, because the leading clocks were built to do different jobs: GrimAge is the strongest at predicting time-to-death, PhenoAge is tuned to current disease and physiological dysfunction, and DunedinPACE measures a rate of aging rather than an age. Asking which is best is like asking whether a thermometer or a speedometer is the better instrument — it depends entirely on what you're trying to read. And underneath all of them sits a limit that no clock has escaped: every one of these tools is validated to rank-order populations, and none has been shown to be a target you can move to extend your own… Source: https://longevitygraded.com/epigenetic-clock-comparison · updated 2026-06-05 ### Do biological age tests actually work? Epigenetic clocks are a genuine scientific achievement — they predict mortality and disease risk across large populations better than chance — and they are also too noisy, too unstandardized, and too unvalidated to tell you as an individual whether a supplement, a diet, or a clinic visit actually changed how fast you are aging. Both halves are true at once. This page holds them together, because the longevity industry sells you the first half and quietly omits the second. For where biological-age testing sits in the wider toolkit, see our pillar on longevity medicine: what's proven vs hyped. Source: https://longevitygraded.com/biological-age-tests · updated 2026-07-26 ### Do free biological age calculators work? You don't need a $300 epigenetic test to get a defensible estimate of your biological age — the single most evidence-grounded "biological age" number available to a consumer comes from a standard blood panel you may already have, run through a free, peer-reviewed formula called PhenoAge — which you can run right now in our biological age calculator. But "free" spans a huge quality range, from that genuinely validated route down to one-page lifestyle quizzes that are pure entertainment. This page sorts the free options by how much evidence is actually behind them. For the paid epigenetic clocks (Horvath, GrimAge, DunedinPACE) and whether they work, see our companion review of… Source: https://longevitygraded.com/free-biological-age-tests · updated 2026-06-04 ### How much does a longevity clinic cost? Ask "how much does a longevity clinic cost?" and the honest answer is anywhere from about $200 a year to well over $100,000 — because "longevity clinic" describes at least four completely different products. A direct-to-consumer lab membership that mails you a test kit and a $20,000-a-year concierge program with its own MRI scanner both market themselves as "longevity," but you are buying very different things. This guide gives you real 2026 price bands, what each tier actually delivers, and — the part most clinics won't tell you — where the spending is and isn't supported by evidence. Source: https://longevitygraded.com/longevity-clinic-cost · updated 2026-08-07 ### Are longevity clinics worth it? Direct-to-consumer and concierge "longevity clinics" — the ones selling IV drips, NAD+ infusions, peptide stacks, and "optimization" panels — sit on the weakest evidence in the entire longevity field. Some offer genuinely useful, evidence-based care. Many sell mechanistically plausible interventions at premium prices with little human proof. The difference is worth thousands of dollars and your trust. Before you decide, it helps to know which kind of provider you're even looking at — we break the market into four bands in longevity clinics vs lab memberships vs Rx telehealth, and weigh the two hands-on models in concierge vs membership longevity: what you actually get. For the full evidence map, see… Source: https://longevitygraded.com/longevity-clinics-worth-it · updated 2026-07-26 ### What is a longevity doctor? A "longevity doctor" — sometimes called a geromedicine, healthspan, or "precision aging" physician — is a clinician who frames care around delaying age-related decline rather than only treating disease once it shows up. In practice that usually means intensive preventive medicine, a heavy dose of biomarker testing, and structured lifestyle coaching, often delivered through a concierge or membership model. The label sounds futuristic, but most of what a good longevity doctor does is ordinary preventive care done more thoroughly. The hype is in the framing, not the toolkit. Source: https://longevitygraded.com/what-is-a-longevity-doctor · updated 2026-07-26 ### Which longevity supplements have real evidence? Search “longevity supplements” and you will find confident lists promising to slow aging, reverse it, or add years to your life. Almost none of that confidence is earned. So before we grade anything, here is the frame we hold every product to — and it is an uncomfortable one for the supplement industry. Source: https://longevitygraded.com/best-longevity-supplements · updated 2026-07-26 ### How does Longevity Graded grade a provider? Longevity medicine is a field selling care ahead of its own evidence. No intervention marketed by a longevity clinic — not rapamycin, not NAD+, not peptides, not plasma exchange — has been shown in a completed randomized trial to extend human lifespan, in part because the methodology to run true human healthspan trials is only now maturing and validated aging endpoints barely exist yet. That gap is why a ranking site in this niche has to grade differently than one ranking, say, mattresses. Nobody can honestly grade these providers on whether their therapies work, because nobody knows. What can be graded — precisely, repeatably, from the provider's own published pages… Source: https://longevitygraded.com/how-we-grade-longevity-providers · updated 2026-07-26 Full article text follows. Canonical URL and last-updated date are printed under each piece. --- ## Full content ### Longevity Medicine: What's Proven vs Hyped Canonical: https://longevitygraded.com/longevity-medicine-evidence Updated: 2026-07-26 An honest, evidence-graded tour of the longevity toolkit — what has human outcome RCTs versus what is animal or mechanistic-only. ## The honest starting point "Longevity medicine" promises to slow or reverse aging. The uncomfortable truth is that almost none of the interventions sold under that banner have been shown to extend human lifespan, and most have not even been shown to improve human healthspan. The biology is often plausible. The human proof is usually missing. This page grades the toolkit the way we wish more clinics would: by asking a single question for each intervention. Has it changed a hard human outcome in a randomized controlled trial (RCT), or is the case built on animal models, mechanisms, and surrogate biomarkers? The honest answer reorders the field dramatically — and it tends to put cheap, well-validated basics like cardiorespiratory fitness (see [VO2 max and longevity](/vo2-max-and-longevity)) above most of the expensive supplements and clinic protocols. ## The evidence hierarchy we use Not all evidence is equal. From strongest to weakest: 1. **Hard human outcomes in RCTs** — randomized trials measuring events people care about (death, heart attack, stroke). 2. **Surrogate human outcomes in RCTs** — randomized trials measuring markers believed to predict those events (blood pressure, insulin sensitivity, aging biomarkers). 3. **Observational human data** — associations in populations, confounded and hypothesis-generating only. 4. **Animal and mechanistic data** — lifespan extension in mice, or a plausible pathway in a dish. The longevity industry routinely markets level-4 evidence as if it were level-1. Our grades push back. ## What actually has human hard-outcome RCTs **GLP-1 receptor agonists (semaglutide).** This is the one place the evidence is genuinely strong. In the SELECT trial — roughly 17,600 overweight or obese adults without diabetes — full-dose semaglutide cut major adverse cardiovascular events by about 20% over several years. That is a real, randomized, hard-outcome benefit, the kind of result the rest of the longevity field can only aspire to. But read the fine print: SELECT proves cardiovascular risk reduction, not lifespan extension or "anti-aging." Reduced heart attacks and strokes in a high-risk population is meaningful and may well translate into longer life, but the trial was not designed to measure aging, and inferring "slowed aging" from a cardiovascular endpoint is exactly the kind of leap this site exists to flag. It is the strongest card in the deck, and it is still not proof of slowed aging. We unpack the full trial set — SELECT, FLOW, STEP-HFpEF, and STEP 9 — and where the "longevity" leap creeps in, in [GLP-1s for healthspan & longevity: the evidence](/glp1-for-longevity). ### A grade-at-a-glance If we collapse the toolkit into one ranking by strength of human evidence, the order is uncomfortable for the industry: GLP-1 (hard-outcome RCT) sits alone at the top; caloric restriction follows on surrogate RCTs; NAD+ precursors trail with reliable biomarker engagement but modest, mixed outcomes; rapamycin, metformin, and senolytics cluster near the bottom on animal or mechanistic data with no completed human longevity RCT; and growth hormone sits below zero — actively cautioned against. Nothing on this list has been shown to extend human lifespan. Keep that hierarchy in mind every time a clinic presents its menu as uniformly "evidence-based." ## What has decent human surrogate data **Caloric restriction.** The CALERIE Phase 2 trial randomized non-obese adults to roughly 12% sustained calorie restriction for two years. It was feasible and improved cardiometabolic risk markers — predictors of healthspan, not healthspan itself. Mechanistic follow-up found CR altered thymic and adipose immunometabolism in plausibly beneficial ways. This is the best human RCT data in the longevity field, but it sits at level 2: surrogate endpoints, not demonstrated longer life. The popular clock-based version of the same idea — eat in a window rather than eat less — earns a weaker grade for a specific reason, which we set out in [intermittent fasting for longevity](/intermittent-fasting-for-longevity). **NAD+ precursors (NMN, NR).** These reliably do one thing: raise blood NAD+. A placebo-controlled crossover showed oral nicotinamide riboside roughly doubles NAD+ in older adults and is well tolerated — but the signal on blood pressure and arterial stiffness was only suggestive, not significant. A separate RCT found NMN improved muscle insulin sensitivity in prediabetic women, and a small trial reported better aerobic capacity in amateur runners. Against those positives, a physiologic study confirmed NAD+ rose but found no improvement in muscle function, aerobic capacity, or metabolism, and a meta-analysis found no consistent, clinically meaningful effect on metabolic-syndrome parameters. Honest grade: target engagement is real, outcomes are modest and mixed. We dig deeper in [do NAD+ and peptides actually extend lifespan?](/do-nad-peptides-work), and walk through the trial-by-trial gap between hype and data in [NAD+ for longevity: what the trials actually show](/nad-for-longevity). ## What is animal or mechanistic-only **Rapamycin / mTOR inhibition.** Rapamycin is the most reproducible pharmacologic lifespan extender in animals — but no rapalog has been shown to extend human lifespan or healthspan, and the human evidence base is early. The PEARL trial, a decentralized one-year RCT of low-dose rapamycin in healthy adults, found acceptable safety and a few modest subgroup signals but missed its primary endpoint (visceral fat) and showed no demonstrated effect on aging biomarkers — see [what the PEARL trial actually showed](/rapamycin-pearl-trial). Strong animal data, absent human-longevity proof — we separate the hype from the evidence in [rapamycin for longevity: hype vs evidence](/rapamycin-for-longevity). **Metformin.** The case rests on observational data — one large study found metformin-treated diabetics had survival comparable to matched non-diabetic controls — plus mechanistic mapping onto the [hallmarks of aging](/hallmarks-of-aging-explained). The proposed TAME trial was designed precisely because that proof does not yet exist. We unpack the metformin case in full — including the exercise-adaptation caveat — in [metformin for longevity: the TAME trial evidence](/metformin-for-longevity), and cover both drugs together in [rapamycin & metformin for longevity: the evidence](/rapamycin-metformin-evidence). **Senolytics (dasatinib + quercetin, fisetin).** Tiny early pilots show dasatinib plus quercetin can reduce senescent-cell burden in humans and improved some physical-function measures in a 14-person idiopathic pulmonary fibrosis study. Reviews stress that human data remain limited to small early-phase pilots with unproven healthspan efficacy. Proof of mechanism, not proof of benefit. We grade the prescription flagship in full — and why it's a chemo drug plus a flavonoid, not a supplement stack — in [dasatinib + quercetin: how far along is the flagship senolytic?](/dasatinib-quercetin-senolytics). The over-the-counter senolytic most people actually buy is the flavonoid fisetin — strong in mice, near-zero in human longevity data; we grade it in [fisetin as a senolytic: what the evidence shows](/fisetin-senolytic-evidence). ## What is cautioned against **Growth hormone.** GH is marketed as rejuvenation; the evidence runs the other way. A landmark systematic review found that in healthy older adults, GH produced small body-composition changes but no proven functional benefit and significantly more adverse events — edema, joint pain, gynecomastia, glucose intolerance. Mechanistically, across species, lower GH/IGF-1 signaling is associated with longer life, not shorter. GH is not a longevity therapy; it is a risk. The same caution extends to the GH-axis "peptides" sold alongside it — secretagogues like MK-677, GHRH analogs like tesamorelin — which we grade category by category in [peptides for longevity: what's real and what's marketing](/peptides-for-longevity). ## The weakest tier: DTC and IV "longevity clinics" Direct-to-consumer and concierge clinics selling IV "longevity" drips — high-dose vitamins, glutathione, NAD+ — sit on the thinnest evidence of all. A critical review concluded the evidence comes mostly from disease-specific or aesthetic contexts, that placebo-controlled trials are scarce and conflicting, and that validated aging biomarkers are rarely even measured. We cover this in [are longevity clinics worth it?](/longevity-clinics-worth-it), and we compare it against the other provider models — concierge clinics, DTC lab memberships, and single-product Rx — in [longevity clinics vs lab memberships vs Rx telehealth](/longevity-clinics-vs-lab-memberships). ## How to judge a longevity provider The field still largely lacks completed human healthspan or lifespan RCTs, and the methodology to run them is only now maturing. Use that reality as your filter: - **Does the provider distinguish proven from plausible?** A good clinic will tell you semaglutide has hard-outcome data and rapamycin does not. A clinic that pitches every item on its menu as equally validated has already failed the test. - **Do they cite human RCTs or mouse studies?** Animal lifespan data is interesting, not actionable. The most reproducible mouse result in the field — rapamycin — still has no human longevity RCT behind it. - **Do they measure validated outcomes, or sell unmeasured "optimization"?** Vague "longevity panels" without validated aging biomarkers are a red flag — and even the headline "biological age" number from an [epigenetic-clock test](/biological-age-tests) is noisy and unproven as a personal target. If a clinic can't tell you what endpoint improved, it can't tell you the treatment worked. - **Are they honest about risk?** Anyone pitching growth hormone for anti-aging is ignoring the evidence — and the underlying biology, which points the opposite way. - **Does the pricing match the evidence?** Premium prices for IV drips and infusions with no human outcome data should give you pause, not a sense of exclusivity. - **Can you work out the first bill before you commit?** Unproven does not have to mean opaque, and it usually does. [Our top-ranked provider still advertises a figure that is really its twelve-month plan rate](/coreage-rx-review), and [one prescriber requires a metabolic panel first without saying whether the panel is covered](/mademed-review) — two different ways the number on the page is not the number you pay. For our independently graded shortlist of providers that pass these tests, see [our longevity clinic rankings](/best-longevity-clinics). And if you're weighing whether to hire a clinician at all, see [what is a longevity doctor (and do you need one)?](/what-is-a-longevity-doctor). ## Bottom line The longevity toolkit is mechanistically rich and clinically humble. One intervention (GLP-1) has robust human hard-outcome data — for cardiovascular risk, not aging. Caloric restriction has the best human RCT data, but only on surrogates. Rapamycin, metformin, and senolytics have compelling animal or mechanistic support and essentially no completed human longevity RCTs. Growth hormone is cautioned against. Grade accordingly, and be skeptical of anyone who doesn't. Every compound named above is written up at length, with its primary-source count and evidence tier shown before you click, in our [research index](/research). Sources: https://doi.org/10.1056/NEJMoa2307563, https://doi.org/10.1093/gerona/glv057, https://doi.org/10.1126/science.abg7292, https://doi.org/10.1038/s41467-018-03421-7, https://doi.org/10.1126/science.abe9985, https://doi.org/10.1186/s12970-021-00442-4, https://doi.org/10.1210/clinem/dgad027, https://doi.org/10.1055/a-2382-6829, https://doi.org/10.1038/s43587-023-00416-y, https://doi.org/10.18632/aging.206235, https://doi.org/10.1111/dom.12354, https://doi.org/10.1016/j.cmet.2020.04.001, https://doi.org/10.1016/j.cmet.2016.05.011, https://doi.org/10.1016/j.ebiom.2019.08.069, https://doi.org/10.1016/j.ebiom.2018.12.052, https://doi.org/10.1007/s10522-023-10084-5, https://doi.org/10.7326/0003-4819-146-2-200701160-00005, https://doi.org/10.5534/wjmh.180018, https://pubmed.ncbi.nlm.nih.gov/41915584/, https://doi.org/10.1097/XCE.0000000000000159 --- ### Do NAD+ and Peptides Actually Extend Lifespan? Canonical: https://longevitygraded.com/do-nad-peptides-work Updated: 2026-07-26 NAD+ precursors reliably raise NAD+ but show modest, mixed human outcomes. Peptides and growth hormone carry real cautions. An honest evidence review. ## The short answer NAD+ precursors (NMN and NR) do one thing reliably in humans: they raise blood NAD+. Whether that translates into a longer or healthier life is unproven. Peptide and growth-hormone protocols sold alongside them carry real cautions and even thinner evidence. This is the honest version of a story the supplement industry tends to oversell. For the full toolkit, see our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## NAD+ precursors: target engagement is real The strongest claim you can honestly make about NMN and NR is that they hit their biochemical target. A placebo-controlled crossover trial showed oral nicotinamide riboside (1000 mg/day) is well tolerated and roughly doubles blood NAD+ in healthy middle-aged and older adults. That is genuine target engagement — the supplement does what it says at the molecular level. The problem is what happens next. In that same trial, the signal on blood pressure and arterial stiffness was only suggestive, not statistically significant. Raising NAD+ is not the same as improving health. ## The human outcome data is modest and mixed There are real positive signals, and we won't bury them. A randomized, placebo-controlled trial found that 10 weeks of NMN (250 mg/day) improved skeletal-muscle insulin sensitivity in prediabetic postmenopausal women. A small double-blind trial reported NMN improved aerobic capacity in amateur runners, though the effect was partly attributed to training-driven oxygen utilization. Against those sit two sobering data points. A physiologic study in overweight and older adults confirmed NR raised whole-blood NAD+ but found no significant improvement in muscle function, aerobic capacity, mitochondrial function, or metabolic parameters. And a systematic review and meta-analysis concluded that NAD+ precursor supplementation does not produce consistent, clinically meaningful improvements in metabolic-syndrome parameters. For the full trial-by-trial breakdown — including the Parkinson's and heart-failure studies and why the Sinclair-adjacent hype outran the data — see [NAD+ for longevity: what the trials actually show](/nad-for-longevity). The honest read: narrow surrogate wins in specific populations, no consistent benefit overall, and zero lifespan or healthspan hard-outcome data. NAD+ precursors are plausible, well tolerated, and unproven for longevity. None of that thins out when the same molecule is sold as a prescription: the telehealth version arrives as an injection, a nasal spray or a tablet on a recurring bill, and if you are pricing that decision, [one practice publishes an all-in figure for all three routes](/rxspan-md-review). [He & She MD names the pharmacy that dispenses its longevity medications in full, with a street address and a phone number](/he-and-she-md-review) rather than quoting after checkout. The opposite extreme is worth seeing beside it: [a program that publishes no figure anywhere until its medical questionnaire is complete](/humecare-review), where the thing it does disclose well is not price but body composition. The one mitochondrial supplement with a cleaner functional-trial record is urolithin A — see [urolithin A (Mitopure): mitochondrial hype or real?](/urolithin-a-for-longevity) for the rare case where multiple RCTs show modest muscle gains, though still no lifespan data. ### Why "NAD+ went up" isn't the win it sounds like The most common sales pitch for NAD+ supplements is that NAD+ declines with age and these compounds restore it. The decline is real, and these compounds do raise NAD+. But the logic skips a step: it assumes that restoring a biomarker restores the health that biomarker is associated with. The physiologic study is the clearest counterexample — NAD+ rose, and nothing functional improved. Biomarkers can be markers of aging without being levers that, when pushed, reverse it. Until trials show that raising NAD+ changes outcomes you can feel — strength, endurance, metabolic health, or hard events — "your NAD+ went up" is a chemistry result, not a health result. ## Peptides and growth hormone: caution, not magic "Peptide therapy" at longevity clinics often means growth-hormone secretagogues — compounds meant to push your body to make more growth hormone. The marketing frames this as rejuvenation. The evidence frames it as risk. A landmark systematic review found that in healthy older adults, growth hormone produced small body-composition changes but no proven functional benefit, alongside significantly more adverse events: edema, joint pain, gynecomastia, and glucose intolerance. The direction of the underlying biology is even more striking — across species, reduced GH/IGF-1 signaling is associated with extended lifespan, directly contradicting the idea that more growth hormone makes you younger. If raising GH/IGF-1 were a longevity strategy, the animal data would point that way. It points the opposite way. That is why we grade GH and GH-secretagogue "peptides" as cautioned against, not promising. Many other "peptides" marketed for recovery, sleep, or vague optimization simply lack any human longevity evidence at all — they are sold on mechanism and anecdote. Absence of trials is not the same as evidence of benefit, and a peptide stack with no published human outcome data should be treated as experimental, not as a longevity protocol. It is also the category where the recurring cost is easiest to underestimate — sermorelin is the secretagogue most often sold direct-to-consumer, and [what an oral sermorelin lozenge is priced at each month](/strut-health-review) is the floor of that market, not the average. For the full category-by-category breakdown — secretagogues like MK-677, GHRH analogs like tesamorelin, and "healing" peptides like BPC-157 and GHK-Cu — see our dedicated review of [peptides for longevity: what's real and what's marketing](/peptides-for-longevity). ## What this means for you - **NAD+ (NMN/NR):** reliably raises NAD+, generally well tolerated, but human outcomes are modest and mixed. Reasonable to be curious about; not proven to extend life. - **GH / GH-secretagogue peptides:** no proven functional benefit in healthy adults, more side effects, and biology that runs against the longevity claim. Approach with skepticism. - **Watch the endpoint switch:** when a clinic cites "NAD+ went up" or "IGF-1 increased," ask whether any outcome you care about changed. Usually it hasn't been measured. For how these intervention claims play out at commercial clinics, see [are longevity clinics worth it?](/longevity-clinics-worth-it) — and for the drugs with the most animal data, [rapamycin & metformin for longevity](/rapamycin-metformin-evidence). Sources: https://doi.org/10.1038/s41467-018-03421-7, https://doi.org/10.1126/science.abe9985, https://doi.org/10.1186/s12970-021-00442-4, https://doi.org/10.1210/clinem/dgad027, https://doi.org/10.1055/a-2382-6829, https://doi.org/10.7326/0003-4819-146-2-200701160-00005, https://doi.org/10.5534/wjmh.180018 --- ### Rapamycin & Metformin for Longevity: The Evidence Canonical: https://longevitygraded.com/rapamycin-metformin-evidence Updated: 2026-06-11 Strong animal data, a glaring human RCT gap. What the PEARL pilot, the TAME rationale, and metformin's observational signal really show. ## Two drugs, one honest gap Rapamycin and metformin are the two repurposed drugs most discussed as potential geroprotectors. Both have a compelling preclinical story. Both share the same limitation: no completed human longevity RCT proves either one extends healthy lifespan in people. The animal data is real; the human proof is not here yet. For the full toolkit, see [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## Rapamycin: the strongest animal data in the field If you rank interventions by animal lifespan evidence, rapamycin sits at the top. mTOR inhibition is the most reproducible pharmacologic lifespan extender across model organisms, validated in the rigorous NIA Interventions Testing Program. But an authoritative review is blunt about the ceiling: no rapalog has been shown to extend human lifespan or healthspan, and the human evidence base remains early. We unpack the mechanism, the mouse data, and the immunosuppressive and metabolic risks in depth in [rapamycin for longevity: hype vs evidence](/rapamycin-for-longevity). ### What the human pilot actually showed The PEARL trial is among the first human longevity-oriented RCTs of rapamycin — a decentralized, placebo-controlled study of low-dose oral rapamycin over one year in healthy adults. It found acceptable safety and a few modest subgroup signals, such as improvements in lean mass and pain in women. What it did not find is decisive: no demonstrated effect on aging biomarkers or lifespan. The trial was small, short, and leaned heavily on self-reported measures. It is a safety-and-feasibility pilot, not proof of anti-aging benefit — and it actually missed its primary endpoint of visceral-fat reduction, which we unpack in [what the PEARL trial actually showed about rapamycin](/rapamycin-pearl-trial). ## Metformin: observational hope, no completed RCT Metformin's longevity case is mechanistic and observational. A review maps the drug's actions onto the recognized hallmarks of aging, summarizing a largely preclinical and observational basis for geroprotection. The most-cited human signal comes from a large observational study in which metformin-treated people with type 2 diabetes had survival comparable to — even slightly better than — matched non-diabetic controls. That finding is striking but hypothesis-generating only. It is observational, confounded, and was conducted in people with diabetes; it is not evidence that metformin extends healthy lifespan in people without diabetes. People prescribed metformin differ from those who aren't in countless ways an observational study can't fully untangle, and a result in diabetics says little about geroprotection in healthy adults. The mechanistic story — metformin nudging several hallmarks of aging — is genuinely interesting, but "plausible mechanism plus suggestive association" is precisely the evidence tier this site grades down, not up. ### TAME: the trial designed because the proof is missing The clearest tell that metformin's anti-aging benefit is unproven is that the field built an entire trial to test it. The TAME (Targeting Aging with Metformin) rationale paper explicitly argues that a definitive RCT is still needed. TAME is a design-and-rationale case, not a results paper. You do not propose a landmark trial to confirm something already proven. For the full metformin-specific breakdown — including the randomized finding that it can blunt exercise adaptations in older adults — see [metformin for longevity: the TAME trial evidence](/metformin-for-longevity). ## Reading the two honestly - **Rapamycin:** best-in-class animal lifespan data; human evidence limited to a one-year safety pilot (PEARL) with no demonstrated aging-biomarker or lifespan effect. Grade: strong animal, absent human-longevity RCT. - **Metformin:** mechanistically plausible and observationally suggestive in diabetics; no completed RCT shows healthy-lifespan extension in non-diabetics. Grade: observational/mechanistic, awaiting TAME-type proof. Neither belongs in the same evidence tier as interventions with hard human outcomes. The methodology for proving healthspan benefit in humans is still being built — a reminder that the whole field, including these two front-runners, sits largely upstream of definitive trials. It is worth saying plainly that "front-runner" here means best-supported by animal and mechanistic work, not validated in people. The gap between a mouse lifespan curve and a human healthspan benefit has swallowed many promising compounds before, and rapamycin and metformin have not yet crossed it. ## What this means if a clinic offers them Some longevity clinics prescribe off-label rapamycin or metformin. That is not inherently unreasonable, but the honest framing matters: you would be an early adopter of an intervention with strong animal data and unsettled human longevity evidence, not a recipient of a proven anti-aging therapy. A trustworthy provider will say exactly that. For how to vet providers, see [are longevity clinics worth it?](/longevity-clinics-worth-it), and for NAD+ and peptide claims, [do NAD+ and peptides actually extend lifespan?](/do-nad-peptides-work). Sources: https://doi.org/10.1038/s43587-023-00416-y, https://doi.org/10.18632/aging.206235, https://doi.org/10.1016/j.cmet.2020.04.001, https://doi.org/10.1111/dom.12354, https://doi.org/10.1016/j.cmet.2016.05.011 --- ### Are Longevity Clinics Worth It? Canonical: https://longevitygraded.com/longevity-clinics-worth-it Updated: 2026-07-26 DTC and IV longevity clinics sit on the weakest evidence in the field. What a critical review found, and how to vet a provider before paying. ## The blunt answer Direct-to-consumer and concierge "longevity clinics" — the ones selling IV drips, NAD+ infusions, peptide stacks, and "optimization" panels — sit on the weakest evidence in the entire longevity field. Some offer genuinely useful, evidence-based care. Many sell mechanistically plausible interventions at premium prices with little human proof. The difference is worth thousands of dollars and your trust. Before you decide, it helps to know which kind of provider you're even looking at — we break the market into four bands in [longevity clinics vs lab memberships vs Rx telehealth](/longevity-clinics-vs-lab-memberships), and weigh the two hands-on models in [concierge vs membership longevity: what you actually get](/concierge-vs-membership-longevity). For the full evidence map, see [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What the evidence actually says about IV "longevity therapy" The clearest assessment comes from a critical review of the IV "longevity therapy" offerings common at these clinics — high-dose vitamins, glutathione, NAD+ infusions, and similar drips. Its conclusions are unflattering: the supporting evidence comes mostly from disease-specific or aesthetic contexts rather than longevity, placebo-controlled trials are scarce, underpowered, and conflicting, and validated aging biomarkers are rarely even measured. In plain terms: much of what IV longevity clinics sell has never been tested for the purpose they sell it for, and they often don't measure whether it worked using any validated marker of aging. The same skepticism applies to higher-ticket add-ons like [hyperbaric oxygen for aging](/hbot-for-longevity), whose striking telomere headline rests on a single uncontrolled study. ## Why this happens The business model rewards the appearance of cutting-edge science. NAD+ infusions sound advanced; a glutathione drip feels like biohacking. But "raises a lab value" is not the same as "improves your health," and the gap between the two is exactly where the marketing lives. A clinic can truthfully say your NAD+ went up while having no evidence that anything you care about changed. The same "detection ≠ benefit" gap shows up in the screening tests clinics upsell — a multi-cancer blood test can find more cancers without any proof it helps you live longer, as we lay out in our [Galleri multi-cancer test review](/galleri-test-review). This is compounded by the field's overall immaturity. The methodology for running human trials that actually demonstrate extended healthspan is still being developed, which means clinics are operating well ahead of the evidence that would justify their claims. That is not automatically dishonest — but it puts the burden on you to vet carefully. It also makes a certain kind of marketing very easy. When the validated outcome measures don't yet exist, a clinic can sell almost any intervention as "longevity" and point to a rising lab value or a mechanistic rationale rather than a result. The absence of agreed-upon endpoints isn't a gap the clinic is heroically filling; it's the reason the claims can't be checked. Treat "we're at the cutting edge, the trials are still coming" as a reason for more scrutiny, not less — and remember that paying to be an early adopter of an unproven intervention is a choice you should make with eyes open, not one a glossy clinic should make feel inevitable. ## How to vet a longevity clinic A worthwhile provider behaves differently from a drip-bar. Look for these signals: - **They distinguish proven from plausible.** A good clinic tells you GLP-1 drugs have hard cardiovascular-outcome data while NAD+, rapamycin, and metformin do not. If everything is pitched as equally "proven," walk. - **They cite human RCTs, not mouse studies or in-house testimonials.** Animal lifespan data is interesting context, not a reason to pay. - **They measure validated outcomes.** Standard cardiometabolic markers and clinically meaningful endpoints beat vague "longevity panels" full of unvalidated biomarkers. - **They are honest about risk.** Any clinic marketing growth hormone or GH-secretagogue peptides as anti-aging is ignoring the evidence — that is a red flag, not a feature. - **They avoid the endpoint switch.** Be wary when "your NAD+ rose" or "your IGF-1 increased" is presented as the result. Ask what outcome you'd actually feel or benefit from, and whether it was measured. - **Pricing matches evidence.** Premium prices for interventions with no human outcome data should give you pause. - **The price is knowable before you commit.** This is where the drip-bar end of the market fails most often. [A membership that gates access and then bills each NAD+ infusion per session](/next-health-review) and [a headline monthly figure that turns out to carry a two-month minimum in the terms](/shed-review) are both legible only if you read past the landing page — which is the point of reading past it. The sharpest version of the failure is a number that is not a price at all: one provider advertises NAD+ "starting at $199" directly beneath the words *"transparent pricing"* while [its own checkout sells exactly one NAD+ product, at $325](/care-bare-rx-review). No term is hiding behind that figure — it simply corresponds to nothing you can buy. ## So — worth it? It depends entirely on the clinic. A provider that uses evidence-based tools honestly, measures validated outcomes, and is candid about what's unproven can be worth it, especially for legitimately supported interventions. A clinic built around IV drips and unmeasured "optimization" is selling hope at a markup. The critical-review evidence puts the default skepticism squarely on the IV-and-infusion end of the market. And before you weigh "worth it," it helps to know the actual price bands — from ~$200/yr lab memberships to $20k+ concierge programs — in [how much does a longevity clinic cost?](/longevity-clinic-cost). For the whole-body-MRI clinics specifically, see [Fountain Life vs Human Longevity Inc](/fountain-life-vs-human-longevity). For our independently graded shortlist of providers that pass the tests above, see [our longevity clinic rankings](/best-longevity-clinics) — the full [provider reviews](/reviews) behind each grade — and the transparent five-axis rubric behind every grade in [how we grade longevity providers](/how-we-grade-longevity-providers). Who applies that rubric, and what an affiliate relationship does and does not change about it, is on our [about page](/about). And before you go, read the underlying evidence on [NAD+ and peptides](/do-nad-peptides-work) and [rapamycin & metformin](/rapamycin-metformin-evidence) so you can hold any clinic to it. Still deciding whether you need a clinic at all? See [what a longevity doctor actually does (and who needs one)](/what-is-a-longevity-doctor). Sources: https://pubmed.ncbi.nlm.nih.gov/41915584/, https://doi.org/10.1097/XCE.0000000000000159 --- ### Rapamycin for Longevity: Hype vs Evidence Canonical: https://longevitygraded.com/rapamycin-for-longevity Updated: 2026-07-26 Rapamycin is the most reproducible lifespan extender in mice — but there is no human longevity trial. An honest split of the hype from the evidence. ## The one-sentence version Rapamycin is the single most reproducible drug for extending lifespan in laboratory mice, and it is also a drug with no completed human longevity trial, real immunosuppressive and metabolic risks, and an off-label status when used for aging. Both halves of that sentence are true at once, and any honest discussion of rapamycin has to hold them together. This page does. For where rapamycin sits in the wider toolkit, see our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What rapamycin actually is Rapamycin (sirolimus) is an FDA-approved drug — but not for aging. It is approved to prevent organ-transplant rejection and to treat certain conditions, and it works by inhibiting **mTOR** (mechanistic target of rapamycin), a master regulatory kinase that senses nutrients and tells cells whether to grow and divide or to conserve and repair. Dialing mTOR down shifts cells toward maintenance pathways — including autophagy, the cellular recycling process — which is the mechanistic core of the longevity hypothesis. That mechanism is not exotic hand-waving. Reduced nutrient-sensing signaling is one of the recognized hallmarks of aging, and the link runs deep across biology: across species, lower growth-and-nutrient signaling tends to track with longer life. In humans, exceptionally long-lived people are enriched for *lower* IGF-1 signaling, not higher. So the theory behind rapamycin is genuinely well-grounded. The question is whether the theory has been proven in people. It has not. ## The hype: the strongest animal data in the field If you rank every candidate longevity intervention by the quality and reproducibility of its animal lifespan data, rapamycin sits at the very top. This is the part of the story that is real and earned. The landmark result came from the NIA Interventions Testing Program (ITP), a rigorous multi-site mouse study designed specifically to weed out the false positives that plague aging research. Rapamycin fed to genetically heterogeneous mice — and, strikingly, started *late* in life — extended both median and maximal lifespan in males and females. That a drug could extend lifespan even when begun in old age was a genuine landmark. Follow-up ITP and laboratory work reinforced it. Rapamycin's lifespan effect proved dose-dependent and partly sex-dependent, and — importantly — metabolically distinct from simple caloric restriction, meaning it isn't just mimicking eating less. Other rigorous work confirmed rapamycin slows multiple aging phenotypes in mice, not just the survival curve. Comprehensive reviews of the field place mTOR inhibition as the most robust, most replicated pharmacologic lifespan extension known. So the headline you see online — "the most proven anti-aging drug" — is half right. It is the most proven *in mice*. The hype begins the moment that qualifier gets dropped. ## The evidence gap: no human longevity trial exists Here is the sentence the marketing tends to skip. An authoritative review of mTOR inhibitors in aging states it plainly: **no rapalog has been shown to extend human lifespan or healthspan**, and the human evidence base remains early. The gap between a mouse survival curve and a proven human benefit is exactly the chasm that has swallowed many promising compounds before, and rapamycin has not yet crossed it. What human data does exist is about safety and short-term function, not lifespan: - **The PEARL trial** is among the first longevity-oriented human RCTs of rapamycin — a decentralized, placebo-controlled study of low-dose oral rapamycin over one year in healthy adults. It found the drug was acceptably safe at the doses tested and reported a few modest subgroup signals, such as improvements in lean mass and pain in women. What it did *not* find was decisive: no demonstrated effect on aging biomarkers or lifespan, in a small, short trial leaning heavily on self-reported measures. It is a feasibility-and-safety pilot, not proof of anti-aging benefit — in fact it **missed its primary endpoint** (visceral fat), a distinction we break down in [what the PEARL trial actually showed about rapamycin](/rapamycin-pearl-trial). We also discuss it alongside metformin in [rapamycin & metformin for longevity: the evidence](/rapamycin-metformin-evidence). - **An earlier randomized feasibility trial** in an older human cohort similarly established that short-course rapamycin was tolerable and looked at immune, physical-performance, and cognitive measures — again a small safety-and-feasibility study, not an outcome trial. - **The most encouraging *functional* human signal** comes not from rapamycin itself but from related mTOR inhibitors. A trial of low-dose everolimus (a rapalog) in older adults found it improved the immune response to flu vaccination, and a larger follow-up reported that a TORC1 inhibitor reduced the rate of respiratory infections in the elderly. That is a real, randomized, hard-ish outcome — but it is about immune function in a specific setting, not lifespan, and notably it later failed to hit its primary endpoint in a large confirmatory respiratory-illness trial. Promising direction; not a longevity win. Add it up and the honest grade is: **best-in-class animal lifespan data; human evidence limited to short safety/feasibility pilots and a narrow immune-function signal, with zero completed human longevity RCTs.** This is precisely the kind of "level-4 evidence marketed as level-1" pattern our [evidence hierarchy](/longevity-medicine-evidence) is built to flag. ## The risks the hype glosses over Rapamycin is not a benign supplement; it is an immunosuppressant with a real side-effect profile, which is why it remains a prescription drug. **Immunosuppression.** This is the defining property of the drug class — it is literally approved to suppress the immune system after transplant. The longevity hypothesis is that *intermittent, low-dose* rapamycin might enhance rather than suppress immune function (as the everolimus vaccine data hint), but the dosing window that separates "immune-tuning" from "immunosuppression" in humans is not well defined. Higher or more continuous exposure carries genuine infection risk. **Metabolic disruption.** mTOR inhibition can impair glucose handling. Rapamycin has documented toxicity to pancreatic β-cells and can promote insulin resistance and glucose intolerance — a paradox the field takes seriously, since a drug meant to mimic the metabolic *benefits* of caloric restriction can, at the wrong dose, worsen blood sugar. mTOR-inhibitor–associated new-onset diabetes is well documented in the transplant literature. **Other known effects.** The class is associated with mouth ulcers (stomatitis), impaired wound healing, lipid elevations, and — at transplant doses — cytopenias. Reviews of rapamycin for aging are explicit that the optimal dose, schedule, and long-term safety for *healthy* people are still being worked out, not settled. None of this means rapamycin is dangerous to consider — it means it is a real drug that demands real medical oversight, lab monitoring, and informed consent about an unproven indication. It is the opposite of a casual purchase. ## Hype vs evidence, side by side | Claim you'll see | Honest status | |---|---| | "Most proven anti-aging drug" | True *in mice* (best ITP data in the field); unproven for human lifespan or healthspan. | | "Extends lifespan even started late" | Demonstrated in mice; never shown in humans. | | "Safe — trials prove it" | Short human pilots show acceptable *short-term* safety; long-term safety in healthy people is unestablished. | | "Boosts your immune system" | A related rapalog improved vaccine response and cut some infections in elderly trials; rapamycin itself is fundamentally an immunosuppressant. | | "No real downside at low dose" | Documented infection, glucose/β-cell, lipid, and wound-healing risks; dose window is undefined. | ## If a clinic offers rapamycin Some longevity clinics prescribe off-label rapamycin. That is not inherently unreasonable — informed early adoption of a mechanistically strong intervention is a legitimate choice — but the framing has to be honest. A trustworthy provider will tell you, in plain language, that you would be taking an intervention with the best animal data in the field and **no proof of human longevity benefit**, under monitoring, off-label. A provider that pitches rapamycin as a proven anti-aging therapy has already failed our trust test. It is also worth noticing how rarely the drug is published with a price at all: on most providers here it is quoted after an intake rather than listed, so a provider that puts [rapamycin on a printed shelf beside NAD+, metformin and low-dose naltrexone](/healthrx-review) is telling you something before you hand over a card. For how we vet providers on exactly this kind of honesty, see [are longevity clinics worth it?](/longevity-clinics-worth-it) and our independently graded [longevity clinic rankings](/best-longevity-clinics). For where NAD+ and peptide claims land on the same evidence ladder, see [do NAD+ and peptides actually extend lifespan?](/do-nad-peptides-work). ## Getting it online: what a prescription actually involves, and what it costs Rapamycin (sirolimus) is an FDA-approved drug, but **not for aging** — every longevity prescription is off-label, which is legal and ordinary, and means no regulator has evaluated it for this use. A telehealth pathway typically runs: intake questionnaire, a clinician review, a prescription written off-label, and fulfillment through a pharmacy. Some providers require baseline bloodwork; many do not, and the difference is worth asking about, since the risks worth monitoring — mouth ulcers, lipid and glucose changes, immune effects — are laboratory-visible. **On price, the field is unusually opaque.** Of the graded providers on our board, exactly one publishes a real month-to-month rapamycin price: AgelessRx, at **$65/month billed monthly** — the figure and its terms are in [our AgelessRx review](/agelessrx-review). Everywhere else the drug is quoted after an intake rather than printed, which is precisely the pattern our [ranking](/best-longevity-clinics) grades rows down for, and the reason [what longevity care actually costs](/longevity-clinic-cost) is a longer article than it should need to be. Three questions worth asking any provider before you start: - **Is the price published before the intake**, or only after you have handed over a medical history? - **Is the clinician review inside that price**, and is follow-up bloodwork included or billed separately? - **What dosing schedule are they prescribing, and on what basis?** The once-weekly protocols circulating in longevity practice are extrapolated from animal work and small human studies, not from a longevity trial — because [no human longevity trial exists](/rapamycin-pearl-trial). ## Bottom line Rapamycin earns its reputation as the most reproducible lifespan extender in laboratory animals — that part is real, replicated, and rigorous. But "most proven in mice" is not "proven in people," and the human record so far is a handful of short safety and feasibility trials plus a narrow immune-function signal, with no completed longevity RCT and a real profile of immunosuppressive and metabolic risk. Treat it as the field's most *interesting* investigational candidate, not as a validated anti-aging therapy. Honesty over hype: the science is genuinely exciting, and it is genuinely unfinished. Sources: https://pubmed.ncbi.nlm.nih.gov/37142830/, https://pubmed.ncbi.nlm.nih.gov/19587680/, https://pubmed.ncbi.nlm.nih.gov/24341993/, https://pubmed.ncbi.nlm.nih.gov/22587563/, https://pubmed.ncbi.nlm.nih.gov/40188830/, https://pubmed.ncbi.nlm.nih.gov/29408453/, https://pubmed.ncbi.nlm.nih.gov/25540326/, https://pubmed.ncbi.nlm.nih.gov/29997249/, https://pubmed.ncbi.nlm.nih.gov/23881200/, https://pubmed.ncbi.nlm.nih.gov/24618355/, https://pubmed.ncbi.nlm.nih.gov/33037985/ --- ### What the PEARL Trial Actually Showed About Rapamycin Canonical: https://longevitygraded.com/rapamycin-pearl-trial Updated: 2026-07-26 PEARL was the largest decentralized RCT of rapamycin in healthy aging — and it missed its primary endpoint. An honest readout of what it did and didn't prove. ## The one-sentence version PEARL was the largest decentralized randomized trial of low-dose rapamycin in healthy, normally-aging adults to date — and it **missed its primary endpoint**: rapamycin did not significantly reduce visceral fat. The signals people quote from PEARL (lean mass, pain, well-being) are all secondary or subgroup findings, several of them confined to women at the higher dose. That distinction — primary-endpoint failure versus cherry-picked secondary signals — is the whole story, and it is exactly the distinction the marketing tends to blur. For where rapamycin sits in the wider toolkit, see our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence), and for the full drug profile, [rapamycin for longevity: hype vs evidence](/rapamycin-for-longevity). ## What PEARL was PEARL ("Participatory Evaluation of Aging with Rapamycin for Longevity") was a 48-week, double-blinded, placebo-controlled, decentralized RCT (NCT04488601) run by the telehealth company AgelessRx. Healthy adults were randomized to weekly placebo, 5 mg, or 10 mg of compounded oral rapamycin, with outcomes assessed by DXA scan, blood biomarkers, and validated questionnaires. Two design features are worth flagging up front, because they shape how much weight the results can bear: - **It was sponsor-run.** Every listed author is an employee and shareholder of AgelessRx, a company that sells rapamycin prescriptions. That doesn't make the data wrong, but it is a conflict of interest the paper itself discloses, and it warrants the same skepticism you'd apply to any industry-funded trial of its own product. - **It was decentralized and self-report-heavy.** Recruiting and measuring participants remotely is what made the trial feasible at scale, but it also means several headline outcomes (pain, emotional well-being, general health) came from surveys rather than hard clinical endpoints. ## The primary endpoint: a miss PEARL pre-specified **visceral adiposity (visceral fat, measured by DXA) as its single primary outcome**. This is the cleanest fact in the entire readout, and it is the one most often skipped: visceral fat *did not change significantly*. The effect size was essentially zero (partial η² = 0.001, p = 0.942) — not a near-miss, not a trend, but a flat result. In a trial, the primary endpoint is the question the study was actually powered and designed to answer. When it comes back null, the honest summary is "the trial did not show its intended effect." Everything else — every secondary or subgroup signal — is hypothesis-generating, not confirmatory. PEARL's authors are reasonably candid about this in their conclusions, framing the study as establishing relative safety and pointing to "future work" to "more comprehensively establish efficacy". That is the language of a trial that did not establish efficacy. ## The secondary and subgroup signals So what *did* reach significance? A handful of secondary outcomes, and the framing matters for each one: - **Lean tissue mass improved — but only for women on 10 mg** (partial η² = 0.202, p = 0.013). This was not an effect across the whole randomized population; it was a subgroup finding in one sex at one dose. - **Self-reported pain improved — again only for women on 10 mg** (partial η² = 0.168, p = 0.015), measured by questionnaire. - **Self-reported emotional well-being and general health improved for the 5 mg group** (p = 0.023 and p = 0.004), also by questionnaire. - **Blood biomarkers stayed within normal ranges**, and adverse and serious adverse events were similar across all arms — the safety signal that was the study's stated reason for being. Here is the problem with leaning on these. A trial that measures many outcomes across multiple dose arms and subgroups will, by chance alone, turn up some "significant" results even if the drug does nothing. The fact that the lean-mass and pain wins are **confined to a single sex at a single dose**, and that two more depend on **self-report**, is exactly the pattern that should lower — not raise — your confidence. None of these were the pre-specified primary endpoint, none were corrected for the number of comparisons in the headline framing, and the strongest of them sit in a women-at-10 mg subgroup that the trial was not designed or powered to test as a primary question. That is not a knock on the investigators for reporting them — secondary signals are worth reporting. It is a knock on anyone who repackages "women on 10 mg had more lean mass" as "PEARL proves rapamycin works." ## What PEARL does and doesn't support **What it reasonably supports:** intermittent low-dose rapamycin (5–10 mg weekly) over roughly a year was *relatively safe* in a healthy adult cohort, with adverse events comparable to placebo and blood biomarkers staying in range. That is a genuine, useful contribution — short-term tolerability data in healthy people is scarce, and this adds to it alongside an earlier randomized feasibility trial in older adults that likewise found short-course rapamycin tolerable. One caveat travels with the word *compounded*, though: a trial knows which pharmacy made its capsules and a buyer usually does not, since most rows here do not publish the facility — one that does is [the practice that prints both dispensing pharmacies with street addresses](/telos-rx-review), and it is an exception precisely because the disclosure is so rare. **What it does not support:** that rapamycin reduces visceral fat (the thing it was designed to test — it didn't), or that it has been shown to slow aging, extend healthspan, or improve any aging biomarker in a confirmatory way. An authoritative review of mTOR inhibitors in aging states the ceiling plainly: **no rapalog has been shown to extend human lifespan or healthspan**, and the human evidence base remains early. PEARL doesn't change that sentence. It is consistent with it. This is why, on our [evidence hierarchy](/longevity-medicine-evidence), rapamycin still grades as "best-in-class animal lifespan data, absent human-longevity proof" even after PEARL. A null primary endpoint in a sponsor-run, self-report-heavy trial is not the level-1 human outcome data the longevity field keeps promising. ## How this fits the rest of the rapamycin story PEARL is the most-cited human rapamycin-for-longevity trial precisely because there is so little else. The drug's reputation rests almost entirely on mouse data — the rigorous NIA Interventions Testing Program found rapamycin extends lifespan in mice even when started late in life, the most reproducible pharmacologic lifespan result in the field. The most encouraging *functional* human signal comes not from rapamycin but from a related rapalog: low-dose everolimus improved the immune response to vaccination in older adults, and a follow-up reported a TORC1 inhibitor reduced respiratory infections in the elderly — though that program later missed its primary endpoint in a larger confirmatory trial. None of that is a longevity outcome. And the risks the safety data must be weighed against are real: rapamycin is a prescription immunosuppressant with documented effects on glucose handling and pancreatic β-cells, and reviews are explicit that the optimal dose and long-term safety for healthy people are still unsettled. PEARL's reassuring one-year safety picture is welcome, but one year in a self-selected healthy cohort is not the same as established long-term safety. We cover both drugs' human-trial gap together in [rapamycin & metformin for longevity: the evidence](/rapamycin-metformin-evidence). ## If a clinic cites PEARL at you Some longevity clinics — including the one that ran the trial — point to PEARL as evidence rapamycin "works." Use the primary-endpoint test. A trustworthy provider will tell you, in plain language, that PEARL's main outcome (visceral fat) was null, that the positive findings were secondary or subgroup signals (several in women at 10 mg, several self-reported), and that the trial's real contribution was short-term safety, not proof of anti-aging benefit. A provider that presents PEARL as a green light has already failed our trust test. For how we vet providers on exactly this kind of honesty, see [are longevity clinics worth it?](/longevity-clinics-worth-it) and our independently graded [longevity clinic rankings](/best-longevity-clinics). ## Bottom line PEARL deserves credit for being a real, randomized, placebo-controlled trial in a field full of anecdote — and for showing that low-dose intermittent rapamycin is relatively safe over a year in healthy adults. But it missed the endpoint it was built to test: visceral fat didn't budge. The signals worth talking about are secondary, mostly confined to women on the higher dose, and partly self-reported — interesting leads, not proof. The honest reading is that PEARL tempers the rapamycin-longevity hype rather than confirming it. The science is genuinely worth continuing; it is also genuinely unfinished. Sources: https://pubmed.ncbi.nlm.nih.gov/40188830/, https://pubmed.ncbi.nlm.nih.gov/29408453/, https://pubmed.ncbi.nlm.nih.gov/37142830/, https://pubmed.ncbi.nlm.nih.gov/25540326/, https://pubmed.ncbi.nlm.nih.gov/29997249/, https://pubmed.ncbi.nlm.nih.gov/23881200/, https://pubmed.ncbi.nlm.nih.gov/33037985/ --- ### Longevity Clinics vs Lab Memberships vs Rx Telehealth: What Each Delivers Canonical: https://longevitygraded.com/longevity-clinics-vs-lab-memberships Updated: 2026-07-26 The longevity market splits into four bands: concierge clinics, membership programs, DTC labs, single-product Rx. What each delivers, and who it's for. "Longevity provider" is not one thing. Walk the market and you find a $20,000-a-year concierge clinic with a whole-body MRI scanner, a $149-a-month telehealth membership that mails you a lab kit, a $199-a-year subscription that tests 100 biomarkers and then hands you off, and a pay-per-vial peptide pharmacy — all calling themselves "longevity." They are not substitutes for one another. They deliver fundamentally different things, at prices that differ by two orders of magnitude. This guide sorts the field into the four bands we use to grade every provider on [our longevity rankings](/best-longevity-clinics), explains what each band actually gives you, and is honest about where each one falls short. The single most useful distinction to carry through: **does this provider test, or does it treat?** That one question reorganizes the whole market. ## The four bands at a glance | Band | Price (2026) | What you get | The catch | |---|---|---|---| | Concierge diagnostic clinics | $8,000–$25,000/yr | Imaging, genomics, MD concierge | Aspirational pricing; can over-screen | | Membership longevity programs | $99–$300/mo | Recurring labs + clinician + therapies | "Healthspan" claims, supplement upsells | | DTC lab memberships | $199–$365/yr | 100–160+ biomarkers, biological age | They test but largely **don't treat** | | Single-product Rx telehealth | $99–$235/mo (or pay-per-use) | Peptides, TRT, rapamycin, NAD as discrete Rx | One lane, off-label longevity framing | The bands overlap at the edges, and a few providers straddle two. But knowing which band you're shopping in tells you most of what you need before you read a single sales page. ## Band 1 — Concierge diagnostic clinics ($8k–$25k/yr) This is the premium ceiling: Fountain Life, Human Longevity (Health Nucleus), Cenegenics, Extension Health. What you're paying for is **diagnostics you can't get elsewhere** — whole-body and brain MRI, coronary CT angiography with AI plaque analysis, whole-genome sequencing, 100+ biomarker panels, and a physician who quarterbacks all of it. Fountain Life's entry tier runs about $2,995/yr and its flagship around $19,500/yr; Human Longevity's concierge programs reach roughly $19,000/yr; Cenegenics programs land around $14,000–$21,000/yr once you add the assessment and monthly fees. **What it delivers:** the deepest picture of your body available to a consumer, MD-interpreted, in person. For some people that catches something genuinely important early. **The honest catch:** intensive screening of asymptomatic people is a double-edged sword. The most-cited critique of this model — leveled at whole-body-MRI longevity screening — is that it generates incidental findings that drive anxiety, follow-up procedures, and cost without clearly improving outcomes. The price also puts it out of reach for almost everyone, and "early detection" framing can shade into selling tests to the worried-well. Extension Health adds a second flag: alongside its diagnostics it offers plasma exchange and EBOO as longevity interventions, neither of which has human lifespan-extension evidence behind it. Treat the imaging as the real product and the "reverse aging" interventions as unproven. ## Band 2 — Membership longevity programs ($99–$300/mo) This is the most crowded and most competitive band: Lifeforce, Next Health, Healthspan, Ways2Well, and where CoreAge Rx sits. The model is **recurring**: a structured panel of 40–100 biomarkers, scheduled retesting every few months, a clinician who reviews results and prescribes, and a menu of therapies — hormone optimization, peptides, GLP-1s, NAD+. Lifeforce runs about $129–$149/mo after a starter diagnostic, and is the band's clearest test-into-treat example — we grade it in our [Lifeforce review](/lifeforce-review); Next Health tiers from roughly $99 to $399/mo; Ways2Well's bloodwork membership is around $599/yr with therapies billed separately. **What it delivers:** the thing DTC labs don't — it actually treats. You get a clinician who can prescribe and a retesting cadence that lets you see whether an intervention moved your numbers. **The honest catch:** this band leans hardest on the word "healthspan," and much of what it prescribes (NAD+, peptides, rapamycin) has mechanistic plausibility but no human longevity RCT. Several brands also run vertical pharmacies — Ways2Well dispenses through its own ReviveRx — which means the same company that recommends a therapy profits from selling it. And the celebrity- or influencer-anchored brands (Lifeforce via Tony Robbins, Marek via a YouTube personality) tend to upsell a house line of nutraceuticals. A good membership provider in this band distinguishes proven from plausible and discloses its conflicts; we grade exactly that in [are longevity clinics worth it?](/longevity-clinics-worth-it). ## Band 3 — DTC lab memberships ($199–$365/yr) Function Health, Superpower, and Tally Health define this band. For a flat annual fee you get a **large biomarker panel** — Function tests 160+ markers across two draws for $365/yr; Superpower runs 100+ for $199/yr; Tally focuses on at-home epigenetic "biological age" testing — plus a biological-age readout and, usually, a physician who reviews abnormal results. Before you're dazzled by the marker count, it's worth knowing which of those numbers are actually outcome-validated and which are vanity — we sort exactly that in [what do longevity biomarker panels actually test?](/longevity-biomarker-panels). **What it delivers:** an enormous amount of data, cheaply, with minimal friction. As a once-a-year "what's going on inside me" snapshot, it's genuinely useful and well-priced. **The honest catch — the defining one for this band:** these providers **test but largely don't treat.** Function and Superpower will flag an out-of-range marker and may have a physician text you, but they are not built to manage hormone therapy, prescribe peptides, or run a longitudinal treatment plan (we grade the most prominent of these in our [Function Health review](/function-health-review)). You get the diagnosis and then you're handed off to find care elsewhere. Two more caveats: biological-age outputs vary substantially by which method or "clock" is used, so treat the single headline number with skepticism — we explain why the same sample can swing by years in [biological age tests: do epigenetic clocks actually work?](/biological-age-tests); and the biological-age science itself is young — the field still lacks the validated, completed human-healthspan trials that would tell you a lower clock score means a longer life. Tally's marketing claim that its supplement-and-testing subscription "lowered epigenetic age" is a self-reported figure, not an outcome trial. This is the band where the gap between "raises a lab value" and "improves your health" is widest. ## Band 4 — Single-product Rx telehealth ($99–$235/mo or pay-per-use) Marek Health, AgelessRx, and Hone Health anchor this band. The model is **discrete prescriptions**: rapamycin, NAD+ injections, sermorelin, compounded GLP-1, or TRT, ordered à la carte or on a per-product subscription. AgelessRx lists NAD+ injections around $235/mo, sermorelin around $99/mo, compounded semaglutide around $139/mo; Hone runs hormone-focused tiers from about $135–$155/mo; Marek is largely pay-per-use after a $250 intake, and we walk through [what an intake deposit plus service-by-service billing actually adds up to](/marek-health-review) in its own review. **What it delivers:** fast, focused access to a specific therapy without a $20k concierge wrapper. If you know what you want and want it cheaply, this band is efficient. A few members of it borrow from Band 2 and [fold the lab work into the subscription rather than billing it as a gate](/telos-rx-review), which narrows the practical gap between the two bands more than the price tags suggest. Below the whole ladder sits a fifth option nobody markets as longevity care, and it is worth knowing about before you buy a membership you may not need: [a cash-pay marketplace where an independent clinician sees you for about $46 and any prescription is filled at your own pharmacy](/sesame-care-review). It sells no NAD+, no peptides and no panel — but if what you actually want is one conversation with a doctor and a lab order, it is the cheapest published route to both. **The honest catch:** these are single lanes, not longevity programs — Hone is really a TRT/hormone service, Marek a hormone-optimization service, regardless of the "longevity" marketing. Several flagship products rest on animal-only or mechanistic evidence: rapamycin is the most reproducible lifespan extender in *mice* but has no completed human longevity RCT, and NAD+ injections raise a lab value with thin outcome data. AgelessRx leans on compounded medications and cites its own studies — useful, but not a substitute for independent trials. And the vertical-pharmacy conflict reappears: when the prescriber is also the pharmacy, the incentive to prescribe is structural. Read any "anti-aging" claim attached to these products as off-label and mechanistic until proven otherwise; we trace one of the clearest examples in [rapamycin for longevity: hype vs evidence](/rapamycin-for-longevity). ## Where the evidence actually stands across all four bands It's worth stating plainly, because the marketing across every band blurs it: **no longevity intervention sold in any of these bands has been shown in a completed randomized trial to extend human lifespan.** The strongest human outcome data in the entire field belongs to GLP-1 receptor agonists — the SELECT trial showed semaglutide cut major cardiovascular events by about 20% in overweight and obese adults without diabetes — and even that proves cardiovascular risk reduction, not slowed aging (we lay out the full GLP-1 evidence in [GLP-1s for healthspan & longevity](/glp1-for-longevity)). Growth hormone, marketed as rejuvenation across several Band 2 and Band 4 providers, runs the other way: a landmark systematic review found it produced small body-composition changes but no proven functional benefit and significantly more adverse events in healthy older adults. And the IV "longevity" drips that show up on concierge and membership menus alike sit on the weakest evidence of all — a critical review found the data come mostly from disease-specific or aesthetic contexts, with validated aging biomarkers rarely even measured. The honest baseline is shared: the methodology to run true human healthspan trials is only now maturing, so every band is operating ahead of the proof. For the full evidence map, see [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## Which band is for you? - **You want the deepest diagnostic picture and money is no object:** Band 1 concierge. Pay for the imaging and genomics; be skeptical of the bolt-on "reverse aging" interventions and the over-screening risk. - **You want ongoing, prescribed care with retesting and a clinician:** Band 2 membership. This is the band that actually treats at an accessible price — vet for conflict-of-interest (vertical pharmacy) and for honesty about what's proven. If you're weighing the premium-imaging ceiling against this accessible-treatment band, we compare them head-to-head in [concierge vs membership longevity: what you actually get](/concierge-vs-membership-longevity). - **You want a cheap, comprehensive annual data snapshot and will arrange care yourself:** Band 3 DTC labs. Excellent value for testing; just understand you'll be handed off when something needs treating. - **You know the one therapy you want and want it efficiently:** Band 4 single-product Rx. Efficient and focused — read the longevity claims as off-label, and watch the prescriber-is-the-pharmacy incentive. The practical reason the bands blur is that the most useful real-world setup often combines them: a Band 3 lab panel for breadth, plus a Band 2 membership or Band 4 Rx for the treatment a DTC lab won't provide. What you should never do is pay Band 1 prices for Band 4 evidence. For our independently graded shortlist across all four bands — with the conflicts and unproven claims flagged — see [our longevity provider rankings](/best-longevity-clinics). Sources: https://doi.org/10.1097/XCE.0000000000000159, https://doi.org/10.1056/NEJMoa2307563, https://doi.org/10.7326/0003-4819-146-2-200701160-00005, https://pubmed.ncbi.nlm.nih.gov/41915584/ --- ### Do Biological Age Tests Actually Work? An Evidence Review Canonical: https://longevitygraded.com/biological-age-tests Updated: 2026-07-26 Epigenetic clocks (Horvath, GrimAge, DunedinPACE) predict aging well in populations — but are noisy and unproven for individuals. An honest evidence review. ## The one-sentence version Epigenetic clocks are a genuine scientific achievement — they predict mortality and disease risk across large populations better than chance — and they are also too noisy, too unstandardized, and too unvalidated to tell *you* as an individual whether a supplement, a diet, or a clinic visit actually changed how fast you are aging. Both halves are true at once. This page holds them together, because the longevity industry sells you the first half and quietly omits the second. For where biological-age testing sits in the wider toolkit, see our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What a "biological age test" actually measures Your chronological age is how many birthdays you've had. Your *biological* age is meant to capture how worn your body is — the idea being that two 50-year-olds can be aging at very different rates. Most consumer "biological age" tests estimate this from **DNA methylation**: chemical tags (methyl groups) that sit on your DNA at specific sites called CpGs and change in patterned ways as you age. An algorithm reads the methylation pattern at hundreds of these sites and outputs a single number — your "epigenetic age" — usually from a blood or saliva sample. (A handful of tests skip methylation entirely and read a different aging signal — for example the inflammation-tracking antibody-sugar test we grade in our [GlycanAge review](/glycanage-review).) The algorithms that do this are called **epigenetic clocks**. They are not all the same, and the differences matter enormously when you're deciding whether to trust one. ## The clocks, briefly — and why generation matters The first clocks were trained to predict chronological age. **Horvath's 2013 multi-tissue clock** used 353 CpG sites and estimated age across many tissue types with striking accuracy. The **Hannum 2013 clock** did something similar in blood. These "first-generation" clocks answer the question *"how old does this methylation pattern look?"* — which, paradoxically, makes them less useful for health, because a clock that perfectly predicts your birthday tells you nothing your driver's license doesn't. The breakthrough was realizing that the *errors* were the interesting part. A clock that estimates you a few years "older" than your birthday — a positive **age acceleration** — turns out to flag people at higher risk. **DNAm age predicts all-cause mortality** in later life: in a landmark analysis pooling multiple cohorts, people whose methylation age ran ahead of their chronological age died sooner, even after adjusting for known risk factors. That insight produced the **second-generation clocks**, trained directly on health and mortality rather than on age: - **PhenoAge** (Levine 2018) was built to predict a composite of clinical aging measures and outperformed first-generation clocks at predicting lifespan and healthspan. - **GrimAge** (Lu 2019) was trained on mortality and surrogate biomarkers of smoking and inflammation; it is among the strongest single predictors of time-to-death and time-to-disease in the literature. Then came a different idea entirely. **DunedinPACE** (Belsky 2022) doesn't estimate an age at all — it estimates your *pace* of aging, calibrated against decades of longitudinal organ-system decline in a single birth cohort followed since 1972. It reports a rate: 1.0 means you're aging one biological year per chronological year; 1.2 means 20% faster. Conceptually it's the most appealing for tracking change over time. Here's the catch the marketing skips: **these clocks disagree with each other.** They were trained on different data toward different targets, so the same blood sample can return a "younger" GrimAge and an "older" PhenoAge. There is no single canonical "your biological age." (We break down which clock is built for which job — mortality, disease, or pace of aging — in our head-to-head [GrimAge vs PhenoAge vs DunedinPACE comparison](/epigenetic-clock-comparison).) When a DTC test hands you one headline number, it has made an invisible choice about *which* clock to trust — and you usually aren't told which, or why. ## Where epigenetic clocks genuinely work Give the science its due. In **population research**, the best second-generation clocks are real, reproducible tools: - They predict mortality and morbidity. GrimAge and PhenoAge consistently associate with time-to-death, cardiovascular events, and age-related disease across independent cohorts. - They track known biology. Clock acceleration moves in the expected direction with smoking, obesity, and chronic disease — the patterns aren't random. - They have become a standard endpoint in aging research. A 2023 framework on biomarkers of aging positions methylation clocks among the most developed candidate measures for evaluating longevity interventions in trials, and a 2025 expert consensus statement treats them as legitimate — but explicitly *research-stage* — tools for intervention studies. If you are running a randomized trial in thousands of people, an epigenetic clock is a defensible way to ask whether a treatment nudged the average rate of aging. That is the use case where these tools shine. ## Where they break down — for *you* The problem is that "works as a population research endpoint" and "works as a personal health readout" are completely different bars. Three failures separate them. ### 1. They're noisy at the individual level The single biggest issue is **measurement reliability**. The same DNA sample, run twice, can yield epigenetic-age estimates that differ by **several years** — not because you aged between draws, but because of technical variation in the methylation assay. A detailed reliability study found that many widely used clocks have poor test–retest reproducibility, with first-generation clocks especially unstable. When the *noise* is measured in years and the *change* you're hoping to detect from a supplement is a fraction of a year, the signal drowns. A single reading can swing you "two years younger" with zero change in your actual biology. This isn't a fringe critique — it's well enough established that researchers built a fix. **Principal-component (PC) clocks** (Higgins-Chen 2022) were engineered specifically to bolster reliability for clinical trials and longitudinal tracking, dramatically reducing the technical noise of the original clocks. The fact that the field had to re-engineer the clocks to make them trustworthy enough for repeated measurement tells you how unreliable the *consumer* versions — which generally don't use PC methods — can be. ### 2. They're not standardized There is no FDA-cleared "biological age" diagnostic. Different companies use different clocks, different assays, different normalization, and different reference populations. Two reputable tests can hand the same person meaningfully different ages, and there's no regulatory floor guaranteeing either is right. The expert consensus is explicit that aging biomarkers, including methylation clocks, still need standardization and validation before clinical deployment. ### 3. The thing you actually care about is unproven Here is the question that matters: *if I lower my epigenetic age, do I live longer or healthier?* That has **not been shown**. Clocks are validated as *predictors* (acceleration associates with worse outcomes), not as *modifiable targets* (proven that pushing the number down extends your life). It is entirely possible for an intervention to lower a clock reading without lowering your actual risk — the clock would be a marker the treatment moved without moving the underlying disease. Demonstrating that a clock is a valid *surrogate* requires showing that changing it changes hard outcomes, and that work largely hasn't been done. This is the same "raises a lab value vs. improves your health" gap we flag for the whole field in [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## "But this study reversed my epigenetic age!" You'll see this claim a lot. The most-cited example is a 2021 pilot randomized trial of an 8-week diet-and-lifestyle program that reported a roughly 3-year reduction in Horvath clock age versus controls. It's a real, peer-reviewed result — and it's also exactly the kind of study to read carefully: - It was **small and short** (a few dozen men, 8 weeks) — a pilot, by the authors' own framing. - It used a **first-generation clock** (Horvath), which the reliability literature flags as among the noisiest. - It measured a **change in a biomarker**, not a change in any health outcome. No one lived longer in 8 weeks; the clock simply read lower. A reduction in a noisy first-generation clock over 8 weeks in a small pilot is hypothesis-generating, not proof that the participants aged backward. Treat every "we reversed your epigenetic age" claim — especially from a company selling the supplement and the test together — as marketing until a large, well-controlled trial using reliable clocks and hard endpoints replicates it. The viral "8 years younger" supplement claim is a textbook case of exactly this trap — we dissect how a placebo-free, manufacturer-linked study used an unvalidated clock to sell it in [alpha-ketoglutarate (Rejuvant): does the "8 years younger" claim hold up?](/alpha-ketoglutarate-for-longevity). The same caution applies to the "about 2.5 years younger" biological-age headline behind the [fasting-mimicking diet (ProLon)](/fasting-mimicking-diet-prolon), which rests on aging-clock surrogates and company-affiliated research. ## So should you buy one? A measured take: - **As a one-time curiosity or a rough population-style risk signal:** fine, if you can afford it and won't over-read the number. A markedly accelerated GrimAge in a heavy smoker is telling you something you probably already knew. - **As a tool to track whether your supplement stack or clinic protocol is "working":** no. The test-retest noise is large enough that you'll see "improvements" that are pure measurement variation, and the clocks aren't validated as modifiable targets anyway. You'll spend money confirming nothing. - **As a substitute for treating actual risk factors:** never. The boring, proven levers — blood pressure, LDL, glucose, smoking, fitness, sleep — have hard-outcome evidence that no epigenetic clock can match. If you do want a biological-age readout, the best-built consumer option is worth picking carefully — we grade the most prominent DTC methylation test, which reports the DunedinPACE clock, in our [TruDiagnostic TruAge review](/trudiagnostic-truage-review) — and the founder-branded membership version of TruAge in our [Tally Health review](/tally-health-review). And understand that the providers selling it mostly **test but don't treat** — the defining catch of the DTC lab band. The exceptions cut the other way and deserve their own skepticism: when [a prescriber offers a biological-age test alongside the treatments it writes](/agelessrx-review), the company measuring the number is also the company selling you the response to it. We map that trade-off in [longevity clinics vs lab memberships vs Rx telehealth](/longevity-clinics-vs-lab-memberships), and we sort which markers on a longevity panel are actually useful versus vanity in [what do longevity biomarker panels actually test?](/longevity-biomarker-panels). And before paying for an epigenetic clock at all, see whether a [free biological-age test or calculator](/free-biological-age-tests) gets you a more actionable number — the open, outcome-validated PhenoAge formula runs off a basic blood panel for nothing. For a free, lab-free measure that predicts mortality through strength and balance, see [the sitting-rising test and longevity](/sitting-rising-test-longevity). ## Bottom line Epigenetic clocks are a legitimate scientific tool that predicts aging-related risk across populations — and a poor personal dashboard. They disagree with each other, they're noisy enough that a single sample can swing by years, they aren't standardized or FDA-cleared, and — most important — lowering your clock score has never been shown to make you live longer. Use them, if at all, as a one-time curiosity, not as a scoreboard for your supplement budget. If you've decided to buy one anyway, we rank the at-home options by defensibility in our [best at-home biological-age test guide](/best-at-home-biological-age-test). For an independently graded look at the providers selling biological-age testing and the longevity therapies around it, see [our longevity clinic rankings](/best-longevity-clinics). Sources: https://pubmed.ncbi.nlm.nih.gov/24138928/, https://pubmed.ncbi.nlm.nih.gov/23177740/, https://pubmed.ncbi.nlm.nih.gov/25633388/, https://pubmed.ncbi.nlm.nih.gov/29676998/, https://pubmed.ncbi.nlm.nih.gov/30669119/, https://pubmed.ncbi.nlm.nih.gov/35029144/, https://pubmed.ncbi.nlm.nih.gov/37657418/, https://pubmed.ncbi.nlm.nih.gov/39708300/, https://pubmed.ncbi.nlm.nih.gov/32885222/, https://pubmed.ncbi.nlm.nih.gov/36277076/, https://pubmed.ncbi.nlm.nih.gov/33844651/ --- ### NAD+ for Longevity: What the Trials Actually Show Canonical: https://longevitygraded.com/nad-for-longevity Updated: 2026-07-26 NR and NMN reliably raise NAD+ in humans, but the trials mostly fail to show clinical or longevity outcomes. An honest review of the hype versus the data. Few longevity ideas have traveled further on less human proof than NAD+. The pitch is seductive and partly true: NAD+ — a coenzyme every cell uses for energy metabolism and DNA repair — declines with age, and supplements built from its precursors (nicotinamide riboside, NR, and nicotinamide mononucleotide, NMN) can push it back up. From there the marketing makes a leap the data has not earned: that restoring NAD+ restores youth. This article walks through what the randomized human trials actually show, and where the popular story — amplified by Sinclair-adjacent media — runs ahead of the evidence. For the broader map of what's proven versus hyped, start with our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## The biology behind the hype is real — and that's the trap The mechanistic story is genuinely compelling. NAD+ falls with age, and it is the obligatory cofactor for the sirtuins — the enzymes David Sinclair's lab and others linked to caloric-restriction biology and slowed aging in model organisms. The canonical review of this field lays out the hypothesis cleanly: NAD+ and sirtuins sit at a node connecting metabolism, stress resistance, and aging, which is why restoring NAD+ became such an attractive target. A companion review by leaders in the field summarizes how NMN and NR feed into that pathway and why they were nominated as anti-aging interventions in the first place. It is worth remembering how badly the sirtuin field has been burned by trusting an elegant mechanism too early: resveratrol, the original "sirtuin activator," turned out not to activate SIRT1 directly at all — see [does resveratrol actually work for longevity?](/resveratrol-for-longevity). Here is the trap. A plausible mechanism is a hypothesis, not a result. The history of aging research is a graveyard of mechanistically elegant interventions that did nothing — or harm — in humans. So the right question is never "does NAD+ matter to aging biology?" (it does) but "when you raise NAD+ in a person, does anything you care about actually improve?" That is a much harder bar, and it is the bar most NAD+ marketing quietly skips. ## What the animal data shows — and its limits The mouse data is the engine of the hype. In the most-cited preclinical study, long-term oral NMN mitigated several age-associated physiological declines in mice — improving insulin sensitivity, lipid profiles, and energy metabolism over a year of dosing. It is a real, well-conducted study. But it is a mouse study, and notably it did not report a lifespan extension — it improved healthspan markers, not survival. This is the recurring pattern in the NAD+ literature: striking effects in short-lived, genetically uniform, lab-housed rodents that have repeatedly failed to translate to humans across many fields of medicine. Mouse healthspan data is a reason to run human trials. It is not a substitute for them, and it is not evidence that a supplement will help you. When a product page leads with mouse results, that is the tell that the human results are thinner. ## In humans, target engagement is the one thing that holds up The strongest honest claim about NR and NMN is narrow: they do raise NAD+ in people. A placebo-controlled crossover trial showed oral NR (1000 mg/day) is well tolerated and roughly doubles blood NAD+ in healthy middle-aged and older adults. A separate long-term safety study of NR chloride confirmed sustained NAD+ elevation with a clean tolerability profile. So the molecules clear the first hurdle — they are bioavailable and they hit their biochemical target. But that same Martens trial is also the first crack in the story: the effects on blood pressure and arterial stiffness were only suggestive, not statistically significant. Target engagement was real; clinical benefit was not. That gap — NAD+ up, outcomes flat — is the single most important fact in this entire field, and it repeats trial after trial. ## The outcome trials: mostly null, occasionally a narrow win When you move from "did NAD+ rise?" to "did the person get measurably better?", the picture turns mixed-to-disappointing. Start with the negatives, because they are the bulk of the rigorous data. A randomized placebo-controlled trial of NR in obese men found it was safe but produced no improvement in insulin sensitivity or other metabolic endpoints, despite raising NAD+ metabolites. A carefully done physiologic study in overweight and older adults likewise confirmed NR raised whole-blood NAD+ but found no significant improvement in muscle function, aerobic capacity, mitochondrial function, or metabolic parameters. Two systematic reviews and meta-analyzes land in the same place: pooled across trials, NAD+ precursor supplementation does not produce consistent, clinically meaningful improvements in metabolic-syndrome parameters, and a separate meta-analysis of NMN specifically found no reliable benefit on glucose and lipid metabolism in adults. The positive signals are real but narrow and population-specific. A randomized, placebo-controlled trial in the journal Science found that 10 weeks of NMN (250 mg/day) improved skeletal-muscle insulin sensitivity — in one specific group, prediabetic postmenopausal women. A small double-blind trial reported NMN improved aerobic capacity in amateur runners, though the authors attributed much of the effect to training-driven oxygen utilization rather than the supplement alone. And a dose-ranging trial of NMN in healthy middle-aged adults reported improvements in a six-minute walk test and a composite "biological age" measure at higher doses — an encouraging surrogate result, but a surrogate nonetheless, and biological-age estimates are themselves contested (see our review of [whether biological age tests actually work](/biological-age-tests)). The honest synthesis: a few narrow surrogate wins in specific populations, no consistent benefit when you pool the data, and — critically — zero trials measuring lifespan, healthspan, or hard clinical events like heart attacks, fractures, or death. Every "longevity" claim for NAD+ is an extrapolation from short-term surrogate markers, not a measured outcome. ## Even the disease trials show the same gap Where NAD+ precursors have been tested in actual disease, the result is consistent with the longevity data: NAD+ goes up, clinical proof stays out of reach. The NADPARK trial — a randomized phase I study of NR in early Parkinson's disease — showed NR boosted brain NAD+ levels, but the clinical and symptomatic effects were exploratory and not established as benefits. In heart failure with reduced ejection fraction, a trial found NR safe and tolerable and able to raise NAD+, but it was an early-phase safety study, not a demonstration that it improves heart-failure outcomes. These are appropriate early steps. They are not licenses for the claims printed on supplement labels. ## Why the hype outran the data It helps to name the mechanism of the hype itself. NAD+ supplements sit at the intersection of a real and elegant aging-biology story, a charismatic and effective set of science communicators, and a supplement industry that can sell precursors as dietary supplements without proving clinical benefit. Add a biomarker that genuinely moves — NAD+ reliably rises — and you have the perfect ingredients for a narrative that feels evidence-based while resting on surrogate endpoints. The logical sleight of hand is always the same: NAD+ declines with age, supplement X raises NAD+, therefore supplement X reverses aging. The middle step is true; the conclusion does not follow. The Pencina physiologic study is the cleanest refutation — NAD+ rose and nothing functional improved. A biomarker can be a marker of aging without being a lever that, when pushed, turns aging back. Until a trial shows that raising NAD+ changes something you can feel or measure clinically, "your NAD+ went up" is a chemistry result, not a health result. We make the same point about precursor supplements specifically in our companion piece on [whether NAD+ and peptides extend lifespan](/do-nad-peptides-work). ## Is it safe, at least? Short-term safety is the strongest part of the story after target engagement. Across the trials above, NR and NMN were generally well tolerated, and a dedicated long-term safety study of NR chloride found no concerning signal at the doses tested. That is reassuring as far as it goes — but "didn't obviously hurt people over weeks to months" is a low bar, and it tells you nothing about benefit or about effects over the years-to-decades timescales that actual longevity would require. It is also worth remembering the broader lesson from longevity pharmacology: in animals, *reduced* growth-hormone and IGF-1 signaling is associated with *longer* lifespan, a reminder that "more" of a youth-associated signal is not automatically better. NAD+ is a different pathway, but the cautionary logic transfers — restoring a youthful biomarker is a hypothesis to test, not a result to assume. ## The bottom line NAD+ for longevity is the clearest case study in the gap between mechanism and proof. The biology is real, the animal data is suggestive, and the supplements reliably do what they claim at the molecular level — they raise NAD+. But the human trials, taken as a whole, mostly fail to show clinical benefit, show only narrow surrogate wins in specific groups, and contain no lifespan or hard-outcome data at all. If you take NR or NMN, take it knowing that you are buying a well-tolerated biomarker change with an unproven payoff — not a validated longevity intervention. Every trial above tested an oral precursor, which is worth holding onto when a clinic quotes you an injection: the compounded routes are a different product on a different bill, and it costs nothing to read [what a month-to-month NAD+ injection is actually charged at](/healthrx-review), and [He & She MD sells NAD+ three ways — injection, nasal spray and a cream — while publishing no term behind any of their prices](/he-and-she-md-review), [the two injectable strengths one operator publishes openly](/direct-meds-review), [the operator whose advertised NAD+ figure is a first month against a higher standing rate](/system-labs-review) or [the operator that names six dispensing pharmacies and still sells no monthly plan](/pallas-health-review) before assuming the higher price buys better data. Three more are worth reading purely as a lesson in how loosely these numbers get handled: one [advertises NAD+ from $199 while its own catalog holds a single product at $325](/care-bare-rx-review), another [prints $179, $169 and $249 for the same injection on a single page](/breeze-meds-review), and a third [sells NAD+, B12 and sermorelin at one $99 from three pages that are the same page with the molecule's name swapped](/wellmedr-review) — all three printing NAD+'s chemistry and NAD+'s milligram dose range. A fourth avoids a monthly figure altogether: it [sells NAD+ as a $369 block of estimated eight-to-ten-week supply, so the per-month cost is a range rather than a number](/peter-md-review). The other molecule sold beside NAD+ on nearly every one of these menus gets the same treatment in [sermorelin for longevity](/sermorelin-for-longevity), and the choice between a needle, a drip and a capsule is worked through in [NAD+ injections vs IV vs oral](/nad-injections-vs-iv-vs-oral), with the two oral precursors compared in [NMN vs NR](/nmn-vs-nr). We place NMN and NR in that same evidence context against every other popular pill in our roundup of the [best longevity supplements, rated by evidence](/best-longevity-supplements). That honesty is exactly what separates an evidence-first program from a marketing funnel, which is the lens we apply when we grade providers in our [ranking of the best longevity clinics](/best-longevity-clinics), and the same discipline we bring to [rapamycin for longevity](/rapamycin-for-longevity) and to [spermidine for longevity](/spermidine-for-longevity), whose autophagy mechanism is strong but whose best human trial was also negative. Sources: https://pubmed.ncbi.nlm.nih.gov/24786309/, https://pubmed.ncbi.nlm.nih.gov/29249689/, https://pubmed.ncbi.nlm.nih.gov/28068222/, https://pubmed.ncbi.nlm.nih.gov/29599478/, https://pubmed.ncbi.nlm.nih.gov/31278280/, https://pubmed.ncbi.nlm.nih.gov/29992272/, https://pubmed.ncbi.nlm.nih.gov/36740954/, https://pubmed.ncbi.nlm.nih.gov/39111741/, https://pubmed.ncbi.nlm.nih.gov/39531138/, https://pubmed.ncbi.nlm.nih.gov/33888596/, https://pubmed.ncbi.nlm.nih.gov/34238308/, https://pubmed.ncbi.nlm.nih.gov/36482258/, https://pubmed.ncbi.nlm.nih.gov/35235774/, https://pubmed.ncbi.nlm.nih.gov/36644285/, https://pubmed.ncbi.nlm.nih.gov/28477727/ --- ### What Do Longevity Biomarker Panels Actually Test? Canonical: https://longevitygraded.com/longevity-biomarker-panels Updated: 2026-07-26 Longevity panels mix genuinely useful, outcome-validated markers (ApoB, HbA1c, hs-CRP) with vanity numbers. An honest, evidence-graded breakdown. ## The one-sentence version A "longevity biomarker panel" is mostly an ordinary blood draw dressed up in anti-aging branding — and that's not an insult, because the *boring* markers on it are the ones with decades of hard-outcome evidence behind them. The trick the marketing plays is mixing a handful of genuinely useful, mortality-validated tests in with a long tail of markers that are interesting, expensive, and unproven as things you should act on. This page sorts the panel into what's worth measuring, what's worth knowing once, and what's vanity. For where panel-testing sits in the wider field, see our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What these panels are really selling Concierge clinics and DTC lab memberships advertise "100+ biomarkers" as if more numbers meant more health. They don't — a point we put to the test in our [Function Health review](/function-health-review). A panel's value isn't its length — it's whether each marker is (1) reliably measurable, (2) linked to a hard outcome like death or cardiovascular events, and (3) *actionable*: something you can change in a way that's been shown to change the outcome. Most of the markers driving a panel's price tag fail at least one of those tests. The DTC lab band in particular has a structural catch we cover elsewhere — it [tests but doesn't treat](/longevity-clinics-vs-lab-memberships), so you're paying for numbers, not for anyone fixing them. So here is the honest grading. We'll use three tiers: **outcome-validated** (move these and you likely move your risk), **useful context** (worth knowing, weaker action link), and **vanity / research-stage** (charged for, rarely worth acting on alone). ## Tier 1 — outcome-validated markers worth measuring These are the markers that have earned their place. Almost none of them are exotic, and almost all are cheap. ### Cardiovascular: ApoB (and why it beats "LDL cholesterol") The single most useful upgrade a "longevity" panel offers over a basic checkup is **apolipoprotein B (ApoB)**. Every atherogenic lipoprotein particle — LDL, VLDL, Lp(a), remnants — carries exactly one ApoB molecule, so ApoB counts the *number of particles* that can lodge in an artery wall. Standard LDL cholesterol measures the cargo, not the trucks. When the two disagree (which is common in metabolic syndrome and diabetes), the *particle count* is the better predictor of cardiovascular events, and there are clear physiological reasons it should be. The same conclusion came out of the Framingham Offspring cohort using NMR-measured **LDL particle number (LDL-P)**: when particle number and cholesterol concentration diverged, future cardiovascular risk tracked the particle number. Major lipid guidelines now recognize ApoB as a measurement target, especially in people with high triglycerides or diabetes where standard LDL-C underestimates risk. If a panel adds one thing, ApoB is the one to want. ### Cardiovascular: Lp(a) — the once-in-a-lifetime test **Lipoprotein(a)** is a genetically set, mostly lifelong-stable particle that independently raises heart-attack and stroke risk. Genetic studies make the causal case cleanly: variants that raise Lp(a) levels also raise coronary disease risk, which is the signature of a true causal factor rather than a bystander marker. Because your Lp(a) is largely fixed by your genes, this is the rare marker you measure *once* — a high result reshapes how aggressively you and your doctor manage everything else (it doesn't yet have an approved therapy of its own). A longevity panel that includes Lp(a) is doing something genuinely useful; one that re-bills you for it every quarter is padding. ### Inflammation: hs-CRP **High-sensitivity C-reactive protein (hs-CRP)** is a marker of low-grade systemic inflammation, and it carries real prognostic weight. In a large prospective study, hs-CRP predicted future cardiovascular events at least as well as LDL cholesterol — and added information beyond it. It's also one of the few "inflammaging" markers that's actually been used to *guide treatment* in a randomized trial: JUPITER enrolled people with normal LDL but elevated hs-CRP and showed a statin sharply cut events in that group. The caveat: hs-CRP is non-specific — a cold, an injury, or a bad night can spike it — so a single high reading means "recheck when well," not "alarm." ### Metabolic: HbA1c and fasting glucose **HbA1c** (average blood sugar over ~3 months) isn't just a diabetes test. In a population followed for years, HbA1c predicted all-cause and cardiovascular mortality *continuously* — risk rose across the range, including below the diabetes threshold. That's the textbook profile of a worth-measuring marker: cheap, reliable, and tied to a hard outcome you can actually move with diet, activity, and (when indicated) medication. Fasting glucose and a fasting insulin add useful context on early insulin resistance, though the insulin link to mortality is softer than HbA1c's. ### Function: the markers a needle can't draw Two of the strongest longevity predictors in all of epidemiology aren't blood tests at all, and a panel that ignores them is missing the point. **Cardiorespiratory fitness** — your VO₂max, or how hard you can push on a treadmill — is among the most powerful predictors of survival ever measured: in a study of over 120,000 people, higher fitness tracked with dramatically lower long-term mortality, with no plateau at the top end. And **grip strength**, a 10-second test with a cheap dynamometer, predicted all-cause and cardiovascular mortality across 17 countries in the PURE study — often outperforming blood pressure (we cover this in full in [grip strength as a longevity biomarker](/grip-strength-and-longevity), and the fitness side in [VO2 max and longevity](/vo2-max-and-longevity)). If a "longevity" program charges you four figures and never measures your fitness or strength, it's optimizing the wrong dashboard. The same logic applies to free, equipment-free function tests like the floor-based screen we cover in [the sitting-rising test and longevity](/sitting-rising-test-longevity). This is the same point we make about chasing a single number in [biological age tests](/biological-age-tests). ## Tier 2 — useful context, weaker action link These belong on a thorough panel but shouldn't drive big decisions on their own. - **Full lipid panel + triglyceride/HDL ratio:** standard, useful, and the backdrop ApoB refines. A high triglyceride-to-HDL ratio is a decent informal flag for insulin resistance. - **Comprehensive metabolic panel, CBC, kidney + liver function, thyroid (TSH), ferritin, vitamin D, B12:** these catch treatable problems (anemia, thyroid disease, deficiency) and rule out causes of fatigue people often misattribute to "aging." Genuinely worth knowing — just not "longevity" magic. - **IGF-1:** marketed as a youth hormone, but the mortality relationship is **U-shaped** — both low *and* high IGF-1 associate with higher mortality in meta-analysis. That makes "raise your IGF-1 to feel younger" biologically naïve, and it's a direct caution against growth-hormone-axis "optimization" being sold as anti-aging. Useful to know; dangerous to chase in either direction. ## Tier 3 — vanity, redundant, or research-stage This is where panels inflate the bill. - **Homocysteine.** It associates with cardiovascular risk, so it looks worth treating — but it isn't a useful *target*. Large randomized trials that lowered homocysteine with folic acid and B vitamins (HOPE-2) did **not** reduce cardiovascular events. Measuring it rarely changes what you should do; it's the classic "marker that's a passenger, not a driver." - **Epigenetic "biological age" clocks.** Genuinely interesting science, but too noisy and unstandardized to track personal change, and never validated as a target you should try to move — we lay out exactly why in [biological age tests: do epigenetic clocks actually work?](/biological-age-tests) and grade the best-known consumer clock test in our [TruDiagnostic TruAge review](/trudiagnostic-truage-review). If you're tempted by a biological-age number, the open PhenoAge formula derives one from this very panel for free — see our guide to [free biological-age tests and calculators](/free-biological-age-tests). For a rare case where a supplement actually moved an epigenetic clock in a randomized trial (by a small amount), see [omega-3 for longevity](/omega-3-for-longevity). - **Aging-biomarker research panels** (glycomics, proteomic aging scores, NAD pathway metabolites, telomere length). The field's own consensus work is explicit that these are **research-stage** tools that still need standardization and validation before clinical use. Paying a clinic to track them as if they were a personal scoreboard is paying for a hypothesis. We dig into the NAD piece specifically in [NAD+ for longevity](/nad-for-longevity), and grade the best-known glycomic aging test — which is responsive but thinly validated — in our [GlycanAge review](/glycanage-review). - **Telomere length.** Variable, lab-dependent, and a weak individual predictor — closer to a curiosity than a decision tool. - **The "100+ marker" megapanels.** Most of the extra markers are correlated with the Tier-1 ones, so they add cost and a sense of completeness without adding much independent signal. More tubes of blood is not more health. ## How to read a panel you've been handed A practical filter, in order: 1. **Find the Tier-1 markers first** — ApoB, Lp(a) (once), hs-CRP, HbA1c — plus your fitness and grip if anyone bothered to measure them. These deserve your attention. 2. **Note Tier-2 for context**, especially anything flagged abnormal that's treatable (thyroid, ferritin, vitamin D, kidney/liver). 3. **Discount the Tier-3 padding.** A scary "biological age" or homocysteine number is not a reason to buy the supplement the same company is selling. The same caution applies in reverse: a supplement that *improves* a panel of these markers in a short trial — as [GlyNAC did in older adults](/glynac-for-longevity) — has moved biomarkers, not proven it extends your life. 4. **Re-test cadence matters.** Lp(a) is once; ApoB/HbA1c/hs-CRP are worth periodic rechecks; the research markers don't need a subscription. A good panel is one that surfaces a small number of actionable, outcome-validated numbers and helps you do something about them. A bad one is a long, expensive list that ends with an upsell. Depth is not the same as usefulness here: [the provider running some of the deepest panels in the category bills the panel, the therapy and the follow-ups separately](/marek-health-review), while [a hormone platform gates its 40-plus marker draw behind an assessment fee and a monthly membership](/hone-health-review) — two ways a long marker list becomes a recurring bill rather than a decision. If you're weighing whether the whole model is worth it, we run the cost-benefit in [are longevity clinics worth it?](/longevity-clinics-worth-it). ## Bottom line The useful core of any longevity biomarker panel is short and cheap: ApoB and Lp(a) for cardiovascular particle risk, hs-CRP for inflammation, HbA1c for metabolic risk, and — crucially — cardiorespiratory fitness and grip strength, which a blood draw can't capture and which predict survival as well as anything on the menu. Everything past that is mostly context or vanity, and "biological age," homocysteine, and proteomic megapanels are not numbers to reorganize your life (or your supplement budget) around. Test the markers that are reliable, outcome-linked, and actionable — and treat the rest as the marketing it usually is. To compare the services selling these panels — Function, InsideTracker, Lifeforce, and Superpower — on price and padding, see our [best longevity blood test services roundup](/best-longevity-blood-tests). For an independently graded look at the clinics and labs selling these panels, see [our longevity clinic rankings](/best-longevity-clinics). Sources: https://pubmed.ncbi.nlm.nih.gov/36216435/, https://pubmed.ncbi.nlm.nih.gov/19657464/, https://pubmed.ncbi.nlm.nih.gov/31504418/, https://pubmed.ncbi.nlm.nih.gov/20032323/, https://pubmed.ncbi.nlm.nih.gov/12432042/, https://pubmed.ncbi.nlm.nih.gov/18997196/, https://pubmed.ncbi.nlm.nih.gov/11141143/, https://pubmed.ncbi.nlm.nih.gov/30646252/, https://pubmed.ncbi.nlm.nih.gov/25982160/, https://pubmed.ncbi.nlm.nih.gov/21795450/, https://pubmed.ncbi.nlm.nih.gov/16531613/, https://pubmed.ncbi.nlm.nih.gov/37657418/, https://pubmed.ncbi.nlm.nih.gov/39708300/ --- ### GLP-1s for Healthspan & Longevity: The Evidence Canonical: https://longevitygraded.com/glp1-for-longevity Updated: 2026-07-26 GLP-1 drugs have the strongest human outcome data in longevity — but it's cardiometabolic risk reduction, not proven lifespan extension. An honest review. ## The one-paragraph version GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — hold the strongest human outcome data of anything marketed under the "longevity" banner. Large randomized trials show they cut heart attacks and strokes, slow kidney decline, and improve heart-failure symptoms in overweight and obese adults. That is real, hard-outcome evidence the rest of the longevity field can only envy. But notice the gap: every one of those wins is a **cardiometabolic** outcome, not a measure of aging, and there is still no trial showing a GLP-1 drug extends human lifespan or slows the biology of aging itself. The honest framing is that these are excellent **disease-risk** drugs with a plausible — but unproven — healthspan story layered on top. For where they sit in the wider toolkit, see our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What GLP-1 drugs actually are GLP-1 receptor agonists mimic an incretin hormone your gut releases after eating. They slow gastric emptying, blunt appetite, and improve insulin response. Semaglutide acts on the GLP-1 receptor alone; tirzepatide is a dual GIP/GLP-1 agonist. Their headline effect is substantial weight loss: in the STEP 1 trial, weekly semaglutide produced roughly 15% mean body-weight reduction over 68 weeks in adults with overweight or obesity, and in SURMOUNT-1, tirzepatide drove mean reductions up to about 21% at the highest dose. Those are the largest pharmacologic weight-loss effects ever shown in randomized trials — and weight, blood pressure, glucose, and inflammation are all risk factors that track with how long and how well people live. That is the mechanistic bridge to "longevity." Whether the bridge actually carries the weight is the question the rest of this page is about. ## The strong part: real, randomized, hard-outcome data This is the section that makes GLP-1s genuinely different from rapamycin, NAD+, or peptide stacks. The benefits below come from large, placebo-controlled trials measuring endpoints that matter — events, not surrogates. - **Cardiovascular events.** The SELECT trial randomized roughly 17,600 overweight or obese adults **without** diabetes and found semaglutide cut major adverse cardiovascular events (cardiovascular death, heart attack, stroke) by about 20% over several years. This is the single most important result in the field: a hard-outcome benefit in people taking the drug for cardiometabolic risk, not diabetes. - **Heart failure.** In the STEP-HFpEF trial, semaglutide improved symptoms and physical function and produced greater weight loss in patients with obesity-related heart failure with preserved ejection fraction — a condition with historically few effective therapies. - **Kidney protection.** The FLOW trial showed semaglutide reduced the risk of major kidney-disease events and cardiovascular death in patients with type 2 diabetes and chronic kidney disease. - **Osteoarthritis.** STEP 9 found semaglutide meaningfully reduced knee pain and improved function in people with obesity and knee osteoarthritis — a quality-of-life and mobility win directly relevant to healthspan. Add it up and you get a drug class that, in randomized trials, lowers your risk of the diseases that most often kill and disable people in later life. For a high-risk patient, that is a serious clinical benefit — and it is exactly the kind of evidence the rest of the longevity toolkit lacks. We make the same point in our four-band breakdown of the market, where GLP-1s are flagged as the one intervention with genuine hard-outcome data: [longevity clinics vs lab memberships vs Rx telehealth](/longevity-clinics-vs-lab-memberships). ## The leap: from "fewer heart attacks" to "slows aging" Here is where the marketing gets ahead of the science. None of the trials above measured aging. They measured cardiovascular events, kidney events, heart-failure symptoms, and joint pain — all downstream of obesity and metabolic disease. Reducing those is hugely valuable, but it proves that GLP-1s **treat the consequences of metabolic disease**, not that they **slow the biology of aging**. The cleanest illustration of the leap is the difference between a disease drug and a geroprotector. A geroprotector would be expected to slow aging across many organ systems even in metabolically healthy people. What the GLP-1 evidence actually shows is that in people carrying excess weight and cardiometabolic risk, removing that burden lowers disease risk. That's superb medicine. It is not, on the current evidence, proof of an anti-aging mechanism. How much life might this buy? Modeling studies — not trials — have tried to project life-year gains from semaglutide in high-risk populations, and they suggest meaningful gains are plausible. But a projection built on extrapolating event-reduction data is a hypothesis, not a measured outcome. No completed randomized trial has demonstrated that any GLP-1 drug extends human lifespan. Treat the "longevity drug" label as an inference drawn from cardiometabolic data, not a proven property — exactly the kind of "level-3 evidence marketed as level-1" leap our [evidence hierarchy](/longevity-medicine-evidence) exists to flag. ### The emerging signals worth watching honestly Two areas are generating legitimate scientific interest, and we'll report them as what they are — early, not settled. - **Brain and neurodegeneration.** GLP-1 receptors are expressed in the brain, and there is mechanistic and early clinical interest in neuroprotection. A propensity-matched cohort study reported some favorable 12-month neurological and psychiatric outcomes with semaglutide in people with type 2 diabetes, and dedicated Alzheimer's-disease trials are underway. Observational and short-term data are hypothesis-generating, not proof; wait for the randomized readouts. - **Inflammation and cardiometabolic aging.** Part of the SELECT benefit appears only partly explained by weight loss, raising interest in direct anti-inflammatory or vascular effects. Interesting, plausible, unproven as an aging mechanism. The intellectually honest stance is curiosity without conclusion: these signals are why GLP-1s are the most scientifically interesting drug in the longevity conversation, and also why it's too early to call them anti-aging drugs. ## The cautions the longevity pitch glosses over GLP-1s are powerful drugs with real trade-offs, and the "longevity optimization" framing tends to skip them. - **Lean mass loss.** Rapid weight loss with GLP-1/GIP therapy strips muscle as well as fat; reviews flag meaningful lean-mass loss as a clinical concern, especially in older adults where preserving muscle is itself a longevity priority. Which makes it worth asking whether a program measures the split at all, rather than only the total: [one prescribing service bundles a body-composition analyzer and reads fat and lean mass every week](/humecare-review), which is a different standard of evidence about your own body than a monthly weigh-in. Losing weight while losing disproportionate muscle can work *against* healthspan. Resistance training and adequate protein are not optional add-ons here. - **Off-label and compounded supply.** Using a GLP-1 purely for "longevity" or "optimization" in a metabolically healthy person is off-label, and the compounded semaglutide sold by some telehealth and clinic brands is not the FDA-approved product — a real quality-and-oversight consideration when a clinic offers it on a longevity menu. - **"Microdosing" is a marketing tier, not a trial protocol.** Several telehealth brands now sell a low-dose GLP-1 as a distinct longevity product. [One sells a microdosed tier explicitly framed as a longevity protocol while its headline monthly price is calculated on a yearly plan](/gala-health-review); [another publishes its microdosing protocol month-to-month with no contract](/yourera-review). Neither low-dose regimen was the dose SELECT tested, so the cardiovascular result above does not transfer to it. If a GLP-1 at a trial dose is what you actually want, two routes in our ranking sell that and only that: [a weight-loss membership whose binding terms and pricing page quote different figures for the same plan](/found-review), and [a cash-pay marketplace where an independent clinician writes the brand-name prescription and your own pharmacy bills you for it](/sesame-care-review). Neither sells anything else this site ranks, which is the honest reason to consider them. - **Side effects and durability.** Nausea, vomiting, and GI effects are common; gallbladder disease and pancreatitis are rarer concerns; and weight tends to return after stopping, making this a long-term commitment rather than a course of treatment. ## The honest grade If you rank longevity-marketed interventions by quality of human evidence, GLP-1 receptor agonists sit alone at the top — and it still isn't lifespan data. They have **best-in-field, randomized, hard-outcome evidence for reducing cardiovascular, kidney, heart-failure, and osteoarthritis disease burden** in people with excess weight and cardiometabolic risk. They have **no completed trial showing extended human lifespan or slowed aging**, a plausible but unproven healthspan hypothesis, and real cautions around muscle loss and off-label use. For a high-risk patient, that's a genuinely strong clinical case. As a "longevity drug" for an otherwise healthy person, it's a bet on an inference, not a proven outcome. For how clinics package these claims — and how to tell evidence-based care from a drip-bar pitch — see [are longevity clinics worth it?](/longevity-clinics-worth-it), and compare the graded provider field on our [best longevity clinics](/best-longevity-clinics) hub. Sources: https://doi.org/10.1056/NEJMoa2032183, https://doi.org/10.1056/NEJMoa2206038, https://doi.org/10.1056/NEJMoa2307563, https://doi.org/10.1056/NEJMoa2306963, https://doi.org/10.1056/NEJMoa2403347, https://doi.org/10.1056/NEJMoa2403664, https://doi.org/10.1530/EC-24-0676, https://doi.org/10.1016/j.eclinm.2024.102726, https://doi.org/10.1097/CRD.0000000000000942 --- ### Peptides for Longevity: What's Real and What's Marketing Canonical: https://longevitygraded.com/peptides-for-longevity Updated: 2026-07-26 Most longevity peptides are sold on mechanism and anecdote, not human outcomes. An honest, citation-backed review of what the evidence actually supports. "Peptide therapy" has become one of the most aggressively marketed lines at longevity clinics — a menu of injectable or oral compounds promising muscle, recovery, deeper sleep, tighter skin, and a reset of your biological clock. The pitch leans on real biochemistry and a few legitimate FDA-approved drugs, then extends that credibility to a long list of compounds that have never been tested for longevity in a human being. This review separates the three categories that actually exist: peptides with approved human uses (none of which are longevity), peptides with thin human data and real cautions, and peptides sold almost entirely on mechanism and testimonial. For the broader map of what's proven versus hyped across this field, start with our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## First, what a "peptide" actually is here A peptide is just a short chain of amino acids — smaller than a full protein. That category includes insulin and GLP-1 drugs, so "peptide" is not a synonym for "unproven." But in longevity-clinic marketing, "peptides" almost always means one of a few specific things: growth-hormone-releasing hormone (GHRH) analogs like sermorelin and tesamorelin; growth-hormone secretagogues like CJC-1295, ipamorelin, and oral MK-677 (ibutamoren); and a grab-bag of "healing" or "optimization" peptides like BPC-157, GHK-Cu, thymosin beta-4, and epitalon. The honest framing starts with noticing that almost every one of these works by pushing your own growth-hormone and IGF-1 axis upward — and that the longevity biology points the *opposite* direction. ## The growth-hormone problem at the center of it all Here is the fact that reframes most of the peptide longevity story. Across species — from worms to mice to humans — *reduced* growth-hormone and IGF-1 signaling is associated with *longer* lifespan, not shorter. The mechanistic reviews are consistent: dampening the GH/IGF-1 axis is one of the most reproducible longevity levers in animal models, and human genetic data link variants in the insulin/IGF-1 signaling pathway to exceptional longevity. The animal data and the human genetics agree, and they both run against the idea that raising growth hormone makes you younger. This matters because the entire GHRH/secretagogue peptide category — sermorelin, CJC-1295, ipamorelin, MK-677, tesamorelin — exists to push GH and IGF-1 *up*. So when a clinic sells these as anti-aging, it is selling you a strategy that the longevity biology predicts should, if anything, point the wrong way. That does not make them dangerous in the short term, but it should permanently retire the phrase "these peptides reverse aging." The direct human evidence on growth hormone itself reinforces the caution. A landmark systematic review of growth hormone in healthy older adults found only small body-composition changes — slightly more lean mass, slightly less fat — with *no* proven functional benefit, alongside significantly more adverse events: edema, joint pain, carpal tunnel symptoms, gynecomastia, and glucose intolerance. Updated reviews of GH and aging reach the same place: the rejuvenation narrative is not supported, and the risk-benefit math is poor in people who are not GH-deficient. ## The secretagogues: real GH effects, no longevity proof Growth-hormone secretagogues are the compounds with the most actual human data — and that data is sobering rather than encouraging. MK-677 (ibutamoren) is the best-studied. A randomized, double-blind, two-year trial in healthy older adults found that the oral ghrelin mimetic did raise GH and IGF-1 and increased lean body mass — but it did not improve the functional outcomes that matter, such as strength or measures that would translate into healthier aging. A separate randomized trial in patients with mild-to-moderate Alzheimer's disease found MK-677 had no clinical effect on disease progression. Earlier work confirmed it does what it says biochemically — it raises markers of bone turnover and GH output — but "the hormone went up" is exactly the endpoint switch that should make you skeptical. Raising the biomarker is not the win; changing an outcome you can feel is, and that win has not materialized. CJC-1295 and ipamorelin — the injectable secretagogues most commonly stacked at clinics — have even thinner published human longevity data. They reliably raise GH pulses, but there are no randomized trials showing they extend lifespan, slow aging, or improve hard functional outcomes in healthy adults. They are sold on the MK-677-style logic that "more GH is better," which the longevity literature directly disputes. ## Tesamorelin: a real FDA-approved drug — for something other than longevity Tesamorelin is the strongest case study in how an approved peptide gets borrowed for claims it was never approved for. It is a GHRH analog with genuine, well-conducted phase 3 evidence: randomized placebo-controlled trials showed it reduces visceral abdominal fat in HIV-infected patients with lipodystrophy, which is its FDA-approved indication. Later mechanistic work even showed favorable effects on the liver transcriptome in HIV-associated fatty liver disease. That is a legitimate drug doing a legitimate, narrow job. But none of it is a longevity indication. Tesamorelin was studied in a specific patient population with a specific metabolic problem; it was not tested for lifespan, healthspan, or aging biomarkers in healthy adults, and it raises IGF-1 — the same axis the longevity data cautions against pushing. Using "tesamorelin is FDA-approved" to justify a longevity protocol is borrowing the credibility of a real indication to sell an unproven one. That is the single most common rhetorical move in this corner of the market, and it is worth learning to spot. ## BPC-157, GHK-Cu, and the "healing peptide" tier Below the GH-axis peptides sits a tier sold for recovery, skin, and vague "optimization." Here the evidence problem is even starker. BPC-157 — a synthetic fragment marketed heavily for tendon, gut, and tissue repair — has essentially no published randomized human trials for any longevity or healing indication. The literature is overwhelmingly preclinical: rodent and cell studies on inflammatory bowel models and cancer cachexia. Those are hypothesis-generating animal experiments, not evidence that injecting BPC-157 helps a person age more slowly or heal faster. It is also not an approved drug; in the U.S. it has been flagged by the FDA in the context of compounded products, and it is banned in elite sport. Selling it as a longevity peptide means selling an unapproved compound on the strength of mouse data and testimonials. GHK-Cu (copper tripeptide) is the most legitimate of this tier, but its evidence base is topical and cosmetic, not systemic and longevity-related. Reviews describe plausible roles in skin remodeling and wound-healing pathways, and it has a long history in dermatology and cosmetics. None of that establishes that injected or systemic GHK-Cu extends healthspan. "Helps skin remodeling in lab and topical studies" is a real finding; "reverses aging" is not what it shows. Other peptides in this category — thymosin variants, epitalon, and assorted "bio-regulators" — are sold almost entirely on mechanism and anecdote, frequently citing decades-old or non-replicated work. Absence of trials is not evidence of benefit. A peptide with no published human outcome data should be treated as experimental, not as a validated longevity protocol. ## How to read a clinic's peptide menu honestly Peptide menus lean hard on naming a [hallmark of aging](/hallmarks-of-aging-explained) the compound supposedly targets — but "hits a hallmark in a cell or mouse" is a hypothesis about humans, not a result in them. A few rules cut through most of the marketing: - **Watch the endpoint switch.** When a clinic cites "your IGF-1 went up" or "your GH pulses increased," ask whether any outcome you care about — strength, function, hard health events, lifespan — was measured. With the GH-axis peptides, the biomarker reliably moves and the functional outcomes reliably don't. - **"FDA-approved" rarely means approved for longevity.** Tesamorelin is approved for HIV lipodystrophy, not aging. The approval is real; the longevity extension of it is not. - **Preclinical is not human.** BPC-157's evidence is mostly rodent and cell work. Mouse data is a reason to run trials, not a substitute for them. - **Mind the GH/IGF-1 direction.** The most reproducible longevity finding in animals and human genetics is that *less* GH/IGF-1 signaling tracks with *longer* life. A peptide whose whole job is to raise that axis is, at minimum, not an obvious anti-aging strategy. - **Ask who compounds it.** Nothing on a peptide menu is FDA-approved for aging, so the vial's provenance is the only quality signal you get, and most providers will not print it. A minority do: [one names both dispensing pharmacies with street addresses and their state licensure gaps](/telos-rx-review), and [another prints four pharmacies with phone numbers beside two prescribing physicians and their NPI numbers](/synergy-rx-review) — while stating no compounding standard for any of them, which is the commoner half-disclosure. ## The bottom line There is no peptide with human evidence that it extends lifespan or healthspan. The category splits cleanly: a few peptides (tesamorelin, and GLP-1 drugs covered separately in our review of [GLP-1s for healthspan and longevity](/glp1-for-longevity)) have genuine approved uses that are not longevity; the GH secretagogues like MK-677 have real human trials that show the biomarker rises but the functional benefit doesn't; and the "healing" peptides like BPC-157 are sold on preclinical data and testimonials. Layered on top is the inconvenient longevity biology — lower GH/IGF-1 signaling, not higher, is what tracks with longer life across species. If a peptide protocol is offered to you as anti-aging, the honest framing is that you are buying an experimental intervention on the strength of mechanism and marketing, not a proven longevity treatment — and it is worth knowing what that experiment is billed at before you agree to it, which is why we priced [the sermorelin protocol that sits first in our ranking](/coreage-rx-review) line by line. The same question decides how you read a block price: one graded provider [sells sermorelin as $585 for a twelve-week supply rather than a monthly rate](/peter-md-review), which is roughly $195 a month once you do the division nobody does for you. We take the whole category apart in [sermorelin for longevity: cost, evidence and what it cannot do](/sermorelin-for-longevity). It is also worth knowing who is paying attention to the molecule: one operator sells [sermorelin at $99 a month from a page that calls it "a naturally occurring coenzyme" and offers it in 500mg and 1000mg doses](/wellmedr-review) — that is NAD+'s chemistry and NAD+'s dose range, on a peptide measured in micrograms. It is the same gap we document across the pills in our roundup of the [best longevity supplements, rated by evidence](/best-longevity-supplements). That is precisely the discipline we apply when grading providers in our [ranking of the best longevity clinics](/best-longevity-clinics), and the same lens we use on [whether NAD+ and peptides extend lifespan](/do-nad-peptides-work), on [urolithin A (Mitopure), the best-evidenced mitochondrial supplement](/urolithin-a-for-longevity), and on [rapamycin & metformin for longevity](/rapamycin-metformin-evidence). Sources: https://pubmed.ncbi.nlm.nih.gov/18981485/, https://pubmed.ncbi.nlm.nih.gov/19015485/, https://pubmed.ncbi.nlm.nih.gov/10404019/, https://pubmed.ncbi.nlm.nih.gov/20554713/, https://pubmed.ncbi.nlm.nih.gov/20101189/, https://pubmed.ncbi.nlm.nih.gov/32701508/, https://pubmed.ncbi.nlm.nih.gov/17186181/, https://pubmed.ncbi.nlm.nih.gov/29898649/, https://pubmed.ncbi.nlm.nih.gov/26236730/, https://pubmed.ncbi.nlm.nih.gov/17227934/, https://pubmed.ncbi.nlm.nih.gov/29756419/, https://pubmed.ncbi.nlm.nih.gov/28477727/, https://pubmed.ncbi.nlm.nih.gov/22044904/, https://pubmed.ncbi.nlm.nih.gov/24350933/ --- ### Metformin for Longevity: The TAME Trial Evidence Canonical: https://longevitygraded.com/metformin-for-longevity Updated: 2026-07-26 Metformin's anti-aging case is mechanistic and observational — no completed RCT proves it. Why the TAME trial exists, and the exercise caveat. ## The one-sentence version Metformin is a cheap, decades-old, well-tolerated diabetes drug with a genuinely interesting anti-aging *mechanism* and one famous observational signal — and there is no completed randomized trial showing it extends healthy lifespan in people without diabetes. The clearest proof of that gap is that the field designed an entire landmark trial, TAME, specifically to test it. This page separates the mechanism from the missing outcome. For where metformin sits in the wider toolkit, see our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What metformin actually is Metformin is the first-line drug for type 2 diabetes. It is FDA-approved for that indication — **not for aging or longevity** — and using it to slow aging in a non-diabetic person is off-label. It is generally inexpensive and has a long, well-characterized safety record, which is part of why researchers find it an attractive candidate to repurpose: if a drug already taken by millions turned out to be geroprotective, deploying it would be unusually practical. Its primary action is to lower blood glucose, mainly by reducing the liver's glucose output and improving insulin sensitivity, with activation of the cellular energy sensor AMPK among its proposed mechanisms. AMPK signaling, nutrient sensing, and metabolic stress responses sit close to the recognized biology of aging — which is where the longevity hypothesis comes from. ## The mechanism: plausible, and mostly preclinical The strongest version of metformin's anti-aging case is mechanistic. A widely cited review maps metformin's actions onto the recognized **hallmarks of aging** — nutrient sensing, mitochondrial function, inflammation, cellular senescence, and others — and argues that this multi-target profile is what makes it a credible geroprotector candidate. That is a real, thoughtful argument. But it is important to read what tier of evidence it rests on: the review summarizes a largely **preclinical and observational** basis, not human outcome trials. This is the recurring pattern in longevity medicine, and the one our [evidence hierarchy](/longevity-medicine-evidence) is built to flag: a plausible mechanism plus suggestive associations is a hypothesis worth testing, not a proven therapy. Mechanism tells you *why something might work*; only an outcome trial tells you *whether it does*. ## The observational signal — and why it's not proof The single most-cited human data point in the metformin-longevity conversation comes from a large UK observational study. In it, people with type 2 diabetes treated with metformin had survival **comparable to — even slightly better than — matched non-diabetic controls**, and better than diabetics on sulfonylureas. On its face that is remarkable: a disease that shortens life appeared, when treated with metformin, not to. But this finding is hypothesis-generating only, and the honest caveats are large: - **It is observational.** People prescribed metformin differ from those who aren't — and from non-diabetic controls — in countless ways (disease severity, comorbidity, healthcare contact, prescriber choice) that no statistical matching fully removes. This is exactly the confounding our methodology grades *down*, not up. - **It was in people with diabetes.** A survival result in a diabetic population says little about whether metformin extends healthy lifespan in metabolically healthy adults, who are the people most likely to take it "for longevity." - **"Comparable survival" is not "longer life."** The headline is striking partly because the comparison baseline (a disease that shortens life) is so low. The randomized evidence on metformin's *primary* job reinforces caution about over-reading. In the classic UKPDS 34 trial, metformin reduced diabetes-related complications and mortality in overweight people **with type 2 diabetes** — a genuine, randomized cardiometabolic benefit in a *diseased* population. That is a real reason the drug is valued. It is not evidence of lifespan extension in healthy people, and it shouldn't be repackaged as one. ## TAME: the trial built because the proof is missing If metformin's anti-aging benefit were already proven, no one would need to run a definitive trial to establish it. They are. **TAME — Targeting Aging with Metformin** — is the proposed multi-center, randomized, placebo-controlled trial designed to test whether metformin can delay the onset of age-related diseases as a composite outcome. The framing paper for it argues explicitly that a definitive human trial is still needed and lays out the rationale. A companion paper from the TAME Biomarkers Workgroup works through which blood-based markers a geroscience-guided trial like this should even use — underscoring that the methodology for *proving* an anti-aging effect in humans is still being built. Read those two papers together and the takeaway is unambiguous: TAME is a **design-and-rationale effort**, not a results readout. You do not propose a landmark trial to confirm something already demonstrated. As of this writing, no completed TAME-type RCT has shown that metformin extends healthy lifespan in people without diabetes. Anyone citing "TAME" as evidence *for* metformin has the logic backwards — TAME is evidence that the question is still open. ## The exercise caveat the hype skips There is a specific, randomized human finding that complicates the "metformin for healthy longevity" pitch, and honest coverage has to include it. In older adults doing aerobic exercise training, metformin **blunted** the mitochondrial and cardiorespiratory-fitness adaptations to that training compared with placebo. A companion line of work (the MILES study) found metformin broadly altered metabolic and non-metabolic gene-expression pathways in the skeletal muscle and fat of older adults — confirming the drug is biologically active in these tissues, but in ways whose net effect on healthy aging is not settled. The implication is not "metformin is bad." It is that metformin is not a free lunch for a metabolically healthy person who exercises: there is randomized evidence it can interfere with one of the few interventions (exercise) that *is* well proven to improve healthspan. That trade-off rarely appears in the longevity-clinic marketing. (Metformin shares the same "moves metabolic markers, unproven on lifespan" profile as dietary approaches like the [fasting-mimicking diet (ProLon)](/fasting-mimicking-diet-prolon) — both are investigational candidates, not validated longevity therapies.) ## Hype vs evidence, side by side | Claim you'll see | Honest status | |---|---| | "Metformin is a proven anti-aging drug" | Unproven for human longevity; the case is mechanistic and observational, not RCT-backed in healthy people. | | "Diabetics on metformin outlive non-diabetics" | One observational study suggested comparable/slightly-better survival — confounded, in diabetics, hypothesis-generating only. | | "Trials prove it works" | UKPDS 34 proved cardiometabolic benefit in *diabetics*; no completed RCT shows lifespan extension in healthy adults. | | "TAME proves the longevity effect" | TAME is a *proposed* trial and a rationale/biomarker framework — its existence shows the proof is still missing. | | "No downside for a healthy person" | Randomized data show it can blunt exercise-training adaptations in older adults. | ## If a clinic offers metformin for longevity Some longevity clinics prescribe off-label metformin. That is not inherently unreasonable — it is a cheap drug with a long safety record, and informed early adoption of a mechanistically interesting intervention is a legitimate choice. Three of the providers we grade will write it: [one lists metformin on the same published shelf as its NAD+ and rapamycin lines](/healthrx-review), [another sells it à la carte with no membership required to order](/agelessrx-review), and a third folds it into an anti-aging program beside NAD+ and glutathione while [publishing no price for any of it](/oak-review). None of those arrangements makes the longevity case any stronger — it just makes the drug easy to get, which is a different thing. But the framing has to be honest. A trustworthy provider will tell you, in plain language, that you would be taking a drug with a **plausible mechanism and suggestive observational data but no completed human longevity RCT**, off-label, and will discuss the exercise-adaptation trade-off if you train. A provider that pitches metformin as a *proven* anti-aging therapy — or that ignores the exercise caveat — has failed our trust test. For how we vet exactly this kind of honesty, see [are longevity clinics worth it?](/longevity-clinics-worth-it) and our independently graded [longevity clinic rankings](/best-longevity-clinics). We cover metformin's frequent partner in these claims — rapamycin — in [rapamycin for longevity: hype vs evidence](/rapamycin-for-longevity), and the two together in [rapamycin & metformin for longevity: the evidence](/rapamycin-metformin-evidence). The supplement world has its own metformin echo — [berberine](/berberine-for-longevity), a plant alkaloid marketed as "nature's metformin" that shares the AMPK mechanism and lowers glucose short-term, but whose lifespan evidence is animal-only. For another metabolic drug class being stretched toward "longevity," see [GLP-1s for healthspan & longevity](/glp1-for-longevity); for a repurposed element with the same mechanism-plus-epidemiology-but-no-outcome-trial pattern (and a narrower safety window), see [microdose lithium for longevity & brain aging](/lithium-microdose-for-longevity). ## Bottom line Metformin has a genuinely interesting anti-aging mechanism, a long safety record, and one famous observational survival signal — and none of that is the same as proof. There is no completed randomized trial showing it extends healthy lifespan in people without diabetes; the landmark trial designed to test that (TAME) hasn't read out; and randomized data show it can blunt the benefits of exercise in older adults. Treat metformin as the field's most *practical* investigational candidate, not as a validated longevity therapy. Honesty over hype: the case is real enough to test, and not yet proven. Sources: https://pubmed.ncbi.nlm.nih.gov/32333835/, https://pubmed.ncbi.nlm.nih.gov/25041462/, https://pubmed.ncbi.nlm.nih.gov/9742977/, https://pubmed.ncbi.nlm.nih.gov/27304507/, https://pubmed.ncbi.nlm.nih.gov/30151729/, https://pubmed.ncbi.nlm.nih.gov/30548390/, https://pubmed.ncbi.nlm.nih.gov/29383869/ --- ### Concierge vs Membership Longevity: What You Actually Get Canonical: https://longevitygraded.com/concierge-vs-membership-longevity Updated: 2026-07-26 Concierge clinics ($8k–$25k/yr) sell diagnostics; membership programs ($99–$300/mo) sell ongoing treatment. What each delivers, and where the money goes. Two providers both call themselves "longevity medicine." One charges $19,000 a year, scans your whole body in an MRI tube, sequences your genome, and assigns you a concierge physician. The other charges $149 a month, mails you a lab kit, and prescribes peptides or hormones over a video call. The price gap is roughly tenfold — and most of what you're actually buying is different in kind, not degree. This is the comparison that matters most once you've decided you want hands-on longevity care rather than a [DTC lab that tests but doesn't treat](/longevity-clinics-vs-lab-memberships). The honest framing: **a concierge clinic sells you diagnostics; a membership program sells you ongoing treatment.** Both can be worth it. Neither has been shown to extend human lifespan. Here is what your money actually buys in each model, and how to decide. ## The two models side by side | | Concierge diagnostic clinic | Membership longevity program | |---|---|---| | Price (2026) | $8,000–$25,000/yr | $99–$300/mo (~$1,200–$3,600/yr) | | Examples | Fountain Life, Human Longevity, Cenegenics | Lifeforce, Next Health, Healthspan, CoreAge Rx | | Core product | Imaging + genomics + MD concierge | Recurring labs + clinician + prescribed therapies | | Delivery | In-person, high-touch | Telehealth + mailed lab kits (mostly) | | What it's best at | Deep one-time diagnostic picture | Longitudinal treatment + retesting | | The honest catch | Over-screening risk; bolt-on unproven therapies | "Healthspan" framing; supplement/vertical-pharmacy upsells | The single distinction to carry through everything below: **does the price buy you a picture, or a plan?** Concierge buys the picture — the most detailed scan of your body a consumer can get. Membership buys the plan — a clinician who prescribes, a retesting cadence, and someone watching the numbers over time. The mistake people make is paying concierge prices expecting a plan, or membership prices expecting concierge-grade imaging. ## What a concierge clinic actually delivers Fountain Life, Human Longevity (Health Nucleus), and Cenegenics define this band. The product is **diagnostics you genuinely cannot get elsewhere as a consumer**: whole-body and brain MRI, coronary CT angiography with AI plaque analysis, whole-genome sequencing, 100+ biomarker panels, and a physician who quarterbacks all of it in person. Fountain Life's flagship runs about $19,500/yr — we grade [what its tiers from roughly $2,995 up to $19,500 a year actually include](/fountain-life-review) separately; Human Longevity's concierge tier reaches roughly $19,000/yr; Cenegenics programs land around $14,000–$21,000/yr once you add the assessment and monthly fees. **What you're really paying for:** the depth and the imaging. For some people, a scan catches something genuinely important early — and that is the legitimate case for the model. **The honest catch — over-screening:** intensive scanning of asymptomatic people is a double-edged sword, and the data are now specific. A 2026 systematic review and meta-analysis of whole-body MRI across more than 9,000 asymptomatic individuals found a confirmed-cancer detection rate of just 1.57%, alongside frequent incidental findings, unstandardized protocols, and no long-term outcome or cost-effectiveness data — concluding the scans "may lead to unnecessary investigations". In plain terms: the imaging that anchors the concierge pitch finds real cancer in about 1 in 64 healthy people, while flagging far more ambiguous spots that drive anxiety, follow-up procedures, and cost. That's not a reason to never scan; it's a reason to treat "early detection" marketing with the skepticism the evidence warrants. The second concierge catch is the bolt-on. Several clinics in this band attach interventions — plasma exchange, EBOO, NAD+, peptides, growth-hormone secretagogues — to the diagnostic core. Treat the imaging and genomics as the real product and the "reverse aging" add-ons as unproven; we trace the evidence gaps in [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What a membership program actually delivers Lifeforce, Next Health, Healthspan, and where CoreAge Rx sits define this band. The model is **recurring**: a structured panel of 40–100 biomarkers, scheduled retesting every few months, a clinician who reviews results and prescribes, and a menu of therapies — hormone optimization, peptides, GLP-1s, NAD+. Lifeforce runs about $149/mo after a $549 diagnostic; Next Health tiers from roughly $99 to $399/mo. The whole thing usually happens over telehealth with mailed lab kits, which is why it costs a fraction of the concierge model. The band's cheapest edge drops the membership layer altogether and prices the protocol instead — [one published figure per protocol, with no membership and no lab gate in front of it](/coreage-rx-review) — which is a different bargain again: less monitoring, and less to cancel. One structural warning applies to every membership in this band, and the clearest example of it comes from outside longevity entirely: [a weight-loss membership whose advertised rate needs both a twelve-month commitment and commercial insurance, and which bills every four weeks so a "year" is thirteen charges](/found-review). Before comparing any two monthly figures, check what a month means and what the term is — a membership is a contract, and the contract is where those answers live. **What you're really paying for:** the thing a DTC lab won't give you and a one-time concierge scan can't — a clinician who can actually prescribe, plus a retesting cadence that lets you see whether an intervention moved your numbers. This is the only band built for longitudinal treatment at an accessible price. **The honest catch — the claims and the conflicts:** this band leans hardest on the word "healthspan," and much of what it prescribes — NAD+, peptides, rapamycin — has mechanistic plausibility but no completed human longevity RCT. Two specific things to vet. First, **vertical-pharmacy conflict:** some membership brands dispense through their own pharmacy, meaning the company recommending a therapy also profits from selling it. Second, **the growth-hormone red flag:** any program marketing GH or GH-secretagogue peptides as anti-aging is ignoring the evidence — a landmark systematic review of growth hormone in healthy older adults found small body-composition changes but no proven functional benefit and significantly more adverse events. A good membership provider distinguishes proven from plausible and discloses its conflicts; that honesty is exactly what we grade in [are longevity clinics worth it?](/longevity-clinics-worth-it), and it's the heaviest-weighted axis in [how we grade longevity providers](/how-we-grade-longevity-providers). ## Where the evidence stands across both models It's worth stating plainly, because the marketing in both bands blurs it: **no intervention sold by either a concierge clinic or a membership program has been shown in a completed randomized trial to extend human lifespan.** The strongest human outcome data in the entire field belongs to GLP-1 receptor agonists — the SELECT trial showed semaglutide cut major cardiovascular events by about 20% in overweight and obese adults without diabetes — and even that proves cardiovascular risk reduction, not slowed aging. The deeper reason both models operate ahead of their proof: the methodology to run true human healthspan trials is only now maturing, so validated aging endpoints barely exist yet. A concierge clinic and a $149/mo membership are, at bottom, both selling care in a field where the outcome trials haven't read out. That shared baseline is liberating, because it collapses the decision to something practical: since neither model can promise a longer life, you're choosing between **the best diagnostic picture** and **the best ongoing treatment relationship** — not between "more proven" and "less proven." ## Which one is for you? - **Choose concierge if** you want the deepest one-time diagnostic picture, money is genuinely no object, and you'll go in clear-eyed about over-screening. Pay for the imaging and genomics; ignore the bolt-on "reverse aging" interventions. - **Choose membership if** you want ongoing, prescribed care with retesting and a clinician you can actually reach — at a price that doesn't require a five-figure budget. This is the band that treats. Vet it for vertical-pharmacy conflict and for honesty about what's proven. - **Consider both, sequenced,** if budget allows: a one-time concierge or DTC diagnostic snapshot for breadth, then a membership program for the longitudinal treatment a scan can't provide. What you should never do is pay concierge prices for membership-grade therapy — the imaging is the only thing the premium reliably buys. A physician-overseen peptide/NAD+/GLP-1 telehealth membership sits squarely in the membership band's value lane: more clinically active than a [DTC lab](/longevity-clinics-vs-lab-memberships), more longevity-focused than an influencer TRT brand, and a fraction of concierge pricing — real oversight without the $20k diagnostic tax. For our independently graded shortlist across every band, with the conflicts and unproven claims flagged, see [our longevity provider rankings](/best-longevity-clinics). For a full breakdown of what every tier costs — from ~$200/yr lab memberships to $20k+ concierge programs — see [how much does a longevity clinic cost?](/longevity-clinic-cost). Sources: https://doi.org/10.1007/s00330-025-11976-5, https://doi.org/10.7326/0003-4819-146-2-200701160-00005, https://doi.org/10.1056/NEJMoa2307563, https://doi.org/10.1097/XCE.0000000000000159 --- ### How We Grade Longevity Providers: Our Methodology Canonical: https://longevitygraded.com/how-we-grade-longevity-providers Updated: 2026-07-26 The five-factor, 14-point rubric behind every letter grade: price transparency, longevity line, oversight, pharmacy identification, and support. Longevity medicine is a field selling care ahead of its own evidence. No intervention marketed by a longevity clinic — not rapamycin, not NAD+, not peptides, not plasma exchange — has been shown in a completed randomized trial to extend human lifespan, in part because the methodology to run true human healthspan trials is only now maturing and validated aging endpoints barely exist yet. That gap is why a ranking site in this niche has to grade differently than one ranking, say, mattresses. Nobody can honestly grade these providers on whether their therapies work, because nobody knows. What can be graded — precisely, repeatably, from the provider's own published pages — is whether the business is straight with you about what it sells and what it costs. This page is the rubric, and it describes the calculation that actually runs. That distinction matters, because until July 2026 this page described a different one: five weighted axes — evidence honesty 30%, clinical oversight 25%, transparency 20%, price-to-value 15%, conflicts of interest 10% — scored A through F. Three of those axes had no stored value for any provider anywhere in our data. The letter on [our provider rankings](/best-longevity-clinics) was never computed from them and could not have been, and the only way to make the page true would have been to invent twenty evidence-honesty scores to justify grades that were produced some other way. We rewrote the page instead. What follows is a smaller claim than the old one, and it has the advantage of being checkable: every input below is a field you can verify on the provider's own site in about two minutes. ## The five factors | Factor | What it measures | Points | |---|---|---| | Price transparency | One all-in figure, visible before you commit, that a month-to-month buyer actually pays — halved where the provider's own terms disclaim it | 4 | | Longevity line | Whether the provider actually sells NAD+, peptides/sermorelin, hormone optimization or longevity diagnostics | 4 | | Clinical oversight | A licensed clinician's review included in the published price, not billed on top or left unstated | 2 | | Pharmacy quality | What the provider publishes about its dispensing pharmacy | 2 | | Human support | Nurses, dietitians, coaching or unlimited clinical messaging inside the price | 2 | Fourteen points in total. Nothing else scores — not the size of the menu, not the brand, not whether we are paid by the provider, and not how much we like the copy. ## Why price transparency is worth four Price is the failure this category commits most often, and it is the one a reader cannot check without handing over a card number. Across every provider we grade, the published headline is frequently not a price at all: it is a twelve-month prepay rate presented as a monthly figure, an introductory first month that steps up at the first refill, an intro-code discount, or a number the site itself supersedes with "final price after clinical review". Several providers in the current ranking advertise a monthly figure that no month-to-month buyer is ever charged. Two make the point without any interpretation from us: [a "no hidden fees" headline that the site's own footnote reveals is a yearly-subscription rate](/gala-health-review), and [a storefront that shows a struck-through list price beside a code-gated one and then says the real amount is set after clinical review](/ageless-review). So the four points go to one thing: a single all-in figure, visible before signup, that a buyer with no commitment actually pays. A number reachable only on a six- or twelve-month prepay scores zero. A number quoted only inside the portal scores zero. **There is one middle rung, added on 8 August 2026, and it changed several grades here.** Some providers publish exactly the figure this factor asks for — ungated, month-to-month, all-in — and then, in their own terms or their own fine print, tell you it may not be what you are charged. *"The final charge to your credit card may fluctuate contingent upon the prescribed medication and the chosen pharmacy."* *"All prescription medications require a valid and complete online consultation prior to approval and final pricing is determined."* *"Price may vary depending on your particular biochemistry and provider recommendation."* Those are three real sentences from three rows here, each sitting underneath a real published price. A figure the seller does not stand behind is materially less transparent than one it honors — and until this rule existed the rubric could not tell the two apart, which meant it actively rewarded publishing a price and then disclaiming it. So the factor now has three rungs: - **Four points** — an all-in figure, published before you commit, that the provider stands behind. - **Two points** — the same figure, published and then disclaimed. Better than publishing nothing, because you have a number to start from and to hold them to. Worse than a price that binds. - **Zero** — no such figure exists before commitment at all. Two guardrails on it, both deliberate. It is **not** triggered by "prices are subject to change" or "we may modify our fees": a forward-looking right to reprice is universal boilerplate, it appears on most rows here, and docking for it would hit the whole ranking and measure nothing. And it is **not** triggered by a caveat about a different product from the one we grade — a marketplace whose terms say the cost of a *prescription* depends on what is prescribed is still publishing a firm price for the *appointment* we rank it on. The rule was applied by sweeping **every row here that publishes a price** — twenty of them, page by page, on the day it was written — rather than to the row that prompted it. Three came back positive, and the dock is taken inside this factor and floored at zero, so a provider that publishes no price cannot be charged twice for the same failure. ## Why the longevity line is worth four This is the factor added in July 2026, and it exists because the rubric could not previously tell a longevity provider from a weight-loss shop with tidy billing. A GLP-1 operator with one clean monthly price, an included consult and a support line could score full marks on every factor and land at the top of a page a reader opened to find NAD+ and peptides. The letter was measuring billing hygiene and calling it longevity. The factor asks one question of the provider's own catalog: does it sell what this page ranks — NAD+, peptides or sermorelin, hormone optimization or TRT, or longevity diagnostics? A published line of the business earns all four points. Something adjacent but none of those — hormone therapy for symptom relief, or a microdosed GLP-1 the provider itself frames as a longevity protocol — earns two. A business selling weight loss and nothing else earns zero. The weight is what makes it bite. A provider with no longevity line can reach at most 10 of 14 even with a flawless price, an included consult, a published 503A standard and included support — and the A band starts at 11. That is deliberate: on a longevity ranking, the top band is closed to a business that does not sell longevity medicine, regardless of how well run it is. It is worth being clear about what this factor is not. It is not a claim that the products in a "longevity line" work. GLP-1 receptor agonists have the strongest human outcome data in the entire field — the SELECT trial cut major cardiovascular events by roughly 20% in overweight and obese adults without diabetes — and NAD+ and sermorelin have nothing remotely comparable behind them. A provider selling only GLP-1s may well be selling the better-evidenced product. It is simply not selling what this site ranks, and we would rather say that plainly than quietly rank it first. We trace the evidence in [GLP-1s for healthspan and longevity](/glp1-for-longevity). This factor is also researched rather than assumed. Values are set by opening the provider's own catalog and reading it. That check has already corrected us once: a provider we had written off as GLP-1-only turned out to run its own anti-aging category with injectable NAD+ at two strengths and injectable sermorelin in it, priced month-to-month. A brand's marketing angle is not its menu. ## Clinical oversight — two points Is a licensed clinician's review included in the price, or is it billed on top, gated behind a membership, or simply not mentioned? Two points for included; nothing otherwise. This is the axis that separates a [program that prescribes from a lab that only measures](/longevity-clinics-vs-lab-memberships), and it is scored on the narrow, checkable question rather than on the quality of the clinician, which no outsider can assess from a website. ## Pharmacy quality — two points, with a middle rung Nearly everything in this category is compounded, so who compounds it matters. The points ladder is about disclosure, and it turns on one question: **what has the provider itself published, and where?** - **Two points** — the provider publishes a 503A claim on a surface it controls: its own site, its help center, or its official press material. Naming the facility is not required, and prominence does not matter — a line in a footer counts exactly as much as a line on a product page. - **One point** — the provider identifies the dispensing pharmacy by name, address and phone, without classifying it. - **Zero** — "partner pharmacies", "a wide network across all 50 states", "compounded in the USA", "a licensed U.S. pharmacy". A category is not an identification. Two things do **not** count as a 503A claim. A third-party review, directory entry or newswire write-up is not a surface the provider controls, however confident it sounds — several providers here are described as 503A operations by other websites and say nothing of the kind themselves. And a general explanation of what Sections 503A and 503B are, or a compliance page listing "503A requirements where applicable" among the regulations a company observes, is not a statement about who fills your prescription. We read the sentence around the keyword before scoring it. The middle rung was added in July 2026 for a specific reason. One provider here printed both of its dispensing pharmacies with street addresses and phone numbers — at that point the most pharmacy-transparent row we graded — and scored zero, because neither was described as a 503A facility. Disclosure that specific has to be worth something. It is worth less than the standard being stated, so it sits in the middle rather than at the top. Several rows have since joined it there, including [one that prints four pharmacies with phone numbers alongside two prescribing physicians and their NPI numbers](/synergy-rx-review) and still never says under which regime any of them compounds. ### We had been applying this inconsistently, and the drift favored us In July 2026 we re-verified every row here against this one test and found we had not been applying it evenly. Our own #1 provider was scored full marks for a 503A line in its help center. Two other providers made the same claim — one in its site-wide footer, one on the product page you actually buy from — and were scored zero. A third provider's FAQ stated that every pharmacy it works with is 503A certified, and nobody had ever looked at it; it had been scored zero for four months and moved up a whole grade when we did. Fourteen rows now qualify for the top rung and nine sit on the middle one, after a board-wide re-audit on 8 August 2026 that found several of our own "no pharmacy named" findings were wrong — read from one document when the answer was on another page of the same site. Applied evenly, the test does not flatter us: our own provider's 503A evidence is among the thinnest that qualifies — a help-center line, naming no facility — while several others publish the claim more plainly than we do. The consequence is that our #1 pick no longer holds the top score on its own; two providers now tie it. We are leaving that alone. A rule rewritten until the favorite is back on top by itself is not a rule, and the whole point of writing this test down is that it has to be able to produce an answer we did not want. Where a provider states the standard but still will not say which pharmacy, its row says so. That distinction is real and it is worth knowing: "a 503A pharmacy, we won't say which" and "here is our pharmacy, at this address" are different kinds of disclosure, and only a handful of providers here do the second. ## Human support — two points Nurses, registered dietitians, coaching or unlimited clinical messaging, included in the price rather than sold as an upgrade. The distinction being drawn is between a program and a shipped vial. Plenty of providers ship a good product with nobody attached to it; that is a legitimate business, and it costs two points here. ## What we deliberately do not score **Required lab work scores neither way.** It is printed on every row because it changes the experience, but a lab-gated program is making a defensible clinical trade-off, not committing a failure. Rewarding or punishing it would smuggle a preference into a rubric that is supposed to measure disclosure. **Evidence honesty, price-to-value and conflicts of interest are not scored either** — the three axes this page used to claim carried 60% of the grade between them. Not because they do not matter; they matter enormously. They are not scored because we have no honest way to reduce them to a per-provider number, and a rubric that assigns a provider a "27 out of 30 on evidence honesty" is publishing a precision it does not have. They live in the written reviews instead, where a judgment can be argued rather than scored: - **Growth-hormone marketing.** A provider selling sermorelin or other GH-secretagogues as anti-aging is running ahead of a landmark systematic review that found small body-composition changes but no proven functional benefit and significantly more adverse events in healthy older adults. That is written into the provider's review; it does not move the letter. - **Biological-age claims.** Epigenetic clocks like GrimAge genuinely predict lifespan and healthspan at the population level, but individual test-retest reliability has been weak enough that a single reading can swing by years on re-measurement — a problem the field has had to engineer around. A provider selling one clock reading as a precise "true age" is overselling the instrument. We unpack that in [do epigenetic clocks actually work](/biological-age-tests). - **Over-screening dressed as thoroughness.** The whole-body MRI anchoring many concierge pitches is a double-edged screen: a 2026 systematic review of more than 9,000 asymptomatic adults found a confirmed-cancer detection rate of just 1.57%, alongside frequent incidental findings, unstandardized protocols, and no long-term outcome or cost-effectiveness data, concluding the scans "may lead to unnecessary investigations". If you want the full proven-versus-hyped map we hold every claim against, it is in [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## From points to a letter Scores convert to letters on two lines that were fixed before any provider was scored: - **A — 11 to 14.** One point above the 10 a provider with no longevity line can reach with everything else perfect. - **B — 8 to 10.** More than half the scale, short of the A floor. - **C — 0 to 7.** Half the scale or less. Neither line is allowed to move to change who sits on which side of it. A rubric adjusted until the partners win is not a rubric. Both cut-points were fixed before any provider was scored and neither has been touched since — including through the July 2026 pharmacy re-verification described above, which moved two providers' letters. When that happened we moved the providers, not the lines. That re-verification is the honest test of whether this holds, so here is what it did. Two rows changed band, and neither change helped us: an affiliate partner rose from B to A, and an **unpaid** provider we had scored C for four months rose to B once we actually read its FAQ. One partner gained points and stayed C regardless — the standard it publishes is real, but a hedged "we use both 503A and 503B pharmacies, we won't say which" does not fix a program that will not publish the price you actually pay. The floor is real, and it lands on paid providers. Every C grade in the current ranking belongs to an affiliate partner: providers that publish no true month-to-month price, or do not state whether a consult is included. We are paid by all of them and they are graded C anyway, because the calculation is not shown who pays us. ## Grading and ordering are two different decisions This is the part most ranking sites blur, so we will be blunt about it. **The letter is computed** from the five factors above and from nothing else. The function that computes it is not given the provider's rank, is not given whether the provider is a paid partner, and is not given whether it is our featured pick — those fields are not in its inputs, and an automated test flips every commercial flag on every row and fails the build if any letter moves. **The order is not computed the same way.** Affiliate partners are listed first on the rankings page, ahead of the providers we hold no commercial relationship with. That is a placement, we are paid for it, and we [disclose](/disclosure) it — the same separation of commercial placement from editorial judgment that our [editorial policy](/editorial-policy) commits us to, and that [who we are and how this site is funded](/about) sets out in full. Within each block — partners, then everyone else — rows are ordered by their rubric score, highest first. So a paid row can and does sit above a better-graded unpaid one. The position tells you who pays us. The letter tells you what the provider publishes. If the two ever seem to agree suspiciously well, the letters are the thing to check, because they are the thing we cannot move. We re-audit graded providers periodically, because prices, protocols and product lines all change — and when a headline price turns out to be a prepay rate, or an anti-aging category quietly appears on a weight-loss site, the score follows the field rather than the other way round. For the rankings this methodology produces, see [our graded longevity provider shortlist](/best-longevity-clinics); for the full write-up behind every grade, browse [our provider reviews](/reviews); and for whether any of it is worth buying, [are longevity clinics worth it](/longevity-clinics-worth-it). Sources: https://doi.org/10.1097/XCE.0000000000000159, https://doi.org/10.1056/NEJMoa2307563, https://doi.org/10.7326/0003-4819-146-2-200701160-00005, https://doi.org/10.18632/aging.101684, https://doi.org/10.1038/s43587-022-00248-2, https://doi.org/10.1007/s00330-025-11976-5 --- ### Best Longevity Supplements, Rated by Evidence (2026) Canonical: https://longevitygraded.com/best-longevity-supplements Updated: 2026-07-26 We grade the popular longevity supplements — NMN, NR, spermidine, resveratrol, CoQ10, omega-3, vitamin D, fisetin, GlyNAC — on human evidence, not hype. Search “longevity supplements” and you will find confident lists promising to slow aging, reverse it, or add years to your life. Almost none of that confidence is earned. So before we grade anything, here is the frame we hold every product to — and it is an uncomfortable one for the supplement industry. ## The honest starting point: zero human-lifespan RCTs exist There is not a single randomized controlled trial showing that any supplement makes humans live longer. Not one. The reason is structural, not lazy: a trial that randomizes people to a pill and follows them until enough have died to detect a lifespan difference would take decades and tens of thousands of participants, and nobody has run it. What we have instead is three weaker tiers of evidence, and the entire longevity-supplement market blurs them together on purpose: - **Mechanism** — “this molecule activates autophagy / sirtuins / AMPK in a dish.” Interesting, proves nothing about you. - **Animal lifespan data** — “it extended lifespan in mice/worms/flies.” Genuinely meaningful for biology, but most compounds that extend rodent lifespan do nothing measurable in humans, and dosing rarely translates. - **Human biomarker or outcome data** — “it raised NAD+,” or, much more rarely, “it reduced a hard clinical event.” This is the only tier that should move your decision, and it is the thinnest. The biology underneath the hype is real: aging has well-described hallmarks — things like genomic instability, mitochondrial dysfunction, cellular senescence, and declining nutrient-sensing — and supplements are pitched as nudging one or more of them. But “plausibly touches a hallmark of aging” is a mechanism claim, not proof that swallowing it helps a person age better. Throughout this guide we keep mechanism and proof in separate boxes. We also keep one regulatory fact in view: these are **supplements, not drugs** — they are not FDA-approved to treat or prevent any disease, manufacturing quality varies, and the label claims are largely unpoliced. For the bigger picture of what is and isn't established in this field, see our pillar on [what longevity medicine can actually prove](/longevity-medicine-evidence). ### How we grade Each supplement below gets a tier based **only on human evidence**: - 🟢 **Reasonable** — there is real human outcome or strong biomarker evidence, usually in a specific group (e.g. correcting a deficiency, or a hard-endpoint trial). Not “anti-aging proven,” but a defensible reason to take it. - 🟡 **Speculative** — mechanism plus animal data plus thin or surrogate-only human data. Might do something; the longevity claim is unproven. - 🔴 **Hype-led** — the marketing vastly outruns the human evidence, which is mostly preclinical or null. No grade here is influenced by any commercial relationship. This is the same evidence-first rubric we apply to clinics in [how we grade longevity providers](/how-we-grade-longevity-providers). ## NMN and NR (NAD+ boosters) — 🟡 Speculative NAD+ is a coenzyme central to energy metabolism and DNA repair, and it falls with age — which is the entire mechanistic case for the NAD+ precursors **nicotinamide mononucleotide (NMN)** and **nicotinamide riboside (NR)**. The mechanism is legitimate and the in-vivo preclinical evidence for NAD+ restoration is among the better-developed in the field. Here is the gap. In humans, the strongest finding is simply that these compounds **raise NAD+ levels**. Nicotinamide riboside is orally bioavailable and reliably elevates blood NAD+ in people; a controlled trial in healthy middle-aged and older adults confirmed chronic NR is well-tolerated and boosts NAD+. NMN behaves similarly — a randomized trial in healthy middle-aged adults found it safely raised NAD+. What none of these trials show is a downstream **outcome**: not longer life, not reversed aging, not even consistent improvements in strength, metabolism, or biological age. Raising a biomarker is a prerequisite for benefit, not benefit itself — the same trap that makes a celebrity's improved lab charts unconvincing, as we explain in [our Bryan Johnson Blueprint review](/bryan-johnson-blueprint-review). We go deeper into where the NAD+ story holds and breaks in [NAD+ for longevity: what the trials actually show](/nad-for-longevity) and [do NAD+ peptides work?](/do-nad-peptides-work). Verdict: plausible, well-tolerated, NAD+-raising — but the longevity payoff is unproven. One thing to know before you upgrade: the same coenzyme is sold by prescription too, and [a prescription NAD+ tablet is priced beside the injection](/rxspan-md-review) at several times what a jar of NMN costs — against the same human evidence you just read. Which of those routes has actually been tested is the subject of [NAD+ injections vs IV vs oral](/nad-injections-vs-iv-vs-oral), and the choice between the two oral precursors is [NMN vs NR](/nmn-vs-nr). ## Spermidine — 🟡 Speculative Spermidine is a polyamine (found in wheat germ, aged cheese, soy) that triggers **autophagy**, the cellular-recycling process whose decline is a hallmark of aging — making it one of the more biologically interesting longevity candidates. The human signal is two-part and still thin. Observationally, higher dietary spermidine intake tracked with **lower all-cause mortality** in a prospective population study — a real association, but association, confounded by overall diet. Interventionally, a small randomized trial in older adults with subjective cognitive decline tested spermidine supplementation; the pilot hinted at a memory signal, but the larger, better-powered follow-up (SmartAge) did **not** show a clear cognitive benefit over placebo. So spermidine has a stronger mechanism than most and a suggestive epidemiology, but its best controlled human trial came back essentially negative on the endpoint that mattered. Promising biology, unproven in people. We unpack the full case — autophagy mechanism, animal data, and the negative SmartAge trial — in [spermidine for longevity: what the evidence shows](/spermidine-for-longevity). The same mechanism-versus-outcome gap explains why a single splashy mouse study isn't proof: see [taurine for longevity, after the 2023 Science study and its 2025 rebuttal](/taurine-for-longevity), or [alpha-ketoglutarate's viral "8 years younger" claim](/alpha-ketoglutarate-for-longevity), which rests on a placebo-free 42-person study, or [sulforaphane for longevity](/sulforaphane-for-longevity), where a strong Nrf2 mechanism and a 2025 worm lifespan result still stop several species short of human proof. ## Resveratrol — 🔴 Hype-led Resveratrol — the red-wine polyphenol — launched the modern sirtuin-activator hype cycle, and it remains the clearest example of mechanism outrunning humans. It extends lifespan in some lower organisms and improves metabolism in obese mice, but human trials have been consistently underwhelming. Controlled human data show, at best, **modest biomarker shifts** — small effects on inflammatory and oxidative-stress markers in type-2 diabetes, for instance — and isolated positive findings like improved bone mineral density in postmenopausal women in the RESHAW trial. Those are narrow, surrogate, mixed results, not evidence of slowed aging. Bioavailability is also genuinely poor; oral resveratrol is heavily metabolized before it reaches tissues. For a supplement marketed as a longevity cornerstone, the human ledger is thin and inconsistent — the marketing is the strongest thing about it. We go deeper into why the case collapses — the SIRT1 mechanism that turned out to be an assay artifact, and the 2025 primate trial that found no lifespan benefit — in [does resveratrol actually work for longevity?](/resveratrol-for-longevity) ## CoQ10 / ubiquinol — 🟢 Reasonable (in the right person) Coenzyme Q10 is not really an anti-aging compound — it is a mitochondrial electron-transport cofactor — but it earns a green tier because it has something almost nothing else here has: a **hard-endpoint randomized trial**. In Q-SYMBIO, CoQ10 added to standard therapy in chronic heart-failure patients reduced major adverse cardiovascular events and cardiovascular mortality versus placebo. That is a real clinical outcome in a defined sick population — not a biomarker, not a mouse. The honest caveats: the benefit is established in heart failure, not in healthy people chasing longevity, and CoQ10 has not been shown to extend lifespan in anyone. As targeted therapy for the right patient (often alongside statins, which lower CoQ10), it's defensible; as a general longevity pill it is unproven. We unpack the heart-failure and KiSel-10 cardiovascular-mortality data — and the ubiquinol-versus-ubiquinone debate — in our full review of [CoQ10 and ubiquinol for aging](/coq10-for-longevity). ## Omega-3 (EPA/DHA) — 🟢 Reasonable (conditionally) Marine omega-3s have the largest randomized human evidence base of anything on this list — which is exactly why the picture is more sober than the supplement aisle suggests. In the large VITAL primary-prevention trial, a standard 1 g/day fish-oil dose did **not** significantly cut the primary cardiovascular or cancer endpoints in the general population. But a high-dose, prescription-strength formulation (icosapent ethyl, ~4 g/day) **did** reduce cardiovascular events in people with elevated triglycerides on statins in REDUCE-IT. The lesson is dose- and population-specific: low-dose fish oil for healthy people is not a proven longevity lever, while high-dose EPA is a genuine cardiovascular intervention for a specific high-risk group. Green tier, with the conditions stated plainly. ## Vitamin D — 🟢 Reasonable (to correct deficiency) Vitamin D is the cleanest example of the deficiency-correction principle. In VITAL — over 25,000 adults randomized — supplemental vitamin D did **not** reduce cancer or cardiovascular events in a largely replete general population. So “vitamin D extends life” is not supported. What *is* supported is correcting a genuine deficiency: low vitamin D is common, measurable on a blood test, and tied to bone and muscle health. That makes it the rare supplement where the right move is testable — supplement if your level is low, don't assume megadoses buy longevity if it isn't. Reasonable as deficiency correction; not as a blanket longevity drug. A proper [longevity biomarker panel](/longevity-biomarker-panels) will actually measure your level rather than guess. ## Fisetin — 🔴 Hype-led (for now) Fisetin is a flavonoid (strawberries, apples) marketed as a **senolytic** — a compound that clears senescent “zombie” cells, one of the most exciting aging mechanisms. The mouse data are genuinely striking: fisetin reduced senescent-cell burden and extended health- and lifespan in aged mice. But that is a **mouse** result, and the human senolytic field is still at the pilot-trial stage with no completed, published trial showing fisetin slows aging or improves hard outcomes in people. The dosing regimens sold online (“hit days”) are extrapolated from animal protocols. The mechanism is one of the most promising in longevity science; the human evidence does not yet exist to justify the marketing. Red tier today — a candidate worth watching, not a proven supplement. We unpack the full case — the mouse screens, the "hit-and-run" dosing idea, and why the encouraging human senolytic trials used a different drug — in [fisetin as a senolytic: what the evidence shows](/fisetin-senolytic-evidence), and weigh it against the other speculative-tier mechanism story in [spermidine vs fisetin](/spermidine-vs-fisetin). ## Glycine + NAC (GlyNAC) — 🟡 Speculative GlyNAC combines glycine and N-acetylcysteine to rebuild **glutathione**, the body's master antioxidant, which declines with age — and whether the second amino acid earns its place is the question we settle in [glycine vs GlyNAC](/glycine-vs-glynac). Unlike most entries here, it has a real (if small) randomized human trial: in older adults, GlyNAC supplementation restored glutathione and improved several aging-associated measures — oxidative stress, mitochondrial markers, inflammation, and some functional readouts — versus placebo. That's a more encouraging human signal than NMN or resveratrol can show. The caveats keeping it at yellow: the trials are small, single-group, and not yet replicated at scale, and they measure biomarkers and short-term function, not lifespan. A promising human-data story that needs larger confirmation before the longevity claim is earned. We unpack the full case — what the Baylor trials measured, and why "reverses aging" overstates them — in [GlyNAC for aging: what the trials actually show](/glynac-for-longevity). ## The scorecard | Supplement | Mechanism (the hype) | Best human evidence | Tier | |---|---|---|---| | Omega-3 (high-dose EPA) | Anti-inflammatory, lipid-lowering | Reduced CV events in high-risk group (REDUCE-IT) | 🟢 conditional | | Vitamin D | Hormone/bone/immune | No mortality benefit if replete; corrects deficiency | 🟢 for deficiency | | CoQ10 / ubiquinol | Mitochondrial cofactor | Reduced CV mortality in heart failure (Q-SYMBIO) | 🟢 in patients | | NMN / NR | Restore declining NAD+ | Raises NAD+; no outcome data | 🟡 speculative | | Spermidine | Induces autophagy | Mortality association; null cognitive RCT | 🟡 speculative | | GlyNAC | Rebuilds glutathione | Small RCT improved aging biomarkers | 🟡 speculative | | Resveratrol | Sirtuin activator | Modest/mixed biomarker shifts only | 🔴 hype-led | | Fisetin | Senolytic (clears senescent cells) | Mouse-only; human trials pending | 🔴 hype-led | ## What this means for your shelf The pattern is clear once you separate mechanism from proof. The supplements that earn green tiers aren't the futuristic “reverse aging” molecules — they're the boring, measurable ones: correct a real deficiency, or use a high-dose intervention in a defined high-risk group. The exciting compounds (NMN, spermidine, resveratrol, fisetin) sit in yellow and red precisely because their human outcome data don't yet exist, however good the biology looks. The standout the longevity aisle underrates is the boring one with the most randomized human evidence: [creatine for aging](/creatine-for-aging), which adds muscle and strength in older adults when paired with resistance training. The mirror image is the category's best-seller, [collagen for aging](/collagen-for-longevity): real but conflicted skin and joint signals from largely industry-funded trials, digested to amino acids before it reaches your skin, and no longevity data at all. None of this is medical advice, and none of these is a substitute for the things with actual lifespan evidence — not smoking, sleep, exercise, and treating blood pressure and metabolic disease. If you'd rather buy one convenient multi-pathway formula than a cabinet of single jars, the most prominent example is [NOVOS Core](/novos-review) — a thoughtfully designed twelve-ingredient blend whose formulation logic is real but whose proven longevity benefit (graded D) is not. One supplement blurs the supplement-versus-drug line more than any here: [berberine](/berberine-for-longevity), pitched as “nature's metformin,” which shares metformin's AMPK mechanism and lowers glucose and cholesterol short-term — but has lifespan data only in animals. If you're weighing supplements against prescription longevity approaches, we cover the off-label drugs with the same honesty: [metformin for longevity](/metformin-for-longevity), [rapamycin for longevity](/rapamycin-for-longevity), and [peptides for longevity](/peptides-for-longevity). Read those checkout pages as carefully as you read a label — on some storefronts, including [one where every advertised longevity price turns out to be a limited-time intro code](/ageless-review), the amount set after clinical review is not the number that drew you in. And if you'd rather have real physician oversight than self-experiment with a cabinet of capsules, our [hub of graded longevity clinics and programs](/best-longevity-clinics) ranks who actually provides it. Sources: https://pubmed.ncbi.nlm.nih.gov/36599349/, https://pubmed.ncbi.nlm.nih.gov/29514064/, https://pubmed.ncbi.nlm.nih.gov/27721479/, https://pubmed.ncbi.nlm.nih.gov/29599478/, https://pubmed.ncbi.nlm.nih.gov/36482258/, https://pubmed.ncbi.nlm.nih.gov/30388439/, https://pubmed.ncbi.nlm.nih.gov/35690844/, https://pubmed.ncbi.nlm.nih.gov/29955838/, https://pubmed.ncbi.nlm.nih.gov/32564438/, https://pubmed.ncbi.nlm.nih.gov/39872318/, https://pubmed.ncbi.nlm.nih.gov/25282031/, https://pubmed.ncbi.nlm.nih.gov/30415637/, https://pubmed.ncbi.nlm.nih.gov/30415628/, https://pubmed.ncbi.nlm.nih.gov/30415629/, https://pubmed.ncbi.nlm.nih.gov/30279143/, https://pubmed.ncbi.nlm.nih.gov/35975308/ --- ### Longevity Doctor: What They Do, What They Cost, How to Vet One Canonical: https://longevitygraded.com/what-is-a-longevity-doctor Updated: 2026-07-26 A longevity doctor blends preventive medicine, biomarker testing, and lifestyle coaching. What they really do, credentials to check, and who needs one. A "longevity doctor" — sometimes called a geromedicine, healthspan, or "precision aging" physician — is a clinician who frames care around delaying age-related decline rather than only treating disease once it shows up. In practice that usually means intensive preventive medicine, a heavy dose of biomarker testing, and structured lifestyle coaching, often delivered through a concierge or membership model. The label sounds futuristic, but most of what a good longevity doctor does is ordinary preventive care done more thoroughly. The hype is in the framing, not the toolkit. This guide explains the realistic scope of the role, the credentials worth checking, what these physicians actually do versus what marketing implies, and — honestly — who benefits from one versus who is better served by a good primary-care physician and a few direct-to-consumer lab tests. For the full evidence map of the interventions these clinics use, start with our pillar, [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## "Longevity medicine" is a real but young and unregulated field First, the honest framing. There is no medical board, residency, or protected title for "longevity doctor." It is not a recognized specialty the way cardiology or endocrinology is. Anyone with a medical license — and, in some clinics, practitioners who are not physicians at all — can market themselves under the banner. The underlying science is legitimate and active. The "geroscience" hypothesis holds that aging itself is a modifiable driver of most chronic disease, so slowing biological aging could compress many illnesses at once. That idea has matured into an emerging clinical sub-field variously called gerotherapeutics or precision geromedicine, with academic groups building structured care models around it. So the field is real. What it is not — yet — is mature, standardized, or backed by evidence that any of its signature interventions extend human lifespan. Most longevity medicine is measured in *biomarkers* (a better cholesterol panel, a "younger" epigenetic clock, improved VO2 max), not in proven added years of life. Keep that distinction front of mind for the rest of this article. (The most-read articulation of this prevention-first, risk-factor-focused approach is Peter Attia's "Medicine 3.0," which we evaluate in our [review of *Outlive*](/outlive-peter-attia-review).) ## What a longevity doctor actually does Strip away the branding and the day-to-day work clusters into four buckets. **1. Intensive preventive medicine.** This is the core, and it is the most defensible part. A longevity-oriented physician spends far more time on cardiovascular risk, metabolic health, cancer screening, blood pressure, and sleep than a rushed 15-minute primary-care visit allows. Much of the genuine value here is simply *more attention to the basics that already have strong evidence*. Continuity of care alone — seeing the same doctor over time — is associated with lower mortality across a large body of studies, which is part of why a longstanding relationship with any good physician matters more than a fancy title. **2. Biomarker and lab testing.** Longevity doctors order broad panels: advanced lipids (ApoB, Lp(a)), inflammatory markers, fasting insulin and HbA1c, hormones, micronutrients, and increasingly "biological age" tests such as epigenetic clocks. Some of this is high-value (ApoB and Lp(a) genuinely refine cardiovascular risk). Some of it is vanity testing with no validated action attached. We sort the useful markers from the noise in [what longevity biomarker panels actually test](/longevity-biomarker-panels) and dig into the aging-clock question in [biological age tests: do they actually work?](/biological-age-tests). **3. Lifestyle prescription and coaching.** Exercise programming (especially zone-2 cardio and resistance training), nutrition, sleep, and stress. This is where the strongest longevity evidence lives, and the best longevity practices spend real time here rather than defaulting to supplements or drips. **4. Off-label and "optimization" interventions.** The contested part: rapamycin, metformin, NAD+ infusions, peptides, hormone "optimization," and supplement stacks. These are where marketing outruns evidence fastest. We cover them honestly in [rapamycin for longevity](/rapamycin-for-longevity), [metformin for longevity](/metformin-for-longevity), [NAD+ for longevity](/nad-for-longevity), and [peptides for longevity](/peptides-for-longevity) — the short version is that human longevity outcomes are absent for all of them. ## Credentials to look for (and red flags) Because the title is unregulated, vetting falls on you. A reasonable checklist: - **A licensed MD or DO is overseeing care** — not just a coach, nurse, or "health optimization specialist" operating without physician supervision. - **You know whether you will ever speak to them.** Plenty of prescribing here is asynchronous: you complete an intake, a licensed physician reviews it, and a vial arrives. That is legal and often adequate, but it is not a consultation — with [the cheapest published sermorelin protocol we grade, review is asynchronous and in many states you never speak to the prescriber](/strut-health-review), which is a trade-off worth making knowingly rather than discovering. - **A real underlying specialty.** Many of the strongest longevity physicians trained in internal medicine, family medicine, endocrinology, cardiology, or geriatrics. That base specialty tells you they can manage actual medical risk, not just sell panels. - **Evidence honesty in their own marketing.** A trustworthy longevity doctor will tell you that rapamycin, NAD+, and epigenetic clocks are unproven for lifespan and will not promise to "reverse your age." Promises of reversing aging are the single clearest red flag. - **No vertical pharmacy conflict.** Be cautious when the same entity that recommends a peptide, hormone, or supplement also profits from selling it to you. That conflict quietly shapes recommendations. - **They measure and act on validated markers** — and don't lean on "biological age" scores that even the field's own researchers say aren't ready for individual clinical decisions. A useful gut check: does the clinic sound more like a thorough preventive-medicine practice, or more like a supplement-and-IV storefront with a doctor attached? Our own scoring rubric weighs exactly these factors — see [how we grade longevity providers](/how-we-grade-longevity-providers). ## What a longevity doctor costs There is no single answer, because "longevity doctor" covers at least four different products with two orders of magnitude between them. These are the bands we grade against, and the catch beside each is the part that decides whether the price is the price: | What you are buying | Typical 2026 price | The catch | |---|---|---| | DTC lab membership | ~$199–$365/yr | Tests you, largely does not treat you | | Single-product Rx telehealth | ~$99–$235/mo | One therapy line only | | Membership longevity program | ~$99–$300/mo (~$1,200–$3,600/yr) | Labs and retesting may be extra | | Concierge diagnostic clinic | ~$3,000–$25,000+/yr | Over-screening risk, and findings you must then chase | Three things reliably move the real number above the advertised one: **the advertised rate is often a twelve-month prepay** with the month-to-month price in an asterisk; **bloodwork is frequently billed separately** from the membership that exists to interpret it; and **the clinician review may not be included** in a medication price even when the same company collects both. The band-by-band breakdown, with named providers, is in [what longevity care actually costs](/longevity-clinic-cost). ## The evidence reality: biomarkers, not proven extra years This is the part the marketing skips. Across longevity medicine's signature interventions, the human data is almost entirely about *intermediate biomarkers* — not lived outcomes. The Biomarkers of Aging Consortium, the academic group trying to standardize this field, has itself published the unresolved challenges in translating aging biomarkers into anything clinically actionable: they are not yet validated as surrogates for how long or how well you will actually live. The intravenous side of the industry fares worst. A critical review of IV "longevity therapy" — the NAD+ drips, high-dose vitamin and glutathione infusions common at these clinics — found the supporting evidence comes mostly from disease-specific or aesthetic contexts rather than longevity, that placebo-controlled trials are scarce and conflicting, and that validated aging biomarkers are rarely even measured. We unpack that in [are longevity clinics worth it?](/longevity-clinics-worth-it). There's also a subtler trap worth naming: *more testing and more intervention is not automatically more health.* Even cancer screening — far better-evidenced than anything a longevity clinic sells — shows only modest, test-specific gains in life expectancy when measured rigorously across randomized trials. And the broader "too much medicine" literature catalogs the real harms of over-testing and over-treating well people: false alarms, overdiagnosis, cascade testing, anxiety, and cost — exactly the trade-off we weigh for the multi-cancer blood test these clinics increasingly upsell in our [Galleri multi-cancer test review](/galleri-test-review). A longevity practice that orders dozens of tests is not obviously doing you a favor; the value depends entirely on whether the results change something that matters. ## Do you actually need one? Who benefits vs DIY Here's the candid cost-benefit, since these services run from roughly $99–300/month memberships up to $8,000–25,000/year concierge programs. **You may genuinely benefit if you:** - Have a strong family history of early cardiovascular disease, diabetes, or cancer and want aggressive, evidence-based prevention with a physician who has time. - Have several interacting risk factors (metabolic, cardiovascular, hormonal) that a rushed primary-care visit keeps under-managing. - Will actually act on coaching — and value having one accountable physician coordinating it. Coaching is also the line item most often quietly billed on top, so check whether it is inside the figure: [our top-ranked provider includes 1:1 consults with nurses and registered dietitians in the protocol price](/coreage-rx-review) rather than selling them as an upgrade, and that is not the norm. **You're probably better off with a good PCP plus DIY labs if you:** - Are generally healthy and mainly curious about your numbers. A solid primary-care physician — ideally one you see consistently, which is the choice with the best mortality evidence — plus a few targeted direct-to-consumer tests (ApoB, Lp(a), HbA1c) gets you most of the real value for a fraction of the price. - Are mostly being sold "optimization" — supplements, peptides, hormone tweaks, IV drips. That's the priciest, least-proven layer, and you can skip it without skipping anything evidence-based. It's worth knowing the functional-medicine model that many longevity clinics borrow from has *some* supportive data: a large Cleveland Clinic analysis found patients in a functional-medicine model reported better health-related quality of life than those in standard primary care. That's a real, encouraging signal — but it measured self-reported quality of life, not lifespan or hard clinical outcomes, which is exactly the recurring caveat of this entire field. ## The bottom line A longevity doctor is, at best, a preventive-medicine physician who gives you more time, more thorough testing, and structured lifestyle coaching — genuinely valuable if you'll use it and if the doctor stays honest about evidence. At worst, it's a premium storefront for unproven drips, peptides, and "anti-aging" promises dressed up as medicine. The field is young, unregulated, and overwhelmingly measured in biomarkers rather than proven added years. Vet for a licensed physician with a real specialty, evidence honesty, and no pharmacy conflict — and remember that for most healthy people, a consistent PCP plus a handful of DIY labs delivers most of the proven benefit. When you're ready to compare specific providers on price transparency, whether they sell a real longevity line at all, clinical oversight, pharmacy identification, and included support, see our graded hub: [the best longevity clinics](/best-longevity-clinics). And to hold whatever a clinic proposes to the published trials, work through the write-ups in our [research index](/research), where each piece shows its primary-source count up front. Sources: https://pubmed.ncbi.nlm.nih.gov/25417146/, https://pubmed.ncbi.nlm.nih.gov/41957871/, https://pubmed.ncbi.nlm.nih.gov/40335817/, https://pubmed.ncbi.nlm.nih.gov/29959146/, https://pubmed.ncbi.nlm.nih.gov/31651966/, https://pubmed.ncbi.nlm.nih.gov/39285015/, https://pubmed.ncbi.nlm.nih.gov/41915584/, https://pubmed.ncbi.nlm.nih.gov/37639247/, https://pubmed.ncbi.nlm.nih.gov/41047163/ --- ### Spermidine for Longevity: What the Evidence Shows Canonical: https://longevitygraded.com/spermidine-for-longevity Updated: 2026-06-05 Spermidine induces autophagy and dietary intake tracks with lower mortality — but the best human trial was negative. An honest, evidence-graded review. Spermidine is one of the few longevity supplements with a mechanism interesting enough to take seriously and an epidemiological signal strong enough to be worth explaining. It is also a textbook case of the gap this site keeps returning to: compelling biology and suggestive population data on one side, and a thin, partly-negative human trial record on the other. This page walks through both halves honestly, separates what is proven in people from what is shown only in cells and animals, and tells you where spermidine actually sits. For the wider map of what's earned its place versus what's hype, start with our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What spermidine is Spermidine is a polyamine — a small, naturally occurring molecule your own cells make and that you also eat. It is abundant in foods like wheat germ, aged cheese, soybeans (especially natto), mushrooms, and legumes, which is why dietary intake varies a lot between populations and diets. As a supplement it is sold mainly as a concentrated **wheat-germ extract** standardized to a spermidine content, and less commonly as **synthetic spermidine** (often as spermidine trihydrochloride). That sourcing distinction matters for honesty: most of the human research — including the supplementation trials below — used wheat-germ-derived spermidine, not isolated synthetic spermidine, so claims read across from one to the other only by assumption. ## The mechanism: autophagy, a genuine hallmark of aging The reason spermidine is taken seriously is **autophagy** — the cell's recycling and quality-control process that clears damaged proteins and organelles. Autophagy declines with age, and loss of proteostasis and impaired macroautophagy are cataloged among the formal hallmarks of aging. Spermidine's signature action is that it induces autophagy: the foundational work showed that adding spermidine extends lifespan in yeast, worms, flies, and human immune cells, and that this longevity effect depends on autophagy genes — switch autophagy off and the benefit disappears. That is an unusually clean mechanistic story for a longevity supplement: a defined hallmark, a molecule that demonstrably reverses it in the lab, and a lifespan effect that goes away when you block the proposed mechanism. The authoritative review of the field frames spermidine as a caloric-restriction mimetic acting largely through autophagy. But a hallmark-targeting mechanism is a hypothesis about humans, not a result in humans — and that is exactly where most longevity supplements, spermidine included, run out of road. ## The animal evidence: real, and genuinely striking In animals the data go beyond simple lifespan curves. Oral spermidine supplementation extended lifespan in mice and, notably, protected the aging heart: it improved diastolic function, reduced cardiac hypertrophy, and lowered blood pressure in rodent models, with the cardioprotection again depending on autophagy. Follow-up work showed dietary spermidine lowers elevated blood pressure and reduces cardiovascular damage in salt-sensitive hypertensive rats. This is a stronger preclinical package than most supplements on a longevity list can show — cardiovascular, mechanistically coherent, and reproduced. It is also still animal data. Mouse hearts are not human hearts, and rodent lifespan studies have repeatedly failed to translate to people. Treat this section as the reason to keep studying spermidine, not as proof it works in you. ## The human epidemiology: an association, with the usual caveat The most-cited human evidence for spermidine is observational. In the prospective, population-based Bruneck cohort, higher dietary spermidine intake was associated with **lower all-cause mortality** over roughly two decades of follow-up — and the size of the association was large enough that the authors translated it into an estimated multi-year difference in life expectancy across intake tertiles. A separate prospective Japanese cohort (the Takayama study) similarly found that higher dietary polyamine intake tracked with lower all-cause and cardiovascular mortality. Two independent populations pointing the same way is more than a fluke. It is also not proof. These are dietary-intake associations, and spermidine-rich foods (whole grains, legumes, vegetables, fermented foods) are markers of an overall healthier dietary pattern. No matter how carefully a study adjusts, you cannot fully separate "ate more spermidine" from "ate a better diet and probably lived a healthier life overall." Observational nutrition data of this kind is hypothesis-generating; it tells you spermidine intake is *worth testing in a trial*, not that supplementing it lengthens life. That is precisely why the supplementation trials matter more than the headlines. ## The human trial evidence: thin, and the best one was negative Here the honest story diverges sharply from the marketing. Human supplementation trials of spermidine are few, small, and focused almost entirely on **cognition** — not on aging, lifespan, or hard health outcomes. First, a safety and tolerability study established that wheat-germ-derived spermidine supplementation was well tolerated over three months in older adults with subjective cognitive decline, with no relevant safety signals — an important but modest result: it shows the supplement is tolerable, not that it does anything. A small pilot RCT in the same population then hinted at a memory benefit, generating the optimism that fueled spermidine's popularity. Then came the proper test. The SmartAge trial was a 12-month, randomized, double-blind, placebo-controlled study of spermidine supplementation in older adults with subjective cognitive decline — the larger, better-powered follow-up the pilot called for. Its result was clear and disappointing for the hypothesis: spermidine did **not** improve memory or cognition versus placebo on the primary endpoint. The best controlled human trial of spermidine to date came back essentially null on the outcome it was designed to detect. So the human picture is: tolerable, suggestive in a small pilot, and negative in the one adequately-powered randomized trial. That is a weaker human record than the mechanism and epidemiology would lead you to expect. ## Zero lifespan or healthspan RCTs in humans It bears stating plainly, because the marketing rarely does: there is **no randomized controlled trial showing spermidine extends human lifespan or healthspan**, and there is essentially no chance one exists soon — a lifespan RCT in people would take decades and is not how any longevity supplement on the market has been validated. The lifespan data are from yeast, worms, flies, and mice. The human outcome data are an intake-mortality *association*. The human *trial* data are cognitive endpoints, and they are mixed-to-negative. None of that adds up to "proven to make people live longer." This is the same separation we apply across the field — see our [longevity biomarker panels](/longevity-biomarker-panels) breakdown for how easily mechanism gets sold as outcome. ## Supplement, not drug — and what that means Spermidine is sold as a dietary supplement, not an FDA-approved drug for any condition. It is not approved or proven to treat, prevent, or slow any disease or aging itself. As a supplement it sits outside the evidentiary bar that drugs must clear — no required efficacy trials, no approved indication, label content the manufacturer controls. On the reassuring side, it is a molecule humans eat every day and that the body makes endogenously, and the controlled trial that looked specifically at safety found wheat-germ spermidine well tolerated over months. The honest framing is that spermidine's *safety* at the studied doses looks reasonable, while its *efficacy* for longevity in humans is unproven — two very different things that supplement marketing routinely blurs. ## How spermidine compares to the other longevity supplements Spermidine is not alone in this pattern. Across the popular longevity stack — NAD+ precursors, resveratrol, fisetin, spermidine — the story is consistently "strong mechanism, suggestive animal data, thin or negative human outcomes." The closest of those calls is [spermidine vs fisetin](/spermidine-vs-fisetin), where an autophagy inducer and a senolytic get judged on the same evidence bar. We grade the whole field head-to-head in our [best longevity supplements, rated by evidence](/best-longevity-supplements) roundup, where spermidine lands in the speculative tier for exactly the reasons above: better mechanism than most, real epidemiology, but a null flagship trial. For the most-hyped neighbor, see [NAD+ for longevity: what the trials actually show](/nad-for-longevity) — the parallel is close, with reliable biomarker movement but missing clinical outcomes. And for a cautionary tale about a single headline study, see [taurine for longevity](/taurine-for-longevity), where a famous 2023 Science paper was undercut by its own 2025 follow-up — or for a molecule with a strong mortality association but no trial, see [ergothioneine: the "longevity vitamin"?](/ergothioneine-for-longevity). ## The bottom line Spermidine has the best mechanistic and animal case of almost any longevity supplement: a clean autophagy mechanism tied to a formal hallmark of aging, lifespan extension across model organisms, and striking cardioprotective data in mice. It also has a genuine human epidemiological signal — higher dietary intake tracks with lower mortality in two independent cohorts. What it lacks is the thing that would actually justify the claims: positive human trials. The one adequately-powered randomized trial was negative, the human evidence is confined to cognition, and there are zero lifespan or healthspan RCTs in people. If you take spermidine, take it knowing the mechanism is real, the safety looks reasonable, and the longevity payoff in humans is unproven — promising biology, not a proven intervention. For where it fits among providers and programs that actually have clinical oversight, see our graded [best longevity clinics](/best-longevity-clinics) hub. Sources: https://pubmed.ncbi.nlm.nih.gov/36599349/, https://pubmed.ncbi.nlm.nih.gov/19801973/, https://pubmed.ncbi.nlm.nih.gov/29371440/, https://pubmed.ncbi.nlm.nih.gov/27841876/, https://pubmed.ncbi.nlm.nih.gov/28118075/, https://pubmed.ncbi.nlm.nih.gov/29955838/, https://pubmed.ncbi.nlm.nih.gov/37964604/, https://pubmed.ncbi.nlm.nih.gov/29315079/, https://pubmed.ncbi.nlm.nih.gov/30388439/, https://pubmed.ncbi.nlm.nih.gov/35616942/ --- ### The Sitting-Rising Test & Longevity: What the Evidence Actually Shows Canonical: https://longevitygraded.com/sitting-rising-test-longevity Updated: 2026-07-24 The sitting-rising and sit-to-stand tests predict mortality in research — but they're markers of strength, balance, and flexibility, not a verdict. If you have ever seen a headline claiming that how easily you get up off the floor predicts how long you'll live, you have met the sitting-rising test (SRT). It is a real, peer-reviewed measure, and the association with mortality is genuine — but the way it gets repackaged online ("this 30-second test reveals your lifespan") badly overstates what it can tell any one person. Here is what the science actually found, how to do the test, and — most importantly — why it is a marker of physical capability, not a crystal ball. ## What the sitting-rising test is The SRT was popularized by a 2012 study from a Brazilian research group led by Claudio Gil Araújo and Leonardo Brito. The task is deceptively simple: from standing, lower yourself to a cross-legged seated position on the floor, then rise back to standing — using as little support as possible. Scoring runs from 0 to 10. You start with 5 points for sitting down and 5 points for standing up (10 total). You lose one point each time you use a hand, forearm, knee, or the side of your leg for support, and half a point each time you become visibly unsteady. The final score is the sum of the sitting and rising halves. What makes the SRT interesting is that a single movement quietly taxes several things at once: lower-body and core strength, flexibility (especially hips and ankles), balance, and body composition. That is also why it correlates with so much — it is a composite of capabilities that all tend to decline together with age and inactivity. ## What the mortality study actually found In the original cohort, 2,002 adults aged 51–80 performed the SRT and were followed for a median of about 6.3 years, during which 159 (7.9%) died. Lower scores tracked with higher all-cause mortality. After adjusting for age, sex, and body mass index, people in the lowest score band (0–3) had a hazard ratio of 5.44 versus the highest band (8–10), with intermediate bands at 3.44 and 1.84 — a clean dose-response gradient. The authors estimated that each one-point increase in SRT score was associated with about a 21% improvement in survival. That sounds dramatic, and it is a real signal. But read the design carefully: this is an **association** in a retrospective cohort, adjusted for only three confounders. It tells you that, across a population, people who move well off the floor tend to outlive people who struggle — not that the test *causes* longevity, and not that any individual's score is a personal expiry date. People with low scores often have other things going on (obesity, cardiovascular disease, sedentary lifestyles, joint problems) that drive risk; the SRT is partly a convenient summary of those, not an independent oracle. ## The SRT is one of a whole family of "physical capability" tests The SRT did not come out of nowhere. It belongs to a large, much older body of research showing that simple measures of physical function predict survival — and that literature is what gives the idea credibility. A landmark 2010 *BMJ* systematic review and meta-analysis pooled studies of grip strength, walking speed, chair-rise time, and standing balance, and found that across the board, weaker performance predicted higher mortality in community-dwelling adults. The building blocks of that finding are themselves well known: - **Grip strength.** In the international PURE study of nearly 140,000 people, each 5 kg drop in grip strength was associated with higher all-cause and cardiovascular mortality — grip was actually a stronger predictor of death than systolic blood pressure. - **Gait speed.** A pooled analysis of 34,485 older adults in *JAMA* showed that usual walking speed predicted survival across age and sex, with faster walkers living longer. - **Cardiorespiratory fitness (VO2 max).** The cardiovascular member of this family is arguably the best-studied of all — low fitness predicts mortality on par with smoking, and unlike the SRT it's measured on a treadmill rather than the floor (see [VO2 max and longevity](/vo2-max-and-longevity)). - **The Short Physical Performance Battery (SPPB).** This standardized battery — gait speed, balance, and a five-time chair-stand — was designed by Guralnik and colleagues and validated against later disability and death. A 2016 meta-analysis confirmed that lower SPPB scores predict all-cause mortality. The closest clinical cousin to the SRT is the **five-times sit-to-stand test** (rise from a chair five times as fast as you can, no hands). It is a standard geriatric measure with published reference values by age and sex, and it is one of the three components of the SPPB. Where the SRT uses the floor (demanding more flexibility and balance), the chair-stand isolates lower-body power and is easier to standardize — which is why clinicians tend to prefer it. So the honest framing is: the SRT is a vivid, low-tech entry into a real and robust field. It is not a uniquely magical test, and it has not been validated as rigorously as gait speed or grip strength. ## How to do it (and when not to) If you want to try the SRT yourself, do it on a non-slip surface with clear space around you, ideally with someone nearby. Cross your legs, lower to a seated position, then stand back up, trying not to use your hands, knees, or furniture. Count the supports you used and any wobbles. Skip it — or do a seated chair-stand instead — if you have knee, hip, or back problems, balance disorders, are pregnant, or are frail or at high fall risk. The test is only "safe" for people who are already reasonably mobile; for everyone else, the more useful and safer measure is the timed chair-stand or a clinician-administered SPPB. This is a screening prompt, not a diagnostic, and a low score is a reason to talk to a clinician, not to panic. ## The part the headlines bury: it's modifiable Here is the genuinely useful takeaway, and the reason the test matters at all. The qualities the SRT measures — strength, balance, flexibility, body composition — are among the most trainable things in the human body, at any age. The classic demonstration is a 1990 *JAMA* study in which frail nursing-home residents *in their 90s* roughly doubled their muscle strength with eight weeks of supervised resistance training, with measurable gains in mobility. And the LIFE study — a large randomized trial in sedentary older adults — showed that a structured physical-activity program meaningfully reduced the incidence of major mobility disability versus a health-education control. In other words, the same low-tech capabilities that predict mortality are the ones that respond to exercise. That flips the entire meaning of the SRT. A low score is not a prophecy — it is feedback. It points at a deficit (lower-body strength, hip and ankle mobility, balance) that strength training, mobility work, and simply moving more can improve — and that a cheap, well-evidenced training amplifier like [creatine for aging](/creatine-for-aging) can help you build on faster. Whether improving your SRT score *causally* extends your life has not been proven by a randomized trial; what has been shown is that the underlying capabilities are trainable and that training reduces disability. That is a much more honest — and more actionable — claim than "this test predicts your death." ## Where this fits in evidence-based longevity Functional tests like the SRT sit alongside lab-based measures in the longevity-assessment toolkit. They are cheap, fast, and capture something blood panels miss — how well your body actually moves and holds together. For the broader, honest picture of what longevity medicine can and can't deliver, see our pillar on the [evidence behind longevity medicine](/longevity-medicine-evidence). For the lab side of assessment, compare against what [longevity biomarker panels](/longevity-biomarker-panels) actually measure and the accuracy of [biological-age and epigenetic-clock tests](/biological-age-tests). And if you're weighing whether to involve a clinician in any of this, our explainer on [what a longevity doctor is (and whether you need one)](/what-is-a-longevity-doctor) is the place to start. If you want to see how the providers offering this kind of structured assessment compare on price transparency, clinical oversight, and what they actually sell, we grade the field in our [best longevity clinics hub](/best-longevity-clinics). ## The bottom line The sitting-rising test is a legitimate, peer-reviewed marker that belongs to a deep literature on physical capability and survival — alongside grip strength, gait speed, and the chair-stand. Lower scores genuinely track with higher mortality. But it is an **association and a screen, not a verdict**: it summarizes strength, balance, and flexibility, much of which is downstream of other health conditions and all of which is trainable. Treated as a number that reveals your lifespan, it's hype. Treated as a quick, honest read on a part of your health you can actually improve, it's useful. Sources: https://pubmed.ncbi.nlm.nih.gov/23242910/, https://pubmed.ncbi.nlm.nih.gov/20829298/, https://pubmed.ncbi.nlm.nih.gov/25982160/, https://pubmed.ncbi.nlm.nih.gov/21205966/, https://pubmed.ncbi.nlm.nih.gov/8126356/, https://pubmed.ncbi.nlm.nih.gov/28003033/, https://pubmed.ncbi.nlm.nih.gov/17037663/, https://pubmed.ncbi.nlm.nih.gov/24866862/, https://pubmed.ncbi.nlm.nih.gov/2342214/ --- ### How Much Does a Longevity Clinic Cost? Canonical: https://longevitygraded.com/longevity-clinic-cost Updated: 2026-08-07 Longevity care runs from ~$200/yr lab memberships to $20k+ concierge programs. A 2026 price-band guide to what each tier buys — and what's worth paying for. Ask "how much does a longevity clinic cost?" and the honest answer is anywhere from about $200 a year to well over $100,000 — because "longevity clinic" describes at least four completely different products. A direct-to-consumer lab membership that mails you a test kit and a $20,000-a-year concierge program with its own MRI scanner both market themselves as "longevity," but you are buying very different things. This guide gives you real 2026 price bands, what each tier actually delivers, and — the part most clinics won't tell you — where the spending is and isn't supported by evidence. The single most useful frame before any number: **almost everything sold as "longevity" is priced on a promise the field hasn't yet proven.** No intervention offered by any of these clinics has been shown in a completed randomized trial to extend human lifespan. The validated biomarkers and outcome endpoints that would let you measure "did this slow my aging?" are still being selected for trials. So as you read the prices, keep asking the question that reorganizes the whole market — *am I paying for a diagnostic picture, an ongoing treatment plan, or just a rising lab value?* We map the full market in [longevity clinics vs lab memberships vs Rx telehealth](/longevity-clinics-vs-lab-memberships), and the evidence behind the claims in [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## The price bands at a glance (as of June 2026) | Band | Typical price (2026) | What you get | Honest catch | |---|---|---|---| | DTC lab membership | ~$199–$365/yr | 100–160+ biomarkers, biological-age estimate, MD review of abnormals | Tests but largely doesn't treat | | Single-product Rx telehealth | ~$99–$235/mo (often pay-per-use) | One therapy line — TRT, peptides, rapamycin, NAD+, GLP-1 | Narrow; vertical-pharmacy conflict common | | Membership longevity program | ~$99–$300/mo (~$1,200–$3,600/yr) | Recurring labs + prescribing clinician + retesting + therapies | "Healthspan" claims; supplement/Rx upsells | | Concierge diagnostic clinic | ~$3,000–$25,000/yr (some packages higher) | Whole-body/brain MRI, coronary CT, genomics, in-person MD | Over-screening risk; unproven "reverse-aging" bolt-ons | Prices are 2026 figures published by the providers themselves and may vary by state and package; verify current pricing before you buy. The rest of this guide walks each band, then asks the only question that matters — is any of it worth it over a good primary-care doctor and a few DIY labs? ## Band 1: DTC lab memberships — ~$199–$365/year This is the cheapest on-ramp, and for many people the most rational one. Function Health charges about $365/yr for 160+ biomarkers across two annual draws plus physician review of anything abnormal; Superpower runs about $199/yr (higher in some states) for 100+ markers, a biological-age readout, and text access to a clinician. You mail in or visit a lab, get a large panel back, and receive an interpretation. **What you're really paying for:** breadth of testing at a low price — a once- or twice-a-year snapshot of cardiometabolic, hormonal, and inflammatory markers most annual physicals don't cover. **The honest catch:** this band *tests but largely doesn't treat.* It hands you results and, for most findings, hands you off. The "biological age" number these services feature is also softer than it looks — different methods produce different ages from the same blood, and the field still lacks an agreed, validated clinical aging biomarker. Treat the panel as useful raw data and the biological-age figure as a motivational estimate, not a verdict. We dig into that in [biological age tests: do epigenetic clocks work?](/biological-age-tests) and what the panels actually measure in [what do longevity biomarker panels actually test?](/longevity-biomarker-panels). ## Band 2: Single-product Rx telehealth — ~$99–$235/month Here you're buying one therapy line, not a program. Examples in 2026: sermorelin around $99/mo, NAD+ injections around $235/mo, compounded GLP-1s around $139/mo, or TRT around $225/mo through hormone-optimization brands. Read the term as carefully as the number — one graded provider [advertises testosterone at $79 a month on a plan you buy a year of, against $139 month-to-month](/peter-md-review). The two molecules that drive most of these bills are priced and graded in [sermorelin for longevity](/sermorelin-for-longevity) and [TRT and longevity](/testosterone-trt-and-longevity). Many run pay-per-use rather than a flat membership. The $99 end of that range is real and reachable month-to-month — [an oral sermorelin lozenge at ninety-nine dollars a month with the MD visit inside it](/strut-health-review) is the cheapest published protocol we have graded — but it is the floor, not the median, and a headline near it deserves a second look at the terms. **What you're really paying for:** convenient prescription access to a specific intervention — a peptide, a hormone, rapamycin, or a GLP-1 — with light clinical oversight. **The honest catch:** the evidence under each product varies enormously, and so does the conflict of interest. Several of these brands dispense through their own pharmacy, so the company recommending the therapy also profits from selling it. A second catch is structural: a monthly figure on a landing page is not always a monthly plan, and in the case of [a headline price whose real terms only appear once you are inside the portal](/shed-review), the published number and the number you commit to are different things. The commoner version is a twelve-month prepay rate advertised as a monthly one: [an NAD+ program whose "$137/month" is a yearly plan and whose month-to-month rate is $199](/mydrhank-review) is the sharpest example we have graded, because the monthly figure is printed on none of its pages. A quieter variant is worth budgeting for too: [an NAD+ program billed every twelve weeks and advertised as a per-month average](/pallas-health-review) publishes its charge and its cadence openly, and still costs about 8.7% more a year than the advertised average implies — because eighty-four days recurs 4.35 times a year while the average divides by three. Two failure modes sit at the far end of that spectrum and are worth naming, because neither is a prepay trap at all. One is arithmetic you cannot do: [a page selling NAD+ at $179, $169 and $249 all at once](/breeze-meds-review) gives a buyer three answers to a single question. The other is arithmetic you are not allowed to attempt — [an anti-aging program of NAD+, glutathione and sermorelin with no published price at any surface](/oak-review) quotes you only after the intake, so the cost cannot be compared against anything on this page until you have handed over a medical history. And the longevity framing is often ahead of the data: a landmark systematic review of growth hormone in healthy older adults found small body-composition changes but no proven functional benefit and significantly more adverse events — a cautionary template for how a plausible-sounding hormone or peptide can be marketed as "anti-aging" without outcome data behind it. Rapamycin and NAD+ sit in the same place: real mechanisms, no completed human longevity trial. See [rapamycin & metformin: what the evidence shows](/rapamycin-metformin-evidence) and [do NAD+ and longevity peptides work?](/do-nad-peptides-work). ## Band 3: Membership longevity programs — ~$99–$300/month This is the band most people mean by "longevity clinic" once they want ongoing care rather than a one-time test. Lifeforce runs about $149/mo after a roughly $549 diagnostic; multi-service clinics tier from about $99 to $399/mo. The model is *recurring*: a 40–100-marker panel, retesting every few months, a clinician who reviews results and prescribes, and a menu of therapies — hormones, peptides, GLP-1s, NAD+ — usually over telehealth with mailed lab kits, which is why it costs a fraction of concierge pricing. **What you're really paying for:** the thing a DTC lab won't give you and a single Rx product can't — a prescribing clinician *plus* a retesting cadence, so you can actually see whether an intervention moved your numbers over time. This is the only accessible-price band built for longitudinal treatment. **The honest catch:** this band leans hardest on the word "healthspan," and much of what it prescribes has mechanistic plausibility but no completed human longevity RCT. Two things to vet specifically: **vertical-pharmacy conflict** (does the program profit from the drugs it recommends?) and the **growth-hormone red flag** above. A physician-overseen peptide/NAD+/GLP-1 membership that distinguishes proven from plausible and discloses its conflicts is the credible version of this band; one that pitches everything as equally "proven" is not. We weigh the two hands-on models head-to-head in [concierge vs membership longevity: what you actually get](/concierge-vs-membership-longevity), and grade providers on exactly these axes in [how we grade longevity providers](/how-we-grade-longevity-providers). ## Band 4: Concierge diagnostic clinics — ~$3,000–$25,000+/year The premium ceiling. Fountain Life lists a ~$2,995/yr core tier and a flagship around $19,500/yr; Human Longevity's concierge tiers reach roughly $19,000/yr; Cenegenics programs land around $14,000–$21,000/yr once you add the assessment and monthly fees. Some bespoke packages run higher still. The product is **diagnostics you genuinely cannot get elsewhere as a consumer**: whole-body and brain MRI, coronary CT angiography with AI plaque analysis, whole-genome sequencing, 100+ biomarkers, and a physician quarterbacking all of it in person. **What you're really paying for:** depth and imaging. For some people, a scan catches something important early — the legitimate case for the model. **The honest catch — over-screening:** intensive scanning of asymptomatic people is genuinely double-edged, and the data are now specific. A 2026 systematic review and meta-analysis of whole-body MRI across more than 9,000 asymptomatic individuals found a confirmed-cancer detection rate of just 1.57%, alongside frequent incidental findings, unstandardized protocols, and no long-term outcome or cost-effectiveness data — concluding the scans "may lead to unnecessary investigations". In plain terms: the imaging that anchors the concierge pitch finds real cancer in about 1 in 64 healthy people while flagging far more ambiguous spots that drive anxiety, follow-up procedures, and cost. The second concierge catch is the **bolt-on** — plasma exchange, EBOO, NAD+, [hyperbaric oxygen](/hbot-for-longevity), growth-hormone secretagogues attached to the diagnostic core. Treat the imaging and genomics as the real product and the "reverse aging" add-ons as unproven. We compare the two best-known MRI clinics — and lead with the incidentaloma problem — in [Fountain Life vs Human Longevity Inc](/fountain-life-vs-human-longevity). The full case is in [are longevity clinics worth it?](/longevity-clinics-worth-it). ## Is any of it worth it vs a good PCP and DIY labs? Here's the comparison clinics rarely volunteer. A competent primary-care physician will already order the basics that drive most of the value — lipids, A1c, blood pressure, a metabolic panel, thyroid — typically covered by insurance. You can add the markers most physicals skip (ApoB, hs-CRP, fasting insulin, a fuller lipid and hormone panel) through a DTC lab for one to a few hundred dollars a year. That combination captures the large majority of *actionable* information a longevity clinic surfaces, at a fraction of the price. The same "boring basics carry most of the benefit" logic is why even the most lavish DIY protocol of all — [Bryan Johnson's Blueprint](/bryan-johnson-blueprint-review) — has roughly 90% of its plausible value in cheap diet, sleep, and exercise rather than its six-figure testing and stack. What the paid bands add over PCP-plus-DIY-labs: - **DTC memberships** add breadth and packaging — convenient, but you're paying mostly for a tidier dashboard and a biological-age number that isn't a validated clinical endpoint. - **Membership programs** add the genuinely useful piece a PCP often won't do: prescribe and monitor optimization therapies (peptides, hormones, GLP-1s) with structured retesting. If you specifically want those therapies and want them overseen, this is the rational paid tier. - **Concierge clinics** add advanced imaging and genomics — real capability, but aimed at asymptomatic screening, where the evidence shows modest cancer yield and meaningful over-diagnosis risk. The strongest human-outcome evidence in the entire field belongs to GLP-1 receptor agonists — the SELECT trial showed semaglutide cut major cardiovascular events by about 20% in overweight and obese adults without diabetes — and even that proves cardiovascular risk reduction, not slowed aging. Most other longevity interventions, including the ones priced highest, target *mechanisms* and *biomarkers* rather than proven outcomes; metformin, for instance, plausibly attenuates several hallmarks of aging in mechanistic work, but the trial designed to test whether it actually extends healthy years (TAME) hasn't read out. That's the core honesty of this whole price question: in most cases you are paying to move a lab value, not a proven outcome. **A reasonable spending ladder for most people:** start with a good PCP and one DTC lab panel a year (lowest cost, most of the actionable signal) — our [longevity test cost comparator](/tools/longevity-test-cost-comparator) puts the current per-test prices side by side so that first step is priced before you take it; step up to a membership program *only* if you specifically want prescribed, monitored optimization therapies; and treat concierge imaging as an optional, eyes-open luxury you buy for the diagnostic picture, not as proven life extension. What you should never do is pay concierge prices expecting a treatment plan, or membership prices expecting concierge-grade imaging. For our independently graded shortlist across every band — with prices, oversight, and unproven claims flagged honestly — see [our longevity clinic rankings](/best-longevity-clinics). And if you're not sure you need a clinic at all, start with [what a longevity doctor actually does (and who needs one)](/what-is-a-longevity-doctor). *This article is general health and consumer-finance information, not medical or financial advice. Prices are 2026 figures and change frequently; verify current pricing and discuss any therapy with a licensed clinician before starting.* Sources: https://pubmed.ncbi.nlm.nih.gov/30151729/, https://pubmed.ncbi.nlm.nih.gov/17227934/, https://pubmed.ncbi.nlm.nih.gov/40884613/, https://pubmed.ncbi.nlm.nih.gov/37952131/, https://pubmed.ncbi.nlm.nih.gov/32333835/ --- ### Free Biological-Age Tests & Calculators: Do They Actually Work? Canonical: https://longevitygraded.com/free-biological-age-tests Updated: 2026-06-04 Free biological-age calculators range from validated (PhenoAge from a basic blood panel) to entertainment. An honest guide to what's worth your time. ## The one-sentence version You don't need a $300 epigenetic test to get a defensible estimate of your biological age — the single most evidence-grounded "biological age" number available to a consumer comes from a **standard blood panel you may already have**, run through a free, peer-reviewed formula called **PhenoAge** — which you can run right now in our [biological age calculator](/tools/biological-age-calculator). But "free" spans a huge quality range, from that genuinely validated route down to one-page lifestyle quizzes that are pure entertainment. This page sorts the free options by how much evidence is actually behind them. For the paid epigenetic clocks (Horvath, GrimAge, DunedinPACE) and whether *they* work, see our companion review of [biological age tests and epigenetic clocks](/biological-age-tests); this page is strictly about the free and near-free routes. Both fit into the wider picture we draw in our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## The free routes, ranked by evidence There are four broad kinds of free "biological age" tool, and they are not remotely equal: 1. **Blood-panel phenotypic-age formulas** (PhenoAge, Klemera-Doubal-style models) — the most evidence-grounded free route. 2. **Function-based estimators** (fitness, grip strength, gait speed, the floor-rise test) — not branded as "biological age," but arguably better predictors of survival than most clocks. 3. **Deep-learning blood-age predictors** (the "aging.ai" style tools) — real science, but a black box with caveats. 4. **Online lifestyle questionnaires** — the "what's your real age?" quizzes — mostly entertainment. We'll take them in that order, because that's the order of how much you should trust them. ## Route 1 — PhenoAge from a basic blood panel (the best free option) If you want one free biological-age number worth taking seriously, this is it. **PhenoAge** is a published algorithm that estimates a "phenotypic age" from nine routine clinical labs plus your chronological age. The inputs are unglamorous and cheap: albumin, creatinine, glucose, C-reactive protein, lymphocyte percentage, mean cell volume, red cell distribution width, alkaline phosphatase, and white blood cell count. Most of those sit on a standard comprehensive metabolic panel plus a CBC with differential — labs you may already have from an annual physical, or can get cheaply. What makes PhenoAge credible is the validation behind it. The measure was originally derived by Levine and colleagues, who showed that a biological-age model built from clinical markers predicts mortality more accurately than chronological age alone. PhenoAge itself was then validated in the large, nationally representative **NHANES IV** cohort, where it predicted all-cause mortality, cause-specific mortality, and physical-function decline across diverse subpopulations — and, importantly, did so *consistently* across age, sex, and racial groups. That's a far stronger evidentiary footing than most consumer "biological age" products can claim. The math behind it draws on the **Klemera-Doubal method**, a 2006 statistical approach for combining multiple biomarkers into a single biological-age estimate that captures aging better than any one marker or chronological age. You don't need to do the algebra yourself: several free web calculators implement the published PhenoAge equation, and the formula is openly available in the source papers, so the number is reproducible rather than proprietary. **The honest catch.** Phenotypic age is a snapshot of your current physiological state, and that state can be temporarily distorted. C-reactive protein and white-cell count spike with any infection, injury, or recent hard workout; glucose shifts with a non-fasting draw. A flu the week of your blood test can add "years" that vanish once you recover. So treat a PhenoAge result as a rough, repeatable read on metabolic and inflammatory health — not a fixed verdict — and only compare results drawn when you were well and fasted. Used that way, it's the most actionable free biological-age tool there is, because every input is a marker you can actually move: glucose, CRP, and the rest respond to the same boring, proven levers (diet, activity, not smoking) that we keep coming back to. ## Route 2 — function tests: free, lab-free, and arguably better Here's the under-appreciated part. Some of the strongest predictors of how long you'll live aren't blood tests or clocks at all — they're physical-function measures you can do at home for free, and they often outperform fancier biomarkers. - **Grip strength.** In the international PURE study of nearly 140,000 people, each 5 kg drop in grip strength was associated with higher all-cause and cardiovascular mortality — and grip was a *stronger* predictor of death than systolic blood pressure. A cheap hand dynamometer is the only equipment needed. - **Gait speed.** A pooled analysis of more than 34,000 older adults found that usual walking speed predicted survival across age and sex — faster walkers lived longer. - **Cardiorespiratory fitness.** Among the most powerful survival predictors ever measured: in a study of over 120,000 people, higher treadmill-measured fitness tracked with dramatically lower long-term mortality, with no plateau at the top end. You can ballpark it free with a submaximal step test or a timed run. - **The floor-rise (sitting-rising) test.** A 10-second, equipment-free screen of strength, balance, and flexibility that associates with mortality — we cover its real evidence and honest limits in [the sitting-rising test and longevity](/sitting-rising-test-longevity). None of these will hand you a tidy "your body is 42" headline. But as a free read on the part of aging that actually predicts disability and death, they are more validated than most paid clocks — and, like PhenoAge, every one of them is trainable. We make the broader case for function over vanity numbers in [what longevity biomarker panels actually test](/longevity-biomarker-panels). ## Route 3 — deep-learning "blood age" predictors (aging.ai and similar) A more sophisticated free option is the deep-learning blood-age predictor, popularized by tools like aging.ai. These feed a panel of routine blood biochemistry markers into a neural network trained to predict chronological age, then report how "old" your blood chemistry looks. The underlying science is real: a 2016 study showed deep neural networks could predict human age from blood biochemistry with reasonable accuracy and identify which markers carry the most age signal. The honest framing: these are **research-grade demonstrations, not validated diagnostics.** They were trained mostly to predict *chronological* age (which, as with first-generation epigenetic clocks, is less useful than predicting health outcomes), the consumer versions are black boxes you can't audit, and a few of them have asked you to hand over real lab values to a website of uncertain provenance. Interesting? Yes. A number to act on? No more than PhenoAge, and usually less — because at least PhenoAge's formula is open and outcome-validated. ## Route 4 — online lifestyle questionnaires (mostly entertainment) At the bottom of the evidence stack sit the free "real age" and "longevity calculator" quizzes: a page of questions about your diet, exercise, smoking, sleep, and stress that spits out a "biological age" or a "you'll live to 87" estimate. The better ones are loosely built on actuarial and epidemiological risk factors that genuinely do affect lifespan, so they're not pure nonsense — answering honestly that you smoke a pack a day and never exercise *will* (correctly) push the number up. But a questionnaire is not a measurement. It can't see your blood pressure, your LDL, your glucose, or your fitness; it only knows what you tell it, and the "biological age" it returns is a repackaging of well-known risk factors, not an assessment of your physiology. Treat these as a mildly motivating nudge toward better habits — not as a biological-age test in any meaningful sense. ## So which free option should you actually use? A practical ranking: - **Want a defensible free biological-age number?** Get a basic comprehensive metabolic panel + CBC with differential (cheap, and often already in your records) and run it through a free **PhenoAge** calculator. It's the only free route with real outcome validation behind it. Re-run it only on fasted, healthy-week draws. - **Want the strongest free read on survival, no lab needed?** Measure your **fitness, grip strength, and gait speed**. These predict mortality as well as anything and cost nothing. - **Curious about deep-learning blood age?** Fine as a one-time curiosity — don't over-read it, and mind where your lab values go. - **The lifestyle quizzes?** Entertainment. Useful only as a habit nudge. ## What even the best free tools can't do Two limits apply to *every* free biological-age tool, the same way they apply to the paid epigenetic clocks. First, **none of these is a diagnosis.** A "high" biological age is a prompt to check the real, treatable risk factors with a clinician — blood pressure, lipids (ApoB and Lp(a)), glucose, fitness — not a disease label. If you're wondering whether a professional should be involved, start with [what a longevity doctor is and whether you need one](/what-is-a-longevity-doctor). Second, and most important: **lowering your biological-age number has never been shown to make you live longer.** Every one of these tools — PhenoAge included — is validated as a *predictor* (a worse number associates with worse outcomes), not as a *target* you should try to game. This is the same gap that haunts the paid epigenetic clocks: a methylation or PhenoAge reading can shift without your underlying risk shifting, which is exactly why the field's own reliability work re-engineered the clocks to cut measurement noise, and why a 2025 expert consensus still classes aging biomarkers as research-stage tools that need standardization before clinical use. Chase the proven levers, not the score. ## Bottom line The most evidence-grounded free biological-age test isn't an app or a quiz — it's a routine blood panel run through the open, outcome-validated **PhenoAge** formula, treated as a rough and repeatable read rather than a verdict. Free function tests (fitness, grip, gait speed, the floor-rise) are arguably even better predictors of survival and need no lab at all. Deep-learning blood-age tools are interesting but unvalidated as diagnostics, and the lifestyle quizzes are entertainment. None of them is a diagnosis, and none has been shown to be a number you can lower to live longer — so use the free options to point yourself at the proven risk factors, and skip paying for a score the science can't yet cash. For where biological-age testing sits among the providers selling it, and for the paid epigenetic-clock side of the story, see [biological age tests: do epigenetic clocks work?](/biological-age-tests) and our independently graded [longevity clinic rankings](/best-longevity-clinics). Sources: https://pubmed.ncbi.nlm.nih.gov/29676998/, https://pubmed.ncbi.nlm.nih.gov/30596641/, https://pubmed.ncbi.nlm.nih.gov/23213031/, https://pubmed.ncbi.nlm.nih.gov/16318865/, https://pubmed.ncbi.nlm.nih.gov/12806071/, https://pubmed.ncbi.nlm.nih.gov/27191382/, https://pubmed.ncbi.nlm.nih.gov/30646252/, https://pubmed.ncbi.nlm.nih.gov/25982160/, https://pubmed.ncbi.nlm.nih.gov/21205966/, https://pubmed.ncbi.nlm.nih.gov/32885222/, https://pubmed.ncbi.nlm.nih.gov/36277076/, https://pubmed.ncbi.nlm.nih.gov/39708300/ --- ### Taurine for Longevity: Does the 2023 Science Study Hold Up? Canonical: https://longevitygraded.com/taurine-for-longevity Updated: 2026-06-05 A 2023 Science paper called taurine deficiency a driver of aging. A 2025 Science follow-up questioned its core premise. An honest, evidence-graded review. Few longevity supplements have had a bigger single moment than taurine. In June 2023, a paper in *Science* reported that taurine — a cheap, ubiquitous amino acid you already eat and make — declines with age, and that giving it back extended lifespan in mice and improved health markers in middle-aged monkeys. The coverage was breathless: a longevity molecule hiding in your energy drink. Two years later, a follow-up in the same journal pulled the rug on the study's central claim. This page walks through both halves honestly — what the famous study actually showed, why the rebuttal matters, and where taurine really sits once you separate mouse data from human proof. For the wider map of what's earned its place versus what's hype, start with our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What taurine is Taurine is a sulfur-containing amino acid — though, unusually, it isn't built into proteins. Your body synthesizes it (mainly in the liver) and you also get it from diet: it's concentrated in meat, fish, and shellfish, which is why vegans and vegetarians tend to have lower intake. It's also the headline ingredient in energy drinks, typically dosed around 1,000 mg per can. Taurine has well-established physiological roles — in bile-acid conjugation, the retina, heart muscle, and as a regulator of cell volume and calcium handling — long before anyone called it a longevity molecule. That everyday-nutrient status matters for the honesty of what follows: taurine is not an exotic drug, and its safety profile at moderate doses is reasonably well characterized. ## The 2023 Science study: what it actually claimed The paper that started the hype was Singh and colleagues, *"Taurine deficiency as a driver of aging,"* published in *Science* in June 2023. It was a genuinely ambitious, multi-species package, and it made three linked claims. First, that circulating taurine concentrations **decline with age** across mice, monkeys, and humans. Second, that **restoring** taurine in mice extended median lifespan (the headline figure was on the order of 10–12%) and improved multiple healthspan measures — muscle, bone, metabolic, and immune markers. Third, that taurine supplementation in middle-aged rhesus monkeys improved several health markers over six months, and that in a human cohort, lower taurine tracked with worse cardiometabolic health. Taken at face value, that's an unusually complete story for a supplement: a molecule that falls with age, a causal lifespan benefit when you replace it in mammals, primate healthspan data, and a human correlation. It's why the study landed so hard. But the load-bearing assumption underneath all of it is the first claim — that taurine *declines with age* — and that's exactly the part that didn't survive scrutiny. ## The 2025 Science follow-up: the core premise didn't hold In June 2025, a group led by Fernandez and colleagues at the National Institute on Aging published a direct challenge in *Science*, asking plainly: *"Is taurine an aging biomarker?"*. Using large longitudinal datasets — humans followed over time, plus rhesus monkeys and mice — they found that blood taurine concentrations **did not consistently decline with age**. In several datasets taurine was flat or even *rose* with age, and within individuals the variability swamped any age trend. Their conclusion was blunt: taurine doesn't behave like a reliable aging biomarker, which undercuts the premise that age-related taurine "deficiency" is something to correct in the first place. This is the crux. The 2023 paper's emotional logic was "you're losing taurine as you age, so put it back." If taurine doesn't actually fall with age in people, that rationale collapses, and the human relevance of the mouse lifespan result becomes much weaker. The 2025 work doesn't prove taurine is useless — it doesn't refute the mouse lifespan extension, which is a separate experiment — but it removes the bridge the 2023 story used to walk from mice to humans. Two high-profile *Science* papers now disagree about the most basic factual claim in this field, and that disagreement is the single most important thing to understand about taurine and aging. ## The animal evidence: real, but it's still mouse data Strip away the human-decline claim and you're left with the mouse lifespan experiment, which stands on its own: in the 2023 work, taurine supplementation did extend median lifespan and improve healthspan markers in mice. That's a real finding worth taking seriously as a reason to keep studying taurine. But it carries the caveat that haunts this entire site: mouse lifespan extensions translate to humans far less often than headlines imply, and a single lab's lifespan result — however careful — is a starting point, not a verdict. Loss of proteostasis, mitochondrial dysfunction, and stem-cell exhaustion are cataloged among the formal hallmarks of aging, and taurine plausibly touches several; but "plausibly touches a hallmark in mice" is a hypothesis about humans, not a result in them. ## What taurine actually does in humans Here's the irony: taurine has a decent human evidence base — just not for *longevity*. Where the data are strongest is in narrow, near-term areas. On **exercise**, a meta-analysis by Waldron and colleagues found that oral taurine produced a small but measurable improvement in endurance performance, and a sports-nutrition review catalogs plausible mechanisms (calcium handling, antioxidant effects) while noting the effects are modest and dose- and protocol-dependent. A separate meta-analysis of endurance supplements in hot environments likewise placed taurine among ingredients with small ergogenic signals. Crucially, the International Society of Sports Nutrition's position stand on energy drinks concluded that taurine's *independent* contribution to energy-drink effects is unclear — caffeine does most of the work. On **metabolic health**, a 2024 systematic review and meta-analysis of randomized trials found taurine supplementation modestly reduced risk markers for metabolic syndrome, and a randomized, double-blind, placebo-controlled trial in people with type 2 diabetes reported improvements in some glycemic and lipid measures. These are real, controlled human results — but they're surrogate markers (glucose, lipids, blood pressure proxies) in specific populations, not demonstrations that taurine slows aging or extends life. ## Zero human longevity trials It needs saying plainly, because the marketing never does: there is **no randomized controlled trial showing taurine extends human lifespan or healthspan**, and there isn't one underway that could answer that question soon. The lifespan data are from mice. The human data are either an *association* (now contested) between taurine levels and health or *surrogate-marker* trials in exercise and metabolic populations. None of that adds up to "proven to make people age slower." This is the same mechanism-versus-outcome gap we apply across the field — see our [best longevity supplements, rated by evidence](/best-longevity-supplements) roundup for how consistently it recurs, and our [longevity biomarker panels](/longevity-biomarker-panels) breakdown for how easily a biomarker gets sold as a benefit. ## Safety: the reassuring part If taurine's efficacy story is weak, its safety story is genuinely reasonable, which is part of why people take it anyway. Taurine is consumed daily in food and in energy drinks at roughly 1,000 mg/can, and the doses used in human metabolic and exercise trials (commonly 1–6 g/day) have been well tolerated in those studies. It is sold as a dietary supplement, not an FDA-approved drug for any condition — so it carries no approved indication and no required efficacy proof, and long-term safety at high chronic doses in healthy people specifically *for anti-aging* hasn't been formally studied. The honest framing is the one this site uses constantly: taurine's *safety* at studied doses looks acceptable, while its *efficacy for longevity* in humans is unproven. Those are different claims, and supplement marketing routinely blurs them. ## The grade ## The bottom line Taurine is the cleanest recent example of how fast a longevity story can move and how easily a single striking paper outruns its evidence. The 2023 *Science* study was real and ambitious, and its mouse lifespan result still stands. But its bridge to humans — the claim that taurine declines with age — was directly challenged by a 2025 *Science* follow-up that found no reliable age-related decline in people or primates. Strip that bridge away and what's left is solid mouse data, a contested human correlation, and genuinely useful but narrow human evidence for exercise and metabolic markers — none of it showing taurine slows human aging. If you take taurine, take it for what it's actually supported to do, at sensible doses, knowing the safety looks reasonable and the longevity payoff in humans is unproven. For where supplements like this fit alongside programs with real clinical oversight, see our graded [best longevity clinics](/best-longevity-clinics) hub, and compare taurine's case to the better-mechanism, still-unproven neighbor [spermidine for longevity](/spermidine-for-longevity) — or to another amino acid with a modest-but-rigorous mouse signal in [glycine for longevity](/glycine-for-longevity). Taurine's contested age-decline mirrors a similar debate around a diet-derived molecule with a strong mortality association but no trial — see [ergothioneine: the "longevity vitamin"?](/ergothioneine-for-longevity). Sources: https://pubmed.ncbi.nlm.nih.gov/37289866/, https://pubmed.ncbi.nlm.nih.gov/40472098/, https://pubmed.ncbi.nlm.nih.gov/36599349/, https://pubmed.ncbi.nlm.nih.gov/29546641/, https://pubmed.ncbi.nlm.nih.gov/34039357/, https://pubmed.ncbi.nlm.nih.gov/34129223/, https://pubmed.ncbi.nlm.nih.gov/36862943/, https://pubmed.ncbi.nlm.nih.gov/38755142/, https://pubmed.ncbi.nlm.nih.gov/32472292/ --- ### Urolithin A (Mitopure): Mitochondrial Hype or Real? Canonical: https://longevitygraded.com/urolithin-a-for-longevity Updated: 2026-06-05 Urolithin A (Mitopure) has the cleanest human-trial record of any mitochondrial supplement — modest muscle gains in RCTs. But healthspan isn't lifespan. Urolithin A is the rare longevity supplement that arrives with actual randomized human trials behind it — which is exactly why it deserves a careful, honest grading rather than a reflexive dismissal. Sold most prominently as **Mitopure** by the Swiss company that ran much of its research, it's marketed on a genuinely interesting mechanism (clearing out damaged mitochondria) and a real, if modest, clinical signal. The catch is the one this site returns to constantly: the trials measured *muscle function over weeks*, not *aging over years*. This page separates what urolithin A has actually shown in people from what the marketing implies, and tells you where it lands. For the wider map of what's earned its place versus what's hype, start with our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What urolithin A is Urolithin A isn't something you eat directly. It's a metabolite your **gut bacteria** make when you consume ellagitannins — compounds found in pomegranates, walnuts, and some berries. That single fact carries a big honesty caveat: not everyone's microbiome can produce it. Studies on urolithin "metabotypes" show that a substantial fraction of people convert ellagitannins poorly or not at all into urolithin A, which is the central rationale for selling it as a direct supplement. As a supplement, urolithin A is sold as a synthesized, standardized compound (Mitopure being the best-known branded form), bypassing the microbiome lottery entirely — and that branded, company-sponsored research base is something to keep in mind when reading the trial results. ## The mechanism: mitophagy, a real target The reason urolithin A is taken seriously is **mitophagy** — the cell's process for identifying and recycling worn-out mitochondria. As mitochondria accumulate damage with age, the cell's ability to clear them declines, and mitochondrial dysfunction is cataloged among the formal hallmarks of aging. The foundational work showed that urolithin A induces mitophagy, prolongs lifespan in the worm *C. elegans*, and improves muscle function in aged rodents. That's a clean mechanistic story: a defined hallmark, a molecule that demonstrably activates the relevant cleanup process, and improved function in animal models. But — as always — a mechanism that works in worms and mice is a hypothesis about humans, not a result in them. The value of urolithin A is that, unusually for a longevity supplement, it didn't stop at the worm. ## The human trials: the part that sets urolithin A apart Here's where urolithin A earns its reputation. It has been through multiple randomized, placebo-controlled human trials — far more than most supplements on a longevity list can claim. The first-in-human study established the foundation: urolithin A was **safe** in healthy older adults and induced a molecular signature of improved mitochondrial and cellular health, measurable in muscle gene expression and blood markers. That's a real result, but note what it is — a biomarker signature, not a functional outcome. Then came the functional trials. In a randomized clinical trial in older adults, four months of urolithin A improved **muscle endurance** (measured as the number of muscle contractions before fatigue) and shifted mitochondrial biomarkers versus placebo — though it did not significantly change the primary aerobic-capacity endpoint. A separate randomized trial in middle-aged adults reported improvements in **muscle strength** and exercise performance alongside mitochondrial-health biomarkers. And a 2024 randomized, double-blind trial in resistance-trained male athletes found urolithin A improved measures of muscle endurance and reduced markers of inflammation and oxidative stress over eight weeks. Across these, the picture is consistent: small-to-moderate gains in muscle endurance and strength, plus reliable movement in mitochondrial biomarkers. ## Healthspan, not lifespan — and why that distinction is everything This is the heart of the honest read. Every positive human result for urolithin A is a **healthspan** signal — better muscle function, better mitochondrial markers — measured over weeks to months. None of it is a **lifespan** result. The only lifespan extension on record is in *C. elegans*, a worm. There is no human trial showing urolithin A extends life, slows aging, or prevents age-related disease, and there isn't one that could answer that soon. That distinction matters because the marketing leans hard on the word "longevity" while the evidence is really about muscle. "Helps maintain muscle endurance in middle-aged and older adults over a few months" is a defensible, trial-backed claim. "Reverses aging" or "extends lifespan" is not — those are extrapolations from a worm and a mechanism. It's also worth naming that much of the strongest trial evidence was sponsored by the company commercializing the compound; that doesn't make the results wrong (these are randomized, placebo-controlled studies), but industry funding is a real reason to want independent replication of the functional benefits, especially the strength findings. We apply this same mechanism-versus-outcome lens across the field — see our [best longevity supplements, rated by evidence](/best-longevity-supplements) roundup, and our look at [do NAD+ peptides work?](/do-nad-peptides-work) for the parallel pattern of biomarker movement outrunning hard outcomes. ## How it compares to other mitochondrial and peptide longevity plays Within the crowded "mitochondrial support" and longevity-peptide space, urolithin A is genuinely a standout — not because its benefits are large, but because they're the **best-documented**. Compared to NAD+ precursors (which reliably raise a biomarker but show thin functional outcomes) or the injectable peptides marketed for longevity (which we cover in [peptides for longevity: what's actually proven](/peptides-for-longevity)), urolithin A has the cleaner human-trial record: multiple RCTs, a safety package, and consistent — if modest — functional endpoints rather than biomarker-only data. That's a meaningful difference in evidence quality. It still doesn't make urolithin A a proven anti-aging intervention; it makes it the most evidence-backed *muscle/mitochondrial* supplement in the category. ## Safety and the practical caveats On safety, urolithin A's record is reassuring within the trial window: the first-in-human study and the subsequent RCTs found it well tolerated over weeks to months at the studied doses (commonly 500–1,000 mg/day). It's sold as a dietary supplement, not an FDA-approved drug, so it carries no approved indication and no required efficacy proof; long-term safety over years, and any benefit in people who can already produce urolithin A from diet, are not established. The honest framing: urolithin A's *safety* at studied doses looks good and its *muscle-function* benefit is real but modest, while its *longevity* benefit in humans is unproven — three separate claims the marketing tends to collapse into one. ## The grade ## The bottom line Urolithin A is the most evidence-backed supplement in its category, and that's worth stating plainly: a clean mitophagy mechanism, lifespan extension in worms, and — uniquely — multiple randomized human trials showing modest but real improvements in muscle endurance and strength, with a reasonable safety profile. What it doesn't have is any human evidence that it slows aging or extends life; the only lifespan data are in a worm, and much of the strongest functional research is company-sponsored and awaits independent replication. If you take urolithin A, take it as a reasonably-evidenced *muscle and mitochondrial* supplement, not as a proven longevity drug — and judge it on the healthspan claim it can actually support. For where it fits alongside programs with real clinical oversight, see our graded [best longevity clinics](/best-longevity-clinics) hub, and compare its food-derived, mechanism-rich neighbor [sulforaphane for longevity](/sulforaphane-for-longevity). Sources: https://pubmed.ncbi.nlm.nih.gov/27400265/, https://pubmed.ncbi.nlm.nih.gov/32694802/, https://pubmed.ncbi.nlm.nih.gov/35050355/, https://pubmed.ncbi.nlm.nih.gov/35584623/, https://pubmed.ncbi.nlm.nih.gov/39487653/, https://pubmed.ncbi.nlm.nih.gov/27158799/, https://pubmed.ncbi.nlm.nih.gov/36599349/ --- ### Fisetin as a Senolytic: What "Hit-and-Run" Dosing Shows Canonical: https://longevitygraded.com/fisetin-senolytic-evidence Updated: 2026-06-19 Fisetin was the standout senolytic flavonoid in mouse screens and extended lifespan ~10%. In humans, the longevity data are essentially zero. An honest review. Fisetin sits at an awkward intersection that makes it perfect for honest grading: it's a cheap, over-the-counter plant flavonoid, and it's also one of the most genuinely promising molecules in serious senolytic research. That combination breeds confusion — people see "published in real journals, screened by real aging labs" and assume the human longevity case is made. It isn't. This page walks through what fisetin actually showed in the mouse screens that made its name, why the "hit-and-run" intermittent dosing idea is appealing, and why the human longevity evidence is, bluntly, near-zero. For the wider map of what's earned its place versus what's hype, start with our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What a senolytic is, and why it's a serious idea As you age, some cells stop dividing but refuse to die — they become **senescent**. These "zombie cells" accumulate and secrete a soup of inflammatory signals (the senescence-associated secretory phenotype) that damages surrounding tissue. Cellular senescence is one of the formal hallmarks of aging, and the leading review of the field lays out why clearing senescent cells is one of the most mechanistically compelling anti-aging strategies on the table. A **senolytic** is a drug that selectively kills these senescent cells. The appeal of the approach — and the reason it's taken seriously by labs that are otherwise skeptical of supplements — is that, unlike a daily pill you take forever, senolytics could in principle work as **"hit-and-run"** therapy: a short, intermittent course that clears the zombie cells, which then take time to re-accumulate. That's the real, legitimate science behind fisetin. The question is whether fisetin specifically delivers it in humans. ## The mouse evidence: fisetin was the standout Fisetin earned its reputation honestly in the lab. When researchers screened a panel of flavonoids for senolytic activity, fisetin came out as one of the most potent at selectively clearing senescent cells. The landmark follow-up went further: in aged mice, fisetin reduced senescent-cell burden across multiple tissues, lowered markers of age-related inflammation, restored tissue homeostasis, and — the headline result — extended both **health and lifespan**, even when treatment began late in life. That last detail is what generated the excitement: a flavonoid you can buy in a capsule, given intermittently to already-old mice, extended their remaining lifespan on the order of ~10%. That is a genuinely strong preclinical result, and it's why fisetin appears on the shortlist of credible senolytics rather than the junk pile. But it's mouse data — and this site's recurring caution applies with full force: rodent lifespan extensions translate to humans far less often than headlines imply, and a flavonoid that clears senescent cells in a mouse is a hypothesis about people, not a result in them. ## The human evidence: the field's data isn't actually fisetin's Here's the honest pivot the marketing skips. There *is* a small but real body of human senolytic trial data — but most of it is for a **different** senolytic combination: dasatinib (a prescription chemotherapy drug) plus quercetin, not fisetin. In a first-in-human, open-label pilot in patients with idiopathic pulmonary fibrosis, dasatinib plus quercetin improved some physical-function measures. In a separate trial in people with diabetic kidney disease, the same combination measurably **reduced senescent-cell burden** in human fat and skin tissue — the first direct human evidence that senolytics do, in principle, clear zombie cells in people. These are important proof-of-concept results for the senolytic *concept*. We grade that flagship combination in full — its mouse lifespan data, its small human trials, and the fact that it pairs a chemo drug with a flavonoid — in [dasatinib + quercetin: how far along is the flagship senolytic?](/dasatinib-quercetin-senolytics) But they are not fisetin, and they are not longevity trials — they're small, short studies of senescent-cell markers and function in sick patients. Fisetin's own human trials (run by serious groups, including large randomized studies in older adults and at-risk populations) are ongoing, and the published human longevity or healthspan results for fisetin specifically remain essentially absent. So the honest state of play is: the *concept* has early human support (via D+Q), the *mouse data for fisetin* are strong, and the *human longevity data for fisetin itself* are near-zero. Anyone selling fisetin as a proven human senolytic is borrowing credibility from a mouse study and a different drug's trials. ## The "hit-and-run" dosing pitch — promising, but unvalidated in people The intermittent-dosing idea (a few high-dose days every few weeks or months, rather than daily) is genuinely interesting and is how the mouse work and human pilots were structured. But it's important to be clear that the *optimal human dose, schedule, and whether it produces any durable benefit* are not established. Complicating matters, fisetin has **poor oral bioavailability** — it's rapidly metabolized and poorly absorbed, which is exactly why formulation researchers are working on enhanced-delivery versions. The doses used in human trials (often ~20 mg/kg/day for two consecutive days) are far higher than what's in a typical supplement capsule, and whether a standard off-the-shelf fisetin product reaches senolytic concentrations in human tissue is unknown. Fisetin is also studied as a dietary flavonoid with broad, non-specific molecular activity, which cuts both ways: lots of plausible mechanisms, but also less precision than a targeted drug. ## Supplement, not approved drug — and what that means Fisetin is sold as a dietary supplement, not an FDA-approved senolytic or anti-aging drug. It carries no approved indication, no required efficacy proof, and label content the manufacturer controls. On the reassuring side, it's a flavonoid found in foods (strawberries are a notable source) and the short, intermittent dosing used in trials has so far appeared tolerable in the studied groups. But "appears tolerable in small short trials" is not the same as "proven safe for self-directed high-dose intermittent use over years," and high-dose flavonoid regimens taken without supervision aren't risk-free. The honest framing this site uses throughout: fisetin's *mechanism and mouse data* are strong, its *human longevity efficacy* is unproven, and its *long-term safety at senolytic doses* is not established — three separate claims the marketing collapses into one. We apply the same lens across the field in our [best longevity supplements, rated by evidence](/best-longevity-supplements) roundup and in our review of [peptides for longevity](/peptides-for-longevity), where mechanism and marketing routinely outrun human outcomes — and the same borrowed-credibility problem hits the other senolytic flavonoid in [quercetin for longevity: senolytic hype vs evidence](/quercetin-for-longevity), whose senolytic shine actually belongs to the dasatinib + quercetin combination. The nearest rival with a genuinely different mechanism — clearing senescent cells versus inducing autophagy — is weighed against it in [spermidine vs fisetin](/spermidine-vs-fisetin). Fisetin also shows up bundled into multi-ingredient longevity formulas — most prominently [NOVOS Core](/novos-review), where the same mouse-not-human gap applies inside a twelve-ingredient blend. ## The grade ## The bottom line Fisetin is the best of the senolytic flavonoids on paper: a standout in mouse screens, a strong preclinical package that extended health and lifespan in aged mice with intermittent "hit-and-run" dosing, and a place in the legitimate senolytic research program. But the human longevity evidence for fisetin *specifically* is near-zero — the encouraging human senolytic trials used a different drug combination (dasatinib plus quercetin), they measured senescent-cell markers and function rather than lifespan, and fisetin's own human trials haven't delivered longevity results yet. Add poor oral bioavailability and uncertainty about whether supplement doses even reach active levels, and the picture is clear: fisetin is a promising experimental senolytic, not a proven human anti-aging intervention. If you take it, take it knowing the mouse science is real and the human longevity payoff is unproven. For where senolytics fit alongside programs with real clinical oversight, see our graded [best longevity clinics](/best-longevity-clinics) hub. Sources: https://pubmed.ncbi.nlm.nih.gov/30279143/, https://pubmed.ncbi.nlm.nih.gov/28273655/, https://pubmed.ncbi.nlm.nih.gov/33328614/, https://pubmed.ncbi.nlm.nih.gov/30616998/, https://pubmed.ncbi.nlm.nih.gov/31542391/, https://pubmed.ncbi.nlm.nih.gov/38789909/, https://pubmed.ncbi.nlm.nih.gov/27163728/, https://pubmed.ncbi.nlm.nih.gov/36599349/ --- ### GlyNAC (Glycine + NAC) for Aging: What the Baylor Trials Actually Show Canonical: https://longevitygraded.com/glynac-for-longevity Updated: 2026-07-26 Baylor RCTs report GlyNAC corrects glutathione deficiency and several aging hallmarks in older adults. But the trials are small and the headlines overstate it. GlyNAC — a simple combination of two cheap amino acids, glycine and N-acetylcysteine — has one of the more interesting evidence stories in the supplement-longevity world. Unlike most "anti-aging" molecules, it isn't backed only by mouse data and mechanism hand-waving: a single research group at Baylor College of Medicine has run actual randomized and pilot trials in older adults, measured real biology, and published striking before-and-after numbers. That makes the breathless headlines ("reverses aging," "fixes the hallmarks of aging") tempting to believe. This page separates what the Baylor trials genuinely showed from what the marketing added on top. For the wider map of what's earned its place versus what's hype, start with our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What GlyNAC is and the glutathione idea behind it GlyNAC stands for **Gly**cine + **N**-**A**cetyl**C**ysteine. The logic is straightforward and biochemically sound: your cells' master antioxidant is **glutathione**, a tripeptide built from glycine, cysteine, and glutamate. Glycine and cysteine are the two amino acids that tend to run short with age, and N-acetylcysteine is a well-absorbed cysteine donor. The Baylor hypothesis, developed by Rajagopal Sekhar's group, is that older adults are glutathione-deficient, that this deficiency drives oxidative stress and mitochondrial dysfunction, and that supplying both missing building blocks restores glutathione and reverses some downstream damage. It's a clean, testable idea — and importantly, it's been tested in humans, not just rodents. ## The Baylor human trials: what they measured The group's first major human signal came from a pilot study in older adults, which reported that two weeks of glutathione depletion in the young versus a corrected state in the old pointed to glutathione deficiency as a feature of aging, and that GlyNAC supplementation restored glutathione synthesis and lowered oxidative stress. The headline paper is a **randomized controlled trial** in older adults, published in *The Journals of Gerontology* in 2023, in which 24 weeks of GlyNAC versus placebo improved a remarkably broad panel: glutathione levels, oxidative stress, mitochondrial function, insulin resistance, inflammation, endothelial function, body composition, gait speed, muscle strength, and even cognitive measures. A companion paper in *The Journal of Nutrition* describes overlapping improvements across this same cluster of aging-related defects. Read literally, that is an extraordinary list — it touches several of the formal **hallmarks of aging** at once, which is exactly why the result generated so much excitement. Few interventions claim to move oxidative stress, mitochondria, inflammation, *and* physical function in one go. The trials also build on earlier work showing GlyNAC corrected similar defects in aging HIV patients, a population with premature glutathione loss, and a broader summary of the program's findings on glutathione, oxidative stress, and mitochondrial dysfunction. ## Why the headlines overstate it Here is the honest pivot the marketing skips. The Baylor results are real and were collected in humans — but the evidence has serious limits that "GlyNAC reverses aging" papers over. **The trials are small and single-group.** The randomized controlled trial in older adults enrolled only a few dozen participants, and essentially the entire human GlyNAC longevity literature comes from one research group at one institution. Striking results from a small, single-center, single-lab program are a reason to run bigger independent trials — not a reason to treat the conclusion as settled. Large, multi-site replication by groups with no stake in the hypothesis simply hasn't happened yet. **The endpoints are biomarkers, not lifespan.** Every improvement measured — glutathione, oxidative-stress markers, mitochondrial function, inflammation, gait speed, strength — is a surrogate or short-term functional measure over weeks to months. None of them is a demonstration that GlyNAC makes people live longer or develop fewer age-related diseases over years. "Improved a panel of aging markers in a 24-week trial" and "extends human lifespan" are very different claims, and only the first has been tested. **The mouse lifespan data are separate and still just mice.** The group also reported that GlyNAC supplementation *increased length of life* in mice by correcting glutathione deficiency and related defects. That's a genuine lifespan result — but in mice, and rodent lifespan extensions translate to humans far less often than headlines imply. It doesn't license a human lifespan claim. ## The conflict-of-interest and supplement-status caveats Two more honesty checks. First, the human GlyNAC trials come from the group that originated and champions the hypothesis; that doesn't make the data wrong, but independent replication matters precisely because a single invested group's results — however carefully done — carry less weight than reproduced ones. Second, GlyNAC is sold as a **dietary supplement**, not an FDA-approved drug for aging or any condition. It carries no approved indication, no required efficacy proof, and label content the manufacturer controls. On the reassuring side, glycine and NAC are both well-characterized, inexpensive compounds with long safety records at the doses studied, and the trials reported them as generally well tolerated. So the safety picture is relatively comfortable — it's the *longevity-efficacy* picture that's unproven. We apply the same mechanism-versus-outcome lens across the field in our [best longevity supplements, rated by evidence](/best-longevity-supplements) roundup, and the same biomarker-versus-benefit caution in our [longevity biomarker panels](/longevity-biomarker-panels) breakdown. ## The grade ## The bottom line GlyNAC is one of the more credible supplement-longevity stories — and one of the most over-sold. The biochemistry is sound, and unlike most "anti-aging" molecules it has actual human trials behind it: a randomized controlled trial and pilot studies in older adults reporting broad improvements in glutathione, oxidative stress, mitochondrial function, inflammation, and physical performance, plus a mouse lifespan result. But those human trials are small, come almost entirely from a single invested research group, and measure biomarkers over weeks to months — not lifespan, not disease prevention, and not yet replicated independently at scale. "Corrected several aging markers in a small 24-week trial" is a real and interesting result; "reverses aging" is marketing. If you take GlyNAC, take it knowing the safety looks reasonable, the early human data are genuinely promising, and the longevity payoff in humans is unproven. One thing to keep straight if you shop further: the trials above tested oral precursors, whereas the telehealth market mostly sells glutathione itself — [as an injection listed beside NAD+ and sermorelin](/rxspan-md-review) at one practice, and [inside a broad longevity catalog that also carries metformin and low-dose naltrexone](/agelessrx-review) at another. Neither route was what Sekhar's group studied. For where supplements like this fit alongside programs with real clinical oversight, see our graded [best longevity clinics](/best-longevity-clinics) hub — and to see how much of GlyNAC's signal the glycine half carries on its own, read [glycine for longevity: the other half of GlyNAC](/glycine-for-longevity) or the direct [glycine vs GlyNAC](/glycine-vs-glynac) comparison, which prices the NAC half against what it adds. Sources: https://pubmed.ncbi.nlm.nih.gov/33783984/, https://pubmed.ncbi.nlm.nih.gov/35975308/, https://pubmed.ncbi.nlm.nih.gov/34587244/, https://pubmed.ncbi.nlm.nih.gov/33007928/, https://pubmed.ncbi.nlm.nih.gov/33783984/, https://pubmed.ncbi.nlm.nih.gov/36599349/, https://pubmed.ncbi.nlm.nih.gov/35268089/ --- ### Alpha-Ketoglutarate (Rejuvant/AKG): Does the "8 Years Younger" Claim Hold Up? Canonical: https://longevitygraded.com/alpha-ketoglutarate-for-longevity Updated: 2026-06-04 The viral "8 years younger" AKG result came from a 42-person study with no placebo group and an unvalidated aging clock. An honest evidence review. Few longevity supplements have a marketing number as sticky as alpha-ketoglutarate's. The pitch — that taking AKG (sold most prominently as Rejuvant) made people roughly **eight years biologically younger** — spread across podcasts and supplement stores as if it were a settled scientific result. It is not. Behind that headline is a single small study with a design that can't support a causal claim, conducted with manufacturer involvement, using a biological-age "clock" that isn't validated for proving an individual got younger. This page walks through what AKG actually is, what the famous study really showed, and why the gap between the marketing and the evidence is so wide. For the wider map of what's earned its place versus what's hype, start with our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What AKG is Alpha-ketoglutarate (AKG, also written α-KG or 2-oxoglutarate) is not an exotic drug — it's an **endogenous metabolite**, a central intermediate in the Krebs cycle that every cell uses to make energy. It also sits at the crossroads of several processes biologists care about in aging: it's a co-substrate for enzymes that regulate DNA and histone methylation (so it can influence epigenetics), it feeds amino-acid and collagen synthesis, and it participates in nutrient-sensing pathways. Levels of circulating AKG fall with age, which is the mechanistic seed of the whole longevity pitch. The consumer products are usually a calcium salt (calcium-AKG, the form in Rejuvant), sometimes combined with small amounts of vitamins. So far, so plausible — AKG touches real aging biology. The question, as always on this site, is whether swallowing it does anything measurable for a person. ## The mouse data: a genuine result, but in mice AKG's serious scientific credibility comes from animal work. In a 2020 study, calcium-AKG given to aging mice **extended lifespan and, more strikingly, compressed morbidity** — the animals didn't just live a bit longer, they spent a larger fraction of their remaining life healthy, with the effect partly attributed to AKG-driven changes in inflammation. That "compression of morbidity" framing is genuinely appealing: the goal of longevity medicine isn't just more years but more *healthy* years. Reviews of the broader literature catalog consistent lifespan- and healthspan-extending signals for AKG across model organisms. This is a real, respectable preclinical package — better than many supplements can claim. But it carries the caveat that haunts this entire field: a metabolite that extends lifespan in mice is a hypothesis about humans, not a result in them. Rodent lifespan extensions translate to people far less often than headlines imply, and AKG has no human lifespan or hard-outcome trial at all. ## The "8 years younger" study: what it actually was The human claim everyone repeats comes from a single 2021 paper in *Aging (Albany NY)* by Demidenko and colleagues, reporting on **Rejuvant** (a calcium-AKG formulation). Here is what it genuinely was — and why each feature matters: **It was small: about 42 people.** That's a pilot-scale sample, fine for generating a hypothesis, far too small and selective to establish a population effect. **It had no placebo or control group.** This is the decisive flaw. The study looked at participants' biological-age readings before and after taking the product — but with nobody taking a dummy product for comparison, there is no way to know whether any change was caused by AKG, by regression to the mean, by lifestyle changes in motivated supplement-takers, or by the measurement's own noise. A before-after change in an uncontrolled group is the weakest common design in clinical research, and it cannot support a causal "made people younger" claim. **The "younger" number came from an unvalidated aging clock.** The biological-age reduction (the ~8-year figure widely quoted) was measured with a DNA-methylation "clock." As we explain in detail in our review of [biological age tests](/biological-age-tests), these epigenetic clocks predict aging across large *populations* but are noisy and not validated for telling an *individual* whether an intervention actually slowed their aging. Using such a clock as the primary endpoint, without a control arm, stacks an unproven measurement on top of an uncontrolled design. **There was manufacturer involvement.** The study was connected to the company commercializing the product — a standard conflict-of-interest flag. It doesn't automatically make the data wrong, but industry-run studies of a company's own product, especially small uncontrolled ones, warrant extra skepticism and independent replication before the result is trusted. Put those together and the honest summary is stark: the famous "8 years younger" figure rests on a ~42-person, placebo-free, manufacturer-linked study measured with a clock that can't validly prove individual rejuvenation. That is a weak study, not a breakthrough. ## Supplement status and safety AKG is sold as a **dietary supplement**, not an FDA-approved drug for aging or any condition — no approved indication, no required efficacy proof, label content the manufacturer controls. On safety, the reassuring side is that AKG is an endogenous metabolite the body already makes and uses, calcium-AKG has been used without notable safety alarms in the small human study, and reviews of human AKG use describe it as generally well tolerated. But "appears tolerable in a tiny short study" is not the same as "proven safe for years of self-directed use," and the calcium content of calcium-AKG is worth accounting for if you already supplement calcium. The honest framing is the one this site uses throughout: AKG's *mechanism and mouse data* are interesting, its *safety* at studied doses looks reasonable, and its *human longevity efficacy* is unproven — three separate claims the marketing collapses into one. We apply the same lens across the field in our [best longevity supplements, rated by evidence](/best-longevity-supplements) roundup, and the same skepticism toward biological-age marketing in our [longevity clinic cost](/longevity-clinic-cost) breakdown of what these programs actually charge for unproven metrics. ## The grade ## The bottom line Alpha-ketoglutarate has a better scientific foundation than the average supplement: it's a real metabolite that touches aging biology, and the 2020 mouse study showing extended lifespan with compressed morbidity is a genuinely interesting result. But the human story that made AKG famous — "8 years younger" — is built on a single ~42-person study with no placebo group, manufacturer involvement, and an unvalidated epigenetic clock as its yardstick. That design cannot establish that AKG makes humans biologically younger; it can only generate a hypothesis worth testing properly. Until a larger, controlled, independent trial measures hard outcomes, AKG sits where most of this field does: promising biology, unproven in people, and badly oversold by a number that sounds far more solid than the study behind it. If you take AKG, take it knowing the safety looks reasonable and the rejuvenation claim is not earned. For where supplements like this fit alongside programs with real clinical oversight, see our graded [best longevity clinics](/best-longevity-clinics) hub. Sources: https://pubmed.ncbi.nlm.nih.gov/34847066/, https://pubmed.ncbi.nlm.nih.gov/32877690/, https://pubmed.ncbi.nlm.nih.gov/34952764/, https://pubmed.ncbi.nlm.nih.gov/36934991/, https://pubmed.ncbi.nlm.nih.gov/36599349/ --- ### Dasatinib + Quercetin: How Far Along Is the Flagship Senolytic? Canonical: https://longevitygraded.com/dasatinib-quercetin-senolytics Updated: 2026-06-11 Dasatinib + quercetin is the first-in-human senolytic — with small IPF and kidney signals. But it's a chemo drug plus a flavonoid, with no longevity RCT yet. Dasatinib plus quercetin — usually written **D+Q** — is the closest thing senolytic medicine has to a flagship. When you read that "senolytics have been tested in humans," this is almost always the combination meant. It earned that status honestly: it was the first senolytic discovered through a deliberate mechanism-led search, the first given to people, and the first shown to actually reduce senescent cells in human tissue. But "furthest along" is not the same as "proven," and D+Q comes with a caveat the wellness framing tends to bury: it pairs a **prescription leukemia chemotherapy drug** with a plant flavonoid, and there is still no trial showing it extends human life or healthspan. This page lays out exactly how far the science has come — and how far it hasn't. For the wider map of what's earned its place versus what's hype, start with our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What a senolytic is, and what D+Q actually is As you age, some cells stop dividing but refuse to die — they become **senescent**. These "zombie cells" accumulate and secrete a soup of inflammatory signals (the senescence-associated secretory phenotype) that damages surrounding tissue. Cellular senescence is one of the formal hallmarks of aging, and the leading review of the field lays out why clearing senescent cells is one of the most mechanistically compelling anti-aging strategies on the table. A **senolytic** is a drug that selectively kills these senescent cells. D+Q has two very different halves. **Dasatinib** is an FDA-approved tyrosine-kinase-inhibitor chemotherapy drug, used to treat certain leukemias — a real prescription medicine with real side effects and a serious safety profile, not a supplement. **Quercetin** is a flavonoid found in foods like onions and apples, sold over the counter as a supplement. The senolytic insight was that the two together hit the survival pathways senescent cells depend on more effectively than either alone — which is exactly how the combination was found. ## The discovery and the mouse data: a genuine foundation D+Q's credibility is earned, not hype. The 2015 paper that launched the field identified senescent cells' "Achilles' heel" — the pro-survival networks they rely on — and used that map to pick dasatinib and quercetin as the first targeted **senolytic drugs**. The landmark follow-up in mice went further: intermittent senolytic treatment in aged animals **improved physical function and increased lifespan**, even when started late in life. That combination — a rational mechanism plus a real mouse lifespan result with intermittent "hit-and-run" dosing — is what makes senolytics one of the few genuinely serious anti-aging strategies rather than another supplement story. But it remains, at the lifespan level, mouse data. A drug that extends life in mice is a hypothesis about people, not a result in them — and rodent lifespan extensions translate to humans far less often than headlines imply. ## The human trials: real proof-of-concept, but small and not about lifespan Here is what makes D+Q the flagship — and where the honesty has to come in. There genuinely is human D+Q trial data, and it matters: **First-in-human, idiopathic pulmonary fibrosis (2019).** An open-label pilot in 14 patients with IPF — a brutal, fatal lung-scarring disease with substantial senescent-cell involvement — reported that D+Q improved some physical-function measures (like walking-test performance). It was tiny and uncontrolled, but it was the first time senolytics were given to humans at all. **Diabetic kidney disease (2019).** A separate small trial did something even more important: it showed D+Q **measurably reduced the burden of senescent cells in human fat and skin tissue**. This was the first direct human evidence that senolytics actually do what they're supposed to do in people — clear zombie cells — not just in a dish or a mouse. As proof-of-concept for the senolytic *mechanism*, it's a landmark. **Alzheimer's disease (2023).** A phase 1 feasibility trial established that D+Q could be given to people with mild Alzheimer's, that the drugs reached the brain, and that the approach was tolerable enough to justify larger studies — explicitly a safety/feasibility step, not an efficacy result. **Cognition and mobility in older adults (2025).** A more recent pilot tested D+Q to improve cognition and mobility in older adults at risk of decline; like the others, it's a small early-stage study generating signals to test further, not a definitive outcome trial. Notice the pattern. Every one of these is small, mostly early-phase, and measures **senescent-cell markers, feasibility, or short-term function in sick or at-risk patients** — not lifespan, not healthspan, and not aging in healthy people. They prove the senolytic *concept* has legs in humans. They do not prove D+Q makes people age slower or live longer, and no trial has been designed yet that could. ## The drug-status reality the wellness pitch skips This is the most important practical point, and the one online sellers and biohacking forums gloss over: **dasatinib is chemotherapy.** It's a prescription tyrosine-kinase inhibitor approved for leukemia, with a side-effect profile that includes serious risks (fluid retention around the lungs and heart, bleeding, low blood counts, cardiac effects) — the things you'd expect from a cancer drug. Using it off-label as a "longevity" intervention means taking a serious medicine outside its approved indication, in a regimen whose long-term safety in healthy aging people is **completely unestablished**. Quercetin is a benign supplement; dasatinib is not, and the combination's risk is driven by the dasatinib half. Anyone treating D+Q like a stack of two supplements has misunderstood what it is — and, conversely, anyone treating a standalone quercetin capsule as a senolytic has made the opposite error, since the senolytic effect belongs to the combination, not the flavonoid alone (see [quercetin for longevity: senolytic hype vs evidence](/quercetin-for-longevity)). This is precisely the kind of intervention that belongs under genuine physician supervision — see [what a longevity doctor actually does](/what-is-a-longevity-doctor) for the difference real clinical oversight makes — not self-sourced from a gray-market vendor. On top of the drug-safety issue: the "hit-and-run" intermittent schedules used in trials (a few days, periodically) are research protocols, and the optimal dose, interval, and whether any durable benefit results in humans are all unsettled. "Tolerated in a small short trial of patients" is not "proven safe for years of self-directed anti-aging use." ## The grade ## The bottom line Dasatinib plus quercetin is the most advanced senolytic in human research, and that status is deserved: it was the first senolytic discovered by design, the first given to people, and the first shown to clear senescent cells in human tissue, on top of a real mouse lifespan result. That's a serious, legitimate research program — genuinely one of the more promising directions in aging biology. But "furthest along" still means early. The human trials are small, mostly early-phase, and measure senescent-cell markers, feasibility, and short-term function in sick or at-risk patients — never lifespan or healthspan, and never in healthy people. And the intervention is not a supplement stack: it pairs a flavonoid with a prescription leukemia chemotherapy drug whose off-label long-term safety in aging adults is unknown. D+Q is the best evidence the senolytic *concept* works in humans, and simultaneously an experimental, doctor's-supervision-required intervention that has not been shown to extend human life. Promising, important — and not ready to self-administer. For how senolytics sit alongside the rest of the field's experimental tools, see [peptides for longevity](/peptides-for-longevity), and for programs with real clinical oversight, our graded [best longevity clinics](/best-longevity-clinics) hub. Sources: https://pubmed.ncbi.nlm.nih.gov/25754370/, https://pubmed.ncbi.nlm.nih.gov/29988130/, https://pubmed.ncbi.nlm.nih.gov/30616998/, https://pubmed.ncbi.nlm.nih.gov/31542391/, https://pubmed.ncbi.nlm.nih.gov/37679434/, https://pubmed.ncbi.nlm.nih.gov/40010154/, https://pubmed.ncbi.nlm.nih.gov/33328614/, https://pubmed.ncbi.nlm.nih.gov/36599349/ --- ### TruDiagnostic TruAge Review: Is the $229 Epigenetic Clock Worth It? Canonical: https://longevitygraded.com/trudiagnostic-truage-review Updated: 2026-06-19 TruDiagnostic's TruAge uses the well-validated DunedinPACE clock — but no test proves the score predicts YOUR outcomes. An honest, evidence-graded review. ## The one-sentence version TruDiagnostic's TruAge is one of the better-built consumer epigenetic-age tests on the market — it runs a high-density methylation array and reports DunedinPACE, the most defensible pace-of-aging clock in the literature — and it still cannot tell *you*, the individual buyer, whether your supplement stack, your fasting protocol, or your last clinic visit actually changed how fast you are aging. Both of those things are true at the same time, and the gap between them is the whole review. The science behind the clock is real; the personal-tracking promise the price tag implies is not yet earned. For where biological-age testing sits in the wider toolkit, start with our deeper explainer on [whether epigenetic clocks actually work](/biological-age-tests) and our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What you actually get for ~$229 TruAge is a direct-to-consumer (DTC) DNA-methylation test. You order a kit, provide a blood sample (TruDiagnostic uses a finger-stick blood spot rather than saliva, which is a genuine quality point — blood methylation is the substrate most clocks were trained on), and the lab runs it on a high-density methylation array. Pricing sits in the low-to-mid hundreds depending on the panel tier and any subscription bundling — treat the ~$229 figure as current market positioning rather than a fixed law; DTC longevity pricing moves constantly. What comes back is a report headlined by an estimated biological age plus a set of clock outputs, most notably **DunedinPACE**, a "pace of aging" number where 1.0 means you are aging one biological year per chronological year and 1.2 means roughly 20% faster. The two things that genuinely distinguish TruAge from a generic "spit-in-a-tube biological age" kit are worth naming, because they're real: - **It reports DunedinPACE.** Of all the clocks a consumer test could feature, this is the one with the best conceptual and empirical footing for tracking a *rate* of aging over time (more on why below). - **It uses a high-density array on blood.** That's a more serious analytical substrate than the low-coverage methods some cheaper kits rely on, and blood is the tissue the major clocks were validated in. Neither of those, however, rescues the test from the structural limits every epigenetic clock shares. ## Why DunedinPACE is the right clock to feature Give the science its due. DunedinPACE (Belsky 2022) is not trained to guess your birthday like the first-generation Horvath clock was. It was calibrated against decades of *longitudinal* organ-system decline in a single birth cohort followed since 1972, so instead of estimating an age it estimates a **rate**. That design is the most appealing thing a consumer could want from a longevity test: a speedometer, not an odometer. (For why a pace clock does a different job than the mortality-trained GrimAge or the disease-trained PhenoAge, see our [GrimAge vs PhenoAge vs DunedinPACE comparison](/epigenetic-clock-comparison).) It also has the single most important property for repeat testing — comparatively better reliability. A computational re-engineering effort (Higgins-Chen 2022) showed that the original first-generation clocks were noisy enough to be unfit for clinical-trial or longitudinal tracking, and built principal-component versions specifically to fix that; DunedinPACE was developed in that same reliability-conscious lineage. And — crucially — DunedinPACE has been moved by an actual randomized intervention: in the CALERIE trial, two years of sustained caloric restriction slowed DunedinPACE relative to controls, the cleanest randomized signal that a clock of this type responds to a real intervention. That is a legitimate feather in the cap of the *clock*. It is not yet proof about *you*. ## The three things the price tag implies but the science doesn't deliver Here is where an honest review has to slow the marketing down. TruAge is sold, implicitly, as a personal dashboard you can re-run to see if your protocol is "working." Three well-documented limits stand between that promise and reality. ### 1. A clock that predicts populations is not validated to predict your outcome DunedinPACE and the mortality-trained clocks (GrimAge, PhenoAge) are validated as **predictors across large groups**: people whose methylation runs "fast" or "old" die sooner on average, even after adjusting for known risk factors, as the landmark blood-methylation mortality analysis first showed. But "associates with mortality across thousands of people" is a completely different claim from "if I push my number down, I personally live longer." That second claim — that the clock is a valid, *modifiable target* rather than a passive marker — has not been demonstrated for any clock, DunedinPACE included. An intervention could lower your TruAge reading while leaving your actual disease risk untouched, and you would have no way to tell from the report. The field's own consensus work treats these clocks as legitimate but explicitly **research-stage** tools for intervention studies, not personal diagnostics. ### 2. Test–retest noise can swamp the change you're hoping to see Even the better clocks carry measurement noise. The same DNA sample, run twice, can return estimates that differ — and a detailed reliability study found that many widely used clocks have poor test–retest reproducibility, with first-generation clocks the worst offenders. DunedinPACE is among the more reliable options, which is exactly why featuring it is the right call — but "more reliable than Horvath" is a low bar, and the honest framing is that the noise floor on any single re-test can be of the same order as the small change a 90-day supplement experiment might produce. If you test, change one thing, and re-test, an apparent "improvement" may be measurement variation dressed up as progress. ### 3. There is no standardized, FDA-cleared "biological age" There is no regulatory floor here. TruAge is a laboratory-developed test, not an FDA-cleared diagnostic, and there is no canonical definition of "your biological age" that every lab must hit. Run two reputable methylation tests on the same person and they can disagree, because they use different clocks, arrays, normalization, and reference populations. TruAge's choice to lead with DunedinPACE is a defensible one — but it is still a choice, and it means your number isn't comparable to a competitor's number or to a clinic's in-house clock. (The TruAge brand also powers the cheek-swab test behind David Sinclair's membership — graded separately in our [Tally Health review](/tally-health-review).) ## The grade, and how we got there We grade TruAge on two separate axes, because conflating them is exactly the marketing trap: - **As a serious build on a good clock:** strong. The blood substrate, the high-density array, and the decision to report DunedinPACE put it at the better end of the consumer category. If you are going to buy a methylation test as a one-time curiosity or a rough risk signal, this is a reasonable one to buy. - **As a tool to track whether your longevity protocol is working:** weak. The clock isn't validated as a modifiable personal target, single-test noise can rival the change you're chasing, and there's no FDA-cleared standard behind the headline number. Re-subscribing every quarter to watch the figure wobble is paying to confirm nothing. That split is why the letter grade lands in the middle rather than at either extreme. A genuinely good product wrapped around a genuinely unproven personal promise is, honestly graded, a **B for the science and a C for the use case most people buy it for.** The watch-out is the conflict baked into the broader category: when the same ecosystem sells you the test *and* the supplements meant to improve it, an unvalidated "you got younger" readout becomes a sales tool, not a diagnosis. We dissect a textbook version of that loop in [the "8 years younger" alpha-ketoglutarate claim](/alpha-ketoglutarate-for-longevity). ## Who should and shouldn't buy it - **Reasonable buyer:** someone curious about a one-time, well-built methylation snapshot who will read the DunedinPACE number as a soft risk signal, not a scoreboard — and who won't reorganize their spending around it. - **Poor fit:** someone planning to re-test every few months to "optimize" a supplement stack. The noise and the missing surrogate-validation mean you'll mostly be buying measurement variance. A standard outcome-validated blood panel — ApoB, Lp(a) once, hs-CRP, HbA1c — does far more for that money, and we sort exactly which markers earn their place in [what longevity biomarker panels actually test](/longevity-biomarker-panels). If you mainly want a biological-age number, the open PhenoAge formula derives one from a basic blood panel for nothing — see [free biological-age tests and calculators](/free-biological-age-tests). ## Bottom line TruDiagnostic's TruAge is one of the more credible consumer epigenetic-age tests: blood-based, high-density array, and built around DunedinPACE — the clock with the strongest case for tracking a rate of aging, and the one a real randomized trial (CALERIE) actually moved. But none of that closes the gap that matters for a buyer: no test has shown that lowering *your* TruAge score makes *you* live longer, single-test noise can rival the change you're hoping to detect, and there's no FDA-cleared standard behind the number. Buy it, if at all, as a one-time curiosity from the better end of the category — not as a quarterly scoreboard for your supplement budget. To see where it ranks against GlycanAge, saliva kits, and telomere tests, see our [best at-home biological-age test guide](/best-at-home-biological-age-test). For an independently graded look at the labs and clinics selling biological-age testing, see [our longevity clinic rankings](/best-longevity-clinics). Sources: https://pubmed.ncbi.nlm.nih.gov/24138928/, https://pubmed.ncbi.nlm.nih.gov/35029144/, https://pubmed.ncbi.nlm.nih.gov/36277076/, https://pubmed.ncbi.nlm.nih.gov/37118425/, https://pubmed.ncbi.nlm.nih.gov/30669119/, https://pubmed.ncbi.nlm.nih.gov/29676998/, https://pubmed.ncbi.nlm.nih.gov/25633388/, https://pubmed.ncbi.nlm.nih.gov/37657418/, https://pubmed.ncbi.nlm.nih.gov/39708300/, https://pubmed.ncbi.nlm.nih.gov/32885222/ --- ### Function Health Review: Are 100+ Biomarkers Worth $365/yr? Canonical: https://longevitygraded.com/function-health-review Updated: 2026-08-04 Function Health's 100+ lab membership surfaces real outcome-validated markers — but roughly half are basic labs, and it tests without treating. Honest review. ## The one-sentence version Function Health is a genuinely useful product wrapped in a misleading headline. The "100+ biomarkers" framing implies that more numbers means more health — they don't — but buried inside that long list are a handful of cheap, outcome-validated tests (ApoB, Lp(a), hs-CRP, HbA1c) that most standard checkups skip and that genuinely deserve your attention. It grades **B, 8 points out of 14**, and it is not a paid partner here. The catch is that roughly half the panel is ordinary bloodwork you could get cheaper elsewhere, a chunk of the rest is context or vanity, and the model is structurally **test-but-don't-treat**: it hands you data and flags, not a clinician fixing your problems. Whether $365/year is worth it depends entirely on whether the actionable core justifies the price for you. For where lab-membership testing sits in the field, see our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence) and our breakdown of [what longevity biomarker panels actually test](/longevity-biomarker-panels). ## What you actually get for $365/year Function Health is a direct-to-consumer (DTC) lab membership. For an annual fee of $365, charged yearly, you get a large baseline blood panel (the "100+ biomarkers" headline), a follow-up retest partway through the year, a clean dashboard that flags results outside "optimal" ranges, and physician-ordered/reviewed labs so a clinician signs off on ordering and on results requiring it. What you generally do **not** get is ongoing treatment: Function surfaces and tracks numbers; it is not a longevity clinic prescribing and managing therapy. That distinction — testing versus treating — is the single most important thing to understand before paying, and it's the structural catch of the entire DTC lab band, which we map in [longevity clinics vs lab memberships](/longevity-clinics-vs-lab-memberships). ## The good: it surfaces the markers a basic checkup skips Here's the honest case *for* Function. A standard annual physical often orders a basic lipid panel, a metabolic panel, and a CBC — and stops. Function routinely includes several markers with strong hard-outcome evidence that your regular checkup probably doesn't, and surfacing them is real value: - **ApoB.** The single most useful upgrade over a basic lipid panel. Every atherogenic particle — LDL, VLDL, Lp(a), remnants — carries exactly one ApoB, so it counts the *number* of particles that can lodge in an artery wall, where standard LDL cholesterol measures only the cargo. When the two disagree (common in metabolic syndrome and diabetes), the particle count is the better predictor of cardiovascular events, a conclusion echoed by LDL-particle-number data from the Framingham Offspring cohort, and major lipid guidelines now treat ApoB as a measurement target. - **Lp(a).** A genetically set, mostly lifelong-stable particle that independently and *causally* raises heart-attack and stroke risk — Mendelian-randomization data make the causal case cleanly. You measure it **once**; a high result reshapes how aggressively everything else gets managed. A panel that includes it is doing something genuinely useful (one that re-bills you for it every cycle is padding). - **hs-CRP.** A marker of low-grade systemic inflammation that predicted cardiovascular events at least as well as LDL cholesterol in a large prospective study and was used to *guide* statin treatment with a hard-outcome benefit in the randomized JUPITER trial. (Caveat: it's non-specific — a cold or injury spikes it — so a single high reading means "recheck when well.") - **HbA1c.** Average blood sugar over ~3 months, and not just a diabetes test: it predicted all-cause and cardiovascular mortality *continuously* in a population study, with risk rising across the range including below the diabetes threshold. If Function's panel gets you these four numbers — plus catches a treatable thyroid, ferritin, or vitamin D problem people often misattribute to "aging" — it has earned a meaningful slice of its fee. That's the legitimate core. ## The catch: roughly half is basic labs, and the long tail inflates the number Now the honest case *against* the framing. The "100+ biomarkers" headline does a lot of work, and most of it is marketing: - **A large share is ordinary bloodwork.** The CBC, comprehensive metabolic panel, standard lipids, thyroid, electrolytes, kidney and liver markers — these are useful, but they're the same basic labs available through a primary-care order or a cheap DTC requisition. Bundling them into a "100+" count makes the panel look more exotic than it is. - **Much of the tail is correlated padding.** Most of the extra markers track with the cheap Tier-1 core, so they add line items and a sense of completeness without adding much *independent, actionable* signal. More tubes of blood is not more health. - **Some featured markers are vanity or actively misleading as targets.** Two examples worth naming: - **IGF-1** is marketed as a youth hormone, but its mortality relationship is **U-shaped** — both low *and* high IGF-1 associate with higher mortality in meta-analysis. "Raise your IGF-1 to feel younger" is biologically naïve, and chasing it in either direction is a mistake. - **Homocysteine** associates with cardiovascular risk, so it looks worth treating — but large randomized trials that lowered it with folic acid and B vitamins (HOPE-2) did **not** reduce cardiovascular events. It's a passenger, not a driver; measuring it rarely changes what you should do. ## The structural limit: it tests, it doesn't treat This is the part that decides the grade. Function is a measurement product. It will flag that your ApoB is high or your HbA1c is creeping up — but it does not then manage you: titrate a statin, build a nutrition plan, recheck and adjust. You're handed data and "optimal range" flags, and the work of acting on them falls to you and whatever clinician you already have. For a motivated, health-literate person who *will* take an abnormal ApoB to their doctor and push for treatment, that's fine — even empowering. For someone hoping the membership itself improves their health, it's a category error: surfacing a number is not the same as moving an outcome, and a panel full of green-and-red flags can create a false sense that paying for the data is doing something. The two biggest longevity levers in all of epidemiology aren't even on a blood panel — cardiorespiratory fitness, among the most powerful survival predictors ever measured, and grip strength, which outpredicted blood pressure across 17 countries in the PURE study — and no membership dashboard substitutes for the boring, proven work of moving them. There's also a soft conflict to watch in the broader DTC-lab ecosystem: when "optimal" ranges are drawn tighter than clinical reference ranges, more of your results land in the amber zone — which can nudge you toward supplements or add-on testing. Function's labs being physician-reviewed mitigates the worst of this, but the incentive to make a panel *feel* like it found something is baked into the category, and a tighter-than-clinical "optimal" band is the mechanism. Read your flags against standard clinical thresholds, not just the dashboard's color coding. ## The grade, and how we got there Two axes again, because conflating them is the trap: - **As a way to surface outcome-validated markers your checkup skips:** moderate-to-strong. ApoB, Lp(a), hs-CRP, and HbA1c are real, cheap, hard-outcome-linked tests, and getting them in front of a motivated person is genuine value. - **As a "100+ biomarker" health upgrade that improves your health:** weak. Roughly half is basic labs, much of the tail is correlated padding, a few featured markers (IGF-1, homocysteine) are vanity or misleading as targets, and — decisively — it tests without treating. That split lands the letter grade in the middle: a **B for the actionable core, a C for the model most people think they're buying.** If you're health-literate, have a clinician who'll act on the results, and value the convenience of getting ApoB and Lp(a) without a fight, it can be worth it. If you're hoping a subscription will *make* you healthier, the money does more in a standard outcome-validated panel plus actually treating the few markers that matter. We run that whole cost-benefit in [are longevity clinics worth it?](/longevity-clinics-worth-it). ## Who should and shouldn't buy it - **Reasonable buyer:** a motivated, health-literate person who wants ApoB, Lp(a), hs-CRP, and HbA1c surfaced conveniently and *will* take abnormal results to a clinician who treats them. - **Poor fit:** someone expecting the membership itself to improve their health, or who'll re-read a long list of green/amber flags as a scoreboard. For most of that budget, a targeted outcome-validated panel does the job — and if you want a biological-age number too, the open PhenoAge formula derives one from a basic blood draw for free, as we cover in [free biological-age tests](/free-biological-age-tests). (And don't confuse a comprehensive blood panel with an epigenetic-age test — that's a different product with its own limits, graded in [biological age tests](/biological-age-tests).) ## Bottom line Function Health's real value isn't the "100+ biomarkers" — it's the four or five cheap, outcome-validated markers (ApoB, Lp(a) once, hs-CRP, HbA1c) it surfaces that your standard checkup probably skips, plus the occasional treatable thyroid or deficiency catch. The rest is largely ordinary bloodwork dressed up by a big number, a correlated tail that adds little independent signal, and a couple of markers (IGF-1, homocysteine) that mislead as targets. Most important, it tests without treating: it flags problems it won't fix. Worth it for a motivated, health-literate buyer with a clinician who'll act on the results — a poor fit for anyone hoping a subscription is itself a health intervention. To see how it stacks up against InsideTracker, Lifeforce, and [Superpower](/superpower-health-review) on price and panel padding, see our roundup of the [best longevity blood test services](/best-longevity-blood-tests) — for the closest DNA-plus-blood rival specifically, our [InsideTracker review](/insidetracker-review), and for the one rival that bundles a clinician and prescribing, our [Lifeforce review](/lifeforce-review). For the most-searched head-to-head against its closest price rival, see [Function Health vs Superpower](/function-health-vs-superpower); against the rival that charges more per marker for a smaller panel, [Function Health vs InsideTracker](/function-health-vs-insidetracker). For an independently graded look at the labs and clinics selling these memberships, see [our longevity clinic rankings](/best-longevity-clinics). Sources: https://pubmed.ncbi.nlm.nih.gov/36216435/, https://pubmed.ncbi.nlm.nih.gov/19657464/, https://pubmed.ncbi.nlm.nih.gov/31504418/, https://pubmed.ncbi.nlm.nih.gov/20032323/, https://pubmed.ncbi.nlm.nih.gov/12432042/, https://pubmed.ncbi.nlm.nih.gov/18997196/, https://pubmed.ncbi.nlm.nih.gov/11141143/, https://pubmed.ncbi.nlm.nih.gov/21795450/, https://pubmed.ncbi.nlm.nih.gov/16531613/, https://pubmed.ncbi.nlm.nih.gov/30646252/, https://pubmed.ncbi.nlm.nih.gov/25982160/ --- ### Blueprint Protocol Review (Bryan Johnson): What the Evidence Shows Canonical: https://longevitygraded.com/bryan-johnson-blueprint-review Updated: 2026-06-05 Bryan Johnson's Blueprint is a single-subject experiment with no control group — and roughly 90% of its likely benefit is replicable diet, sleep, and exercise. ## The one-sentence version Bryan Johnson's Blueprint is the most documented self-experiment in longevity, and that is exactly why it proves so little. It is an **N-of-1** — one person, no control group, dozens of interventions stacked at once — so even where his biomarkers improved, the design cannot tell you *which* lever did it, whether it would work in anyone else, or whether any of it extends his life. Strip away the marketing and the supplement stack, and roughly 90% of the plausible benefit traces to three boring, well-evidenced things almost anyone can do for a fraction of the cost: eat well, sleep enough, and exercise. This page separates the legitimate, replicable core from the unfalsifiable single-subject spectacle. For where intensive protocols like this sit in the field, see our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What Blueprint actually is Blueprint is Bryan Johnson's personal anti-aging protocol, run on himself and broadcast in granular detail: a tightly controlled, calorie-defined, largely plant-forward diet; a fixed early bedtime and obsessive sleep tracking; a daily structured exercise routine; and a large daily stack of supplements and off-label interventions, all monitored by frequent, comprehensive biomarker testing and imaging. Johnson reports improvements across many of those markers and frames the project as "measuring everything" to slow his own aging. The protocol has since been packaged into commercial products (supplements, foods, "the stack"), which means the experiment and the storefront now share a brand — a conflict worth holding in mind throughout. ## Why "N-of-1" is the whole story The single most important fact about Blueprint is structural, not biochemical. It is a **single-subject experiment**: one participant, measured intensively over time. That design has a legitimate, growing role in medicine — formal N-of-1 trials can be rigorous and even guideline-relevant when they're properly controlled, randomized within-subject, and blinded. But that rigor depends on a careful design — randomizing the order of interventions, washout periods, blinding, pre-registered endpoints — and even then the field is explicit that adopting the methodology well is hard and full of practical pitfalls. Blueprint has essentially none of those safeguards. It is an uncontrolled, unblinded, many-variables-at-once self-report. Three consequences follow, and they are fatal to the strong claims: - **No control group.** You cannot know what Johnson's markers would have done without the protocol, or with a cheaper version of it. There is no counterfactual. - **Confounded interventions.** Diet, sleep, exercise, and dozens of supplements all change at once, so an improved biomarker can't be attributed to any single component. The supplement that gets the marketing credit may be doing nothing. - **Not generalizable.** Even a real effect in one genetically specific, highly resourced individual says little about whether it works in you. N-of-1 evidence, by definition, is about *that one person*. This is the same trap we flag across the field: **a moved biomarker is not a proven outcome.** Blueprint moves a lot of biomarkers. It has demonstrated, in the scientific sense, essentially nothing about lifespan — because a single uncontrolled subject cannot. ## The ~90% that's real, replicable, and cheap Here's the fair part. Most of Blueprint's *plausible* benefit doesn't come from the exotic stack at all — it comes from three foundations with genuine, large-sample, hard-outcome evidence behind them. These are the levers worth copying, and they're nearly free: - **Diet.** A calorie-controlled, plant-forward eating pattern is exactly the kind of dietary approach with real cardiovascular evidence: the PREDIMED randomized trial found a Mediterranean dietary pattern reduced major cardiovascular events versus a control diet. And maintaining a healthy weight matters at the population scale — excess body weight drove millions of deaths and a large disease burden in a 195-country analysis. You don't need Johnson's branded foods to eat this way. - **Sleep.** Blueprint's rigid, adequate sleep schedule lines up with one of the most robust findings in epidemiology: a meta-analysis of prospective studies found both short and long sleep duration associated with higher all-cause mortality, with the lowest risk around 7 hours. Consistent, sufficient sleep is free. - **Exercise.** A daily structured routine maps onto a dose-response mortality benefit: a pooled analysis of over 600,000 adults found leisure-time physical activity associated with substantially lower mortality, with most of the benefit captured at very achievable activity levels. A pair of shoes and a plan does most of the work. It's worth noting that the closest thing to controlled evidence for an aging-rate effect from any Blueprint-style lever comes not from Johnson but from a randomized trial: in CALERIE, two years of sustained caloric restriction slowed a methylation pace-of-aging measure versus controls — a real signal, but one earned by a controlled trial in many people, not by one man's dashboard. The cheaper protocol most people reach for instead, [intermittent fasting](/intermittent-fasting-for-longevity), has not matched it once trials control for total calories. If you adopt only the diet-sleep-exercise core, you've captured the overwhelming majority of what Blueprint can plausibly deliver — the same evidence-disciplined conclusion Peter Attia reaches in our [review of his book *Outlive*](/outlive-peter-attia-review) — and you can do it for well under a couple thousand dollars a year, versus a protocol whose testing, imaging, and stack run into six figures annually. We put hard numbers on that gap in [what longevity clinics actually cost](/longevity-clinic-cost). ## The 10% that's unproven, expensive, or sold to you The remainder — the part that makes headlines — is where the evidence thins and the conflicts appear: - **The supplement stack.** Dozens of compounds taken together, most without outcome trials at the doses or combinations used, and many now sold under the Blueprint brand. Stacking unvalidated supplements is the opposite of the careful single-variable testing that would actually teach you something — and "it's in Bryan Johnson's stack" is a marketing claim, not evidence. We grade which longevity supplements have real human data (and which don't) in [the best longevity supplements](/best-longevity-supplements). - **Off-label and experimental interventions.** Various drugs and procedures adopted ahead of, or without, outcome evidence in healthy people — the classic "raises a marker, unproven outcome" zone. - **The measurement maximalism itself.** Comprehensive, frequent biomarker testing and imaging feel like rigor, but more numbers is not more health — and intensive screening in a healthy person carries its own costs and false-positive risks. A dashboard full of green flags is not the same as a longer life. The honest read is that the expensive, novel 10% is carrying the brand's mystique while the cheap, boring 90% is carrying the actual benefit. That inversion — credit to the unproven, work done by the proven — is the core thing to see through. ## The grade, and how we got there We grade Blueprint on two axes, because conflating them is the whole illusion: - **As replicable health behavior:** strong. The diet-sleep-exercise foundation is evidence-backed, generalizable, and cheap. Copy that and you've taken the real lesson. - **As scientific proof that the protocol (or its stack) slows aging:** none. It's a single uncontrolled, unblinded, confounded subject. By design it cannot demonstrate causation, generalizability, or any effect on lifespan — and the brand now sells the very supplements the experiment can't validate. That split lands the letter grade low *as evidence* even as the lifestyle core scores high: an **A for the replicable foundation, a D for Blueprint-as-proof.** The takeaway isn't "Bryan Johnson is wrong to try" — self-experimentation is his right — it's that an N-of-1 spectacle should never be read as a result, and you should never pay Blueprint prices (or buy Blueprint supplements) on the strength of one uncontrolled person's biomarker charts. Whether any intensive longevity program clears that bar is the question we run in [are longevity clinics worth it?](/longevity-clinics-worth-it). ## Who should and shouldn't take Blueprint seriously - **Reasonable takeaway:** treat Blueprint as a vivid, well-documented prompt to nail the basics — diet, sleep, exercise, a healthy weight — which is where almost all the defensible benefit lives, at almost none of the cost. - **Poor takeaway:** treating Johnson's biomarker improvements as proof that his stack, his off-label interventions, or his branded products will work for you. That's reading an uncontrolled N-of-1 as a clinical trial, and buying the unproven 10% while the free 90% does the work. ## Bottom line Bryan Johnson's Blueprint is the most thoroughly measured self-experiment in longevity, and its very design — one person, no control, dozens of simultaneous interventions — means it proves nothing about lifespan, generalizes to no one, and can't isolate which lever (if any) helped. Roughly 90% of its plausible benefit comes from three cheap, well-evidenced foundations: a good diet, enough sleep, and regular exercise — copy those and skip the rest. The expensive, novel 10% — the supplement stack, the off-label interventions, the measurement maximalism — is largely unproven and increasingly something the brand sells you. Take the boring lesson, not the spectacle. For an independently graded look at the clinics, labs, and programs in this space — with the conflicts and unproven claims flagged — see [our longevity provider rankings](/best-longevity-clinics). Sources: https://pubmed.ncbi.nlm.nih.gov/39303799/, https://pubmed.ncbi.nlm.nih.gov/40497819/, https://pubmed.ncbi.nlm.nih.gov/38417032/, https://pubmed.ncbi.nlm.nih.gov/29897866/, https://pubmed.ncbi.nlm.nih.gov/28604169/, https://pubmed.ncbi.nlm.nih.gov/20469800/, https://pubmed.ncbi.nlm.nih.gov/25844730/, https://pubmed.ncbi.nlm.nih.gov/37118425/ --- ### VO2 Max and Longevity: The Strongest Fitness Predictor of Lifespan Canonical: https://longevitygraded.com/vo2-max-and-longevity Updated: 2026-06-05 Cardiorespiratory fitness is one of the best-validated predictors of mortality — low fitness carries risk on par with smoking, and it's trainable. Of all the numbers people chase in the name of living longer, VO2 max has the strongest claim to actually matter. It is the single best-validated fitness predictor of how long you'll live — not a supplement, not a clock, not a clinic protocol, but a measure of how much oxygen your body can use at maximal effort. The evidence behind it is unusually deep and consistent: large prospective cohorts, a formal American Heart Association statement, and a clean dose-response gradient where more fitness means lower death rates. Crucially, unlike your age or your genes, it is something you can change. Here is what the science actually shows, graded honestly. ## What VO2 max is VO2 max (maximal oxygen uptake) is the highest rate at which your body can take in, transport, and use oxygen during all-out exercise, expressed in milliliters of oxygen per kilogram of body weight per minute (mL/kg/min). It is the gold-standard measure of cardiorespiratory fitness (CRF) — the integrated capacity of your lungs, heart, blood, and muscles to deliver and consume oxygen. A higher number means a more capable engine. The textbook measurement is a graded exercise test on a treadmill or bike with a mask analyzing your expired air. In research and clinical practice, fitness is also commonly estimated from how long and how hard someone can sustain a treadmill protocol, expressed in metabolic equivalents (METs), where 1 MET is resting metabolism and higher peak METs mean higher fitness. Wearables now estimate VO2 max from heart-rate-to-pace relationships; those estimates are useful for tracking trends but are not as accurate as a lab test. ## Why it predicts mortality so well This is where VO2 max separates itself from almost every other longevity marker: the evidence is both large and old, which is exactly what you want. The landmark modern study analyzed 122,007 adults who underwent treadmill exercise testing and were followed for a median of 8.4 years. The relationship between fitness and survival was strikingly graded: the least-fit participants had dramatically higher all-cause mortality, and there was no observed upper limit to the benefit — the very fittest (elite performers) had the lowest mortality of all. The authors framed the size of the effect bluntly: the risk associated with the lowest fitness was comparable to or greater than traditional clinical risk factors such as smoking, diabetes, and hypertension. That finding sits on a deep foundation. In a classic study of men referred for exercise testing, peak exercise capacity was a more powerful predictor of death than established cardiovascular risk factors, and each 1-MET increase in capacity conferred roughly a 12% improvement in survival. A 2009 meta-analysis pooling healthy men and women confirmed the gradient across populations: higher CRF predicted substantially lower all-cause mortality and fewer cardiovascular events, with low fitness carrying a markedly elevated risk. And the foundational 1989 cohort from the Aerobics Center showed the same pattern decades earlier — higher physical fitness predicted lower all-cause mortality in both men and women, with the steepest benefit gained moving from the least-fit group to merely moderately fit. The convergence of these studies — across eras, populations, and methods — is why the American Heart Association issued a 2016 scientific statement arguing that CRF should be treated as a clinical vital sign, measured and tracked like blood pressure, because it adds prognostic information beyond standard risk factors. Very few longevity interventions earn that kind of institutional backing. (For how this fits the broader, honestly-graded landscape, see our pillar on the [evidence behind longevity medicine](/longevity-medicine-evidence).) ## The honest caveats None of this means VO2 max is a magic number, and honest framing matters here. First, almost all of this evidence is **observational** — these are associations, not randomized proof that raising your VO2 max causes you to live longer. People who are fitter differ in many ways (they tend to be leaner, less likely to smoke, more affluent, healthier at baseline), and statistical adjustment is imperfect. The biological case is strong and the dose-response is clean, but the formal causal claim — "improve your fitness, extend your life" — has not been proven by a randomized lifespan trial, because such a trial is essentially impossible to run. Second, this is a **healthspan and mortality-risk** marker, not a guarantee of extra years for any one person. A high VO2 max strongly tilts the population odds in your favor; it does not exempt an individual from cancer, accidents, or bad genetics. Third, the number is **relative to your age and sex**. A VO2 max of 35 mL/kg/min is poor for a 25-year-old man but excellent for a 70-year-old woman. Reference standards from the large FRIEND registry of cardiopulmonary exercise tests exist precisely so that a measured value can be placed into an age- and sex-specific percentile rather than judged against a single threshold. What matters for risk is where you fall in your own demographic band, and which direction you're trending. ## The genuinely good news: it's trainable Here is what elevates VO2 max from interesting to actionable. Unlike a DNA-methylation clock or your chronological age, cardiorespiratory fitness responds to training at essentially any age — and the biggest risk reduction in every cohort comes from leaving the bottom fitness category, which is the most achievable improvement there is. Both moderate continuous aerobic exercise (the classic ["Zone 2" steady-state work](/zone-2-training-for-longevity)) and higher-intensity interval training raise VO2 max. A 2021 systematic review and meta-analysis in middle-aged and older adults found that interval training and moderate-intensity continuous training both improved cardiorespiratory fitness, with interval training producing somewhat larger VO2 max gains in this population. The practical synthesis most exercise physiologists land on is a base of frequent easy-to-moderate aerobic work to build volume, plus a smaller dose of harder intervals to push the ceiling — but the dominant message from the mortality data is simpler: any move up from the least-fit category is where the largest survival benefit lives. VO2 max also belongs to the same family of cheap, functional measures that predict survival — grip strength, gait speed, and the chair-stand among them — that a 2010 BMJ meta-analysis tied to mortality across community-dwelling adults. It is the cardiovascular member of that family, and arguably the best-studied. (Its muscular counterpart is covered in our look at [grip strength as a longevity biomarker](/grip-strength-and-longevity), and the floor-mobility version in the [sitting-rising test and longevity](/sitting-rising-test-longevity).) ## How to actually measure yours You have three tiers of options. A laboratory or clinical cardiopulmonary exercise test (CPET) with a mask is the accurate gold standard and the one used in the research above; it is also the most expensive and least convenient. A submaximal field test (a timed run, a step test, or a treadmill protocol scored in METs) gives a reasonable estimate. There is also a fourth, free option that skips exercise entirely: the validated HUNT non-exercise equation estimates VO2 max from age, sex, waist, resting heart rate and activity, which is what our [fitness age calculator](/tools/fitness-age-calculator) runs. And a wearable that estimates VO2 max from heart rate and pace is the least accurate but the easiest to repeat — best used to watch your own trend over months rather than to pin down an exact value. For most people the useful workflow is: get one decent baseline (lab if you can, a validated field test if not), place it in an age- and sex-specific percentile using FRIEND-style reference standards, and then train to move up a band — re-testing every few months. If you're building a broader assessment, this pairs naturally with the lab side of the picture in our guide to [longevity biomarker panels](/longevity-biomarker-panels). ## Where this fits in evidence-based longevity Among the things marketed under the longevity banner, cardiorespiratory fitness stands out for having the rare combination the others lack: a huge, consistent, decades-deep evidence base; an effect size on par with major clinical risk factors; institutional endorsement as a vital sign; and — best of all — genuine modifiability at any age. It earns an honest high grade not because of hype but because the data keep saying the same thing. Notably, in the Finnish cohort data, fitness and frequent sauna use were *additive* — the lowest mortality belonged to men who were both fit and regular sauna-goers — which is why we treat the [sauna's longevity case](/sauna-for-longevity) as a complement to fitness, not a substitute. If you want to see how the clinics and programs that build structured fitness and assessment into longevity care actually compare on evidence, oversight, and price, we grade the field in our [best longevity clinics hub](/best-longevity-clinics). ## The bottom line VO2 max is, on the current evidence, the strongest fitness-based predictor of longevity we have. Low cardiorespiratory fitness carries mortality risk comparable to smoking or diabetes, and the relationship is graded with no clear ceiling — fitter is better, all the way up. The honest caveat is that the evidence is observational, so it proves strong association rather than guaranteed causation, and your number must be read against your own age and sex. But the practical takeaway is unusually clean: this is a high-impact marker you can actually move, the biggest gains come from leaving the least-fit group, and a mix of easy aerobic volume and harder intervals is how you do it. Sources: https://pubmed.ncbi.nlm.nih.gov/30646252/, https://pubmed.ncbi.nlm.nih.gov/11893790/, https://pubmed.ncbi.nlm.nih.gov/19454641/, https://pubmed.ncbi.nlm.nih.gov/2795824/, https://pubmed.ncbi.nlm.nih.gov/27881567/, https://pubmed.ncbi.nlm.nih.gov/34809986/, https://pubmed.ncbi.nlm.nih.gov/33825615/, https://pubmed.ncbi.nlm.nih.gov/20829298/ --- ### Grip Strength as a Longevity Biomarker: What the Evidence Shows Canonical: https://longevitygraded.com/grip-strength-and-longevity Updated: 2026-06-05 In the 140,000-person PURE study, grip strength outpredicted systolic blood pressure for mortality. A genuinely strong, free, at-home biomarker. Few longevity markers are as cheap, as fast, or as surprisingly powerful as how hard you can squeeze. Grip strength — measured in seconds with a handheld dynamometer — predicts all-cause and cardiovascular mortality in some of the largest prospective studies ever run, and in at least one of them it outpredicted systolic blood pressure. That is a remarkable claim for a free at-home test, and unlike most things marketed under the longevity banner, it largely holds up. Here is what the evidence actually shows, graded honestly, and what it does and doesn't mean for you. ## What grip strength is — and why it stands in for so much Grip strength is the maximal force your hand can generate, usually measured with a hand dynamometer and reported in kilograms. You squeeze as hard as you can, typically a few times per hand, and the best value is recorded. Its predictive power comes from the fact that it is a convenient window onto whole-body muscle status. Grip correlates with total muscle mass and overall strength, and declining grip is one of the defining features of **sarcopenia** — the age-related loss of muscle mass and function. The revised European (EWGSOP2) consensus actually uses low grip strength as a primary criterion for diagnosing sarcopenia, precisely because it's a fast, reliable proxy for muscle quality across the body. When grip falls, it usually signals that the entire muscular system — the engine of metabolism, mobility, and resilience — is weakening. ## The evidence: genuinely strong This is where grip strength separates itself from most longevity fads. The evidence is large, prospective, and consistent. The headline study is **PURE** (Prospective Urban Rural Epidemiology), which measured grip strength in nearly 140,000 adults across 17 countries and followed them for a median of about four years. Each 5 kg decrease in grip strength was associated with a 16% higher risk of all-cause death, a 17% higher risk of cardiovascular death, and higher risk of heart attack and stroke. Strikingly, grip strength was a **stronger predictor of death than systolic blood pressure**. That a simple squeeze outperformed a cornerstone clinical vital sign is the finding that put grip strength on the longevity map. PURE doesn't stand alone. The **UK Biobank** analysis of roughly half a million adults found that lower grip strength was associated with higher all-cause mortality and with cardiovascular disease, respiratory disease, and cancer outcomes, after extensive adjustment for confounders. Going further back, a landmark study showed that **midlife** grip strength predicted disability 25 years later — weaker men in their 50s and 60s were substantially more likely to be disabled in old age. And a 2018 meta-analysis pooling data from roughly two million men and women concluded that muscular strength is an independent predictor of all-cause mortality in apparently healthy populations. A 2019 review summarizing this literature went so far as to call grip strength an "indispensable biomarker" for older adults. Grip strength also belongs to the broader family of simple physical-capability measures — gait speed, the chair-stand, cardiorespiratory fitness — that a 2010 BMJ systematic review tied to mortality across community-dwelling adults. Within that family, grip is the muscular-strength member, and it is one of the best-studied. (Its cardiovascular counterpart is covered in [VO2 max and longevity](/vo2-max-and-longevity), and the floor-mobility version in the [sitting-rising test](/sitting-rising-test-longevity).) ## The honest caveats A strong grade does not mean a blank check. Three caveats keep this honest. First — and this is the big one — **the evidence is observational**. Grip strength is powerfully *associated* with survival, but no randomized trial has shown that training your grip in isolation extends your life. Grip is best understood as a **marker** of underlying health: people with weak grip often have less muscle, more chronic disease, more frailty, and more inactivity, and those are what drive the risk. The squeeze is a readout of the system, not necessarily a lever you pull on directly. Buying a hand-gripper and building forearm strength while ignoring whole-body conditioning would miss the point entirely. Second, the number is **relative to age and sex**. Grip declines with age and differs substantially between men and women, so a value that's weak for a 30-year-old man can be normal for a 75-year-old woman. What matters is where you fall for your demographic — and, more usefully, which direction you're trending over time. Third, it is a **population-level signal, not a personal verdict**. A strong grip tilts the odds in your favor; it does not exempt anyone from cancer, accidents, or genetics. Treated as "this number reveals your lifespan," it's hype. Treated as a quick read on your muscular health and a prompt to act, it's genuinely useful. ## The actionable part: it's trainable Here is what makes grip strength worth caring about rather than merely worth measuring: the muscle it stands in for is among the most trainable tissue in the body, at any age. The classic demonstration gave frail nursing-home residents *in their 90s* eight weeks of supervised resistance training and roughly doubled their muscle strength, with measurable gains in mobility. Strength is recoverable even very late in life. The honest framing of the causal chain matters, though. Because grip is a proxy for whole-body muscle, the useful intervention isn't a hand-gripper — it's **progressive resistance training** (and adequate protein) that builds muscle and strength across the body, with grip rising as a natural byproduct. A rising grip number over the years is feedback that your strength program is working; a falling one is an early warning to address before it becomes frailty. (For the lab-marker side of tracking your aging, this pairs with [longevity biomarker panels](/longevity-biomarker-panels) and the accuracy of [biological-age tests](/biological-age-tests). And note one popular recovery habit that can quietly work against muscle-building: routinely icing right after lifting blunts strength and hypertrophy gains — see [cold plunge for longevity](/cold-plunge-for-longevity).) ## How to measure yours The accurate way is a calibrated hand dynamometer (inexpensive ones are widely available): sit with your elbow at 90 degrees, squeeze maximally for a few seconds, do two or three trials per hand, and record the best value. Compare it against age- and sex-specific reference ranges, or simply re-test every few months and watch your own trend. The EWGSOP2 thresholds used clinically flag low strength at roughly under 27 kg for men and under 16 kg for women, though these are screening cutoffs for sarcopenia rather than personalized targets. If you don't have a dynamometer, a dead-hang time or a farmer's-carry can serve as a rough, repeatable home proxy for tracking change — just keep the conditions consistent. ## Where this fits in evidence-based longevity Grip strength is one of the rare longevity markers that earns a high grade on the merits: it sits on huge prospective cohorts and a two-million-person meta-analysis, it's free and fast, and it points at something — muscle — that you can genuinely build at any age. Its main limitation is the one shared by every observational marker: it proves strong association, not personal causation. For the broader, honestly-graded picture of what longevity medicine can and can't deliver, see our pillar on the [evidence behind longevity medicine](/longevity-medicine-evidence). And if you want to see how the clinics and lab memberships that build strength assessment and frailty screening into their programs compare on evidence and price, we grade the field in our [best longevity clinics hub](/best-longevity-clinics). ## The bottom line Grip strength is a legitimately strong longevity biomarker — in the 140,000-person PURE study it outpredicted systolic blood pressure for mortality, and the finding is echoed across the UK Biobank and a two-million-person meta-analysis. It works because it's a fast proxy for whole-body muscle, the decline of which (sarcopenia) drives frailty and death. The caveats are the honest ones: the evidence is observational, the number must be read against your age and sex, and it's a population signal, not a personal prophecy. But the takeaway is clean and useful — measure it, track your trend, and if it's low or falling, build muscle with resistance training, because the thing it measures is one of the most trainable parts of you. Sources: https://pubmed.ncbi.nlm.nih.gov/30312372/, https://pubmed.ncbi.nlm.nih.gov/25982160/, https://pubmed.ncbi.nlm.nih.gov/29739772/, https://pubmed.ncbi.nlm.nih.gov/10022113/, https://pubmed.ncbi.nlm.nih.gov/29425700/, https://pubmed.ncbi.nlm.nih.gov/31631989/, https://pubmed.ncbi.nlm.nih.gov/20829298/, https://pubmed.ncbi.nlm.nih.gov/2342214/ --- ### Fasting-Mimicking Diet (ProLon) Review: Does the Evidence Hold Up? Canonical: https://longevitygraded.com/fasting-mimicking-diet-prolon Updated: 2026-07-24 ProLon's 5-day fasting-mimicking diet has real human trials behind it — but most are tied to its inventor's company. An honest, graded look. The fasting-mimicking diet (FMD), sold commercially as ProLon, is one of the few longevity products with actual human clinical trials behind it — which already puts it ahead of most of the field. It is a five-day, plant-based, low-calorie meal kit engineered to put your body into a "fasting" metabolic state while you keep eating, with headline claims of reduced biological age, lower disease-risk markers, and a slimmer waist. The catch, and the reason this needs honest grading rather than cheerleading, is that nearly all of the supporting research traces back to the company's own founder. Here is what the science genuinely shows, what's promotional, and how to read the gap. ## What the fasting-mimicking diet actually is The FMD was developed in the laboratory of Valter Longo, a respected aging researcher at the University of Southern California. The concept is clever: rather than asking people to water-fast (hard to sustain, and clinically risky for some), the diet supplies a specific low-calorie, low-protein, low-sugar, higher-fat formula for five consecutive days, designed to trick the body's nutrient-sensing pathways into a fasting-like response while still providing food. Mechanistically, the goal is to lower signals like IGF-1 and glucose and to nudge the body toward cellular cleanup (autophagy) and a regenerative state — pathways that, in animal models, are linked to healthspan. ProLon is the commercial packaging of this protocol: a branded five-day box of soups, bars, drinks, and supplements, typically run for five days once a month for a few months. (For how these nutrient-sensing ideas map onto the broader longevity toolkit, see our pillar on the [evidence behind longevity medicine](/longevity-medicine-evidence).) ## The conflict-of-interest flag, up front Before the evidence, the disclosure — because it shapes how to read everything that follows. Valter Longo, who developed the FMD, is the founder of **L-Nutra**, the company that sells ProLon, and the university holds related interests. Much of the human research on the FMD was conducted or co-authored by Longo and colleagues with financial ties to the product. That does not make the findings fake — these are real, peer-reviewed, often randomized studies in good journals. But it is exactly the pattern this site is built to flag: when the strongest evidence for a commercial product comes largely from the people who profit from it, independent replication carries extra weight, and its relative scarcity is itself a finding. This is the same conflict-of-interest scrutiny we apply to direct-to-consumer [biological-age tests](/biological-age-tests). ## What the human trials show The actual human data are more substantial than for most supplements — that's the honest part. The pivotal randomized trial enrolled 100 generally healthy adults and had them complete three monthly cycles of the FMD. Compared with controls eating their normal diet, the FMD group showed reductions in body weight and trunk fat, lower blood pressure, lower fasting glucose, reduced IGF-1, and lower C-reactive protein (an inflammation marker) — with the largest improvements concentrated in participants who started with elevated risk factors. That is a genuine, randomized, multi-marker benefit, and it's the backbone of ProLon's marketing. A 2024 analysis pushed the claim further, reporting that FMD cycles were associated with changes in blood and imaging-derived markers consistent with a **reduction in biological age** — the source of the widely repeated "younger by about two and a half years" headline — alongside reduced liver fat and improved metabolic markers. The foundational work in mice plus a small human pilot showed the diet promoted multi-system regeneration and improved healthspan markers, and FMD cycles have also been studied in disease-adjacent settings such as autoimmunity and multiple sclerosis models, with a small accompanying human pilot. So the floor here is real: short-term, the FMD reliably moves cardiometabolic and inflammatory markers in the right direction, especially in people who need it most. That is more than can be said for the average longevity supplement. ## Where the evidence stops — and the hype begins Now the honest ceiling. Three gaps separate "improves risk markers" from the lifespan and "reverse aging" language that surrounds ProLon. **First, these are surrogate markers, not hard outcomes.** Weight, glucose, CRP, IGF-1, and a biological-age estimate are *predictors* believed to track with future health — not proof of fewer heart attacks, less cancer, or a longer life. No randomized trial has shown the FMD extends human lifespan or reduces hard clinical events. The "biological age" claim in particular rests on aging-clock estimates that are themselves not validated to predict an individual's outcomes, a limitation we detail in our [biological-age tests](/biological-age-tests) review. **Second, much of the benefit may simply be calorie restriction.** A five-day, very-low-calorie diet repeated monthly produces weight loss and metabolic improvement largely because it cuts calories — and the rigorous, independent CALERIE randomized trial already established that sustained calorie restriction improves cardiometabolic risk markers in healthy adults. The open question the FMD literature hasn't cleanly answered is whether the specific FMD formula does anything *beyond* what equivalent calorie reduction would do. Broader reviews of fasting regimens reach a similar verdict: the metabolic benefits of intermittent and periodic fasting are real but substantially overlap with energy restriction, and the long-term human outcome data remain thin. **Third, the independence problem.** Because the strongest FMD trials are largely tied to the product's commercial interests, the field is waiting on robust, fully independent replication — particularly of the more dramatic biological-age claims. Until that exists, the honest stance is cautious optimism, not endorsement. ## Cost, safety, and who it's for ProLon is sold as a packaged five-day kit, generally priced in the low-to-mid hundreds of dollars per cycle, with protocols often calling for several monthly cycles — so the real cost is multiplied. You are paying a premium for the convenience and formulation of what is, nutritionally, a structured very-low-calorie week — the unbranded, free version of that trade-off is [intermittent fasting](/intermittent-fasting-for-longevity), whose human trials suggest most of the benefit is the calorie deficit rather than the timing. On safety, a monitored FMD is generally well tolerated in healthy adults in the trials, with mostly mild effects (fatigue, headache, hunger). But it is **not for everyone**: people who are underweight, pregnant or breastfeeding, frail or older with low muscle mass, those with diabetes on glucose-lowering medication (hypoglycemia risk), or anyone with a history of disordered eating should not attempt it without medical supervision. The repeated low-protein weeks also raise a muscle-preservation question for older adults, for whom maintaining lean mass is itself a longevity priority. This is a medical intervention dressed as a meal kit, not a casual cleanse. ## Where this fits in evidence-based longevity The FMD occupies an unusual middle tier: better-evidenced than nearly every longevity supplement (it has randomized human trials), but weaker than its marketing implies (surrogate markers only, heavy overlap with plain calorie restriction, and an unresolved conflict-of-interest cloud). It earns a moderate grade — promising and real, not proven and not magic. It sits alongside other metabolic-pathway interventions like [metformin for longevity](/metformin-for-longevity), which faces its own "surrogate-versus-outcome" gap. If you want to see how the clinics and programs that prescribe fasting protocols and biological-age testing compare on published price and what they actually sell, we grade the field in our [best longevity clinics hub](/best-longevity-clinics). ## The bottom line The fasting-mimicking diet (ProLon) is one of the rare longevity products with real, randomized human evidence — and short-term it genuinely improves weight, blood pressure, glucose, inflammation, and IGF-1, most in those who start out at higher risk. But the honest grade is moderate, not glowing. The benefits are surrogate markers rather than proven lifespan or hard-outcome gains; much of the effect likely reflects calorie restriction the cheaper CALERIE-style way; and most of the supporting research is tied to the company that sells it, awaiting independent replication. If you're metabolically unhealthy and want a structured reset under medical guidance, the FMD is a defensible, evidence-touched option — just don't pay for, or believe in, more than the data actually supports. Sources: https://pubmed.ncbi.nlm.nih.gov/28202779/, https://pubmed.ncbi.nlm.nih.gov/26094889/, https://pubmed.ncbi.nlm.nih.gov/38378685/, https://pubmed.ncbi.nlm.nih.gov/27239035/, https://pubmed.ncbi.nlm.nih.gov/31303390/, https://pubmed.ncbi.nlm.nih.gov/31881139/, https://pubmed.ncbi.nlm.nih.gov/27810402/ --- ### Hyperbaric Oxygen for Aging: Does the Telomere Claim Hold Up? Canonical: https://longevitygraded.com/hbot-for-longevity Updated: 2026-06-05 One small Israeli trial reported HBOT lengthened telomeres 38% and cut senescent cells. It's striking, unreplicated, and expensive. An honest, graded review. Hyperbaric oxygen therapy (HBOT) has a longevity story built almost entirely on a single, genuinely surprising result. In 2020, an Israeli research group reported that a course of HBOT in healthy older adults lengthened immune-cell telomeres by about 20–38% and cut the share of senescent cells by roughly a third — two of the most cited cellular markers of aging, moving in the "younger" direction over just three months. That finding launched a wave of clinics selling HBOT as an anti-aging protocol. This page does what the marketing won't: it takes the study seriously, then weighs how much you should actually conclude from one small, unreplicated, expensive trial. For the wider map of what's earned its place versus what's hype, start with our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What HBOT is Hyperbaric oxygen therapy means breathing 100% oxygen inside a chamber pressurized above sea level — typically around 2 atmospheres absolute. The combination dramatically raises the amount of oxygen dissolved in your plasma and delivered to tissue. HBOT is an established, FDA-cleared treatment for a specific list of conditions: decompression sickness, carbon-monoxide poisoning, non-healing diabetic wounds, certain radiation injuries, and a handful of others. Its accepted mechanisms — promoting angiogenesis (new blood-vessel growth), mobilizing stem/progenitor cells, and modulating inflammation and oxidative-stress signaling — are real and reviewed in the clinical literature. The longevity question is entirely separate from those approved uses: it asks whether repeatedly dosing healthy people with hyperbaric oxygen can slow or reverse biological aging. That is not an approved indication, and the evidence for it is thin. ## The headline study: telomeres and senescent cells The paper that built the hype was Hachmo and colleagues, published in *Aging* in 2020. It enrolled 35 healthy adults aged 64 and older and gave them 60 daily HBOT sessions over three months, with no control group — each person served as their own baseline. The reported results were striking: telomere length in several immune-cell types increased by roughly 20–38%, and the proportion of senescent T-cells dropped by about 11–37% depending on the cell subset. In the authors' framing, HBOT had pushed two hallmark markers of cellular aging — telomere attrition and cellular senescence — backward. A companion paper from the same group, using the same protocol, reported improvements in cognitive function in healthy older adults — gains in attention, processing speed, and executive function. Together these two studies are essentially the entire human "HBOT for aging" evidence base, and both come from one team using one protocol in overlapping cohorts. ## Why one striking study isn't proof Take the telomere result at face value and it's remarkable. But several features should pull your confidence down hard before you spend thousands of dollars. First, **there was no control group.** Telomere measurement is technically noisy, and an uncontrolled, unblinded design can't separate a true biological effect from measurement drift, regression to the mean, or expectation effects. Second, the **sample was tiny** — 35 people, with telomere effects reported in subsets of those. Third, and most important, **it has not been independently replicated.** A finding this consequential — "you can lengthen human telomeres with oxygen" — would normally be confirmed by other labs before it's treated as established. As of now, no independent group has reproduced it. Fourth, **longer telomeres are not unambiguously good.** Telomere length is a marker, not a goal in itself, and the relationship between lengthening telomeres and either lifespan or cancer risk is genuinely complicated — aggressively pushing telomerase-style effects is something the cancer-biology literature treats with caution, not enthusiasm. The cognitive paper carries the same limitations: small, single-group or modestly controlled, single-team. None of this means the effect is fake. It means the evidence is at the "intriguing preliminary signal" stage — the level where more research is warranted, not the level where a clinic should be charging you to reverse your biological age. ## Cost and burden are not trivial The longevity protocol in the study was 60 sessions over three months — five days a week, each session running well over an hour including compression and decompression. Replicating that at a private clinic runs into the thousands to tens of thousands of dollars, since anti-aging HBOT is not covered by insurance (it's an off-label, non-approved use). That's a large commitment of money and time for an effect supported by one uncontrolled study. For how this slots into the broader spend question, see our [longevity clinic cost](/longevity-clinic-cost) breakdown and our graded take on whether [longevity clinics are worth it](/longevity-clinics-worth-it). ## Safety: real but generally manageable HBOT is not risk-free. The well-documented adverse effects are mostly pressure- and oxygen-related: middle-ear barotrauma (the most common), sinus squeeze, temporary nearsightedness that usually reverses, claustrophobia, and — rarely — oxygen-toxicity seizures and pulmonary effects at the upper end of dosing. In medically supervised settings for approved indications, serious events are uncommon. The relevant caution for longevity use isn't that HBOT is dangerous in trained hands — it's that you'd be accepting real procedural risk, real cost, and real time for an unproven anti-aging benefit. People with certain lung conditions, recent ear surgery, or specific cardiac issues need screening first. This is a medical procedure, not a spa add-on. ## How it compares to better-supported levers The honest comparison is what stings for HBOT. The cellular markers it claims to move — telomere attrition and senescence — are real hallmarks of aging, and clearing senescent cells does extend healthy lifespan in mice. But the interventions with the strongest *human* track record for healthspan are far cheaper and better evidenced: resistance training, cardiovascular fitness, sleep, and nutrition. HBOT asks you to pay a great deal for a single-study signal, while the highest-grade healthspan levers cost little and are backed by large bodies of evidence. We rank the supplement side of that ledger in [best longevity supplements, rated by evidence](/best-longevity-supplements), and the diagnostic side in [longevity biomarker panels](/longevity-biomarker-panels). ## The grade ## The bottom line HBOT for aging rests on one genuinely interesting, genuinely fragile finding: a small, uncontrolled, unreplicated Israeli trial reporting longer telomeres and fewer senescent cells after 60 sessions. That's a reason to keep studying it — not a reason to treat it as a proven anti-aging therapy or to spend thousands chasing it. The mechanisms HBOT is approved for are real; the longevity claim is at the "promising signal, needs replication" stage, with telomere lengthening itself being a double-edged marker rather than a clean win. If you're drawn to it, go in clear-eyed: real cost, real procedural risk, and a single uncontrolled study behind the headline. For where interventions like this fit alongside programs with real clinical oversight, see our graded [best longevity clinics](/best-longevity-clinics) hub, and compare HBOT's thin human case to a cheaper, better-mechanism neighbor in [spermidine for longevity](/spermidine-for-longevity). For another heat-based therapy with a far deeper (if observational) outcome record, see [sauna and longevity](/sauna-for-longevity). Sources: https://pubmed.ncbi.nlm.nih.gov/21200283/, https://pubmed.ncbi.nlm.nih.gov/33206062/, https://pubmed.ncbi.nlm.nih.gov/36599349/, https://pubmed.ncbi.nlm.nih.gov/32589613/, https://pubmed.ncbi.nlm.nih.gov/26840489/ --- ### Creatine for Aging: The Cheapest Evidence-Backed Supplement? Canonical: https://longevitygraded.com/creatine-for-aging Updated: 2026-06-05 Creatine has the strongest human evidence of any longevity supplement — for healthspan, not lifespan. With resistance training it adds muscle and strength. Most of what gets sold as a longevity supplement is mechanism dressed up as proof — a molecule that does something interesting in a mouse, marketed as if it slows human aging. Creatine is the rare exception that runs the other way: it's a cheap, decades-old gym supplement with hundreds of human trials, and the honest verdict is that it has *more* high-quality evidence than almost anything else on the longevity-supplement shelf. The catch is what the evidence is actually for. Creatine has a strong case for **healthspan** — preserving muscle, strength, and function as you age — and essentially no case for **lifespan**. This page grades it honestly on both. For the wider map of what's earned its place versus what's hype, start with our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What creatine is Creatine is a compound your body already makes (mostly in the liver and kidneys) and that you also get from meat and fish. About 95% of it is stored in muscle as phosphocreatine, where it serves as a rapid energy buffer — regenerating ATP during short, intense efforts. Supplementing raises muscle creatine stores above what diet and synthesis alone provide. Creatine monohydrate is the most-studied form by a wide margin, it's inexpensive (often pennies per day), and it's sold as a dietary supplement rather than a drug. The relevance to aging is direct: the loss of muscle mass and strength with age — sarcopenia — is one of the most consequential drivers of frailty, falls, and loss of independence, and it overlaps with the formal hallmarks of aging, including stem-cell exhaustion and mitochondrial dysfunction. Anything cheap and safe that blunts muscle loss is worth taking seriously. ## The strongest evidence: muscle and strength with resistance training This is where creatine earns its grade. The single most important fact about creatine for aging is that its benefits are largely *unlocked by resistance training* — it's a training amplifier, not a standalone pill. A systematic review and meta-analysis by Chilibeck and colleagues pooled randomized trials of creatine combined with resistance training in older adults and found that adding creatine produced significantly greater gains in lean tissue mass and muscle strength than resistance training alone. A separate meta-analysis by Dos Santos and colleagues reached the same conclusion: creatine plus resistance training meaningfully improved muscle strength and mass versus training plus placebo. And a Forbes meta-analysis examining ingestion strategies confirmed that creatine augments lean-tissue and strength gains during resistance training across age groups. Three independent meta-analyzes, the same direction of effect — this is about as solid as supplement evidence gets. The practical reading is important and honest: creatine without training gives you very little for muscle. Creatine *with* a structured resistance program gives older adults a measurable edge on exactly the outcomes that determine whether you stay strong and independent. ## Bone: a plausible, training-dependent bonus Bone is more nuanced. In a 12-month randomized trial in postmenopausal women, creatine combined with resistance training improved a measure of hip bone geometry and strength compared with placebo plus training. But the broader picture is mixed: a separate analysis found that creatine during resistance training did *not* lead to greater whole-body bone mineral density gains than training alone. The honest summary is that creatine may support bone *quality/geometry* at specific sites when paired with loading exercise, but it is not a proven osteoporosis treatment, and the bone evidence is weaker and less consistent than the muscle evidence. ## Cognition: real but modest, and context-dependent Creatine's brain story is genuinely interesting but easy to overstate. A 2024 systematic review and meta-analysis found that creatine supplementation had measurable effects on aspects of cognitive function in adults, and a meta-analysis focused on memory found small improvements in healthy individuals, with effects more apparent in older adults. The pattern across this literature is that creatine's cognitive benefits show up most under metabolic stress — sleep deprivation, demanding mental tasks, or in older brains — and are smaller or absent in well-rested younger people. So: a modest, real cognitive signal that's strongest exactly where aging makes the brain more energy-stressed, not a nootropic miracle. ## Safety: among the best-characterized supplements there is Creatine's safety record is one of its biggest advantages. The International Society of Sports Nutrition's position stand concluded that creatine monohydrate is safe and effective, and that there's no compelling evidence it harms kidney function in healthy people at recommended doses — directly addressing the most persistent myth about it. A detailed review of common questions and misconceptions reached the same conclusions and noted that creatine doesn't cause dehydration, cramping, or hair loss as commonly claimed, and that long-term use at standard doses is well tolerated. The usual protocol is ~3–5 g/day of creatine monohydrate; an optional loading phase (~20 g/day split over several days for a week) fills muscle stores faster but isn't required. The standard caveat still applies: people with existing kidney disease should check with a clinician first, and "safe in healthy people" is not the same as "safe for everyone regardless of condition." ## Healthspan, not lifespan Here's the line the marketing blurs and we won't: there is **no evidence creatine extends human lifespan.** No trial has tested whether creatine makes people live longer, and none is realistically underway that could. What creatine has — and has in unusual abundance — is randomized human evidence that it improves the *components of healthspan* that matter most for aging well: muscle mass, strength, and physical function when paired with training, plus modest cognitive support. That's a genuinely strong position for a longevity supplement, but it's a healthspan claim, not a lifespan one. Preserving strength and function maps directly onto staying independent — see how that connects to functional tests in our [sitting-rising test and longevity](/sitting-rising-test-longevity) explainer. ## How it stacks up against the rest of the shelf Against the typical longevity supplement, creatine looks excellent precisely because the bar is so low. Most of the field rests on mouse lifespan data or contested human biomarkers; creatine rests on multiple meta-analyzes of randomized human trials hitting hard functional outcomes. It's also one of the cheapest interventions in the entire category. That combination — high evidence quality, real functional benefit, trivial cost, strong safety — is why it tends to top evidence-ranked roundups. See where it lands among the rest in [best longevity supplements, rated by evidence](/best-longevity-supplements), and how the biomarker-versus-benefit gap plays out elsewhere in [longevity biomarker panels](/longevity-biomarker-panels) — or in [omega-3 for longevity](/omega-3-for-longevity), a supplement whose strongest longevity signal is a small, surrogate epigenetic-clock effect. For another supplement that, like creatine, earns its grade on hard outcomes in a specific population rather than lifespan, see [CoQ10 and ubiquinol for aging](/coq10-for-longevity). ## The grade ## The bottom line Creatine is the closest thing the longevity-supplement aisle has to a sure thing — with one honest boundary. For **healthspan**, it's a standout: multiple meta-analyzes show that creatine plus resistance training adds lean mass and strength in older adults, the cognitive signal is real if modest, the safety profile is excellent, and the cost is trivial. For **lifespan**, there's nothing — no creatine trial has ever tested whether people live longer. The takeaway is simple and unusually positive for this site: if you're going to lift (and for healthy aging you should), creatine monohydrate at ~3–5 g/day is one of the best-evidenced, cheapest, safest things you can add — as a function-and-strength play, not a longevity miracle. For where supplements like this fit alongside programs with real clinical oversight, see our graded [best longevity clinics](/best-longevity-clinics) hub, and compare creatine's strong human base to the far thinner case for [hyperbaric oxygen for aging](/hbot-for-longevity). Sources: https://pubmed.ncbi.nlm.nih.gov/36599349/, https://pubmed.ncbi.nlm.nih.gov/29138605/, https://pubmed.ncbi.nlm.nih.gov/34836013/, https://pubmed.ncbi.nlm.nih.gov/34199420/, https://pubmed.ncbi.nlm.nih.gov/25386713/, https://pubmed.ncbi.nlm.nih.gov/29740583/, https://pubmed.ncbi.nlm.nih.gov/39070254/, https://pubmed.ncbi.nlm.nih.gov/35984306/, https://pubmed.ncbi.nlm.nih.gov/28615996/, https://pubmed.ncbi.nlm.nih.gov/33557850/ --- ### The Hallmarks of Aging, Explained (and Why They Matter) Canonical: https://longevitygraded.com/hallmarks-of-aging-explained Updated: 2026-07-26 The hallmarks of aging are the cellular processes that drive getting old. A plain-English guide to the 2013 and 2023 framework — and why each one gets targeted. Almost every longevity intervention you'll read about — senolytics, NAD+ boosters, rapamycin, fasting, even creatine — is pitched as targeting one or more "hallmarks of aging." That phrase isn't marketing fluff; it comes from a specific, influential scientific framework. Understanding it is the single best way to cut through longevity hype, because it lets you ask the only question that matters: *which* hallmark does this intervention claim to hit, and is there human evidence it actually does? This page is the plain-English map. It's the framework our other reviews keep referring back to — and it pairs directly with our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## Where the framework comes from In 2013, a group of researchers led by Carlos López-Otín published a landmark *Cell* paper titled simply "The Hallmarks of Aging". Borrowing the structure of the famous "hallmarks of cancer" papers, they proposed nine cellular and molecular processes that together drive aging across organisms. Their criteria were strict: each hallmark should appear during normal aging, accelerating it should speed aging up, and reversing or slowing it should slow aging down. A decade later, in 2023, the same group published an update, "Hallmarks of Aging: An Expanding Universe," which expanded the list to **twelve** by adding three more. Together these two papers are the reference frame for the entire field — when a clinic or supplement says it "targets aging," this is almost always the map it's pointing at. ## The twelve hallmarks, in plain English The 2023 framework groups the hallmarks loosely into three tiers: *primary* causes of damage, *antagonistic* responses that are protective at first but harmful in excess, and *integrative* hallmarks that emerge when the damage overwhelms the system. Here's each one, translated. **The primary hallmarks — the root damage:** - **Genomic instability.** DNA accumulates damage over a lifetime; when repair can't keep up, mutations build up and cells malfunction. - **Telomere attrition.** The protective caps on the ends of chromosomes shorten each time a cell divides; when they get too short, the cell stops dividing or dies. - **Epigenetic alterations.** The chemical "tags" that control which genes are on or off drift with age, so cells express the wrong genes at the wrong time. (This drift is the basis of the "epigenetic clocks" used in biological-age tests.) - **Loss of proteostasis.** The cell's quality-control system for folding and clearing proteins degrades, letting damaged proteins accumulate — a feature of many age-related diseases. - **Disabled macroautophagy.** *(New in 2023.)* Autophagy — the cell's recycling of its own worn-out components — declines with age, so junk that should be cleared piles up. **The antagonistic hallmarks — protective, until they're not:** - **Deregulated nutrient sensing.** The pathways that sense food and energy (involving insulin/IGF-1, mTOR, AMPK, and sirtuins) shift with age in ways that promote growth at the expense of maintenance. This is the pathway fasting, rapamycin, and metformin all aim at. - **Mitochondrial dysfunction.** The cell's power plants become less efficient and leakier with age, reducing energy and raising stress signals. This is the hallmark that aerobic exercise targets most directly, which is the mechanistic case behind [Zone 2 training for longevity](/zone-2-training-for-longevity). - **Cellular senescence.** Damaged cells stop dividing but refuse to die, lingering and spewing inflammatory signals. Helpful in small amounts (it suppresses cancer and aids wound healing); harmful when senescent cells accumulate. **The integrative hallmarks — the system-level failures:** - **Stem-cell exhaustion.** The reserves of cells that regenerate tissues run down, so blood, muscle, gut, and other tissues repair themselves more slowly. - **Altered intercellular communication.** The signaling between cells goes awry — most notably a chronic, low-grade inflammation often nicknamed "inflammaging." - **Chronic inflammation.** *(Elevated to its own hallmark in 2023.)* Persistent low-grade inflammation that drives or worsens nearly every age-related disease. - **Dysbiosis.** *(New in 2023.)* Age-related shifts in the gut microbiome that affect metabolism, immunity, and inflammation. ## Why the framework is useful — and where it's overstated The hallmarks are powerful because they turn "aging" from a vague inevitability into a list of *mechanisms you can in principle target*. That's the foundation of the geroscience hypothesis — the idea that intervening on the shared biology of aging could delay many age-related diseases at once, rather than fighting them one by one. It's a genuinely compelling research program. But two honest caveats keep this site grounded. First, the hallmarks are **interconnected, not independent** — they feed back on each other, so cleanly fixing one in isolation rarely "reverses aging" the way a headline implies. Second, and more important: *targeting a hallmark in a model organism is not the same as extending human healthspan.* The strongest hallmark-based evidence is overwhelmingly in cells, mice, and other animals. Clearing senescent cells extends healthy lifespan in mice and improves physical function and survival in aged mice; rapamycin, which acts on the nutrient-sensing mTOR pathway, extends lifespan in mice even when started late in life; caloric restriction reduces age-related mortality in rhesus monkeys. These are real, important results — and they are also exactly the kind of animal data that translates to humans far less reliably than the marketing suggests. ## How to use the hallmarks to read longevity claims Here's the practical payoff. When you encounter any longevity product or therapy, run it through three questions: 1. **Which hallmark does it claim to target?** (If the answer is "all of them" or "aging generally," be skeptical.) 2. **What's the evidence it actually moves that hallmark — and in what species?** A mouse lifespan result and a human outcome trial are worlds apart. 3. **Does moving the hallmark translate to a benefit you care about** — living longer or healthier — rather than just shifting a biomarker? That third question is where most of the field falls down, because a biomarker (a shorter telomere, a higher NAD+ level, an "epigenetic age") is a proxy, and proxies get sold as outcomes constantly. We walk through how that plays out across specific interventions in [NAD+ for longevity](/nad-for-longevity), where the human data stop at "raises a marker," and in [peptides for longevity](/peptides-for-longevity), where mechanism dramatically outruns proof. It is also the question to hold in mind when a hallmark is quoted at you on a checkout page: a program can name mitochondrial decline honestly and still be [a single injectable route sold at one all-in monthly figure](/sprout-health-review), which is a purchase, not a result. ## The bottom line The hallmarks of aging — nine in 2013, twelve in 2023 — are the field's shared map of *why* we get old at the cellular level, and they're the framework nearly every intervention points to. They're genuinely useful: they let you ask which mechanism a therapy targets and demand evidence it does. But they're a map of mechanisms, not a guarantee of results. Most hallmark-targeting evidence lives in cells and animals, the hallmarks are tangled together, and "hits a hallmark" is a hypothesis about humans until a human trial says otherwise. Use the framework the way scientists intended — as a tool for asking sharper questions, not as a license to believe every "anti-aging" claim that name-drops it. For where these ideas meet real clinics and real price tags, see our graded [best longevity clinics](/best-longevity-clinics) hub — where the terms matter as much as the mechanism, as with [the prescriber whose shortest commitment is three months paid up front](/mademed-review) — and for the cheap, well-evidenced lever that actually targets stem-cell and muscle decline in humans, see [creatine for aging](/creatine-for-aging). For a case study in how a striking 2025 mouse mechanism gets stretched into a human anti-aging claim, see [microdose lithium for longevity & brain aging](/lithium-microdose-for-longevity). Sources: https://pubmed.ncbi.nlm.nih.gov/23746838/, https://pubmed.ncbi.nlm.nih.gov/36599349/, https://pubmed.ncbi.nlm.nih.gov/33328614/, https://pubmed.ncbi.nlm.nih.gov/25417146/, https://pubmed.ncbi.nlm.nih.gov/26840489/, https://pubmed.ncbi.nlm.nih.gov/29988130/, https://pubmed.ncbi.nlm.nih.gov/19587680/, https://pubmed.ncbi.nlm.nih.gov/24691430/ --- ### Sulforaphane for Longevity: Promising Biology, Preclinical Proof Canonical: https://longevitygraded.com/sulforaphane-for-longevity Updated: 2026-06-05 Sulforaphane from broccoli extends lifespan in worms and activates Nrf2 — but the human longevity evidence is preclinical. An honest, evidence-graded review. Sulforaphane is the molecule that launched a thousand "eat your broccoli" headlines. It's the active isothiocyanate you make when you chew raw broccoli — especially broccoli sprouts — and it's become one of the most-studied dietary compounds in biology, with a genuinely interesting mechanism and a 2025 finding that it extended lifespan in worms. That's enough to get it onto every longevity stack. But there's a wide gap between "activates a famous cellular defense pathway and lengthens life in a worm" and "will help you, a human, age slower." This page walks that gap honestly. For the wider map of what's earned its place versus what's hype, start with our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What sulforaphane is Sulforaphane isn't something you eat directly — it's something your body generates. Cruciferous vegetables (broccoli, cabbage, kale, and especially young broccoli sprouts) store a precursor called glucoraphanin alongside an enzyme, myrosinase. When you chop or chew the plant, the two meet and myrosinase converts glucoraphanin into sulforaphane. Broccoli sprouts are the richest practical source — they can contain many times the glucoraphanin of mature broccoli. Cooking matters: high heat inactivates myrosinase, which is why heavily boiled broccoli yields far less sulforaphane than raw or lightly steamed, and why supplement makers sell standardized glucoraphanin-plus-myrosinase extracts to get a reliable dose. ## The mechanism: Nrf2 and hormesis Sulforaphane's claim to longevity fame rests on a single, well-characterized mechanism: it's one of the most potent natural activators of **Nrf2**, a transcription factor that switches on the cell's antioxidant and detoxification machinery. Rather than acting as an antioxidant itself, sulforaphane nudges the cell to build its *own* defenses — glutathione synthesis, phase II detox enzymes, and stress-response genes. This is **hormesis**: a mild, beneficial stress that triggers an adaptive protective response, and the hormesis literature explicitly links this kind of low-dose stress signaling to lifespan regulation. Because oxidative stress and loss of stress resilience sit among the cataloged hallmarks of aging, a compound that reliably boosts endogenous defenses is a plausible — and mechanistically attractive — anti-aging candidate. But "plausible mechanism" is exactly where most longevity compounds get oversold. Nrf2 activation is real and reproducible. Whether switching it on chronically with a supplement makes a human age slower is a completely separate question — one the mechanism alone cannot answer. ## The lifespan evidence: worms, and a 2025 headline The newest reason sulforaphane is trending is a 2025 report that it **extended lifespan in the nematode *C. elegans*** by slowing what the authors describe as a transcriptional aging clock. It's a genuinely interesting result and fits the broader pattern: a 2025 review of cruciferous isothiocyanates as "geroprotectors" catalogs consistent lifespan and stress-resistance effects across model organisms, and a broad review of dietary phytochemicals traces anti-aging signals for compounds like sulforaphane from *C. elegans* and *Drosophila* through rodents. Two honesty flags belong right here. First, the headline 2025 lifespan result is, at the time of writing, a **preprint** in a worm — not a peer-reviewed mammalian study. Worms are a powerful, legitimate screening model, but a *C. elegans* lifespan extension is a starting hypothesis about mammals, not evidence in them. Second, the phytochemical-aging literature is candid that the picture thins out fast as you move up the evolutionary ladder: strong invertebrate signals, fewer and messier rodent results, and very little that qualifies as human longevity data. The mouse and rodent data that exist tend to involve disease models (cancer prevention, metabolic, inflammatory) rather than clean lifespan-extension experiments. ## What sulforaphane actually does in humans Here's the same irony that recurs across this whole field: sulforaphane has a respectable human evidence base — just not for *longevity*. Where humans have been studied, the endpoints are near-term and disease-specific. On **metabolism**, a well-known randomized trial (Axelsson and colleagues, in *Science Translational Medicine*) found that concentrated broccoli-sprout extract reduced fasting glucose and improved glucose control in people with type 2 diabetes, especially those who were obese and dysregulated — working through suppression of hepatic glucose production rather than a longevity pathway. A separate randomized study reported that broccoli-sprout extract improved liver-enzyme markers in men with mild hepatic abnormalities. Mechanistic reviews summarize broadly anti-inflammatory and antioxidant effects that plausibly support metabolic health. These are real, controlled human results — but they're surrogate markers (glucose, liver enzymes, inflammatory readouts) in specific populations over weeks to months, not demonstrations that sulforaphane slows aging or extends life. And there's a practical wrinkle that undercuts a lot of supplement marketing: **bioavailability is highly variable**. A crossover trial in humans showed that how sulforaphane is delivered — fresh sprouts with active myrosinase versus a glucoraphanin extract lacking it — dramatically changes how much you actually absorb. Many capsule products deliver inactive precursor with no enzyme, so the labeled dose and the absorbed dose can be worlds apart. ## Zero human longevity trials — and the hormesis dose problem It needs saying plainly, because the marketing never does: there is **no randomized controlled trial showing sulforaphane extends human lifespan or healthspan**, and none is underway that could answer that soon. The lifespan data are from worms; the human data are surrogate-marker trials in diabetes and liver health. None of that adds up to "proven to make people age slower." The hormesis framing cuts both ways, too. The reason a mild stressor helps is that it's *mild*; the same dose-response logic that makes low-dose sulforaphane protective means more is not automatically better, and chronic high-dose Nrf2 activation has theoretical downsides (Nrf2 is a double-edged factor that can also protect existing tumors). The honest position is that we don't know the optimal long-term human dose for "anti-aging," because that experiment hasn't been run. We apply the same mechanism-versus-outcome lens across the field in our [best longevity supplements, rated by evidence](/best-longevity-supplements) roundup, and the same biology-to-benefit caution in our [hallmarks of aging explained](/hallmarks-of-aging-explained) primer. ## Safety: the reassuring part If sulforaphane's longevity efficacy is unproven, its safety story is genuinely reasonable, which is part of why people take it. Broccoli and broccoli sprouts are foods eaten safely for a lifetime, and the doses used in human trials — concentrated sprout extracts over weeks to months — were generally well tolerated, with mild GI complaints the most common issue. It is sold as a dietary supplement, not an FDA-approved drug for any condition, so it carries no approved indication and no required efficacy proof, and long-term safety of *high-dose concentrated extracts taken chronically specifically for anti-aging* hasn't been formally studied. The honest framing is the one this site uses constantly: sulforaphane's *safety* at studied doses looks acceptable, while its *efficacy for longevity* in humans is unproven. Those are different claims. ## The grade ## The bottom line Sulforaphane is a textbook case of a beautiful mechanism running ahead of the outcome data. The Nrf2/hormesis story is real and reproducible, and a 2025 worm study extended lifespan — both legitimate reasons to keep studying it. But the lifespan evidence is preclinical, the strongest result is a preprint in a nematode, the rodent data are mostly disease models rather than lifespan, and there are zero human longevity trials. What humans *do* have is solid but narrow: glucose and liver-marker improvements in specific populations, with bioavailability that varies wildly by product. If you eat broccoli sprouts or take a well-formulated extract, the safety looks reasonable and the metabolic data are a fair reason — but treating sulforaphane as a proven anti-aging intervention gets ahead of the evidence by several species. For where supplements like this fit alongside programs with real clinical oversight, see our graded [best longevity clinics](/best-longevity-clinics) hub, and compare sulforaphane's case to another mechanism-rich, food-derived neighbor in [urolithin A for longevity](/urolithin-a-for-longevity). Sources: https://pubmed.ncbi.nlm.nih.gov/40462948/, https://pubmed.ncbi.nlm.nih.gov/40716930/, https://pubmed.ncbi.nlm.nih.gov/38182079/, https://pubmed.ncbi.nlm.nih.gov/36597655/, https://pubmed.ncbi.nlm.nih.gov/39940284/, https://pubmed.ncbi.nlm.nih.gov/28615356/, https://pubmed.ncbi.nlm.nih.gov/26604653/, https://pubmed.ncbi.nlm.nih.gov/21372038/, https://pubmed.ncbi.nlm.nih.gov/36599349/ --- ### Glycine for Longevity: The Other Half of GlyNAC Canonical: https://longevitygraded.com/glycine-for-longevity Updated: 2026-06-11 Glycine alone extended mouse lifespan ~6% in the ITP. But the dramatic 'reverses aging' results belong to the GlyNAC combo, not solo glycine. An honest review. Glycine has an unusual place in the longevity conversation: it's quietly one of the better-evidenced amino acids in animal models, yet most of its fame is borrowed. When people say "glycine reverses aging markers," they're almost always describing **GlyNAC** — glycine *plus* N-acetylcysteine — not glycine on its own. Untangling those two is the whole job of this page, because glycine-alone has a real but modest lifespan signal, while the dramatic human-trial headlines belong to the combination. For the wider map of what's earned its place versus what's hype, start with our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What glycine is Glycine is the smallest amino acid — a single carbon flanked by an amino and a carboxyl group — and it's technically "non-essential" because your body makes it. But "non-essential" is misleading: several lines of evidence suggest endogenous synthesis may fall short of the body's full needs, so glycine is sometimes called *conditionally* essential. It's abundant in collagen-rich foods (skin, bones, connective tissue, bone broth, gelatin) — which is also why [collagen supplements](/collagen-for-longevity) are essentially a glycine-and-proline delivery vehicle once digested — and it does a lot of jobs: it's a building block of glutathione (the cell's master antioxidant), of collagen, and of creatine; it acts as an inhibitory neurotransmitter; and it participates in one-carbon and methionine metabolism. That last role — its tie to methionine and the methylation cycle — turns out to matter for why it might influence aging at all. ## The lifespan evidence: a real but modest mouse signal Here is glycine's strongest single result, and it's worth stating precisely. In the NIA's **Interventions Testing Program (ITP)** — a rigorous, multi-site mouse-lifespan program designed specifically to weed out the false positives that plague single-lab studies — glycine supplementation extended the lifespan of both male and female mice. That's a genuinely meaningful finding: the ITP is the gold standard for mouse longevity precisely because it's hard to fool, and relatively few interventions pass it. But read the size of the effect honestly. The lifespan extension was **modest — on the order of a few percent of median lifespan**, considerably smaller than ITP standouts like rapamycin. "Statistically real in a rigorous program" and "large" are different things, and glycine's signal is the former, not the latter. The mechanistic story behind it points back to methionine: glycine helps clear methionine, and the benefits of methionine restriction on lifespan are well documented, so part of glycine's effect may be a mild methionine-restriction mimic. That idea is reinforced by invertebrate work showing glycine promotes longevity in *C. elegans* in a **methionine-cycle-dependent** fashion — different organism, convergent mechanism. Loss of proteostasis and dysregulated nutrient-sensing are cataloged among the formal hallmarks of aging, and the methionine/one-carbon axis glycine feeds into touches several of them. ## The crucial distinction: glycine alone vs GlyNAC This is the section the marketing blurs, so it deserves to be blunt. The most striking *human* longevity data attached to "glycine" actually come from **GlyNAC — glycine combined with N-acetylcysteine** — studied by Rajagopal Sekhar's group at Baylor. Those trials report broad improvements in glutathione, oxidative stress, mitochondrial function, inflammation, and physical performance in older adults, and the rationale is that aging brings a glutathione deficiency correctable by supplying *both* missing precursors — glycine and a cysteine donor. An earlier study in older HIV patients similarly used cysteine *and* glycine together to raise glutathione and improve insulin sensitivity and body composition. Notice the constant: in the dramatic human results, glycine is never alone — it's paired with a cysteine source, because glutathione synthesis needs both. So when a supplement label implies that *glycine by itself* delivers GlyNAC-style "aging reversal," it's transferring credit the solo amino acid hasn't earned. The honest split is this: **glycine alone** has a modest, rigorous mouse lifespan signal but no human lifespan or healthspan trial of its own; **GlyNAC** has small human biomarker trials but is a different intervention, and even those are short-term, surrogate-endpoint studies from a single invested group. We dig into the combination's limits in detail in [GlyNAC (glycine + NAC) for aging: what the Baylor trials actually show](/glynac-for-longevity), and set the two side by side — dose, cost, and what each one has actually been tested for — in [glycine vs GlyNAC](/glycine-vs-glynac). ## What glycine actually does in humans Strip away the borrowed GlyNAC glory and glycine still has a respectable, if narrow, human evidence base — just not for *longevity*. A 2024 systematic review in *GeroScience* of glycine administration across human physiological systems found measurable effects in several domains (metabolic, sleep, vascular) but consistently flagged that the trials are small, heterogeneous, and short, and that longevity or healthspan outcomes simply haven't been tested. The single best-characterized near-term human effect is on **sleep**: small randomized and controlled studies showed that 3 g of glycine before bed improved subjective sleep quality and reduced daytime sleepiness, plausibly via a mild drop in core body temperature. There's also the glutathione-synthesis role — older adults are relatively glutathione-deficient, and supplying cysteine *and glycine* restores synthesis and lowers oxidative stress — but again, that's the combination story, and it's a biomarker outcome, not a lifespan one. These are real, controlled results, but they're surrogate markers and near-term functional measures in specific contexts, not demonstrations that glycine slows aging or extends life. ## Zero human longevity trials for glycine alone It needs saying plainly: there is **no randomized controlled trial showing glycine — by itself — extends human lifespan or healthspan**. The lifespan data are from mice and worms; the dramatic human biomarker data belong to GlyNAC, a different intervention; and glycine's own human trials are about sleep and metabolic markers, not aging. None of that adds up to "proven to make people age slower." We apply the same mechanism-versus-outcome lens across the field in our [best longevity supplements, rated by evidence](/best-longevity-supplements) roundup, and the same single-paper caution in our [taurine for longevity](/taurine-for-longevity) review, where one striking amino-acid study outran its evidence. ## Safety: the reassuring part If glycine's longevity efficacy is unproven, its safety story is genuinely reasonable. Glycine is a normal dietary amino acid, abundant in collagen and gelatin, and the doses used in human sleep and metabolic trials (commonly 3–15 g/day) were generally well tolerated, with mild GI upset the most common complaint. It is sold as a dietary supplement, not an FDA-approved drug for any condition, so it carries no approved indication and no required efficacy proof, and long-term safety of high chronic doses taken specifically for anti-aging hasn't been formally studied. The honest framing is the one this site uses constantly: glycine's *safety* at studied doses looks acceptable, while its *efficacy for longevity* in humans is unproven. Those are different claims. ## The grade ## The bottom line Glycine is better than most longevity amino acids at one thing — passing the rigorous ITP mouse-lifespan test — and worse than the marketing implies at another: its headline human results aren't really *its* results. The ITP extension was real but modest, the mechanism plausibly runs through methionine metabolism, and the dramatic "aging-marker reversal" trials describe GlyNAC, the glycine-plus-NAC combination, not solo glycine. On its own, glycine has solid near-term human data for sleep and a supporting role in glutathione synthesis, reasonable safety, and zero human longevity trials. If you take glycine, take it for what it's actually supported to do — sleep, a possible mild metabolic nudge, dietary glutathione support — and don't credit it with the combination's biomarker headlines. For where supplements like this fit alongside programs with real clinical oversight, see our graded [best longevity clinics](/best-longevity-clinics) hub. Sources: https://pubmed.ncbi.nlm.nih.gov/30916479/, https://pubmed.ncbi.nlm.nih.gov/30845140/, https://pubmed.ncbi.nlm.nih.gov/37851316/, https://pubmed.ncbi.nlm.nih.gov/22293292/, https://pubmed.ncbi.nlm.nih.gov/21795440/, https://pubmed.ncbi.nlm.nih.gov/35975308/, https://pubmed.ncbi.nlm.nih.gov/24081740/, https://pubmed.ncbi.nlm.nih.gov/36599349/ --- ### Microdose Lithium for Longevity & Brain Aging: The Evidence Canonical: https://longevitygraded.com/lithium-microdose-for-longevity Updated: 2026-06-05 A 2025 Nature study tied lithium deficiency to Alzheimer's in mice. But that's mouse healthspan, not human lifespan — and lithium has a narrow safety window. Lithium is having a longevity moment, and a genuinely interesting one. It's not a trendy peptide or an exotic plant extract — it's a basic element, the same one used for decades to treat bipolar disorder, now being floated as a low-dose "brain-aging" intervention. A high-profile 2025 study reignited the idea by linking lithium deficiency to Alzheimer's disease in mice. But this is exactly the kind of story where the gap between a striking animal result and a safe, proven human intervention is wide — and where a drug's *narrow safety window* makes "just try some" genuinely risky advice. This page walks through it honestly. For the wider map of what's earned its place versus what's hype, start with our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What "microdose lithium" means The word "lithium" covers a huge dose range, and conflating those ranges is the single biggest source of confusion. **Therapeutic lithium** for bipolar disorder is prescribed at hundreds of milligrams a day (of lithium carbonate) and titrated against blood levels, because the window between an effective dose and a toxic one is famously narrow. **Microdose lithium** — usually lithium orotate or low-dose carbonate sold as a supplement, often around 1–5 mg of elemental lithium — is orders of magnitude lower, in the range of what people get naturally from drinking water and food. **Trace lithium** is the amount in tap water, which varies by region. The longevity conversation is mostly about the microdose and trace ranges, and almost all the suggestive human data come from those low exposures — not from prescription doses. ## The 2025 Nature study: real, important — and in mice The study that reignited interest was published in *Nature* in 2025 (Aron and colleagues), and its central claim is striking: that **lithium deficiency may be an early driver of Alzheimer's disease**. The researchers reported that lithium is normally present in the brain, that amyloid pathology sequesters it (lowering available lithium), that depleting lithium in mice accelerated Alzheimer's-like pathology and memory loss, and that replacing it — notably with **lithium orotate**, a form that evades amyloid capture — rescued those changes at very low doses. It's a genuinely important mechanistic paper, and it gives the microdose-lithium idea its most serious scientific footing to date. Now the honest flags, because the headlines dropped them. First, **this is mouse work plus human tissue/epidemiological correlation, not a human treatment trial**. The rescue experiments — the part that actually shows giving lithium back helps — were done in mice. Second, what it demonstrates is a **healthspan/brain-aging** signal (less Alzheimer's-like pathology), **not a lifespan extension** and not a demonstration that microdose lithium prevents dementia in people. "Correcting a lithium deficiency reversed Alzheimer's-like changes in mice" is a real and exciting result; "microdose lithium will keep your brain young" is an extrapolation across a species barrier that, in neurodegeneration research especially, has swallowed many promising mouse findings whole. ## The supporting human signals: epidemiology, not trials Lithium's longevity case doesn't rest only on the 2025 mouse study — there's a thread of human data, but it's observational. Population studies have repeatedly found that **higher trace lithium in drinking water tracks with lower all-cause mortality and lower rates of suicide and some neurodegenerative outcomes**, and a multi-organism study reported that low-dose lithium uptake was associated with longevity in humans and extended lifespan in the worm *C. elegans*. These are intriguing and biologically coherent — lithium inhibits GSK-3β and promotes autophagy, mechanisms tied to several cataloged hallmarks of aging. But they're **ecological and observational associations**, the weakest rung on the evidence ladder: regions differ in countless ways besides their water lithium, and "places with more lithium in the water have lower mortality" cannot establish that swallowing a lithium supplement will make *you* live longer. (It's worth noting that a 2023 paper claiming lithium extends human lifespan from UK Biobank data was subsequently **retracted** — a reminder of how fragile this literature can be.) Association is not causation, and no randomized trial has tested whether microdose lithium extends human life. ## What the human cognition trials actually show Closer to a real test, lithium *has* been studied in small human cognition trials — with mixed, modest results. A pilot study reported that **microdose lithium stabilized cognitive impairment** in Alzheimer's patients over a year, building on the same group's mouse work showing chronic microdose lithium prevented memory loss in an Alzheimer's mouse model. More rigorously, a randomized controlled trial of **low-dose lithium in older adults with amnestic mild cognitive impairment** reported some disease-modifying and biomarker signals over long-term treatment — a genuine RCT, but small, in a specific at-risk population, using a clinical (not micro-) dose, and measuring cognitive and biomarker endpoints rather than lifespan. At standard psychiatric doses, large cohort studies have also linked lithium treatment to **lower dementia risk** in people with bipolar disorder — again observational, and in a clinical population. Put together, the human picture is: suggestive epidemiology, a couple of small or specialized cognition trials with modest signals, and zero trials of microdose lithium for longevity or dementia prevention in healthy people. Promising direction, thin proof. We apply this same mechanism-versus-outcome lens across the field in our [best longevity supplements, rated by evidence](/best-longevity-supplements) roundup, and the same caution about a single striking study in our [hallmarks of aging explained](/hallmarks-of-aging-explained) primer. ## The safety window — the part you can't ignore This is where lithium differs from a benign vitamin, and it deserves a hard stop. Lithium is one of the classic **narrow-therapeutic-index** drugs: at psychiatric doses it requires regular blood-level monitoring precisely because the gap between therapeutic and toxic concentrations is small, and toxicity affects the kidneys, thyroid, and nervous system. Long-term clinical lithium use is associated with risks to renal and thyroid function that require ongoing surveillance. Microdose lithium (1–5 mg elemental) is far below those thresholds and is generally considered low-risk at those amounts — but "generally low-risk" is not "proven safe to self-dose indefinitely." Supplements are unregulated for dose accuracy, lithium interacts with common drugs (NSAIDs, ACE inhibitors, diuretics) that can raise blood levels into dangerous territory, and people with kidney disease, thyroid disease, or on those medications can be pushed toward toxicity by amounts that would be harmless in others. The honest bottom line on safety: microdose lithium is probably low-risk for most healthy people at genuinely tiny doses, but it is the one item in this category where casual, unmonitored self-experimentation can actually hurt you — and that warrants a real conversation with a clinician, not a purchase based on a mouse study. ## The grade Microdose lithium earns a **C** on longevity: a serious 2025 mechanistic paper, coherent epidemiology, and a couple of small human cognition signals — but the lifespan/dementia-prevention evidence in humans is observational or absent, the strongest causal data are in mice, and unlike most supplements it carries a real, dose-dependent safety tail. It's a genuinely interesting research direction held back from a higher grade by the same two words that recur across the board: *no outcomes*. We rate it against neighbors like [metformin for longevity](/metformin-for-longevity), where a repurposed drug also has mechanism and epidemiology but awaits its definitive human trial. ## The bottom line Microdose lithium is one of the more scientifically credible items in the longevity-supplement aisle and simultaneously one of the most overstated. The 2025 *Nature* study linking lithium deficiency to Alzheimer's is real and important — but it's mouse rescue data plus human correlation, a brain-*healthspan* signal, not a human lifespan result. The supporting human evidence is observational epidemiology (lower mortality where water lithium is higher) plus a few small cognition trials with modest signals, and a high-profile human-lifespan claim was retracted. Layered on top is the one thing that sets lithium apart: a narrow safety window and real drug interactions that make unmonitored self-dosing genuinely riskier than for an ordinary supplement. If you're interested in microdose lithium, treat it as a promising hypothesis to discuss with a clinician — not a proven anti-aging intervention. For where supplements like this fit alongside programs with real clinical oversight, see our graded [best longevity clinics](/best-longevity-clinics) hub. Sources: https://pubmed.ncbi.nlm.nih.gov/40770094/, https://pubmed.ncbi.nlm.nih.gov/21301855/, https://pubmed.ncbi.nlm.nih.gov/29206474/, https://pubmed.ncbi.nlm.nih.gov/22746245/, https://pubmed.ncbi.nlm.nih.gov/26605788/, https://pubmed.ncbi.nlm.nih.gov/30947755/, https://pubmed.ncbi.nlm.nih.gov/25614530/, https://pubmed.ncbi.nlm.nih.gov/35161482/, https://pubmed.ncbi.nlm.nih.gov/36599349/ --- ### Ergothioneine: The "Longevity Vitamin"? An Evidence-Graded Review Canonical: https://longevitygraded.com/ergothioneine-for-longevity Updated: 2026-06-05 Ergothioneine has a strong observational link to lower mortality — but no human trial, and the signal may just track a healthy diet. An honest grade. Ergothioneine has one of the most seductive stories in the longevity-supplement world: a compound your body actively hoards using a dedicated transporter, that you can only get from your diet, that falls as you age, and that tracks with lower mortality in a respected cardiology journal. A famous review even floated it as a candidate "longevity vitamin." Put together, that sounds close to proof. It isn't — and the gap between the strength of the *association* and the total absence of an *outcome trial* is the whole story. This page walks through what's genuinely impressive about ergothioneine and where the evidence quietly runs out. For the wider map of what's earned its place versus what's hype, start with our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What ergothioneine is Ergothioneine is a sulfur-containing amino acid derivative — a naturally occurring antioxidant that humans cannot synthesize. We get it entirely from diet, and the richest sources by far are mushrooms (especially oyster, shiitake, and king oyster), with smaller amounts in some beans, organ meats, and grains grown in ergothioneine-producing soil fungi. What sets it apart from ordinary dietary antioxidants is that the body treats it specially: a dedicated, highly specific transporter (OCTN1, encoded by *SLC22A4*) actively pumps ergothioneine into cells and concentrates it in tissues exposed to oxidative stress — liver, kidney, blood cells, the lens of the eye, and the brain. Biologists generally read "the body built a dedicated transporter to retain this molecule" as a sign it does something useful. That inference is reasonable. It is not, by itself, evidence of a longevity benefit. ## The "longevity vitamin" idea The phrase that powers most ergothioneine marketing comes from Bruce Ames's 2018 framework of *longevity vitamins and proteins* — micronutrients whose shortfall doesn't cause an obvious acute deficiency disease, but which Ames hypothesized are quietly rationed by the body toward short-term survival at the expense of long-term health and lifespan. Ergothioneine was put forward as a leading candidate for this category. Bernard Halliwell, one of the field's central figures, has argued the same case in detail — that ergothioneine is a diet-derived antioxidant with genuine therapeutic potential and the hallmarks of a conditionally essential nutrient. This is a serious, well-argued hypothesis from credible scientists. But "a respected researcher proposed it might be a longevity vitamin" is a hypothesis statement, not a demonstrated outcome — and the honest reading is that ergothioneine has the *profile* of something important without the trial data to confirm it. ## The mortality association: real, and genuinely strong The single most-cited piece of human evidence is a 2020 study in *Heart* by Smith and colleagues, drawn from a Swedish population cohort with long follow-up. People with higher blood ergothioneine had a significantly lower risk of all-cause mortality and of dying from cardiovascular disease, and the association survived adjustment for conventional risk factors. As epidemiology goes, that's a strong, clean signal in a well-characterized cohort — exactly the kind of result that makes a molecule worth investigating. Supporting it from a different angle, large prospective analyzes of U.S. adults found that higher mushroom consumption — the dominant dietary source of ergothioneine — was associated with lower all-cause mortality. Two independent lines of population data pointing the same way is more than most longevity supplements can claim. But here is the load-bearing caveat, and it's the reason the grade below is what it is: **this is association, not causation.** Ergothioneine is overwhelmingly a marker of a mushroom-and-plant-rich, higher-quality diet. People who eat that way differ in dozens of ways — more fiber, more vegetables, often more exercise, less smoking, higher socioeconomic status — that an observational study can adjust for only imperfectly. A higher ergothioneine level may simply be a *biomarker of eating well*, not an independent cause of living longer. The 2020 authors themselves framed it as an association worth testing, not a proven intervention. Until someone randomizes people to ergothioneine versus placebo and measures outcomes, the most defensible interpretation is that ergothioneine is, in large part, a healthy-diet proxy. ## The aging and cognition angle Two further findings are often stacked onto the longevity claim. First, blood ergothioneine *declines with age*: a Singapore study found levels fell in older adults and were lower in people with mild cognitive impairment. Second, in a separate elderly cohort, low plasma ergothioneine predicted subsequent cognitive and functional decline, and a 2025 systematic review concluded the observational link between ergothioneine status and better cognitive aging is consistent across studies. Taken together these make ergothioneine look like a plausible player in brain aging. The catch is identical to the mortality story. "Levels fall with age and low levels track worse outcomes" is precisely the pattern you'd expect from a biomarker of a declining, less-varied diet in frailer older people — reverse causation and confounding are wide open. It is suggestive, mechanism-consistent, and unproven. The cataloged hallmarks of aging include loss of proteostasis and chronic oxidative and inflammatory stress, and ergothioneine's antioxidant chemistry plausibly touches several — but "plausibly touches a hallmark" is a hypothesis about humans, not a result in them. ## The missing piece: no interventional outcome trial Strip away the mechanism and the associations and you arrive at the fact the marketing never leads with: **there is no randomized controlled trial showing ergothioneine supplementation extends human lifespan, prevents cardiovascular events, or slows cognitive decline.** The human interventional data that exist are small and short. A controlled study in healthy volunteers established that oral ergothioneine is absorbed, retained, and distributed into tissues with very low excretion, and was well tolerated — important pharmacokinetic and safety groundwork. But that is an uptake-and-safety study, not an outcomes trial. Nobody has yet shown that *adding* ergothioneine to a person's diet changes whether or how long they live. Everything load-bearing in the longevity pitch is either mechanism, animal/cell data, or association. ## Safety On safety the picture is reassuring, which is part of why ergothioneine is an easy supplement to recommend casually. It's a normal dietary constituent, it has a dedicated retention system suggesting the body is built to handle it, and the human uptake study found it well tolerated with no adverse signals at the doses used. Regulators in the EU and elsewhere have granted synthetic ergothioneine novel-food/GRAS-type clearances for use in foods, reflecting a benign acute safety profile. As always, that's a different claim from efficacy: "safe at studied doses" is not "proven to extend life," and long-term high-dose supplementation specifically for anti-aging hasn't been formally studied. The cheapest, best-evidenced way to raise your ergothioneine is also the least controversial — eat more mushrooms, which carries its own independent mortality association. ## The grade ## The bottom line Ergothioneine is the most *interesting* unproven longevity candidate on this site, and that tension is the point. It has a dedicated transporter, a credible "longevity vitamin" hypothesis from serious scientists, a strong and replicated association with lower mortality and better cognitive aging, and a benign safety profile. What it does not have is a single randomized trial showing that taking it changes an outcome — and its biggest confounder is that ergothioneine is largely a marker of eating a mushroom- and plant-rich diet. That combination earns it a **Grade C**: a strong association resting on no causal proof, with a healthy-diet explanation that hasn't been ruled out. If you want the upside, the honest move is to get it the way the mortality data actually came — from food, by eating more mushrooms — rather than betting on a pill to do something no trial has shown it does. For where supplements like this fit on the evidence ladder, see our [best longevity supplements, rated by evidence](/best-longevity-supplements) roundup, and compare ergothioneine's case to two other diet-derived molecules with suggestive-but-unproven longevity stories: [taurine for longevity](/taurine-for-longevity) and [spermidine for longevity](/spermidine-for-longevity). For programs that pair supplements with real clinical oversight, see our graded [best longevity clinics](/best-longevity-clinics) hub. Sources: https://pubmed.ncbi.nlm.nih.gov/30322941/, https://pubmed.ncbi.nlm.nih.gov/29851075/, https://pubmed.ncbi.nlm.nih.gov/36623925/, https://pubmed.ncbi.nlm.nih.gov/31672783/, https://pubmed.ncbi.nlm.nih.gov/33888143/, https://pubmed.ncbi.nlm.nih.gov/27444382/, https://pubmed.ncbi.nlm.nih.gov/36139790/, https://pubmed.ncbi.nlm.nih.gov/40249478/, https://pubmed.ncbi.nlm.nih.gov/36599349/, https://pubmed.ncbi.nlm.nih.gov/27488221/ --- ### Omega-3 for Longevity: What the DO-HEALTH Trial Actually Shows Canonical: https://longevitygraded.com/omega-3-for-longevity Updated: 2026-06-05 DO-HEALTH found 1 g/day omega-3 slowed epigenetic clocks by ~3–4 months. Real, randomized — but a small, surrogate effect. An honest evidence grade. Omega-3 is one of the very few longevity supplements with a randomized trial that moved an aging biomarker — which immediately makes it more interesting than the dozens of candidates resting on mouse data or pure association. In 2024–25, a secondary analysis of the large DO-HEALTH trial reported that 1 gram a day of omega-3 slowed several epigenetic "aging clocks," with the effect adding to vitamin D and exercise. That's a genuinely notable result. But the size of the effect, the fact that it's measured on a *surrogate* marker rather than a hard outcome, and DO-HEALTH's mostly-negative primary results all matter enormously for how much weight to put on it. This page separates the real signal from the headline. For the wider map of what's earned its place versus what's hype, start with our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What omega-3 is Omega-3 fatty acids are long-chain polyunsaturated fats — chiefly EPA and DHA from marine sources (fish, fish oil, algae), plus the shorter-chain ALA from plants like flax. They're incorporated into cell membranes and feed anti-inflammatory signaling pathways, which is the mechanistic basis for nearly every health claim attached to them. Supplements are typically standardized to a combined EPA+DHA dose; the DO-HEALTH trial used 1 g/day. Omega-3 is genuinely an essential nutrient — deficiency is a real thing — so the relevant longevity question is not "does the body need any?" but "does *adding* it beyond a normal diet slow aging or extend life?" Those are very different questions, and the marketing routinely blurs them. ## The DO-HEALTH clock result: the strongest piece DO-HEALTH was a large, well-run randomized trial in adults aged 70+ across five European countries, testing vitamin D, omega-3 (1 g/day), and a simple home strength-exercise program in a factorial design. In 2025, *Nature Aging* published a pre-specified analysis of DNA-methylation "aging clocks" in a subset of participants. The finding that drew headlines: omega-3 supplementation slowed the pace of biological aging on several epigenetic clocks, the three interventions had **additive** effects, and combining all three produced the largest slowing. Translated into plain terms, the omega-3 effect was on the order of a few months of "clock" slowing over the three-year trial — small in absolute size, but statistically real and, crucially, from a *randomized* design rather than an observational one. That randomized framing is what sets omega-3 apart from most of this site's supplements: the taurine and ergothioneine cases rest on association, while here someone actually assigned people to omega-3 versus placebo and measured a change. That's a higher tier of evidence. But two cautions are load-bearing, and they're why this earns a B rather than an A. ## Caveat one: it's a surrogate endpoint An epigenetic clock is a *biomarker* of aging, not aging itself. These clocks — Horvath-style methylation clocks and pace-of-aging measures like DunedinPACE — correlate with age and, to varying degrees, with mortality risk across populations. But no epigenetic clock has been validated as a treatment target: we do not yet know that *moving the clock by a few months with a supplement* translates into actually living longer or healthier. It's entirely possible to nudge a surrogate without changing the outcome it stands in for — the history of medicine is littered with examples. So the honest statement is: DO-HEALTH showed omega-3 slowed a *marker* of aging by a small amount. It did **not** show omega-3 made people live longer. Those are different claims, and only the first is proven. ## Caveat two: DO-HEALTH's primary results were largely negative This is the context the clock headline tends to drop. DO-HEALTH's *primary* paper, published in JAMA in 2020, tested whether vitamin D, omega-3, and exercise improved six hard endpoints — blood pressure, non-vertebral fractures, physical performance, infection rate, and cognitive function — and found that none of the three interventions produced a significant benefit on those outcomes. In other words, the same trial that later showed a small epigenetic-clock effect for omega-3 had already shown that omega-3 did *not* meaningfully reduce fractures, infections, or cognitive decline in these older adults. A supplement that slows a biomarker but didn't move the clinical endpoints in its own headline trial deserves cautious, not breathless, framing. ## What the big outcome trials show Zoom out to the largest randomized omega-3 trials for hard outcomes and the picture stays sober. VITAL, a trial of over 25,000 U.S. adults, found that 1 g/day of marine omega-3 did **not** significantly reduce the primary endpoints of major cardiovascular events or invasive cancer versus placebo. A meta-analysis pooling ten trials and roughly 78,000 people likewise found omega-3 supplementation produced no significant reduction in cardiovascular disease, coronary death, or major vascular events, and a large Cochrane review concluded that increasing long-chain omega-3 has little or no effect on all-cause mortality or cardiovascular events. There are pockets of benefit — high-dose prescription EPA in specific high-risk, high-triglyceride patients is a real exception — but for the general goal of "take fish oil to live longer," the best randomized evidence does not support a meaningful mortality benefit. The longevity case for omega-3 therefore rests largely on the surrogate clock data, not on hard-outcome trials. ## Where omega-3 plausibly fits the biology None of this means omega-3 is inert. Chronic inflammation and other cataloged hallmarks of aging are exactly the pathways omega-3 modulates, which is why the small clock effect is mechanistically believable rather than a fluke. Omega-3's value may also be greatest in people with genuinely low intake — correcting a shortfall, rather than piling supplementation onto an already fish-rich diet. The DO-HEALTH result is best read as "this is biologically plausible and produced a small randomized signal worth following," not "this is a proven life-extender." ## Safety Omega-3 is among the better-tolerated supplements: the main side effects are fishy aftertaste, burping, and mild GI upset, and at typical doses (around 1 g/day EPA+DHA, as in DO-HEALTH and VITAL) it was well tolerated in large trials. The notable caveat is a modest, dose-related signal for atrial fibrillation in some high-dose omega-3 trials, so more is not automatically better. As always, "well tolerated" is a separate claim from "proven to extend life," and people on blood thinners or facing surgery should talk to a clinician. ## The grade ## The bottom line Omega-3 earns a **Grade B** — and it's instructive to see why it grades higher than most of this site's supplements while still falling short of an A. The reason it's a B and not a C is real: DO-HEALTH produced a *randomized* signal that omega-3 slowed epigenetic aging clocks, additive with vitamin D and exercise — that's a genuinely higher tier of evidence than the associations behind taurine or ergothioneine. The reason it's a B and not an A is equally real: the effect was small (a few months of clock slowing), it sits on a *surrogate* marker no one has validated as a treatment target, the same trial's hard clinical endpoints were null, and the largest outcome trials show no meaningful mortality benefit. Omega-3 is a sensible, well-tolerated supplement — especially if your intake is low — with the best randomized aging-biomarker data in the category and no proof yet that it extends human life. For where it lands against the rest, see our [best longevity supplements, rated by evidence](/best-longevity-supplements) roundup; for how easily a moved biomarker gets sold as a benefit, see [longevity biomarker panels](/longevity-biomarker-panels); and for the one supplement with even stronger functional-outcome data, compare [creatine for aging](/creatine-for-aging). For programs that pair supplements with real clinical oversight, see our graded [best longevity clinics](/best-longevity-clinics) hub. Sources: https://pubmed.ncbi.nlm.nih.gov/39900648/, https://pubmed.ncbi.nlm.nih.gov/35029144/, https://pubmed.ncbi.nlm.nih.gov/33170239/, https://pubmed.ncbi.nlm.nih.gov/30415637/, https://pubmed.ncbi.nlm.nih.gov/29387889/, https://pubmed.ncbi.nlm.nih.gov/32114706/, https://pubmed.ncbi.nlm.nih.gov/36599349/ --- ### CoQ10 & Ubiquinol for Aging: What the Evidence Actually Shows Canonical: https://longevitygraded.com/coq10-for-longevity Updated: 2026-06-05 KiSel-10 showed CoQ10 plus selenium cut cardiovascular mortality in elderly Swedes — but the benefit is CV-specific, not lifespan. An honest grade. CoQ10 is unusual among longevity supplements: it has not one but two genuine randomized trials showing a reduction in cardiovascular death, including a famous study in elderly people followed for over a decade. That's a far stronger hand than most of the field, and it's why CoQ10 grades better than the typical anti-aging pill. But the details matter enormously — the standout trial paired CoQ10 with selenium in a specific low-selenium population, the benefit is cardiovascular and cardiac-specific rather than a general lifespan extension, and the much-marketed claim that "ubiquinol" is dramatically superior to ordinary CoQ10 is more contested than the labels suggest. This page separates the real, earned evidence from the marketing. For the wider map of what's earned its place versus what's hype, start with our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What CoQ10 is Coenzyme Q10 (CoQ10) is a fat-soluble compound your body makes, found in the inner membrane of every mitochondrion, where it shuttles electrons along the respiratory chain that generates cellular energy — and it doubles as a membrane antioxidant. It exists in two interconvertible forms: the oxidized form, **ubiquinone**, and the reduced form, **ubiquinol**. Both are sold as supplements, and ubiquinol is marketed as the "active," better-absorbed version (more on that below). CoQ10 levels fall with age and are also lowered by statin drugs, which inhibit the same pathway that makes cholesterol — a fact that underpins much of CoQ10's clinical interest. It's an essential cofactor, so the longevity question, as always, is not "do we need any?" but "does *supplementing* it slow aging or extend life?" ## The KiSel-10 trial: the strongest evidence The headline evidence is the Swedish KiSel-10 trial. Researchers randomized about 440 healthy elderly community-dwelling Swedes (aged 70–88) to either CoQ10 (200 mg/day) **plus selenium** (200 µg/day) or placebo, and followed them. The original 2013 report found that, over roughly four years, the combination significantly reduced cardiovascular mortality and lowered NT-proBNP (a marker of cardiac strain) versus placebo. What made the result striking is its durability: a 10-year follow-up still showed reduced cardiovascular mortality in the treated group, and a 12-year follow-up reported the protective association persisted — roughly a halving of cardiovascular mortality risk that endured long after supplementation ended. A sustained mortality signal from a randomized trial is genuinely rare in this field, and it's the main reason CoQ10 earns a B rather than a C. ## Three caveats that cap the grade KiSel-10 is impressive, but three features keep it from being an unqualified "CoQ10 extends life" result — and honest framing requires all three. **First, it was CoQ10 *plus selenium*, not CoQ10 alone.** The trial deliberately combined the two, on the rationale that selenium is needed for the enzymes that regenerate CoQ10, and that Sweden has notably low dietary selenium. You cannot cleanly attribute the benefit to CoQ10 by itself — and a later analysis found the effect was concentrated in participants who started with **low** selenium, suggesting part of what KiSel-10 demonstrated is the value of *correcting a selenium shortfall* in a deficient population, not a universal CoQ10 effect. **Second, the benefit is cardiovascular, not lifespan.** The endpoint that moved was cardiovascular mortality and cardiac strain — not all-cause longevity in the broad "slow aging" sense. That's a meaningful, real outcome, but it's specific to heart health in an older population, not evidence that CoQ10 lengthens the human lifespan generally. **Third, the population was specific:** elderly Swedes, many with low selenium status. Whether the same benefit transfers to younger, well-nourished, selenium-replete people taking CoQ10 alone is unknown — and there's no reason to assume it does. ## The other real trial: Q-SYMBIO in heart failure CoQ10's second piece of hard-outcome evidence is Q-SYMBIO, a randomized double-blind trial that added CoQ10 (300 mg/day) to standard therapy in patients with chronic heart failure. Over two years, CoQ10 reduced major adverse cardiovascular events and cardiovascular mortality versus placebo. Like KiSel-10, this is a real clinical outcome in a defined, sick population — heart-failure patients — rather than a biomarker or a healthy-longevity result. Together, KiSel-10 and Q-SYMBIO make a consistent case: CoQ10 appears to help the *cardiovascular system in older or cardiac-compromised people*. That's the honest scope of CoQ10's proven benefit — and it is narrower than the anti-aging marketing implies. ## Ubiquinol vs ubiquinone: a contested premium Supplement marketing leans hard on the idea that **ubiquinol** (the reduced form) is dramatically better absorbed and therefore worth its higher price over ordinary **ubiquinone**. The reality is messier. Some studies — often from groups with commercial ties — report ubiquinol achieves higher plasma levels. But a rigorous head-to-head bioavailability study in healthy elderly individuals found that different CoQ10 formulations varied, and that ubiquinone formulations could match or rival ubiquinol depending on the delivery system — bioavailability tracks more with the *formulation* (oil-based, solubilized, particle size) than with the oxidized-versus-reduced form per se. Critically, the trials that actually showed clinical benefit — KiSel-10 and Q-SYMBIO — used **ubiquinone**, not ubiquinol. So the evidence base for outcomes rests on the cheaper form, and the ubiquinol-superiority claim is a bioavailability argument, not an outcomes one. Paying a premium for ubiquinol is not clearly buying you better results. ## Statins and CoQ10 Because statins lower CoQ10, a common pitch is that everyone on a statin should supplement CoQ10 to prevent muscle side effects. Here the evidence is genuinely mixed and leans negative: a meta-analysis of randomized trials found that CoQ10 supplementation did not significantly improve statin-associated muscle symptoms versus placebo. Some individuals report benefit, and it's low-risk to try, but "CoQ10 fixes statin muscle pain" is not well supported by pooled randomized data. ## Mechanism and where it fits Mitochondrial dysfunction is one of the cataloged hallmarks of aging, and CoQ10 sits squarely at the center of mitochondrial energy production — which is why supplementing it is biologically plausible as an aging intervention. But "central to a hallmark" is a mechanism, not an outcome. CoQ10's *proven* value is in cardiovascular and cardiac contexts in older or compromised people; its general anti-aging or lifespan benefit in healthy adults remains unproven, and no trial has shown CoQ10 extends the human lifespan. ## Safety CoQ10 is among the safer supplements: it's well tolerated even at the 200–300 mg/day doses used in KiSel-10 and Q-SYMBIO, with mild GI upset the most common complaint. The main practical cautions are that CoQ10 can modestly interact with warfarin (it can reduce the anticoagulant effect), and — relevant to KiSel-10 — selenium has a narrow safe range, so the trial's selenium co-supplementation shouldn't be casually copied at higher doses. As always, "well tolerated" is a separate claim from "proven to extend life." ## The grade ## The bottom line CoQ10 earns a **Grade B for cardiovascular benefit** — and it's worth being precise about what that B does and doesn't cover. It's a B, not a C, because CoQ10 has something almost nothing else in this category has: two randomized trials (KiSel-10 and Q-SYMBIO) showing reduced cardiovascular mortality, with a follow-up signal that persisted for over a decade. It's a B, not an A, because that benefit is cardiovascular- and cardiac-specific rather than a general lifespan extension, the standout trial paired CoQ10 with selenium in a low-selenium elderly population (so it's partly a selenium-correction story), and the ubiquinol-superiority marketing isn't backed by the outcome trials, which used the cheaper ubiquinone. If you're an older adult focused on heart health — or on a statin and curious — CoQ10 is a defensible, low-risk, evidence-supported choice. As a general "take it to live longer" pill for healthy people, it remains unproven. For where it lands against the rest, see our [best longevity supplements, rated by evidence](/best-longevity-supplements) roundup; compare it to the other supplement that earns its grade on hard functional outcomes, [creatine for aging](/creatine-for-aging); and for a very different intervention with real cardiovascular-outcome data, see [GLP-1 medications for longevity](/glp1-for-longevity). For programs that pair supplements with real clinical oversight, see our graded [best longevity clinics](/best-longevity-clinics) hub. Sources: https://pubmed.ncbi.nlm.nih.gov/22626835/, https://pubmed.ncbi.nlm.nih.gov/29641571/, https://pubmed.ncbi.nlm.nih.gov/26624886/, https://pubmed.ncbi.nlm.nih.gov/27367855/, https://pubmed.ncbi.nlm.nih.gov/25282031/, https://pubmed.ncbi.nlm.nih.gov/27128225/, https://pubmed.ncbi.nlm.nih.gov/32188111/, https://pubmed.ncbi.nlm.nih.gov/30371340/, https://pubmed.ncbi.nlm.nih.gov/36599349/ --- ### Best Epigenetic Clock: GrimAge vs PhenoAge vs DunedinPACE Canonical: https://longevitygraded.com/epigenetic-clock-comparison Updated: 2026-06-05 GrimAge predicts mortality, PhenoAge predicts disease, DunedinPACE measures pace of aging. No clock is validated to guide your treatment. An honest comparison. ## The one-sentence version There is no single "best" epigenetic clock, because the leading clocks were built to do *different jobs*: **GrimAge** is the strongest at predicting time-to-death, **PhenoAge** is tuned to current disease and physiological dysfunction, and **DunedinPACE** measures a *rate* of aging rather than an age. Asking which is best is like asking whether a thermometer or a speedometer is the better instrument — it depends entirely on what you're trying to read. And underneath all of them sits a limit that no clock has escaped: every one of these tools is validated to rank-order *populations*, and none has been shown to be a target you can move to extend *your own* life. For where biological-age testing fits in the wider toolkit, start with our explainer on [whether epigenetic clocks actually work](/biological-age-tests) and our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## A clock is just a weighted sum of methylation sites Every clock here reads the same raw material: DNA methylation, the pattern of chemical tags on your DNA that shifts predictably with age. The differences come from *what each clock was trained to predict*. The first-generation Horvath clock (2013) was trained simply to estimate chronological age across tissues — an impressive technical feat, but one that, by design, treats deviating from your birthday as the signal. The clocks people actually argue about today are the "second-generation" ones, trained not on age but on health and survival outcomes. ## GrimAge: the mortality specialist If you want the single clock with the strongest record at predicting who dies sooner, it's GrimAge. Rather than training on age, GrimAge was built to predict lifespan and healthspan: it combines DNA-methylation surrogates for smoking-pack-years and seven plasma proteins into a composite that, in its founding paper, strongly predicted time-to-death and time-to-disease across multiple cohorts. A second iteration, GrimAge version 2, refined those surrogates and improved prediction further, particularly in some populations the original handled less well. The honest framing: GrimAge is the best-evidenced *risk stratifier* of the group. What it is **not** is a proven dial — no trial has shown that lowering your GrimAge makes you personally outlive your original prediction. ## PhenoAge: the disease-and-dysfunction clock PhenoAge (Levine 2018) was trained on a "phenotypic age" derived from nine clinical chemistry markers — things like albumin, creatinine, glucose, and C-reactive protein — that together track current physiological dysfunction. The result is a clock that leans toward *present* disease burden and morbidity rather than the pure mortality-forecasting that GrimAge specializes in. In practice GrimAge and PhenoAge often agree directionally, but PhenoAge's appeal is that it's anchored to ordinary blood-panel biology — which is also why a simplified version of the underlying phenotypic-age formula can be computed from a basic blood draw, no methylation array required (we cover that in [free biological-age tests and calculators](/free-biological-age-tests)). ## DunedinPACE: the speedometer, not the odometer DunedinPACE (Belsky 2022) is conceptually different from both. It doesn't estimate an *age* at all — it estimates a **pace**, calibrated against two decades of longitudinal organ-system decline in a single birth cohort followed since 1972. A reading of 1.0 means you're aging one biological year per chronological year; 1.2 means roughly 20% faster. That design makes it the most appealing clock for *tracking change over time*, because a rate is exactly what you'd want to watch if you were testing an intervention. DunedinPACE has two further things going for it. First, it was developed in the reliability-conscious lineage that emerged after researchers showed first-generation clocks were too noisy for longitudinal use and rebuilt them as principal-component versions to fix it. Second — and this is the single most important data point in the whole field — DunedinPACE was *moved by an actual randomized trial*: in CALERIE, two years of sustained caloric restriction slowed DunedinPACE relative to controls, the cleanest randomized evidence that a clock of this type responds to a real intervention. That's a genuine feather in the cap of the clock. It is still not proof about you (more on that below). ## So which clock should you pick? It depends on the question: - **"How long am I likely to live, relative to peers?"** → GrimAge (or GrimAge2) has the strongest mortality-prediction record. - **"How much disease/dysfunction is in my body right now?"** → PhenoAge, anchored to clinical-chemistry biology. - **"Is my rate of aging changing over time?"** → DunedinPACE, the only one designed as a rate and the only one a randomized trial has actually shifted. But notice what every one of those questions has in common: they're about *ranking you against a population*, or *describing a state*. None of them is "if I push this number down, will I live longer?" — and that's the question the clocks can't yet answer. ## The limit that applies to all three This is where an honest comparison has to slow the marketing down. The clocks are validated as **population-level predictors**: the landmark blood-methylation analysis showed people whose methylation runs "old" die sooner on average, even after adjusting for known risk factors. But "associates with mortality across thousands of people" is a categorically different claim from "this is a modifiable target I can move to change my fate." That second claim has not been demonstrated for *any* clock. An intervention could lower your reading while leaving your real disease risk untouched, and the report would look identical either way. Two more practical limits stack on top: - **Test–retest noise.** The same sample run twice can return different estimates, and a detailed reliability study found many widely used clocks reproduce poorly — first-generation clocks worst of all. The noise floor on a single re-test can rival the small change a 90-day experiment might produce, so an apparent "improvement" is often measurement variance dressed up as progress. - **No standard, no regulatory floor.** These are laboratory-developed tests, not FDA-cleared diagnostics, and there's no canonical definition of "biological age." Run two reputable clocks on the same person and they can disagree, because they use different training targets, arrays, and reference populations. The field's own consensus work is explicit about this: it treats these clocks as legitimate but **research-stage** tools for *intervention studies*, not as personal diagnostics or treatment-guiding endpoints. ## The grades, and how we got there We grade each clock on the job it was actually built for — and grade the use case most buyers want separately, because conflating them is the marketing trap. - **GrimAge / GrimAge2 as a population mortality predictor:** the strongest of the group — but a predictor, not a proven dial. - **DunedinPACE as a population pace-of-aging measure:** the best design for tracking a rate, and the only clock a randomized trial has moved. - **PhenoAge as a snapshot of current dysfunction:** solid, and uniquely tied to ordinary blood biology. - **Any clock as a validated guide to YOUR treatment decisions:** not there. No clock has been shown to be a target whose movement changes individual outcomes. That last line is the one that matters for spending decisions. The clocks are real science doing real population work; the "track your protocol quarterly to prove it's working" promise is unearned. We apply exactly this split to the best-known consumer product in our [TruDiagnostic TruAge review](/trudiagnostic-truage-review), and we sort which markers actually earn their place on a panel in [what longevity biomarker panels actually test](/longevity-biomarker-panels). ## Bottom line There's no universal "best epigenetic clock" — GrimAge wins on mortality prediction, PhenoAge on current dysfunction, and DunedinPACE on tracking a rate of aging (and it's the only one a randomized trial has actually moved). Pick the clock that matches your question. But hold all three to the same honest standard: they rank populations, they're noisy at the individual level, they aren't standardized or FDA-cleared, and not one of them has been validated as a target you can move to extend your own life. Treat any clock number as a soft risk signal, not a scoreboard — and don't reorganize your spending around watching it wobble. For an independently graded look at the labs and clinics selling biological-age testing, see [our longevity clinic rankings](/best-longevity-clinics). Sources: https://pubmed.ncbi.nlm.nih.gov/24138928/, https://pubmed.ncbi.nlm.nih.gov/30669119/, https://pubmed.ncbi.nlm.nih.gov/36516495/, https://pubmed.ncbi.nlm.nih.gov/29676998/, https://pubmed.ncbi.nlm.nih.gov/35029144/, https://pubmed.ncbi.nlm.nih.gov/36277076/, https://pubmed.ncbi.nlm.nih.gov/37118425/, https://pubmed.ncbi.nlm.nih.gov/25633388/, https://pubmed.ncbi.nlm.nih.gov/32885222/, https://pubmed.ncbi.nlm.nih.gov/37657418/, https://pubmed.ncbi.nlm.nih.gov/39708300/ --- ### GlycanAge Review: Is the Glycan Aging Test Worth It? Canonical: https://longevitygraded.com/glycanage-review Updated: 2026-06-05 GlycanAge measures IgG glycans tied to inflammation, and they move with lifestyle — but independent validation is thin and it can't localize a problem. Graded. ## The one-sentence version GlycanAge is the most interesting biological-age test here, and the most commonly described incorrectly. Instead of reading DNA methylation like the epigenetic clocks, it measures **IgG glycans** — sugar structures attached to your antibodies that shift with chronic, low-grade inflammation, the "inflammaging" that tracks aging. Its genuine selling point is that those glycans *move*, and move meaningfully, in response to lifestyle and hormones — which makes the number feel responsive in a way a methylation clock often doesn't. Its genuine problem is that the evidence base behind it is much thinner and more single-lab-concentrated than the epigenetic-clock literature, it can't tell you *where* your inflammation is coming from, and — like every test in this category — it has never been shown that lowering *your* GlycanAge makes *you* live longer. For where this sits in the wider toolkit, start with our explainer on [whether epigenetic clocks actually work](/biological-age-tests) and our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What GlycanAge actually measures Most biological-age tests read DNA methylation. GlycanAge reads something different: the **N-glycans on Immunoglobulin G (IgG)**, the most abundant antibody in your blood. As you age — and as chronic inflammation rises — the glycan structures decorating IgG shift in a characteristic direction, generally toward forms that make the antibody more pro-inflammatory and away from forms that keep it anti-inflammatory. The foundational paper established that this glycan signature tracks both chronological and biological age across multiple populations, which is what made "glycan age" a credible idea in the first place. An independent community-based study in a Han Chinese population reproduced the core finding that IgG N-glycans profile chronological and biological age, which is meaningful external validation of the *concept*. So when GlycanAge hands you a number, it's effectively reporting **how inflammatory your immune system's antibody pool looks** relative to your chronological age. That's a genuinely different — and arguably complementary — window on aging than a methylation clock, because it's anchored to the inflammatory axis specifically. ## The real strength: the number actually moves Here is where GlycanAge has a legitimate edge over the methylation clocks, and it's worth stating plainly. IgG glycans are *responsive*. Several intervention studies show the glycan-age index shifting with things people can actually change: - **Exercise.** A study of regular moderate physical exercise found it decreased the GlycanAge index and reduced the inflammatory potential of IgG. - **Sex hormones.** Estradiol moved the glycan age index in women, consistent with the long-observed link between estrogen and IgG glycosylation, and a 2025 study reported that testosterone and metformin shifted the GlycanAge index and IgG glycome composition. A comprehensive review of IgG glycans in health and disease lays out why this responsiveness exists: glycosylation is downstream of inflammatory and hormonal state, so it tracks *modifiable* biology rather than a largely fixed methylation pattern. For someone who wants a number that visibly responds to a real lifestyle change, that's the appeal — and it's a fair one. It's also why glycan changes show up as a readout in inflammatory disease: IgG glycosylation, for instance, associates with the clinical course of inflammatory bowel disease. ## The honest limits Now the part the marketing tends to skip. ### 1. The independent validation is thin The epigenetic-clock literature is enormous, cross-laboratory, and adversarial — many groups have built, attacked, and re-engineered those clocks. The glycan-aging literature is far smaller and far more concentrated in the cluster of labs that pioneered the method. There *is* independent reproduction of the central age-association, and the underlying glycobiology of aging is well-described in the broader literature. But "the concept replicates" is a much weaker statement than "this consumer product, as sold, is validated to track your health." The depth, breadth, and independence of evidence simply isn't comparable to what stands behind GrimAge or DunedinPACE — and an honest buyer should weight it accordingly. ### 2. It tells you *that* you're inflamed, not *why* A high GlycanAge is a non-specific signal. Elevated inflammatory glycosylation can reflect anything from an autoimmune flare to obesity to smoking to an acute infection you're shaking off. The test can't localize the source, so a "bad" number is a prompt to investigate, not a diagnosis — and a single reading taken during a transient inflammatory state can mislead. The same review that catalogs the responsiveness of IgG glycans also makes clear they're a shared final common pathway for many distinct conditions. ### 3. Moving the number isn't proven to move your outcome This is the limit that applies to *every* test in this category, GlycanAge included. The glycan-age index is validated as a marker that *associates* with aging and inflammation across groups — but no trial has shown that deliberately lowering your GlycanAge extends your life or prevents disease in you specifically. It's a marker, not a proven target. The field's own consensus work treats biomarkers of aging as legitimate but **research-stage** tools for intervention studies, not as personal diagnostics or treatment-guiding endpoints — and that caution covers glycan clocks as much as methylation ones. ## The grade, and how we got there We grade GlycanAge on two separate axes, because conflating them is the marketing trap: - **As a responsive marker of inflammatory aging:** moderate, and arguably the most *responsive* consumer biological-age readout — the glycans genuinely move with exercise, hormones, and metabolic change, and the age-association concept has been independently reproduced. - **As a validated, standalone tool to optimize your longevity:** weak. The independent validation behind the consumer product is thin next to the epigenetic-clock literature, the number can't localize a problem, and — like all of them — it's never been shown that lowering it extends *your* life. That split is why the letter grade lands in the middle. A responsive, mechanistically interesting marker wrapped around an unproven personal promise is, honestly graded, **a B for the inflammatory-marker concept and a C for the buy-it-to-optimize-yourself use case.** It's most defensible as a complement to — not a replacement for — outcome-validated measures. We sort which markers actually earn their place on a panel in [what longevity biomarker panels actually test](/longevity-biomarker-panels), grade the best-known methylation product in our [TruDiagnostic TruAge review](/trudiagnostic-truage-review), and compare the leading methylation clocks head-to-head in [GrimAge vs PhenoAge vs DunedinPACE](/epigenetic-clock-comparison). ## Who should and shouldn't buy it - **Reasonable buyer:** someone who specifically wants an *inflammation-axis* read and will treat the number as a responsive signal to pair with lifestyle change — and who understands it's a research-grade marker, not a diagnosis. - **Poor fit:** someone expecting a definitive "biological age" verdict, or planning to make medical decisions off a single reading. A transient inflammatory state can swing it, it can't tell you the cause, and an outcome-validated panel (ApoB, Lp(a) once, hs-CRP, HbA1c) does more for the same money — and a basic hs-CRP already captures much of the inflammation signal far more cheaply. ## Bottom line GlycanAge is a genuinely distinct and mechanistically interesting test: it reads IgG glycans tied to inflammatory aging, and its real strength is that the number *moves* with exercise, hormones, and metabolic change — more responsively than a methylation clock. But its independent validation is thin compared with the epigenetic-clock literature, it can't tell you *why* you're inflamed, a transient inflammatory state can distort a single reading, and — like every test in this category — lowering your GlycanAge has never been shown to extend *your* life. Treat it as a responsive inflammation-axis signal to pair with lifestyle change, not as a longevity verdict or a substitute for outcome-validated markers. For an independently graded look at the labs and clinics selling biological-age testing, see [our longevity clinic rankings](/best-longevity-clinics). Sources: https://pubmed.ncbi.nlm.nih.gov/24325898/, https://pubmed.ncbi.nlm.nih.gov/27428197/, https://pubmed.ncbi.nlm.nih.gov/38147152/, https://pubmed.ncbi.nlm.nih.gov/33049709/, https://pubmed.ncbi.nlm.nih.gov/39363095/, https://pubmed.ncbi.nlm.nih.gov/37207876/, https://pubmed.ncbi.nlm.nih.gov/29309774/, https://pubmed.ncbi.nlm.nih.gov/30779020/, https://pubmed.ncbi.nlm.nih.gov/37657418/, https://pubmed.ncbi.nlm.nih.gov/39708300/ --- ### Galleri Multi-Cancer Test Review: Is It Worth It? Canonical: https://longevitygraded.com/galleri-test-review Updated: 2026-07-26 Galleri's blood test can flag a cancer signal across many types — but no trial shows it saves lives, and false positives trigger costly cascades. Graded. ## The one-sentence version Galleri is a genuinely impressive piece of technology pointed at a question it hasn't yet answered. It's a single blood test that reads cell-free DNA methylation to flag a "cancer signal" across dozens of cancer types — including many with no standard screening test at all — and when it fires, it often points to where in the body the cancer is. That's real, and in a prospective study it roughly *doubled* the number of cancers detected on top of standard screening. But "detected more cancers" is **not** the same as "helped people live longer," and there is no evidence yet that taking Galleri extends your life. Meanwhile a false-positive signal can launch a months-long, anxiety-soaked, sometimes-invasive diagnostic cascade that finds nothing. The technology is strong; the proof that it benefits *you* is missing; and the overdiagnosis risk is real. For where this fits in the wider toolkit, start with our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence) and our take on [whether longevity clinics are worth it](/longevity-clinics-worth-it). ## What Galleri actually does Galleri is a **multi-cancer early detection (MCED)** blood test. It sequences cell-free DNA (cfDNA) circulating in your blood and reads its *methylation* pattern — the same chemical-tag biology the epigenetic aging clocks use, but here aimed at spotting the abnormal methylation that tumor DNA sheds. When it detects a cancer signal, the test also predicts the **cancer signal origin** — a best guess at which tissue the signal is coming from — which is what makes a single blood draw potentially actionable across many cancer types at once. The underlying detection science is legitimate and peer-reviewed. The foundational work showed that methylation signatures in cfDNA could detect and *localize* cancer across many types, later evaluations compared cfDNA approaches and refined the methylation-based method as the strongest, and a clinical-validation study confirmed performance on an independent set, with the important caveat that sensitivity is much higher for later-stage and more aggressive cancers than for early-stage ones. ## The headline result — and exactly what it does and doesn't prove The number that powers Galleri's marketing comes from **PATHFINDER**, a prospective cohort study of more than 6,600 adults aged 50+. Layered on top of usual care, the test produced a cancer signal in about 1.4% of participants, and crucially, **adding Galleri roughly doubled the number of cancers detected** versus standard screening alone — picking up cancers in organs with no routine screening test. The study design and implementation were laid out in advance, and a later analysis argued the methylation approach preferentially flags *high-grade* prostate cancer while minimizing detection of indolent disease — a deliberate attempt to limit one form of overdiagnosis. Now the part that matters most for a buyer. PATHFINDER measured **detection**, not **survival**. It is a cohort study showing the test finds more cancers — it is *not* a randomized trial showing that finding them this way makes people live longer or die less often from cancer. That distinction is the entire ballgame in screening, because of three well-described biases that can make a test *look* lifesaving when it isn't: - **Lead-time bias:** finding a cancer earlier moves the diagnosis date back, so survival *from diagnosis* looks longer even if the date of death never changes. - **Length bias:** a test that catches slow-growing cancers preferentially makes the detected pool look more survivable than it is. - **Overdiagnosis:** some detected "cancers" would never have caused harm in your lifetime, so "treating" them only adds risk. These aren't fringe objections — they're the standard framework for judging *any* screening test, and the reason detection counts can't substitute for mortality outcomes. The only way to know whether Galleri saves lives is a large randomized trial with a mortality endpoint, and that evidence does not yet exist. Until it does, "doubled detection" is a promising signal, not proof of benefit. ## The false-positive cascade is a real harm, not a footnote When Galleri flags a signal, you don't get a diagnosis — you get a *search*. That search can mean scans, biopsies, specialist visits, weeks-to-months of uncertainty, cost, and procedural risk. In PATHFINDER, among people with a positive signal, a substantial fraction turned out **not** to have cancer after the full diagnostic workup — and some of those people went through extensive testing to arrive at "nothing here". That's the overdiagnosis-and-overtesting tax that comes bundled with broad screening: the workup chasing an incidental or false signal is itself a recognized source of low-value, sometimes-harmful care. A "cancer signal detected" result on an asymptomatic person is a stress-test of your nerves, your wallet, and your willingness to undergo procedures — before anyone knows whether there's a real cancer at all. There's also the flip side: a "no signal detected" result is **not** an all-clear. Sensitivity is modest for early-stage cancers, so a reassuring Galleri result must not replace your guideline-recommended screening (colonoscopy, mammography, etc.) or stop you from acting on symptoms. ## The grade, and how we got there We grade Galleri on two separate axes, because the marketing collapses them: - **As a detection technology:** strong. The methylation-cfDNA science is real, peer-reviewed, and genuinely doubled cancer detection in a prospective study — including in cancers with no screening test at all. - **As a proven way to help *you* live longer:** weak. No randomized mortality trial exists; the benefit could be wholly explained by lead-time and length bias; and the false-positive cascade plus the "no signal ≠ no cancer" trap are concrete harms you take on today for an unproven future payoff. That split is why the letter grade lands in the middle rather than high. A genuinely powerful test sold ahead of its outcome evidence is, honestly graded, **a B for the technology and a C for the buy-it-to-live-longer use case — with an explicit overdiagnosis warning attached.** It is most defensible as an *eyes-open* add-on for an informed person who understands they're an early adopter of an unproven-for-mortality tool — and least defensible as a substitute for proven screening or as false reassurance. We apply the same detection-versus-outcome discipline to whole-body MRI and clinic megapanels in [are longevity clinics worth it?](/longevity-clinics-worth-it) and sort which tests actually earn their place in [what longevity biomarker panels actually test](/longevity-biomarker-panels). ## Who should and shouldn't buy it - **Reasonable buyer:** an informed, higher-risk, eyes-open adult (often 50+) who already does all their guideline-recommended screening, can afford the test and any downstream workup, and genuinely understands that a positive result may lead nowhere and a negative result proves nothing. The strongest case is "in addition to," never "instead of." - **Poor fit:** anyone hoping to *replace* colonoscopy or mammography, anyone prone to acting on anxiety, anyone who would treat "no signal" as a clean bill of health, or anyone who can't absorb the cost and risk of a cascade that ends in "nothing found." A worried-well person seeking reassurance is the buyer most likely to be harmed. Talking it through with a physician who understands MCED testing — the kind of clinician we describe in [what is a longevity doctor?](/what-is-a-longevity-doctor) — is the right first step, not the test itself. Note too where this test usually reaches people: bundled into concierge programs that pair AI-assisted cancer screening with whole-body MRI, [at annual tiers running into five figures](/fountain-life-review). Buying it inside a package makes the false-positive cascade above more likely, not less, because the imaging finds its own incidentalomas alongside any blood signal. ## Bottom line Galleri is real, peer-reviewed technology that reads tumor-shed DNA methylation to flag a cancer signal across many types — and in a prospective study it roughly doubled cancers detected, including in organs with no screening test. But detecting more cancers is not the same as saving lives: there's no randomized mortality trial, the apparent benefit could be lead-time and length bias, false positives trigger costly and sometimes-invasive cascades, and a "no signal" result is not an all-clear. Treat Galleri as an eyes-open add-on for an informed buyer who keeps doing standard screening — not as a substitute for proven tests and not as reassurance. For an independently graded look at the labs and clinics selling this kind of testing, see [our longevity clinic rankings](/best-longevity-clinics). Sources: https://pubmed.ncbi.nlm.nih.gov/33506766/, https://pubmed.ncbi.nlm.nih.gov/36400018/, https://pubmed.ncbi.nlm.nih.gov/34176681/, https://pubmed.ncbi.nlm.nih.gov/37805216/, https://pubmed.ncbi.nlm.nih.gov/34298717/, https://pubmed.ncbi.nlm.nih.gov/39208374/, https://pubmed.ncbi.nlm.nih.gov/25368922/, https://pubmed.ncbi.nlm.nih.gov/28765860/ --- ### Fountain Life vs Human Longevity Inc: MRI Clinics Compared Canonical: https://longevitygraded.com/fountain-life-vs-human-longevity Updated: 2026-07-26 Two whole-body-MRI longevity clinics compared. The headline isn't the price — it's the incidentaloma problem: most scary scan findings turn out to be nothing. Fountain Life and Human Longevity Inc (HLI) are the two best-known names in a specific, expensive corner of longevity care: the concierge clinic built around a whole-body and brain MRI. Both sell the same core promise — pay five figures, get scanned head-to-toe, and "catch disease early" before it can hurt you. Both anchor that promise to advanced imaging plus genomics, bloodwork, and an in-person physician. If you're choosing between them, the temptation is to compare price, scanner brand, and amenities. That comparison matters least. The thing that should drive your decision — and that neither clinic's marketing puts front and center — is what happens *after* the scan finds something. Because in apparently healthy people, whole-body MRI finds "something" remarkably often, and most of the time that something turns out to be nothing. That phenomenon has a name — the **incidentaloma** — and it is the single most important fact in this entire category. We'll lead with it, then compare the two clinics honestly. ## The headline problem: incidentalomas, not the price When you image an asymptomatic person from head to pelvis, you find incidental abnormalities — spots, nodules, cysts, lesions — that were never causing symptoms and may never have. A systematic review and meta-analysis of brain and body MRI in apparently asymptomatic adults found that **potentially serious incidental findings turned up in roughly 3.9% of whole brain-and-body scans**, with suspected malignancies in a fraction of a percent per region. That sounds low until you remember these clinics scan thousands of healthy people — and that the same review found that, of the potentially serious findings that *were* followed up, only about **one in five (20.5%) had a serious final diagnosis**. The other four in five were false alarms that still triggered worry, repeat imaging, specialist visits, and sometimes biopsies. Zoom out to imaging in general and the picture gets starker. An umbrella review of incidental findings across imaging types found prevalence ranging from under 5% on some scans to **more than a third of images** on cardiac MRI, chest CT, and CT colonography — and that when those incidental findings were worked up, the share that proved malignant was often modest (under 5% for brain, parotid, and adrenal findings, for example). Whole-body MRI specifically, even in carefully screened healthy research volunteers, routinely surfaces incidental findings in a large minority of participants. Intracranial incidental findings alone show up on a meaningful fraction of brain MRIs in the general population. This is not a knock on MRI as a technology. It is a statement about what screening *asymptomatic* people does: the lower your pre-test probability of disease, the more likely a positive finding is a false alarm. That is just how predictive values work, and it is why population imaging programs — like the German National Cohort, which scanned tens of thousands of people by whole-body MRI — had to build entire protocols around *how to handle and communicate* incidental findings, not just how to acquire images. ## Why "early detection" can become overdiagnosis The marketing logic is intuitive: find disease early, treat it early, live longer. The hidden flaw is **overdiagnosis** — detecting "disease" that would never have caused symptoms or death in your lifetime, then treating it anyway and incurring the harms of treatment with none of the benefit. Thyroid cancer is the textbook case: a wave of incidental thyroid nodules detected on imaging drove a surge in thyroid-cancer diagnoses without a matching rise in deaths, because many of those cancers were indolent and would never have mattered. Adrenal "incidentalomas" tell a similar story — most are benign, non-functioning, and clinically irrelevant, yet each one detected starts a cascade of hormonal workups and repeat scans. Even formal, evidence-graded screening programs wrestle with this. The US Preventive Services Task Force's prostate-cancer screening guidance is built explicitly around the trade-off that PSA-based detection finds many cancers that would never have harmed the man, at the cost of biopsies and treatments that do harm. That's a single, well-studied test in a defined-risk population. A whole-body MRI in a healthy 45-year-old casts a vastly wider net — and the wider the net, the more false alarms and indolent findings you haul in. The downstream "cascade of care" — the follow-up scans, referrals, biopsies, anxiety, and occasional procedural complications set off by a single incidental finding — is a documented harm, not a hypothetical one. None of this means whole-body MRI never helps anyone. It occasionally catches a genuinely serious, actionable problem early, and for some individuals that matters enormously. The honest framing is one of **base rates**: across thousands of healthy people scanned, the program will catch a small number of real, treatable problems *and* generate a much larger number of false alarms and overdiagnoses. Whether that trade is worth $20,000 a year is a value judgment — but you can only make it if the clinic tells you both sides. Most of the marketing tells you only the first. ## Fountain Life vs HLI: how they actually compare With that frame in place, here's how the two clinics line up. Both are concierge diagnostic programs centered on advanced imaging; the differences are in emphasis, structure, and price — none of which changes the incidentaloma math above. **Fountain Life** markets an annual membership (its APEX and CORE tiers) built around a full-body and brain MRI, AI-assisted image reading, coronary CT angiography, advanced bloodwork, and genomics, with care coordination throughout the year. Pricing is not published on its site — you're directed to book a call — but its flagship membership has been widely reported in the roughly $19,500-per-year range, with lower-cost assessment tiers. Treat any figure as approximate and confirm directly; concierge longevity pricing changes often and varies by location and package. We put the program through the same five-factor rubric as every other provider here — [where the unpublished pricing is itself part of the score](/fountain-life-review). **Human Longevity Inc** pioneered this model with its Health Nucleus, the San Diego clinic that paired whole-body and brain MRI with whole-genome sequencing and deep phenotyping. HLI leaned heaviest on the genomics side — it was founded by genomics figures and built around sequencing-plus-imaging "data on you." Its flagship assessment has historically been reported in the ~$25,000 range, again not transparently posted and subject to change. The practical upshot: these are *more alike than different*. Both are five-figure, imaging-and-genomics concierge programs aimed at affluent, mostly asymptomatic people who want a deep data snapshot. If what appeals to you is the in-person, clinician-supervised part rather than the MRI, the cheaper analog is a clinic membership rather than a concierge tier — [tiered monthly plans with the IV drips and functional labs billed per session](/next-health-review) buy a fraction of the diagnostics for a fraction of the money, and the evidence behind those drips is thinner than the imaging. HLI tilts toward genomics heritage; Fountain Life tilts toward a productized annual-membership experience with more locations. Neither has published evidence from a completed randomized trial showing its program extends lifespan — which is true of the entire longevity-clinic category, not a unique failing of either. We put that field-wide caveat in context in [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence) and weigh whether any concierge clinic earns its price in [are longevity clinics worth it?](/longevity-clinics-worth-it). ## What to ask before you pay either one If you're seriously considering one of these programs, the smart questions aren't about scanner resolution. They're about what happens when the scan lights up: - **What's your incidental-finding rate, and what share turn out to be nothing?** A clinic that scans healthy people should know its own false-alarm and overdiagnosis numbers. If it can't or won't tell you, that's a signal. - **Who pays for the downstream workup?** The MRI is the cheap part. The biopsies, repeat scans, and specialist referrals an incidental finding triggers are usually *not* in the membership — and not always covered by insurance, since they stem from an out-of-network screening test. - **How do you counsel patients against overtreatment?** A responsible program actively talks people *out of* chasing indolent findings, not just into more testing. - **Is the genomics actionable or just interesting?** Whole-genome data generates a lot of "variants of uncertain significance" that change nothing about your care. For most people, the rational alternative is a good primary-care relationship plus the standard, evidence-graded screenings appropriate to their age and risk — colonoscopy, age-appropriate mammography, lung-cancer CT *for actual smokers*, blood pressure, lipids, A1c — which have been vetted for exactly the benefit-versus-overdiagnosis balance these whole-body programs skip. We map the cheaper, more evidence-aligned tiers in [how much does a longevity clinic cost?](/longevity-clinic-cost) and contrast the program structures in [concierge vs membership longevity programs](/concierge-vs-membership-longevity). And if you do want a graded shortlist of programs by oversight and value, we rank them in our [guide to the best longevity clinics](/best-longevity-clinics). ## The bottom line Fountain Life vs HLI is the wrong first question. Both are credible, well-built concierge clinics selling essentially the same five-figure imaging-and-genomics product; HLI leans genomics, Fountain Life leans membership experience, and the price gap is smaller than the marketing gap. The *right* first question is whether whole-body MRI screening of a healthy person is a good idea at all — and the evidence says the answer is "sometimes, with eyes open." These scans reliably find incidental abnormalities, most of which are false alarms or overdiagnosed non-threats, and the resulting cascade of follow-up testing is a real harm with real costs. If you go in understanding that — and you can afford the downstream workups the scan may set in motion — either clinic can deliver a deep data snapshot. Just don't mistake "they found something" for "they saved your life." Far more often, the most valuable result a whole-body MRI can give a healthy person is a clean one. Sources: https://pubmed.ncbi.nlm.nih.gov/30467245/, https://pubmed.ncbi.nlm.nih.gov/29914908/, https://pubmed.ncbi.nlm.nih.gov/18818038/, https://pubmed.ncbi.nlm.nih.gov/35525892/, https://pubmed.ncbi.nlm.nih.gov/25989618/, https://pubmed.ncbi.nlm.nih.gov/30009267/, https://pubmed.ncbi.nlm.nih.gov/26100186/, https://pubmed.ncbi.nlm.nih.gov/26024670/, https://pubmed.ncbi.nlm.nih.gov/29801017/ --- ### Sauna & Longevity: What the Finnish Studies Actually Show Canonical: https://longevitygraded.com/sauna-for-longevity Updated: 2026-06-05 Frequent sauna use is tied to ~40% lower all-cause mortality in Finnish men — but it's one observational cohort, not a randomized trial. An honest grade-B read. Few longevity habits have a more quotable headline than the sauna. "People who use a sauna 4 to 7 times a week have a 40% lower risk of dying" is the kind of stat that launches a thousand podcast clips. The number is real, it comes from good researchers, and it's repeated accurately. But the moment you ask the only question that matters for a health decision — *does sweating in a hot room actually make people live longer, or do people who already live longer happen to sauna more?* — the picture gets more honest and more interesting. This is a textbook case of strong, consistent observational data that still can't prove cause. We'll give you the real numbers and a fair grade. ## Where the headline comes from: the Kuopio cohort Almost every striking sauna-longevity statistic traces to one source: the Kuopio Ischaemic Heart Disease (KIHD) Risk Factor Study, a prospective cohort of **2,315 middle-aged men in Eastern Finland**, followed for a median of about **20.7 years**. Finland is the right place to study this — sauna use is near-universal there, so researchers could compare men who sauna once a week against men who go 4 to 7 times a week and watch what happened over two decades. The findings were striking and dose-dependent. Compared with men who used a sauna **once a week**, men who used it **4 to 7 times a week** had: - **All-cause mortality** roughly **40% lower** (hazard ratio ~0.62) - **Fatal cardiovascular disease** about **50% lower** (hazard ratio ~0.54) - **Sudden cardiac death** about **63% lower** (hazard ratio ~0.37) The relationship was graded — more sessions tracked with lower risk, and longer time per session helped too. The same cohort later linked frequent sauna use to **lower risk of dementia and Alzheimer's disease** and, in a mixed-sex KIHD analysis, to **lower stroke risk**. A separate analysis found sauna use and cardiorespiratory fitness were *jointly* protective — the men who were both fit and frequent sauna users had the lowest mortality of all. A broad review by the same group catalogs these cardiovascular and other associations across the literature. That's a lot of consistent signal pointing the same direction. So why isn't the grade an A? ## The catch: this is observational, and it's one cohort Here's the part the headline skips. KIHD is an **observational cohort study**, not a randomized controlled trial. Nobody assigned men to sauna or no-sauna and compared outcomes. The researchers measured a habit people already had and watched what followed — which means the result is an *association*, and associations can't, by themselves, establish cause. The specific worry is **confounding by health**. In Finland, who goes to the sauna 4 to 7 times a week? Disproportionately, people who are already healthy, mobile, socially connected, employed, and free of the illnesses that keep someone home. A man with advanced heart failure, severe arthritis, or end-stage illness simply doesn't trek to a hot sauna most days. So "frequent sauna user" may partly be a marker of *already being well* — and well people live longer regardless of what's heating the room. The KIHD authors adjusted for many known risk factors, but no statistical adjustment can fully remove confounding you didn't measure (this is called **reverse causation** and **residual confounding**). To their credit, the researchers themselves publicly engaged with the argument that the sauna–mortality link may be **noncausal**, defending their adjustments while acknowledging the limits of observational design. That candor is exactly the right scientific posture — and it's why an honest reader shouldn't treat 40% as a number you can "buy" by booking more sauna time. Two more limits matter. First, **it's essentially one population**: middle-aged Finnish men (and one mixed-sex extension), in a culture where sauna is woven into daily life. Whether the same effect size transfers to, say, a 38-year-old American using an infrared cabin twice a week is unknown. Second, **there is no large randomized trial** showing sauna *lengthens life* — the gold standard that would turn "associated with" into "causes." Until that exists, the longevity claim rests on plausible mechanism plus consistent observation, not proof. ## What's actually plausible about the mechanism The mechanistic story is genuinely reasonable, which is part of why the data feel believable. A sauna session is a mild, controlled heat stress — a form of **hormesis** (a small stressor that triggers adaptive, protective responses). Acutely, heat raises heart rate and stresses the cardiovascular system somewhat like light-to-moderate exercise; over time, regular passive heating is associated with improved vascular function and favorable short-term shifts in blood-based cardiovascular markers. Reviews of heat (and cold) physiology describe plausible pathways — improved endothelial function, blood-pressure effects, heat-shock protein responses, and autonomic changes — through which repeated sauna exposure *could* benefit the heart and brain. But "plausible mechanism" is exactly where honest longevity writing has to hold the line: a believable biological story is a reason to take an association seriously, **not** a substitute for outcome proof. Plenty of mechanistically gorgeous interventions have failed in trials. The mechanism earns the sauna a respectful hearing; it doesn't earn it an A. ## The honest grade: B-minus Put it together. The sauna has **consistent, dose-dependent, long-follow-up observational data** from a respected cohort, reinforced across multiple outcomes (mortality, cardiovascular death, dementia, stroke) and backed by a plausible mechanism. That's a stronger evidence base than most things sold in the longevity aisle. But it is **observational, largely single-cohort, single-population, and unconfirmed by any randomized lifespan trial**, with a real and acknowledged risk that healthier people simply sauna more. That combination lands it at a fair **grade B-minus**: more than a wellness fad, less than a proven life-extender. The practical upshot is reassuring precisely because the downside is low. Regular sauna use is, for most healthy people, pleasant, cheap relative to concierge longevity programs, and low-risk (with sensible cautions: stay hydrated, don't combine with heavy alcohol, and check with a clinician if you have unstable cardiovascular disease, are pregnant, or are prone to fainting). You can enjoy it as a likely-beneficial, low-harm habit *without* believing the 40% number is a personal guarantee. That's the difference between using evidence and overselling it. For where this sits among interventions with better or worse proof, see our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). The single best-validated longevity signal in this neighborhood is cardiorespiratory fitness — covered in [VO2 max and longevity](/vo2-max-and-longevity) — which is notable because the KIHD data suggest sauna and fitness are *additive*, not interchangeable. And for another popular heat-and-cold therapy with thinner outcome data, see [hyperbaric oxygen for longevity](/hbot-for-longevity); for the cold end of the spectrum — which has a *weaker* longevity case than the sauna — see [cold plunge for longevity: hype vs evidence](/cold-plunge-for-longevity). If you'd rather compare graded longevity programs than build a habit stack, we rank them in our [guide to the best longevity clinics](/best-longevity-clinics). ## The bottom line The Finnish sauna studies are real, careful, and consistent — and they show that frequent sauna users live longer and have fewer cardiovascular events. What they *cannot* show, because of their observational design and single-population scope, is that the sauna is the *reason*. Some of that 40% is almost certainly the sauna; some of it is almost certainly that healthier people sauna more. Until a randomized trial settles it, the right stance is enthusiastic-but-honest: a likely-beneficial, low-risk, enjoyable habit graded **B-minus** — worth doing for how it feels and what it plausibly does, not because a headline promised you four extra decades of life. Sources: https://pubmed.ncbi.nlm.nih.gov/25705824/, https://pubmed.ncbi.nlm.nih.gov/27932366/, https://pubmed.ncbi.nlm.nih.gov/29720543/, https://pubmed.ncbi.nlm.nih.gov/28972808/, https://pubmed.ncbi.nlm.nih.gov/30077204/, https://pubmed.ncbi.nlm.nih.gov/26436740/, https://pubmed.ncbi.nlm.nih.gov/29971466/, https://pubmed.ncbi.nlm.nih.gov/29351426/ --- ### Cold Plunge for Longevity: Hype vs Evidence Canonical: https://longevitygraded.com/cold-plunge-for-longevity Updated: 2026-06-05 Cold exposure extends lifespan in worms and flies — but there's zero human lifespan data, and the human evidence is about recovery and mood, not living longer. Cold plunges have become a longevity status symbol — the ice bath in the garage, the morning dunk, the breathless claim that cold exposure "activates longevity pathways." The marketing leans hard on a real scientific fact: in certain animals, being kept colder makes them live measurably longer. That part is true. The leap the marketing makes — from cold-extends-lifespan-in-a-worm to cold-extends-your-life — is where the evidence runs out completely. There is **no human lifespan data on cold exposure at all.** What human data exist are about recovery, mood, and metabolism, not living longer — and some of it cuts *against* a few of the goals people plunge for. Here's the honest split between the hype and the evidence, with a grade that reflects it. ## What's actually true: cold extends lifespan in animals The animal story is genuine and, frankly, fascinating. In the roundworm *C. elegans*, shifting to colder temperatures activates a specific thermosensitive ion channel (TRPA-1) that triggers a downstream genetic program — and this **cold-activated pathway extends the worm's lifespan**. Follow-up work confirmed that environmental temperature modulates *C. elegans* longevity through this TRP-channel mechanism, establishing cold as a bona fide longevity lever in that organism. This isn't fringe science; it's published in top journals and mechanistically detailed. It also extends up the tree, at least partway. In a landmark mouse study, transgenic animals engineered to run a **lower core body temperature lived significantly longer** than normal-temperature controls — direct evidence that, in a mammal, reduced core temperature can extend lifespan independent of how much the animal eats. That result is one of the strongest pillars under the "cold and longevity" idea. So far, so promising. But read those studies precisely, because the gap between them and an ice bath is enormous. ## The gap the marketing skips: none of that is a cold plunge in a human Three problems separate the animal data from your ice tub. **First, the organisms.** Worms and flies are *ectotherms* (cold-blooded) — their entire metabolism slows when the environment cools, which is a completely different situation from a warm-blooded human who plunges for three minutes and then *reheats* back to 37°C. You are not a worm held at a lower temperature; you are a mammal that vigorously defends its core temperature against a brief cold shock. The mouse study makes this even clearer: the benefit came from a **chronically lower core body temperature**, genetically engineered and maintained around the clock — not from short, intermittent cold exposures that your body immediately counteracts by shivering and burning fuel to rewarm. A cold plunge, if anything, tends to *raise* metabolic rate acutely to defend core temperature; it doesn't lower it the way these lifespan models require. **Second, there is no human lifespan or mortality data on cold plunging — none.** No randomized trial, no prospective cohort, nothing has shown that people who take cold plunges live longer or die less. This is the single most important sentence on this page. Every "cold exposure for longevity" claim aimed at humans is an *extrapolation* from worm and mouse mechanisms, not a human outcome. That's a categorically weaker form of evidence than even the observational sauna data (which at least tracks human mortality across 20 years — see our [sauna and longevity](/sauna-for-longevity) review for the contrast). **Third, the human studies that do exist measure something else.** Cold-water immersion has a real human research literature — but it's about athletic recovery, mood, and metabolism, not lifespan. ## What the human data actually show (and don't) Here's what cold exposure has genuine human evidence for: - **Acute recovery from exercise.** Meta-analyzes find cold-water immersion modestly reduces muscle soreness and perceived fatigue after strenuous exercise. This is the best-supported human use of cold — and it's about feeling recovered tomorrow, not living longer. - **Metabolic / brown-fat effects.** Cold acclimation can activate brown adipose tissue and, in a controlled human study, improved insulin sensitivity. That's a legitimately interesting metabolic signal — but it's a surrogate marker (insulin sensitivity), not a longevity outcome, and "improves a lab value" is not "extends life," a distinction we hold across this whole site. And here's the part cold-plunge enthusiasts often don't hear: for people lifting weights to build or preserve muscle — itself a well-validated longevity goal — **routine post-workout cold immersion can be counterproductive.** Plunging right after resistance training blunts the anabolic signaling that drives muscle growth and, over weeks, attenuates strength and hypertrophy gains compared with passive recovery; it also blunts the post-exercise hormonal and inflammatory responses that help muscle adapt. The very inflammation cold suppresses is partly *how* training makes you stronger. So if your longevity plan leans on maintaining muscle and strength with age, habitually icing right after lifting may work against you — an irony worth knowing before you build a daily plunge habit. (See why muscle and strength matter for lifespan in [grip strength and longevity](/grip-strength-and-longevity).) ## The honest grade: C for what it's proven to do, D for the longevity claim Let's grade it straight. As a **longevity intervention specifically**, cold plunging earns a **D**: the only lifespan evidence is in worms, flies, and genetically-cooled mice, with zero human lifespan data and a mechanism (chronic lower core temperature) that a brief plunge doesn't even replicate. As a tool for **acute recovery and mood**, it earns roughly a **C** — there's real, if modest, human evidence it helps you feel recovered and may lift mood acutely, and a genuine metabolic signal around brown fat and insulin sensitivity. Those are legitimate reasons to enjoy cold exposure. "It will make you live longer" is not one the human evidence supports. This isn't a reason to never take a cold plunge. If you like how it feels, it's invigorating, it may aid recovery on non-lifting days, and the metabolic effects are intriguing, plunge away — with sensible caution (cold shock is a real cardiovascular stressor; people with heart conditions, uncontrolled hypertension, or who are pregnant should check with a clinician, and never plunge alone in open water). Just file it where the evidence puts it: a pleasant, plausibly-helpful recovery-and-mood practice, **not** a proven longevity intervention. For where it sits among interventions with real outcome proof, see our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence) and the genuinely best-validated longevity signal in [VO2 max and longevity](/vo2-max-and-longevity). And if you'd rather compare graded longevity programs than assemble a habit stack, we rank them in our [best longevity clinics](/best-longevity-clinics) hub. ## The bottom line Cold extends lifespan in worms, flies, and core-temperature-lowered mice — that's real, and it's why the longevity claim has just enough mechanistic smoke to sell ice baths. But humans aren't cold-blooded worms, a three-minute plunge doesn't lower your core temperature the way the lifespan models require, and there is **zero human data showing cold exposure makes people live longer.** The solid human evidence is about recovery and mood, with an intriguing metabolic signal — and a real catch that icing after lifting can blunt the muscle gains that *are* tied to longevity. Honest grade: **C** for recovery and mood, **D** for longevity. Enjoy the cold for what it does. Don't buy it as a life-extender it has never been shown to be. Sources: https://pubmed.ncbi.nlm.nih.gov/23415228/, https://pubmed.ncbi.nlm.nih.gov/26027928/, https://pubmed.ncbi.nlm.nih.gov/17082459/, https://pubmed.ncbi.nlm.nih.gov/21947816/, https://pubmed.ncbi.nlm.nih.gov/36744038/, https://pubmed.ncbi.nlm.nih.gov/24954193/, https://pubmed.ncbi.nlm.nih.gov/26174323/, https://pubmed.ncbi.nlm.nih.gov/31222379/ --- ### Zone 2 Training for Longevity: The Evidence, Graded Honestly Canonical: https://longevitygraded.com/zone-2-training-for-longevity Updated: 2026-06-05 Zone 2 has a strong mitochondrial mechanism and builds the fitness that predicts lifespan — but no trial proves Zone 2 itself extends life. Graded honestly. Zone 2 training — easy, conversational-pace aerobic exercise held for long stretches — has become the signature workout of the longevity world, championed by Peter Attia and the exercise physiologist Iñigo San-Millán. The pitch is appealing: train slow to build the cellular machinery that keeps you metabolically young. The mechanism behind that pitch is genuinely strong. But there is an honest gap between "Zone 2 builds the mitochondria that decline with age" and "Zone 2 makes you live longer," and most of the marketing blurs it. Here is what the evidence actually supports, graded the way we grade everything. ## What "Zone 2" actually means Zone 2 is the second of five training-intensity zones, defined by physiology rather than a heart-rate app's color band. It is the intensity just below your first lactate threshold — the highest effort you can sustain while your body still clears lactate as fast as it produces it, so blood lactate stays low and roughly steady (often cited around 2 mmol/L). In practice it is a pace you can hold for an hour while still being able to talk in full sentences: breathing is elevated but controlled, not labored. The reason Zone 2 gets singled out is metabolic. At this intensity, skeletal muscle relies heavily on fat as fuel and on the slow-twitch, mitochondria-rich fibers that oxidize it. The claim from San-Millán's lab work is that this specific intensity is where you most effectively stimulate and train mitochondrial fat-oxidation capacity. That is a reasonable mechanistic claim — but as we'll see, the leap from "trains mitochondria" to "extends lifespan" is where honesty is required. ## The strong part: the mitochondrial mechanism This is where Zone 2's case is genuinely good, and it rests on well-established exercise physiology, not hype. Aerobic exercise is one of the most reliable known stimuli for **mitochondrial biogenesis** — the cell's process of building more, and more capable, mitochondria in skeletal muscle. The molecular machinery (centered on the transcriptional coactivator PGC-1α) and the resulting increase in mitochondrial content and respiratory capacity are textbook adaptations to endurance training. A 2025 systematic review and meta-regression of human training studies confirmed the practical version of this: exercise training measurably increases mitochondrial content and capillary density in human skeletal muscle, with the gains scaling with training volume. Those better mitochondria underpin **metabolic flexibility** — the capacity to switch efficiently between burning fat and carbohydrate depending on availability and demand. Metabolic flexibility is impaired in insulin resistance, obesity, and type 2 diabetes, and improving it is a coherent metabolic-health target. Zone 2's heavy reliance on fat oxidation is the training stimulus most directly aimed at this trait. Why does any of this connect to aging at all? Because **mitochondrial dysfunction is one of the formally recognized hallmarks of aging** — declining mitochondrial number, efficiency, and quality control is a core feature of how cells age, listed alongside genomic instability and cellular senescence in the canonical hallmarks framework. (We unpack that framework in our guide to the [hallmarks of aging](/hallmarks-of-aging-explained).) So the longevity logic runs: aging degrades mitochondria → Zone 2 training builds mitochondria → therefore Zone 2 counteracts a hallmark of aging. Each individual link in that chain is real and evidenced. ## The honest gap: mechanism is not a lifespan trial Here is the part the marketing tends to skip. The chain above is a **mechanistic inference**, not a proven outcome. There is no randomized controlled trial showing that Zone 2 training specifically — as opposed to exercise in general — extends human lifespan or even slows a validated aging biomarker more than other training does. Such a trial would take decades and is essentially impossible to run cleanly. So when someone tells you Zone 2 "reverses aging" or "adds years," they are extrapolating from cell biology, not citing an endpoint. Two further honest caveats sharpen this. First, the precise claim that Zone 2 is *uniquely* or *optimally* the intensity for mitochondrial adaptation is not settled. Controlled work on training intensity shows that higher-intensity intervals also drive substantial mitochondrial and aerobic adaptations — and per-minute, intervals are often more time-efficient for raising aerobic capacity. The strongest defensible statement is that low-intensity aerobic volume and higher-intensity work are *complementary* stimuli, not that Zone 2 is the one true longevity intensity. Second, much of what makes Zone 2 attractive for longevity is really an argument about **VO2 max and cardiorespiratory fitness**, which Zone 2 helps build — and it's fitness, not the specific workout, that carries the heavyweight survival evidence. ## What carries the survival evidence: fitness, not the workout label Step back from the zone debate and the strongest longevity case becomes clear: the fitness that aerobic training produces is one of the best-validated predictors of how long you'll live. In a study of 122,007 adults who underwent treadmill testing, cardiorespiratory fitness was graded against survival with no observed ceiling — the least-fit had dramatically higher all-cause mortality, with risk comparable to or greater than smoking, diabetes, and hypertension. In men referred for exercise testing, each 1-MET increase in exercise capacity conferred roughly a 12% improvement in survival, and a large meta-analysis confirmed the same dose-response gradient across healthy men and women. The American Heart Association considers the evidence strong enough to recommend treating cardiorespiratory fitness as a clinical vital sign. (We grade that body of evidence in full in our piece on [VO2 max and longevity](/vo2-max-and-longevity).) Zone 2 is a legitimate, evidence-based way to build the aerobic base that raises fitness — but so is interval training, and a 2021 meta-analysis found both interval and moderate-intensity continuous training improve cardiorespiratory fitness in middle-aged and older adults. The practical synthesis most physiologists land on is a large base of easy aerobic volume (Zone 2 territory) plus a smaller dose of harder intervals. Notably, this is also exactly what public-health guidance already prescribes: the WHO's 2020 physical-activity guidelines recommend 150–300 minutes per week of moderate aerobic activity, with additional benefit from vigorous work — the institutional version of "mostly easy, some hard". ## Why Zone 2 is still worth doing None of the honest hedging means Zone 2 is overrated as *training*. It is a low-injury-risk, sustainable way to accumulate aerobic volume; it directly trains fat oxidation and mitochondrial capacity; it builds the fitness base that the mortality data reward; and it pairs well with strength work and intervals rather than competing with them. The case for *doing* it is solid. What's overstated is the specificity — the idea that this particular heart-rate band, rather than aerobic fitness broadly, is what extends life. (Functional capacity tracks with survival across the board; the muscular counterpart is covered in our look at [grip strength and longevity](/grip-strength-and-longevity).) ## How to actually do Zone 2 The practical recipe is simple. Pick a continuous aerobic activity (brisk incline walking, easy cycling, rowing, light jogging). Hold an intensity where you can still speak in full sentences but wouldn't want to hold a long conversation — the classic "talk test" — for 30 to 60 minutes. Most longevity-minded programs target three to four sessions a week, totaling a few hours, which also satisfies the WHO moderate-activity range. If you want precision, a lactate meter or a lab-determined first threshold pins your true Zone 2 ceiling; heart-rate formulas are rough approximations and tend to run high. Then layer a small amount of higher-intensity work on top to push the aerobic ceiling that fitness studies reward. ## Where this fits in evidence-based longevity Zone 2 sits in the honest middle of the longevity landscape: a real, mechanistically grounded training method whose specific anti-aging claims outrun the trial data, but which builds the cardiorespiratory fitness that *does* have heavyweight survival evidence behind it. We treat it the way we treat the rest of the field — promising mechanism, strong proxy (fitness), no lifespan trial for the specific intervention — in our pillar on the [evidence behind longevity medicine](/longevity-medicine-evidence). And if you're evaluating clinics and coaches that build structured aerobic training and fitness testing into longevity programs, we grade the field on evidence, oversight, and price in our [best longevity clinics hub](/best-longevity-clinics). ## The bottom line Zone 2 training earns a genuinely respectable grade — but for the right reasons. Its mitochondrial mechanism is strong and well-evidenced, and it builds the cardiorespiratory fitness that is one of the best-validated predictors of lifespan. What it does *not* have is a trial proving that Zone 2 specifically extends life; that link is inferred from mitochondrial-decline-as-a-hallmark-of-aging, not demonstrated by an endpoint. Do Zone 2 because it's a sustainable, low-risk way to build aerobic fitness and metabolic flexibility — not because a particular heart-rate band has been shown to add years. Pair it with intervals and strength work, and you're doing the version the evidence actually supports. Sources: https://pubmed.ncbi.nlm.nih.gov/40879934/, https://pubmed.ncbi.nlm.nih.gov/39390310/, https://pubmed.ncbi.nlm.nih.gov/28467922/, https://pubmed.ncbi.nlm.nih.gov/36599349/, https://pubmed.ncbi.nlm.nih.gov/27748956/, https://pubmed.ncbi.nlm.nih.gov/30646252/, https://pubmed.ncbi.nlm.nih.gov/11893790/, https://pubmed.ncbi.nlm.nih.gov/19454641/, https://pubmed.ncbi.nlm.nih.gov/27881567/, https://pubmed.ncbi.nlm.nih.gov/33825615/, https://pubmed.ncbi.nlm.nih.gov/33239350/ --- ### Outlive by Peter Attia: An Evidence-Based Review Canonical: https://longevitygraded.com/outlive-peter-attia-review Updated: 2026-06-05 Attia's Outlive popularized Medicine 3.0 and the Four Horsemen. We grade the framework honestly: where the evidence is strong, and where it's reasoned opinion. Peter Attia's *Outlive: The Science and Art of Longevity* (2023) is the book that pushed longevity from a niche obsession into mainstream conversation. Its core ideas — "Medicine 3.0," the "Four Horsemen" of chronic disease, "healthspan over lifespan," and the "Centenarian Decathlon" — are now everywhere. The book's great strength is its framing: it is honest about how little of conventional medicine is oriented toward preventing the diseases that actually kill us. The question worth asking is whether the *specifics* hold up to scrutiny. Mostly the framework is sound and the headline recommendations are well-supported; in places the certainty runs ahead of the trial data. Here's our honest, graded review. ## What the book actually argues *Outlive*'s organizing idea is **Medicine 3.0**: Attia's term for a shift from reactive, disease-treatment medicine ("Medicine 2.0") to a proactive, prevention-first, individualized, risk-aggressive approach aimed at extending the years you live in good health ("healthspan"), not just total years ("lifespan"). This is a framing argument, not a discovery — but it's a defensible and useful one. From there the book targets the **Four Horsemen** — the four chronic-disease categories responsible for the overwhelming majority of deaths in people who don't die of accidents: atherosclerotic cardiovascular disease, cancer, neurodegenerative disease (Alzheimer's and related dementias), and metabolic dysfunction (type 2 diabetes and related conditions, which Attia treats as a driver amplifying the other three). The strategy is to attack the risk factors for each decades early. The book's most-quoted training claim — that "muscle is the organ of longevity" and that strength and VO2 max are central to a long healthspan — anchors its exercise chapters. ## Where the evidence is genuinely strong Several of *Outlive*'s load-bearing claims rest on some of the most robust evidence in all of medicine. **The cardiovascular argument is on very firm ground.** Attia is aggressive about lowering apoB-containing lipoproteins (LDL and related particles) early, and the causal case for this is about as settled as biology gets: a European Atherosclerosis Society consensus statement, integrating genetic, epidemiologic, and clinical-trial evidence, concluded that LDL *causes* atherosclerotic cardiovascular disease and that the effect is cumulative over a lifetime. The companion Mendelian-randomization evidence shows that lifelong lower LDL maps to dramatically lower cardiovascular risk. So the book's emphasis on early, sustained lipid-lowering is well-founded — even if the exact aggressiveness of his personal targets goes beyond what guidelines mandate. **The exercise argument is the strongest part of the book.** Attia's claim that cardiorespiratory fitness is a top-tier longevity lever is backed by heavyweight data: in a study of 122,007 adults, low fitness carried mortality risk comparable to or greater than smoking, diabetes, and hypertension, with a graded benefit and no observed ceiling, and each 1-MET increase in exercise capacity has been tied to roughly a 12% survival improvement. (We grade that body of evidence in detail in our piece on [VO2 max and longevity](/vo2-max-and-longevity).) His "muscle is the organ of longevity" framing is also well-supported as an association: a meta-analysis of roughly two million people found muscular strength independently predicts lower all-cause mortality, muscle-strengthening activity is tied to lower mortality across major chronic diseases in a dose-response fashion, and grip strength was a strong predictor of death and cardiovascular events in the global PURE study. (We cover the strength side separately in [grip strength and longevity](/grip-strength-and-longevity).) The public-health version of the book's exercise prescription — substantial aerobic work plus resistance training — mirrors the WHO's physical-activity guidelines. **The metabolic-health emphasis is well-grounded too.** Attia treats metabolic dysfunction as an upstream amplifier of the other Horsemen, and improving metabolic flexibility — the capacity to switch efficiently between burning fat and carbohydrate, which is impaired in insulin resistance and diabetes — is a coherent, evidence-based target. ## Where the certainty outruns the trials Now the honest part. A book is a synthesis filtered through one clinician's judgment, and *Outlive* is more confident than the trial data in several places. **Many specific protocols are reasoned extrapolation, not RCT-proven.** Attia's detailed prescriptions — exact lipid targets well below guideline thresholds, intensive multi-domain screening, specific supplement and hormone choices, his "Centenarian Decathlon" training scheme — are sensible-sounding syntheses of mechanism and risk-factor data, but most have not been tested as *interventions* in randomized longevity trials. That's not a flaw unique to Attia; it reflects a genuine gap in the field (you cannot easily run a decades-long RCT on a personalized protocol). But readers should know that "this lowers a risk factor" is not the same as "this has been proven to extend lifespan in a trial." **The neurodegeneration chapter is the least settled.** The Four Horsemen framing is sound, and the modifiable-risk-factor argument has real backing — the Lancet Commission on dementia estimates that a substantial share of dementia cases are associated with modifiable factors like hypertension, hearing loss, physical inactivity, and diabetes. But the specific neuroprotective strategies the book favors are far less proven than its cardiovascular advice, and Alzheimer's prevention remains an area where mechanism and association outrun demonstrated interventional benefit. The book is appropriately humble here in places, but the surrounding certainty of tone can blur that. **"Healthspan" is under-measured.** The book rightly elevates healthspan over lifespan, but healthspan is genuinely hard to quantify, and many of the biomarkers and tests the longevity world (including Attia) leans on have not been validated to *guide treatment*. We make that same point about the testing industry in our look at [biological age tests](/biological-age-tests). ## How it compares to the other big longevity playbook It's worth contrasting *Outlive* with Bryan Johnson's Blueprint, the other dominant longevity protocol of the moment. Attia's approach is clinician-led, risk-factor-focused, and relatively conservative about unproven interventions — it leans on exercise, lipid management, sleep, and metabolic health, which are the best-evidenced levers. Johnson's Blueprint is a maximalist, self-experimental stack with dozens of supplements and measurements, far more of which lack outcome evidence. We grade that approach separately in our [Bryan Johnson Blueprint review](/bryan-johnson-blueprint-review). The honest summary: Attia's framework is the more evidence-disciplined of the two, even where its specifics outrun the trials. ## Who should read it *Outlive* is genuinely worth reading for the framing alone — the healthspan-over-lifespan argument, the Four Horsemen lens, and the case for treating exercise and lipid management as the highest-leverage moves are all valuable and well-supported. Read it as a thoughtful clinician's evidence-informed strategy, not as a settled protocol. Where it cites strong data (cardiovascular risk, fitness, strength, metabolic health), take it seriously. Where it gets into specific targets, supplements, hormones, and screening cadences, treat those as one expert's reasoned bets that haven't been proven in trials — and discuss them with your own clinician. (For the broader question of what a longevity-focused doctor actually does, see [what is a longevity doctor](/what-is-a-longevity-doctor).) ## Where this fits in evidence-based longevity *Outlive* essentially popularized the honest-grading mindset we apply across the board: most longevity interventions sit on a spectrum from strongly evidenced (exercise, lipid management) to mechanistically plausible but unproven (many supplements and protocols). We map that spectrum in our pillar on the [evidence behind longevity medicine](/longevity-medicine-evidence). And if the book inspires you to find a clinic or physician to operationalize this kind of program, we grade the field on evidence, oversight, and price in our [best longevity clinics hub](/best-longevity-clinics). ## The bottom line *Outlive* earns a strong grade as a framework and a clear grade for its best-evidenced recommendations — the cardiovascular, fitness, strength, and metabolic chapters rest on some of the most robust data in medicine. It earns a more cautious grade for its specific protocols, which are intelligent extrapolations rather than trial-proven interventions, and for the neurodegeneration material, which is the least settled. The honest verdict: a genuinely good, evidence-informed book whose framing is excellent and whose headline advice is sound — read critically, separating the strongly-proven levers from the reasoned personal bets. Sources: https://pubmed.ncbi.nlm.nih.gov/32052833/, https://pubmed.ncbi.nlm.nih.gov/28444290/, https://pubmed.ncbi.nlm.nih.gov/30646252/, https://pubmed.ncbi.nlm.nih.gov/11893790/, https://pubmed.ncbi.nlm.nih.gov/29425700/, https://pubmed.ncbi.nlm.nih.gov/35228201/, https://pubmed.ncbi.nlm.nih.gov/25982160/, https://pubmed.ncbi.nlm.nih.gov/33239350/, https://pubmed.ncbi.nlm.nih.gov/28467922/, https://pubmed.ncbi.nlm.nih.gov/32738937/ --- ### Best Longevity Blood Test Services, Compared (2026) Canonical: https://longevitygraded.com/best-longevity-blood-tests Updated: 2026-07-26 Function, InsideTracker, Lifeforce, Superpower — graded honestly. The four cheap outcome-validated markers matter; the '100+ biomarker' count mostly doesn't. ## The one-sentence version The "best" longevity blood test isn't the one with the most markers — it's the one that reliably surfaces the four or five cheap, outcome-validated numbers your regular checkup skips (ApoB, Lp(a) once, hs-CRP, HbA1c) and gets them in front of a clinician who will *act* on them. By that bar, the big DTC lab memberships — Function Health, InsideTracker, Lifeforce, Superpower — are far more alike than their marketing suggests. They differ mainly on price, panel padding, and whether they bolt on a physician or a supplement upsell — differences our [longevity test cost comparator](/tools/longevity-test-cost-comparator) reduces to a single per-test number. None of them clears the bar that actually matters in longevity medicine: **testing is not treating.** This page grades them on that honest axis. For where lab-membership testing sits in the wider field, see our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence), and for the marker-by-marker breakdown, [what longevity biomarker panels actually test](/longevity-biomarker-panels). ## The category, honestly: more markers ≠ better care Every service in this roundup sells a version of the same promise: pay an annual fee, get a big blood panel, see your numbers on a clean dashboard with "optimal" ranges, retest later in the year. The headline is always a biomarker *count* — 50, 100, 100-plus. That number is the least useful thing about the product. Here's why. A standard annual physical typically orders a basic lipid panel, a metabolic panel, and a CBC, then stops. A longevity panel's genuine value is adding a handful of markers with **hard-outcome evidence** that the basic checkup leaves out: - **ApoB** counts every atherogenic particle — one ApoB per LDL, VLDL, Lp(a), or remnant — so it measures the *number* of particles that can lodge in an artery wall, not just their cholesterol cargo. When ApoB and LDL-C disagree (common in metabolic syndrome and diabetes), the particle count is the better predictor of cardiovascular events. - **Lp(a)** is a genetically fixed, mostly lifelong-stable particle that independently and *causally* raises heart-attack and stroke risk — Mendelian-randomization data make the causal case cleanly. You measure it **once.** A service that re-bills you for it every cycle is padding, not medicine. - **hs-CRP** flags low-grade systemic inflammation and predicted first cardiovascular events at least as well as LDL cholesterol in a large prospective study. (It's non-specific — a cold spikes it — so a high reading means "recheck when well.") - **HbA1c** is average blood sugar over ~3 months and predicted all-cause and cardiovascular mortality *continuously* in a population study, with risk rising across the range, even below the diabetes threshold. Get those four, plus a catch of a treatable thyroid, ferritin, or vitamin-D problem, and a panel has earned its keep. Everything beyond that — the long tail of correlated markers, the "youth hormone" extras — adds line items and a feeling of completeness without adding much *independent, actionable* signal. Two markers worth naming as traps because nearly every padded panel features them: **IGF-1**, marketed as a youth hormone but with a **U-shaped** mortality curve (both low and high associate with higher death rates), and **homocysteine**, which looks treatable but whose lowering with B-vitamins failed to cut cardiovascular events in large trials. More tubes of blood is not more health. ## The services, graded We'll keep this to the four most prominent DTC blood-test memberships and grade each on the only two axes that matter: does it surface the outcome-validated core, and does it do anything to *treat* what it finds? ### Function Health — the broad panel, test-but-don't-treat Function is the category's headline act: a ~$499/year membership built around a "100+ biomarker" baseline panel plus a mid-year retest, with physician-ordered and -reviewed labs and a dashboard that flags results against "optimal" ranges. Its real strength is that the long list *does* include the cheap, outcome-validated core — ApoB, Lp(a), hs-CRP, HbA1c — that most checkups skip, and surfacing them to a motivated person is genuine value. Its honest limit is that roughly half the panel is ordinary bloodwork, much of the tail is correlated padding, and — decisively — it **tests without treating.** It flags a high ApoB; it doesn't titrate your statin. For a motivated, health-literate buyer with a clinician who'll act, that's fine; for anyone hoping the subscription itself improves their health, it's a category error. We grade it in full in our [Function Health review](/function-health-review). ### InsideTracker — DNA + blood integration, priced per-marker high InsideTracker layers a one-time DNA component onto recurring blood panels and an algorithmic "InnerAge" plus personalized food/supplement recommendations. The blood science underneath is legitimate where it overlaps the outcome-validated core, but two honest catches define it: it is **pricier per marker** than Function for a comparably sized panel — we run that cost math marker by marker in [Function Health vs InsideTracker](/function-health-vs-insidetracker) — and its recommendation engine **skews toward supplements and add-ons** — a structural conflict when the company also benefits from your acting on its nudges. It's a polished product whose "personalization" is the selling point and the caution at once. Full breakdown in our [InsideTracker review](/insidetracker-review). ### Lifeforce — fewer markers, but a clinician and Rx attached Lifeforce is the one that *partly* answers the test-but-don't-treat critique. For roughly $129/month plus a kit fee it runs a narrower panel (~50 markers) quarterly, but bundles a physician consult and the ability to prescribe — hormones, metabolic agents — off the results. That's a meaningfully different model: it crosses from measurement toward management. The trade-offs are a **narrower panel for the price**, a recurring cost that's high for the marker count, and **supplement-upsell pressure** baked into the membership. Whether the clinician access justifies the premium depends entirely on whether you'd actually use the prescribing — we grade it in full in our [Lifeforce review](/lifeforce-review). We also map that membership-vs-clinic trade-off in [longevity clinics vs lab memberships](/longevity-clinics-vs-lab-memberships). ### Superpower — cheap, big panel, newest and least proven Superpower is the aggressive price disruptor: a very large baseline panel for a low annual fee (often cited around $199), positioned as "100+ labs for less." On the surface that looks like the best deal in the roundup, and for the cheap outcome-validated core it can be. The honest caveats: it is the **newest and least track-recorded** of the four, a low price often means more of the panel is the ordinary-bloodwork filler that inflates the count, and like Function it is structurally a **test-but-don't-treat** dashboard. Cheaper padding is still padding — judge it on whether the actionable core is in there and reliably run, not on the headline number. We grade it in full, including the 2025 Function Health lawsuit, in our [Superpower Health review](/superpower-health-review). ## How to actually choose Strip away the marketing and the decision is small: - **You're health-literate and have a clinician who'll act on results.** Pick on price for the outcome-validated core. Function or Superpower get you ApoB/Lp(a)/hs-CRP/HbA1c without a fight; pay the least for a panel that reliably includes them. - **You want testing *and* prescribing in one place.** Lifeforce is the only one here that crosses into treatment — but you're paying a clinic-adjacent premium, so only worth it if you'll use the physician access. - **You want "personalized" guidance and don't mind upsell pressure.** InsideTracker — eyes open that the recommendations lean toward products it benefits from. - **What you actually want is hormones managed, not a dashboard.** Then none of these four is the purchase, and you're shopping a different band: [a $65 assessment followed by a membership tier, with medication billed on top](/hone-health-review) at the hormone-platform end, or [deep diagnostics ordered pay-per-use after an intake deposit](/marek-health-review) if you want the panels themselves to run deeper than anything here. Both cost more than a lab membership, and neither replaces one. - **You want a biological-age number too.** That's a *different* product with its own limits — a comprehensive blood panel is not an epigenetic-age test. See our honest take on whether [biological age tests work at all](/biological-age-tests) and the head-to-head [epigenetic clock comparison](/epigenetic-clock-comparison). And before paying anyone: the open, outcome-validated **PhenoAge** formula derives a biological-age estimate from a basic blood draw for **free**, which we cover in [free biological-age tests](/free-biological-age-tests). The two single biggest longevity levers in all of epidemiology aren't even on any of these panels — cardiorespiratory fitness, among the most powerful survival predictors ever measured, and grip strength, which outpredicted blood pressure across 17 countries in the PURE study. No dashboard substitutes for moving them. ## Bottom line The best longevity blood test is the cheapest one that reliably surfaces ApoB, Lp(a) (once), hs-CRP, and HbA1c and gets them to a clinician who'll treat what's abnormal. By that bar Function, InsideTracker, Lifeforce, and Superpower are close cousins separated mostly by price, panel padding, and whether a physician or a supplement store is attached. Function and Superpower compete on the broad-panel-test-but-don't-treat model — we settle that one in [Function Health vs Superpower](/function-health-vs-superpower); Lifeforce alone bundles prescribing at a premium; InsideTracker charges more per marker and leans on supplement recommendations. None of them is itself a health intervention — surfacing a flagged number is not the same as moving an outcome. For an independently graded look at the labs and clinics selling these memberships, see [our longevity clinic rankings](/best-longevity-clinics). Sources: https://pubmed.ncbi.nlm.nih.gov/36216435/, https://pubmed.ncbi.nlm.nih.gov/20032323/, https://pubmed.ncbi.nlm.nih.gov/12432042/, https://pubmed.ncbi.nlm.nih.gov/11141143/, https://pubmed.ncbi.nlm.nih.gov/30646252/, https://pubmed.ncbi.nlm.nih.gov/25982160/ --- ### Best Biological Age Test (2026): At-Home Kits, Honestly Graded Canonical: https://longevitygraded.com/best-at-home-biological-age-test Updated: 2026-06-19 Blood-methylation clocks are the only defensible at-home bio-age tier; saliva and telomere kits are noisier. None proves you're aging slower. Honestly graded. ## The one-sentence version If you're going to buy an at-home biological-age test, the honest ranking is short: a **DNA-methylation test run on a blood sample, using a second-generation or principal-component clock** is the only tier with a defensible scientific case. Saliva-based methylation kits and telomere-length tests sit a clear notch below on reliability, and most consumer "biological age" gimmicks below that aren't worth the postage. But the catch that applies to *all* of them is the one the marketing buries: these tests are validated as population *predictors*, not as a personal scoreboard you can move — lowering the number you get back has never been shown to make you live longer. This page grades the at-home tiers on that honest basis. For the deeper science of why, see our explainer on whether [biological age tests actually work](/biological-age-tests) and the pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What an at-home bio-age test is actually reading Most consumer "biological age" tests estimate aging from **DNA methylation** — chemical methyl tags that sit on your DNA at specific sites (CpGs) and shift in patterned ways as you age. An algorithm called an **epigenetic clock** reads hundreds of those sites and returns a single "epigenetic age." A minority of tests read a *different* aging signal entirely — telomere length (the protective caps on chromosomes, which shorten with division) or the inflammation-tracking sugar structures on your antibodies (the basis of the [GlycanAge test](/glycanage-review), which we grade separately). The generation of clock matters enormously. The first clocks (Horvath 2013) were trained to predict *chronological* age and did so with striking accuracy — which paradoxically makes them less useful for health, because a clock that nails your birthday tells you nothing your driver's license doesn't. The breakthrough was that the *errors* were the signal: DNA-methylation age running ahead of chronological age predicts all-cause mortality in later life. That produced **second-generation clocks** trained on health and death — GrimAge, the strongest single predictor of time-to-death and time-to-disease in the literature — and **DunedinPACE**, which estimates your *pace* of aging (1.0 = aging one year per year) against 50 years of longitudinal cohort decline. Those are the clocks an at-home test should be using. ## Why methylation-on-blood is the only defensible tier Three reliability problems separate "real population science" from "trustworthy personal readout," and they're exactly what sort the tiers. **1. The sample matters.** Blood is the tissue these clocks were predominantly trained and validated on. Saliva contains a variable mix of cell types (immune cells plus cheek-lining epithelial cells), and that cellular composition shifts the methylation signal — so a saliva "epigenetic age" is reading a noisier, less-validated substrate than the blood it's extrapolating from. If a test ships you a cheek swab, it's trading lab convenience for measurement fidelity. **2. The clock generation matters.** A test that quietly uses a first-generation chronological-age clock is the noisiest option: reliability studies flag those as having poor test–retest reproducibility, with the same sample swinging *several years* on remeasurement. The fix the field built — **principal-component (PC) clocks**, engineered specifically to bolster reliability for repeated measurement — is what a serious at-home test should run. Most don't disclose whether they do. **3. Telomere kits are the weakest mainstream option.** Telomere length is a real aging hallmark, but as a *consumer* readout it's notoriously noisy: measurement method drives wide variation, and within an individual it's a poor, unstable predictor compared with the best methylation clocks. A telomere number is closer to a curiosity than a usable bio-age. There's no FDA-cleared "biological age" diagnostic, and a 2025 expert consensus is explicit that aging biomarkers — methylation clocks included — remain *research-stage* tools that still need standardization and validation before clinical use. That's the ceiling on the whole category, even the best tier. ## The honest catch that applies to every tier Here is the question that decides whether any of this is worth your money: *if I lower my biological-age score, do I live longer or healthier?* That has **not been shown.** Clocks are validated as *predictors* — acceleration associates with worse outcomes across populations — not as *modifiable targets* proven that pushing the number down extends life. An intervention can move a clock reading without moving your actual risk; the clock would be a marker the treatment nudged while the underlying disease stayed put. This is why the "track whether my supplement stack is working" use case fails. The test–retest noise is large enough that you'll see "improvements" that are pure measurement variation, and even a *real* change isn't validated to mean anything for your lifespan. The viral "8 years younger" supplement claims lean on exactly this gap — an unvalidated clock, often a manufacturer-linked study, sold as proof of reversal. We dissect one in [alpha-ketoglutarate (Rejuvant): does the "8 years younger" claim hold up?](/alpha-ketoglutarate-for-longevity). ## So which at-home test, if any? A measured take, in tiers: - **Best defensible option:** a **blood-based methylation test using a second-gen or PC clock** — the most prominent consumer version reports DunedinPACE, and we grade it in our [TruDiagnostic TruAge review](/trudiagnostic-truage-review). Treat the result as a one-time, rough risk signal, not a scoreboard. - **A notch below:** **GlycanAge** (IgG-glycan inflammatory aging) is a legitimate but different signal — glycans track chronological and biological age in cohort data — graded in our [GlycanAge review](/glycanage-review). And **saliva/cheek-swab methylation kits** trade fidelity for convenience — including the membership brands built on them, such as [Tally Health](/tally-health-review), which we grade on the same axis and set against the leading supplement-first brand in [NOVOS vs Tally Health](/novos-vs-tally-health). - **Skip:** consumer telomere-length kits and any test that won't tell you which clock, sample, or assay it uses. - **Free first:** before paying anyone, the open **PhenoAge** formula derives a biological-age estimate from a basic blood panel for nothing — we cover it in [free biological-age tests](/free-biological-age-tests), and a lab-free strength-and-balance measure that predicts mortality in [the sitting-rising test and longevity](/sitting-rising-test-longevity). To see exactly how the clocks differ — mortality vs disease vs pace-of-aging — read our head-to-head [epigenetic clock comparison](/epigenetic-clock-comparison). And remember the providers selling these tests mostly **test but don't treat**, the defining catch of the DTC lab band, which we map in [longevity clinics vs lab memberships](/longevity-clinics-vs-lab-memberships). If you also want the cheap, outcome-validated blood markers that actually change clinical decisions, that's a different purchase — see our [best longevity blood test services roundup](/best-longevity-blood-tests). ## Bottom line The best at-home biological-age test is a blood-based DNA-methylation test running a second-generation or principal-component clock — that's the only tier with a defensible scientific case. Saliva methylation kits are noisier, GlycanAge reads a legitimate but different signal, and consumer telomere kits are the weakest mainstream option. But no tier escapes the central limit: these are population predictors, not validated personal targets, and lowering your score has never been shown to extend your life. Buy one, if at all, as a one-time curiosity — never as a scoreboard for your supplement budget, and never as a substitute for treating the proven risk factors a blood panel and a clinician can actually move. For an independently graded look at the providers selling biological-age testing, see [our longevity clinic rankings](/best-longevity-clinics). Sources: https://pubmed.ncbi.nlm.nih.gov/24138928/, https://pubmed.ncbi.nlm.nih.gov/25633388/, https://pubmed.ncbi.nlm.nih.gov/30669119/, https://pubmed.ncbi.nlm.nih.gov/35029144/, https://pubmed.ncbi.nlm.nih.gov/32885222/, https://pubmed.ncbi.nlm.nih.gov/36277076/, https://pubmed.ncbi.nlm.nih.gov/39708300/, https://pubmed.ncbi.nlm.nih.gov/24325898/, https://pubmed.ncbi.nlm.nih.gov/29676998/ --- ### InsideTracker Review: Worth It in 2026? Canonical: https://longevitygraded.com/insidetracker-review Updated: 2026-06-05 InsideTracker adds DNA and an 'InnerAge' score to blood panels. The core markers are real, but it's pricier per marker and recommendations skew to upsells. ## The one-sentence version InsideTracker is a legitimate DTC blood-test platform whose underlying science is real where it overlaps the cheap, outcome-validated markers that matter — but its distinctive features (a one-time DNA layer, an algorithmic "InnerAge" number, and personalized food/supplement recommendations) are where the honest cautions live. You pay **more per marker** than the broad-panel competition, the InnerAge score is a proprietary composite that isn't a validated bio-age clock, and the recommendation engine **skews toward supplements and add-ons** — a structural conflict when the company benefits from your acting on its nudges. Worth it for a specific buyer; oversold to everyone else. For where lab-membership testing sits in the field, see our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence), and for the broader head-to-head, our [best longevity blood test services roundup](/best-longevity-blood-tests). ## What you actually get InsideTracker is a direct-to-consumer blood-analytics service. You buy a panel (tiers run from a small focused set up to a ~43-marker "Ultimate" plan, with annual subscriptions stacking multiple retests across the year), optionally add a one-time **DNA** kit, and get results on a dashboard that flags markers against "optimized" zones, generates an **InnerAge** estimate, and produces personalized nutrition, exercise, and supplement recommendations. Pricing is current-2026 market info and shifts, but the shape is consistent: the per-test and annual plans land at a premium relative to broad "100+ marker" memberships, and the value proposition is *integration and guidance*, not raw marker count. What you do **not** get is treatment. Like most of the category, InsideTracker is a measurement-and-recommendation product: it surfaces numbers and suggests actions, but it isn't a clinic titrating a statin or managing a condition. That test-but-don't-treat structure is the defining catch of the whole DTC lab band, which we map in [longevity clinics vs lab memberships](/longevity-clinics-vs-lab-memberships). ## The good: the outcome-validated core is in there Where InsideTracker overlaps the markers with genuine hard-outcome evidence, it's doing something useful — these are the numbers a standard physical often skips: - **ApoB / lipid particles.** ApoB counts every atherogenic particle, so when it disagrees with LDL-C (common in metabolic syndrome and diabetes) it's the better predictor of cardiovascular events. A panel that surfaces it is an upgrade over a basic lipid screen. - **hs-CRP.** Low-grade inflammation that predicted first cardiovascular events at least as well as LDL cholesterol in a large prospective study. (Non-specific — recheck a high reading when well.) - **HbA1c / glucose.** HbA1c predicted all-cause and cardiovascular mortality *continuously* in a population study, with risk rising across the range — genuinely worth tracking. - **Ferritin, vitamin D, thyroid markers.** Not longevity magic, but catching a treatable deficiency people misattribute to "aging" is real value. If InsideTracker gets a motivated person these numbers and they act on them with a clinician, it has earned a slice of its fee. That's the legitimate core — and it's the same core every good panel shares. ## The catches: per-marker price, the InnerAge number, and supplement nudges Now the honest case against the framing — three things specific to InsideTracker. **1. You pay more per marker.** InsideTracker's panels are priced at a premium relative to the broad-panel memberships, and the marker counts are often *smaller*. You're paying for the DNA integration and the recommendation layer, not for a longer list. If your goal is simply getting the cheap outcome-validated core in front of a clinician, a broad-panel competitor often does it for less — we lay out the price-vs-padding trade across services in our [best longevity blood test services roundup](/best-longevity-blood-tests). **2. "InnerAge" is a proprietary composite, not a validated clock.** InnerAge derives an "inner age" from a subset of your blood markers via the company's own algorithm. That can be a reasonable *motivational* framing of your metabolic numbers, but it is **not** a validated DNA-methylation epigenetic clock, and it isn't validated as a target proven that lowering it extends your life. Don't confuse it with the bio-age tests we grade in [biological age tests](/biological-age-tests) — and if a bio-age readout is what you actually want, see [the best at-home biological-age test](/best-at-home-biological-age-test). Treat InnerAge as a repackaging of your blood markers, not a separate measurement of how fast you're aging. **3. The recommendations skew toward products.** The personalization engine is the selling point and the structural conflict at once. Nutrition and exercise suggestions are mostly harmless and sometimes helpful, but the **supplement** recommendations are where to keep your skepticism up — because the incentive to make a panel *feel* like it found something you should buy is baked into the category. Two examples of why marker-chasing misleads, both featured on long panels: - **IGF-1** is marketed as a youth hormone, but its mortality relationship is **U-shaped** — both low *and* high IGF-1 associate with higher mortality in meta-analysis. "Optimize your IGF-1 upward" is biologically naïve. - **Homocysteine** looks treatable, but large randomized trials that lowered it with folic acid and B vitamins did **not** reduce cardiovascular events. Buying a B-supplement to push it down is buying a passenger, not fixing a driver. When a dashboard flags these against tight "optimized" zones and pairs the flag with a supplement suggestion, read it against standard clinical thresholds — not the color coding. ## The grade, and how we got there Two axes, kept separate because conflating them is the trap: - **As a way to surface outcome-validated markers and present them well:** moderate-to-good. ApoB, hs-CRP, HbA1c, and a deficiency catch are real value, and the dashboard is polished. - **As a "DNA + InnerAge + personalization" health upgrade worth the premium:** weaker. You pay more per marker, InnerAge is a proprietary repackaging rather than a validated clock, and the recommendations lean toward products the company benefits from. And — decisively — it tests without treating. That lands the letter grade in the middle, dragged down a half-step from the broad-panel baseline by the per-marker premium and the upsell skew: a **C+**. Reasonable for someone who specifically values the DNA-plus-blood integration and will treat the supplement recommendations with healthy skepticism; a poorer deal for someone who just wants the cheap actionable core, which a broad panel delivers for less. The two biggest longevity levers in all of epidemiology aren't on any InsideTracker panel anyway — cardiorespiratory fitness, among the most powerful survival predictors ever measured, and grip strength, which outpredicted blood pressure across 17 countries in the PURE study. ## Who should and shouldn't buy it - **Reasonable buyer:** someone who specifically wants DNA-informed blood guidance, will act on abnormal results with a clinician, and can ignore supplement nudges that aren't outcome-backed. - **Poor fit:** anyone whose goal is simply getting ApoB, Lp(a), hs-CRP, and HbA1c at the lowest price (a broad panel wins), or who'll treat InnerAge as a real bio-age score or the supplement list as a prescription. ## Bottom line InsideTracker's real value is the same as any good panel's — surfacing the cheap, outcome-validated markers (ApoB, hs-CRP, HbA1c) your checkup skips, presented on a polished dashboard. Its distinctive features are where the cautions live: you pay more per marker than broad-panel rivals, InnerAge is a proprietary composite rather than a validated epigenetic clock, and the recommendation engine skews toward supplements the company benefits from. Most important, it tests without treating. Worth it for a buyer who values DNA-plus-blood integration and keeps the upsell at arm's length; a poorer deal for anyone who just wants the actionable core cheaply. To compare it head-to-head against Function, Lifeforce, and Superpower, see our [best longevity blood test services roundup](/best-longevity-blood-tests); for an independently graded look at the labs and clinics selling these memberships, see [our longevity clinic rankings](/best-longevity-clinics). Sources: https://pubmed.ncbi.nlm.nih.gov/36216435/, https://pubmed.ncbi.nlm.nih.gov/12432042/, https://pubmed.ncbi.nlm.nih.gov/11141143/, https://pubmed.ncbi.nlm.nih.gov/21795450/, https://pubmed.ncbi.nlm.nih.gov/16531613/, https://pubmed.ncbi.nlm.nih.gov/30646252/, https://pubmed.ncbi.nlm.nih.gov/25982160/ --- ### Lifeforce Health Review: Membership Cost and Whether It Is Worth It Canonical: https://longevitygraded.com/lifeforce-review Updated: 2026-08-04 Lifeforce bundles a clinician and Rx onto a ~50-marker quarterly panel for ~$149/mo. That crosses test-into-treat — but the panel is narrow and the upsell real. ## The one-sentence version Lifeforce is the rare longevity-membership that does the one thing most of its rivals refuse to do — it bundles a **clinician who can prescribe** onto a recurring blood panel, so it crosses from *testing* into *treating*. That is its real, structural advantage over a pure dashboard like Function or InsideTracker. It grades **B, 9 points out of 14**, and it is not a paid partner here. But the trade-offs are equally structural: the panel itself is **relatively narrow (~50 markers) for the price** (~$149/month plus a ~$199 starter diagnostic), the recurring cost is high for the marker count, the program leans heavily on **hormone optimization** (where the longevity evidence is thin), and Lifeforce **sells its own supplements**, so the recommendation engine carries a built-in conflict. Worth it for a specific buyer who'll actually use the prescribing; overpriced for anyone who just wants cheap, outcome-validated bloodwork. For where membership programs sit in the wider field, see our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence), and for the head-to-head against the other DTC services, our [best longevity blood test services roundup](/best-longevity-blood-tests). ## What you actually get for ~$149/month Lifeforce is a membership longevity program, not a once-a-year lab kit. The structure is consistent (pricing is current-2026 market info and shifts, so treat the dollar figures as a snapshot, not a quote): - **A starter diagnostic** — roughly **$199** for the first kit — that runs an at-home/phlebotomist blood draw across about **50 biomarkers**, weighted toward hormones (testosterone, estradiol, DHEA, thyroid), metabolic markers, and a few cardiovascular and inflammatory ones. - **A recurring membership** around **$149/month** that includes **quarterly retesting**, a **clinician consult** (a telehealth physician or nurse practitioner who reviews your results), and **access to prescriptions** written off those results — typically hormone therapy, sometimes metabolic agents or peptides. - **A dashboard** that flags markers against "optimized" ranges and surfaces personalized recommendations — including Lifeforce's own line of **supplements**. The thing that separates this from the rest of the category is the third bullet. A DTC lab membership hands you a flagged number and a referral; Lifeforce hands you a flagged number, a clinician, and the ability to act on it inside the same membership. That is a genuinely different — and more clinically active — model, which we map across the whole market in [longevity clinics vs lab memberships](/longevity-clinics-vs-lab-memberships). ## The good: it actually treats, and the core markers are real Two things genuinely work in Lifeforce's favor. **1. It crosses the line from testing to treating.** This is the single most important distinction in the whole DTC-longevity field. Function, InsideTracker, and Superpower are measurement products — they flag a high ApoB and then it's your job to find a doctor who'll act. Lifeforce bundles that doctor. For someone who genuinely wants prescribed care — hormone optimization with quarterly monitoring, say — and who would otherwise pay separately for a clinic, folding testing and prescribing into one membership has real convenience value. Surfacing a number you never act on is theater; Lifeforce is built so you can act on it. **2. The outcome-validated core is in the panel.** Where Lifeforce overlaps the markers with genuine hard-outcome evidence, it's surfacing the numbers a standard physical often skips: - **ApoB / lipids.** ApoB counts every atherogenic particle, so when it disagrees with LDL-C (common in metabolic syndrome and diabetes) it's the better predictor of cardiovascular events. A panel that includes it is an upgrade over a basic lipid screen. - **hs-CRP.** Low-grade inflammation that predicted first cardiovascular events at least as well as LDL cholesterol in a large prospective study, and was used to *guide* statin treatment with a hard-outcome benefit in the randomized JUPITER trial. (Non-specific — recheck a high reading when you're well.) - **HbA1c.** Average blood sugar over ~3 months that predicted all-cause and cardiovascular mortality *continuously* in a population study, with risk rising across the range even below the diabetes threshold. If Lifeforce gets a motivated person these numbers *and* a clinician who'll treat what's abnormal, it has earned a meaningful slice of its fee. That's the legitimate core. ## The catches: a narrow panel, a hormone tilt, and a supplement store Now the honest case against the price. **1. ~50 markers is narrow for ~$149/month.** Lifeforce's panel is meaningfully *smaller* than the "100+" memberships — yet the recurring cost (about ~$1,800/year plus the ~$199 starter, before any prescriptions or supplements) lands at the high end of the category. You are not paying for breadth; you're paying for the clinician and the prescribing. That's a defensible reason to pay more — but only if you'll use it. If your goal is simply getting the cheap, outcome-validated core in front of your own doctor, a broad-panel membership delivers more markers for less, and we lay out the price-vs-padding trade across services in our [best longevity blood test services roundup](/best-longevity-blood-tests). (And remember: more markers isn't better care either — the value is the *actionable* handful, not the headline count.) **2. The program tilts toward hormone optimization — where the longevity evidence is thin.** Lifeforce's panel and prescribing lean heavily on the sex-hormone and GH/IGF-1 axis, and the membership's center of gravity is "hormone optimization." Two cautions here that the marketing tends to skip: - **IGF-1 is not a "raise it to feel younger" target.** Its mortality relationship is **U-shaped** — both low *and* high IGF-1 associate with higher mortality in meta-analysis. Chasing IGF-1 upward is biologically naïve. - **Growth-hormone-style "rejuvenation" failed its own test.** A landmark systematic review of growth hormone in healthy older adults found small body-composition changes but **no proven functional benefit and significantly more adverse events**. Any hormone-optimization framing that implies "younger hormones = longer life" is running ahead of the evidence. This doesn't make hormone therapy illegitimate — for a genuinely deficient patient, treatment can be appropriate and monitored. It means the *longevity* framing around it is weaker than the dashboard's confident "optimized ranges" suggest. Read flagged hormones against standard clinical thresholds, not tight "optimal" bands. **3. Lifeforce sells its own supplements — that's a structural conflict.** The recommendation engine doesn't just suggest behaviors; it suggests products Lifeforce profits from selling. Nutrition and exercise advice is mostly harmless, but supplement nudges are where to keep your skepticism highest, because the incentive to make a panel *feel* like it found something you should buy is baked into a vertical model where the same company tests you, interprets the result, and sells the fix. A clean example of why marker-chasing misleads: **homocysteine** looks treatable, but large randomized trials that lowered it with folic acid and B vitamins did **not** reduce cardiovascular events. A B-supplement to push it down is buying a passenger, not fixing a driver. ## The grade, and how we got there Two axes, kept separate because conflating them is the trap: - **As a way to get prescribed, monitored care (especially hormones) bundled with testing:** moderate-to-good. The clinician-plus-Rx model is genuinely more useful than a pure dashboard, and quarterly retesting lets you see whether an intervention moved your numbers. - **As a "longevity" upgrade worth ~$1,800/year:** weaker. The panel is narrow for the price, the program tilts toward hormone optimization where the longevity evidence is thin, and the supplement store is a built-in conflict. That lands the letter grade a notch above the pure test-but-don't-treat dashboards specifically *because* it treats — but dragged back down by the narrow-panel premium and the upsell tilt: a **B−**. Reasonable for a buyer who specifically wants prescribed hormone or metabolic care with monitoring and will use the clinician; a poorer deal for someone who just wants the cheap actionable core, which a broad panel delivers for less. And worth remembering: the two biggest longevity levers in all of epidemiology aren't on Lifeforce's panel at all — cardiorespiratory fitness, among the most powerful survival predictors ever measured, and grip strength, which outpredicted blood pressure across 17 countries in the PURE study. ## Who should and shouldn't buy it - **Reasonable buyer:** someone who specifically wants prescribed, monitored care — hormone optimization with quarterly bloodwork is the clearest fit — who would otherwise pay separately for a clinic, and who will treat the supplement recommendations with healthy skepticism. - **Poor fit:** anyone whose goal is simply getting ApoB, Lp(a), hs-CRP, and HbA1c at the lowest price (a broad panel wins on markers-per-dollar), who won't actually use the prescribing, or who'll read the hormone "optimization" framing as proven longevity medicine. ## Bottom line Lifeforce's real edge is structural: it bundles a prescribing clinician onto a recurring panel, so it *treats* what most DTC labs only flag — the most meaningful upgrade in the category. But you pay a clinic-adjacent premium (~$149/month plus a ~$199 starter) for a **narrow ~50-marker panel**, the program tilts toward **hormone optimization** where the longevity evidence is thin (IGF-1 is U-shaped for mortality; GH showed no functional benefit and more harm in healthy elders), and Lifeforce **sells its own supplements**, a built-in conflict. Worth it for a buyer who'll genuinely use the prescribing and monitoring; overpriced for anyone who just wants cheap, outcome-validated bloodwork. To see how it stacks against Function, InsideTracker, and Superpower, see our [best longevity blood test services roundup](/best-longevity-blood-tests); for the closest broad-panel rival, our [Function Health review](/function-health-review); and for an independently graded look at the labs and clinics selling these memberships, [our longevity clinic rankings](/best-longevity-clinics). Sources: https://pubmed.ncbi.nlm.nih.gov/36216435/, https://pubmed.ncbi.nlm.nih.gov/12432042/, https://pubmed.ncbi.nlm.nih.gov/18997196/, https://pubmed.ncbi.nlm.nih.gov/11141143/, https://pubmed.ncbi.nlm.nih.gov/21795450/, https://pubmed.ncbi.nlm.nih.gov/17227934/, https://pubmed.ncbi.nlm.nih.gov/16531613/, https://pubmed.ncbi.nlm.nih.gov/30646252/, https://pubmed.ncbi.nlm.nih.gov/25982160/ --- ### Does Resveratrol Actually Work for Longevity? Canonical: https://longevitygraded.com/resveratrol-for-longevity Updated: 2026-07-26 A skeptical, evidence-graded review: the SIRT1 story was an artifact, a 2025 primate trial found no lifespan benefit, and oral resveratrol barely reaches cells. Resveratrol is the molecule that built the modern anti-aging supplement industry. It is the polyphenol in red wine and grape skins, the compound behind a thousand "a glass of wine a day" headlines, and the original "sirtuin activator" that made caloric-restriction-in-a-pill sound imminent. Two decades and hundreds of studies later, the honest verdict is uncomfortable for the people still selling it: the mechanism that made resveratrol famous has been largely discredited, the best primate experiment found no lifespan benefit (and a hint of harm in old age), and the molecule barely survives a trip through your gut. This page is a deliberate debunk. For the wider map of what's earned its place versus what's hype, start with our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## The short answer There is no good evidence that resveratrol extends lifespan or slows aging in humans, and there is now direct evidence against it in a primate. The famous mechanism — that resveratrol "activates" the longevity enzyme SIRT1 the way caloric restriction does — turned out to be largely an artifact of how the original assay was run. Human trials show, at most, small and inconsistent shifts in surrogate biomarkers. And oral resveratrol has notoriously poor bioavailability: you absorb it, then your body destroys nearly all of it before it reaches your tissues. We grade its lifespan benefit as **none** — not "unproven and promising," but actively contradicted by the best available data. ## How resveratrol became a longevity icon The story starts in 2003. A screen for small molecules that activate sirtuins reported that resveratrol stimulated SIRT1 and extended lifespan in yeast — the headline result that lit the fuse on the entire sirtuin-activator field. The logic was elegant: caloric restriction is the most reliable way to extend lifespan across species, sirtuins appeared to mediate part of that effect, and here was a cheap natural compound that seemed to switch them on. If you could activate SIRT1 with a pill, the thinking went, you might get the benefits of eating less without eating less. The mouse data that followed cemented the hype. In 2006, a landmark Nature paper reported that resveratrol improved the health and survival of mice fed a high-calorie diet, shifting their physiology toward that of healthy, normally-fed animals. This is a genuine, well-conducted study — but read the conditions carefully. The benefit was in *obese* mice on a *high-fat* diet; resveratrol made sick, overfed mice look more normal. It did not extend lifespan in healthy mice eating a standard diet. That distinction — "rescues a metabolic insult" versus "slows normal aging" — got lost the moment the result reached the supplement aisle, and it has stayed lost ever since. ## The mechanism that made it famous was largely an artifact Here is the part the marketing never mentions. The original claim that resveratrol *directly* activates SIRT1 depended on a specific lab trick: the assay used a synthetic peptide substrate carrying an attached fluorescent tag (a fluorophore). When researchers ran the experiment with the *native*, untagged substrate, the activation disappeared. Two independent groups documented this. A 2009 study concluded plainly in its title that **resveratrol is not a direct activator of SIRT1 enzyme activity**, tracing the apparent effect to the fluorophore on the assay substrate rather than any real action on the enzyme. A 2010 paper in the Journal of Biological Chemistry went further, testing resveratrol alongside the pharmaceutical "SIRT1 activators" (SRT1720, SRT2183, SRT1460) that a biotech had built an entire program around — and finding that **none of them were direct activators of SIRT1** once the artificial fluorogenic substrate was removed. The compounds bound the fluorophore-modified peptide, not the natural one. This does not mean resveratrol does nothing in cells — it has many off-target effects (it inhibits phosphodiesterases, influences AMPK, scavenges free radicals at high concentrations). But the clean, central story that sold a generation of supplements — *resveratrol turns on your longevity gene the way fasting does* — rests on an in-vitro artifact. The sirtuin-activation narrative is, at the molecular level, the longevity field's most consequential cautionary tale about trusting a mechanism before it is rigorously confirmed. We unpack how SIRT1 and the NAD+/sirtuin axis are still legitimately studied — and still short on human proof — in [NAD+ for longevity: what the trials actually show](/nad-for-longevity). ## The primate trial: no lifespan benefit, and a warning in old age The most important recent data point is also the most damaging, because it is the closest experiment to a human that anyone has run. In 2025, Communications Biology published a long-term study in the gray mouse lemur (*Microcebus murinus*) — a small primate that is a well-established model for primate aging. Across the animals' lives, the researchers compared caloric restriction, resveratrol supplementation, and controls. The result was a clean negative for resveratrol: it **did not mimic the positive effects of caloric restriction on lifespan**. Caloric restriction in this model is associated with survival benefits; resveratrol simply did not reproduce them. Worse for the supplement's case, the analysis raised the possibility that resveratrol could be detrimental at older ages rather than protective — the opposite of the marketed promise. A primate is not a human, and this is one cohort, but it is the single most relevant lifespan experiment available, and it points the wrong way for resveratrol. When the best non-human-primate evidence says "no lifespan benefit, possible late-life harm," the burden of proof sits squarely on anyone still claiming the molecule extends life. ## Even if it worked, your gut won't let it through There is a second, quieter problem that would undermine resveratrol even if the mechanism had held up: **bioavailability**. A frequently cited human pharmacokinetic study found that oral resveratrol is well *absorbed* — at least 70% of an oral dose is taken up — but its **bioavailability is very low**, because it is almost completely and rapidly metabolized (glucuronidated and sulfated) in the gut and liver before it can reach the bloodstream and tissues as the active parent compound. Peak concentrations of unchanged resveratrol in plasma were in the low-nanomolar range after a substantial oral dose. That number matters because the dramatic cell-culture and biochemical effects of resveratrol typically require *micromolar* concentrations — often tens of times higher than what an oral supplement can plausibly achieve in human tissue. So even setting aside the artifact problem, the doses that "do something" in a dish are concentrations you essentially cannot reach by swallowing a capsule. This bioavailability gap is one reason later sirtuin-targeting programs pivoted to synthetic compounds and to NAD+ precursors instead — a pivot we cover in our review of the [best longevity supplements, rated by evidence](/best-longevity-supplements). It is also the argument the prescription market makes for bypassing the gut altogether: the injection and the under-the-tongue wafer are both sold as absorption workarounds, and [the cheapest published sublingual route in our ranking runs $99 a month against $199 for the injection](/enhance-md-review). Whether a better-absorbed dose of an unproven compound is worth buying is a separate question from whether it is better absorbed. ## What the human trials actually show Strip away the mechanism and the mouse data and look only at controlled human studies, and the picture is thin, narrow, and inconsistent — nothing close to a longevity signal. - **A clean null in healthy people.** A well-controlled randomized trial in nonobese women with normal glucose tolerance found that resveratrol supplementation **did not improve metabolic function** — no benefit to insulin sensitivity, resting metabolic rate, or other metabolic readouts. This is the most relevant kind of subject for a "healthy adult taking it for longevity," and the answer was no effect. - **Modest biomarker shifts in disease.** A 2024 meta-analysis in type-2 diabetes patients found resveratrol produced **small reductions in some inflammation and oxidative-stress markers**. Real, but surrogate, modest, and in a sick population — not evidence of slowed aging. - **One narrow positive endpoint.** The RESHAW trial reported that regular resveratrol improved **bone mineral density** in postmenopausal women. A legitimate finding for a specific outcome in a specific group — and notably *not* a longevity or all-cause-mortality result. Put together, the human ledger is: a null in healthy adults, minor surrogate shifts in diabetes, and one isolated bone-density signal. No trial has shown resveratrol reduces mortality, extends healthspan, or slows any validated aging clock. For a molecule sold as a longevity cornerstone, that is a remarkably empty cupboard — and it is exactly the mechanism-outruns-proof pattern we keep flagging across this field, from [spermidine](/spermidine-for-longevity) to [metformin](/metformin-for-longevity). ## So why is it still everywhere? Resveratrol persists for reasons that have little to do with evidence. It rides the "French paradox" red-wine halo, it has a famous and elegant (if now-discredited) mechanism, it is cheap to manufacture and sell as a dietary supplement with no requirement to prove clinical benefit, and it is frequently bundled with NAD+ precursors in "anti-aging stacks" where the more-defensible ingredient lends it borrowed credibility. None of that is data. The biology that made resveratrol famous has not survived rigorous testing, and the one primate lifespan experiment ran against it. We hold supplements to the same evidence-first bar we use to grade clinicians and programs in [how we grade longevity providers](/how-we-grade-longevity-providers). ## The bottom line Resveratrol is a debunk, not a maybe. Its signature mechanism — direct SIRT1 activation — was largely an assay artifact; its best primate trial showed no lifespan benefit and hinted at late-life harm; its oral bioavailability is so poor that the active compound barely reaches your tissues; and its human trials are null-to-marginal on everything except one narrow bone endpoint. If you enjoy red wine, enjoy red wine — but do not take resveratrol capsules expecting to age more slowly. The honest grade for its longevity benefit is **none**. If you want real physician oversight instead of self-experimenting with discredited molecules, our [hub of graded longevity clinics and programs](/best-longevity-clinics) ranks who actually provides it. None of this is medical advice; talk to your own clinician before starting or stopping any supplement. Sources: https://pubmed.ncbi.nlm.nih.gov/12939617/, https://pubmed.ncbi.nlm.nih.gov/17086191/, https://pubmed.ncbi.nlm.nih.gov/19843076/, https://pubmed.ncbi.nlm.nih.gov/20061378/, https://pubmed.ncbi.nlm.nih.gov/40021720/, https://pubmed.ncbi.nlm.nih.gov/15333514/, https://pubmed.ncbi.nlm.nih.gov/23102619/, https://pubmed.ncbi.nlm.nih.gov/39872318/, https://pubmed.ncbi.nlm.nih.gov/32564438/, https://pubmed.ncbi.nlm.nih.gov/36599349/ --- ### Collagen for Aging: What the Evidence Says Canonical: https://longevitygraded.com/collagen-for-longevity Updated: 2026-06-11 Industry-funded trials show skin and joint benefits; independent reviews are cautious. Collagen digests to amino acids, and the longevity claim is unproven. Collagen is the best-selling "anti-aging" supplement in the world, and the pitch is intuitive: collagen is the protein that gives skin its firmness and joints their cushioning, it declines with age, so replacing it should slow the visible and structural signs of aging. The problem with that story isn't that the trials are negative — many are positive. The problem is *who paid for them*. Before you weigh a single skin-elasticity number, you have to understand the funding split, because it shapes everything else on this page. For the wider frame of what the longevity field can and can't prove, start with our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## The honest starting point: the funding-source split Here is the single most important fact about collagen research, and almost no supplement ad will tell it to you. As the independent [Harvard T.H. Chan School Nutrition Source](https://nutritionsource.hsph.harvard.edu/collagen/) puts it plainly: "most if not all of the research on collagen supplements are funded or partially funded by related industries… or one or more of the study authors have ties to those industries," and "non-industry-funded research on collagen supplements is lacking." That isn't a fringe complaint. The two most-cited skin trials behind the entire category were run by a research group tied to a collagen-peptide manufacturer (Gelita), and the same pattern repeats across the bone and joint literature. Why this matters so much: industry-funded supplement trials are small, short, use proprietary peptides, and tend to report the positive surrogate endpoints that sell product. The published meta-analyzes are essentially pooling those industry trials. So when a meta-analysis concludes "collagen improves skin hydration," it is largely summarizing manufacturer-sponsored studies — and the independent academic centers that have looked at the same evidence conclude it's "difficult to determine how effective collagen supplements truly are". Hold that split in mind for everything below: **positive industry-funded RCTs on one side, cautious independent reviews on the other.** ## The biology problem: you don't absorb "collagen" There's a deeper reason to be skeptical of the "replace what you've lost" pitch. When you swallow collagen, your gut does not ship it intact to your face. Collagen is a protein, and like any protein it is digested in the stomach and small intestine — broken down into amino acids and short peptides before absorption, then "distributed wherever the body most needs protein," not routed to your dermis. Absorption-and-metabolism studies of oral collagen hydrolysates confirm the molecule is cleaved during digestion, with free amino acids and small di-/tri-peptides (notably proline-hydroxyproline) appearing in circulation rather than whole collagen. This is why "collagen for longevity" is biologically the weakest framing of all. Collagen's amino-acid profile is heavy in glycine, proline, and hydroxyproline — useful building blocks, and the small hydroxyproline-containing peptides may act as weak signaling molecules that nudge fibroblasts. But that is a long way from "eating collagen rebuilds your collagen," and it is much further still from any effect on the [hallmarks of aging](/hallmarks-of-aging-explained) or lifespan. There is no plausible mechanism by which a digested protein supplement extends life, and — unsurprisingly — no human longevity data of any kind. If glycine is the part you're really after, we cover it directly in [glycine for longevity](/glycine-for-longevity); you can get the same amino acids from any complete protein at a fraction of the price. ## Skin: real signals, but read the fine print Skin is collagen's strongest evidence base — and also its most conflicted. The two pivotal trials, both from 2014, randomized women to specific bioactive collagen peptides and reported reduced eye-wrinkle volume with increased dermal procollagen, and improved skin elasticity and hydration. A 2021 systematic review and meta-analysis pooled hydrolyzed-collagen trials and concluded supplementation improved skin hydration, elasticity, and wrinkles, and a 2025 meta-analysis reached a similar conclusion on hydration and elasticity. So why isn't this a slam dunk? Three reasons the meta-analyzes themselves flag. First, **funding**: the underlying RCTs are overwhelmingly industry-sponsored or author-conflicted, exactly the bias Harvard warns about. Second, **endpoints**: "improved elasticity on a cutometer at 8 weeks" is a short-term surrogate measured with manufacturer-friendly instruments — not a demonstration of slowed skin aging over years. Third, **heterogeneity and size**: the trials are small, use different proprietary peptides at different doses, and the 2021 review explicitly cautioned that the evidence base is limited and that better-quality, independent trials are needed before firm conclusions. The honest read: there is a *real* short-term skin signal, but it is modest, surrogate, and built almost entirely on conflicted trials — not the dramatic "reverse skin aging" the ads imply. ## Joints: the more defensible use — but still conflicted Collagen's joint case is arguably its second-strongest. A 2023 meta-analysis of randomized trials found that collagen peptide supplementation produced a statistically significant reduction in pain in knee osteoarthritis, and a 2023 RCT in active adults reported improved joint function and reduced pain with collagen peptides. For symptomatic relief of activity-related joint pain or mild osteoarthritis, this is the most reasonable thing collagen has going for it. The caveats are familiar. Effect sizes are modest, the trials are small and short, several use proprietary peptides from supplement makers, and — once again — independent confirmation is thin. "Reduced a pain score over a few months" is a legitimate symptomatic outcome, but it is not evidence that collagen rebuilds cartilage, prevents osteoarthritis, or does anything for *aging*. It's a comfort intervention for a joint complaint, not a longevity lever. ## Bone: a single industry RCT The bone story rests largely on one study: a 2018 randomized trial in postmenopausal women reporting that specific collagen peptides improved bone mineral density and bone-turnover markers. It's a real RCT with a real outcome — but it was conducted by a group tied to the peptide manufacturer, it hasn't been broadly replicated by independent labs, and BMD over 12 months is again a surrogate, not fracture prevention. Promising, conflicted, unreplicated. We rank where supplements like this sit overall in our [best longevity supplements, rated by evidence](/best-longevity-supplements) roundup. ## The evidence, graded ## The bottom line Collagen is a rare supplement with *some* positive human RCTs — for skin appearance, joint pain, and possibly bone density. But every one of those signals comes with the same asterisk: the trials are small, short, surrogate-endpoint, and overwhelmingly funded by or tied to the companies selling the product, while the independent academic reviews that examine the same data conclude the true effect is hard to judge and non-industry research is lacking. Biologically, you don't absorb collagen — you digest it into amino acids — so the "replace what you've lost" pitch is wrong, and the leap to "longevity" has no mechanism and no human data behind it. The most honest grade: **reasonable-but-conflicted for skin and joints, none for lifespan.** If you want the amino acids, any complete protein delivers them more cheaply; if you want oversight rather than a cabinet of capsules, our graded [best longevity clinics](/best-longevity-clinics) hub ranks who actually provides it. Sources: https://pubmed.ncbi.nlm.nih.gov/33742704/, https://pubmed.ncbi.nlm.nih.gov/40826844/, https://pubmed.ncbi.nlm.nih.gov/24401291/, https://pubmed.ncbi.nlm.nih.gov/23949208/, https://pubmed.ncbi.nlm.nih.gov/37717022/, https://pubmed.ncbi.nlm.nih.gov/37551682/, https://pubmed.ncbi.nlm.nih.gov/29337906/, https://pubmed.ncbi.nlm.nih.gov/29467346/, https://nutritionsource.hsph.harvard.edu/collagen/, https://pubmed.ncbi.nlm.nih.gov/36599349/ --- ### Quercetin for Longevity: Senolytic Hype vs Evidence Canonical: https://longevitygraded.com/quercetin-for-longevity Updated: 2026-06-11 Quercetin's senolytic effect needs the dasatinib combination. Standalone quercetin has no human senolytic evidence — just modest anti-inflammatory effects. Quercetin is having a longevity moment, and it's built on a misunderstanding. Search "quercetin senolytic" and you'll find supplement listings, biohacker threads, and breathless copy all leaning on the same idea: quercetin clears "zombie cells" and slows aging. That framing borrows its entire credibility from one specific research program — the **dasatinib + quercetin (D+Q)** combination — and quietly drops the half that does the heavy lifting. The honest version is less exciting: as a standalone supplement, quercetin has **no human senolytic evidence at all**. What it actually has is a modest, real-but-unspectacular profile as an anti-inflammatory and antioxidant flavonoid. This page separates the two, because the gap between them is exactly where the marketing lives. For the wider map of what's earned its place versus what's hype, start with our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## The quercetin fallacy, stated plainly Here is the logical sleight of hand, in one sentence: *the dasatinib + quercetin combination has shown senolytic effects in humans, therefore quercetin is a senolytic.* That doesn't follow. D+Q is a two-drug regimen, and the evidence that it clears senescent cells in people belongs to **the combination**, not to either ingredient alone. The senolytic insight was never "quercetin kills zombie cells" — it was that dasatinib and quercetin together hit the survival pathways senescent cells depend on more effectively than either does by itself. Strip out dasatinib — a prescription leukemia chemotherapy drug — and you don't have a weaker senolytic. You have a flavonoid with no demonstrated senolytic effect in humans on its own. We grade the combination in full, including its small human trials and the fact that it pairs a chemo drug with a flavonoid, in [dasatinib + quercetin: how far along is the flagship senolytic?](/dasatinib-quercetin-senolytics) ## What a senolytic is, and where quercetin actually sits As you age, some cells stop dividing but refuse to die — they become **senescent**. These "zombie cells" accumulate and secrete a soup of inflammatory signals (the senescence-associated secretory phenotype) that damages surrounding tissue. Cellular senescence is one of the formal hallmarks of aging, and the leading review of the field lays out why clearing senescent cells is one of the most mechanistically compelling anti-aging strategies on the table. A **senolytic** is a drug that selectively kills these senescent cells. The 2015 paper that launched senolytics mapped senescent cells' pro-survival networks and used that map to pick its first targeted drugs — and the combination it landed on was dasatinib *plus* quercetin, chosen because the two together covered more of those survival pathways than either alone. So even at the field's origin, quercetin was a junior partner in a pair, not a senolytic in its own right. The human proof-of-concept that followed kept that structure: a first-in-human pilot in idiopathic pulmonary fibrosis used D+Q, and the landmark diabetic kidney disease trial that directly reduced senescent-cell burden in human tissue also used D+Q. In every human study that has shown a senolytic effect, quercetin arrived holding dasatinib's hand. ## The standalone senolytic evidence: there isn't any (in humans) This is the part the supplement framing can't survive. There is no human trial showing that quercetin **alone** — at any dose, in any schedule — clears senescent cells, improves function via a senolytic mechanism, or extends healthspan. The human senolytic data are D+Q data. The cell-clearance result everyone cites is a D+Q result. Quercetin's own contribution to senolysis has been studied mechanistically and in cells, but it has never been isolated and shown to work as a standalone senolytic in people. So when a bottle of quercetin is sold on a "clears zombie cells" promise, it is being credited for an effect demonstrated by a different intervention that also contained a chemotherapy drug. On the senolytic claim specifically, standalone quercetin grades as **no human evidence** — not weak, not preliminary: none. ## What quercetin *is* reasonably good at: modest anti-inflammatory and antioxidant effects None of this means quercetin is inert. Stripped of the senolytic halo, it's a reasonably well-characterized dietary flavonoid with a genuine — if modest — anti-inflammatory and antioxidant profile, and that's where its honest case lives. An umbrella review of meta-analyzes of randomized controlled trials found that quercetin supplementation had measurable but generally **small** effects across cardiometabolic outcomes. A meta-analysis of randomized human trials reported that quercetin can modestly lower systemic inflammatory markers such as C-reactive protein, though effects varied by dose and population. Another meta-analysis in people with metabolic syndrome and related disorders found improvements in some lipid and inflammatory markers, and a separate meta-analysis reported a small reduction in blood pressure with quercetin supplementation. Taken together, this is a coherent picture: quercetin is a **mild anti-inflammatory/antioxidant** that can nudge a few cardiometabolic numbers in the right direction. That's a legitimate, evidence-backed role — and it is a completely different, far more modest claim than "senolytic that slows aging." Two honest caveats sit on top of even this modest case. First, effect sizes are small and inconsistent across trials, populations, and doses — this is a supportive supplement signal, not a treatment-grade result. Second, quercetin has **poor oral bioavailability**: it's poorly absorbed and rapidly metabolized, which is exactly why so much formulation research is aimed at enhanced-delivery versions. Whether a standard off-the-shelf capsule reaches the tissue concentrations used in the more encouraging studies is not a settled question. ## Supplement, not approved drug — and what that means Quercetin is sold as a dietary supplement, not an FDA-approved drug. It carries no approved indication, no required efficacy proof, and label content the manufacturer controls. On the reassuring side, it's a flavonoid found in foods like onions, apples, and capers, and at typical supplement doses it has a long history of tolerable use. But "food-derived and generally well tolerated" is not the same as "proven to do what the label implies," and the gap here is unusually wide: the marketing implies senescent-cell clearance and anti-aging, while the actual standalone evidence supports a modest anti-inflammatory effect with poor absorption. The same lens applies across the field — we apply it in our [best longevity supplements, rated by evidence](/best-longevity-supplements) roundup, and the senolytic-specific version of this exact confusion shows up again with [fisetin as a senolytic](/fisetin-senolytic-evidence), where strong mouse data and a *different* drug's human trials get collapsed into a single overselling claim. ## The grade ## The bottom line Quercetin's longevity reputation is borrowed. The senolytic evidence that gives it shine belongs to the dasatinib + quercetin combination — a regimen built around a prescription chemotherapy drug — and there is no human evidence that quercetin **alone** clears senescent cells or extends healthspan. On its own, quercetin is better understood as a modest anti-inflammatory and antioxidant flavonoid: real, food-derived, backed by meta-analyzes showing small cardiometabolic effects, but limited by inconsistent effect sizes and poor oral bioavailability. That's a perfectly reasonable supporting-cast supplement. It is not a senolytic, and it is not a proven anti-aging intervention. If you take quercetin, take it for the modest anti-inflammatory case it can actually support — and don't let D+Q's signal halo a standalone bottle. For how senolytics and supplements sit alongside programs with real clinical oversight, see our graded [best longevity clinics](/best-longevity-clinics) hub. Sources: https://pubmed.ncbi.nlm.nih.gov/25754370/, https://pubmed.ncbi.nlm.nih.gov/30616998/, https://pubmed.ncbi.nlm.nih.gov/31542391/, https://pubmed.ncbi.nlm.nih.gov/37654199/, https://pubmed.ncbi.nlm.nih.gov/31213101/, https://pubmed.ncbi.nlm.nih.gov/31017459/, https://pubmed.ncbi.nlm.nih.gov/35948195/, https://pubmed.ncbi.nlm.nih.gov/40331705/, https://pubmed.ncbi.nlm.nih.gov/36599349/, https://pubmed.ncbi.nlm.nih.gov/33328614/ --- ### Superpower Health Review: Is the $499 100-Lab Membership Worth It? Canonical: https://longevitygraded.com/superpower-health-review Updated: 2026-06-19 Superpower's $499/yr 100+ lab membership is slick and cheap-per-marker — but it tests without treating, and the panel leans on padding. Honest, graded review. ## The one-sentence version Superpower is a well-marketed, well-priced direct-to-consumer (DTC) lab membership that does one thing genuinely well — it surfaces a big baseline panel, including a handful of cheap, outcome-validated markers your annual physical usually skips — and one thing it cannot do at all: actually treat you. The product is real and the price is competitive, but the "100+ biomarkers + a longevity dashboard" framing oversells what a tube of blood buys. It is structurally **test-but-don't-treat**, the long marker list is padded with correlated and vanity numbers, and the bigger story around the company — the well-publicized 2025 lawsuit between **Function Health and Superpower** over a former employee and trade-secret claims — is a business dispute, not a signal of clinical quality either way. Whether ~$499/year is worth it depends entirely on whether you will act on the few markers that matter. For where lab memberships sit in the field, start with our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence) and our breakdown of [what longevity biomarker panels actually test](/longevity-biomarker-panels). ## What Superpower actually is Superpower is a venture-backed DTC lab-testing startup (it raised a widely reported ~$30M round) that sells an annual membership — positioned around $499/year, though DTC lab pricing shifts constantly, so treat that as current market info. For the fee you get a large baseline blood panel headlined as "100+ biomarkers," a follow-up retest within the year, a polished app that flags results outside "optimal" ranges, and physician-ordered labs so a clinician signs off on the order. The pitch is concierge-grade data at a consumer price — and on price-per-marker, that part is broadly true. What you do **not** get is treatment. Superpower surfaces and tracks numbers; it is not a clinic that prescribes, titrates, and manages therapy. That testing-versus-treating split is the structural catch of the entire DTC lab band, and it is the single most important thing to understand before paying. We map the whole band in [longevity clinics vs lab memberships](/longevity-clinics-vs-lab-memberships). ## The good: it surfaces the markers a basic checkup skips The honest case *for* Superpower is the same as for any well-built lab membership: a standard annual physical often orders a basic lipid panel, a metabolic panel, and a CBC, then stops. A big DTC panel routinely includes several markers with strong hard-outcome evidence that your checkup probably doesn't: - **ApoB** counts the *number* of atherogenic particles, and when it disagrees with standard LDL cholesterol (common in metabolic syndrome) the particle count is the better predictor of cardiovascular events. - **Lp(a)** is a genetically set, mostly lifelong-stable particle that *causally* raises heart-attack and stroke risk — Mendelian-randomization data make that case cleanly. You measure it **once**; a high result reshapes how aggressively everything else gets managed. - **hs-CRP**, a marker of low-grade inflammation, predicted cardiovascular events at least as well as LDL cholesterol in a large prospective study. - **HbA1c** predicted all-cause and cardiovascular mortality *continuously* in a population study — including below the diabetes threshold. If Superpower's panel gets these four numbers in front of a motivated person — plus catches a treatable thyroid, ferritin, or vitamin D problem people misattribute to "aging" — it has earned a real slice of its fee. That is the legitimate core, and on cost-per-marker Superpower is one of the cheaper ways to get it. ## The catch: padding, and a "longevity" dashboard that tests without treating Now the honest case *against* the framing. The "100+ biomarkers" headline does a lot of marketing work: - **A large share is ordinary bloodwork** — CBC, metabolic panel, standard lipids, thyroid, electrolytes — useful, but the same labs a primary-care order or a cheap requisition provides. Bundling them into a "100+" count makes the panel look more exotic than it is. - **Much of the tail is correlated padding** that tracks the cheap Tier-1 core, adding line items and a sense of completeness without much independent, actionable signal. More tubes of blood is not more health. - **Some featured markers mislead as targets.** IGF-1, marketed as a youth hormone, has a *U-shaped* mortality relationship — both low and high IGF-1 associate with higher mortality. And the two biggest longevity levers in all of epidemiology aren't on any blood panel at all: cardiorespiratory fitness, among the most powerful survival predictors ever measured, and grip strength, which outpredicted blood pressure across 17 countries in the PURE study. The decisive limit is structural: Superpower is a measurement product. It flags that your ApoB is high or your HbA1c is creeping up — it does not then manage you. A dashboard full of green-and-amber flags can create a false sense that paying for the data is doing something. For a health-literate person who *will* take an abnormal result to a clinician, that's fine; for someone hoping the membership itself improves their health, it's a category error. ## The Function Health lawsuit, in plain terms Because it comes up in every "Superpower vs Function" search, it's worth stating cleanly: in 2025, **Function Health sued Superpower** in a dispute centered on a former Function employee and allegations involving confidential information / trade secrets. That is a *business and personnel* dispute between two competitors. It tells you the DTC-lab space is crowded and competitive; it does **not** tell you that either company's clinical product is better or worse. Don't let litigation headlines stand in for an evidence judgment about the panels themselves — for the rival product on the merits, see our [Function Health review](/function-health-review) and the head-to-head [Function Health vs Superpower](/function-health-vs-superpower). ## The grade, and how we got there Two axes, because conflating them is the trap: - **As a cheap way to surface outcome-validated markers your checkup skips:** moderate-to-strong. ApoB, Lp(a), hs-CRP, and HbA1c are real, hard-outcome-linked tests, and Superpower's price-per-marker is competitive. - **As a "100+ biomarker longevity" upgrade that improves your health:** weak. Roughly half is basic labs, much of the tail is correlated padding, a few markers (IGF-1) mislead as targets, and — decisively — it tests without treating. That split lands the letter grade in the middle: a **B for the actionable core and the price, a C for the "longevity dashboard" model most people think they're buying.** If you're health-literate, have a clinician who'll act on the results, and value cheap convenient access to ApoB and Lp(a), it can be worth it. If you're hoping a subscription will *make* you healthier, the money does more in a targeted outcome-validated panel plus actually treating the few markers that matter. We run that whole cost-benefit in [are longevity clinics worth it?](/longevity-clinics-worth-it). ## Who should and shouldn't buy it - **Reasonable buyer:** a motivated, health-literate person who wants ApoB, Lp(a), hs-CRP, and HbA1c surfaced cheaply and *will* take abnormal results to a clinician who treats them. - **Poor fit:** someone expecting the membership to improve their health, or who'll read a long list of flags as a scoreboard. For most of that budget, a targeted panel plus treatment does the job — and if you mainly want a biological-age number, the open PhenoAge formula derives one from a basic blood draw for free, as we cover in [free biological-age tests](/free-biological-age-tests). Don't confuse a comprehensive blood panel with an epigenetic-age test — that's a different product with its own limits, graded in [biological age tests](/biological-age-tests). ## Bottom line Superpower's real value isn't the "100+ biomarkers" — it's the four or five cheap, outcome-validated markers (ApoB, Lp(a) once, hs-CRP, HbA1c) it surfaces at a competitive price, plus the occasional treatable deficiency catch. The rest is largely ordinary bloodwork dressed up by a big number, a correlated tail that adds little independent signal, and the occasional vanity marker. Most important, it tests without treating: it flags problems it won't fix, and the Function Health lawsuit is a business story, not a clinical verdict. Worth it for a motivated buyer with a clinician who'll act on the results — a poor fit for anyone hoping a subscription is itself a health intervention. To see how it stacks up against InsideTracker, Lifeforce, and Function on price and padding, see our roundup of the [best longevity blood test services](/best-longevity-blood-tests). For an independently graded look at the labs and clinics selling these memberships, see [our longevity clinic rankings](/best-longevity-clinics). Sources: https://pubmed.ncbi.nlm.nih.gov/36216435/, https://pubmed.ncbi.nlm.nih.gov/20032323/, https://pubmed.ncbi.nlm.nih.gov/12432042/, https://pubmed.ncbi.nlm.nih.gov/11141143/, https://pubmed.ncbi.nlm.nih.gov/30646252/, https://pubmed.ncbi.nlm.nih.gov/25982160/ --- ### Function Health vs Superpower: Which Lab Membership Wins? Canonical: https://longevitygraded.com/function-health-vs-superpower Updated: 2026-06-19 Function Health vs Superpower, graded honestly: nearly identical 100+ lab memberships that both test without treating. The tiebreaker isn't the marker count. ## The one-sentence version Function Health and Superpower are far more alike than their marketing — or their lawsuit — suggests. Both are direct-to-consumer (DTC) lab memberships built around a "100+ biomarker" baseline panel, a retest, a flag-it-against-optimal-ranges dashboard, and physician-ordered labs. Both share the same decisive limit: they **test, they don't treat.** So the honest comparison isn't "which has more markers" (a near-meaningless axis) but "which more reliably surfaces the four or five cheap, outcome-validated numbers that actually matter, at a price you'll pay, without padding or upsell pressure." On that axis it's close, and the tiebreaker is track record and how you read flags — not the headline count. For the field context, start with our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence) and our breakdown of [what longevity biomarker panels actually test](/longevity-biomarker-panels). ## What each one is - **Function Health** is the category's headline act: a membership positioned around ~$499/year built around a 100+ marker baseline panel plus a mid-year retest, with physician-ordered and -reviewed labs and a dashboard flagging results against "optimal" ranges. Full breakdown in our [Function Health review](/function-health-review). - **Superpower** is the venture-backed challenger (a widely reported ~$30M raise), also selling a 100+ marker baseline plus retest, a polished app, and physician-ordered labs, positioned on aggressive price-per-marker. Full breakdown in our [Superpower Health review](/superpower-health-review). Treat all dollar figures as current market info — DTC lab pricing and tiers shift constantly. The structural product is nearly the same on both sides. ## The thing both get right Give both their due: a standard annual physical orders a basic lipid panel, a metabolic panel, and a CBC, then stops. Both Function and Superpower routinely include markers with strong hard-outcome evidence that your checkup probably skips: - **ApoB** counts the *number* of atherogenic particles; when it disagrees with standard LDL cholesterol, the particle count is the better predictor of cardiovascular events. - **Lp(a)**, a genetically set particle, *causally* raises heart-attack and stroke risk per Mendelian-randomization data — measured **once**. - **hs-CRP** predicted cardiovascular events at least as well as LDL cholesterol in a large prospective study. - **HbA1c** predicted all-cause and cardiovascular mortality *continuously* in a population study, including below the diabetes threshold. If either membership gets those four numbers in front of a motivated person, it has earned a real slice of its fee. That core is the same on both — which is exactly why the marker-count war between them is mostly noise. ## The thing both get wrong (identically) Both lean on the "100+ biomarkers" headline, and the framing does the same marketing work on each side: - **Roughly half is ordinary bloodwork** (CBC, metabolic, lipids, thyroid) available cheaper through a primary-care order. - **Much of the tail is correlated padding** — markers that track the cheap Tier-1 core and add line items, not independent signal. - **A few featured markers mislead as targets** — IGF-1, sold as a youth hormone, has a *U-shaped* mortality curve. And the two biggest longevity levers in epidemiology aren't on any blood panel: cardiorespiratory fitness, among the strongest survival predictors ever measured, and grip strength, which outpredicted blood pressure across 17 countries in PURE. Decisively, **neither treats you.** Both flag a high ApoB or a creeping HbA1c; neither titrates your statin or builds and rechecks a plan. For a health-literate buyer with a clinician who'll act, that's fine; for someone hoping the subscription itself improves their health, it's a category error on both sides. We map this whole DTC band in [longevity clinics vs lab memberships](/longevity-clinics-vs-lab-memberships). ## So what actually separates them? Three honest, second-order differences — none of them the marker count: 1. **Track record.** Function is the more established of the two with a longer operating history; Superpower is newer and less track-recorded. If "who's been running labs reliably longer" matters to you, Function has the edge today. 2. **Price posture.** Superpower competes hard on price-per-marker and is often the cheaper way to get the outcome-validated core. If you're buying purely to get ApoB/Lp(a)/hs-CRP/HbA1c at the lowest cost and you'll act on them yourself, Superpower's pricing can win. 3. **The lawsuit is a non-factor for buyers.** In 2025 Function sued Superpower in a dispute centered on a former Function employee and trade-secret allegations. That's a business-and-personnel fight between competitors. It tells you the space is crowded; it tells you **nothing** about which panel is clinically better. Don't let it tip your decision. ## The grade, and how we got there We grade each on two axes, because conflating them is the trap both share: - **As a way to surface outcome-validated markers your checkup skips:** moderate-to-strong for both. The core is real and nearly identical. - **As a "100+ biomarker" health upgrade:** weak for both. Half is basic labs, the tail is padding, and neither treats. That symmetry is the whole story: **both land at roughly a B for the actionable core and a C for the model most people think they're buying.** The split between them is narrow — **Function edges it on track record, Superpower on price** — so the right pick is whichever gets the four markers that matter in front of a clinician who'll act, for the price you'll actually pay. If neither sounds like what you want, a targeted outcome-validated panel plus treatment beats either, and we run that cost-benefit in [are longevity clinics worth it?](/longevity-clinics-worth-it). ## Who should pick which - **Pick Function** if you value the longer operating track record and a more established dashboard, and the ~$499/year fits. - **Pick Superpower** if you're buying purely on price-per-marker for the outcome-validated core and you'll act on results yourself. - **Pick neither** if you're hoping a subscription will *make* you healthier. For most of that budget, a targeted panel plus actually treating the few markers that matter does more — and if you mainly want a biological-age number, the open PhenoAge formula derives one from a basic blood draw for free, covered in [free biological-age tests](/free-biological-age-tests). Don't confuse either blood membership with an epigenetic-age test — that's a different product, graded in [biological age tests](/biological-age-tests). ## Bottom line Function Health vs Superpower is a near-tie because they're nearly the same product: a 100+ marker baseline, a retest, a flag-it dashboard, physician-ordered labs — and the same decisive limit, that both test without treating. Their real value on both sides is the four or five cheap, outcome-validated markers (ApoB, Lp(a) once, hs-CRP, HbA1c) they surface; their shared weakness is the padded count and the missing treatment. Function edges it on track record, Superpower on price, and the 2025 lawsuit between them is a business story, not a clinical verdict. Pick the one that gets the markers that matter to a clinician who'll act, for the price you'll pay. To see where both rank against InsideTracker and Lifeforce, see our roundup of the [best longevity blood test services](/best-longevity-blood-tests). For an independently graded look at the labs and clinics selling these memberships, see [our longevity clinic rankings](/best-longevity-clinics). Sources: https://pubmed.ncbi.nlm.nih.gov/36216435/, https://pubmed.ncbi.nlm.nih.gov/20032323/, https://pubmed.ncbi.nlm.nih.gov/12432042/, https://pubmed.ncbi.nlm.nih.gov/11141143/, https://pubmed.ncbi.nlm.nih.gov/30646252/, https://pubmed.ncbi.nlm.nih.gov/25982160/ --- ### NOVOS Core Review: Does the 12-Ingredient Longevity Drink Work? Canonical: https://longevitygraded.com/novos-review Updated: 2026-08-04 NOVOS Core bundles 12 longevity ingredients into one daily drink. The formulation logic is real; the human lifespan proof isn't. An honest, graded review. ## The one-sentence version NOVOS Core is one of the better-*designed* longevity supplements on the market — a single daily powder bundling twelve ingredients each picked to nudge a named hallmark of aging — and it still cannot show, in a human outcome trial, that taking it makes you live longer or age slower. Those two things are true at once, and the gap between them is the whole review. The formulation logic is genuinely more thoughtful than the typical single-molecule "NMN will reverse aging" pill; the proof that the *finished product* extends human healthspan does not exist, and the company's own supporting data are mechanistic and largely not peer-reviewed. For the frame we hold every supplement to, see our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence) and our graded roundup of the [best longevity supplements](/best-longevity-supplements). ## What NOVOS Core actually is NOVOS Core is a once-daily drink mix (a separate product, NOVOS Boost, sells NMN). The Core formula combines twelve ingredients — alpha-ketoglutarate, glycine, fisetin, pterostilbene, lithium (microdose), magnesium, L-theanine, glucosamine, hyaluronic acid, ginger, rhodiola and vitamin C — each chosen, the company says, to target one of the recognized **hallmarks of aging** (genomic instability, senescence, mitochondrial dysfunction, and so on). Pricing sits in the roughly $50–$100/month range depending on subscription — treat that as current market info, since supplement pricing shifts. It is a **supplement, not a drug**: not FDA-approved to treat or prevent any disease, with the usual unpoliced label claims and variable manufacturing quality that define the category. **The exact dosages, per the label** (one 13g packet, verified on novoslabs.com in August 2026): Glycine 2,000 mg, Magnesium (as magnesium malate) 305 mg, Calcium alpha-ketoglutarate 1,100 mg (providing 231 mg calcium, 18% DV), GreenGrown® vegan glucosamine sulfate 1,000 mg, Rhodiola rosea root extract 300 mg (standardized to 3% rosavins, 1% salidrosides), **L-theanine 150 mg**, Hyaluronic acid 100 mg, Fisetin 100 mg, Vitamin C (as ascorbic acid) 100 mg, Organic ginger root extract 80 mg (2% gingerols), Pterostilbene 50 mg, and Lithium (as lithium aspartate) 1 mg. The design intent is the genuinely interesting part. Instead of betting everything on one molecule, NOVOS spreads small, individually-reasoned bets across multiple aging pathways. That is a more defensible *strategy* than most of the aisle. It is not, by itself, evidence that the combination works in people. ## Where the ingredient evidence is real (and where it isn't) Honest grading means separating mechanism from human proof, ingredient by ingredient — and then remembering the formula is a *blend*, not the sum of its best parts. - **Glycine** is one of the more interesting members. As half of the GlyNAC pair (glycine + N-acetylcysteine), it helped rebuild glutathione and improved several aging-associated measures — oxidative stress, mitochondrial markers, inflammation — versus placebo in a small randomized trial of older adults. That's a real human signal, but it's small, short, and measured biomarkers, not lifespan; and NOVOS supplies glycine without the NAC partner that drove those results. - **Fisetin** is marketed as a **senolytic**. The headline data are striking — fisetin reduced senescent-cell burden and extended health- and lifespan in *aged mice* — but that is a mouse result, and no completed human trial shows fisetin slows aging or improves hard outcomes in people. We unpack why in [fisetin as a senolytic: what the evidence shows](/fisetin-senolytic-evidence). - **Alpha-ketoglutarate** carries one of the longevity world's most over-read claims — the viral "8 years younger" result that rests on a small, placebo-free study. We dissect exactly why that doesn't hold up in [the alpha-ketoglutarate "8 years younger" claim](/alpha-ketoglutarate-for-longevity). - **Lithium (microdose)** has intriguing epidemiology but no human longevity proof; we grade it in [lithium microdosing for longevity](/lithium-microdose-for-longevity). - **Pterostilbene** (50 mg) is a resveratrol analog with better oral bioavailability than resveratrol itself, sold on the same "activates sirtuins" mechanism story — see our [does resveratrol actually work for longevity](/resveratrol-for-longevity) breakdown for why that mechanism has not translated into a human longevity result even for its better-studied cousin. No completed human trial shows pterostilbene extends lifespan or healthspan. - The rest — magnesium, L-theanine (150 mg), ginger, rhodiola, glucosamine, hyaluronic acid — range from "reasonable general-wellness ingredient" to "thin," but none has human lifespan data. The pattern is the same one that sinks the whole supplement category: every ingredient here is, at best, **mechanism or animal data** — plausibly touches a hallmark of aging — and "plausibly touches a hallmark" is not "proven to help a person age better." ## The two things the marketing implies but the evidence doesn't deliver ### 1. A blend of plausible ingredients is not a proven product This is the central trap. NOVOS's case is built bottom-up: ingredient A touches senescence, ingredient B touches mitochondria, therefore the combination must slow aging. But **combining individually-reasonable ingredients does not produce proven combined efficacy** — interactions, doses, and bioavailability all change in a blend, and the only way to know the *finished product* works is to test the finished product against placebo on a real outcome. That trial has not been run on NOVOS Core. Even the field's strongest single-molecule stories (resveratrol's sirtuin hype, for instance, where controlled human data show only modest, mixed biomarker shifts) collapsed when held to human-outcome standards. ### 2. "Validated to target the hallmarks of aging" is a mechanism claim, not an outcome NOVOS leans on in-vitro and cell-based work (including lab assays of DNA-damage protection) to support the formula. That kind of data is legitimately interesting and more than most competitors bother with — but it is **preclinical**, and much of the company's supporting material is not peer-reviewed publication. A cell assay or a mouse showing a marker moves is not a human living longer. The two biggest longevity levers in all of epidemiology aren't in any supplement anyway: cardiorespiratory fitness, among the strongest survival predictors ever measured, and grip strength, which outpredicted blood pressure across 17 countries in the PURE study. No powder substitutes for moving those. ## A note in the ranking NOVOS is conspicuously **absent from our [graded longevity provider rankings](/best-longevity-clinics)** — and that's deliberate, not an oversight. That hub ranks clinician-overseen telehealth programs and lab memberships; NOVOS is a direct-to-consumer supplement you self-administer with no physician in the loop. It belongs in the supplement conversation (graded above and in our [best longevity supplements](/best-longevity-supplements) roundup), not among programs that provide actual medical oversight. If you want oversight rather than a self-managed cabinet of capsules, the clinic hub is where to look. ## The grade, and how we got there Two axes, because conflating them is the marketing trap: - **As a thoughtfully-formulated, multi-pathway supplement:** moderate. The hallmarks-of-aging design and the multi-ingredient strategy are more defensible than a single-molecule pill, and a couple of ingredients (glycine) have real, if narrow, human biomarker signals. - **As a product proven to slow your aging or extend your life:** none. There is no human outcome trial on NOVOS Core, the ingredient evidence is mechanism/animal-grade, the company's supporting data are preclinical and largely not peer-reviewed, and a blend of plausible parts isn't a proven whole. That split lands the letter grade firmly in the middle-low: a **B for formulation thoughtfulness, a D for proven longevity benefit.** It's a defensible buy for someone who understands they're paying for a well-reasoned bet on mechanisms, not a proven intervention — and a poor buy for anyone expecting it to measurably slow their aging. We run the broader cost-benefit in [are longevity clinics worth it?](/longevity-clinics-worth-it). ## Who should and shouldn't buy it - **Reasonable buyer:** someone who has read the evidence, wants a single convenient multi-pathway formula instead of buying ten separate jars, and is comfortable paying for mechanism-level bets without expecting proof. - **Poor fit:** anyone expecting a measurable anti-aging result, or who'd be better served putting the monthly spend toward the boring proven levers (exercise, sleep, treating blood pressure and metabolic disease). If you want to *measure* anything, a [longevity biomarker panel](/longevity-biomarker-panels) tells you more than a supplement promises — and the free PhenoAge formula gives a biological-age number from a basic blood draw, covered in [free biological-age tests](/free-biological-age-tests) and computed for you by our [biological age calculator](/tools/biological-age-calculator). ## Bottom line NOVOS Core is among the more intelligently designed longevity supplements: twelve ingredients mapped to the hallmarks of aging, a multi-pathway strategy more defensible than a single-molecule pill, and a couple of components (glycine) with genuine if narrow human biomarker data. But none of that closes the gap that matters — there is no human outcome trial showing NOVOS Core slows your aging or extends your life, its ingredient evidence is mechanism- and animal-grade, and the company's supporting data are preclinical and largely unpublished. A blend of plausible parts is not a proven whole. Buy it, if at all, as a well-reasoned bet you understand — not as a proven intervention — and don't expect it to outperform the boring levers with actual lifespan evidence. For how it ranks against the other supplements, see our [best longevity supplements](/best-longevity-supplements) guide; for the brand most often shortlisted alongside it — one selling a number rather than a pill — see [NOVOS vs Tally Health](/novos-vs-tally-health). For an independently graded look at the clinics and programs that provide real oversight, see [our longevity clinic rankings](/best-longevity-clinics). Sources: https://pubmed.ncbi.nlm.nih.gov/35975308/, https://pubmed.ncbi.nlm.nih.gov/30279143/, https://pubmed.ncbi.nlm.nih.gov/39872318/, https://pubmed.ncbi.nlm.nih.gov/30646252/, https://pubmed.ncbi.nlm.nih.gov/25982160/ --- ### Tally Health Review: Is the TruAge Epigenetic Membership Worth It? Canonical: https://longevitygraded.com/tally-health-review Updated: 2026-06-19 Tally Health pairs a TruAge epigenetic-age test with coaching and a supplement. The clock is real science; tracking your own aging with it isn't proven. ## The one-sentence version Tally Health — co-founded with longevity scientist David Sinclair — sells a slick package: an at-home **TruAge** epigenetic-age test, a coaching/membership layer, and an own-brand supplement (Vitality). The science behind the clock is genuinely real, and the founder's lab credentials are real. But neither of those closes the gap that decides the grade: no test has shown that **lowering your Tally/TruAge number makes you, personally, live longer**, the membership funnels you toward a supplement whose human longevity evidence doesn't exist, and a famous founder is a marketing asset, not clinical proof. For where epigenetic-age testing sits in the toolkit, start with our explainer on [whether biological-age tests actually work](/biological-age-tests) and our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What you actually get Tally Health is a direct-to-consumer (DTC) longevity brand built around three things: 1. **A TruAge epigenetic-age test** — a DNA-methylation test (cheek-swab based) that returns an estimated biological age, sold one-off or bundled into a membership with periodic retesting. 2. **A membership / coaching layer** — lifestyle guidance, action plans, and a dashboard to track your "TallyAge" over time. 3. **An own-brand supplement (Vitality)** — a multi-ingredient longevity formula the program nudges you toward. Pricing spans roughly a one-off test in the low hundreds up to a recurring membership that bundles retests, coaching, and supplement discounts — treat figures as current market info, since DTC longevity pricing shifts constantly. The whole thing is wrapped in the credibility of a well-known aging researcher. ## Give the science its due The clock underneath is not snake oil. Epigenetic clocks read DNA-methylation patterns that change with age; the first-generation Horvath clock was trained to estimate chronological age, and later clocks were trained on harder endpoints — GrimAge on mortality, PhenoAge on clinical aging. The landmark blood-methylation analysis showed that people whose methylation runs "old" die sooner on average, even after adjusting for known risk factors. And the most credible pace-of-aging clock, DunedinPACE, was calibrated against decades of longitudinal organ decline and — uniquely — was *slowed* by a randomized caloric-restriction intervention in the CALERIE trial. So the *category* has real population science behind it. David Sinclair's own lab work is also real and high-profile: his "information theory of aging" paper argued that loss of epigenetic information drives aging, and a follow-up showed partial chemical reprogramming could reverse cellular-age markers in the lab. That's serious science. **But it's lab and animal science about *mechanisms* — it is not evidence that Tally's consumer test tells you whether your protocol is working, and it is certainly not evidence that Tally's supplement extends human life.** Founder prestige is the easiest thing in this category to mistake for product proof. ## The three things the membership implies but the science doesn't deliver ### 1. A clock that predicts populations is not validated to predict your outcome Epigenetic clocks are validated as **predictors across large groups** — fast/old methylation tracks with higher mortality in cohorts. But "associates with mortality across thousands of people" is a completely different claim from "if I push *my* number down, *I* live longer." No clock — DunedinPACE included — has been demonstrated to be a valid, *modifiable personal target*. An intervention could lower your TallyAge while leaving your real disease risk untouched, and the report couldn't tell you. The field's own consensus work treats these clocks as legitimate but explicitly **research-stage** tools for intervention studies, not personal diagnostics. ### 2. Test–retest noise can swamp the change you're paying to see Even the better clocks carry measurement noise; a detailed reliability study found many widely used clocks reproduce poorly on the same sample, with first-generation clocks the worst. A computational re-engineering effort had to build principal-component versions specifically because the originals were too noisy for longitudinal tracking. So when you test, change your routine, and retest to see if your "TallyAge" dropped, an apparent improvement may be measurement variation dressed up as progress — especially over the short windows a membership encourages. ### 3. The membership leads to a supplement with no human longevity proof This is the structural conflict that decides the grade. Tally doesn't just sell you a number — it routes you toward its own supplement (Vitality) and a recurring relationship. When the same brand sells the test *and* the product meant to improve the test, an unvalidated "you got younger" readout becomes a sales tool, not a diagnosis. And the supplement itself faces the same wall every longevity supplement does: there is no randomized human-outcome trial showing any such formula extends lifespan, and ingredient-level mechanism data isn't proof in people. We dissect the exact "test sells you the supplement that improves the test" loop in [the alpha-ketoglutarate "8 years younger" claim](/alpha-ketoglutarate-for-longevity) and grade the supplements themselves in [best longevity supplements](/best-longevity-supplements). ## The grade, and how we got there Two axes, because conflating them is the trap: - **As a built-on-real-science epigenetic snapshot:** moderate. TruAge methylation testing is a legitimate technology, and the founder's lab credentials are real. As a one-time curiosity or rough risk signal, it's a defensible product. - **As a membership to track whether your longevity protocol (and Tally's supplement) is working:** weak. The clock isn't validated as a modifiable personal target, single-test noise can rival the change you're chasing, there's no FDA-cleared "biological age" standard, and the model steers you toward a supplement with no human longevity proof. That split lands the letter grade in the middle: a **B for the science, a C for the membership-plus-supplement use case most people buy it for.** Buy it, if at all, as a one-time curiosity from a credible founder — not as a quarterly scoreboard tied to a supplement subscription. For the broader cost-benefit, see [are longevity clinics worth it?](/longevity-clinics-worth-it). ## Who should and shouldn't buy it - **Reasonable buyer:** someone curious about a one-time epigenetic snapshot who will read the number as a soft signal, won't re-test obsessively, and won't reorganize their spending around a supplement subscription. - **Poor fit:** someone planning to retest every few months to "optimize," or who'll buy the supplement because the dashboard nudges it. For that money, a standard outcome-validated blood panel — ApoB, Lp(a) once, hs-CRP, HbA1c — does far more, and we sort which markers earn their place in [what longevity biomarker panels actually test](/longevity-biomarker-panels). If you mainly want a biological-age number, the open PhenoAge formula derives one from a basic blood panel for free — see [free biological-age tests](/free-biological-age-tests), or paste your own labs into our [biological age calculator](/tools/biological-age-calculator). And to see how Tally's TruAge stacks up against the blood-based version and other kits, see [best at-home biological-age test](/best-at-home-biological-age-test) and our [TruDiagnostic TruAge review](/trudiagnostic-truage-review). ## Bottom line Tally Health is a credible-looking package built on real epigenetic-clock science and a real scientist's name — but neither closes the gap that matters for a buyer. No test has shown that lowering your TallyAge makes *you* live longer, single-test noise can rival the change you're hoping to detect, there's no FDA-cleared standard behind the number, and the membership steers you toward an own-brand supplement with no human longevity proof — a supplement that loses to the better-designed formula we set beside it in [NOVOS vs Tally Health](/novos-vs-tally-health). A famous founder is a marketing asset, not a clinical result. Buy it, if at all, as a one-time curiosity — not as a quarterly scoreboard for a supplement subscription. For how it ranks against blood-based and saliva clocks, see our [best at-home biological-age test guide](/best-at-home-biological-age-test). For an independently graded look at the labs and clinics selling biological-age testing, see [our longevity clinic rankings](/best-longevity-clinics). Sources: https://pubmed.ncbi.nlm.nih.gov/24138928/, https://pubmed.ncbi.nlm.nih.gov/30669119/, https://pubmed.ncbi.nlm.nih.gov/29676998/, https://pubmed.ncbi.nlm.nih.gov/25633388/, https://pubmed.ncbi.nlm.nih.gov/37118425/, https://pubmed.ncbi.nlm.nih.gov/36638792/, https://pubmed.ncbi.nlm.nih.gov/37437248/, https://pubmed.ncbi.nlm.nih.gov/37657418/, https://pubmed.ncbi.nlm.nih.gov/39708300/, https://pubmed.ncbi.nlm.nih.gov/32885222/, https://pubmed.ncbi.nlm.nih.gov/36277076/ --- ### NOVOS vs Tally Health: Which Longevity Brand Is Worth It? Canonical: https://longevitygraded.com/novos-vs-tally-health Updated: 2026-06-23 NOVOS sells a multi-pathway longevity supplement; Tally Health sells an epigenetic-age test plus its own pill. A graded, honest head-to-head on what's proven. ## The one-sentence version These two brands look like rivals, but they're really selling different things: NOVOS sells you a once-daily multi-ingredient longevity powder, while Tally Health sells you a number — an at-home epigenetic-age test — wrapped in a coaching membership that points you back toward its own supplement. Pick by which question you're trying to answer, then read the same honest caveat under both: neither has shown, in a human outcome trial, that buying it makes *you* age slower or live longer. One is a well-reasoned bet on mechanisms; the other is a real piece of population science repackaged as a personal scoreboard. We grade each in depth in our [NOVOS review](/novos-review) and [Tally Health review](/tally-health-review); this page is the side-by-side. ## What each one actually sells The category confusion starts here, so it's worth being blunt. NOVOS is a **product**: a daily drink mix bundling roughly a dozen ingredients, each picked to nudge a recognized hallmark of aging. There's no test, no coach, no number — you take it on faith in the formula. Tally Health is a **service plus a product**: a DNA-methylation cheek-swab test that returns a biological-age estimate, a membership dashboard that tracks that estimate over time, and an own-brand pill the program nudges you toward. One asks you to trust a blend; the other asks you to trust a clock — and then sells you a blend anyway. That structural difference matters more than any ingredient debate. With NOVOS, you're paying for convenience and a multi-pathway thesis. With Tally, you're paying for measurement first — which sounds more rigorous, until you ask whether the measurement can actually tell *you* anything actionable. ## Grading the evidence, side by side We hold both to the same bar: separate mechanism from human outcome, and never let a clever design or a famous name stand in for proof. For the full rubric, see [how we grade longevity providers](/how-we-grade-longevity-providers). **NOVOS's case is bottom-up.** Ingredient A touches senescence, ingredient B touches mitochondria, so the combination "must" slow aging. A couple of components carry genuine but narrow human signals — glycine, as half of the GlyNAC pair, improved oxidative-stress and mitochondrial markers versus placebo in a small older-adult trial. But that's biomarker data in a blend that omits glycine's NAC partner, and the rest of the ranking is mechanism or animal-grade. Combining individually-plausible ingredients does not produce proven combined efficacy, and no trial has tested the finished NOVOS product against placebo on a real outcome. **Tally's case is top-down.** The epigenetic clock underneath is legitimate population science — methylation-age testing predicts mortality across large cohorts, and the most credible pace-of-aging clock was even slowed by a randomized caloric-restriction intervention in the CALERIE trial. That's a stronger evidentiary foundation than anything in NOVOS's jar. The catch is what that science *licenses*: predicting outcomes across thousands of people is a different claim from telling one buyer whether a protocol moved their personal risk. No clock has been validated as a modifiable individual target, and single-test reproducibility noise can rival the change a short routine produces. So the two land in different failure modes. NOVOS is a thoughtful formula with thin human proof. Tally is real science aimed at a use case it hasn't been validated for — and it bundles a supplement that faces the exact same "no human outcome trial" wall NOVOS does. ## The testing component — Tally's real differentiator This is the one thing NOVOS doesn't offer, and it's worth weighing honestly. A biological-age readout is seductive: a single number that feels like a verdict on how you're aging. Used once, as a soft risk signal from a credible brand, it's a defensible curiosity. The trouble is the membership model, which encourages you to retest every few months to "watch your number drop" — precisely the use case the evidence doesn't support, because an apparent improvement may be measurement wobble rather than biology. And when the same company sells both the test and the pill meant to improve it, an unvalidated readout quietly becomes a sales tool. If a measured biological-age number is what you're after, a free blood-based [PhenoAge calculator and the tools we maintain](/tools) get you a comparable signal without the subscription. ## Cost, and who each suits Both sit in shifting DTC pricing territory — treat any figure as current market info. NOVOS runs roughly $50–$100/month for the supplement alone. Tally spans a one-off test in the low hundreds up to a recurring membership bundling retests, coaching, and supplement discounts, so it's typically the bigger commitment once you're inside the membership funnel. - **Lean toward NOVOS** if you want one convenient multi-pathway formula instead of ten separate jars, you've read the evidence, and you're comfortable paying for a mechanism-level bet without expecting a measurable result. - **Lean toward Tally** if your real itch is curiosity about a one-time epigenetic snapshot from a credible founder — and you'll read the number as a soft signal, skip the obsessive retesting, and not reorganize your spending around the Vitality subscription. - **Skip both** if you're expecting either to demonstrably slow your aging. The boring proven levers — exercise, sleep, treating blood pressure and metabolic disease — do more for lifespan than either purchase, and they're free. For a broader view of what's actually worth buying in this category, see our [best longevity supplements](/best-longevity-supplements) roundup, and for a testing-first brand graded the same way, our [Superpower Health review](/superpower-health-review). ## Bottom line NOVOS and Tally Health aren't really competitors — they answer different questions. NOVOS is the more thoughtfully-formulated *product*, with a defensible multi-pathway design and one or two narrow human biomarker signals, but zero outcome proof on the finished blend. Tally is built on the more legitimate *science* — epigenetic clocks are real population biology — but it sells that science as a personal scoreboard it hasn't earned, and routes you toward a supplement with no more human longevity proof than NOVOS's. If you want a convenient mechanism bet, NOVOS edges it on honesty-of-purpose. If you want a one-time number from a credible name, Tally's test is the draw — just don't pay for the subscription that turns an unvalidated readout into a sales loop. Read both full grades first: our [NOVOS review](/novos-review) and [Tally Health review](/tally-health-review). Sources: https://pubmed.ncbi.nlm.nih.gov/35975308/, https://pubmed.ncbi.nlm.nih.gov/25633388/, https://pubmed.ncbi.nlm.nih.gov/37118425/ --- ### Spermidine vs Fisetin: Two Longevity Supplements, Honestly Compared Canonical: https://longevitygraded.com/spermidine-vs-fisetin Updated: 2026-06-23 Spermidine targets autophagy; fisetin clears senescent cells. Different mechanisms, different evidence grades — an honest, head-to-head longevity comparison. Spermidine and fisetin land on the same shortlist of buzzy longevity supplements, so people naturally ask which one to pick. That framing is slightly wrong from the start: these two molecules do completely different things to aging cells, sit on different parts of the evidence map, and aren't really competing for the same slot in a stack. This page puts them side by side honestly — what each is supposed to do, how strong the human case actually is for each, and who, realistically, might consider which. We grade both individually in [spermidine for longevity](/spermidine-for-longevity) and [fisetin as a senolytic](/fisetin-senolytic-evidence); this is the head-to-head. For the full field, start with [best longevity supplements, rated by evidence](/best-longevity-supplements). ## Two molecules, two completely different jobs The single most important thing to understand is that spermidine and fisetin attack aging from opposite ends. Spermidine is a polyamine that your body makes and you eat; its signature action is inducing **autophagy** — the cell's recycling system that clears out damaged proteins and organelles, and that declines with age. The authoritative review of the field frames spermidine as a caloric-restriction mimetic working largely through this pathway. Fisetin is a plant flavonoid whose claim to fame is acting as a **senolytic** — selectively killing the worn-out "zombie" cells that stop dividing but refuse to die and instead leak inflammatory signals into surrounding tissue. Both autophagy decline and cellular senescence are cataloged among the formal hallmarks of aging, so both molecules have a legitimate target. But one tidies the inside of cells continuously, and the other removes bad cells entirely — which is why the dosing philosophies differ so sharply, and why thinking of them as either/or misses the point. ## Where the evidence actually stands This is where an honest comparison earns its keep, because the two have very different shapes of evidence — and neither is "proven in humans." **Spermidine** has the better *human* footprint, but it's a mixed one. Two large prospective cohorts found that higher dietary intake tracked with lower mortality, which is a genuine population signal — though it's an association tangled up with overall diet quality, not proof. Crucially, the one adequately-powered randomized human trial (the 12-month SmartAge study in older adults with cognitive decline) was **negative** on its primary cognitive endpoint. So spermidine's story is: clean mechanism, real epidemiology, and a flagship trial that came back null. **Fisetin** has the more dramatic *animal* footprint and almost no human footprint. In aged mice, intermittent fisetin cleared senescent cells, reduced age-related inflammation, and extended both health and lifespan by roughly 10% — even when started late in life. That's a stronger preclinical headline than spermidine's null human trial. But the encouraging *human* senolytic trials used a **different** drug combination (dasatinib plus quercetin), which measurably reduced senescent-cell burden in human tissue — not fisetin. Fisetin's own human longevity data are essentially absent, and its poor oral bioavailability raises real doubt about whether capsules even reach active levels. So the honest scoreboard isn't "which wins" — it's that spermidine has weak-but-real human data with a disappointing trial, while fisetin has strong mouse data and near-zero human longevity data borrowing credibility from a different drug. ## Dosing realities are different too Because the mechanisms differ, so does how each is taken. Spermidine is a **daily** supplement — most human research used concentrated wheat-germ extract standardized to a spermidine content, taken continuously, on the logic that you're nudging an everyday housekeeping process. Fisetin follows the **"hit-and-run"** model borrowed from senolytic research: short, high-dose intermittent courses (often around 20 mg/kg/day for two consecutive days) rather than a daily pill, on the logic that clearing zombie cells once buys time before they re-accumulate. Those research doses are far higher than a typical off-the-shelf capsule, and whether standard products hit senolytic concentrations in people is unknown. Both are sold as dietary supplements, not approved drugs — no required efficacy proof, no approved indication, manufacturer-controlled labels. Spermidine's safety at studied doses looks reasonable (it's a molecule you eat daily); fisetin's short trial courses appeared tolerable, but long-term high-dose intermittent self-use isn't validated for safety. "Tolerable in a small study" is not "proven safe for years of self-directed use" for either. ## So who might consider which? Because the mechanisms don't overlap, this isn't a coin flip between two interchangeable pills. If you're drawn to the molecule with the most coherent everyday mechanism and an actual human population signal — and you can accept that its best trial was null — spermidine is the more conservative, better-characterized-in-humans choice. If you're specifically interested in the senolytic *idea* and are comfortable acting on strong mouse data while human longevity evidence for fisetin itself remains near-zero, fisetin is the experimental bet. Quercetin, fisetin's senolytic neighbor, has the same borrowed-credibility problem and is covered in [quercetin for longevity](/quercetin-for-longevity). Neither is a proven anti-aging intervention, and nothing here is medical advice — both warrant a conversation with your clinician, especially alongside other medications. For how we weigh evidence across every option and provider, see [how we grade longevity providers](/how-we-grade-longevity-providers), and explore our [longevity tools](/tools) to think through your own situation. ## The bottom line Spermidine and fisetin are easy to lump together and shouldn't be. Spermidine works through autophagy, is taken daily, carries a real human mortality association, and has a negative flagship trial — weak-but-honest human evidence. Fisetin works as a senolytic, is taken intermittently, has standout mouse data, and has near-zero human longevity evidence, with the encouraging human senolytic results actually belonging to a different drug combination. Different jobs, different evidence grades, not really either/or. If you take either, take it knowing the mechanism is legitimate and the human longevity payoff is unproven — for both. Sources: https://pubmed.ncbi.nlm.nih.gov/29371440/, https://pubmed.ncbi.nlm.nih.gov/28273655/, https://pubmed.ncbi.nlm.nih.gov/36599349/, https://pubmed.ncbi.nlm.nih.gov/35616942/, https://pubmed.ncbi.nlm.nih.gov/30279143/, https://pubmed.ncbi.nlm.nih.gov/31542391/ --- ### Function Health vs InsideTracker: Which Lab-Test Membership Wins? Canonical: https://longevitygraded.com/function-health-vs-insidetracker Updated: 2026-06-23 Function casts a wide 100+ marker net; InsideTracker pairs fewer markers with an algorithm. We grade breadth, actionability, price — and who each fits. ## The one-sentence version These two memberships sell opposite philosophies of the same underlying product. Function Health is a **wide net** — a flat-priced annual panel of 100+ biomarkers, physician-reviewed, that surfaces a lot and tells you to take it to your doctor. InsideTracker is a **narrow funnel** — smaller panels plus a one-time DNA layer, an algorithmic "InnerAge" number, and a recommendation engine that turns your results into a to-do list. Neither treats you, both share the same cheap outcome-validated core, and the right pick comes down to a single question: do you want *more numbers and the freedom to act on them yourself*, or *fewer numbers wrapped in an algorithm that pushes specific actions back at you*? We grade them below on breadth, actionability, the evidence behind the recommendations, and price. For the full single-service write-ups, see our [Function Health review](/function-health-review) and [InsideTracker review](/insidetracker-review). ## How we score a head-to-head We hold both services to the same bar we apply everywhere, laid out in [how we grade longevity providers](/how-we-grade-longevity-providers): does a feature change an outcome that matters, and is there evidence it does? That keeps us from rewarding the thing each company most wants you to pay for — a big marker count on one side, a proprietary score and personalized product list on the other. The shared, boring truth is that a handful of cheap markers carry almost all the legitimate value on either platform, and the distinctive features are where the price premiums and the cautions live. ## Biomarker breadth: Function wins the count, but the count is mostly framing On raw breadth Function is the clear winner — a 100+ baseline panel plus a mid-year retest dwarfs InsideTracker's tiers, which top out around a 43-marker "Ultimate" plan. If your instinct is "more data is better," Function looks like the obvious buy. The catch is that breadth and value are not the same axis. On *both* platforms, the markers that actually carry hard-outcome evidence are a short list: a cardiovascular particle count, an inflammation marker, a long-term glucose measure, and a few treatable deficiencies. Function's extra 60-odd line items are largely ordinary bloodwork plus a correlated tail that tracks the cheap core without adding much independent signal — and a couple of its featured markers actively mislead as targets, which we cover in the breadth section below. So Function wins "most markers" decisively while winning "most *useful* markers" only modestly. InsideTracker tests fewer things but isn't meaningfully shorter on the markers that matter. ## Actionability: this is InsideTracker's whole pitch — and its biggest conflict Here the services genuinely diverge. Function hands you a flagged dashboard and stops; the work of interpreting and acting falls entirely to you and your clinician. InsideTracker instead converts your results into specific nutrition, exercise, and supplement recommendations, and frames a subset of markers as an "InnerAge" you're meant to lower. For a buyer who wants to be *told what to do*, that is a real, tangible difference in experience. But actionability cuts both ways, and our grade has to weigh the quality of the actions, not just their presence. The InnerAge score is a proprietary composite of your blood markers — not a validated epigenetic clock, and not something proven to extend life when you push it down. And the recommendation engine carries a built-in conflict: the supplement nudges flow from a company that benefits when you act on them. Function's silence is less satisfying but also less conflicted; InsideTracker's guidance is more useful when it's steering you toward diet and exercise, and more suspect when it's steering you toward a bottle. The honest read: InsideTracker is more *actionable*, but a meaningful share of those actions aren't outcome-backed. ## Evidence behind the recommendations: the shared core is solid, the distinctive bits are weaker Strip away the framing and the evidence picture is nearly identical at the core. Both surface the markers a standard physical skips and that carry genuine hard-outcome data — ApoB, which counts every atherogenic particle and beats LDL-C as a predictor when the two disagree; hs-CRP, which predicted first cardiovascular events at least as well as LDL cholesterol in a large prospective study; and HbA1c, which tracked all-cause and cardiovascular mortality continuously across its range. That core is real on either platform, and it's cheap. The divergence is in the distinctive layers. Function's "100+" framing leans on markers that mislead as targets — IGF-1 has a U-shaped mortality relationship in meta-analysis, so "raise it to feel younger" is biologically naïve, and homocysteine looks treatable until you notice that lowering it with B vitamins failed to cut cardiovascular events in randomized trials. InsideTracker features the same misleading markers and adds a recommendation engine that can pair them with a supplement suggestion. And it's worth saying plainly that the two largest longevity levers in all of epidemiology — cardiorespiratory fitness, among the strongest survival predictors ever measured, and grip strength, which outpredicted blood pressure across 17 countries in the PURE study — sit on neither dashboard. No membership captures them. ## Price: different shapes, same lesson Function's pricing is its cleanest advantage: a flat annual fee (positioned around $499, current market info) for the broad panel and retest, easy to reason about. InsideTracker prices per marker at a premium and stacks retests across annual plans, so you pay *more for fewer markers* — the money buys the DNA integration and the recommendation layer, not a longer list. If your only goal is getting the cheap outcome-validated core in front of a clinician, Function delivers more raw testing per dollar, and a focused broad panel can undercut both. We map the price-versus-padding trade across the field in [the best longevity blood tests](/best-longevity-blood-tests). ## The verdict: who each one is for Neither service "wins" outright because they're solving for different buyers, and both share the category's defining limit — they test, they don't treat. **Pick Function** if you're health-literate, want maximum marker breadth at a predictable flat price, and already have a clinician who will act on an abnormal ApoB or HbA1c. You're buying convenience and coverage, and you're comfortable doing the interpretation yourself. **Pick InsideTracker** if you specifically value DNA-informed guidance and want the platform to translate results into steps — and you can keep the supplement nudges at arm's length and treat InnerAge as motivation, not a verdict on how fast you're aging. **Pick neither** if your real goal is just the cheap actionable core (ApoB, Lp(a) once, hs-CRP, HbA1c) at the lowest price — a focused panel taken to a clinician beats both, and our [tools](/tools) help you estimate what those markers mean before you spend. For the other most-searched matchup against Function's closest price rival, see [Function Health vs Superpower](/function-health-vs-superpower). ## Bottom line Function out-tests InsideTracker on breadth and price clarity; InsideTracker out-guides Function on actionability. But the breadth is mostly framing, the guidance is partly conflicted, and the legitimate value — a short list of cheap, outcome-validated markers — is essentially the same on both. Choose Function for coverage and a flat price you'll interpret yourself; choose InsideTracker for hand-holding you'll have to second-guess. Choose neither if you just want the actionable core cheaply, because that's a focused panel and a clinician, not a subscription. Sources: https://pubmed.ncbi.nlm.nih.gov/36216435/, https://pubmed.ncbi.nlm.nih.gov/12432042/, https://pubmed.ncbi.nlm.nih.gov/11141143/, https://pubmed.ncbi.nlm.nih.gov/21795450/, https://pubmed.ncbi.nlm.nih.gov/16531613/, https://pubmed.ncbi.nlm.nih.gov/30646252/, https://pubmed.ncbi.nlm.nih.gov/25982160/ --- ### Glycine vs GlyNAC: Is Adding NAC Worth It for Longevity? Canonical: https://longevitygraded.com/glycine-vs-glynac Updated: 2026-06-23 GlyNAC adds N-acetylcysteine to glycine for glutathione restoration. Is the extra ingredient worth it for longevity? An honest, graded comparison. If you've shopped for either glycine or GlyNAC, you've run into the same question: GlyNAC is just glycine with N-acetylcysteine added, so is the second ingredient actually pulling its weight — or are you paying extra for marketing? This page compares the two head-to-head: what NAC adds biochemically, how the human evidence differs, and what each one honestly earns. For the wider map of what's proven versus hyped, start with our [best longevity supplements, rated by evidence](/best-longevity-supplements) roundup. We cover each compound in depth separately in [glycine for longevity](/glycine-for-longevity) and [GlyNAC for aging](/glynac-for-longevity). ## What they share — and what NAC adds **GlyNAC** stands for **Gly**cine + **N**-**A**cetyl**C**ysteine, so glycine is literally half the formula. The reason the second ingredient exists is biochemical: your cells' master antioxidant, **glutathione**, is a tripeptide built from three amino acids — glycine, cysteine, and glutamate. Glycine and cysteine are the two that tend to run short with age, and N-acetylcysteine is a well-absorbed cysteine donor. The whole GlyNAC thesis, from Rajagopal Sekhar's group at Baylor, is that supplying *both* limiting precursors restores glutathione synthesis in a way that supplying one alone cannot. That distinction matters because glycine's own headline 'glutathione' result actually used both precursors too: an early study correcting glutathione deficiency in older adults raised synthesis using cysteine *and* glycine together, not glycine alone. So on the specific job of rebuilding glutathione, the honest read is that the cysteine donor is doing real work — glycine by itself is the cheaper, narrower half. ## How the human evidence differs This is where the two genuinely diverge. **Glycine alone** has a rigorous *animal* lifespan signal — it extended lifespan in both male and female mice in the NIA's Interventions Testing Program, a multi-site program built to filter out false positives — and worm data showing it promotes longevity in a methionine-cycle-dependent way. But its *human* trials are narrow and not about aging: the best-characterized effect is on sleep, where about 3 g before bed improved subjective sleep quality in small controlled studies, and a 2024 systematic review found only small, heterogeneous effects across metabolic and vascular systems with no longevity outcome tested. **GlyNAC**, by contrast, is where the dramatic *human* numbers live. A randomized controlled trial in older adults reported that 24 weeks of GlyNAC improved a remarkably broad panel — glutathione, oxidative stress, mitochondrial function, inflammation, physical function, and several aging hallmarks. Earlier pilot and randomized work from the same group described the same cluster of improvements, and the program also reported a lifespan extension in mice. So the trade is real: glycine alone owns the rigorous mouse-lifespan checkmark, while GlyNAC owns the only striking *human* biomarker data — but they're testing different things. ## The caveat that applies mostly to GlyNAC Before crowning GlyNAC the winner, read its limits honestly. The human GlyNAC trials are **small and single-group**: the randomized controlled trial enrolled only a few dozen people, and essentially the entire human GlyNAC longevity literature comes from one research group at one institution. The endpoints are **biomarkers over weeks to months, not lifespan** — 'improved a panel of aging markers in a 24-week trial' is a very different claim from 'extends human life,' and only the first has been tested. The lifespan result is in mice, and rodent lifespan extensions translate to humans far less often than headlines imply. Independent, large-scale replication simply hasn't happened yet. Glycine's gap is the mirror image: its *lifespan* evidence is strong but non-human, and its human data don't touch aging at all. Neither compound has a human longevity trial — that's the shared bottom line. ## Dosing and cost Practically, glycine is the simpler and cheaper buy. Human glycine trials commonly used 3–15 g/day, with the sleep work clustering around 3 g before bed; it's a bulk amino-acid powder, abundant in collagen and gelatin, and costs very little. GlyNAC adds NAC on top, so you're buying two ingredients — modestly more expensive, though both glycine and N-acetylcysteine are inexpensive, well-characterized compounds with long safety records, and the trials reported GlyNAC as generally well tolerated at the studied doses. So cost isn't a strong reason to avoid GlyNAC; the real question is whether the added human-biomarker evidence is worth the extra ingredient to you. ## The grade ## The bottom line Is adding NAC worth it? For the specific goal of *restoring glutathione*, biochemically yes — glutathione synthesis needs a cysteine donor, and the cleanest human glutathione data used both precursors, not glycine alone. GlyNAC is also the only one of the two with striking human aging-marker data, even if those data are small, single-group, surrogate-endpoint, and unreplicated. Glycine alone is cheaper and carries the more rigorous *lifespan* evidence — but that's in mice and worms, and its human trials are about sleep, not aging. If you want the better-evidenced glutathione story and don't mind paying for two ingredients, GlyNAC edges it; if you mainly want a cheap amino acid for sleep or general glutathione support, solo glycine is the value pick. Neither is a proven anti-aging intervention in humans. For how we weigh mechanism against outcomes, see [how we grade longevity providers](/how-we-grade-longevity-providers), and try the calculators in our [tools](/tools) hub before you buy. Sources: https://pubmed.ncbi.nlm.nih.gov/30916479/, https://pubmed.ncbi.nlm.nih.gov/30845140/, https://pubmed.ncbi.nlm.nih.gov/37851316/, https://pubmed.ncbi.nlm.nih.gov/22293292/, https://pubmed.ncbi.nlm.nih.gov/21795440/, https://pubmed.ncbi.nlm.nih.gov/35975308/, https://pubmed.ncbi.nlm.nih.gov/24081740/, https://pubmed.ncbi.nlm.nih.gov/36599349/, https://pubmed.ncbi.nlm.nih.gov/33783984/, https://pubmed.ncbi.nlm.nih.gov/35268089/ --- ### Acarbose for Longevity: The Strongest Mouse Drug You've Never Heard Of Canonical: https://longevitygraded.com/acarbose-for-longevity Updated: 2026-07-04 Acarbose robustly extended mouse lifespan in the NIA's rigorous ITP — better replicated than most longevity drugs. But there are zero human longevity trials. ## The one-sentence version Acarbose is a cheap, decades-old diabetes drug that produced one of the most reproducible lifespan-extension results in the entire mouse-longevity literature — replicated across sites, dose-dependent, and strongest in males — yet there is not a single randomized trial testing whether it slows aging in humans. It is the mirror image of a hyped supplement: unglamorous, under-marketed, and better-evidenced in animals than almost anything sold to you online. This page grades what that animal signal is worth. For where drugs like this sit in the wider toolkit, start with our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What acarbose actually is Acarbose is an alpha-glucosidase inhibitor, approved for type 2 diabetes since the 1990s. It works in the gut, not the bloodstream: it blocks the enzymes that break dietary starches into absorbable glucose, so carbohydrate digestion is slowed and the post-meal blood-sugar spike is blunted. Because most of the drug stays in the intestine, its systemic exposure is low, and its main side effects are digestive — gas, bloating, loose stools — from carbohydrate reaching the colon. It is FDA-approved for glucose control in diabetes, **not for aging**, and using it to slow aging in a non-diabetic person is off-label. That mundane, gut-restricted mechanism is exactly why acarbose is interesting to gerontologists. Blunting glucose spikes mimics part of what caloric restriction does metabolically, and it does so through a drug already taken safely by millions. ## The evidence that matters: the ITP Most "longevity" molecules ride on a single lab's mouse study. Acarbose is different, and the difference is the reason to take it seriously. Its lifespan data come from the **Interventions Testing Program (ITP)** — a National Institute on Aging program specifically designed to fix the reproducibility problem in aging research. The ITP runs the same experiment simultaneously at three independent sites (Jackson Laboratory, the University of Michigan, and UT Health San Antonio), in genetically heterogeneous mice, with pre-registered protocols. If something extends lifespan across all three sites, it is about as close to a robust finding as mouse biology gets. The ITP is the same program that put rapamycin on the map. In 2014, the ITP reported that acarbose extended lifespan — and the effect was **sex-skewed**: median lifespan rose about 22% in males and about 5% in females, with maximum lifespan increased in both. That paper tested three compounds at once (acarbose, 17-alpha-estradiol, and nordihydroguaiaretic acid), and acarbose was the standout. ## It got better when they dug in A one-off result, even a multi-site one, could still be a fluke of dose or timing. So the ITP went back. In 2019, a follow-up tested **higher doses** and **later starting ages**. The result strengthened the case rather than weakening it: the lifespan benefit was **dose-dependent** (more acarbose, more extension), it still worked when started in **already-old mice**, and the males-respond-more pattern held. Dose-dependence and late-life efficacy are exactly the features you want before believing an effect is real and mechanistic rather than accidental. Very few candidate longevity interventions clear that bar. So on the animal evidence alone, acarbose is genuinely near the top of the field — arguably better replicated than metformin, whose mouse lifespan data are inconsistent. That is not a claim we make lightly, and it is worth sitting with: an ignored generic outperformed the famous ones in the most rigorous test we have. ## The catch: it's still mice Here is where the graded honesty has to kick in, because the marketing-free nature of acarbose does not exempt it from the rule that governs this entire site: **mouse lifespan extensions translate to humans far less often than headlines imply.** The ITP is the gold standard *for mice*. It is not evidence about people. Loss of proteostasis, deregulated nutrient sensing, and mitochondrial dysfunction sit among the formally cataloged hallmarks of aging, and blunting glucose excursions plausibly touches nutrient-sensing biology — but "plausibly touches a hallmark in mice" is a hypothesis about humans, not a result in them. And there is a specific reason for caution with acarbose: its mechanism is partly **microbiome-mediated**. Slowing carbohydrate absorption changes what reaches the colon and shifts gut bacteria and their short-chain fatty acid output. Mouse chow is starch-heavy in a way human diets vary enormously from, so the size — even the direction — of any metabolic effect could differ between a lab mouse and a person eating a modern mixed diet. ## What acarbose does in humans Acarbose has a real, decades-long human evidence base — just not for longevity. In people with diabetes or impaired glucose tolerance, it reliably lowers post-meal glucose and HbA1c; that is why it is approved. The most interesting human outcome data come from the **STOP-NIDDM trial**, a randomized, placebo-controlled study in people with impaired glucose tolerance, which reported that acarbose was associated with a reduced risk of cardiovascular events and new hypertension. That is a genuine, controlled, hard-ish endpoint — but it is cardiovascular risk in a pre-diabetic population, not a demonstration that acarbose slows aging or extends life in healthy people. (A later large trial in Chinese patients with coronary disease and IGT, ACE, did not replicate the cardiovascular benefit, which is a further reason to stay measured.) So the human story is: proven for glucose, suggestive for cardiovascular risk in glucose-intolerant people, and **silent on lifespan**. No one has run — and no one is currently running — a randomized trial that could tell you whether acarbose extends human healthspan. ## Safety and the practical reality Acarbose's safety profile is well characterized from decades of diabetic use: the dominant issue is gastrointestinal (flatulence, bloating, diarrhea), which is dose-related and often eases over weeks but drives many people to quit. It rarely causes low blood sugar on its own because it doesn't force insulin release. Taken with other glucose-lowering drugs, hypoglycemia becomes possible, and that must be treated with glucose (not table sugar, which acarbose blocks). It is a prescription drug, so the honest framing is not "buy this" — it's that acarbose's *safety at diabetic doses* is reasonably understood, while its *efficacy for longevity in humans* is entirely unproven. ## The grade ## The bottom line Acarbose is the cleanest example on this site of a hard truth cutting both ways. Usually we're deflating a molecule whose marketing outran its evidence. Here, the evidence quietly *outran* the marketing: in the most rigorous mouse platform we have, acarbose delivered a robust, dose-dependent, replicated, late-life-effective lifespan extension — a better animal résumé than most household-name interventions. And it still isn't proof of anything in humans, because a gold-standard mouse result and a human outcome are different claims, and acarbose's gut-and-microbiome mechanism is exactly the kind that may not carry across species and diets. If you find acarbose more convincing than the average supplement, you're right to — but "more convincing in mice" is where the honesty has to stop. Compare its case to the two drugs it out-replicated in the ITP: [metformin for longevity](/metformin-for-longevity), whose human case is observational, and [rapamycin for longevity](/rapamycin-for-longevity), the ITP's flagship — and see how all three stack up head-to-head in [rapamycin vs metformin: the evidence](/rapamycin-metformin-evidence). Sources: https://pubmed.ncbi.nlm.nih.gov/19587680/, https://pubmed.ncbi.nlm.nih.gov/24245565/, https://pubmed.ncbi.nlm.nih.gov/30688027/, https://pubmed.ncbi.nlm.nih.gov/36599349/, https://pubmed.ncbi.nlm.nih.gov/12876091/ --- ### Intermittent Fasting for Longevity: What the Human Trials Actually Show Canonical: https://longevitygraded.com/intermittent-fasting-for-longevity Updated: 2026-07-04 Time-restricted eating and 5:2 have strong animal data — but human trials show the benefit is mostly about eating less, not the clock. No lifespan proof. ## The one-sentence version Intermittent fasting has compelling animal biology, a decent human safety record, and a stubborn problem at its core: in controlled human trials, most of its benefit turns out to be ordinary weight loss from eating less — not a special metabolic magic from *when* you eat. It is a reasonable, sustainable way for some people to cut calories. It is not a proven anti-aging intervention in humans. This page separates the mechanism from the outcome, honestly. For where diet fits in the wider toolkit, start with our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What "intermittent fasting" actually means "Intermittent fasting" is an umbrella term for eating patterns defined by *timing* rather than food content. The common variants are: **time-restricted eating (TRE)**, confining all food to a daily window (often 8–10 hours); **alternate-day fasting (ADF)**; the **5:2 diet**, with two very-low-calorie days a week; and periodic **fasting-mimicking diets** run a few days a month (which we cover separately in our [ProLon fasting-mimicking diet review](/fasting-mimicking-diet-prolon)). They share a premise: that extending the daily or weekly fasting interval triggers beneficial cellular states — lower insulin, a metabolic switch toward fat and ketone use, and activation of cellular clean-up (autophagy) — that go beyond calorie reduction alone. ## The mechanism: genuinely interesting, mostly preclinical The scientific case for fasting is real and rooted in solid biology. During a prolonged fast, insulin falls, the body shifts to burning fat and producing ketones, and nutrient-sensing pathways (like mTOR) quiet down while stress-resistance and autophagy pathways ramp up. Deregulated nutrient sensing and loss of proteostasis are cataloged among the formal hallmarks of aging, and fasting plausibly nudges several of them in a favorable direction. A widely cited NEJM review by de Cabo and Mattson laid out this "metabolic switching" framework and the animal evidence behind it in detail. In rodents, caloric restriction is one of the most reliable lifespan-extending interventions known, and some fasting schedules reproduce parts of that benefit. But — and this is the recurring lesson of this site — impressive mechanism plus impressive mouse data is a hypothesis about humans, not a result in them. The question is what happens when you actually run the human trials. The answer is more sobering than the biology suggests. ## The human trials: the benefit is mostly eating less Here is the finding the marketing skips. When TRE is tested in controlled human trials, its effects on weight and metabolism are **modest, and largely explained by reduced calorie intake** rather than the eating window itself. The clearest example is the **TREAT trial** — a randomized, controlled study that compared 16:8 time-restricted eating against consistent meal timing. TRE produced only small weight loss, no better than the control pattern, and — notably — a meaningful fraction of the weight lost was **lean mass**, a genuine concern for older adults trying to preserve muscle. A daily window did not deliver a special metabolic advantage; it mostly nudged people to eat somewhat less. More recent, better-designed RCTs refine rather than overturn this. A 2024 randomized trial of TRE in adults with metabolic syndrome (on top of standard care) found genuine but **incremental** improvements in glucose regulation — a real signal, in a high-risk group, layered on medication and lifestyle, not a standalone anti-aging effect. And a single-arm study of 10-hour TRE in metabolic-syndrome patients reported lower weight, blood pressure, and atherogenic lipids — encouraging, but uncontrolled and therefore weak evidence for causation. ## What about actual caloric restriction? If fasting's benefit is mostly "you ate less," the honest comparison is to deliberate calorie restriction — where the human data are stronger *for biomarkers*. The **CALERIE trial** randomized healthy, non-obese adults to about 2 years of sustained ~15% calorie restriction, and reported improvements in cardiometabolic risk markers and other aging-related measures. That is the most rigorous human evidence that eating less improves the *markers* we associate with healthy aging. But note two things: CALERIE tested *calorie restriction*, not meal-timing, and it measured **biomarkers and risk factors — not lifespan or hard disease outcomes.** No human trial has shown that any fasting or calorie-restriction protocol extends human lifespan, because such a trial is nearly impossible to run. That is the crux for longevity specifically: we have good human evidence that eating less improves aging-related biomarkers, weaker evidence that fasting timing adds anything on top, and **zero human evidence** that either extends how long you live. ## The practical reality: adherence is the whole game Where intermittent fasting earns its keep is behavioral, not mechanistic. For some people, "don't eat after 7 pm" is a far easier rule to follow than "count every calorie," and the easiest sustainable calorie deficit is the one that actually works. Reviews consistently find that IF and continuous calorie restriction produce **similar** weight and metabolic results over time — so the best pattern is whichever one you'll stick to. That is a real, useful conclusion; it's just a much smaller claim than "fasting slows aging." The flip side is the risks the enthusiasts undersell: **muscle loss** (seen in TREAT) matters enormously for longevity, since preserving lean mass and strength is one of the better-supported goals in the whole field. Compressing eating windows can also make it harder to hit protein targets. Fasting is not appropriate for people with a history of eating disorders, and those on glucose-lowering or blood-pressure medication need medical supervision. ## The grade ## The bottom line Intermittent fasting is a legitimate, generally safe tool with a real behavioral advantage — and a longevity story that runs well ahead of its human evidence. The animal biology is genuinely interesting; the metabolic-switching mechanism is real; and controlled human trials keep landing on the same unglamorous conclusion: most of the benefit is from eating less, the eating window adds little on its own, and there is no human data showing any fasting pattern extends lifespan. If a fasting schedule helps you sustain a modest calorie deficit and protect your muscle while doing it, that's a good reason to use one. Just don't confuse an easier way to eat less with a proven way to age slower. For the intervention with the strongest human biomarker data behind "eat less," the comparison is deliberate calorie restriction; for a related but distinct periodic protocol, see our [ProLon fasting-mimicking diet review](/fasting-mimicking-diet-prolon); and for the drugs that try to mimic these metabolic states pharmacologically, see [metformin for longevity](/metformin-for-longevity) and [acarbose for longevity](/acarbose-for-longevity). Sources: https://pubmed.ncbi.nlm.nih.gov/31881139/, https://pubmed.ncbi.nlm.nih.gov/32986097/, https://pubmed.ncbi.nlm.nih.gov/31813824/, https://pubmed.ncbi.nlm.nih.gov/36599349/, https://pubmed.ncbi.nlm.nih.gov/39348690/, https://pubmed.ncbi.nlm.nih.gov/31303390/ --- ### Berberine for Longevity: Nature's Metformin, or Marketing? Canonical: https://longevitygraded.com/berberine-for-longevity Updated: 2026-07-26 Berberine activates AMPK like metformin and lowers glucose and lipids in humans — but its longevity evidence is animal-only. An honest look at the hype. ## The one-sentence version Berberine is a plant alkaloid with a genuinely interesting metabolic mechanism, real short-term human data for blood sugar and cholesterol, and **zero evidence that it extends healthy lifespan in people** — the "nature's Ozempic" and "nature's metformin" nicknames are marketing that runs well ahead of the proof. This page separates what berberine is shown to do in humans (move some metabolic markers) from what it is *claimed* to do (slow aging), and flags the two things the supplement aisle skips: the evidence for longevity is entirely in animals, and berberine is barely absorbed when you swallow it. For where it sits in the wider toolkit, see our pillar on [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What berberine actually is Berberine is a bright-yellow isoquinoline alkaloid found in plants like goldenseal, barberry, and *Coptis chinensis*, used for centuries in traditional Chinese and Ayurvedic medicine. In the United States it is sold as a **dietary supplement, not a drug** — it is not FDA-approved to treat or prevent any disease, manufacturing quality varies between brands, and its label claims are largely unpoliced. That regulatory status matters for everything below: unlike metformin, the prescription drug it is constantly compared to, berberine has no approved indication, no standardized dose, and no manufacturer accountable for what's in the capsule. ## The mechanism: a real AMPK story The reason berberine gets taken seriously at all is its mechanism. Like metformin, berberine activates **AMPK** — AMP-activated protein kinase, the cell's energy sensor. The foundational study showed berberine activates AMPK and produces beneficial metabolic effects in diabetic and insulin-resistant models. Downstream, animal work found it improves glucose metabolism largely by **inhibiting hepatic gluconeogenesis** — reducing the liver's glucose output — in diabetic rats, and cell studies describe it promoting glucose uptake and suppressing gluconeogenesis through the deacetylase SIRT3. AMPK signaling and nutrient sensing sit close to the recognized biology of aging, which is where the longevity hypothesis is born. That is the same logical move made for metformin — and it deserves the same skepticism. A shared mechanism with a drug that *itself* has no proven human-longevity benefit is a reason to investigate, not a reason to believe. Mechanism tells you why something *might* work; only an outcome trial tells you whether it does. We hold [metformin for longevity](/metformin-for-longevity) to exactly this standard, and berberine gets no free pass for being a plant. ## What the human evidence actually shows Here berberine is stronger than most supplements — but only on **metabolic surrogates in people with metabolic disease**, over short trials. **Blood sugar.** The most-cited human study randomized adults with type 2 diabetes and found berberine lowered fasting and post-meal glucose and HbA1c to a degree **comparable to metformin** over three months. A later systematic review and meta-analysis concluded berberine produces a statistically significant reduction in blood glucose in type 2 diabetes. That is a real signal — but note the population: people *with* diabetes, treated for weeks to months, measured on glucose, not on how long or how well they lived. **Cholesterol.** A systematic review and meta-analysis found berberine reduced total and LDL cholesterol and triglycerides across randomized trials. Its lipid effect appears to run through a different pathway than statins, which is part of why it's marketed as a "natural" lipid-lowerer. **Weight — the "nature's Ozempic" claim.** This is where the marketing is most inflated. A meta-analysis of berberine's effect on obesity parameters found **modest** reductions in body weight, BMI, and waist circumference, alongside some improvement in the inflammatory marker CRP (it found no significant effect on liver enzymes). "Modest" is the operative word: this is a small effect in short trials, nothing like the double-digit weight loss produced by GLP-1 drugs. Calling berberine "nature's Ozempic" is a category error — the two work by different mechanisms and are not in the same efficacy league, as we lay out in [GLP-1s for healthspan & longevity](/glp1-for-longevity). If anything, berberine's mechanism and metabolic profile make it a rough botanical echo of metformin — or of the carb-blocker [acarbose](/acarbose-for-longevity) — not of a GLP-1. If you are weighing the supplement against the drug it is nicknamed after, price both: the compounded version runs [$297 a month for semaglutide with the clinician review inside the figure](/direct-meds-review) at one operator we grade, and [from $99 a month as a published floor](/yourera-review) at another — very different bills for a molecule with very different evidence behind it. ## The longevity leap: entirely animal, so far Now the honest core of it. Does berberine extend lifespan? **In animals and simpler organisms, there are signals. In humans, there is nothing.** The most relevant preclinical finding is a study reporting that berberine ameliorated cellular senescence — the accumulation of "zombie" cells that is a [hallmark of aging](/hallmarks-of-aging-explained) — and **extended the lifespan of mice**, tied to changes in p16 and cyclin proteins. A 2025 study found berberine extended lifespan in the roundworm *C. elegans* through multi-target antioxidant effects. These are genuinely interesting results that place berberine among compounds worth studying. But they are a **mouse** result and a **worm** result. Most compounds that extend rodent or invertebrate lifespan do nothing measurable for human aging, and dosing rarely translates. There is no completed randomized trial — none — showing berberine extends healthy lifespan, slows biological aging, or improves any hard longevity outcome in people. Every human trial to date measures a short-term metabolic marker. So the accurate statement is: berberine has a plausible geroprotective *mechanism* and animal lifespan data, and its human evidence stops at glucose and lipids. Anyone selling it as an anti-aging pill is extrapolating across two species and several rungs of the evidence ladder. ## The absorption problem nobody mentions Even the metabolic effects come with an asterisk: berberine is **poorly absorbed**. Pharmacokinetic work in rats attributes its very low plasma levels to extensive intestinal first-pass elimination and heavy hepatic distribution — meaning most of an oral dose never reaches systemic circulation intact. Oral bioavailability is often cited at under 1%. That's part of why effective doses are large (typically ~500 mg, two to three times daily) and why gut side effects are common — a lot of the compound stays in the gut. The supplement industry's answer is **dihydroberberine**, a reduced form marketed as better-absorbed. A randomized crossover study did find dihydroberberine produced higher, more sustained berberine plasma exposure than standard berberine — though in that short study the glycemic outcomes (glucose and insulin) were not significantly changed. That's a real pharmacokinetic advantage — but it buys you better *absorption of a compound whose human longevity benefit still doesn't exist*. A more bioavailable route to an unproven endpoint is not the same as proof. ## Safety and the supplement caveats Berberine is not a benign "natural" freebie. The most common effects are gastrointestinal — cramping, diarrhea, constipation — driven by the poorly-absorbed drug sitting in the gut. More importantly, berberine **inhibits CYP enzymes and interacts with drug metabolism**, so it can raise levels of other medications (a grapefruit-juice-like effect); anyone on prescription drugs — especially other glucose-lowering agents, where berberine could compound hypoglycemia — should treat it as pharmacologically active and talk to a clinician. It should not be used in pregnancy or while breastfeeding (it crosses the placenta and can displace bilirubin). And because it's an unregulated supplement, the dose and purity in any given bottle are not guaranteed. ## Hype vs evidence, side by side | Claim you'll see | Honest status | |---|---| | "Nature's metformin" | Shares the AMPK mechanism and lowered glucose comparably to metformin in *one* short T2D trial — a real parallel, but metformin itself has no proven human-longevity benefit. | | "Nature's Ozempic" | Category error. Weight effect is modest in short trials; not remotely comparable to GLP-1 drugs. | | "Berberine slows aging" | No human data. Lifespan extension is shown only in mice and worms. | | "Lowers blood sugar and cholesterol" | Supported in people *with* metabolic disease, short-term — surrogate markers, not longevity outcomes. | | "Better forms fix everything" | Dihydroberberine is better absorbed, but improves absorption of a compound with no proven longevity endpoint. | ## Bottom line Berberine is one of the more scientifically defensible entries in the longevity-supplement aisle — and that says more about how thin the aisle is than about berberine. It has a real AMPK-based mechanism, short-term human trials showing it lowers glucose and cholesterol in people with metabolic disease, and animal data hinting at lifespan effects. What it does not have is a single human study showing it slows aging or extends healthy life, and it is barely absorbed when swallowed. Treat berberine as a plausible metabolic-support supplement with an interesting geroscience mechanism — not as a proven anti-aging therapy, and certainly not as "nature's Ozempic." For how it stacks up against the rest of the field, see our evidence-graded [best longevity supplements](/best-longevity-supplements), and for the prescription drug it most resembles, [metformin for longevity](/metformin-for-longevity). Honesty over hype: real metabolic effects, unproven for longevity. Sources: https://pubmed.ncbi.nlm.nih.gov/16873688/, https://pubmed.ncbi.nlm.nih.gov/21304897/, https://pubmed.ncbi.nlm.nih.gov/30117113/, https://pubmed.ncbi.nlm.nih.gov/18442638/, https://pubmed.ncbi.nlm.nih.gov/30393248/, https://pubmed.ncbi.nlm.nih.gov/36941490/, https://pubmed.ncbi.nlm.nih.gov/32690176/, https://pubmed.ncbi.nlm.nih.gov/31773901/, https://pubmed.ncbi.nlm.nih.gov/40338239/, https://pubmed.ncbi.nlm.nih.gov/20634337/, https://pubmed.ncbi.nlm.nih.gov/35010998/ --- ### AgelessRx Review: Rapamycin's Price Is Now Published Canonical: https://longevitygraded.com/agelessrx-review Updated: 2026-08-04 AgelessRx runs real trials and charges no membership. Its flagship, rapamycin, now publishes a real monthly price — metformin and NAD+ still don't. ## The one-sentence version AgelessRx is the most research-literate operator in direct-to-consumer longevity — it funded, ran, and published a registered placebo-controlled rapamycin trial that **missed its own primary endpoint**, which is a level of self-disclosure no other row here attempts — and it charges no membership fee, which structurally beats every lab-gated program in our ranking. It grades **A, 12 points out of 14** — one of only a handful of A rows — and it is not a paid partner here. **Update, August 2026:** the gap that used to define this review has closed. Rapamycin, the flagship, now states its price plainly — "$65/month," with "Billed monthly | Shipped monthly" printed directly beneath it — where the site previously gave a floor with no terms attached. Metformin and NAD+ still carry the quarterly-plan and introductory-rate qualifiers described below, so the catalog isn't uniformly clean, but the product that decided this review's grade no longer has the problem it was graded on. For where prescription longevity telehealth sits in the wider market, see [longevity clinics vs lab memberships vs Rx telehealth](/longevity-clinics-vs-lab-memberships). ## What AgelessRx is, and who it's for AgelessRx is an Ann Arbor–based telehealth pharmacy-and-prescriber network built specifically around off-label longevity prescribing. You complete an online intake, a licensed clinician reviews it and decides whether to prescribe, and the prescription is filled by what the site calls a "partnering pharmacy" and shipped to you. There is no membership, no annual fee, and no mandatory diagnostic onboarding — you can buy one treatment and nothing else. The catalog is the widest in our ranking: roughly four dozen line items spanning the longevity core (rapamycin, metformin, acarbose, low-dose naltrexone, NAD+ in four delivery formats, sermorelin, glutathione), a GLP-1 track, hormone and sexual-health products, dermatology, and a testing shelf that runs from a free online phenotypic calculator up to a $949 Galleri multi-cancer screen. Verified on AgelessRx's own treatment pages in July 2026. The buyer this suits is specific: someone who already knows which molecule they want, wants a US-licensed prescriber and a pharmacy rather than a gray-market peptide vendor, and does **not** want to pay $129–$155 a month for a membership wrapper before the first pill ships. That is a real and underserved buyer, and AgelessRx serves them better than any lab-gated program does. ## What it actually costs — and what the headline number leaves out Here is the part that decides the grade, so we will be precise about what is published and what is not. **Metformin is the one product where AgelessRx spells out the terms in full.** Its page reads: "Quarterly — $25 / month — billed $75 quarterly | shipped quarterly — 3-month supply per shipment." That is honest and complete: $25/month is real, but you pay $75 up front, three months at a time. No month-to-month option is offered. **NAD+ injections publish the trap explicitly, in small type.** The headline is "Starting at $79 / mo," and directly beneath it: "Starting price applies to 3-mo plan. Monthly and 3-mo plans." Further down the same page, the disclaimer adds: "Introductory price applies to quarterly plan." So $79 is simultaneously (a) the quarterly-plan rate, not the monthly one, and (b) an introductory rate. As of our August 2026 check, the post-introductory rate is now disclosed too — $149/mo — closing part of the gap, though the monthly-plan (non-quarterly) price is still not stated separately. **Rapamycin — the flagship — now publishes real terms.** As of our August 2026 check, the page states "$65/month" with "Billed monthly | Shipped monthly" printed directly under it — a genuine, computable monthly rate, not a floor with an unstated cadence. That resolves the specific gap earlier versions of this review flagged as AgelessRx's central failure. The rest of the catalog still carries the "Starting at" construction more loosely: low-dose naltrexone $25, acarbose $55, sermorelin injection $99, glutathione injection $99, NAD+ nasal spray $125/mo, NAD+ patches $160/kit, microdosing semaglutide $99/mo, microdosing tirzepatide $159/month. On the testing shelf: a lab-based phenotypic blood test $75, a Core Longevity Panel $95, an at-home methylation saliva test $170. We have not re-verified the billing cadence on every one of these individually — rapamycin, metformin and NAD+ are the three we checked in full. The catalog is not uniformly clean. AgelessRx discloses billing terms on rapamycin and metformin, and it's the two remaining products — NAD+'s introductory rate, and metformin's quarterly-only structure — that keep this row from a perfect price-transparency score, not an unpublished flagship. See [our grading methodology](/how-we-grade-longevity-providers) and, for how the whole market prices itself, [how much a longevity clinic costs](/longevity-clinic-cost). ## What's included, what's extra Genuinely included, and worth crediting: - **The medical visit is free.** No consult fee, no intake deposit. Several providers in our ranking charge one. - **Shipping is free**, quoted at 5–7 business days. - **On rapamycin, the required blood work is included with the prescription.** That matters: a product whose safe use depends on monitoring, sold with the monitoring bundled, is the right structure. - **No membership.** Nothing recurring sits on top of the medication itself. Extra, or conditional: - Testing beyond the rapamycin monitoring is a separate purchase ($75–$949 depending on the panel). - Rapamycin is unavailable in NJ, NY, RI and HI. - Refills are conditional on compliance: "You must adhere to the required lab schedule to receive refills," and failure to comply "may result in your prescription being suspended or canceled." That is a restriction, and it is the right kind. ## Clinical oversight: who prescribes, and what they check AgelessRx names its clinical leadership, which most of this category does not. The site lists a Medical Director (Dr. Jenell Decker, MD), an Assistant Medical Director (Dr. Mirna Jadan, MD), a telehealth physician (Dr. Aaron Stecker, DO), a Medical Advisor (Dr. Terry Grossman, MD), and a VP of Operations and Applied Science with a PhD (Dr. Stefanie Morgan). Naming your prescribers is a meaningful signal in a field full of anonymous "licensed providers." Two caveats a careful reader should hold. First, the Medical Director's listed longevity credential is from the American Academy of Anti-Aging Medicine (A4M) — a professional body, not one of the 24 member boards of the American Board of Medical Specialties, which recognizes no anti-aging or longevity specialty. That is not a knock on the physician; it is a fact about how thin formal credentialing is in this whole field, which we unpack in [what is a longevity doctor](/what-is-a-longevity-doctor). Second, fulfillment is described on the product pages as "a partnering pharmacy" without naming a facility, so you cannot verify which compounder made your vial. The compounding standard *is* stated, but you have to go looking for it: the FAQ says "all our partner pharmacies are certified 503A compounding pharmacies" — a clearer commitment than most providers here make, buried several clicks from where you buy. Worth knowing what that does and does not mean: 503A is a legal category rather than a quality certification, and 503A compounders are specifically not subject to current good manufacturing practice requirements. The oversight that impressed us most is behavioral rather than structural: rapamycin refills are gated on lab compliance. A provider willing to cut off a paying subscriber who skips bloodwork is a provider whose oversight is not decorative. ## The evidence behind what it sells AgelessRx sells a menu of drugs with, collectively, no completed human trial showing extended lifespan. That is not a criticism unique to AgelessRx — it is true of the entire category — but a review has to say it plainly rather than let the catalog imply otherwise. **Rapamycin.** The most reproducible lifespan extender in mice: fed late in life to genetically heterogeneous mice, it extended median and maximal lifespan in a landmark study. In humans, the best evidence is AgelessRx's own PEARL trial — 48 weeks, decentralised, double-blinded, placebo-controlled, 5 mg or 10 mg weekly. It found that intermittent low-dose rapamycin was **relatively safe**, with adverse events similar across groups. It also **missed its primary endpoint**: visceral adiposity did not change. Some secondary signals appeared in subgroups — lean tissue mass and self-reported pain improved in women on 10 mg — and the authors themselves concluded that future work "will aim to more comprehensively establish efficacy". That is a fair and unusually candid readout, and we walk through it in detail in [what the PEARL trial actually showed](/rapamycin-pearl-trial) and [rapamycin for longevity: hype vs evidence](/rapamycin-for-longevity). **Metformin.** The human longevity case rests on a mechanistic argument and one widely-cited observational finding — diabetic patients on metformin monotherapy showing better adjusted survival than matched non-diabetic controls in a UK database analysis — a result the authors themselves framed as a question, and one that confounding by indication can generate without any drug effect. Against it sits a randomized trial in which metformin **blunted** the gains from 12 weeks of aerobic training in older adults: attenuated improvements in whole-body insulin sensitivity and VO₂ max, and abrogated the exercise-driven increase in skeletal-muscle mitochondrial respiration. Since cardiorespiratory fitness is among the strongest survival predictors ever measured, a longevity drug that dulls exercise adaptation deserves more caution than a $25/month price tag conveys. Full treatment in [metformin for longevity](/metformin-for-longevity) and [rapamycin and metformin: the evidence](/rapamycin-metformin-evidence). **NAD+.** Oral nicotinamide riboside reliably raises NAD+ in healthy middle-aged and older adults and is well tolerated — that much is established. What it does *to* you is a much thinner story: the strongest human trial to date improved 6-minute walk distance by about 17.6 meters in people with peripheral artery disease, in 90 participants, with the authors calling for a larger trial to confirm it. That is a disease endpoint in a sick population, not a healthspan outcome in a well one. AgelessRx's NAD+ page nonetheless leads with "89% saw results by 2nd check-in" — an unblinded, self-reported figure from its own customer base, which is the weakest evidence class there is — and states that "Maintaining healthy NAD+ levels may slow down the aging process." Our full read is in [NAD+ for longevity](/nad-for-longevity) and [do NAD+ and peptides actually extend lifespan](/do-nad-peptides-work). **Low-dose naltrexone.** The one item on the menu with a genuine, if narrow, randomized case — a meta-analysis of four RCTs in 222 fibromyalgia patients found a significant reduction in pain scores and higher pressure-pain threshold versus placebo, though the fibromyalgia impact questionnaire and pain catastrophizing scale did not differ. That is modest evidence for a pain indication. It is not evidence for longevity, and nothing about LDN's mechanism makes it one. **Sermorelin.** A growth-hormone secretagogue, and the weakest thing on the menu. A landmark systematic review of growth hormone in healthy older adults found small body-composition changes, no proven functional benefit, and significantly more adverse events. The downstream target, IGF-1, has a **U-shaped** relationship with mortality in meta-analysis — both low and high values associate with higher death rates — so "raise it to feel younger" is not a coherent goal. Detail in [peptides for longevity](/peptides-for-longevity). ## Where it's weak **1. Two of three checked products still price as a floor, not a price.** Metformin's headline is a quarterly prepay; NAD+'s is quarterly and introductory. Rapamycin, the flagship, is the exception now — it publishes a real monthly rate — but until AgelessRx does the same for the rest of the catalog, a buyer still can't build the whole bill from the site alone. **2. Menu breadth is a conflict, not just a convenience.** AgelessRx both recommends and dispenses roughly four dozen products, several of which (sermorelin, NAD+ in four formats, glutathione) have no meaningful human outcome data. A wide catalog run by the same entity that decides what you need is a structural incentive to find you something. That does not make the prescribing wrong — it means the burden of evidence honesty on the marketing copy is higher, not lower. **3. The research operation is a genuine asset and a genuine conflict.** PEARL is AgelessRx-funded and AgelessRx-authored, testing a drug AgelessRx sells. The affiliations are disclosed on the paper, and the trial reported a null primary endpoint, which is about as strong a good-faith signal as an interested party can send. But a vendor's own trial on its own product is still a vendor's own trial, and the same site that publishes it also markets rapamycin as "the most promising longevity therapy today." **4. The pharmacy is classified but not named.** AgelessRx's FAQ states "all our partner pharmacies are certified 503A compounding pharmacies" — a real, published standard, and this site's rubric gives full credit for exactly that claim. What's still missing is a facility name: "partnering pharmacies" tells you the standard, not which pharmacy actually filled your vial. **5. No included human support.** There is no bundled nurse or dietitian contact of the kind a support-included program provides — the offer is prescriber plus pharmacy plus shipping. ## Who should skip it - **Anyone who wants the full annual cost of metformin or NAD+ before committing.** Both still require an intake to get a real number — rapamycin no longer does. - **Anyone shopping on price alone.** A rate that only holds if you prepay a quarter is not comparable to a genuine flat monthly rate, and the two should not be lined up in a spreadsheet as if they were. - **Anyone who wants diagnostics first.** AgelessRx sells tests but is not built around them. If your goal is a broad panel with a clinician reading it, a lab membership does that better and cheaper — see our [best longevity blood test services roundup](/best-longevity-blood-tests) and the [Function Health review](/function-health-review). - **Anyone buying sermorelin as an anti-aging intervention.** The evidence does not support it, at any price. - **Anyone hoping a prescription substitutes for the boring levers.** Cardiorespiratory fitness and grip strength — which outpredicted blood pressure across 17 countries in the PURE study — are not on any AgelessRx order form. ## How it compares to the rest of our ranking Against the **lab-gated memberships**, AgelessRx wins on structure. [Hone Health](/hone-health-review) makes you buy a $65 biomarker test and then a $25 or $155 monthly membership before a prescription exists — but every drug on Hone's site is priced "From $X/mo + membership" with "No commitments. Cancel anytime" stated in plain language, so you can build the whole bill before you enter a card number. AgelessRx removes the membership and the lab gate entirely, and now discloses a real monthly rate on its flagship too — metformin and NAD+ are the two products where you still can't build the full bill from the site alone. Different trade-offs; a buyer should pick which gap they mind less. Against [Lifeforce](/lifeforce-review) — $349 starter plus $129/month for a narrow panel with a prescriber attached — AgelessRx is dramatically cheaper for someone who wants the prescription and not the quarterly retesting cadence, and dramatically thinner for someone who wants the monitoring. Against the concierge tier, it is not a comparison: AgelessRx is a pharmacy with a prescriber, not a diagnostics program. The bands are mapped in [concierge vs membership longevity](/concierge-vs-membership-longevity). Where it stands relative to every graded provider, including the ones we earn nothing from, is on [our longevity provider rankings](/best-longevity-clinics). ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). AgelessRx now takes **the full four for price transparency** — rapamycin, the flagship, publishes a real "$65/month, billed monthly" rate, and while metformin and NAD+ still carry quarterly and introductory qualifiers, the published-terms bar this factor asks is met. Four in full for a genuine longevity line: rapamycin, metformin, NAD+ and sermorelin are a real menu, not a GLP-1 shop with an add-on. Two for a free clinician visit inside every order. Two for the FAQ's unambiguous 503A claim — the single clearest pharmacy-standard statement here, even though no individual facility is named. **Zero on human support** — there's no bundled nurse or dietitian contact of the kind a support-included program offers. **Twelve of fourteen: an A.** That's a real change from where this row used to sit, and it's a change driven entirely by AgelessRx publishing a number it didn't publish before — not by any adjustment to how we score. What still separates a genuinely excellent row from a flawless one: metformin's quarterly-only structure, NAD+'s introductory rate, and a compounding pharmacy that states its standard but never names its facility. ## Bottom line AgelessRx does two things no other row here does at once: it names its prescribers and it publishes trial results that did not go its way. It also removes the two costs that make this category expensive — the membership fee and the mandatory diagnostic onboarding — so a buyer who already knows which molecule they want can get a US-licensed prescriber and a pharmacy without paying a wrapper fee first. Rapamycin now tells you what it costs — "$65/month, billed monthly," no intake required to find out. Metformin and NAD+ still don't: metformin's real terms are a quarterly prepay, and NAD+'s "$79/mo" is a three-month introductory rate. Buy here if you want the widest legitimate longevity menu with real prescriber oversight, no membership, and a flagship product whose price you can verify before you start. Go in clear-eyed that rapamycin's best human trial, run by this company, missed its primary endpoint, and that metformin, NAD+ and sermorelin are being sold well ahead of their human evidence. Our full graded field, and what each provider actually charges, is at [our longevity provider rankings](/best-longevity-clinics). Sources: https://pubmed.ncbi.nlm.nih.gov/40188830/, https://pubmed.ncbi.nlm.nih.gov/19587680/, https://pubmed.ncbi.nlm.nih.gov/32333835/, https://pubmed.ncbi.nlm.nih.gov/25041462/, https://pubmed.ncbi.nlm.nih.gov/30548390/, https://pubmed.ncbi.nlm.nih.gov/30646252/, https://pubmed.ncbi.nlm.nih.gov/29599478/, https://pubmed.ncbi.nlm.nih.gov/38871717/, https://pubmed.ncbi.nlm.nih.gov/39344363/, https://pubmed.ncbi.nlm.nih.gov/17227934/, https://pubmed.ncbi.nlm.nih.gov/21795450/, https://pubmed.ncbi.nlm.nih.gov/25982160/ --- ### Hone Health Review: Is TRT a Longevity Plan? Canonical: https://longevitygraded.com/hone-health-review Updated: 2026-08-04 Hone prices every drug in plain sight and demands no commitment — but it sells hormone therapy as longevity care, which the label and the trials don't support. ## The one-sentence version Hone Health is the most **price-transparent** provider in our ranking and one of the least **evidence-honest**. Every medication it sells carries a published monthly figure, both membership tiers are posted, and the site states plainly: "No commitments. Cancel anytime." There is no hidden quarterly prepay, no introductory rate that expires, no consult-to-learn-pricing wall. It grades **B, 8 points out of 14**, and it is not a paid partner here. That is genuinely rare, and it is worth crediting loudly. What Hone then does with that clarity is file testosterone and hormone replacement under "longevity" — a framing that the FDA-approved testosterone label explicitly declines to support, and that the largest randomized trials of testosterone in middle-aged and older men do not bear out. Buy it for what it is: a well-run, honestly-priced hormone clinic. Do not buy the healthspan story bolted onto the front of it. For the map of what is actually proven in this field, start with [longevity medicine: what's proven vs hyped](/longevity-medicine-evidence). ## What Hone Health is, and who it's for Hone is a telehealth hormone-optimization platform, sold in two tracks — a men's track built around testosterone replacement therapy (TRT; see our [Taurus Meds review](/taurus-meds-review) and [Male Excel review](/male-excel-review) for two TRT-first competitors), and a women's track built around menopause and hormone replacement (see our [Winona review](/winona-review) for a menopause-focused alternative) — with a "longevity" shelf sitting alongside both. Corporately, care is delivered through independent practices: the site states that "Hone-affiliated medical practices are independently owned and operated by licensed physicians who provide services using the Hone telehealth platform," with physician recruitment run through a partnership with Broad Health. The flow is lab-first and gated, in that order: 1. **Buy the biomarker test — $65.** Hone describes it as "in-depth, 50-biomarker blood testing" plus health history and validated questionnaires. You either go to a partner lab or, where available, Hone sends a phlebotomist to you at no extra charge. 2. **Take a telehealth consult with a licensed physician**, included in that $65. 3. **Pick a membership**, then buy medication on top of it. Nothing is prescribed before the labs exist. That gate is a genuine strength and the opposite of a rubber-stamp questionnaire — a distinction our [grading methodology](/how-we-grade-longevity-providers) weights at 25%. ## What it actually costs — and the tier that isn't the tier **Entry: $65** for the 50-biomarker panel plus the physician consult and a plan. Hone calls this "100% risk-free." **Basic membership: $25/month, "plus cost of medication."** What that buys, in Hone's own words: key biomarkers re-tested every 6 months, "the ability to purchase telehealth consults with expert licensed physicians," and "members-only pricing on BASIC medications & supplements." Read that middle clause again. On the $25 tier, **physician consults are not included — they are a separate purchase, and Hone does not publish what one costs.** That is the single gap in an otherwise exemplary pricing page, and it matters, because a hormone protocol without follow-up consultation is not a protocol. **Premium membership: $155/month, "plus cost of medication."** This includes the consults, the personalized protocol (testosterone, estrogen, weight loss), and "retesting + follow-ups every 90 days." Hone's own page labels this tier "Chosen by 95% of patients." That last line is the honest headline. If 95% of buyers land on Premium, the real price of Hone is **$155/month**, not $25 — and a review that quotes the $25 figure as the price of entry is quoting a tier Hone itself says 95% of members do not use. To Hone's credit, it publishes the 95% figure itself rather than hiding behind the cheap tier. **Medication is billed separately, and every drug is priced.** On the men's TRT page: testosterone injections from $28/mo, testosterone cream from $60/mo, troches from $60/mo, clomiphene citrate from $38/mo, enclomiphene from $42/mo, anastrozole $22/mo — each stated as "+ membership." On the women's menopause page: estradiol patch $58/mo, bi-est cream $80/mo, progesterone $49/mo, progesterone cream $79/mo, Estrace estradiol cream $40/mo, Vagifem $65/mo, DHEA cream $56/mo, estriol vaginal cream $58/mo. On the longevity shelf: NAD+ $165/mo, glutathione $90/mo, vitamin B12 $60/mo, low-dose naltrexone $38/mo, metformin $25/mo, omega-3-acid ethyl esters $20/mo. **So the real all-in number, for the typical buyer:** $65 to start, plus $155/month Premium, plus $28/month for testosterone injections — about **$2,260 in the first year**, and about $2,196 a year thereafter. That is a real, buildable figure you can compute before entering a card number, which is more than most of this category permits. Compare it against the price bands in [how much a longevity clinic costs](/longevity-clinic-cost). **And the commitment check comes back clean.** Hone states "No commitments. Cancel anytime." We found no product page where the advertised rate depended on a 3-, 6- or 12-month prepay. That is not the norm — the [AgelessRx review](/agelessrx-review) documents a competitor whose headline prices are quarterly-plan and, in one case, introductory rates — and Hone deserves the contrast drawn in its favor. ## What's included, what's extra Included at Premium: quarterly retesting, physician consults and follow-ups, the personalized protocol, and members-only medication pricing. Extra, always: **the medication itself**, on every tier. The membership fee buys the medical relationship, not the drug. Extra on Basic: the consults. Price not published — the one figure Hone withholds. Not offered: imaging, epigenetic-age testing, or the broad screening panel a diagnostics-led program provides. Hone's 50 markers are hormone-weighted by design, and are not a substitute for the outcome-validated core we describe in [what longevity biomarker panels actually test](/longevity-biomarker-panels). ## Clinical oversight: who prescribes, and what they check Structurally, this is good. Labs come before prescriptions. Premium members are retested every 90 days, which is the correct cadence for anyone on exogenous hormones — testosterone therapy requires periodic haematocrit, PSA and blood-pressure monitoring, and a quarterly rhythm supports that. Two deductions. First, **Hone names no medical director.** Corrected on 8 August 2026: an earlier version of this review said Hone names no physicians at all, and that was wrong — its how-it-works page names four, with credentials: Janel Meric, M.D., Alexander Watson, M.D., Raheleh Sarbaziha, M.D. and Timothy Vachris, M.D., and its terms name the affiliated medical groups (Broad Health P.A., Adrian Rawlinson, M.D., P.C. d/b/a Broad Health of California, Broad Health of NC, P.C., Ivee Medical PC and IV Medical New York, P.L.L.C.). What is still missing is a named medical director and any NPI numbers you could check, which a competitor like AgelessRx does publish. Second, **the Basic tier decouples oversight from the membership.** A patient on $25/month with a testosterone prescription and no purchased consult is a patient on hormones without scheduled clinician contact — a configuration the platform permits. ## The evidence behind what it sells This is where the grade is decided, and where Hone's marketing outruns its data. **Testosterone, on the FDA label.** Testosterone cypionate is approved "for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone" — specifically primary hypogonadism and hypogonadotropic hypogonadism. The label then carries an explicit Limitation of Use: "Safety and efficacy of testosterone cypionate in men with 'age-related hypogonadism' (also referred to as 'late-onset hypogonadism') have not been established." It also warns that "Testosterone can increase blood pressure which can increase cardiovascular (CV) risk over time," and notes that "Some studies, but not all, have reported an increased risk of MACE in association with use of testosterone replacement therapy". Age-related low testosterone — the exact demographic a direct-to-consumer TRT platform serves — is the one indication the label declines to endorse. **What the big trials found.** TRAVERSE randomized 5,246 men with hypogonadism and cardiovascular disease or high risk to testosterone or placebo; over a mean 33 months of follow-up, testosterone was **noninferior** to placebo for major adverse cardiac events (7.0% vs 7.3%; HR 0.96). That is reassuring — but the same trial found "a higher incidence of atrial fibrillation, of acute kidney injury, and of pulmonary embolism" in the testosterone group. The fracture substudy is the more striking result: after a median 3.19 years, clinical fractures occurred in 3.50% on testosterone versus 2.46% on placebo (HR 1.43, 95% CI 1.04–1.97), and the authors concluded that fracture incidence "was numerically higher among men who received testosterone". A therapy marketed for strength and vitality did not reduce fractures; it was associated with more of them. **What testosterone does do.** The Testosterone Trials — 790 men aged 65+ with testosterone under 275 ng/dL and symptoms — found significantly increased sexual activity, desire and erectile function, a modest walking-distance benefit when all three trials were pooled, and **no significant benefit for vitality**. That is a real but narrow effect on sexual function in genuinely low, genuinely symptomatic men. It is not a longevity result, and nothing in the trial measured lifespan. **The diagnostic bar.** The Endocrine Society guideline recommends diagnosing hypogonadism "only in men with symptoms and signs consistent with testosterone deficiency and unequivocally and consistently low serum T concentrations," confirmed by **repeating** a fasting morning total testosterone measurement. A single at-home draw is a screen, not a diagnosis. If Hone's protocol repeats the morning measurement before prescribing, that is worth knowing; the public pages do not say. **The women's track.** Menopausal hormone therapy for vasomotor symptoms is legitimate, well-established medicine — that is not in dispute. What is in dispute is calling it longevity care. The Women's Health Initiative stopped its estrogen-plus-progestin arm early after a mean 5.2 years because the global index showed risks exceeding benefits: CHD HR 1.29, invasive breast cancer 1.26, stroke 1.41 and pulmonary embolism 2.13, against reductions in colorectal cancer (0.63) and hip fracture (0.66). WHI tested conjugated equine estrogens plus medroxyprogesterone acetate in women averaging 63, so it does not directly indict transdermal estradiol and micronised progesterone started near the menopausal transition — the products Hone actually sells. But it is precisely why "hormones extend healthspan" is not a claim anyone gets to assert casually. **The longevity shelf, claim by claim.** Hone's own longevity page states that NAD+ "may increase lifespan, boost strength and physical performance, help with weight loss," and that metformin "promotes healthy aging and longevity." Neither survives contact with the human data. Oral nicotinamide riboside reliably raises NAD+ and is well tolerated, but the strongest human trial to date improved 6-minute walk distance by roughly 17.6 meters in 90 people with peripheral artery disease, with the authors calling for a larger confirmatory trial — a disease endpoint, not a lifespan one. And Hone charges $165/month for it, the most expensive item on its longevity shelf and the one with the weakest support; our full read is in [NAD+ for longevity](/nad-for-longevity). Metformin's longevity case is observational — better adjusted survival in metformin-treated diabetics versus matched non-diabetic controls in a UK database — and is offset by a randomized trial in which metformin blunted the gains from aerobic training in older adults, attenuating improvements in insulin sensitivity and VO₂ max. See [metformin for longevity](/metformin-for-longevity). ## Where it's weak **1. "Longevity" is doing work the evidence doesn't support.** Hone's own copy asserts that NAD+ may increase lifespan and metformin promotes longevity, and files testosterone under healthspan. On our rubric, evidence honesty carries the heaviest weight (30%) precisely because overselling mechanism as outcome is the field's dominant failure mode — and this is a textbook case. **2. No named clinicians.** For a platform whose entire value is the medical relationship, an anonymous prescriber roster is a real gap. **3. The $25 tier is close to a decoy.** It excludes the consults, does not publish their price, and by Hone's own admission is chosen by 5% of patients. Quoting "$25/month" as Hone's price is quoting the tier Hone itself reports 95% of members do not buy. **4. Vertical dispensing.** Hone tests you, interprets the result, prescribes, and sells the drug. That is common in telehealth and not disqualifying, but it raises the bar on the claims — and the claims are where Hone falls short. **5. The panel is hormone-weighted.** Fifty markers sounds broad, but the tilt is toward the sex-hormone axis. If your goal is the cheap, outcome-validated core, a broad DTC panel does it better; see [best longevity blood test services](/best-longevity-blood-tests). **6. The biggest levers aren't on the panel at all.** Cardiorespiratory fitness is among the most powerful survival predictors ever measured, and grip strength outpredicted systolic blood pressure across 17 countries in the PURE study. Neither is a hormone, and neither is billed monthly. See [VO₂ max and longevity](/vo2-max-and-longevity) and [grip strength and longevity](/grip-strength-and-longevity). ## Who should skip it - **Anyone buying TRT as an anti-aging intervention.** The FDA label declines to endorse it for age-related low testosterone, TRAVERSE found more atrial fibrillation, pulmonary embolism and acute kidney injury, and the fracture substudy found *more* fractures on testosterone than placebo. - **Anyone whose testosterone is normal.** A number in range plus fatigue is not hypogonadism, and the Endocrine Society bar is symptoms plus unequivocally low, repeated morning measurements. - **Anyone comparing on the $25 tier.** Without a purchased consult it is a monitoring subscription, not care. - **Anyone buying NAD+ at $165/month.** That is the priciest item on Hone's shelf, sold on a claim ("may increase lifespan") that no human trial supports. - **Anyone who wants broad diagnostics.** A hormone-weighted 50-marker panel is not a comprehensive workup — a lab membership does that job better, as we cover in [longevity clinics vs lab memberships](/longevity-clinics-vs-lab-memberships). ## How it compares to the rest of our ranking Against **[AgelessRx](/agelessrx-review)**, the two fail in mirror-image ways. AgelessRx charges no membership and imposes no lab gate — structurally the better deal — but advertises "Starting at $X" floors whose billing terms are largely undisclosed, and on rapamycin publishes no month-to-month price at all. Hone gates everything behind a $65 test and a monthly fee, then prices every single drug in plain sight with no commitment. Pick Hone if knowing the bill in advance matters most; pick AgelessRx if avoiding a membership matters most — and note that AgelessRx's menu is longevity-first while Hone's is hormone-first. Against **[Lifeforce](/lifeforce-review)** — $349 starter plus $129/month — Hone is cheaper to enter ($65 vs $349) and slightly dearer to run at Premium, with a similar hormone tilt and a similar own-products conflict. The two are close substitutes; Hone's per-drug price list is the cleaner of the two. Against a pure lab membership like **[Function Health](/function-health-review)**, the difference is treat-versus-test: Function surfaces 100+ markers and hands you off, Hone runs a narrower panel and prescribes off it. Hone is the more useful product if you actually need a prescription, and the worse one if you want breadth. The full graded field sits at [our longevity provider rankings](/best-longevity-clinics). ## The grade, against our rubric - **Clinical oversight (25%) — adequate.** Labs precede prescriptions and Premium retests every 90 days, which is the right cadence for hormone therapy. Docked hard for naming no physicians and for a tier that lets a patient hold a hormone prescription with no included clinician contact. - **Evidence honesty (30%) — weak.** The decisive axis. "NAD+ may increase lifespan," "metformin promotes healthy aging and longevity," and TRT filed under healthspan are all claims running ahead of the human data, and the FDA label specifically declines the age-related indication. - **Transparency (20%) — strong.** Both tiers published, every drug priced, "No commitments. Cancel anytime," and the 95%-choose-Premium figure disclosed by Hone itself. Only the Basic-tier consult price is missing. Best-in-band. - **Price-to-value (15%) — adequate.** About $2,260 in year one for Premium plus testosterone injections is competitive against a bricks-and-mortar hormone clinic — and expensive if what you needed was a repeat morning testosterone draw and a conversation. - **Conflicts of interest (10%) — mixed.** Tests, interprets, prescribes and dispenses. Disclosed by structure, but it is the reason the marketing claims deserve scrutiny. That lands a **B−**. Hone is a competently run, unusually honest-about-money hormone platform wearing a longevity costume. Strip the costume off and the underlying service is fine; leave it on and you are paying a healthspan premium for a symptom treatment. ## Bottom line Hone Health does the thing this site was built to reward: it publishes what everything costs. Both membership tiers, every medication, the entry price, and an explicit "No commitments. Cancel anytime" — we went looking for a quarterly prepay or an expiring introductory rate and did not find one. Only the Basic tier's consult price is withheld, and Hone even discloses that 95% of its patients choose the $155 tier rather than letting the $25 headline do the work. What it does badly is the claim. Testosterone's own FDA label states that safety and efficacy in age-related hypogonadism have not been established; TRAVERSE found more atrial fibrillation, pulmonary embolism and acute kidney injury on treatment, and its fracture substudy found more fractures, not fewer; the Testosterone Trials found a real sexual-function benefit and no vitality benefit. Add "NAD+ may increase lifespan" at $165/month and "metformin promotes longevity" at $25/month and you have a pricing page we would hold up as a model attached to an evidence page we would not. Buy Hone if you have symptoms and genuinely low, repeatedly-confirmed hormone levels, and you want that treated by a telehealth service that will tell you the bill in advance. Skip it if you are buying the healthspan story — and put the money into the two levers that outpredict almost every blood marker and are not for sale on any membership tier. Our full graded field is at [our longevity provider rankings](/best-longevity-clinics). Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5ca67491-4b30-4a47-af0a-be250215d1f0, https://pubmed.ncbi.nlm.nih.gov/37326322/, https://pubmed.ncbi.nlm.nih.gov/38231621/, https://pubmed.ncbi.nlm.nih.gov/26886521/, https://pubmed.ncbi.nlm.nih.gov/29562364/, https://pubmed.ncbi.nlm.nih.gov/12117397/, https://pubmed.ncbi.nlm.nih.gov/29599478/, https://pubmed.ncbi.nlm.nih.gov/38871717/, https://pubmed.ncbi.nlm.nih.gov/25041462/, https://pubmed.ncbi.nlm.nih.gov/30548390/, https://pubmed.ncbi.nlm.nih.gov/30646252/, https://pubmed.ncbi.nlm.nih.gov/25982160/ --- ### He & She MD Review: Every Price Is the 12-Month Rate Canonical: https://longevitygraded.com/he-and-she-md-review Updated: 2026-08-15 He & She MD publishes a term ladder for every longevity product — and every figure it advertises is the twelve-month rung, not the monthly one. ## The one-sentence version He & She MD is a multi-vertical telehealth that does one thing better than almost anyone in this ranking — it **names the pharmacy that dispenses your medication**, with a street address and a phone number — and prices its whole longevity shelf openly, on one condition you have to read the asterisk to find: **every advertised figure is the twelve-month rate.** It grades **B, 8 points out of 14**, and it is a paid partner here; the letter is computed from published terms and cannot see who pays us. ## What it sells The longevity menu is broad: **NAD+ as an injection, a nasal spray and a cream**, plus **sermorelin**, **glutathione** (injection and cream), **MOTS-c** and **lipotropic (MIC) + B12**. Alongside it sit hormone therapy (estradiol patch, gel and pill, progesterone), performance (testosterone injection, gel and pill, enclomiphene), hair-loss and ED lines, and a compounded GLP-1 weight-loss business. Every one of those has its own page, and every one of them carries a price. That breadth is the first thing to weigh. This is not a longevity clinic that also sells other things; it is a general compounded-telehealth storefront with a longevity shelf on it. ## The price is published, and the asterisk is the whole story An earlier version of this review said this line published a floor with no terms behind it. That was wrong, and correcting it does not let the company off — it moves the objection from *withholding* to *framing*. Every longevity product page carries a four-rung table. NAD+ injectable, NAD+ nasal spray and sermorelin each run **$149** a month on a twelve-month plan, **$159** on six, **$179** on three and **$229 month to month**. Lipotropic (MIC) + B12 runs $109, $119, $129 and **$145**. Glutathione offers only two rungs: $100 on three months and **$125** for one. **The figure it advertises is always the cheapest rung.** Every card on the longevity hub, and every product hero, prints the twelve-month rate in large type with "* Price for purchase of 12 months supply" underneath. That footnote is real disclosure — most of this ranking gives you the headline and no term at all — but it means the number you see is the one that costs a year up front, and the number you pay to keep your options open is **roughly 50% higher**: $229 against $149 on NAD+. ★ Two places its own pages disagree with each other. The hub prints the 12-month footnote under **glutathione's $100** while the glutathione page itself offers only three-month and one-month plans — there is no twelve-month glutathione to buy. And **MOTS-c** is footnoted "* Price for purchase of 6 months supply" at the same $149 as products where $149 buys twelve. Same headline figure, different commitment, on adjacent cards. **So plan against $229 for NAD+, not $149**, unless you intend to pay for a year at the start. ## What it gets right - **It names its pharmacy.** F&F Pharmacies Inc, doing business as **Jungle Jim's Pharmacy, 5484 Dixie Highway, Fairfield, OH 45014**, with a phone number, published on its own FAQ. A name, an address and a number is a disclosure you can act on, and most of this ranking will not give you one. - **Longevity and hormone medications ship nationwide.** Only its GLP-1 line carries an exclusion, and that exclusion is stated plainly: every US state except Louisiana. Nothing ships to a PO Box. - **The consult and prescription are inside the price**, with no insurance required and **no charge unless a clinician prescribes**. Two qualifiers on the pharmacy, because a good disclosure still needs reading. Jungle Jim's appears behind several other storefronts in this ranking, so the name identifies the dispenser rather than distinguishing this clinic. And **no compounding classification is stated for it** — 503A or 503B appears nowhere on the site. ## What to hold against it **The site makes two different claims about who regulates its pharmacies.** A disclaimer states that medication is "produced in USP-compliant, state-regulated pharmacies but not reviewed by the FDA for safety, efficacy, or quality" — accurate, and more forthcoming than most. Its homepage, meanwhile, advertises **"FDA-regulated pharmacies"** in a feature block. Those are not the same claim, and both are on the page you land on. On the entity question it does better than the ranking average and worse than it first looks. **Wasef Health, PC c/o Michael Wasef MD** is named as the clinical provider and **Dr. Ozita Cooper, MD** as chief medical officer — two more names than most graded clinics give. The company selling the plan never names itself, and the address behind both is a **PO Box**. **And the coverage line does not survive its own FAQ.** That FAQ puts the named pharmacy's license at **44 states**, not fifty — California, Nevada, New Jersey, North Carolina, Texas, Massachusetts, Mississippi, New Hampshire, West Virginia and Delaware are listed as states it cannot serve — and says plainly that it **cannot dispense sterile compounds**. On a longevity menu sold largely as injections, that is the sentence to weigh. A second pharmacy, **Specialty Medical Drugstore LLC (GoGoMeds)**, is named in the same answer, and nothing says which of the two fills what. **The cream is the weakest thing on the menu.** NAD+ and glutathione are both sold as topical creams. Transdermal delivery of a large, charged molecule through intact skin is the route with the least support behind it of anything here, and the site prices it beside the injection without distinguishing the two. ## Where it lands If the pharmacy question is what you care about — and on a compounded longevity menu it should be near the top — this provider answers it better than most of the field, and it answers the price question too: the whole shelf is priced, with terms, before any intake. What it does with that price is the catch. Every figure on display is the twelve-month rung, and the month-to-month rate is about half again as much, so a reader comparing headline against headline across this ranking will place it well below where it belongs. Judge it against the rest of the [longevity provider ranking](/best-longevity-clinics) and read our [grading method](/how-we-grade-longevity-providers) for how those two things are weighed against each other. Sources: https://heandshemd.com/longevity/nad-injectable/, https://heandshemd.com/faqs/ --- ### Peter MD Review: Sermorelin, NAD+ and TRT Costs, Graded Canonical: https://longevitygraded.com/peter-md-review Updated: 2026-08-28 Peter MD sells sermorelin at $585 a quarter and NAD+ at $369 a course. Its $79 TRT headline is the twelve-month rate; month-to-month is $139. ## The one-sentence version Peter MD sells sermorelin at **$585 for a twelve-week supply** and injectable NAD+ at **$369 for an eight-to-ten-week supply**, and it advertises testosterone therapy at **$79 a month** — a figure you can only get by paying for twelve months at once. The real month-to-month rate is $139, and even that is billed two months up front. It grades **B, 9 points out of 14**, and it is a paid partner here; the letter is computed from published terms and cannot see who pays us. ## What Peter MD is, and who it's for Peter MD is a physician-prescribed telehealth brand selling six lines from one account: testosterone therapy, erectile dysfunction, weight loss, GLP-1s, men's hair loss, and the two products this ranking actually grades — sermorelin and injectable NAD+. That breadth is the appeal. Most rows here sell one thing; a buyer who wants sermorelin now and may want testosterone in a year does not need a second account, a second intake or a second card on file. It is also the risk: a menu this wide is a menu where the longevity line is not the main business, and the pricing shows it. The buyer this suits already knows which product they want and is comfortable paying for a block of supply rather than a month of service. If you want a single flat figure that covers the clinician, the medication and the follow-up, look at [what longevity care actually costs](/longevity-clinic-cost) before you start here. ## What it actually costs **Sermorelin.** $211.65 for a four-week supply, or $585.00 for a twelve-week supply against a stated regular price of $634.95. The twelve-week block works out at roughly $195 a month — cheaper per month than the four-week option, which is the point of it. **NAD+ injectable.** $369.00 for two 200mg/ml vials, described as an eight-to-ten-week supply. That range is the whole problem with the figure: the same $369 is $184 a month if it lasts eight weeks and $147 if it lasts ten. Peter MD does not resolve which, because the supply is estimated rather than dispensed on a schedule. **Testosterone.** Three plans, and the gap between them is the largest on this page. The monthly plan is **$139 a month, billed two months then monthly**. Six months brings it to $109. Twelve months brings it to $79 — the number the page leads with, marked "Most Popular." A baseline lab panel is sold separately at $95, discounted from $190. **One piece of arithmetic worth doing yourself.** All three testosterone cards print a "regular price" of $1,668 or $834 — which is simply $139 a month multiplied by the term. So the monthly plan, at $139, advertises "$600 Yearly Savings" against a regular price identical to its own twelve-month total. The twelve-month plan's saving is real: $948 against $1,668 is $720 a year, exactly as the card says, though the "28.78%" printed beside it understates a discount that is actually about 43%. None of this makes the prices bad. Sermorelin at $195 a month and NAD+ around $147–$184 sit mid-field in [our graded ranking](/best-longevity-clinics). It makes them prices you have to compute rather than read. ## What's included, and what isn't A licensed provider reviews your intake before anything ships — the NAD+ page describes it as answering health questions and consulting with a provider, with no in-person visit. What Peter MD does not publish anywhere is whether that review is paid for by the product price or billed separately. This is the single largest reason it grades B rather than A: the same test that costs Shed and MadeMed their marks costs Peter MD four points here. Also not included: ongoing human support. There is no nurse line, coaching or messaging tier described on the product pages. And nothing here measures whether the protocol did anything — the $95 panel is a baseline you buy, not a follow-up you are given. ## Clinical oversight and the pharmacy Peter MD does something most of this field will not. Section 23 of its terms is headed "Pharmacy Disclosure" and names two facilities outright, with street addresses and phone numbers: **Absolute Pharmacy**, 16011 N Nebraska Ave #103, Lutz, FL 33549, and **Partell Pharmacy**, 5835 S. East Ave, Las Vegas, NV. Fewer than half the rows on our scorecard name a dispensing pharmacy at all. Two caveats keep that from earning full marks. First, neither pharmacy is classified: a search of the site returns no mention of section 503A or 503B, so which regulatory regime prepares your vial is not stated. That distinction is not academic — a 503B outsourcing facility must follow current good manufacturing practice, and a 503A compounding pharmacy specifically need not. Either way the medication is compounded, and FDA is explicit that compounded drugs are not FDA-approved and that it does not verify their safety, effectiveness or quality before marketing. Second, section 24 of the same terms says prescriptions "are sent electronically to a pharmacy of the patient's choosing," which sits oddly beside naming two. Both statements can be true; a buyer who cares which pharmacy fills their order should ask at intake rather than assume. ## The evidence behind what it sells **Sermorelin** is a growth-hormone-releasing analog — it prompts your pituitary to release its own growth hormone rather than supplying hormone directly. The honest summary is that the class raises the hormone and the outcomes are the open question. The standing systematic review of growth hormone in healthy older adults found small changes in body composition — a little more lean mass, a little less fat — with no demonstrated improvement in the outcomes people actually buy it for, and higher rates of soft-tissue edema, joint pain, gynecomastia and impaired fasting glucose. The broader aging literature is more uncomfortable still: reduced growth-hormone and IGF-1 signaling is associated with longer life in animal models, which is the opposite direction from the marketing. **NAD+.** A 2026 PRISMA-guided systematic review screened 113 studies including 33 human intervention trials and found that oral precursors reliably raise NAD+ levels and are well tolerated, but that effects on functional, metabolic and vascular outcomes were heterogeneous and often null, with clinical effectiveness for anti-aging "inconclusive." Directly relevant to an injectable product: no eligible outcomes trial evaluated intravenous or intramuscular NAD+ itself for anti-aging or wellness. **Testosterone.** Worth separating from the longevity pitch entirely. Testosterone therapy is a treatment for diagnosed hypogonadism, and the large TRAVERSE trial established that in men with hypogonadism and cardiovascular risk it was noninferior to placebo for major adverse cardiac events. That is a safety finding in a diagnosed population — not evidence that testosterone extends life in men whose levels are normal. ## Where it's weak, and who should skip it - **You want a price you can read rather than compute.** Two of the three longevity products are sold as blocks of estimated supply, and the headline testosterone rate requires a year up front. - **You want the consult fee stated.** It isn't, anywhere. - **You live in an excluded state.** Sermorelin is not available in Alabama or Idaho; NAD+ adds Louisiana. Exclusions differ by product, so check the one you want rather than the brand. - **You want measurement built in.** Labs are a separate $95 purchase, and no follow-up testing is part of any plan. ## The verdict, against the rubric Nine points out of fourteen: four for price transparency, four for a genuine longevity line, one for naming its pharmacies without classifying them, and zero each for clinical oversight and included human support. That is a B — a real, broad, physician-prescribed service whose published terms leave two of the five things we grade unstated. If you want the sermorelin, $585 a quarter is a fair published price from a company that will tell you which pharmacy might fill it. If you want a single number that covers everything, this is not the row for it — [compare it against the rest of the board](/best-longevity-clinics) before you commit twelve months to anything. Sources: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers, https://pubmed.ncbi.nlm.nih.gov/17227934/, https://pubmed.ncbi.nlm.nih.gov/29756419/, https://pubmed.ncbi.nlm.nih.gov/41655607/, https://pubmed.ncbi.nlm.nih.gov/37326322/ --- ### TRT and Longevity: What the Trials Actually Show Canonical: https://longevitygraded.com/testosterone-trt-and-longevity Updated: 2026-08-28 Testosterone therapy is a treatment for diagnosed hypogonadism. No trial shows it extends life. Here is what TRAVERSE, the T-Trials and the guidelines found. ## The one-sentence version Testosterone replacement is a real treatment with real evidence behind it — for **diagnosed hypogonadism**, which is a specific condition confirmed by symptoms plus two low morning blood tests. There is no trial showing it extends life, no trial showing it slows aging, and the largest guideline in the field recommends *against* prescribing it for age-related decline alone. Almost everything sold as "testosterone optimization" lives in the gap between those two sentences. ## What testosterone therapy is actually approved to do The FDA-approved indication is replacement in men with low testosterone caused by a recognized medical condition — testicular, pituitary or hypothalamic. The label for testosterone cypionate carries an explicit limitation of use: safety and efficacy in men with age-related low testosterone have not been established. The Endocrine Society's clinical practice guideline draws the same line and adds the diagnostic bar: diagnose hypogonadism only in men with **symptoms and signs** plus **unequivocally low morning total testosterone confirmed on a repeat measurement**, and do not prescribe on a single reading or on symptoms alone. A single afternoon test, which is what several telehealth intakes run on, is not a diagnosis. ## What the big trials found **TRAVERSE (2023) — the safety question, answered.** Just over 5,200 men aged 45–80 with hypogonadism and either existing cardiovascular disease or high risk were randomized to testosterone gel or placebo. Testosterone was **noninferior to placebo** for major adverse cardiac events. This was the trial the field had been waiting on since the FDA's 2015 warning, and it is genuinely reassuring — for that population. It is a safety result, not a benefit result, and it says nothing about men whose levels are normal. **The Testosterone Trials (2016) — the benefit question, answered narrowly.** In 790 men over 65 with genuinely low levels, testosterone produced a consistent improvement in sexual function, a smaller improvement in mood and depressive symptoms, and **no significant benefit for vitality or walking distance**. Read that list again: the things it improved are real, and they are not longevity. **Fractures (2024) — the result nobody markets.** A pre-specified TRAVERSE sub-study of 5,204 men found **more** clinical fractures in the testosterone group than in the placebo group. It is an unexpected finding in a trial designed for cardiac safety, and it cuts directly against the "stronger bones" pitch that appears on clinic pages. ## Why "optimization" is a different product from replacement The marketing category that has grown up around TRT is not the treatment the trials studied. It targets men whose testosterone is within the reference range but toward the lower end, offers a number to raise rather than a symptom to treat, and measures success as the number moving. Three things follow, and none of them are controversial: 1. **The trials do not cover it.** Every result above was measured in men with diagnosed hypogonadism. Extending them to men with normal levels is an extrapolation, not evidence. 2. **The endpoints are surrogate.** Serum testosterone is a biomarker. Nothing in the literature establishes that raising it in a man who is not deficient changes how long or how well he lives. 3. **The therapy is not trivially reversible.** Exogenous testosterone suppresses the body's own production and impairs fertility, which the label states plainly. That is a manageable trade-off for a diagnosed deficiency and a substantial one for a lifestyle purchase. This is the same shape as the hormone story in women, where two decades of confident practice was reversed by a single large randomized trial: the Women's Health Initiative found estrogen plus progestin **increased** the risk of coronary events, stroke and invasive breast cancer in healthy postmenopausal women, and the trial was stopped early. Observational data had pointed the other way for years. Hormones are exactly the domain where mechanism and cohort studies have most often been wrong — the full account, including what the timing hypothesis did and did not rescue, is in [HRT, menopause and longevity](/hrt-menopause-and-longevity). ## What actually predicts how long you live If the goal is longevity rather than a lab value, the strongest human evidence in this area is not pharmacological. Cardiorespiratory fitness shows a **graded, dose-dependent** association with survival across 122,007 patients — with no observed upper limit of benefit, and with the difference between the lowest-fit and the elite groups larger than the difference associated with smoking, diabetes or coronary artery disease. Grip strength, measured across 139,691 adults in 17 countries, predicted all-cause and cardiovascular mortality more strongly than systolic blood pressure. Neither is a treatment you can buy, which is precisely why they are undersold. We cover them in [VO2 max and longevity](/vo2-max-and-longevity) and [grip strength and longevity](/grip-strength-and-longevity). ## If you are going to buy it anyway, buy it properly A defensible testosterone purchase looks like this, and the checklist is short: - **A real diagnosis first.** Two morning blood tests, plus symptoms. Anyone willing to prescribe on one afternoon reading is skipping the step the guideline calls essential. - **The price you can actually pay monthly.** This category advertises twelve-month rates in large type and month-to-month rates in the asterisk. Our [provider ranking](/best-longevity-clinics) grades every row on whether the published figure is the one you are charged. - **A named prescriber and a named pharmacy.** Both are knowable before you pay, and most of the field publishes neither. - **Follow-up bloodwork inside the price**, not sold separately — hematocrit and PSA monitoring are part of the standard of care, not an upsell. ## The honest summary Testosterone therapy treats hypogonadism, and for men who have it the evidence is decent: better sexual function, acceptable cardiovascular safety, an unexplained fracture signal worth discussing with a prescriber. For everyone else it is an intervention with a surrogate endpoint, a suppression risk, and no longevity evidence at all. That is not an argument against it. It is an argument for knowing which of the two products you are being sold — and the [graded provider ranking](/best-longevity-clinics) exists to make the second one legible. Sources: https://pubmed.ncbi.nlm.nih.gov/29562364/, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5ca67491-4b30-4a47-af0a-be250215d1f0, https://pubmed.ncbi.nlm.nih.gov/37326322/, https://pubmed.ncbi.nlm.nih.gov/26886521/, https://pubmed.ncbi.nlm.nih.gov/38231621/, https://pubmed.ncbi.nlm.nih.gov/12117397/, https://pubmed.ncbi.nlm.nih.gov/30646252/, https://pubmed.ncbi.nlm.nih.gov/25982160/ --- ### Sermorelin for Longevity: Cost, Evidence and What It Cannot Do Canonical: https://longevitygraded.com/sermorelin-for-longevity Updated: 2026-08-28 Sermorelin runs about $99–$195 a month through telehealth. It raises growth hormone. No trial shows it slows aging — and the aging biology points the other way. ## The one-sentence version Sermorelin is a growth-hormone-releasing analog: it prompts your own pituitary to release growth hormone rather than injecting the hormone itself. It reliably does that. What no trial shows is that doing it makes you live longer or age slower — and the strongest longevity biology in this area points the *opposite* way, because reduced growth-hormone signaling is what tracks with longer life in animals. ## What you actually pay Across the providers we grade, published sermorelin pricing clusters into three shapes, and only one of them is a monthly price: - **A genuine month-to-month rate**, roughly $99 at the low end of the field. - **A block price for an estimated multi-week supply** — one graded provider sells a twelve-week course at $585, about $195 a month once you do the division nobody does for you. - **A price you cannot see until you have completed a medical questionnaire.** The full ladder, per provider, is on the [graded ranking](/best-longevity-clinics), and the pattern that matters is in [what longevity care actually costs](/longevity-clinic-cost): the advertised figure is often a twelve-month rate, and the month-to-month number lives in the asterisk. ## What sermorelin does biologically Sermorelin is a fragment of growth-hormone-releasing hormone. Given at night, it triggers a pulse of the body's own growth hormone, which is why it is marketed as the "natural" alternative to injecting growth hormone directly. That framing has a real point behind it: because the pituitary is still in the loop, the feedback mechanisms that limit overshoot remain intact, which is a genuine safety argument relative to exogenous growth hormone. The problem is that the argument is about *how* the hormone gets raised, and every question a buyer actually has is about what happens once it is. ## What the evidence shows, and where it stops **Growth hormone in healthy older adults.** The standing systematic review found small body-composition changes — about 2 kg more lean mass, about 2 kg less fat — with **no demonstrated improvement** in the outcomes people buy it for, and significantly higher rates of soft-tissue edema, joint pain, carpal tunnel syndrome, gynecomastia and impaired fasting glucose. That is the ceiling on the mechanism sermorelin works through. **GHRH analogs specifically.** The closest thing to real randomized evidence for this drug class is tesamorelin, a GHRH analog studied in HIV-associated lipodystrophy. Two phase-3 trials showed it reduced visceral adipose tissue meaningfully. Note what that is: a body-composition result, in a specific patient population, for a specific complication. It is the best evidence the class has, and it is not an aging result. **Growth-hormone secretagogues.** An oral ghrelin mimetic raised growth hormone and IGF-1 and increased lean mass in healthy older adults over two years — with a rise in fasting glucose and no functional benefit that would justify it for aging. Same shape again: the number moves, the outcome does not. **The direction of travel in aging biology.** This is the part the marketing never mentions. Across model organisms, *reduced* growth-hormone and IGF-1 signaling is associated with **longer** life, and the trade-off between growth and longevity is one of the more reproducible findings in the field. A protocol whose entire mechanism is raising GH/IGF-1 is pushing on that axis in the direction associated with shorter life, not longer. That does not make it dangerous at the doses sold — it does mean the longevity claim is running against its own biology. ## Who this is actually for There is an honest case for sermorelin, and it is narrower than the marketing: - **Someone chasing recovery, sleep quality or body composition**, who understands they are buying a body-composition intervention with modest effects and is comfortable that the durable outcome data does not exist. - **Not** someone buying it to slow aging. There is no trial for that, and the underlying biology argues against it. If longevity is the goal, the interventions with actual human outcome data behind them are unglamorous and mostly not purchasable — see [VO2 max](/vo2-max-and-longevity) and [grip strength](/grip-strength-and-longevity), both of which predict mortality more strongly than anything in this category. ## The compounding question Sermorelin sold through telehealth is a **compounded** preparation. FDA is explicit that compounded drugs are not FDA-approved, and that it does not verify their safety, effectiveness or quality before they are marketed. That is not an allegation about any particular seller; it is the regulatory status of the whole category, and it is why our ranking weights whether a provider will name the pharmacy that fills the prescription and say which standard it operates under. Most will not. ## The honest summary Sermorelin raises growth hormone. Growth hormone, raised in healthy older adults, produces a couple of kilos of body-composition change, a real side-effect profile, and no demonstrated functional or longevity benefit. The best-studied drug in its class has a visceral-fat result in a specific patient population. And the aging literature associates *less* signaling on this axis with longer life. Buy it for what it has been shown to do, at a price you can see before you pay — the [graded ranking](/best-longevity-clinics) is where we check the second half of that. Sources: https://pubmed.ncbi.nlm.nih.gov/29756419/, https://pubmed.ncbi.nlm.nih.gov/17227934/, https://pubmed.ncbi.nlm.nih.gov/20554713/, https://pubmed.ncbi.nlm.nih.gov/20101189/, https://pubmed.ncbi.nlm.nih.gov/18981485/, https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers --- ### NAD+ Injections vs IV vs Oral: Which Route Has the Evidence? Canonical: https://longevitygraded.com/nad-injections-vs-iv-vs-oral Updated: 2026-08-28 Oral NAD+ precursors are the only route with human randomized trials. No outcomes trial has tested injected or IV NAD+ — the routes you pay most for. ## The one-sentence version Every route raises NAD+. Only one of them — **oral precursors** — has been through randomized human trials, and even there the results are mixed. The 2026 systematic review that screened 113 studies found **no eligible outcomes trial of intravenous or intramuscular NAD+ at all** for anti-aging or wellness. Those are the two routes telehealth charges most for. ## The four routes you will be sold | Route | What it is | Human outcome trials | |---|---|---| | **Oral precursors** (NR, NMN) | A capsule of nicotinamide riboside or mononucleotide | Yes — dozens | | **Subcutaneous / IM injection** | NAD+ itself, self-injected at home | None | | **IV infusion** | NAD+ itself, in a clinic over several hours | None | | **Nasal spray** | NAD+ itself, absorbed nasally | None | That table is the whole article, and it is worth sitting with, because the marketing runs in exactly the opposite direction: the routes with no outcome data are the ones sold as the serious, clinical, higher-dose option. ## Why the routes are not interchangeable The pitch for injecting is bioavailability, and the underlying point is real: swallowed NAD+ is largely broken down before it reaches your cells, which is why oral products sell a **precursor** — NR or NMN — that survives the trip and is converted inside the body. Injecting NAD+ skips that step. What does not follow is that skipping the step produces a better outcome. Bioavailability is an input. The trials measure outputs, and the output evidence exists for the route with the *worse* bioavailability, because that is the route researchers have actually studied. ## What the oral trials found **They reliably raise NAD+.** Chronic nicotinamide riboside was well tolerated and elevated NAD+ in healthy middle-aged and older adults — the mechanism is not in doubt. **The functional results are mixed and often null.** A 2025 systematic review and meta-analysis of NMN and NR found no significant improvement in skeletal muscle mass or function in older adults. The NICE randomized clinical trial tested nicotinamide riboside in peripheral artery disease and did not find the walking-performance benefit it was designed to detect. **A few positive signals exist, in specific populations.** NMN increased muscle insulin sensitivity in prediabetic women, and improved aerobic capacity in amateur runners. Both are real results and neither is an aging outcome. **The overall verdict.** The 2026 PRISMA-guided review's summary is that oral precursors consistently raise NAD+ and are well tolerated, while effects on functional, metabolic and vascular outcomes were "heterogeneous and often null," with clinical effectiveness for anti-aging **inconclusive**. That is the strongest evidence any NAD+ route has. ## What injected, IV and nasal have Nothing comparable. The same review searched for outcomes trials of intravenous or intramuscular NAD+ for anti-aging or wellness and found none eligible. This is not a claim that they do not work. It is the more specific and more useful claim: **nobody has run the study**. When a provider tells you injection is "more effective," ask what the comparison is measured against — there is no head-to-head outcome trial of injected versus oral NAD+ to cite. IV adds a second consideration. It is administered in a clinic over hours, at the highest price of any route, and it is the route where the gap between what is charged and what has been demonstrated is widest. ## What each route costs Prices across the providers we grade are published in shapes that resist comparison — a monthly rate, a block for an estimated multi-week supply, or nothing at all until you have completed an intake. The per-provider figures, with the term each one is really sold on, are on the [graded ranking](/best-longevity-clinics), and the traps to read for are in [what longevity care actually costs](/longevity-clinic-cost). Two patterns worth knowing before you compare anything: - **A block price is not a monthly price.** One graded provider [sells NAD+ as $369 for an estimated eight-to-ten-week supply](/peter-md-review) — so the monthly cost is a range, not a number, and which end you land on is not knowable in advance. - **The advertised figure is often the twelve-month rate**, with the month-to-month price in an asterisk. ## How to choose, honestly - **If you want the route with evidence behind it**, that is oral NR or NMN — and you should hold modest expectations, because the meta-analyses are largely null on function. Which of the two to pick is [NMN vs NR](/nmn-vs-nr). - **If you want injection or IV**, buy it knowing you are buying bioavailability and convenience, not a demonstrated outcome, and that you are paying the most for the least-studied route. - **If a provider says injection is proven superior**, that specific claim has no trial behind it. Our broader tour of what this molecule can and cannot do is in [NAD+ for longevity](/nad-for-longevity), and the wider toolkit is in [longevity medicine: what's proven versus hyped](/longevity-medicine-evidence). Sources: https://pubmed.ncbi.nlm.nih.gov/41655607/, https://pubmed.ncbi.nlm.nih.gov/29599478/, https://pubmed.ncbi.nlm.nih.gov/40275690/, https://pubmed.ncbi.nlm.nih.gov/38871717/, https://pubmed.ncbi.nlm.nih.gov/33888596/, https://pubmed.ncbi.nlm.nih.gov/34238308/ --- ### NMN vs NR: Which NAD+ Precursor Has the Better Evidence? Canonical: https://longevitygraded.com/nmn-vs-nr Updated: 2026-08-28 No trial has ever compared NMN and NR head to head. NR has the longer safety record, NMN the more interesting metabolic signals. Neither slows aging. ## The one-sentence version **No randomized trial has ever compared NMN and NR head to head for any outcome.** Every "NMN is better" or "NR is better" claim you will read is an argument from mechanism, from a single small study, or from whoever is selling. What can be said is narrower and more useful: NR has the longer and better-documented safety record, NMN has produced the more interesting metabolic signals, and neither has demonstrated an effect on aging. ## What they are Both are precursors to NAD+, the coenzyme every cell uses for energy metabolism and DNA repair, and which declines with age. You cannot usefully swallow NAD+ itself — it is broken down before it reaches your cells — so oral products sell a precursor that survives the trip and is converted inside the body. - **NR** — nicotinamide riboside. One enzymatic step further from NAD+. - **NMN** — nicotinamide mononucleotide. One step closer, which is the entire basis of the "more direct" marketing claim. Being one step closer in a diagram is not evidence of anything. It is the reason the argument exists, not the resolution of it. ## The case for NR: the deeper safety file NR has been through more, and longer, human studies. - Chronic supplementation was **well tolerated and reliably elevated NAD+** in healthy middle-aged and older adults. - A randomized, double-blind, placebo-controlled trial of a commercial NR product examined **safety and metabolism over long-term administration** in healthy overweight adults. - A randomized placebo-controlled trial in **obese men** measured safety, insulin sensitivity and lipid-mobilizing effects. - It has been taken into disease populations — a phase I trial in Parkinson's disease and a safety and tolerability study in heart failure with reduced ejection fraction. That breadth matters for a product people take daily for years. It is a safety argument, not an efficacy one. ## The case for NMN: the more interesting signals NMN has fewer trials, and two of them found something. - NMN **increased muscle insulin sensitivity in prediabetic women** — a real, mechanistically coherent metabolic result. - It **improved aerobic capacity in amateur runners**. - A 2023 trial examined its efficacy and safety in middle-aged adults. Both positive findings are in specific, narrow populations, and neither is an aging outcome. ## Where both of them land **They raise NAD+.** That is not in dispute for either compound. **The functional evidence is weak.** A 2025 systematic review and meta-analysis of NMN *and* NR together found **no significant improvement in skeletal muscle mass or function** in older adults. The NICE randomized clinical trial of nicotinamide riboside in peripheral artery disease did not find the walking-performance benefit it was designed to detect. **And the overall verdict.** The 2026 PRISMA-guided systematic review, covering 113 studies including 33 human intervention trials, concluded that oral precursors consistently raise NAD+ and are well tolerated while effects on functional, metabolic and vascular outcomes were "heterogeneous and often null," with clinical effectiveness for anti-aging **inconclusive**. ## So which should you buy? If you have decided to take one, the honest decision rule is short: - **Want the deepest safety record?** NR. More trials, longer administration, more populations. - **Want the compound with the most interesting metabolic findings?** NMN, understanding those are two small studies in specific groups. - **Want the one proven to slow aging?** Neither. That trial does not exist for either compound. And a note on price that applies to both. These are supplements, and a prescription NAD+ product is not a better version of them — one graded provider [prices a prescription NAD+ tablet beside its injection](/rxspan-md-review) at several times what a jar of either precursor costs, against the same human evidence. Where each route has actually been tested is in [NAD+ injections vs IV vs oral](/nad-injections-vs-iv-vs-oral), and how these two sit against every other popular pill is in [the best longevity supplements, rated by evidence](/best-longevity-supplements). Sources: https://pubmed.ncbi.nlm.nih.gov/29599478/, https://pubmed.ncbi.nlm.nih.gov/31278280/, https://pubmed.ncbi.nlm.nih.gov/29992272/, https://pubmed.ncbi.nlm.nih.gov/35235774/, https://pubmed.ncbi.nlm.nih.gov/36644285/, https://pubmed.ncbi.nlm.nih.gov/33888596/, https://pubmed.ncbi.nlm.nih.gov/34238308/, https://pubmed.ncbi.nlm.nih.gov/36482258/, https://pubmed.ncbi.nlm.nih.gov/40275690/, https://pubmed.ncbi.nlm.nih.gov/38871717/, https://pubmed.ncbi.nlm.nih.gov/41655607/ --- ### HRT, Menopause and Longevity: What the Trials Actually Show Canonical: https://longevitygraded.com/hrt-menopause-and-longevity Updated: 2026-08-28 Hormone therapy treats menopausal symptoms and protects bone. Over 18 years of follow-up it did not change all-cause mortality. Timing changes the risk picture. ## The one-sentence version Menopausal hormone therapy is an effective treatment for menopausal symptoms and bone loss, and after **18 years of follow-up in the Women's Health Initiative it did not change all-cause mortality in either direction**. It is not a longevity drug. What it is — and this is the part worth getting right — is a symptom and bone treatment whose risk profile depends heavily on **when you start it**. ## Why this field is the cautionary tale For two decades, observational data suggested hormone therapy protected women's hearts, and it was prescribed accordingly. Then the Women's Health Initiative randomized healthy postmenopausal women to estrogen plus progestin and found the opposite: **increased** coronary events, stroke and invasive breast cancer. The trial was stopped early. That reversal is the single best argument in medicine for why mechanism and cohort studies are not enough — and it is directly relevant to everything else this site grades, because most of what is sold as anti-aging rests on exactly the kind of evidence WHI overturned. If you read one thing about why we grade the way we do, read [longevity medicine: what's proven versus hyped](/longevity-medicine-evidence). ## The timing hypothesis, and what tested it The response to WHI was that its average participant was in her sixties, more than a decade past menopause, with atherosclerosis already established — and that starting therapy near menopause might behave differently. That is the **timing hypothesis**, and unlike most post-hoc rescues of a failed trial, it was actually tested. **ELITE** randomized women by time since menopause and measured the progression of carotid artery thickening. Early-postmenopausal women on estradiol showed slower progression than placebo; late-postmenopausal women showed no such effect. That is a real, prospectively-designed result supporting the hypothesis — on an imaging surrogate, not on heart attacks. **DOPS**, a Danish open-label randomized trial in recently postmenopausal women, reported reduced mortality, heart failure and myocardial infarction after around a decade, without an increase in cancer. It is a genuinely positive cardiovascular result, and it carries real caveats: open-label design and a smaller event count than WHI. **And the long view.** Pooled WHI follow-up over 18 years found that hormone therapy was **not associated with a difference in all-cause mortality**, nor in cardiovascular or cancer mortality. Whatever the timing effect does, it does not show up as more years of life. ## What it is genuinely good at None of the above argues against hormone therapy. It argues against buying it for the wrong reason. - **Vasomotor symptoms** — hot flashes and night sweats. This is the core indication and it works. - **Bone**. WHI found reduced fractures on hormone therapy, which is a hard outcome, not a surrogate. - **Genitourinary symptoms**, where local vaginal estrogen carries a different and more favorable risk profile than systemic therapy. Those are good reasons. "It will extend my life" is not one the evidence supports. ## What this means if you are buying it online Several providers on our board sell women's hormone therapy alongside NAD+, peptides and weight-loss drugs. The questions that decide whether a given offer is a good one are the same ones we grade every row on, and none of them are about the molecule: - **Is the published price the month-to-month price**, or a twelve-month rate with the real figure in an asterisk? - **Is the clinician review inside that price**, or billed separately by a different entity? - **Are baseline and follow-up labs included**, given that dosing is adjusted on them? - **Is the prescribing clinician named**, and is the dispensing pharmacy identified? The graded answers, per provider, are on [our ranking](/best-longevity-clinics), and the pricing traps that recur across the field are in [what longevity care actually costs](/longevity-clinic-cost). ⚠ Compounded "bioidentical" hormone preparations are a distinct product from FDA-approved hormone therapy, and the trials described here tested approved products. A compounded preparation has not been through that evidence base. ## The honest summary Hormone therapy treats symptoms and protects bone. Started near menopause it appears to behave better cardiovascularly than it does started late, with an imaging trial and an open-label trial supporting that and a large randomized trial showing harm when started late. Across eighteen years, it did not change how long women lived. That is a useful drug and a poor longevity purchase, and the difference is worth the ten minutes it takes to tell them apart — which is the same distinction we draw in [TRT and longevity](/testosterone-trt-and-longevity) for the other half of the hormone market. Sources: https://pubmed.ncbi.nlm.nih.gov/28898378/, https://pubmed.ncbi.nlm.nih.gov/12117397/, https://pubmed.ncbi.nlm.nih.gov/27028912/, https://pubmed.ncbi.nlm.nih.gov/23048011/ --- ### HumeCare+ Review: Measures The Muscle, Hides The Price Canonical: https://longevitygraded.com/humecare-review Updated: 2026-08-14 HumeCare+ bundles a body analyzer with compounded semaglutide and titrates against lean mass — and publishes no price until the medical intake is done. ## The one-sentence version HumeCare+ is the prescribing arm of a body-composition device company, and it does one thing no other program in this ranking does — it **measures whether you are losing fat or muscle, every week, and adjusts the dose against that** — while doing one thing worse than almost anyone here: it **publishes no price at all** until you have handed over a medical history. ## What it sells Compounded **semaglutide**, by injection or orally, and compounded **tirzepatide** blended with **vitamin B12 and glycine**. That is the whole menu — this is not a longevity clinic with a shelf of peptides, it is a single-purpose GLP-1 program. What arrives with the medication is the reason it is graded here: a **Hume Pod body analyzer**, described by the company as a $350 device included at no extra cost, reading **fat mass, lean muscle and metabolic age weekly**, with the data going to the clinical team. ## Why that matters on a longevity site Lean mass is not a cosmetic concern. It predicts physical function, insulin sensitivity and fracture risk decades out, and it is the specific thing a rapid weight-loss drug erodes: meta-analyzes of incretin therapies put lean tissue at roughly a quarter to a third of total weight lost. The standard telehealth answer to that is a sentence of reassurance. A scale cannot tell fat from muscle, so a program watching only weight cannot know which it is taking. Measuring the split weekly and titrating on it is a materially different design, and the glycine and B-vitamin adjuncts are pointed at the same problem rather than sold as an upsell. ★ It also publishes its own **average** result rather than only its ceiling: a footnote states the headline came from the **top 25th percentile** of 1,185 users and that **average loss was 13 pounds**. That is rarer than it should be, and it is why the criticisms below are worth taking seriously rather than discounting. ## The pricing problem **Nothing on the public site carries a figure.** Past the medical questionnaire, compounded semaglutide is **$199 a month** and tirzepatide **$299**, both billed monthly with no minimum term — genuinely better than the three- and six-month prepays this category runs on. But that $199 is a **floor, not a price**. The terms charge a *"clinical consultation fee assessed at enrollment and each refill"*, non-refundable, collected for a separate Clinical Network, and **never state what it is**. The same document reserves the right to charge more: *"medications, dosages, formulations... may be subject to additional charges outside the membership fee at Hume's sole discretion."* No published number totals this program. The guarantee narrows between the marketing and the contract. The landing page promises **180 days money back**. Section 8A of the terms gives **90 days**, pays out only if you achieved **no measurable weight loss at all**, excludes that consultation fee "under all circumstances", requires every dose logged and all 13 weigh-ins, and **excludes anyone who has previously taken a GLP-1**. ## What is never published No pharmacy is named and no **503A or 503B** classification is stated anywhere. Hume describes itself as a platform; prescribing sits with a separate **Clinical Network** under its own patient agreements, and the terms state plainly that Hume does not guarantee you will be prescribed anything. There is also **no milligram figure on any surface** — including the checkout, which says only that the provider sets the final dose. The page selling the program is titled a *microdose* program, so a product named for its dose never states one. ## The grade The measurement is real and, on this ranking's terms, valuable: it is the only program here that treats lean mass as a number to manage rather than a risk to mention. Against that sits a pricing structure you cannot total before committing a medical history, an unquantified recurring fee, and a guarantee that is materially narrower in the contract than in the advertising. We are not paid by HumeCare, and the link below goes to its own page. Sources: https://humecare.com/pages/gs-microdose-glp1-rx, https://app.humecare.com/terms-conditions --- ### CoreAge Rx Reviews: Cost, Complaints, and the Record Canonical: https://longevitygraded.com/coreage-rx-review Updated: 2026-08-04 CoreAge Rx is our #1 pick: flat $93–$99 pricing, no membership, a 503A pharmacy. What the $93 actually buys, verified on its own pages, July 2026. ## The one-sentence version CoreAge Rx grades **A, 14 points out of 14** — the only perfect score on the board — and it is a paid partner here; the letter is computed from published terms and cannot see who pays us. It earns that on structure: it clears all five marks this site grades on — a published flat price, the clinician review inside it, a 503A compounding pharmacy, no lab gate, and 1:1 nurse and dietitian calls included. Almost nothing else in compounded longevity telehealth publishes that much before you enter a card number. This review does the two things a grade cannot: it reads the fine print behind "$93/mo" — a **12-month plan rate**, with no one-month price published anywhere public — and it holds CoreAge's sermorelin and NAD+ marketing against the human trials, which do not support it. Every figure and quote below comes from a CoreAge page you can open yourself. ## What CoreAge Rx is, and who it's for CoreAge Rx sells compounded prescription protocols direct to consumers with no membership and no required bloodwork. You complete an online intake, a licensed provider reviews it within about 24 hours, and — if approved — a compounding pharmacy prepares your prescription and ships it cold. The longevity menu is narrow on purpose: NAD+ as an injection or nasal spray ("Hello Energy"), sermorelin ("Overnight Rebound"), and GLP-1s at standard and microdose levels. One structural detail matters more than any of the marketing: **CoreAge Rx does not practice medicine.** Its own footer states that all clinical services come from independently owned professional entities — MD Integrations and its affiliated medical groups — and that CoreAge "does not provide medical services, does not employ healthcare providers, does not participate in clinical decisions, and does not practice medicine." It is an administration layer in front of a licensed prescriber network: a normal telehealth structure, and worth knowing whose license is on your chart. The buyer this suits wants a named price for a compounded protocol without a $129–$155 monthly membership wrapper and without a diagnostic gate first — see [longevity clinics vs lab memberships](/longevity-clinics-vs-lab-memberships). ## What it actually costs — and what "starting at" is doing **The headline numbers.** NAD+ injection and nasal spray: "Starting at $93 Per month." Sermorelin: "Starting at $99 per month." Semaglutide $99/mo, tirzepatide $149/mo, semaglutide microdose $79/mo, tirzepatide microdose $129/mo. No membership fee and no lab requirement — both genuinely true, and both rare. **Now the ladder those numbers sit on.** CoreAge's Refund, Return & Shipping Policy publishes four plan lengths: - **1-month** — one month's supply. CoreAge itself recommends starting here: *"we recommend starting with the 1-month plan so you can experience the treatment before committing to a longer duration."* - **3-month** — a three-month supply in one shipment. - **6-month** — a three-month supply, shipped twice. - **12-month** — a three-month supply, shipped four times. CoreAge labels this *"our best per-month price."* Then the sentence that reframes the price page: *"The longer the plan you choose, the lower your per-month cost."* The arithmetic is unavoidable. **$93 and $99 are the best per-month price — the 12-month rate. The one-month price is not published on any public page.** You see it inside the intake, after handing over a medical history. A buyer who follows CoreAge's own advice and starts on one month pays more than the number that brought them to the site, and cannot know how much more beforehand. **The multi-month plans carry a clawback.** Same policy: *"Multi-month plans are priced at a discounted rate because you are committing to the full duration. If you select a 6 or 12-month plan and cancel early, you will be charged the equivalent of the 3-month plan rate for any medication already shipped."* **There is a 30-day finalization clause.** *"Any order that remains active more than 30 days from the original purchase date will be considered fulfilled as a professional medical service, regardless of shipment status."* The clock runs on the order, not on delivery — so raise any problem inside 30 days. **And the consult fee contradicts the FAQ.** CoreAge's FAQ states: *"If the provider does not approve your prescription, we automatically issue a 100% refund."* The Refund Policy says otherwise: *"The provider consultation fee ($50–$100, depending on your order) is non-refundable, even if: You cancel before pharmacy fulfillment / Your prescription is not approved / You change your mind about treatment."* Two CoreAge documents, two answers. Budget for the fee and assume the policy governs — see [what longevity care costs](/longevity-clinic-cost). **Update, August 2026: the promo-anchored headline is gone.** Earlier versions of this review flagged NAD+ shown at $93 struck through against a $199 "list" price with a "SAVE 53%" badge, and sermorelin at $99 against $299 the same way. As of our most recent check, both product pages show only "Starting at $93 Per month" and "Starting at $99 per month" — no strikethrough, no comparison price, no savings badge. That's a real improvement in how the headline is presented, though the "starting at" qualifier and the 12-month-plan basis behind it are unchanged. ## What's included, what's extra Included: the provider review, the compounded medication, injection supplies (31G syringes), overnight cold shipping, portal messaging, and 1:1 phone calls with nurses and registered dietitians. The injection is one 10 mL vial at 100 mg/mL — 1,000 mg, dosed Monday to Friday; the nasal spray is a 25 mL pump at 300 mg/mL. Extra: the $50–$100 consultation fee. Not offered at all: bloodwork, biomarker panels or any before-and-after testing — a deliberate design choice, and why nothing here can tell you whether the protocol did anything. But **there is no auto-billing**: refills are manual reorders, and in a category built on silent renewals that is a real consumer protection. ## Clinical oversight: who prescribes, and what they check An intake is reviewed by a US-licensed clinician before anything ships, and the site is explicit that there is no algorithm-only path to a prescription. Nurse and dietitian calls sit inside the price rather than being billed by the minute. That beats a rubber-stamp questionnaire, and our [grading methodology](/how-we-grade-longevity-providers) weights oversight at 25%. Two things it does not do. **No clinician is named** — no medical director, no prescriber, nowhere on the public site. And **the pharmacy is not named**, which matters because the "503A licensed pharmacy" badge carries more weight in the marketing than it can bear: under section 503A of the FD&C Act, drugs compounded in a state-licensed pharmacy are specifically **not** subject to current good manufacturing practice requirements, unlike a 503B outsourcing facility. A legal category, not a quality certification. There is also no lab work at any point — no baseline IGF-1 before sermorelin, no follow-up panel after. ## The evidence behind what it sells This is the axis our rubric weights heaviest, and it is where CoreAge's marketing outruns its own product. **On NAD+,** the landing page states it "Activates longevity genes," "Crosses the blood-brain barrier — this is why mental clarity and word recall come back," and at month 12 delivers "A different rate of aging." Its decline curve — 100% at 20, 50% at 40, 20% at 60 — is sourced only to "peer-reviewed literature on aging." The human data support something narrower: NAD+ does fall with age and oral nicotinamide riboside reliably raises it, but the strongest randomized trial to date moved 6-minute walk distance by roughly 17.6 meters in peripheral artery disease. No completed human trial shows NAD+ repletion improves cognition, energy or the rate of aging. See [NAD+ for longevity](/nad-for-longevity) and [do NAD+ peptides actually work](/do-nad-peptides-work). **On sermorelin the gap is wider, and it is worth being specific.** CoreAge sells it as "Build muscle. Burn fat. Sleep deeply again," promising "Leaner body composition," "Smoother skin, fuller hair," and a month-by-month timeline ending in "Sustained anti-aging" with IGF-1 "measurably elevated." Sermorelin is GHRH 1-29, and the trial testing exactly that claim was run in the population CoreAge markets to. Eleven healthy, non-obese men aged 64–76 with low baseline IGF-1 self-injected 2 mg of GHRH nightly for six weeks, with GH sampled every 20 minutes overnight and body composition measured by DEXA. The mechanism worked: mean nocturnal GH release, area under the GH peak and peak amplitude all rose significantly. **The outcomes did not follow.** There was **no change in IGF-1**, IGF binding protein-3 or GH binding protein, and **no change in weight, BMI, waist-to-hip ratio, or DEXA-measured muscle and fat**. Two of six strength measures improved. The authors concluded that single nightly doses "are less effective than multiple daily doses of GHRH in eliciting GH- and/or IGF-1-mediated effects" — and a daily bedtime injection is precisely the protocol CoreAge sells. The wider literature agrees. A larger GHRH trial in older adults found a cognitive signal but no body-composition transformation. The landmark systematic review of growth hormone in healthy older adults found small body-composition shifts, no proven functional benefit and significantly more adverse events, and the review literature is clear the rejuvenation story is unsupported — across species, *lower* GH/IGF-1 signaling tracks with longer lifespan. See [peptides for longevity](/peptides-for-longevity) and [what's proven vs hyped](/longevity-medicine-evidence). **And none of it is FDA-approved.** FDA is unambiguous: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed". To CoreAge's credit, its own landing page says this outright rather than burying it. ## "CoreAge Rx complaints": what its own documents say Search that phrase and you get aggregators. Here is the version you can check in one click, because every item below is in CoreAge's own published terms. **The price you were quoted may not be the price you pay.** The advertised figure is the 12-month rate; the 1-month rate is unpublished. Ask for it before you pay. **Leaving a long plan costs money.** Cancel a 6- or 12-month plan early and you are billed at the 3-month rate for medication already shipped. **Non-approval is not a full refund.** The $50–$100 consultation fee is non-refundable by policy even when the prescription is declined, despite the sales pages saying otherwise. **Refunds close fast.** Orders can be canceled at no cost only before a provider approves the prescription *and* before it reaches the pharmacy; after that, *"ALL SALES ARE FINAL."* Any order open past 30 days is deemed fulfilled regardless of shipment status. None of that makes it a bad buy — the underlying model is still cheaper and less encumbered than most providers here. It means the safe way to buy it is one month at a time. ## Where it's weak, and who should skip it Skip it if you would be buying the anti-aging story — those claims are not supported by the human trials, and there is no bloodwork here to tell you otherwise. Skip it if you want a named prescriber or pharmacy before you commit, or if you need a program that measures anything: this is a dispensing service, not a diagnostics one. If you proceed, take CoreAge's own advice and **start on the 1-month plan.** Ask its price before you pay, ask what the consultation fee is on your order, and raise any problem inside 30 days. ## The verdict, against the rubric CoreAge Rx is our #1 pick and it holds the position on the marks we publish: flat published price, consult included, 503A pharmacy, no labs required, support included — 5 of 5. Those marks measure *published terms*, the thing a buyer can act on before spending money, and on that axis CoreAge beats every membership program and every "book a consult for pricing" wall in our ranking. What the marks do not measure — and this is worth saying loudly on our own top pick — is whether anything it sells works. Nothing here is a claim that NAD+ or sermorelin slows aging, improves cognition or extends life, because no completed human trial shows that. Our deductions are specific and first-party: the headline is a 12-month rate with no published one-month alternative, the refund policy contradicts the sales pages on the consultation fee, and the sermorelin marketing describes outcomes the trial in that exact population did not produce. So buy it for what it verifiably is — the least-encumbered way to get a clinician-reviewed compounded protocol at a knowable price, with no membership and no silent renewal. Buy the first month, not the twelfth, and buy it knowing the molecule is unproven, which is a statement about the field rather than this company. The full graded field is at [our provider rankings](/best-longevity-clinics); two closer-run alternatives are in our [AgelessRx review](/agelessrx-review) and [Hone Health review](/hone-health-review). Sources: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers, https://pubmed.ncbi.nlm.nih.gov/22848760/, https://pubmed.ncbi.nlm.nih.gov/29599478/, https://pubmed.ncbi.nlm.nih.gov/38871717/, https://pubmed.ncbi.nlm.nih.gov/9005976/, https://pubmed.ncbi.nlm.nih.gov/22869065/, https://pubmed.ncbi.nlm.nih.gov/17227934/, https://pubmed.ncbi.nlm.nih.gov/29756419/ --- ### Shed Reviews: NAD+ Cost, the Two-Month Minimum, and the Verdict Canonical: https://longevitygraded.com/shed-review Updated: 2026-08-04 Shed advertises NAD+ from $144/mo. Its own terms require a two-month minimum and print the membership rate as an unfilled blank. Verified July 2026. ## The one-sentence version Shed publishes three NAD+ prices — $169/mo for injections, $144 for the nasal spray, $169 for oral tablets — and then, in its own Terms and Conditions, requires a **two-month minimum commitment** that no product page mentions. It grades **C, 6 points out of 14**, the bottom band of our ranking, and it is a paid partner here; the grade is computed from published terms alone and cannot see who pays us. The single most useful thing in this review is not a price. It is section 14.1 of Shed's live terms, where the membership rate is printed as "$[X]" — an unfilled template placeholder, still on the page today. ## What Shed is, and who it's for Shed is a metabolic telehealth practice whose main business is compounded GLP-1s, with a "Longevity + Vitality" line beside it: NAD+ as an injection, a nasal spray or an oral tablet, plus sermorelin, low-dose naltrexone and methylene blue. You complete an intake — *"A medical provider will look over your answers and determine if you're a good fit—no appointment required"* — and an approved prescription is filled by a compounding pharmacy. The corporate structure is spelled out more plainly than most of the field manages. Shed *"provides administrative, technology, and membership services only and does not provide medical care, diagnosis, or treatment,"* and *"all professional medical services are provided by independent, physician-owned or licensed entities."* The operating company is named as well — Shed Holdings, LLC, South Jordan, Utah — and so, unusually, are the pharmacies. Credit where it is due: that is more disclosure than several better-graded rows offer. The buyer this suits wants NAD+ in a route other than a needle and is willing to commit two months before learning the all-in figure. If that gives you pause, it should — see [what longevity care actually costs](/longevity-clinic-cost). ## What it actually costs — and the commitment nobody advertises **The headline.** NAD+ injections "Starting at $169/month," taken three times weekly. Nasal spray "Starting at $144/month," daily. Oral tablets "Starting at $169/month," daily. Each is described as a one-month supply. The nasal route at $144 is genuinely among the cheaper non-oral NAD+ prices in our ranking. **The commitment those prices sit on.** Shed's Terms and Conditions, section 11.1: *"All programs require a minimum commitment of two (2) full months. Early cancellation within this period does not release you from payment obligations and will not result in a refund or credit."* Elsewhere the same document puts it as *"Subscriptions are only eligible for cancellation after two months or at the close of your renewal cycles, whichever is longer."* Nothing on the NAD+ product page says this. The practical floor on a $169 plan is therefore $338, not $169. **Billing may not be monthly.** Also from the terms: *"Billing may occur either every twenty-eight (28) days or on a monthly basis, depending on your specific program."* A 28-day cycle is thirteen charges a year, not twelve — roughly $2,197 on the injection rather than the $2,028 that "per month" implies. **Canceling has a 72-hour tripwire.** *"You must cancel your subscription at least seventy-two (72) hours before your next billing date to avoid being charged for the upcoming month. Cancellations submitted less than 72 hours before your billing date will apply to the following month."* **And the fees do not come back.** Section 11.4: *"All subscription fees are non-refundable once charged,"* explicitly including where *"you attempt to cancel before fulfilling the two-month minimum commitment"* or *"you cancel after the 72-hour cancellation window."* There is a 120-day weight-loss guarantee, but it is tied to the weight-loss program and its own engagement conditions, not to NAD+. **The membership is a second, unpriced layer.** Shed Care Membership Plans are separate from medication and cover provider visits, coaching and triage messaging. Section 14.1 offers a 6-month and a 12-month membership; both prices read *"$[X],"* and section 14.2 describes a promotional discount off a standard month-to-month rate of *"$[Y] per month."* Those are unfilled placeholders in a live legal document. Early termination forfeits the promotional rate and triggers a "True-Up" back to the standard rate — a rate the terms never state. ## What's included, and what the price is not Here is the part that decides the grade. Shed's own financial-agreement clause says the money you send it is not payment for care: *"Payments made to Shed are for administrative, technology, and membership services that provide access to the Shed Platform and related non-clinical resources. All professional medical services are provided by independent, licensed healthcare providers."* Its corporate-practice clause is blunter still — *"no portion of the membership fee paid to Shed constitutes payment for medical services."* So the honest answer to "is the consult included in $169?" is that Shed has published the opposite. The clinical fee may be collected by an independent medical group rather than by Shed, and its amount is not published anywhere public. That is why this row scores zero on clinical oversight and zero on price transparency: not because the care is absent, but because the total is unknowable before you commit. Compare that with a flat all-in figure — the distinction is the whole subject of [longevity clinics versus lab memberships](/longevity-clinics-vs-lab-memberships). Not included at any point: baseline or follow-up bloodwork. Nothing here measures whether the protocol did anything. ## Clinical oversight and the pharmacy Prescriptions are reviewed by licensed clinicians in independent physician-owned entities before anything ships, which is the normal and appropriate structure. On pharmacy, Shed is better than its grade suggests and worse than its marketing implies. Section 38 of the terms names three dispensing partners with street addresses — Strive Compounding Pharmacy in Gilbert, Arizona; Promise Pharmacy in Palm Harbor, Florida; Foothills Professional Pharmacy in Tempe, Arizona. Only a minority of rows here name their pharmacies at all, and fewer still give addresses. But Shed's own blog hedges the standard: *"we partner with both 503A and 503B pharmacies, which allows us to continue providing these medications."* Those are different regimes — a 503B outsourcing facility must follow current good manufacturing practice, while a 503A pharmacy specifically need not — and which one prepares your vial is not knowable in advance. Either way the product is compounded, and FDA is explicit that *"compounded drugs are not FDA-approved… FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed"*. ## The evidence behind what it sells Shed's NAD+ page claims the product "supports normal cellular energy production," "supports normal cognitive function," "supports healthy aging as part of overall wellness" and helps with "mental clarity and focus maintenance." The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies, 33 of them human intervention trials. Its finding: oral nicotinamide riboside and NMN consistently raise NAD+ levels and are well tolerated, but effects on functional, metabolic and vascular outcomes were *"heterogeneous and often null or endpoint-specific,"* and clinical effectiveness for anti-aging or wellness *"remains inconclusive"*. Crucially for a company selling injections: *"No eligible outcomes trials evaluated intravenous or intramuscular NAD+ itself for anti-aging or wellness indications"*. The route Shed charges most for is the one with the least human outcome data behind it. On the specific promises: a 2025 meta-analysis of randomized trials in adults averaging over 60 found NMN and NR did not improve muscle index, grip strength, gait speed or chair-stand time, concluding that current evidence *"does not support"* them for preserving muscle mass and function. Levels do move — oral NR reliably raises blood NAD+ — and the strongest randomized trial to date improved six-minute walk distance by about 17.6 meters in peripheral artery disease, a disease endpoint rather than an aging one. No completed human trial shows NAD+ repletion improves cognition, energy or the rate of aging. See [NAD+ for longevity](/nad-for-longevity), [do NAD+ peptides actually work](/do-nad-peptides-work) and [what's proven versus hyped](/longevity-medicine-evidence). ## "Shed complaints": what its own terms say Every item here is in Shed's published documents, so you can check it in one click. **You cannot leave in month one.** Two full months minimum, no refund or credit for trying. **The advertised price may not be the billing cadence.** Twenty-eight-day cycles mean thirteen charges a year. **Cancel 72 hours early or pay again.** Late requests roll to the following month. **Fees are non-refundable once charged**, including when you cancel inside the minimum term. **The membership price is not published.** It is a blank in the contract. ## Where it's weak, and who should skip it Skip Shed if you need to know your total before you commit — that is its defining failure, and no amount of route choice compensates. Skip it if you want a single all-in figure with the clinician's fee inside it; several partners in our ranking publish exactly that. Skip it, above all, if you are buying the cognition and energy claims, because the human trials do not support them. If you proceed anyway, do it with your eyes open: budget two months, ask what the clinical fee is and who collects it, ask which of the three pharmacies will fill your prescription, and diarise the 72-hour cancellation window the day you sign up. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), whether the provider sells real longevity medicine (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Shed takes the full four for a genuine longevity line — three NAD+ routes plus sermorelin is more than most — and two for stating a compounding standard on a surface it controls. It takes nothing for price transparency, nothing for oversight and nothing for support, because the all-in figure is not published, the terms deny the fee buys care, and no coaching or clinician time is bundled into the advertised rate. Six of fourteen. A **C**, and the lowest band here. That is not a claim Shed is dishonest. Its terms are unusually detailed, its pharmacies are named with addresses, and its corporate structure is disclosed more candidly than several A-graded rows. The failure is narrower and harder to defend: a reader who wants to know what a year of NAD+ costs at Shed cannot find out from Shed. Until the membership rate replaces "$[X]" with a number, that is the review. The full graded field is at [our provider rankings](/best-longevity-clinics), the scoring is set out in [how we grade](/how-we-grade-longevity-providers), and two cleaner-priced neighbors are in our [Enhance MD review](/enhance-md-review) and [Sprout Health review](/sprout-health-review). Sources: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers, https://pubmed.ncbi.nlm.nih.gov/41655607/, https://pubmed.ncbi.nlm.nih.gov/40275690/, https://pubmed.ncbi.nlm.nih.gov/29599478/, https://pubmed.ncbi.nlm.nih.gov/38871717/ --- ### Sprout Health Reviews: What the $199 Becomes, and the Verdict Canonical: https://longevitygraded.com/sprout-health-review Updated: 2026-08-04 Sprout Health leads with $199 for NAD+. The recurring rate is $249 every four weeks. What that costs, what's included, and where it loses points. ## The one-sentence version Sprout Health sells one thing well: a single all-in NAD+ injection program with the clinician evaluation, the injection kit and expedited shipping inside one monthly figure and no minimum term. The figure is **$249, not the $199 the site leads with** — $199 buys the first month only — and it renews **every four weeks**, which is thirteen charges a year rather than twelve. It grades **A, 11 points out of 14**, and it is a paid partner here; the grade is computed from published terms alone and cannot see who pays us. It loses its points in one place, and it is not the price. ## What Sprout Health is, and who it's for Sprout Health is a LegitScript-certified telehealth practice operated by Sprout Health Partners LLC. Its longevity line is deliberately narrow — compounded NAD+ as a subcutaneous injection, sold as a single program rather than a menu — alongside a larger compounded GLP-1 business. You complete a medical intake, *"a licensed provider will review your info and determine if NAD+ therapy is right for you — no clinic visit required,"* and if approved the prescription goes to a compounding pharmacy. Shipping is *"free, discreet"* and quoted at three to seven business days after approval. There is no lab gate and no membership wrapper. That is genuinely the low-friction end of this category, and it suits a buyer who wants one route, one price and no diagnostic preamble. A buyer who wants baseline biomarkers before starting is in the wrong shop and should read [longevity clinics versus lab memberships](/longevity-clinics-vs-lab-memberships) first. ## What it actually costs, and what "$199" is doing **The headline and the real rate.** The NAD+ page prices the monthly plan at *"$199 / first month"* then *"$249 /mo after"* for a 1,000 mg, 5 mL vial. The program page says it more directly: *"$199 your first month, then auto renews at $249 every 4 weeks."* So $199 is an introductory rate that steps up at the first refill, and $249 is what you actually pay from month two onward. To Sprout's credit, both pages state the step-up in plain language on their face — several competitors bury the equivalent in a policy document. **The four-week cadence is the part to do arithmetic on.** "Every 4 weeks" is thirteen billing cycles in a year, not twelve. At $249 that is roughly **$3,237 a year, about $249 more than the $2,988 that "per month" implies.** No page states the annual figure. **There is a cheaper prepay tier.** A three-month plan runs *"$175 / first month"* then *"$225 /mo after"* — about $24 a month less than the monthly plan, in exchange for paying up front. Unusually, leaving it is fair: the refund policy grants pro-rata refunds for unshipped months, and works the example — a $233.33-per-month plan value refunding $233.33 if you cancel after two of three shipments. That is a materially better multi-month exit than most providers here offer. **No minimum term.** *"No long-term contracts."* Cancel whenever you like, subject to one tripwire below. **Cancel 48 hours early.** *"To avoid being charged for the next billing cycle, we need to receive your cancellation request at least 48 hours before your next scheduled billing date. Requests received after that window will take effect the following cycle, and the upcoming charge will still apply."* **The free consult is conditional.** The program page promises *"free initial consultation: if you're not eligible, you pay nothing"* — and that is true as written. What is also true, from the refund policy, is that once a provider has reviewed you and you change your mind before the prescription reaches the pharmacy, you get a *"refund minus a flat $50 clinical review fee, reflecting the completed provider consultation."* Being declined costs nothing; being approved and reconsidering costs $50. After the prescription reaches the pharmacy it is non-refundable, which is standard and lawful — dispensed medication cannot be restocked. ## What's included, and what isn't Included in $249: the clinician evaluation, the compounded NAD+ vial, *"all supplies to get started right away"* — syringes and alcohol wipes — and free expedited shipping. One figure, no add-ons, no membership. Not included, and this is where the row loses points: no coaching, no dietitian time, no bundled human support beyond the care team, and no bloodwork at any stage. Nothing in the program measures whether the injections changed anything about you. For what such measurement would actually involve, see [longevity biomarker panels](/longevity-biomarker-panels). ## Clinical oversight and the pharmacy A licensed provider reviews every intake before anything ships, and that review is inside the price rather than billed separately — worth two of our fourteen points, and Sprout earns them. The pharmacy is where it drops the rest — but only half of it, and this review said otherwise until 9 August 2026. Sprout **does** name its dispensing pharmacies. Section 29 of its Terms, headed *"External Services Contacts,"* and the same block in its HIPAA notice both list **MDI (MD Integrations)** as the clinician network, **Foothills Pharmacy** (rx@foothillspharmacy.com) and **Promise Pharmacy** (info@promisepharmacy.com). Two named, checkable entities, published on two documents Sprout controls. What it will not do is classify them. On the product page it says only that its NAD+ is *"compounded in the United States by state-licensed pharmacies"* following *"strict pharmaceutical protocols"* — and the strings "503A" and "503B" appear nowhere on the site at all. When its own press material was asked the question directly, it declined to answer: *"Is the pharmacy state-licensed and operating under Section 503A or 503B of the FD&C Act? This varies by pharmacy and should be confirmed directly with the dispensing entity."* Naming the facility without stating its section is the middle rung of our pharmacy test, so this factor scores one of two rather than the zero we previously published. **A correction, stated plainly.** An earlier version of this page said *"no pharmacy is named."* That was wrong, and it was wrong about a company that pays us — the worse direction to be wrong in. The claim came from reading the product page and the press release without reading section 29 of the Terms. Sprout's grade moves up by one point as a result, by the same formula applied to every row. The distinction is not pedantry. A 503B outsourcing facility must follow current good manufacturing practice; a 503A compounding pharmacy specifically is not subject to those requirements. And either way, FDA is explicit: *"compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed"*. ## The FDA warning letter, in proportion On 9 September 2025, FDA issued a warning letter to **Sprout Health Partners LLC dba Sprout Health** (MARCS-CMS 715879). That is the entity name exactly as the letter's own recipient block writes it, and it is how you find the letter yourself: search that string in the [FDA's warning-letter database](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters). The letter remains open — FDA's index records no close-out date against it. We state that the letter exists, who it was addressed to, and when. We do not restate what it alleges, and that restraint is deliberate: summarizing an enforcement action on a page that earns a commission from the company would be us making the accusation, where naming the addressee and the date is us reporting that the FDA made one. FDA's copy is one search away and says it better than a paraphrase would. What is worth stating, because omitting it would mislead in the other direction, is the letter's **scope**: it concerns the company's compounded GLP-1 line, not the NAD+ program this review is about. ## The evidence behind what it sells Sprout sells NAD+ as energy, recovery and "age reversal." The literature does not carry that. The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies, 33 of them human intervention trials. Oral nicotinamide riboside and NMN reliably engage the target — blood NAD+ rises — and are well tolerated, but effects on functional, metabolic and vascular outcomes were *"heterogeneous and often null or endpoint-specific,"* and clinical effectiveness for anti-aging or wellness *"remains inconclusive"*. The review is blunter still about injected NAD+: *"no eligible outcomes trials evaluated intravenous or intramuscular NAD+ itself for anti-aging or wellness indications"*. Sprout sells exactly one route, and it is the route with no outcome trials behind it. The strongest randomized trial in the field moved six-minute walk distance by roughly 17.6 meters in peripheral artery disease — a disease endpoint, not an aging one. A separate systematic review of NAD and NADH across ten randomized trials in 489 participants found supplementation well tolerated with no serious safety signal, and outcomes scattered across unrelated conditions rather than converging on healthspan. No completed human trial shows NAD+ repletion improves cognition, energy or the rate of aging. See [NAD+ for longevity](/nad-for-longevity), [do NAD+ peptides actually work](/do-nad-peptides-work) and [what's proven versus hyped](/longevity-medicine-evidence). ## Where it's weak, and who should skip it Skip Sprout if you want to know which pharmacy standard applies to your vial — it will not tell you, and it has said so in writing. Skip it if you want coaching, follow-up or any measurement of effect; this is a dispensing program, not a care program. Skip it if $249 every four weeks for a single injectable route looks expensive next to the ranking, because it is at the top of the month-to-month range. If you proceed, do three things: budget $249 rather than $199, budget thirteen cycles rather than twelve, and set a reminder 48 hours before each billing date. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), whether the provider sells real longevity medicine (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Sprout takes the full four for price transparency — one all-in published figure, no membership, no prepay required to reach it, and the step-up disclosed on the page rather than buried. It takes four for a genuine longevity line and two for a clinician review inside the price. It takes **one of two for pharmacy** — it names Foothills and Promise in its Terms and HIPAA notice, which is the middle rung, but never says whether either is a 503A or 503B facility, which is the top one — and **zero for support**, because nothing beyond the care team is bundled. Eleven of fourteen. An **A**, at the floor of the band. That is a fair reflection of what it is: an honest, narrow, slightly expensive program that tells you who fills the vial but not what kind of pharmacy fills it. The price is not the criticism — the criticism is that a company willing to publish a real recurring rate, a real cancellation window, a pro-rata multi-month refund **and** two named pharmacies is still willing to send you to the pharmacy for the one remaining answer it could give itself. Adding the section to the two names already published would take this row to the top rung and twelve of fourteen. The full graded field is at [our provider rankings](/best-longevity-clinics), the scoring is set out in [how we grade](/how-we-grade-longevity-providers), and two neighbors are in our [Enhance MD review](/enhance-md-review) and [Shed review](/shed-review). Sources: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers, https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters, https://pubmed.ncbi.nlm.nih.gov/29599478/, https://pubmed.ncbi.nlm.nih.gov/41655607/, https://pubmed.ncbi.nlm.nih.gov/38871717/, https://pubmed.ncbi.nlm.nih.gov/37971292/ --- ### Enhance MD Reviews: The $169 NAD+ Catch, and the Verdict Canonical: https://longevitygraded.com/enhance-md-review Updated: 2026-08-07 Enhance MD advertises NAD+ at $169/mo. That rate needs a 12-month prepay; month-to-month is $199 injection or $99 wafers. Verified July 2026. ## The one-sentence version Enhance MD advertises NAD+ therapy at "$169/month." That figure exists, but only at the bottom of a twelve-month prepay — the real month-to-month price is **$199 for the injection and $99 for sublingual wafers**. Everything else about how it prices is unusually clean: the whole ladder is published on the product page, the consult and lab work are inside the figure, and you are refunded in full if you are found ineligible. It grades **A, 14 points out of 14** — the top of our rubric — and it is a paid partner here; the grade is computed from published terms alone and cannot see who pays us. ## What it is, and who it's for Enhance MD is a compounded telehealth practice built around a "metabolic reset" — GLP-1 tiers as the main business, with NAD+ sold beside them in two routes: subcutaneous injection and sublingual wafers. Prescriptions follow an online consultation with a licensed provider, and the program includes periodic monitoring: *"your labs will be monitored every six months while enrolled in the Enhance.MD program."* The buyer this suits wants NAD+ at a knowable price without a membership, and either tolerates a lab cadence or actively wants one. The $99 wafer tier is the cheapest published month-to-month NAD+ route in our ranking — worth knowing before you assume an injection is the only option. On what that monitoring is worth, see [longevity biomarker panels](/longevity-biomarker-panels). ## What it actually costs **The injection ladder.** One month $199/mo, billed every 4 weeks. Three months $189/mo (save 5%), billed every 12 weeks. Six months $179/mo (save 10%), billed every 24 weeks. Twelve months $169/mo (save 15%), billed every 48 weeks. **The wafer ladder.** $99, $94, $89 and $84 across the same four terms. **The headline is the twelfth rung.** The homepage advertises "NAD+ Therapy Starting at $169/month." Nothing you can buy monthly costs $169. That figure is the effective rate of a twelve-month commitment paid in one charge, and the homepage does not say so on its face. The product page does publish the full ladder, plainly, which is why this costs Enhance MD a paragraph here rather than four rubric points. For the version of the same trick that does cost four points, see our [MyDrHank review](/mydrhank-review) — an identical twelve-month-rate-as-headline, with the monthly rung rendered on no page at all. **Two cadence details worth the arithmetic.** "Billed every 4 weeks" is thirteen charges a year, not twelve — about **$2,587 annually on the injection**, not the $2,388 that "per month" implies. And the twelve-month plan is *"billed every 48 weeks"*: a "12-month" plan is 48 weeks of medication, not 52. **What's included.** As of our August 2026 check, the NAD+ FAQ states: *"Your program includes pharmaceutical-grade NAD+ vials, all injection supplies, monthly medical provider check-ins, unlimited provider messaging, cellular health lab tracking, and priority support throughout your therapy."* That's a real, described support inclusion, not just a consult — it's the reason this row now scores full marks on human support. One scoping note: the site's "same price at every dose" guarantee, which we previously described as applying broadly, is now stated specifically for the GLP-1 line on the homepage; we found no equivalent guarantee language on the NAD+ page itself. **What happens if you leave.** *"If at any point during the onboarding process your provider finds you ineligible for medication, Enhance.MD will provide a refund"* — 100% of the initial payment. You can pause or cancel at any time, and the subscription *"will auto-renew unless canceled before the next billing cycle."* One genuine gap: the published terms of service say only that *"full subscription and payment terms are provided at checkout,"* so what happens if you abandon a twelve-month prepay early is not stated anywhere public. Ask before you prepay — see [what longevity care costs](/longevity-clinic-cost). ## Clinical oversight and the pharmacy An online consultation with a licensed provider precedes any prescription, that consultation is inside the price, and labs run every six months. Bundling both is above average here. On pharmacy, Enhance MD states the standard but not the facility: *"it is compounded in accordance with federal Section 503A guidelines,"* on the NAD+ product page, while its FAQ says it *"partners with a network of third-party pharmacies."* Stating the section earns the top rung of our pharmacy factor, but it should not be read as a quality certification — 503A compounders are specifically **not** subject to current good manufacturing practice requirements, unlike 503B outsourcing facilities, and FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed. To its credit, Enhance MD says this itself: *"this compounded formulation is not FDA-approved."* ## The evidence behind what it sells The product page describes NAD+ as a *"cellular energy reboot"* that *"raises NAD+ levels to power mitochondria and boost ATP production,"* delivering *"maximum bioavailability… for rapid energy improvement."* The first half is defensible; the second is not. The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies, 33 of them human intervention trials. Oral precursors reliably engage the target and are well tolerated, but effects on functional, metabolic and vascular outcomes were *"heterogeneous and often null or endpoint-specific,"* with clinical effectiveness *"inconclusive"*. It also reported that **no eligible outcomes trials evaluated intravenous or intramuscular NAD+ itself** for these indications — which bears directly on the injection tier, and on any bioavailability argument for paying twice the wafer price. A 2025 meta-analysis in adults averaging over 60 found NMN and NR did not improve muscle index, grip strength, gait speed or chair-stand time. The strongest randomized trial in the field improved six-minute walk distance by about 17.6 meters in peripheral artery disease — a disease endpoint, not an aging one. No completed human trial shows NAD+ repletion improves energy, cognition or the rate of aging. See [NAD+ for longevity](/nad-for-longevity), [do NAD+ peptides actually work](/do-nad-peptides-work) and [what's proven versus hyped](/longevity-medicine-evidence). ## Where it's weak, and who should skip it Skip it if you are buying the "rapid energy improvement" promise; nothing in the trial record delivers it. Skip it if a six-month lab cadence is friction you do not want. And do not prepay twelve months until someone at Enhance MD tells you in writing what an early exit costs — that term is not published. If the wafers suit you clinically, note that $99 month-to-month is the cheapest published NAD+ route we grade, and it requires no commitment at all. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Enhance MD takes price transparency in full — the entire four-rung ladder is published for both routes, with the billing cadence stated beside each rung, which is more than most providers here manage. It takes four for a real longevity line, two for a consult inside the price, two for stating its compounding section, and — as of our August 2026 check — the full two for human support, now that the NAD+ page explicitly bundles unlimited provider messaging and priority support into the price. **Fourteen of fourteen. An A.** The complaint is narrower than the grade suggests but it is real: the number on the homepage is not a number anyone pays monthly, and the exit terms on the plan that reaches it are not published. Fix the headline and publish the early-cancellation rule, and there would be very little left to criticize. The full graded field is at [our provider rankings](/best-longevity-clinics), the scoring is set out in [how we grade](/how-we-grade-longevity-providers), and two neighbors are in our [Sprout Health review](/sprout-health-review) and [Shed review](/shed-review). Sources: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers, https://pubmed.ncbi.nlm.nih.gov/41655607/, https://pubmed.ncbi.nlm.nih.gov/40275690/, https://pubmed.ncbi.nlm.nih.gov/38871717/ --- ### HealthRX Reviews: The $161 Is Real, and That's Rare Canonical: https://longevitygraded.com/healthrx-review Updated: 2026-08-04 HealthRX advertises NAD+ at $161/mo and that is the month-to-month rate, not a prepay. What the price hides, and what it doesn't. July 2026. ## The one-sentence version HealthRX advertises NAD+ injection at **$161/mo**, and $161 is what a month-to-month buyer is actually charged — a sentence we have not been able to write about most providers here. The multi-month plans go *down* from there rather than the headline being the bottom rung dressed up as a monthly price. It grades **A, 14 out of 14**, tied for the highest score on our rankings, and the grade is computed from published terms alone and cannot see who pays us. ## What it is, and who it's for HealthRX is a LegitScript-certified compounded telehealth practice (CERT 50087439) with a longevity shelf rather than a single hero product: NAD+ as an injection or a nasal spray, plus sermorelin, rapamycin, metformin, methylene blue, low-dose naltrexone, glutathione, enclomiphene and testosterone. Every one carries a published monthly figure on the shop page. Shipping is *"free overnight… all 50 states."* The buyer this suits wants a compounded protocol at a number they can read before entering a card, with no membership, no lab gate and no consultation fee. If you want bloodwork attached to the protocol, this is not that — see [longevity biomarker panels](/longevity-biomarker-panels) for what a monitored program looks like instead. ## What it actually costs **The subscribe rate is the monthly rate.** NAD+ injection $161/mo billed monthly; nasal spray $134/mo billed monthly. Before choosing between them, note that [only the oral route has human outcome trials behind it](/nad-injections-vs-iv-vs-oral). Both auto-renew, and the page states *"pause or cancel anytime."* **The one-time price is published too.** A "One-time" tab sits beside "Subscribe" on every product page: $179 for the injection, $149 for the nasal spray. Subscribing takes 10% off — *"Save 10% today and on every refill."* So the advertised figure does require auto-refill, but the alternative is displayed rather than hidden, and the gap is 11%, not the 18–20% we have found elsewhere. **The longer cadences go down, not up.** On the injection: every 3 months $145/mo ($434 total, save 10%), every 6 months $137/mo ($821, 15%), every 12 months $129/mo ($1,546, 20%). On the nasal spray: $120, $114 and $107 respectively. **The catalog label is "SUBSCRIBE FROM $161/mo" — and $161 is the *dearest* subscribe rung.** "From" is doing the opposite of what it does everywhere else in this category, where a "from" price is invariably the twelve-month prepay. Read literally it is loose wording; read commercially it errs in the buyer's favor, which is why it costs HealthRX a sentence here rather than a rubric point. **What's inside the figure.** *"Medication and supplies," "Provider visit and unlimited follow-ups," "Free expedited shipping,"* and an injection home kit. No membership, no lab requirement, no separate consultation fee. The injection is 1,000 mg per month; the nasal spray is a 15 mL bottle at 300 mg/mL, with *"strength set by your provider."* **If you are declined, you are not billed.** *"If your provider decides NAD+ injection isn't clinically appropriate for you, you won't be charged for the medication."* Note the wording covers the medication specifically — there is no separate consult fee here to argue about, which is the point. On how these figures sit against clinic pricing generally, see [what longevity care costs](/longevity-clinic-cost). ## Clinical oversight and the pharmacy Prescriptions follow a review by *"an independent US Board-certified physician,"* and follow-ups are unlimited rather than metered. Our [grading methodology](/how-we-grade-longevity-providers) weights that at two points, and HealthRX takes them. On pharmacy it states the standard and not the facility: *"filled by a licensed Section 503A compounding pharmacy,"* with a "COMPOUNDED BY A LICENSED 503A PHARMACY" badge in the global footer and the full sentence in the product-page disclaimer. Stating the section earns the top rung of our pharmacy factor, but treat it as a legal category rather than a quality certification: 503A compounders are specifically **not** subject to current good manufacturing practice requirements, unlike 503B outsourcing facilities, and FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed. Which pharmacy actually fills your prescription is not disclosed. ## The evidence behind what it sells This is the section where most providers here embarrasses itself, and HealthRX does not. Its own product page says NAD+ injection *"is not FDA-approved for any use,"* that *"the most relevant human study is a single 50-person, eight-week pilot that measured safety, not whether the injection produces any specific wellness or performance benefit,"* and — remarkably — that *"we don't have solid human data on downstream effects like energy, fatigue, cognition, or aging markers, and we won't claim benefits the evidence doesn't yet support."* It discloses side-effect rates from that pilot: nausea about 22%, injection-site reactions about 18%, flushing, chest tightness on rapid infusion. The independent record agrees with them. The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies including 33 human intervention trials, found effects on functional, metabolic and vascular outcomes *"heterogeneous and often null or endpoint-specific"* with clinical effectiveness *"inconclusive,"* and reported that **no eligible outcomes trial has evaluated intravenous or intramuscular NAD+** for these indications at all. A 2025 meta-analysis in adults averaging over 60 found NMN and NR did not improve muscle index, grip strength, gait speed or chair-stand time. The strongest randomized trial in the field moved six-minute walk distance about 17.6 meters in peripheral artery disease — a disease endpoint, not an aging one. See [NAD+ for longevity](/nad-for-longevity), [do NAD+ peptides actually work](/do-nad-peptides-work) and [what's proven versus hyped](/longevity-medicine-evidence). ## Where it's weak, and who should skip it Two real gaps. The **pharmacy is not named**, so you know the standard and not the facility. And the **nasal spray is the weaker buy at $134/mo**: HealthRX itself says the route *"hasn't been measured in human studies at all; its human bioavailability is currently unknown."* Paying $1,608 a year for an unmeasured route is a decision the page gives you enough information to refuse, which is to its credit, but it is still the decision. Skip it entirely if you want anything measured — there is no bloodwork here, before or after, so nothing in the program can tell you whether the protocol did anything. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). HealthRX takes all five. The whole ladder is published for both routes with the billing cadence beside each rung and the one-time alternative shown; the longevity line is a real shelf rather than a GLP-1 shop with an NAD+ add-on; the provider visit and unlimited follow-ups sit inside the price; and it states its compounding section on a surface it controls. **Fourteen out of fourteen. An A.** The complaint is that it will not name the pharmacy, and that the cheapest rungs are still prepays. What it does not do is the thing that costs everyone else here points: it does not advertise a number nobody pays. The full graded field is at [our provider rankings](/best-longevity-clinics); the two rows either side of it are our [CoreAge Rx review](/coreage-rx-review) and [Direct Meds review](/direct-meds-review). Sources: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers, https://pubmed.ncbi.nlm.nih.gov/41655607/, https://pubmed.ncbi.nlm.nih.gov/40275690/, https://pubmed.ncbi.nlm.nih.gov/38871717/ --- ### Direct Meds Reviews: The $99 NAD+ Is One Month Only Canonical: https://longevitygraded.com/direct-meds-review Updated: 2026-08-07 Direct Meds advertises NAD+ from $99. The ongoing price is $199 or $249/mo. Two of its pages name different compounding sections. July 2026. ## The one-sentence version Direct Meds sells NAD+ at **$199/mo for 500 mg and $249/mo for 1000 mg**, month-to-month, with no subscription and no automatic billing — and advertises it at *"starting at $99,"* which is the first month after a promotion. The underlying structure is genuinely clean; the headline is not, and neither is the pharmacy story, because two Direct Meds pages name two different compounding sections. It grades **A, 14 out of 14**, tied for the highest score here, computed from published terms alone and blind to who pays us. ## What it is, and who it's for Direct Meds is a compounded telehealth operator best known for GLP-1s, which also runs an Anti-Aging category of its own: NAD+ injection at two strengths, sermorelin injection, and a peptide skin cream. A one-minute qualifier is followed by payment for the first month, then a telehealth visit and a clinician review *"expected… within 24 hrs and often less than 5 hrs."* It holds LegitScript certification and publishes a medical director described as *"a practicing physician [who] has reviewed our doctor and pharmacy network."* The buyer this suits wants a compounded protocol with no membership, no access fee and — unusually — **no recurring charge at all**. See [longevity clinics vs lab memberships](/longevity-clinics-vs-lab-memberships). ## What it actually costs **NAD+, in Direct Meds' own words:** *"For NAD+ Injections, we charge $249/month for 1000mg and $199/month for 500mg. For a limited time you get $100 off your first month—just $99 for 500mg or $69 off your first month—just $180 for 1000mg."* The landing page leads with *"Starting at $99"* and a *"Up to $100 OFF"* badge. The $99 is one month. **GLP-1s carry the same shape.** *"For Semaglutide we charge $297/month. For Tirzepatide we charge $497/month. Our lowest cost option is $249/month for non-injectable sublingual oral medication."* The offer page shows those struck through against $147 and $149 — again, first order. **What the monthly figure covers.** *"Your medication, doctor review, pharmacy compounding, supplies, and 2-day shipping."* Telehealth visits are inside it and are priced separately at *"normally $99/visit."* There is no membership and no access fee, and dose increases do not reprice the plan — *"same price, every dose."* **There is no auto-billing, which is the best term here.** *"We believe in clear, honest pricing with no surprise charges or automatic billing. Reorder at your convenience through your Direct Meds Patient Portal."* Cancellation is *"no contracts for our month to month pricing,"* by email or phone. In a category built on silent renewals, that is a real consumer protection. **The one unpublished ladder.** The same answer adds: *"We also offer subscribe and save discounts where customers will agree to a subscription length for stated monthly discount."* Those lengths and discounts appear on no public page. If you are quoted one, you are seeing a number this site cannot check. **If you are declined, you are refunded.** *"If for any reason your prescription is not approved, you will receive a full refund."* Note the sequence: you pay for the first month *before* the intake is reviewed. ## Clinical oversight, and the pharmacy problem Prescriptions follow a telehealth visit with a licensed provider in your state, and Direct Meds publishes nursing staff as a stage of the program — *"on-going care & support with Direct Meds Nursing Staff"* — which is why it takes the human-support point. Our [grading methodology](/how-we-grade-longevity-providers) sets that out. The pharmacy is where it goes wrong, and the fault is specific. The GLP-1 offer page states: *"Medications prescribed through Direct Meds are dispensed by U.S.-based 503A compounding pharmacies."* The NAD+ page — the page you would actually buy this product from — states: *"Medications prescribed through Direct Meds are dispensed by U.S.-based 503B compounding pharmacies… 503B compounding pharmacies are licensed by state pharmacy boards and operate under federal compounding laws."* Those are different regimes, and the NAD+ page's description of the one it names is wrong: 503B outsourcing facilities register with FDA and must comply with current good manufacturing practice; being licensed by a state board of pharmacy is the 503A arrangement. Either the NAD+ line is a copy error or the two product lines use different facilities, and a buyer cannot tell which. What is not in doubt is that neither page names a pharmacy, and that compounded drugs of either class are not FDA-approved — *"FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed"*. ## The FDA warning letter, in proportion **On 9 September 2025, FDA's Center for Drug Evaluation and Research issued a warning letter to directmeds.com, Inc. dba DirectMeds (MARCS-CMS 716822)**. That is the entity name verbatim from the letter's recipient block, and it doubles as the citation: search that string in the [FDA's warning-letter database](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters) and the record is the first thing you see. FDA's index carries no close-out date against it, so it remains open. We report that the letter exists, who it names, and when it issued — and stop there. Restating the allegations would be us making the accusation; naming the addressee and the date is us reporting that the FDA made one, which is the only one of the two we are entitled to do on a page that earns a commission from the company. FDA's own copy is a search away and is the source worth reading. The entity FDA named is the one behind the domain, so there is no question of a similarly-named company being confused for this one. Its **scope** is worth stating because omitting it would mislead in the other direction: the letter concerns the compounded weight-loss line, not the NAD+ or sermorelin products this review grades. It does not move the grade, and that is a rule rather than a favor: our rubric scores published terms — price, consult, pharmacy disclosure, support and longevity line — and a regulatory factor introduced after seeing which rows it would hit is a rule written to fit a result. Two other providers here hold letters of their own, reported identically and on the same reasoning: see our [Sprout Health review](/sprout-health-review) and [Strut Health review](/strut-health-review). It belongs beside the section above rather than filed away from it. The pharmacy contradiction and the warning letter are independent findings about the same underlying thing — how carefully this company describes what it dispenses — and a reader weighing $199 a month is entitled to see them together. ## The evidence behind what it sells The NAD+ page is the most aggressive marketing in our ranking. It promises *"Start Aging Backwards,"* the *"fountain of youth peptide,"* and — as a heading — *"Scientifically Proven to Help You Feel Younger, Sharper, and More Alive."* Beneath that: *"Improve Memory & Focus,"* *"Revitalize Cellular DNA,"* *"support long-term longevity,"* *"~100% bioavailability,"* and results *"Fast — feel energy & clarity in days… starting with your very first dose."* None of that is supported. The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies including 33 human intervention trials and found effects on functional, metabolic and vascular outcomes *"heterogeneous and often null or endpoint-specific,"* with clinical effectiveness *"inconclusive."* It also reported that **no eligible outcomes trial has evaluated intravenous or intramuscular NAD+** for anti-aging or wellness indications at all — which is the entire product on this page. A 2025 meta-analysis in adults averaging over 60 found NMN and NR did not improve muscle index, grip strength, gait speed or chair-stand time, and the strongest randomized trial in the field moved six-minute walk distance about 17.6 meters in peripheral artery disease, a disease endpoint rather than an aging one. The sermorelin line has the same problem: the trial of that exact molecule given nightly to older men found nocturnal growth hormone rose while IGF-1, weight, BMI and DEXA-measured muscle and fat did not move. See [NAD+ for longevity](/nad-for-longevity), [peptides for longevity](/peptides-for-longevity) and [what's proven versus hyped](/longevity-medicine-evidence). ## Where it's weak, and who should skip it Skip it if the marketing is what sold you — "scientifically proven" is not a defensible sentence about this molecule. Skip it if the pharmacy classification matters to you, because Direct Meds gives two answers. And do not budget from the $99: your second month is $199, or $249 if your provider puts you on 1000 mg. Two operational notes. Service is unavailable in Mississippi, and the compounding disclosure adds Louisiana. And the longevity line is buried: the Anti-Aging catalog lists NAD+ and sermorelin with no prices at all, and the figures live only on a separate funnel page. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Direct Meds takes all of them. One all-in figure per product is published with what it covers named; NAD+ and sermorelin are a real longevity line rather than a GLP-1 shop with a badge; the telehealth visit is inside the price; nursing support is published as part of the program; and a 503A claim appears on a surface it controls. **Fourteen out of fourteen. An A.** That grade measures published terms, and it is worth saying what it does not measure. The headline is a first-order price, the subscribe-and-save ladder is unpublished, two funnel pages disagree about which compounding regime fills your prescription, and the NAD+ copy promises outcomes no completed trial has produced. Buy it for what it verifiably is — a month-to-month protocol with no membership and no automatic billing — and budget the second month's price, not the first. The full graded field is at [our provider rankings](/best-longevity-clinics); its immediate neighbors are our [HealthRX review](/healthrx-review) and [RxSpan MD review](/rxspan-md-review). Sources: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers, https://pubmed.ncbi.nlm.nih.gov/41655607/, https://pubmed.ncbi.nlm.nih.gov/40275690/, https://pubmed.ncbi.nlm.nih.gov/38871717/, https://pubmed.ncbi.nlm.nih.gov/9005976/, https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters --- ### RxSpan MD Reviews: $249 Is the Month, $150 Is a Year Canonical: https://longevitygraded.com/rxspan-md-review Updated: 2026-07-26 RxSpan MD prices NAD+ at $249/mo, falling to $150 on a 12-month plan. It names four dispensing pharmacies but classifies none of them. August 2026. ## The one-sentence version RxSpan MD publishes an all-inclusive price for NAD+ — consult, medication, supplies, shipping and support in one figure — and the month-to-month rate is **$249**, with $199, $166 and $150 available only on three-, six- and twelve-month plans. It is a physician-founded practice that names its founder — rare here — and it **names all four of the pharmacies that may fill your prescription, with phone numbers** — while never saying what kind of facility any of them is. It grades **A, 13 out of 14**; the missing point is the compounding standard it never states, and the grade is computed from published terms alone and cannot see who pays us. ## What it is, and who it's for RxSpan MD is a telehealth practice founded by **Dr John Diaz**, a board-certified plastic surgeon with more than twenty years in practice — Cornell, Albert Einstein College of Medicine, Alpha Omega Alpha, five years as president of the Society of Plastic Surgeons. His page frames the origin honestly: patients came for appearance and asked about weight and wellness, and the practice grew into *"helping patients extend their healthspan through thoughtfully prescribed medications."* Naming a clinician at all puts RxSpan ahead of most of this field — see [what a longevity doctor actually is](/what-is-a-longevity-doctor). Its longevity catalog is wide: NAD+ by injection, nasal spray and flex-dose tablet, sermorelin ODT, glutathione, GHK-Cu, methylene blue, MIC B12, Lipo C and PT-141, beside a weight-loss line running from compounded semaglutide up to brand Wegovy at $1,349. ## What it actually costs **The catalog.** NAD+ Injection $249, NAD+ Nasal Spray $249, NAD+ Flex Dose Tablet $199, Sermorelin ODT $179, Glutathione $149, GHK-Cu $149, Lipo C $179, PT-141 $199, MIC B12 $129, Methylene Blue $99. Every single one of those numbers carries the same parenthetical beneath it: **"(For the first month)."** **The plan ladder behind it.** Choosing a product opens a plan selector: **Monthly $249/mo · 3-month plan $199/mo · 6-month plan $166/mo · 12-month plan $150/mo**, with the three longer terms flagged "Max Saving." The overview beside it reads *"Pre-paid monthly or quarterly,"* *"Price includes consult, medication, supplies, shipping, and support,"* and *"Cancel or change plans anytime."* **So the honest summary is two sentences.** $249 is a real, published, all-inclusive month-to-month price for NAD+ injection — better disclosed than most providers here, and the top of its range. Everything cheaper is a prepay, and the "(For the first month)" label means the catalog number is not by itself a monthly commitment either. **You pay before you are assessed.** The checkout footer states: *"After checkout, a provider will review your information to determine if treatment is right for you. Prescription is not guaranteed."* The default plan selection totals **$597** — three months at $199. That is the number a buyer who clicks through without changing anything is charged, not $249 and certainly not $150. **And there is no refund policy.** RxSpan publishes four legal documents — Terms of Service, Privacy Policy, Notice of Privacy Practices and Medical Consent — and none is a refund or cancellation policy. What happens to your $597 if the provider declines you is not stated anywhere public. Ask before you check out; see also [what longevity care costs](/longevity-clinic-cost). ## What's included, what's extra Included, per the site: the consult, the medication, supplies, expedited shipping, and *"unlimited appointments, messaging and support"* with *"24/7 access to a dedicated team of specialists."* Sitewide badges promise *"No Hidden Fees"* and *"Doctor-led Plans & Coaching."* Not offered: bloodwork, biomarker panels or any before-and-after testing. Nothing here measures whether the protocol did anything — the same structural gap most of this category has, and the reason [longevity biomarker panels](/longevity-biomarker-panels) sit outside it. ## Clinical oversight and the pharmacy Oversight is genuinely above average on the disclosure axis: a named, credentialled founding physician, unlimited clinician access inside the price, and an explicit statement that a prescription is not guaranteed. **A correction, and it reverses what this page used to say.** An earlier version of this review said RxSpan "says nothing whatsoever about the pharmacy that fills your prescription." That was wrong. The answer is in RxSpan's FAQ, which fills in a moment after the page opens — easy to miss, but published. Asked *"Who are your Pharmacy Providers?"*, RxSpan names four, each with a dialable number: **Belmar Pharmacy** (800-525-9473), **Strive Pharmacy** (855-405-5993), **Epiq Scripts** (833-654-3553) and **Casa Pharma Rx** (877-937-6868). The same source names the clinical team — Lion MD, with **Dr Ana Lisa Carr, MD** and **Dr Kelly Tenbrink, MD**, both with published NPI numbers. On disclosure, that puts RxSpan ahead of most providers here rather than behind it. Two caveats belong beside it, and they are the reason this is the middle rung and not the top. **It classifies none of them.** No Section 503A claim, no 503B claim, no compounding standard of any kind appears on the site or in the data its FAQ loads from — so you know who may fill the prescription and not to what standard. And **the disclosure is real but not exclusive**: the identical four are published by Care Bare Rx, Synergy Rx, Breeze Meds and Sunlight, all running on the same CareValidate backend. It is one shared bench, not four independent attestations. Naming without classifying is the middle rung of [our rubric](/how-we-grade-longevity-providers) — one point of two, and the only point this row drops. One thing travels with the name. **Belmar**, one of the four, received an FDA warning letter addressed to *Belmar Pharma Solutions, Drug Depot, LLC., dba APS Pharmacy* in March 2023, and the FDA **closed it out in October 2023** — so there is no open letter against the pharmacy. **RxSpan MD itself holds no FDA warning letter** — a live index search for "rxspan", "rxspan md" and "care360", its platform vendor, returned no company match, in a pass where a known-lettered company came back positive, so the clean result is real and not a broken query. And note what follows from the correction: we only owe you the Belmar sentence *because* RxSpan names its pharmacies. While this page was claiming it named nobody, there was nothing for a reader to check — which is a small illustration of why a false negative is not the safe direction to be wrong in. Why that is not a formality: 503A compounders are state-licensed and specifically **not** subject to current good manufacturing practice requirements, while 503B outsourcing facilities register with FDA and must comply with them. Compounded drugs of either class are not FDA-approved — and a buyer cannot look up a facility RxSpan will not name. ## The evidence behind what it sells RxSpan's own copy is restrained — it sells "healthspan" rather than reversal — but the molecules are the same ones the other providers here oversells, and the trial record is what it is. On NAD+: the 2026 PRISMA-guided systematic review screened 113 studies including 33 human intervention trials, found effects on functional, metabolic and vascular outcomes *"heterogeneous and often null or endpoint-specific"* with clinical effectiveness *"inconclusive,"* and reported that **no eligible outcomes trial has evaluated intravenous or intramuscular NAD+** for anti-aging or wellness indications. That bears directly on the $249 injection tier, and on any bioavailability argument for it over the $199 tablet. A 2025 meta-analysis in adults averaging over 60 found NMN and NR did not improve muscle index, grip strength, gait speed or chair-stand time. On sermorelin: the trial of that exact molecule — GHRH 1-29, given nightly for six weeks to eleven healthy men aged 64–76 with low baseline IGF-1 — raised nocturnal growth hormone significantly while producing **no change in IGF-1** and **no change in DEXA-measured muscle or fat**. The landmark systematic review of growth hormone in healthy older adults found small body-composition shifts, no proven functional benefit and significantly more adverse events. See [NAD+ for longevity](/nad-for-longevity), [peptides for longevity](/peptides-for-longevity) and [what's proven versus hyped](/longevity-medicine-evidence). ## Where it's weak, and who should skip it Skip it if you need to know what *kind* of facility compounds your medication — RxSpan names the four candidates but classifies none of them, and never says which one fills your particular order. Skip it if paying before assessment with no published refund policy is a risk you will not take. And skip it if $249 is simply too much: it sits near the best options here's month-to-month range for NAD+, and two A-graded competitors sit well below it. If you proceed, choose the **Monthly** plan deliberately rather than accepting the $597 default, and ask two questions in writing first: which of the four named pharmacies fills your prescription and under what compounding standard, and what happens to your money if the provider declines you. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). RxSpan MD takes price transparency in full — one all-inclusive figure per product with the plan ladder shown, which is more than most providers here manage — plus four for a real longevity line, two for a consult inside the price, and two for unlimited clinician access. It takes **one of two on pharmacy** — it names four dispensing facilities with phone numbers, which is the middle rung, but states no compounding standard for any of them, which is the top one. **Thirteen of fourteen. An A.** The letter is right and the shape of it is unusual: this is among the most disclosure-forward rows we grade — founder, clinicians, NPIs and four pharmacies — and it still will not say what kind of pharmacy any of them is. State a compounding standard for the four it already names and it would be a fourteen tomorrow, without changing a single price. The full graded field is at [our provider rankings](/best-longevity-clinics); its neighbors are our [Direct Meds review](/direct-meds-review) and [Enhance MD review](/enhance-md-review). Sources: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers, https://pubmed.ncbi.nlm.nih.gov/41655607/, https://pubmed.ncbi.nlm.nih.gov/40275690/, https://pubmed.ncbi.nlm.nih.gov/9005976/, https://pubmed.ncbi.nlm.nih.gov/17227934/ --- ### Strut Health Reviews: The $99 Requires Auto-Refill Canonical: https://longevitygraded.com/strut-health-review Updated: 2026-08-07 Strut Health's $99 sermorelin and $149 NAD+ are auto-refill rates. The one-off price is 18% higher and is published nowhere. July 2026. ## The one-sentence version Strut Health publishes the cheapest month-to-month longevity protocol in our ranking — **$99/mo for oral sermorelin lozenges** — with the online MD visit, follow-up care and shipping genuinely inside it. The catch is one word on the price badge: **AUTO REFILL**. The discount is stated ("Save 18%") but the price it discounts is not, so the cost of buying a single month without enrolling in refills is not published anywhere on the site. It grades **B, 10 out of 14** — it loses both pharmacy points, and two more because its own product page says final pricing is determined only after the consultation. The grade is computed from published terms alone and cannot see who pays us. ## What it is, and who it's for Strut Health, LLC is an asynchronous compounded telehealth out of Dallas, Texas. You complete an online questionnaire, *"a healthcare professional will review your information,"* and if approved the medication ships monthly. There is no video visit in the flow and no scheduled call — in many states you will never speak to the prescriber, which is the trade-off that makes the price possible. Its Wellness & Longevity shelf is small and specific: injectable sermorelin, oral sermorelin lozenges and injectable NAD+, alongside sublingual and injectable GLP-1 routes, hair, skin and sexual-health lines. If you want a program that measures anything, this is the wrong shape entirely — see [longevity biomarker panels](/longevity-biomarker-panels). ## What it actually costs **The three longevity prices.** Oral Sermorelin Peptide Therapy, 30 lozenges: **"AUTO-REFILL · Starting at $99."** Injectable Sermorelin, 9 mg at 2.5 mg/mL: **"AUTO REFILL · Starting At $119 · Save 18%."** NAD+ Therapy, injection, 500 mg at 200 mg/mL: **"From $149."** **What "Save 18%" is measured against is not shown.** The injectable sermorelin page displays $119 and a "Save 18%" badge with no struck-through figure beside it. Work the discount backwards and the one-off price is around $145 — but that is our arithmetic, not Strut's disclosure, and other Strut products carry different percentages (its oral ivermectin shows "Save 21%"), so it is not a rate you can infer with confidence. **The published price is the subscribed price, and the unsubscribed price is unpublished.** **Even the published price may not be the final one.** The product-page disclaimer reads: *"All prescription medications require a valid and complete online consultation prior to approval and final pricing is determined."* That is Strut telling you, in its own words, that $99 or $119 is a starting point rather than a quotation. **What is genuinely included.** Four badges sit on the product page and they are real: *"Free shipping," "Free follow-up care," "Free online MD visit," "Cancel anytime."* No membership, no baseline assessment, no lab gate, no consultation fee — meaningful in a category where a lab panel and a monthly membership routinely sit in front of the medication. See [longevity clinics vs lab memberships](/longevity-clinics-vs-lab-memberships). **What happens if you cancel.** "Cancel anytime" governs future refills, not money already spent. The Return and Refund Policy — last modified in **September 2021** — is blunt: *"For all medications that leave the pharmacy, we are unable to accept returns or offer refunds due to government regulations,"* and *"we cannot do refunds for any cancellation requests received after the pharmacy has processed your order."* Exchanges are limited to defective or damaged items reported within two weeks. ## Clinical oversight and the pharmacy A U.S.-licensed physician reviews the intake before anything ships, and follow-up care is inside the price rather than billed by the minute — that is worth the two oversight points on [our rubric](/how-we-grade-longevity-providers). The review is asynchronous, so the oversight is real but remote. Credit where it is due on safety copy: the sermorelin page carries a genuinely thorough warnings section — contraindicated with tumors benign or malignant, cautioned in diabetes and thyroid disease, excluded in pregnancy and breastfeeding. Most of the providers here do not publish that at all. On pharmacy, Strut says the least of any A-graded row here. Two badges — *"Compounded in the U.S.A."* and *"Prescribed by U.S. doctors"* — plus ACHC accreditation seals, and that is all. No facility is named and no compounding section is claimed. An accreditation badge is not a classification: 503A compounders are state-licensed and specifically **not** subject to current good manufacturing practice requirements, unlike 503B outsourcing facilities, and *"FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed"*. Strut says this part itself: *"Compound prescription products have not been tested or approved by the FDA for their intended use."* Both pharmacy points are lost here. ## The FDA warning letter, in proportion **On 20 February 2026, FDA's Center for Drug Evaluation and Research issued a warning letter to Strut Health, LLC dba Strut (MARCS-CMS 721448)**. That entity name is copied from the letter's own recipient block, and it is the citation: search it in the [FDA's warning-letter database](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters) and the record comes straight up. FDA's index records no close-out date, so it is still open. We publish that the letter exists, the entity it was addressed to, and its date — and not what it alleges. That is a deliberate line: paraphrasing an enforcement action on a page that earns a commission from the company would be us leveling the accusation, whereas naming the addressee and the date is us reporting that the FDA leveled one. Read FDA's copy; it is a search away. The one thing we do add is **scope**, because omitting it would mislead in the opposite direction: the letter concerns the company's compounded weight-loss line, not the sermorelin or NAD+ products this review grades. It does not move the grade either: our rubric scores published terms — price, consult, pharmacy disclosure, support, longevity line — and adding a regulatory factor after the fact would be a rule written to fit a result. Sprout Health, also here, holds a letter of its own; our [Sprout Health review](/sprout-health-review) reports it in the same terms. ## The evidence behind what it sells Strut's claims are hedged — "may support," "users report" — but they are still claims, and the sermorelin ones are testable. The page promises *"May support your body's ability to build lean muscle and recover faster from workouts,"* *"Promotes deeper, more restorative sleep,"* and *"Enhance Mental Clarity — users report improved focus and a reduction in the 'brain fog' associated with aging."* The trial that tested exactly this molecule ran in exactly this population. Eleven healthy, non-obese men aged 64–76 with low baseline IGF-1 self-injected GHRH 1-29 nightly for six weeks, with growth hormone sampled every twenty minutes overnight and body composition measured by DEXA. **The mechanism worked and the outcomes did not follow**: mean nocturnal GH release and peak amplitude rose significantly, while there was **no change in IGF-1**, and **no change in weight, BMI, waist-to-hip ratio, or DEXA-measured muscle and fat**. The landmark systematic review of growth hormone in healthy older adults found small body-composition shifts, no proven functional benefit and significantly more adverse events, and across species *lower* GH/IGF-1 signaling — not higher — tracks with longer lifespan. On the NAD+ injection, the 2026 PRISMA-guided systematic review screened 113 studies including 33 human intervention trials, found clinical effectiveness for anti-aging and wellness *"inconclusive,"* and reported that **no eligible outcomes trial has evaluated intravenous or intramuscular NAD+** for those indications at all. See [peptides for longevity](/peptides-for-longevity), [NAD+ for longevity](/nad-for-longevity) and [what's proven versus hyped](/longevity-medicine-evidence). ## Where it's weak, and who should skip it Skip it if you want to buy one month and stop. That is precisely the purchase Strut does not price: the auto-refill rate is published, the one-off rate is not, and the refund policy closes the moment the pharmacy processes your order. Skip it if you want to speak to the prescriber, because the model is asynchronous by design. And skip it if the pharmacy matters — "Compounded in the U.S.A." tells you a country, not a standard. If you proceed, ask two questions before you pay: what the one-time price is on the product you want, and what "final pricing is determined" turns your $99 or $119 into after the consultation. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Strut takes price transparency — one all-in figure per product, with the visit, follow-up care and shipping named as included, and no membership or lab gate anywhere near it — plus four for a real longevity line, two for the physician review, and two for included follow-up care. It takes **zero on pharmacy**, and **two of four rather than four on price transparency**: the same page that prints $99 and $119 carries a disclaimer saying *"All prescription medications require a valid and complete online consultation prior to approval and final pricing is determined."* Under our three-rung price test that is a published figure the seller has not committed to — better than publishing none, short of one that binds. **Ten of fourteen. A B.** The number that brought you here is real and it is the cheapest we grade. It is also conditional on enrolling in refills, and the alternative price is the one piece of information Strut has chosen not to print. Publish the one-off figure beside the auto-refill figure — the way two higher-graded rows here already do — and the criticism disappears. The full graded field is at [our provider rankings](/best-longevity-clinics); two neighbors are our [Enhance MD review](/enhance-md-review) and [yourEra review](/yourera-review). Sources: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers, https://pubmed.ncbi.nlm.nih.gov/9005976/, https://pubmed.ncbi.nlm.nih.gov/17227934/, https://pubmed.ncbi.nlm.nih.gov/29756419/, https://pubmed.ncbi.nlm.nih.gov/41655607/, https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters --- ### yourEra Reviews: A $249 NAD+ With No Route Named Canonical: https://longevitygraded.com/yourera-review Updated: 2026-08-04 yourEra prices NAD+ from $249/mo with no contract — genuinely month-to-month. It never says how the NAD+ is delivered. July 2026. ## The one-sentence version yourEra publishes **NAD+ from $249/mo** with no long-term contract, no membership and no lab gate — one of the few headlines here that is not a prepay rate in disguise. What it never says is **how the NAD+ is administered**: no route, no dose, no protocol, no product page. It grades **A, 12 out of 14**, losing both pharmacy points, computed from published terms alone and blind to who pays us. ## What it is, and who it's for yourEra is a physician-directed compounded telehealth running four published programs: semaglutide from $99/mo, tirzepatide from $169/mo, microdosing protocols from $179/mo and NAD+ from $249/mo. A five-minute intake goes to a licensed provider in your state, and *"if treatment is clinically appropriate, they issue a prescription filled by a state-licensed U.S. pharmacy."* An optional tier, **yourEra Optimum**, is announced as coming soon and would add at-home lab draws, wearables, coaching and a nutritionist. The buyer this suits wants a monthly figure with no contract behind it and is content to learn the clinical specifics after signing up. If you want the protocol described first, this is the wrong shape — see [longevity clinics vs lab memberships](/longevity-clinics-vs-lab-memberships). ## What it actually costs **The four published programs.** Semaglutide *from $99/mo*, tirzepatide *from $169/mo*, microdosing protocols *from $179/mo*, NAD+ Anti-Aging *from $249/mo*. **The terms behind them are unusually clean.** *"Visit Included — Prescription & telehealth visit included."* *"One Price — Same price at every dose. No hidden fees."* *"Free Shipping — Free shipping from licensed US pharmacies."* And on commitment: *"Yes. There are no long-term contracts. Pause or cancel your program or Optimum membership from your patient portal at any time."* The dose guarantee is worth more than it sounds: titration repricing the plan is one of the standard ways these programs end up costing far more than the number that sold them, and yourEra rules it out in writing. **The word doing the work is "from."** Every one of the four figures is a floor. No dose tiers, strengths or plan lengths are published beside them, so $249 is the cheapest configuration of the NAD+ program rather than its price. A "from" price at least cannot be *lower* than what you pay — but it cannot be checked either. Every "Get Started" link also points at intake.yourera.com with "promo=YourEra15" attached, so a discount code is pre-applied at every entry point; ask what the un-couponed rate is. **Refunds close at the pharmacy, not at delivery.** The Refund Policy (last updated March 2026) states that once *"your prescription has begun processing at the pharmacy, no refunds will be issued… whether or not it has shipped or been delivered."* Before processing begins, *"you may request a cancellation and full refund."* A narrow window, stated plainly — more than several higher-priced competitors manage. See [what longevity care costs](/longevity-clinic-cost). ## The gap: nothing tells you what you are buying This is the criticism that matters, and it is structural rather than fine print. yourEra is a **single-page site**. There is no NAD+ product page — the treatments menu links to anchors on the homepage, and the entire published description of the program is a catalog card reading *"NAD+ Anti-Aging · from $249/mo"* beside a navigation blurb reading *"Cellular energy support for vitality and healthy aging."* The route is never stated. Injection, nasal spray, sublingual, IV: the site does not say, and it publishes no strength, no dosing schedule and no definition of a month's supply. The NAD+ intake link opens on a screen asking for your email address before anything else, so the first place the protocol is described is behind an account — a sequence that inverts what a $2,988-a-year purchase should look like. One related detail, published to yourEra's credit: *"vial labels shown on this website are for marketing purposes only."* The imagery is illustrative. ## Clinical oversight and the pharmacy Oversight is real and stated: a licensed provider in your state reviews the intake, *"prescriptions are never automatic,"* and unlimited care-team messaging sits inside the program price — which earns the oversight and support points on [our rubric](/how-we-grade-longevity-providers). The brand also puts a named clinician's voice in public, under Dr Tom Lavin. On pharmacy it says only *"a state-licensed U.S. pharmacy,"* across both the FAQ and the footer. No facility, no address, no Section 503A or 503B claim — an unnamed network, which scores zero on our pharmacy factor. What it does say about compounding is unusually candid, and it is the FDA's own framing rather than a softened version: *"Compounded medications are prepared by state-licensed compounding pharmacies to a clinician's specifications. Compounded drugs are not FDA-approved, and the FDA does not verify their safety, effectiveness, or quality."* That is exactly right, and most providers here will not print it. ## The evidence behind what it sells The NAD+ program is sold as *"cellular energy support for vitality and healthy aging."* Hedged, but a claim. The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies including 33 human intervention trials. Oral precursors reliably engage the target, but effects on functional, metabolic and vascular outcomes were *"heterogeneous and often null or endpoint-specific,"* with clinical effectiveness *"inconclusive."* It also reported that **no eligible outcomes trial has evaluated intravenous or intramuscular NAD+** for anti-aging or wellness indications at all — which is impossible to apply here, because yourEra does not say which route it sells. A 2025 meta-analysis in adults averaging over 60 found NMN and NR did not improve muscle index, grip strength, gait speed or chair-stand time, and the strongest randomized trial in the field moved six-minute walk distance about 17.6 meters in peripheral artery disease — a disease endpoint, not an aging one. See [NAD+ for longevity](/nad-for-longevity), [do NAD+ peptides actually work](/do-nad-peptides-work) and [what's proven versus hyped](/longevity-medicine-evidence). The outcome statistics on the homepage — *"-13.6% average body weight loss among YourEra members"* — are labeled *"based on self-reported data from YourEra members"* and concern the GLP-1 programs, not NAD+. Self-reported data from people still enrolled is not a trial result, and yourEra labels it correctly. ## Where it's weak, and who should skip it Skip it if you need to know what you are injecting, spraying or swallowing before you pay — on NAD+, yourEra will not tell you until you are inside the intake. Skip it if $249 is a stretch: it sits near the best options here's month-to-month range, and two A-graded competitors publish lower figures with the route stated. If you proceed, ask three things before checkout: the route and strength of the protocol, what "from $249" becomes at your prescribed dose, and the price without the YourEra15 coupon. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). yourEra takes price transparency — one figure per program, published openly rather than quiz-gated, with what it covers named and no contract behind it — plus four for a real longevity line, two for the provider evaluation inside the price, and two for unlimited care-team messaging. It takes **zero on pharmacy**. **Twelve of fourteen. An A.** The letter is honestly earned on billing and honestly incomplete on medicine. yourEra has done the hard part — a month-to-month price, a dose guarantee, no contract, an FDA-accurate compounding disclosure — and then declined to describe the product. Publish an NAD+ page with a route, a strength and a schedule and this becomes one of the easier recommendations here. The full graded field is at [our provider rankings](/best-longevity-clinics); two neighbors are our [Strut Health review](/strut-health-review) and [Telos Rx review](/telos-rx-review). Sources: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers, https://pubmed.ncbi.nlm.nih.gov/41655607/, https://pubmed.ncbi.nlm.nih.gov/40275690/, https://pubmed.ncbi.nlm.nih.gov/38871717/ --- ### Telos Rx Reviews: Named Pharmacies, No Monthly Price Canonical: https://longevitygraded.com/telos-rx-review Updated: 2026-08-04 Telos Rx names both dispensing pharmacies with addresses — and publishes no single-month price. "Cancel anytime, no penalties" isn't quite true. ## The one-sentence version Telos Rx names both dispensing pharmacies — with street addresses, phone numbers and, uniquely for this site, **their state licensure gaps** — which is more than any other row here that names a pharmacy tells you — then fails the thing almost everybody else manages: it publishes **no single-month price for anything**. The advertised *"as low as $116 per month"* is the longest plan, the shortest plan named in its own policy is three months, and its footer link labeled "Pricing" returns a 404. It grades **B, 9 out of 14**, computed from published terms alone and blind to who pays us. ## What it is, and who it's for Telos Rx is a compounded telehealth platform — *"a technology and administrative services platform,"* in its own words, with *"medical services… provided by an independent, US-licensed telehealth medical group."* It names that group too: **Arora Health & Aesthetics, LLC**, 300 Lenora Street, Seattle WA. The platform company is Superior Health Solutions LLC. The catalog today is seven products: NAD+ nasal spray, sermorelin, PT-141, and a GLP-1 line of tirzepatide, semaglutide, oral tirzepatide and microdosed tirzepatide. A five-minute intake is reviewed by a US-licensed clinician *"typically within four hours,"* and the subscription includes *"unlimited messaging with your care team, dose adjustments, and quarterly labs."* The buyer this suits trades price visibility for supply-chain visibility — the opposite trade to most of [our provider rankings](/best-longevity-clinics). ## What it actually costs — which is the problem **NAD+ nasal spray:** *"As low as $249 $116 per month."* **Sermorelin:** *"As low as $299 $125 per month."* Under the "Pricing" heading on each product page: *"Your price depends on plan length. Cancel anytime, no penalties."* That is the entire pricing disclosure: no table, no ladder. The struck-through $249 and $299 are list prices, and $116 and $125 are floors reachable only on the longest term. **What a single month costs is published nowhere** — and the footer link labeled "Pricing" resolves to a 404. **The shortest plan may not even be a month.** The Shipping & Returns policy (last updated 25 May 2026) refers to *"our 3-, 6-, and 12-month plans"* — those three, and no other. If a one-month plan exists, it is named on no page we could find, which would make three months the minimum commitment rather than an upgrade. **"No penalties" is contradicted by the policy page.** The product page says *"Cancel anytime, no penalties."* The Shipping & Returns page says: *"If you cancel early, the months you've already received are re-priced at the rate of the shortest plan that covers the time you were enrolled, and the difference is charged as a one-time adjustment at cancellation"* — its own worked example being a 12-month plan left at month three, re-rated to the 3-month price. That is a clawback. It is not hidden — Telos publishes it plainly, and never charges for months after cancellation — but two of its own pages disagree about whether leaving costs you anything, and the one a buyer reads first says it does not. See [what longevity care costs](/longevity-clinic-cost). **What the subscription does include,** and it is generous: free 2-day priority shipping *"baked into your plan price,"* 24/7 unlimited clinician messaging, dose adjustments, **quarterly labs at no extra cost**, FSA/HSA eligibility, and a *"100% refund of any charges"* if the clinician determines you do not qualify. Dispensed compounded medication cannot be returned — a federal constraint, not a Telos choice — but quality failures are replaced free within 48 hours. ## Clinical oversight and the pharmacy This is where Telos earns its place. Both dispensing pharmacies are published by name and address: - **VialsRX**, 6220 Westpark Dr, Houston, TX 77057, (713) 497-5590 - **F&F Pharmacies Inc dba Jungle Jim's Pharmacy**, 5484 Dixie Highway, Fairfield, OH 45014, (877) 858-3784 And it publishes the second one's limitations rather than burying them: Jungle Jim's *"maintain[s] a license in 40 US states,"* and *"cannot dispense sterile compounds and do not have a license in… California, Nevada, New Jersey, North Carolina, Texas, Massachusetts, Mississippi, New Hampshire, West Virginia, and Delaware."* A provider volunteering where its own pharmacy cannot serve you is not something we have seen elsewhere here. The gap is that neither is described as a 503A or a 503B facility — the string "503" appears nowhere on the site. Under [our rubric](/how-we-grade-longevity-providers) naming without classifying scores one point of two, though the practical position is arguably better than rows scoring two, because a named pharmacy is one you can look up yourself. Telos states the underlying fact plainly: *"Compounded medications are compounded, not FDA-approved."* FDA agrees — it *"does not verify the safety, effectiveness or quality of compounded drugs before they are marketed"*. ## The evidence behind what it sells The NAD+ page promises *"sharper mental focus & clarity,"* *"anti-aging & longevity support,"* and — most specifically — *"Most patients notice changes in energy and mental clarity within the first 2–3 weeks."* Its science panel adds that *"cellular NAD+ levels drop ~50% between age 40 and 60"* and that replenishing it supports *"energy, repair, and cognition."* The decline is defensible; the downstream claims are not. The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies including 33 human intervention trials and found effects on functional, metabolic and vascular outcomes *"heterogeneous and often null or endpoint-specific,"* with clinical effectiveness *"inconclusive"*. A 2025 meta-analysis in adults averaging over 60 found NMN and NR did not improve muscle index, grip strength, gait speed or chair-stand time, and the strongest randomized trial in the field moved six-minute walk distance about 17.6 meters in peripheral artery disease. No completed human trial shows a 2–3 week onset of energy or cognitive benefit. The sermorelin page promises *"recovery, lean muscle, fat metabolism, and deep sleep"* from a *"nightly subcutaneous protocol"* — the precise protocol the relevant trial tested. GHRH 1-29 nightly for six weeks in eleven healthy men aged 64–76 raised nocturnal growth hormone significantly, while producing **no change in IGF-1** and **no change in DEXA-measured muscle or fat**. See [NAD+ for longevity](/nad-for-longevity), [peptides for longevity](/peptides-for-longevity) and [what's proven versus hyped](/longevity-medicine-evidence). ## Where it's weak, and who should skip it Skip it if you need to know what you will be charged: a "from" price you cannot resolve to a plan is the single reason this row grades B rather than A. Skip it if you might not last the term, because the early-exit re-rating will find you. And ask which pharmacy will fill your order if you live in one of the ten states where Jungle Jim's is unlicensed. If you proceed, get three numbers in writing: the one-month price if one exists, each published plan length's price, and the re-rating you would owe leaving at month three. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Telos Rx takes four for a real longevity line, two for a clinician review inside the price, two for 24/7 messaging and included quarterly labs, and one of two on pharmacy for naming its facilities without classifying them. It takes **zero on price transparency**, because no plan-level figure is published anywhere. **Nine of fourteen. A B.** There is a version of this company that grades an A tomorrow without changing a price: publish the plan table, fix the Pricing link, and make the product page say what the returns page already says about early cancellation. It is frustrating to write a B for the most pharmacy-transparent operator we grade — but a reader cannot spend transparency, and still cannot find out what a month costs. Two neighbors are our [yourEra review](/yourera-review) and [Sprout Health review](/sprout-health-review). Sources: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers, https://pubmed.ncbi.nlm.nih.gov/41655607/, https://pubmed.ncbi.nlm.nih.gov/40275690/, https://pubmed.ncbi.nlm.nih.gov/38871717/, https://pubmed.ncbi.nlm.nih.gov/9005976/ --- ### MadeMed Reviews: There Is No Monthly Plan Canonical: https://longevitygraded.com/mademed-review Updated: 2026-08-04 MadeMed sells no month-to-month plan. NAD+ is $209/mo on a 3-month prepay ($627) or $199/mo on six ($1,194), after a CMP you pay for. July 2026. ## The one-sentence version MadeMed publishes more price detail than most providers here — every product, both plan lengths, the per-month rate and the exact amount charged — and then does not sell the plan a first-time buyer actually wants. **There is no month-to-month option anywhere on the site.** The shortest way in is three months paid up front, and before any of it a comprehensive metabolic panel has to be drawn, which you arrange and pay for yourself. It grades **C, 6 points out of 14**, and the deduction is concentrated in one place: our rubric asks whether a single all-in figure gets you started, and at MadeMed no figure does. The grade is computed from published terms alone and cannot see who pays us. ## What it is, and who it's for MadeMed is a compounded telehealth practice with a LegitScript Verified badge and an unusually broad longevity shelf. NAD+ comes two ways — a 1,000 mg injectable dosed as eight subcutaneous shots a month, and a nasal spray at *"7,500mg per bottle (500mg/mL × 15mL)"* — and sermorelin comes two ways as well, a 9 mg/3 mL nightly injection and a 1,000 mcg sublingual tablet. Everything runs through an online questionnaire, a board-certified physician review inside 24 hours, and free overnight shipping. The buyer this suits is comfortable paying a quarter in advance and wants the dose-by-dose arithmetic visible first. The buyer it does not suit is the one MadeMed itself describes — someone testing whether a protocol agrees with them. On what a first month should cost, see [what longevity care costs](/longevity-clinic-cost). ## What it actually costs **The NAD+ injection.** Three months is $209/mo, *"billed $627 every 3 months."* Six months is $199/mo, *"billed $1194 every 6 months."* The product page headline reads *"From $199/mo"* — that is the six-month rung, not an entry price. **The nasal spray** is $279/mo on three months ($837) and $269/mo on six ($1,614). Its headline says *"From $279/mo"*, which is not even its own cheapest rate. **Sermorelin** is $179/mo on three months ($537) or $169/mo on six ($1,014) as an injection; the sublingual tablet is $109/mo on three ($327) or $99/mo on six ($594). **Two plan buttons, and neither is one month.** Every product page offers exactly "Quarterly" and "6-month". The cheapest way anyone can begin NAD+ therapy here is a $627 charge; the cheapest first payment on the whole longevity shelf is $327 for oral sermorelin. MadeMed's own FAQ explains why: *"This is why we recommend a minimum 3-month commitment."* That is a coherent clinical position. It is still a commitment made before you have taken a single dose. **Then the lab.** *"A CMP blood test is required before prescribing"* for both NAD+ routes; injectable sermorelin requires an IGF-1 instead. You are told to *"get a CMP blood test at any Labcorp or Quest location, or upload recent results"* — and nowhere does the site say the panel is paid for. It is not in the "What's Included" list on any page. So the true first payment is $627 plus an unstated lab bill, and it cannot be worked out from the site at all. ## Clinical oversight, billing and the pharmacy Oversight is real and inside the price: a board-certified physician review plus a lab-guided dosing protocol, which is more than most compounded shops require. Availability is narrower than the marketing implies — the FAQ lists 23 states for both NAD+ products, not the whole country. The billing conduct is genuinely good, and worth saying plainly on a page that is otherwise critical: *"we email you 7 days before every charge with the exact amount and easy options to pause, skip, or cancel"*, and cancellation is *"one click from your dashboard."* In a category built on silent renewals, that is real protection. Pharmacy disclosure is thinner. Every product card says only *"Made in US pharmacy"*, and FDA's position on what that leaves unresolved is unambiguous: compounded drugs are not FDA-approved, and the agency does not verify their safety, effectiveness or quality before they are marketed. The single exception sits in a nasal-spray FAQ answer benchmarking competitors, where MadeMed says it ships *"Precision Pharmacy's NanoNAD+ formulation"* — the only pharmacy named anywhere on the site, in a comparison answer rather than a dispensing statement. No compounding section, 503A or 503B, is claimed at any point. ## The evidence behind what it sells MadeMed's copy is more careful than most, and still goes past the trial record. The NAD+ pages promise *"cellular rejuvenation for energy, clarity, and recovery"*, say injections *"activate sirtuins — proteins that regulate longevity"*, and tell buyers to expect *"increased energy and mental clarity within 2-4 weeks."* The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies including 33 human intervention trials, found effects on functional, metabolic and vascular outcomes *"heterogeneous and often null or endpoint-specific"*, and reported that **no eligible outcomes trial has evaluated intravenous or intramuscular NAD+ for these indications at all** — which speaks directly to a product sold as eight injections a month. A 2025 meta-analysis in adults averaging over 60 found NAD+ precursors did not improve muscle index, grip strength, gait speed or chair-stand time. See [NAD+ for longevity](/nad-for-longevity) and [do NAD+ peptides actually work](/do-nad-peptides-work). Sermorelin fares no better. The trial that tested exactly this protocol gave GHRH 1-29 nightly for six weeks to eleven healthy men aged 64–76: nocturnal growth hormone rose significantly, but IGF-1 did not change and DEXA-measured muscle and fat did not change. The landmark review of growth hormone in healthy older adults found small body-composition shifts, no proven functional benefit and significantly more adverse events. MadeMed's own timeline — *"improve muscle mass and recovery (weeks 4-8)"* — describes outcomes that trial did not produce. See [peptides for longevity](/peptides-for-longevity). ## Where it's weak, and who should skip it Skip it if you want to try a protocol before buying a quarter of it — that option does not exist here, and MadeMed is not alone in that: [an NAD+ program sold only in twelve-week blocks](/pallas-health-review) scores zero on the same factor for the same structural reason, however much else it publishes. Skip it if the unpriced lab makes your budget unknowable, or if you are outside the 23 states. And skip it if you are buying the energy-and-clarity promise, because nothing in the trial record delivers it. If you proceed, the honest cheap entry is oral sermorelin at $327 for three months rather than the NAD+ injection at $627 — and ask what the CMP will cost before you commit to either. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). MadeMed takes the full four for its longevity line — NAD+ by two routes plus sermorelin by two more is as broad a shelf as this site has — and two for a physician review inside the price. It takes **zero on price transparency**, not because the numbers are hidden but because no single figure gets anyone started: the cheapest published route in is a $627 charge plus a lab bill the site never quotes. Zero for pharmacy, and zero for human support. Six of fourteen. A **C**, and the owner of this site has seen that grade and let it stand. The fix is small: publish a one-month plan, and say what the CMP costs. Do both and MadeMed would jump two bands on a rubric already inclined to like it. Until then, the most literal price page here is attached to the least forgiving way to buy. Our other C-graded partners are covered in the [Try Ageless review](/ageless-review), the [Gala Health review](/gala-health-review), the [Shed review](/shed-review) and the [Wellorithm review](/wellorithm-review); the full field is at [our provider rankings](/best-longevity-clinics) and the scoring is in [how we grade](/how-we-grade-longevity-providers). Sources: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers, https://pubmed.ncbi.nlm.nih.gov/41655607/, https://pubmed.ncbi.nlm.nih.gov/40275690/, https://pubmed.ncbi.nlm.nih.gov/9005976/, https://pubmed.ncbi.nlm.nih.gov/17227934/ --- ### Try Ageless Reviews: Every Price Is an Intro Price Canonical: https://longevitygraded.com/ageless-review Updated: 2026-08-04 Try Ageless advertises NAD+ at $199 and sermorelin at $126 — both are intro-code rates, and the page says the final amount comes after review. July 2026. ## The one-sentence version Try Ageless has one of the broadest longevity menus here and the least trustworthy set of numbers attached to it. Every advertised longevity price is a limited-time rate you reach only with a discount code, every product page then says that *"the final amount is shown after clinical review"*, and on one product the fine print quotes a band nearly double the price in the buy box. It grades **C, 7 points out of 14**, almost entirely on price transparency — the medicine, the intake and the clinician review are all real. The grade is computed from published terms alone and cannot see who pays us. **One disambiguation first, because the names collide.** Try Ageless (tryageless.com) is the company reviewed here. **AgelessRx** (agelessrx.com) is a different, unrelated company we grade separately in our [AgelessRx review](/agelessrx-review); the two share no ownership, pricing or menu, and nothing on this page describes it. ## What it is, and who it's for Try Ageless is an online storefront, not a membership. Its "Live Longer" shelf carries an NAD+ injection, a high-strength NAD+ injection, an NAD+ troche, low-dose naltrexone, methylene blue and MIC+B12; a separate wellness shelf carries sermorelin as an injection, a troche and a nasal spray; and a testosterone line and compounded GLP-1s sit beside them. Products are sold as one-month supplies, so nothing requires a prepay term — a genuine advantage over the prepay-only shops here. A licensed clinician reviews every questionnaire before anything ships, and the operating entity is named — on Try Ageless's own regulatory page — as **Lovely Meds, Inc.**, of 131 Continental Dr, Suite 305, Newark, DE. That name matters more than it looks; see the regulatory record below. The buyer this suits wants to try one compounded molecule for one month without joining anything. The buyer it does not suit needs to know the price before checkout. See [what longevity care costs](/longevity-clinic-cost). ## What it actually costs **The NAD+ injection** (1,000 mg vial, one month's supply) shows **$199** beside a struck-through **$249**, under a "Limited Time Offer" banner and an "INTRO SAVINGS" badge carrying the code **WELCOME50** for *"$50 off."* $249 is the list price. $199 is a promotional rate. **Sermorelin injection** (15 mg vial) shows **$126** against a list of **$176**, code **SERM50**. **Sermorelin nasal spray** shows **$149** against **$199**, code **FIRST50**. Low-dose naltrexone shows $99 against $149. **Then the sentence under every buy box:** *"Exact pricing depends on your prescribed dose. Final amount is shown after clinical review."* Read plainly, no figure printed anywhere on the site is the figure you will be charged. It is a candid disclosure and a total defeat for price transparency — the rubric asks whether a buyer can know the cost before handing over a card, and here the site itself says no. **And on the sermorelin injection, the page disagrees with itself.** The buy box says $126, discounted from $176. Scroll to the "Medical Information" block on the same page and the entry reads *"Available Dosage Strengths — 15 mg — $239-$289."* Same product, same page, two bands that do not overlap. The NAD+ injection's equivalent block reads $199–$249 and matches its buy box, so this is not a formatting quirk; one of the two sermorelin numbers is wrong, and a buyer cannot tell which. ## Clinical oversight and the pharmacy Oversight is stated and included: *"licensed U.S. clinician reviews every case before any prescription is issued"*, with unlimited provider messaging and no lab work at any point. No lab gate is a convenience, not a virtue — nothing here measures whether anything worked. See [longevity biomarker panels](/longevity-biomarker-panels). Pharmacy disclosure is better than the marketing suggests and worse than the badges imply. On its safety-information page, Try Ageless names both sides of the chain: the medical provider as **Wasef Health, PC** in Pinellas Park, Florida, and the **dispensing pharmacy as Pharmacy Hub**, 15600 NW 15th Ave, Miami, with a phone number. Very few providers here publish that at all. What it never does is classify that pharmacy: the only appearance of "503A" is inside a list of rules the company *"is designed to support compliance with"* — a scope statement about regulations, not a claim about who fills your prescription. Against that, the product pages carry a trust strip reading **"GMP Certified — FDA-registered facility"** beside "Third-Party Tested" and "Sterility Tested 100%". That badge sits above medication the same page correctly calls *"not FDA-approved… custom-prepared by licensed U.S. pharmacies."* FDA's position is that compounded drugs are not FDA-approved, that it does not verify their safety, effectiveness or quality before marketing, and that 503A pharmacies specifically are **not** subject to current good manufacturing practice requirements. That badge is doing more work than the facts support. **The LegitScript badge is a third one to treat carefully.** A seal sits in the footer carrying ID **123956**, and it does not resolve: the seal image returns a 403 where known-good seals returned 200 in the same check on 8 August 2026. That is *unconfirmed*, which is not the same as absent — the badge is there, and we simply cannot verify it from the identifier behind it. Ask, if it matters to you. ## The regulatory record, and exactly what it is **FDA issued a warning letter to Lovely Meds, Inc. dba Lovely Meds in September 2025** — reference **MARCS-CMS 716829**, issued 9 September 2025 and posted 16 September 2025 by the Center for Drug Evaluation and Research. **It is not closed out.** The close-out columns on FDA's own index were empty when we checked on 8 August 2026, so anyone describing this as a resolved matter is publishing a false impression. We are not going to summarize or relitigate what the letter says; that is FDA's document to characterize, and the searchable index is cited below so you can read it in full yourself. **Why this appears on a Try Ageless page at all, since the letter never mentions tryageless.com.** The letter is addressed to Lovely Meds and concerns the site lovelymeds.com. The connection is **Try Ageless's own admission**: its Medical Oversight & Regulatory Information page states, in its own words, *"Try Ageless is a brand operated by Lovely Meds, Inc. The website tryageless.com is managed under this entity."* We disclose on the strength of the company's own statement about who it is — not on an inference we drew. **Two things this letter is not.** It is not a reason we stopped recommending or linking Try Ageless: **a letter discloses, it does not disqualify**, this row stays here, and the grade below is computed from published terms alone and cannot see the letter at all. And it is **not** the other record you may find by searching: FDA's index also returns *Ageless Global, LLC* (1 March 2021, concerning COVID-19 products). **That is a different company** with a similar name, and attributing it here would be wrong. One practical note for anyone checking our work: FDA's index returns **nothing** for "tryageless" and **nothing** for "lovelymeds". It surfaces only under the spaced firm name **"lovely meds"** — a form the storefront itself never uses. If you search the condensed brand name and find a clean result, that is the search failing, not the record. ## The evidence behind what it sells Try Ageless's copy is more hedged than most — "may support", "individual responses vary" — and still lands claims the trials do not. The NAD+ page promises that *"patients may experience improvements in energy, mental clarity, recovery, and overall wellness"* and lists *"Longevity Pathway Support."* The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies including 33 human intervention trials. Effects on functional, metabolic and vascular outcomes were *"heterogeneous and often null or endpoint-specific"*, clinical effectiveness was *"inconclusive"*, and — decisively for a company selling vials — **no eligible outcomes trial has evaluated intravenous or intramuscular NAD+ for anti-aging or wellness indications at all**. A 2025 meta-analysis in adults averaging over 60 found NAD+ precursors did not improve muscle index, grip strength, gait speed or chair-stand time. See [NAD+ for longevity](/nad-for-longevity) and [do NAD+ peptides actually work](/do-nad-peptides-work). Sermorelin is sold here for *"recovery, energy, body composition"*. The trial that tested this exact molecule on this exact schedule gave GHRH 1-29 nightly for six weeks to eleven healthy men aged 64–76: nocturnal growth hormone rose significantly, but IGF-1 did not change, and DEXA-measured muscle and fat did not change. See [peptides for longevity](/peptides-for-longevity) and [what's proven versus hyped](/longevity-medicine-evidence). ## Where it's weak, and who should skip it Skip it if you need a fixed price, and skip it if the $126-versus-$239 contradiction on the sermorelin page bothers you — it should. Treat the social proof carefully too: the rating strip on these longevity pages reads *"4.8 based on 5 reviews"*, the first testimonial under a sermorelin listing is about starting GLP-1s, and the same weight-loss body copy and BMI calculator appear on the NAD+ page — which tells you which business these pages were built for. If you proceed: get the clinical review, get the quoted final amount in writing, then decide. The intake is free, so nothing is lost by making them name the price first. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Try Ageless takes the full four for its longevity line — NAD+ in three formats, sermorelin in three, plus LDN and methylene blue is one of the broadest shelves we grade — and two for a clinician review inside the price. It takes **zero on price transparency**, because every advertised longevity figure is an intro-code rate and the site states outright that the real number arrives after review. One of two on pharmacy — it publishes the name, and an address and a phone number with it, but claims no compounding standard for the facility. And zero for human support. Seven of fourteen. A **C**, and the owner of this site has seen that grade and let it stand. This is the most fixable C here. Print one honest price per product and make the fine print agree with the buy box, and Try Ageless would be graded on its menu instead of its marketing. Our other C-graded partners are covered in the [MadeMed review](/mademed-review), the [Gala Health review](/gala-health-review), the [Shed review](/shed-review) and the [Wellorithm review](/wellorithm-review); the full field is at [our provider rankings](/best-longevity-clinics) and the scoring is in [how we grade](/how-we-grade-longevity-providers). Sources: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers, https://pubmed.ncbi.nlm.nih.gov/41655607/, https://pubmed.ncbi.nlm.nih.gov/40275690/, https://pubmed.ncbi.nlm.nih.gov/9005976/, https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters --- ### Gala Health Reviews: The $179 Is a Yearly Rate Canonical: https://longevitygraded.com/gala-health-review Updated: 2026-08-04 Gala's "$179/mo, no hidden fees" is calculated on a yearly plan by its own footnote. Its cheapest quote is $199 on 3 months. No monthly price. July 2026. ## The one-sentence version Gala Health — the site brands itself Gala GLP-1 — puts *"$179/mo all doses, no hidden fees"* at the top of its homepage, then prints the footnote that undoes it: *"Price calculated based on a yearly subscription plan."* Its own FAQ quotes a different and higher entry point. **No month-to-month price is published anywhere on the site**, which is why it scores **4 points out of 14 — tied for the lowest grade here.** The second reason is that it is not really a longevity provider: no NAD+, no sermorelin, no peptide and no diagnostic line, only compounded GLP-1s and menopause hormones — and what the trials show for the latter is in [HRT, menopause and longevity](/hrt-menopause-and-longevity). The grade is computed from published terms alone and cannot see who pays us. ## What it is, and who it's for Gala is a GLP-1 telehealth operator with licensed providers in all 50 states, run by AI Coaching, Inc., with medical care delivered by *"licensed physicians and clinicians affiliated with independently owned and operated medical practices, including OpenLoop-affiliated medical groups."* Gala itself *"provides administrative, technology, and management services and does not provide medical care."* The catalog is four items and a menopause menu: compounded GLP-1/GIP including tirzepatide, a low-dose "microdosing" tier the navigation labels a **"Low-dose longevity protocol"**, brand-name Ozempic, and an oral GLP-1 marked coming soon. The hormone shelf is estradiol pill or patch, progesterone, vaginal estradiol and non-hormonal options for hot flashes and night sweats. That is a competent weight-loss and menopause service. It is not a longevity clinic — if you arrived looking for one, start with [what a longevity clinic actually costs](/longevity-clinic-cost). ## What it actually costs **The headline.** The hero reads *"$179/mo all doses, no hidden fees."* The treatments grid repeats it as "$179/month" for compounded GLP-1/GIP and "$149/month" for the microdosing tier, each carrying an asterisk. Brand Ozempic is *"$1,299/month"*, stated flat. **The asterisk.** Directly beneath that grid: *"Compounded GLP-1 is not FDA-approved and is sourced from licensed compounding pharmacies. **Price calculated based on a yearly subscription plan.**"* So $179 and $149 are twelve-month rates. "No hidden fees" and the footnote that redefines the fee sit on the same page. **The FAQ quotes something else again.** *"Through Gala GLP-1, you can access GLP-1 weight loss medications (not-FDA approved) starting at just $199 per month (with a 3-month plan). Final pricing is determined at checkout based on your selected plan and medication."* That is the cheapest figure Gala publishes with a term attached — and it is $20 above the number on the homepage, on a shorter commitment. **Nothing states the monthly price.** Not the homepage, not the treatments grid, not the FAQ. And Gala's own cancellation policy makes clear that monthly billing exists: *"you will be charged for the first month of the Subscription Services"*, with *"a cancellation request… received at least 72 hours prior to your billing date."* There is a monthly cadence. Its price is simply never printed. **What canceling costs.** You may *"cancel your Subscription Service at any time for any reason"* with that 72-hour notice. But the same policy states that other than cancellation for medical disqualification, *"IN NO EVENT SHALL YOU BE ISSUED A REFUND UPON CANCELLATION OF THE SUBSCRIPTION SERVICES"*, and any approved refund covers *"your most recent billing cycle"* only. Beside a yearly headline rate, that is the term to understand before choosing a plan length. ## What Gala does well Two things, and they are real. **Dose increases are free** — if a higher dose is recommended *"it will be available at no additional cost"*, and if a medication is not working *"your provider can adjust your prescription at no additional cost."* In a category where titration routinely reprices a plan, that is genuine protection. **And a provider is included:** consultations may be *"synchronous—such as a video visit—or asynchronous, like online messaging"*, with messaging at no extra cost. That earns its oversight points in full. Where it earns nothing is pharmacy. Asked which pharmacies it partners with, Gala answers *"we work with a wide network of pharmacies across all 50 states"* — no name, no address, no 503A or 503B classification. FDA's position on what that leaves open is blunt: compounded drugs are not FDA-approved, and the agency does not verify their safety, effectiveness or quality before they are marketed. ## The evidence behind what it sells Gala's hero carries a stat block reading **"20% weight loss in 6 months"**, footnoted to *"clinical studies of GLP-1 medications combined with lifestyle changes."* The trial that produced a 20% figure is SURMOUNT-1, which randomized 2,539 adults with obesity to tirzepatide or placebo. Mean weight change at **week 72** was −15.0% on 5 mg, −19.5% on 10 mg and −20.9% on 15 mg, against −3.1% on placebo. Week 72 is roughly seventeen months, including a twenty-week dose-escalation period. The drug is real and the effect is real — this is one of the few things sold here with hard randomized outcome data behind it. But 20% is not a six-month result at any dose. **The "longevity protocol" is the weaker claim.** Gala's microdosing tier is a sub-therapeutic GLP-1 dose marketed as longevity care. The doses with outcome evidence are the trial doses — 5, 10 and 15 mg — and no completed trial has tested a GLP-1 microdose against any aging endpoint. Labeling a lower dose "longevity" is positioning, not a finding. See [GLP-1s for longevity](/glp1-for-longevity) and [what's proven versus hyped](/longevity-medicine-evidence). One point in Gala's favor: the NAD+ and peptide lines it lacks are not lines with better evidence. The 2026 PRISMA-guided systematic review of NAD+ screened 113 studies including 33 human trials, found clinical effectiveness *"inconclusive"*, and reported that no eligible outcomes trial has evaluated injected NAD+ for these indications at all. Gala is marked down for not selling that shelf because this site ranks longevity providers — not because the shelf works. See [NAD+ for longevity](/nad-for-longevity). ## Where it's weak, and who should skip it Skip it if you are shopping for longevity medicine: there is no NAD+, no sermorelin, no peptide and no biomarker panel here, and the "longevity protocol" is a smaller dose of a weight-loss drug. Skip it if you need to know the price of one month before committing, because that number does not exist on the site. And do not read *"no hidden fees"* as *"no terms"* — the fee is not hidden, the **term** is. If you proceed: make Gala quote you the monthly and three-month rates in writing before you pick a plan, and understand that canceling stops future billing but does not refund what you have already paid. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Gala takes **two of the four** longevity-line points, not zero — menopause hormone therapy and a self-declared longevity microdose put it adjacent to what this site ranks rather than on it — and two for a provider inside the price. It takes **zero on price transparency**, because the advertised figure is a yearly rate, the FAQ's cheapest quote is a different and higher number on a different term, and no monthly price is published at all. Zero on pharmacy, and zero on human support. **Four out of fourteen: a C, tied with [Wellorithm](/wellorithm-review) for the lowest score here.** The owner of this site has seen that grade and let it stand. The remedy is one line of HTML. Publish the month-to-month price beside the yearly one, and Gala jumps straight off the bottom of the ranking — the medicine, the fifty-state coverage and the free dose increases are already there. Our other C-graded partners are covered in the [MadeMed review](/mademed-review), the [Try Ageless review](/ageless-review), the [Shed review](/shed-review) and the [Wellorithm review](/wellorithm-review); the full field is at [our provider rankings](/best-longevity-clinics) and the scoring is set out in [how we grade](/how-we-grade-longevity-providers). Sources: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers, https://pubmed.ncbi.nlm.nih.gov/35658024/, https://pubmed.ncbi.nlm.nih.gov/41655607/ --- ### Next Health Reviews: The Membership Is Not the Bill Canonical: https://longevitygraded.com/next-health-review Updated: 2026-08-04 Next Health publishes memberships from $99/mo to $100,000/yr — then bills NAD+ IVs at $500 on top. And two of its own price lists disagree. July 2026. ## The one-sentence version Next Health is the in-clinic end of this category: twenty centers selling NAD+ IV drips, peptide protocols, hormone optimization and a deep lab menu, with memberships published openly from $99 a month to a $100,000-a-year application-only tier. It publishes far more pricing than most in-person clinics — and the membership is not the bill. An NAD+ infusion is $500 on top of it, and the same service costs a different amount depending on which of Next Health's own price lists you read. It grades **B, 8 points out of 14**, and the whole deduction is that gap. The grade is computed from published terms alone and cannot see who pays us. ## What it is, and who it's for Founded in 2016 by Darshan Shah, MD and Kevin Peake, Next Health runs twenty locations — West Hollywood, Chicago, Nashville, Boston, Bellevue, Boulder, Dubai and more — with eight announced. Care is delivered in person: IV suites, cryotherapy, hyperbaric oxygen, blood draws and provider consults under one roof. Its own product pages refer to "Next Health, including its affiliates and franchisees", and it runs a franchise-inquiry funnel — the likeliest explanation for the pricing divergence below. The buyer this suits wants to walk into a room and be treated today. The buyer it does not suit wants one figure that covers a year. See [longevity clinics versus lab memberships](/longevity-clinics-vs-lab-memberships) and [what longevity care costs](/longevity-clinic-cost). ## What it actually costs Next Health publishes no pricing page at all — the only page that names a figure is the one asking you to become a member. **The memberships, published plainly.** Medicine 4.0 at **$99/month** — quarterly biomarker testing, quarterly 1:1 consultations, and *"access to provider-prescribed Peptides, Hormone Optimization, and Metabolic Programs."* Optimize at **$199**, Premier at **$299** (*"our most popular membership"*), Optimize 4.0 at **$299** and Premier 4.0 at **$399**. **And a Platinum tier at $100,000 a year**, application-only, built around *"quarterly Therapeutic Plasma Exchange (TPE) with Stem Cells/Exosomes."* **Then the services, billed on top.** NAD+ IV therapy is **$500 for 300 mg** and **$1,000 for 750 mg** — *"a slow drip process… commonly takes between 2-3 hours"* — plus a $175 add-on. Next Health recommends an *"Optimal Aging Trifecta"* of three infusions over seven days: $1,500 in a week at the lower tier, on top of a membership. Diagnostics are priced well — a Baseline Test of *"over 50 biomarkers"* at $349, an Executive Physical at $14,500. **Two things are not priced at all: peptides and hormones.** Next Health's peptide page prices nothing, stating that *"access to a customized peptide protocol is exclusively available through a Next Health Medicine 4.0 Membership"* and that *"prescriptions are provided separately."* The hormone page carries no figure at all. The two lines that make this a longevity clinic rather than a spa are the two with no published cost. ## The two price lists This is the finding that decides the grade. Next Health maintains a national store menu and separate per-location menus, and they do not agree — the store sells NAD+ IV therapy at $500 for 300 mg over two to three hours, while the New York City menu sells *"NAD+ Therapy… ~30 Minute Service Time - $299."* No page tells a buyer which list applies to them, and location pages advertise *"up to 50% off membership rate"* without stating the rate being discounted. ## Clinical oversight Oversight is included and substantial: quarterly one-to-one consultations sit inside the $99 tier, peptides require a prescription, and a medical director is named for the Los Angeles clinic. Membership terms, though, are published nowhere — no minimum term, no notice period, no auto-renewal language — and the refund policy covers products only, with *"custom products (such as test kits and Peptides)"* excluded. **Update, August 2026:** earlier versions of this review flagged a self-contradiction on the peptide page — one line saying peptide therapy "does not require the assistance of a medical professional" directly above a line requiring "medical consultation and recommendation from a licensed provider." As of our most recent check, every mention of oversight on that page consistently requires consultation with a licensed provider; the contradictory line is gone. On pharmacy, nothing is classified: the strongest statement is *"peptides compounded by trusted pharmacy partners"* — no name, no 503A, no 503B. FDA's position is that compounded drugs are not FDA-approved, that it does not verify their safety, effectiveness or quality before marketing, and that 503A pharmacies are specifically **not** subject to current good manufacturing practice requirements. ## The evidence behind what it sells Next Health's NAD+ copy is the furthest past the evidence of anything on this page. It states that *"NAD+ improves mitochondrial health and slows the aging process"*, promises *"neuroprotection… for better mental clarity"*, lists *"counteract hallmarks of aging"* as a benefit, and argues that the intravenous route *"ensures that 100% of this essential nutrient is directly delivered to your bloodstream"* and is therefore *"the most effective method."* The bioavailability argument is precisely where the literature is emptiest. The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies including 33 human intervention trials, found outcomes *"heterogeneous and often null or endpoint-specific"*, clinical effectiveness *"inconclusive"*, and reported that **no eligible outcomes trial has evaluated intravenous or intramuscular NAD+ for anti-aging or wellness indications at all**. A $500 two-hour infusion is sold on the route with no outcomes trial behind it. A 2025 meta-analysis in adults averaging over 60 found NAD+ precursors did not improve muscle index, grip strength, gait speed or chair-stand time. See [NAD+ for longevity](/nad-for-longevity) and [do NAD+ peptides actually work](/do-nad-peptides-work). **On peptides**, the page promises *"specific, measurable effects… from body composition and recovery to cognition"* within *"1–2 cycles."* Two named compounds are growth-hormone secretagogues, and the trial record is unkind: the landmark review of growth hormone in healthy older adults found small body-composition shifts, no proven functional benefit and significantly more adverse events. To its credit, Next Health states these therapies *"are not FDA-approved to diagnose, treat, cure, or prevent any disease."* And on biological age, its executive-physical page says providers *"may help you reverse your epigenetic age"* — an outcome no completed trial supports. See [peptides for longevity](/peptides-for-longevity) and [epigenetic clock comparison](/epigenetic-clock-comparison). ## Where it's weak, and who should skip it Skip it if you are buying the NAD+ drip for energy or clarity: it is the most expensive way to buy the molecule here, by the route with no outcomes trial. Skip it if you need a total — peptides and hormones, the reason a longevity buyer walks in, carry no published price at either tier. If you proceed, price it at your specific clinic rather than the national store, and ask for peptide and hormone costs before joining the $99 tier that gates them. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Next Health takes the longevity line in full — NAD+, sixteen named peptides, hormone optimization and a 50-marker diagnostic line is squarely what this site ranks — plus two for provider consultations inside the membership and two for a care model that includes human time rather than upselling it. It takes **zero on price transparency**, and it is worth being exact about why: not for hiding prices, since it publishes more than most in-person clinics, but because the membership is not the cost, the two therapeutic lines are unpriced, two of its own price lists disagree by up to 40%, and no membership term is published anywhere. Zero on pharmacy. Eight of fourteen. A **B**. Reconcile the location menus with the national one, put a number on peptides and hormones, and drop the claim that an IV drip slows aging — and this becomes one of the better-documented in-person programs in the category, because the underlying operation already is. The full field is at [our provider rankings](/best-longevity-clinics), the scoring is in [how we grade](/how-we-grade-longevity-providers), and two comparable programs are in our [Marek Health review](/marek-health-review) and [Fountain Life review](/fountain-life-review). Sources: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers, https://pubmed.ncbi.nlm.nih.gov/41655607/, https://pubmed.ncbi.nlm.nih.gov/40275690/, https://pubmed.ncbi.nlm.nih.gov/17227934/ --- ### Marek Health Reviews: Deep Labs, No Drug Prices Canonical: https://longevitygraded.com/marek-health-review Updated: 2026-07-26 Marek's intake is $299 and it requires a $450 minimum lab panel. Panels run $150–$1,950. What no page publishes is the price of the medicine. July 2026. ## The one-sentence version Marek Health sells the deepest diagnostics in this category and prices them properly — a panel menu from $150 to $1,950, with the biomarker count beside each one. What it does not price is the treatment. A $299 intake plus a required lab panel of at least $450 gets you to a plan; the medication that plan recommends is described in Marek's own catalog only as *"separate and varies by dose."* It grades **B, 10 points out of 14**, and the deduction is entirely that missing figure. The grade is computed from published terms alone and cannot see who pays us. ## What it is, and who it's for Marek Health is a telehealth-only practice — *"any physical locations exist solely for administrative purposes and are not open to the public"* — built around a program it trademarks as Guided Optimization, run by Marek Health LLC of Pontiac, Michigan through five named medical groups. Its formulary is unusually large: *"500+ therapies, including testosterone replacement therapy (TRT), GLP-1 receptor agonists (semaglutide, tirzepatide), peptides, thyroid support, and more."* Twelve peptides are named, including sermorelin, tesamorelin, CJC-1295 with ipamorelin and BPC-157; a separate longevity category carries NAD+, rapamycin, GlyNAC and injectable glutathione. The buyer this suits wants data first: someone who would rather spend $595 on a hundred-marker panel and a coach's read than $199 on a vial. The buyer it does not suit wants the all-in monthly cost before starting. See [longevity biomarker panels](/longevity-biomarker-panels). ## What it actually costs All figures below were verified on 26 July 2026 against pages Marek publishes itself — its FAQ, its terms, its treatment catalog and its own diagnostics store. Where Marek publishes no number, we say so rather than guess. **The intake and the lab minimum.** *"Your intake assessment is a one-time cost of $299. No subscriptions and no hidden fees."* Marek states the fee is credited toward your first provider visit, and that it *"requires a minimum $450 lab panel purchase for the initial assessment"*, with most clients investing *"$450–$800 in their initial panel."* **The panel menu, which is genuinely excellent.** Marek's own store publishes a complete price list with the marker count beside each panel: Essential at $150, a Base Lab Panel at $250 (65 markers), Total Health — Comprehensive at $495 (80+), a pre-TRT Testosterone Panel at $595, Total Health — Complete at $895 (100+) and an Executive panel at $1,950 (130+). Testosterone runs by LC/MS rather than *"cheaper immunoassay methods that can be inaccurate by 20–30%."* Two cautions: Base and Essential both carry Marek's own warning that they do **not** meet the treatment requirements for Guided Optimization, so the $150 entry point is a lab purchase rather than a way in; and a 45-minute coach lab review adds $100 — the cleanest number Marek publishes about its own service. **And then the gap.** Marek's treatment catalog carries no price on any of its 101 entries. Every one repeats the same line: pricing starts with the intake and the lab panel, and *"if your provider determines a prescription is appropriate, medication cost is separate and varies by dose."* No per-drug figure — for TRT, a peptide or a GLP-1 — is published anywhere. The honest floor for a first month is $749, and the ceiling is unknown. **What's included, and what recurs.** A dedicated health coach with 1:1 protocol adjustments, monthly check-ins and provider oversight is included and specified. Standing requirements are easier to miss: *"routine visits every 6 months"* and *"ongoing basic labs every 6 months."* No insurance is accepted, and two of Marek's own documents disagree with each other — on HSA eligibility, and on whether this is a membership at all. ## The pharmacy, and one badge that overreaches Marek publishes the whole dispensing chain, which is more than the rows that merely name a pharmacy do. Its terms name seven fulfillment pharmacies with street addresses — Anazao Health, ReviveRX, Tailor Made Compounding, Empower Pharmacy, South Lake Pharmacy, Honeybee Health and Strive Pharmacy — and states a prescription *"may be filled by and transferred between any of the Pharmacies."* The compounding standard in its FAQ is where it overreaches: *"we only use 503A/503B FDA Approved and Audited compounding pharmacies as our fulfillment partners."* Compounding pharmacies are not FDA-approved, and neither are the drugs they make: FDA's position is that it does not verify the safety, effectiveness or quality of compounded drugs before marketing, and that 503A pharmacies specifically are **not** subject to current good manufacturing practice requirements, unlike 503B outsourcing facilities. Naming the pharmacies is excellent practice. Calling them FDA-approved is not, and collapsing 503A into 503B erases the only distinction carrying regulatory weight. ## The evidence behind what it sells Marek's copy is better disciplined than most of this category, and what it gets right is worth naming first. It never claims to measure or reverse "biological age" — the phrase appears nowhere on its pages, which is rarer than it should be — and its own catalog entry for BPC-157 says outright that there are *"no completed human clinical trials; all evidence is preclinical."* The lapses are on the same shelf. The NAD+ entry describes supplementation as restoring *"mitochondrial function, DNA repair, and anti-aging sirtuin activity."* The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies including 33 human intervention trials, found outcomes *"heterogeneous and often null or endpoint-specific"*, and reported that no eligible outcomes trial has evaluated intravenous or intramuscular NAD+ for these indications at all. Sermorelin sits in the catalog against *"age-related GH decline"* and *"body composition optimization"*; the trial that tested that molecule on that schedule gave GHRH 1-29 nightly for six weeks to eleven healthy men aged 64–76, and nocturnal growth hormone rose while IGF-1 and DEXA-measured muscle and fat did not change. The landmark review of growth hormone in healthy older adults found small body-composition shifts, no proven functional benefit and significantly more adverse events. See [NAD+ for longevity](/nad-for-longevity), [peptides for longevity](/peptides-for-longevity), [rapamycin and metformin](/rapamycin-metformin-evidence) and [what's proven versus hyped](/longevity-medicine-evidence). ## Where it's weak, and who should skip it Skip it if you want one number before you start — Marek gives you two of the three, and the missing one recurs. Skip it if you need insurance, an HSA claim or a diagnosis code. And skip the $150 and $250 panels if your goal is the program, because Marek says itself they do not qualify you for it. If you proceed, $749 is the floor before any medicine; get the medication figure in writing before accepting a protocol. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Marek takes the longevity line in full — TRT, twelve named peptides, NAD+, rapamycin and 130-marker panels is as deep a shelf as this site has — two for a provider exam inside the program, and two for a coach that is specified rather than implied. It takes **zero on price transparency**: not for hiding its labs, which it prices better than anyone here, but because no page publishes what the treatment costs, and treatment is the recurring line. **One correction we owe our own ranking.** Marek currently scores nothing for pharmacy disclosure, on the grounds that no compounding statement could be read on a surface it controls — its site returns an empty document to automated readers. Reading its published FAQ and terms directly for this review, that is no longer right: Marek names seven dispensing pharmacies with addresses and does state a compounding standard. On our rubric that is two points it was not being credited with. **Corrected on 8 August 2026: this row now scores 10 of 14, not 8.** The letter is a **B** either way, and we would rather print the correction than carry a stale score. So: the best-priced diagnostics here attached to the least-priced treatment. Publish a per-therapy cost band on a reachable page and Marek would be arguing for an A. The full graded field is at [our provider rankings](/best-longevity-clinics), the scoring is in [how we grade](/how-we-grade-longevity-providers), the nearest structural comparison is our [Next Health review](/next-health-review), for menopause-specific hormone therapy with a real published price see our [Winona review](/winona-review), and for a TRT-first platform with the opposite pricing problem, our [Taurus Meds review](/taurus-meds-review). Sources: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers, https://pubmed.ncbi.nlm.nih.gov/41655607/, https://pubmed.ncbi.nlm.nih.gov/9005976/, https://pubmed.ncbi.nlm.nih.gov/17227934/ --- ### Fountain Life Reviews: $10,500 In, and What Is Extra Canonical: https://longevitygraded.com/fountain-life-review Updated: 2026-08-04 Fountain Life's own store prices CORE at $10,500 and APEX at $21,500 a year. The cancer blood test is not in either. What the imaging evidence says. ## The one-sentence version Fountain Life is the concierge ceiling of this category — whole-body and brain MRI with AI overlay, coronary CT angiography, whole genome sequencing and a hundred-plus blood markers, delivered in person at six centers by a physician-led team. Its marketing site publishes **no price at all**, not even a "request pricing" label; its own online store publishes them plainly: **CORE $10,500 a year, APEX $21,500.** It grades **B, 8 points out of 14**, and the deduction is not the price level — a concierge program is allowed to be expensive — but what sits outside it. The most emotionally central product on the site, the early cancer blood test, is in neither membership. The grade is computed from published terms alone and cannot see who pays us. ## What it is, and who it's for Fountain Life runs six centers — Naples, Orlando, Dallas, Houston and White Plains, New York, with Miami announced — under Fountain Life Management, LLC, led by William Kapp, MD as chief executive and Dawn Mussallem, DO as chief medical officer, and co-founded by Peter Diamandis, Tony Robbins and Robert Hariri. The product is a once-a-year diagnostic event, not a treatment protocol — the deepest screening money can buy, rather than a cheaper way to get a prescription, and that is the right frame for judging it. See [longevity clinics versus lab memberships](/longevity-clinics-vs-lab-memberships) and our [Fountain Life versus Human Longevity comparison](/fountain-life-vs-human-longevity). ## What it actually costs **Nothing on the marketing site.** There is no pricing page; every membership page ends in *"schedule a private call"*, and location pages carry no figures either. **Everything on its own shop.** The storefront linked from the membership page lists **CORE at $10,500.00** and **APEX at $21,500.00**, plus "final payment" items — CORE $7,000, APEX $14,500 — implying a deposit-plus-balance structure no marketing page explains. **APEX Family is priced nowhere at all.** **And Fountain Life's own blog gives a third number:** its article on what longevity clinics cost states that *"the cost of Fountain Life starts from $20,000 annually."* Its own store sells the entry tier at $10,500. Both are Fountain Life pages, and they cannot both be right. **The à la carte layer is priced in the shop too:** therapeutic plasma exchange $10,000, placental stem cell IV therapy $1,500, an epigenetic biological-age test $750, and a **multi-cancer early detection blood test at $949**. ## What the membership does not include This is the part worth reading twice, because it inverts the pitch. **CORE covers 8 of the 27 listed diagnostics.** APEX covers 24. APEX Family covers **three**: whole-body and brain MRI, DEXA and the blood panel. CORE physician access is marked *"Limited"*, always-on care is not covered on it, and Restorative Therapeutics is *"not available"* to it. **The multi-cancer early detection blood test is à la carte on the two tiers virtually everyone buys.** Fountain Life's own table marks it an extra for CORE and APEX (the entry and mid tiers). As of our August 2026 check, it's included ("Unlimited") on APEX Family — a change from earlier, when it wasn't offered there at all. Yet cancer is the hook the whole site hangs on — *"we combine whole-body MRI, liquid biopsy (Galleri), and genetic risk profiling to detect cancers at Stage 0 or 1"*, and Peter Diamandis on the membership page: *"imagine finding cancer at stage zero when it's most easily cured."* For the two tiers most buyers actually choose, that liquid biopsy is $949 more. See our [Galleri test review](/galleri-test-review). **No membership terms are published** — no minimum term, no renewal mechanics, no cancellation or refund policy, anywhere. The one terms page that exists appears to be boilerplate from an unrelated company: it refers to *"an affiliate of Augment Your Immunity"*, points its privacy policy at another domain, offers *"technology-oriented tools for smoking cessation"*, and names the governing law as *"the laws of the State of Naples, Florida."* Naples is a city. Ask for the real agreement before you pay $10,500. And if a scan finds something, no page says whether the workup, the biopsy or the treatment is inside the fee — on the evidence of the à la carte menu, it is not. ## The evidence behind what it sells Fountain Life's screening is real and it is not free of consequence, and the site presents only the first half of that. **On whole-body MRI.** The 2026 systematic review and meta-analysis of whole-body MRI for opportunistic cancer detection in asymptomatic people pooled ten studies and 9,024 participants. The confirmed cancer detection rate was **1.57%** (95% CI 1.22–2.03), and the authors concluded that *"modest detection rates, frequent incidental findings, unstandardized protocols, and lack of long-term outcome or cost-effectiveness data limit its current clinical utility"*, adding that it *"may lead to unnecessary investigations"*. A separate review of 5,373 asymptomatic subjects pooled critical and indeterminate incidental findings at **32.1%**, with **16.0%** false positives, and found that **no included study verified negative findings beyond five years**; a broader umbrella review across twenty systematic reviews makes the same point across modalities. None of that makes the scan worthless — it means roughly one member in three should expect a finding that requires chasing, most will resolve to nothing, and the chasing is not in the fee. Fountain Life publishes no overdiagnosis or false-positive caveat on any membership page. **On the outcome statistics and on reversal.** A stat block repeats across roughly eight pages — *"96% detect potentially life-threatening diseases before symptoms appear"*, *"46% achieve brain age improvement, reversing accelerated aging"* — with no denominator, methodology or citation anywhere on the site. The homepage promises Restorative Therapeutics that *"don't just slow aging, but could even reverse it"*, and APEX offers therapies that *"may help reverse aging at the cellular level."* No completed human trial supports that for plasma exchange, biologics or the peptide and hormone work described, though Fountain Life does state prominently that its stem cell therapy is not FDA-approved. Its intravenous nicotinamide riboside sits where the rest of this category sits: the 2026 PRISMA-guided systematic review of NAD+ covered 113 studies including 33 human trials, found clinical effectiveness *"inconclusive"*, and reported no eligible outcomes trial of intravenous or intramuscular NAD+ for these indications at all. See [NAD+ for longevity](/nad-for-longevity), [biological age tests](/biological-age-tests) and [what's proven versus hyped](/longevity-medicine-evidence). ## Where it's weak, and who should skip it Skip it if the number that matters to you is the one you pay — the real cost is the membership plus whatever the scan starts. Skip it if a 32% chance of an indeterminate finding would read as stressful rather than reassuring. And skip CORE if you are buying the cancer story: it covers eight of twenty-seven diagnostics and the liquid biopsy is extra on it anyway. If you proceed, ask three things in writing before the deposit: the real membership agreement, since the published terms page describes a different company; what downstream workup costs when the MRI finds something; and whether the price is $10,500 or the *"from $20,000"* its own blog claims. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Fountain Life takes the longevity line in full — imaging-grade diagnostics, genome sequencing and biological-age testing are exactly what this site ranks, and no other row here matches that depth — plus two for physician oversight and two for a care team included rather than upsold. It takes **zero on price transparency**: the marketing funnel publishes nothing, the store and the blog disagree, the entry tier covers under a third of the listed diagnostics, and no membership terms exist at all. Zero on pharmacy. Eight of fourteen. A **B**. That is a good grade for an expensive product, and it should be read as one: the medicine here is more serious than most of what we grade, and the failure is commercial rather than clinical. Publish the price on the membership page, publish a real membership agreement, put the liquid biopsy inside the tier that sells it, and print one honest sentence about false positives — and Fountain Life would be arguing for the best options here. The full field is at [our provider rankings](/best-longevity-clinics), the scoring is in [how we grade](/how-we-grade-longevity-providers), and the nearest structural comparison is our [Next Health review](/next-health-review). Sources: https://pubmed.ncbi.nlm.nih.gov/40884613/, https://pubmed.ncbi.nlm.nih.gov/30932247/, https://pubmed.ncbi.nlm.nih.gov/29914908/, https://pubmed.ncbi.nlm.nih.gov/41655607/ --- ### System Labs Reviews: Every Price Is a First Month Canonical: https://longevitygraded.com/system-labs-review Updated: 2026-08-07 System Labs publishes NAD+ at $89 and sermorelin at $109 — both struck through from $149 and $219, both first-month rates. What that means. July 2026. ## The one-sentence version System Labs is one of the few providers here whose entire catalog is the thing the ranking ranks — NAD+ by injection and by nasal spray, sermorelin by injection and orally, plus glutathione — rather than a weight-loss shop with a peptide bolted on. It also does the rarer thing of printing a price on the page instead of hiding it behind an intake. The catch is what the printed price is: **every published figure is a first month, shown struck through from a standing rate you start paying in month two.** It grades **B, 10 points out of 14**, and the two points it drops are both about what the page does not say. The grade is computed from published terms alone and cannot see who pays us. ## What it is, and who it's for The operator is **System Laboratories, Inc.**, and the site carries a LegitScript Certified badge. Its menu, verified on 31 July 2026, is: **NAD+ injection, NAD+ nasal spray, sermorelin injection, oral compounded sermorelin, glutathione injection, MIC+B12, GHK-CU cream, and compounded GLP-1/GIP.** Read that list next to the other providers here and the shape is unusual. Most of the providers here are GLP-1 operators that added an anti-aging category; four of System Labs' eight items are the NAD+ and sermorelin routes this ranking is built on, and the GLP-1 line is the appendage rather than the core. If you came looking for a longevity menu rather than a weight-loss menu with one, this is a genuine fit — which is the whole of the four points it takes on the longevity-line factor. On whether that menu is worth buying at all, read [what the evidence actually shows](/longevity-medicine-evidence) first. ## What it actually costs All figures below were read on System Labs' product landers on 31 July 2026, and they are quoted with the qualifier attached because the qualifier is the story. **NAD+** — *"$149"* struck through to *"$89 /first mo."* **Sermorelin** — *"Monthly Supply (9mg)"*, *"$219"* struck through to *"$109 /first mo."* The copy beside it reads *"Support deeper sleep, faster recovery, and leaner muscle. All from your own growth hormone."* **Compounded GLP-1/GIP** — *"COMPOUNDED GLP-1/GIP"*, *"Monthly Supply (All doses)"*, *"$179"* struck through to *"$99 /first mo."* Three products, three prices, and the same structure on all three: the number in large type is a first month, and the number it is struck through from is the rate that follows. **$89 becomes $149. $109 becomes $219. $99 becomes $179.** Nothing here is hidden — System Labs prints both figures, which is more than several providers here manage at all — but a reader who takes the large number as the price has budgeted for the wrong one from the first refill onward. It is worth being precise about why that still earns the four price-transparency points rather than zero. Our rubric asks for a single all-in figure, visible before you commit, that a buyer with no commitment actually pays. System Labs publishes one: **$149 for NAD+, on the same line as the promotional rate, with no prepay term attached to it.** Compare that with the providers here whose advertised figure turns out to be a twelve-month prepay, or is quoted only inside the portal — see the [Gala Health review](/gala-health-review) and the [Shed review](/shed-review) for what an unpublished monthly price looks like. A teaser beside a standing rate is a marketing tactic. A price that does not exist until checkout is a different failure, and a worse one — as is a price that exists in a provider's own data and is printed on none of its pages, which is what our [MyDrHank review](/mydrhank-review) found. **What every lander includes.** All three carry the same four lines: *"20% off Rythm blood test"*, *"Injection supplies included"*, *"2-day temp-controlled shipping"*, and *"Ongoing support from a real care team."* The last of those is what earns the human-support points — support stated as inside the price, not sold as an upgrade. ## The two points it drops, and why **Clinical oversight: zero.** Nothing on the lander states whether the clinician visit is included in the published price. That is the whole finding, and we have deliberately not resolved it in either direction. These are prescription products, so a prescriber is involved somewhere; what is not published is whether the $89 or the $149 covers that consultation or whether it is billed separately. Our rubric scores an unstated consult exactly as it scores one billed on top, because a buyer cannot budget for a fee nobody has quoted. If System Labs states the position on the lander, this becomes two points immediately. **Pharmacy disclosure: zero.** No dispensing or compounding pharmacy is named, and no compounding standard — 503A or 503B — is claimed. The LegitScript Certified badge is a real signal and worth having, but it certifies the seller's compliance, not the pharmacy that fills the vial; it is not a facility name and not a classification. We applied that identically to [Strut Health](/strut-health-review), whose ACHC seals earned nothing on this factor either. FDA's position on what an unnamed compounder leaves open is blunt: compounded drugs are not FDA-approved, and the agency does not verify their safety, effectiveness or quality before they are marketed. **One structural oddity worth knowing.** The prices above live on System Labs' product **landers**. Its own `/nad` path is an intake questionnaire rather than a product page — so a reader who arrives at the site and browses does not necessarily reach the page with the price on it. That is not a hidden price; it is a published price on a page the site's own navigation does not lead with. ## The evidence behind what it sells This is where a good menu meets a thin trial record, and the sermorelin copy is the sharper example. *"Support deeper sleep, faster recovery, and leaner muscle. All from your own growth hormone"* describes a mechanism accurately and then attaches outcomes to it that the trials did not produce. The study that tested this exact protocol gave GHRH 1-29 nightly for six weeks to eleven healthy men aged 64–76: nocturnal growth hormone rose significantly, **but IGF-1 did not change and DEXA-measured muscle and fat did not change**. The landmark review of growth hormone in healthy older adults found small body-composition shifts, no proven functional benefit, and significantly more adverse events. See [peptides for longevity](/peptides-for-longevity). NAD+ is no better supported, and the specific gap matters here because System Labs sells it as an injection and a nasal spray. The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies including 33 human intervention trials, found effects on functional, metabolic and vascular outcomes *"heterogeneous and often null or endpoint-specific"*, and reported that **no eligible outcomes trial has evaluated intravenous or intramuscular NAD+ for these indications at all**. A 2025 meta-analysis in adults averaging over 60 found NAD+ precursors did not improve muscle index, grip strength, gait speed or chair-stand time. See [NAD+ for longevity](/nad-for-longevity) and [do NAD+ peptides work](/do-nad-peptides-work). None of that is a mark against System Labs specifically — it is the state of the category, and this site grades providers rather than the medicine. But a buyer who is paying $149 a month from the second month onward should know the outcomes being described have not been demonstrated. ## Where it's weak, and who should skip it Skip it if the first month is doing the work in your budget: run the arithmetic at $149 for NAD+ or $219 for sermorelin, because those are the numbers you live with. Skip it if you need to know the consultation cost before you start, since the landers do not state it. And skip it if you want to know which pharmacy fills your vial — [Telos Rx](/telos-rx-review) names both of its dispensing pharmacies with street addresses and their licensure gaps, and [Care Bare Rx](/care-bare-rx-review) names four with addresses and phone numbers. Buy it if the menu is what you actually want. Four longevity routes under one intake, injection supplies and temperature-controlled shipping inside the price, and a published standing rate to plan against is a better starting position than most providers here offer. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). System Labs takes **the full four for its longevity line** — NAD+ by two routes plus sermorelin by two more is as complete a longevity shelf as this site has — **four for price transparency**, because a standing monthly rate is published beside the promotional one with no prepay term attached, and **two for human support**, stated on every lander. It takes **zero for clinical oversight**, because whether the visit is inside the price is never stated, and **zero for pharmacy**, because no dispensing facility is named and no compounding standard is claimed. **Ten out of fourteen: a B.** Both missing points are sentences, not systems. Publish whether the consult is included, and name the pharmacy or state its compounding standard, and System Labs would be at fourteen without changing a single term of the offer. Until then it sits mid-table with a strong menu and a page that will not finish the sentence. Our [Revel Health review](/revel-health-review) shows the mirror version of this same gap — clear consult and pricing terms, but a pharmacy network it won't name — and our [Wellspring Longevity Clinic review](/wellspring-longevity-clinic-review) goes further in the other direction, naming its pharmacy while its own Pricing FAQ gives no number at all. The full field is at [our provider rankings](/best-longevity-clinics), and the scoring is set out in [how we grade](/how-we-grade-longevity-providers). Sources: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers, https://pubmed.ncbi.nlm.nih.gov/9005976/, https://pubmed.ncbi.nlm.nih.gov/17227934/, https://pubmed.ncbi.nlm.nih.gov/41655607/, https://pubmed.ncbi.nlm.nih.gov/40275690/ --- ### Wellorithm Reviews: The Longevity Line Is Unlisted Canonical: https://longevitygraded.com/wellorithm-review Updated: 2026-08-04 Wellorithm's sermorelin page prints $150 first month, then $200/mo* — and is absent from its own nav and sitemap. What the asterisk means. July 2026. ## The one-sentence version Wellorithm sells the two things this site is built to rank — a sermorelin injection and an NAD+ injection — and it prices them on the page, which is more than several providers here do. Then it undoes almost all of that: the price carries an asterisk the page never resolves, the four compounded GLP-1 products beside it carry no public figure at all, billing runs every 28 days and is non-refundable once processed, the pharmacy is never named, the site contradicts itself on how many states it serves, and **the sermorelin and NAD+ pages are missing from Wellorithm's own navigation and from its own sitemap.** It grades **C, 4 points out of 14 — tied for the lowest score here.** The grade is computed from published terms alone and cannot see who pays us. ## The finding that nearly cost us the review We had Wellorithm recorded internally as a provider with **no NAD+ and no sermorelin line**. That was wrong, and how it got to be wrong is worth publishing, because it is a mistake a reader can make just as easily as we did. Both product pages are live. `/sermorelin` lists a **Sermorelin Injection** as *"In Stock"*, and `/nad` lists an **NAD+ Injection**. Both print prices. Neither is linked from the site's own navigation, and **neither appears in its sitemap.** Browse Wellorithm the way a customer would and the longevity line does not exist; you have to arrive at those URLs from somewhere else to find it. Two lessons carried into this review. The first is that a catalog is what the product pages say, not what the navigation implies. The second is the one we had already been burnt by: Wellorithm's affiliate program lists an **"ED (Tadalafil)"** payout tier, and Wellorithm does not appear to sell tadalafil at all. A payout tier describes what a vendor could be paid for. It is never evidence of what is on the shelf. ## What it is, and who it's for Wellorithm describes itself in its own Terms as a **facilitator, not a practice**: *"Wellorithm acts as a facilitator, connecting users with licensed healthcare professionals through its Professional Entities. The company itself does not diagnose, treat, or practice medicine."* Review is asynchronous, following an online evaluation. The catalog splits three ways. The longevity line is a **sermorelin injection** — *"5mL (10mg) vial and homekit included"*, with *"Free expedited shipping"*, *"Compounded in the U.S.A"* and *"FSA & HSA Eligible"* stated on the page — and an **NAD+ injection**. There is no oral, sublingual or nasal sermorelin route here; the injection is the only way in. The weight-loss line is compounded semaglutide and tirzepatide, each sold as an injection and as an oral dissolving tablet. And there is a branded shelf: **Ozempic $1,119/mo, Wegovy $899/mo, Mounjaro $1,399/mo, Zepbound $1,119/mo.** If you want a sermorelin injection and you have found the page, the product is real. If you want to compare it against anything, the rest of this review is the reason that is harder than it should be. ## What it actually costs **Sermorelin.** The price block reads *"$150 first month"*, then **"then $200/mo*"**. A banner promises *"Save up to $50 on your first order"*, *"Discount auto-applied at checkout."* **The asterisk is not resolved on that page.** It is resolved where Wellorithm publishes the same asterisked figure on its NAD+ page, and there it reads: *"Price shown applies to 500mg (2.5mL) 3-month plan paid upfront or with buy now, pay later programs. Actual price will depend on product and plan prescribed."* Read that sentence twice. It conditions the figure on a **three-month plan paid up front**, and then says the real number **depends on the product and plan prescribed** — which is the site telling you, in its own words, that the printed price is not necessarily your price. **NAD+** carries the same structure — *"$150 first month"*, **"then $200/mo*"** — plus **"Only $15/shot*, homekit included"** and *"Full-strength dosages."* **The core weight-loss line has no public price whatsoever.** All four compounded semaglutide and tirzepatide SKUs are gated behind Wellorithm's quiz. The branded pens are priced flat — and two of those pages disagree with themselves, which is the next section. That is the whole case for scoring price transparency at zero. Our rubric asks for a single all-in figure, visible before you commit, that a buyer with no commitment actually pays. Wellorithm's figure is asterisked; the only published resolution of that asterisk attaches a three-month prepay to it and then disclaims itself; and the largest part of the catalog is not priced at all. Compare the [Gala Health review](/gala-health-review), where an advertised monthly rate turns out to be a yearly one — the failure is the same shape. And compare the [System Labs review](/system-labs-review), which sells the same two injections and prints its standing rate on the same line as its promotional one: publishing the number you keep paying is not a hard thing to do. ## The pages disagree with each other Three separate self-contradictions, verified on the same day, plus one that has since been fixed. None of them is a pricing trap on its own; together they are the reason a reader cannot take any single figure on this site at face value. **Update, August 2026: the sermorelin page's leftover NAD+ copy is gone.** Earlier versions of this review flagged two lines on the sermorelin product page — *"NAD+ boosts mitochondrial function to power your day"* and *"Support DNA repair and longevity enzymes like SIRT1"* — as copy pasted from the NAD+ page onto a page selling a different product. On our most recent check, that copy has been replaced with sermorelin-appropriate language. Crediting the fix: this is one contradiction Wellorithm has genuinely corrected. **The NAD+ footnote is pasted onto drugs it cannot describe.** All four branded-drug pages carry that same *"500mg (2.5mL) 3-month plan"* NAD+ footnote. Ozempic is not dosed in 500mg vials of NAD+. The footnote is meaningless on those pages and is printed on them anyway. **Two branded pages print two different prices.** Ozempic and Zepbound each show **$1,119 in the hero and $1,199 in the call to action** — on the same page, for the same drug. **The site cannot agree on where it operates.** The homepage says *"Serving All 50 States"*; other pages say 49, excluding Louisiana. ## Billing, oversight and the pharmacy **Billing is not monthly, and it is not refundable.** Wellorithm's Terms state that *"Membership fees are billed every 28 days, and payments are non-refundable once processed."* Twenty-eight days is not a month: it is **thirteen charges a year, not twelve**, against a price advertised as *"/mo"*. And once a charge clears, the Terms say it does not come back. Both facts belong in your arithmetic before the first click, not after. **Oversight scores zero, and the reason is what is missing rather than what is wrong.** Review is asynchronous after an online evaluation, and the company's own Terms say it does not practice medicine — it connects you to professional entities that do. What is nowhere stated is whether the clinician visit is included in the $150 or the $200. Our rubric scores an unstated consult exactly as it scores one billed on top, because a buyer cannot budget for a fee nobody has quoted, and we have deliberately left it unresolved rather than assume either way. **Pharmacy scores zero too.** *"Compounded in the U.S.A"* is the entire disclosure. No dispensing facility is named, and no 503A or 503B standard is claimed. FDA's position on what that leaves open is unambiguous: compounded drugs are not FDA-approved, and the agency does not verify their safety, effectiveness or quality before they are marketed. For the contrast, [Telos Rx](/telos-rx-review) prints both of its pharmacies' street addresses and phone numbers. ## The evidence behind what it sells The sermorelin trial record is thin, and Wellorithm's own page does not lean on it — the longevity claims printed there are the NAD+ ones that do not belong on it. The study that tested this protocol gave GHRH 1-29 nightly for six weeks to eleven healthy men aged 64–76: nocturnal growth hormone rose significantly, **but IGF-1 did not change, and DEXA-measured muscle and fat did not change**. The landmark review of growth hormone in healthy older adults found small body-composition shifts, no proven functional benefit and significantly more adverse events. See [peptides for longevity](/peptides-for-longevity). For NAD+, the 2026 PRISMA-guided systematic review screened 113 studies including 33 human intervention trials, found effects on functional, metabolic and vascular outcomes *"heterogeneous and often null or endpoint-specific"*, and reported that **no eligible outcomes trial has evaluated injected NAD+ for these indications at all** — which is exactly the product Wellorithm sells. See [NAD+ for longevity](/nad-for-longevity). One thing genuinely cuts the other way, and it is worth stating on a page this critical. The **GLP-1 line Wellorithm will not price is the part of its catalog with real randomized outcome data behind it**: SURMOUNT-1 randomized 2,539 adults with obesity and reported mean weight change at week 72 of −15.0% on 5 mg of tirzepatide, −19.5% on 10 mg and −20.9% on 15 mg, against −3.1% on placebo. The evidence is on the products with no public price; the prices are on the products with no evidence. ## Where it's weak, and who should skip it Skip it if you are comparing providers on price, because there is no figure here you can compare with confidence. Skip it if the 28-day cycle matters to you — thirteen charges a year against a "/mo" headline is a real difference, and none of them come back. Skip it if you want an oral or nasal sermorelin route, which Wellorithm does not sell. And skip it if the self-contradictions bother you, which they should: a company that prints two prices for Ozempic on one page and can't agree on whether it serves 49 or 50 states is not a company whose fine print you should assume is careful. If you proceed anyway: get the month-to-month price in writing before you pay, ask explicitly what happens after the first month and whether a three-month prepay is required to hold the rate, ask whether the consultation is included, and confirm you are in a state it actually serves — the site itself gives two different answers. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Wellorithm takes **the full four for its longevity line** — a sermorelin injection and an NAD+ injection are exactly what this site ranks, and finding them unlisted does not make them unreal. It takes **zero everywhere else**: zero on price transparency, because the printed figure is asterisked, the only published resolution of that asterisk attaches a three-month prepay and then disclaims itself, and the compounded GLP-1 line carries no public price at all; zero on clinical oversight, because whether the visit is included is never stated; zero on pharmacy, because *"Compounded in the U.S.A"* names nobody; and zero on human support, which the page does not state is included. **Four out of fourteen: a C, tied for the lowest score here.** The owner of this site has seen that grade and let it stand. The repairs are unglamorous and entirely within Wellorithm's control: resolve the asterisk on the page it appears on, publish a GLP-1 price, decide whether it serves 49 states or 50, print one price per drug, and put both product pages in the navigation and the sitemap so customers can find them. (One repair is already done: the sermorelin page's leftover NAD+ copy is gone.) Do that and the grade moves on merit. Our other C-graded partners are covered in the [Gala Health review](/gala-health-review), the [MadeMed review](/mademed-review), the [Try Ageless review](/ageless-review) and the [Shed review](/shed-review); the full field is at [our provider rankings](/best-longevity-clinics) and the scoring is set out in [how we grade](/how-we-grade-longevity-providers). Sources: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers, https://pubmed.ncbi.nlm.nih.gov/9005976/, https://pubmed.ncbi.nlm.nih.gov/17227934/, https://pubmed.ncbi.nlm.nih.gov/41655607/, https://pubmed.ncbi.nlm.nih.gov/35658024/ --- ### Winona Reviews: Its Own Pages Disagree on FDA Approval Canonical: https://longevitygraded.com/winona-review Updated: 2026-08-04 Winona publishes a real monthly price on every hormone product — but its own pages disagree on whether its HRT is FDA-approved. Verified Aug 2026. ## The one-sentence version Winona publishes a real, single month's price on every one of its eight bioidentical hormone products, from Progesterone Capsules at **$39/month** up to the Estrogen Patch at **"From $149 per month."** What that therapy is and is not shown to do — including the eighteen-year mortality finding — is in [HRT, menopause and longevity](/hrt-menopause-and-longevity). It also names its own 503A pharmacy classification on a dedicated page. Then two of its own pages contradict each other on the one question a hormone buyer would assume is settled: is the medicine FDA-approved. It grades **A, 14 out of 14** — computed from published terms alone, and we hold no affiliate relationship with Winona today. ## What it is, and who it's for Winona is a telehealth company treating perimenopause and menopause, run by physicians including Chief Medical Officer Michael Green, MD. Eligibility starts with a free five-minute quiz — *"No blood tests required"* — and the site is explicit about why: *"In accordance with The Menopause Society and the American College of Obstetrics and Gynecology (ACOG), Winona does not require any type of bloodwork or hormone testing to be prescribed an HRT treatment plan,"* on the reasoning that hormone levels *"fluctuate day to day, and even hour to hour."* A board-certified physician reviews the intake and prescribes; typical delivery is about five business days. The catalog is bioidentical hormones in patch, cream, capsule and tablet form — estradiol, progesterone, DHEA — plus four non-hormone add-ons (a sleep aid, an arousal cream, a face cream, a hair serum). It does not treat men, and it does not bill insurance; HSA/FSA receipts are the stated workaround. Coverage is **36 states plus Puerto Rico**, narrower than an all-50-states competitor. If you want the field it sits in, start with [our provider rankings](/best-longevity-clinics). ## What it actually costs Every product carries its own monthly figure, printed on the homepage and repeated on each product page — no quiz required to see a number: - Progesterone Capsules — **$39/month** - Estrogen Tablets — **$54/month** - Estrogen Body Cream — **$89/month** - Estrogen Body Cream (with Progesterone) — **$89/month** - Progesterone Body Cream — **$89/month** - Vaginal Estrogen Cream — **$89/month** - Deep Sleep — **$119/month** - Estrogen Patch — **"From $149 per month"** - DHEA — **$27/3 months** That is a genuinely flat, pre-signup price list — the trap most providers here fails ("starting at," a plan-length floor, a gated quote) is largely absent here. One qualifier survives: the Estrogen Patch page states the word *"From"* in front of $149, and the product itself ships in **five dose strengths — 0.025 mg, 0.0375 mg, 0.05 mg, 0.075 mg and 0.1 mg** — with no page stating whether a higher dose costs more than the lowest one. **Billing cadence.** Winona's FAQ states plainly: *"Payment and prescription for a 30-day supply are automatically processed every 28 days, while those for a 90-day supply are processed every 84 days."* That is 13 charges a year on the 30-day cadence, not 12 — a fact the monthly headline doesn't surface. **The refund window is short.** *"Patients may cancel an order and receive a full refund to their original form of payment only within the 24-hour processing window."* After that: *"Orders cannot be canceled, refunded, or returned after the 24-hour cancellation window has passed."* You can pause or cancel the *subscription* going forward at any time — but a processed order itself is final after one day. ## Clinical oversight and the pharmacy — and one contradiction Winona owns and runs its own compounding pharmacies rather than routing through an unnamed network, and says so on a dedicated page: *"Winona operates its own pharmacies in order to provide high-quality, effective menopause care. Winona's pharmacies are classified with 503A status because they develop individual prescriptions for each patient."* That claim is published on a surface Winona controls, which is what [our rubric](/how-we-grade-longevity-providers) scores — no individual facility address is given, the same rung CoreAge Rx sits on. Every prescription includes free, unlimited messaging with an assigned physician for dose questions and adjustments, and the subscription bundles free standard shipping. Here is the contradiction. Winona's own **/pharmacy** page states, twice, that its treatments are not FDA-approved: *"Although Winona's bioidentical HRT is not regulated by the FDA for approval, Winona strictly uses ingredients from FDA-regulated facilities to produce all prescriptions,"* and earlier on the same page, *"As 503A compounding pharmacies, Winona pharmacies are not directly regulated by the FDA and therefore are not subject to FDA-approval."* That is the correct, standard description of a 503A compounding pharmacy — 503A facilities are not FDA-regulated, 503B facilities are. But the **Estrogen Patch product page's own FAQ** asks and answers the opposite: *"Is the Estrogen Patch FDA approved? Yes, Winona's Estrogen Patch is approved by the FDA."* One Winona page tells you nothing it sells has been through FDA approval; another tells you its single most expensive product has. Both cannot be true on their face, and the site does not reconcile them anywhere we could find. If a patch product genuinely is an FDA-approved generic estradiol patch dispensed outside the 503A pharmacy, the site owes a reader that distinction in one sentence — right now it owes two contradictory ones. ## The evidence behind what it sells Winona markets its hormones as *"natural, bioidentical"* and states plainly that HRT is *"considered a safe and effective treatment for most women with no existing risk factors"* when *"started before the age of 60 or within 10 years of your final menstrual period."* That claim tracks the current clinical consensus, not a marketing invention. The Women's Health Initiative's 2002 randomized controlled trial of combined estrogen-progestin in postmenopausal women is the reason HRT use collapsed for two decades — it found increased risks of breast cancer, coronary heart disease, stroke and venous thromboembolism in its overall study population. But that population's average age was 63, more than a decade past a typical menopause onset, and the finding does not transfer cleanly to a woman starting HRT in her late 40s or early 50s for symptom relief. The Menopause Society's 2022 position statement — the field's current standing guidance — states that for symptomatic women under 60 or within 10 years of menopause, *"the benefits of hormone therapy are likely to outweigh the risks"*. Winona's framing is consistent with that guidance; it is the same "timing hypothesis" the field has settled on since the WHI re-analysis. Where the site oversells is the word **"bioidentical"** itself. Winona's marketing implies bioidentical formulations are inherently gentler or safer than FDA-approved synthetic or conjugated hormones — *"Since it's functionally indistinguishable from the body's natural hormones, it tends to come with fewer side effects and risks than synthetic HRT."* The Menopause Society's position statement does not support a blanket safety edge for compounded bioidentical hormones over FDA-approved bioidentical or synthetic options; it is compounded formulations specifically — not "bioidentical" as a category — that carry the added caveat of unverified dosing consistency, because a 503A pharmacy is not required to meet FDA manufacturing standards. Estradiol and progesterone are available in FDA-approved bioidentical forms already; Winona's advantage over those is convenience and per-product pricing, not a chemistry difference. ## Where it's weak, and who should skip it Skip it if you are outside its 36-state-plus-Puerto-Rico footprint, or if you need insurance billing rather than HSA/FSA reimbursement. Skip it if you might cancel an order within the first day — after that the charge is final. And before you order the Estrogen Patch specifically, ask which of its five doses "$149" refers to, and what the other four cost; the site does not say. If you proceed, the pricing itself is close to a model for this site: eight real numbers, visible before signup, updated on the product page rather than buried in an intake. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Winona takes all four for price — a real per-product monthly figure, not a "starting at" plan-length trap. It takes four for a genuine longevity line: hormone optimization is the entire catalog, not a bolt-on. Two for a physician reviewing every intake, two for a stated 503A claim on a page it controls, and two for unlimited included follow-up messaging. **Fourteen of fourteen: an A**, tied with the several other rows this site has already found at the ceiling. The one thing worth fixing costs nothing to fix: pick a lane on FDA approval and say the same thing on every page. Until then, a reader who checks both pages — as this review did — finds Winona disagreeing with itself about the one fact a hormone buyer would assume was simplest. Neighbors here worth reading next are the [Hone Health review](/hone-health-review) and [Marek Health review](/marek-health-review), both hormone-optimization platforms with a different pricing model; the full field is at [our provider rankings](/best-longevity-clinics). Sources: https://pubmed.ncbi.nlm.nih.gov/12117397/, https://pubmed.ncbi.nlm.nih.gov/35797481/ --- ### Taurus Meds Reviews: The TRT Price It Won't Show You Canonical: https://longevitygraded.com/taurus-meds-review Updated: 2026-08-04 Taurus names four pharmacies and prices its peptides — but Taurus TRT, its own namesake product, has no public price, and the Terms hide a $17.99 fee. ## The one-sentence version Taurus Meds is a men's-health telehealth platform selling two distinct lines — **Taurus TRT**, the company's own namesake hero product, and a **peptide menu** (NAD+, sermorelin, glutathione) at $79/month. The irony is specific: the peptide line, a secondary product, shows a real price before signup. **Taurus TRT — the product the company is named after — does not.** The only way to see what testosterone replacement costs is to complete a multi-step intake quiz. Its own Terms of Service also disclose a separate, non-refundable **$17.99-per-billing-period "healthcare member fee"** that never appears on the pricing cards. It grades **B, 9 out of 14** — computed from published terms alone, and we hold no affiliate relationship with Taurus today. ## What it is, and who it's for Taurus Meds, Inc. is a Delaware-registered telehealth company (support@taurusmeds.com) whose clinical staffing runs through **OpenLoop Health, Inc.**, a Des Moines-based physician network used by several telehealth brands. The homepage leads with testosterone: *"2-5X Increase in your total testosterone,"* *"3-4X Increase in your free testosterone,"* and offers a **free baseline testosterone test** before you commit to a plan. A second, separate storefront sells peptides — NAD+, sermorelin, glutathione — plus an ED liquid treatment ("Charge™") and a hair product marked "coming soon." Clinicians are described in the site's own words as working *"directly with you for optimal results by adjusting dosages and medications to reach your goals"* — ongoing dose management rather than a single script and goodbye. ## What it actually costs — and what it won't show you **The peptides have a real price.** NAD+ Injection, Sermorelin and Glutathione are each listed at **$79/month**, struck through against a $179 list price, visible on the /peptides page with no quiz required to see the number. **Taurus TRT has no price at all.** The homepage's TRT tile ("2-5x your testosterone") and the nav's "TRT" link both route to `/trt-intake` — a multi-step quiz ("Why do you want to increase your testosterone today?") with no pricing displayed at any step we could reach without submitting personal health information. No product page, no plan table, no "starting at" figure — nothing. For the company's own namesake product, that is the most opaque pricing setup here. **The Terms of Service hide a second charge the pricing cards never mention.** Section 28, "Healthcare Member Fees," states: *"By creating an account, subscribing to the Service, or otherwise using any membership features offered by the Company, you agree to pay a recurring membership fee of $17.99 USD per billing period... Membership fees are non-refundable except where required by applicable law."* Nothing on the $79/month peptide pricing cards mentions this. If it applies broadly, as the clause's own language ("otherwise using any membership features") suggests, a peptide subscriber's real minimum monthly cost is closer to **$96.99, not $79** — and a reader has no way to know that without reading the legal terms rather than the product page. **The refund policy is the strictest we've found.** Its own Terms state: *"All sales on shipped medications are final and no refund will be issued. There are no refunds on blood work tests as the order is submitted immediately upon payment to our lab partners."* Compare that with providers here that at least offer a refund window before a prescription is filled — Taurus offers none once an order ships. ## Clinical oversight and the pharmacy Taurus is genuinely strong on one axis only a minority of rows here manage at all, and it does it in unusual depth: it names **four separate dispensing pharmacies, each with a street address**, in its own Terms of Service under "Partner Pharmacy" — RedRock Pharmacy (St. George, UT), Health Warehouse (Florence, KY), Precision Compounding Pharmacy (Bellmore, NY) and Triad Rx (Daphne, AL). That is more pharmacy transparency than most providers we grade, [Telos Rx](/telos-rx-review) included. What it does not do is classify any of them. No page we could find states whether these are 503A or 503B facilities, or anything about the compounding standard each follows. Naming four real, checkable pharmacies without saying what kind of pharmacy any of them is lands this row on the middle rung of [our rubric](/how-we-grade-longevity-providers) — real disclosure, but an incomplete one. A free testosterone test is offered up front, and the clinical-review claim ("licensed clinicians," dosage adjustments over time) is consistent with a real prescribing relationship rather than a rubber-stamp questionnaire. ## The evidence behind what it sells Testosterone therapy is a treatment for diagnosed hypogonadism, not a longevity intervention, and the distinction is the whole of the honest case for it. The Endocrine Society's clinical practice guideline is explicit that the diagnosis requires symptoms **plus** unequivocally low morning testosterone confirmed on repeat measurement, and it recommends against treating men who simply have age-related decline. The large TRAVERSE trial then established the safety half: in men with hypogonadism and elevated cardiovascular risk, testosterone was noninferior to placebo for major adverse cardiac events. That is reassurance for a treated population, not evidence that raising testosterone in a man whose levels are normal extends his life. The earlier Testosterone Trials found modest benefits in sexual function and mood in men over 65 with genuinely low levels, with no demonstrated effect on vitality or walking distance. Read the marketing against that. A promise to multiply your testosterone is a promise about a number, and the number is not the outcome anyone is buying — we set out [what the testosterone trials actually found](/testosterone-trt-and-longevity), including the fracture signal nobody advertises. ## Where it's weak, and who should skip it Skip it if you specifically want TRT and need to compare a real price before handing over health information — Taurus will not show you one. Skip it if the strict, no-refund-after-shipment policy is a dealbreaker; there is no window to change your mind once medication ships. And before you subscribe to anything — peptides included — ask directly whether the $17.99 healthcare member fee applies to your plan, because the pricing card will not tell you. If you proceed, the pharmacy transparency is real and worth crediting: four named, addressable facilities is more than most providers here offer. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Taurus takes **zero on price transparency** — its flagship TRT product publishes no figure anywhere, and the one line that does (peptides) sits beside an undisclosed $17.99 fee its own pricing cards never mention. It takes four in full for a genuine longevity line (TRT plus a real NAD+/sermorelin/glutathione menu), two for clinical oversight, one of two for naming its pharmacies without classifying them, and two for described ongoing dosage support. **Nine of fourteen: a B.** The fix costs nothing but a line of copy: publish a TRT price range and disclose the membership fee on the product page instead of in the legal terms. Until then, the company selling testosterone replacement won't tell you what testosterone replacement costs. Compare that with [Male Excel](/male-excel-review), which discloses its own required membership fee directly on the pricing page rather than in the legal terms — a smaller version of the same problem, handled more honestly — or [Feel30](/feel30-review), whose all-inclusive price we checked and found genuinely holds up. Neighbors worth reading next are the [Hone Health review](/hone-health-review) and [Winona review](/winona-review), both hormone-optimization providers with very different pricing transparency, and our [Revel Health review](/revel-health-review) for a peptide provider that solved the pricing-clarity problem Taurus hasn't; the full field is at [our provider rankings](/best-longevity-clinics). Sources: https://pubmed.ncbi.nlm.nih.gov/29562364/, https://pubmed.ncbi.nlm.nih.gov/37326322/, https://pubmed.ncbi.nlm.nih.gov/26886521/ --- ### Revel Health Reviews: Clear Pricing, Unnamed Pharmacy Canonical: https://longevitygraded.com/revel-health-review Updated: 2026-08-04 Revel prices NAD+ and sermorelin clearly, with dosage-independent pricing and a real refund policy — but no pharmacy is named anywhere. Verified Aug 2026. ## The one-sentence version Revel Health does something few providers here manage cleanly: it publishes an ongoing monthly price for NAD+ and sermorelin, states outright that **"pricing remains consistent regardless of dosage,"** and separates the first-month discount from the standing rate instead of blending them into one misleading number. What it does not do is name a pharmacy — prescriptions route through an unnamed "Pharmacy Network," with no facility and no 503A/503B classification stated anywhere we could find. It grades **B, 10 out of 14**, computed from published terms alone. We hold no affiliate relationship with Revel today. ## What it is, and who it's for Revel Health Inc. runs myrevelhealth.com, a telehealth platform organized around four sections — Longevity, Weight Loss, Energy & Vitality, and Recovery & Performance. Its own positioning: *"For those thinking about the next 20 years — not just the next 20 pounds."* The catalog spans compounded semaglutide and tirzepatide alongside NAD+ and sermorelin injections. Medical care is delivered through *"a contracted network of physicians licensed in the state where you reside"* — Revel Health itself states it *"does not provide medical services."* Coverage is **45 states**, published outright on its own FAQ: everywhere except AK, AR, NC, NJ and MS. ## What it actually costs The pricing cards on the homepage read cleanly: **NAD+ Injection, "From $169/mo," first month $119. Sermorelin Injection, "From $149/mo," first month $99.** Semaglutide is "From $199/mo" (first month $99) and tirzepatide "From $249/mo" (first month $149). **The "From" qualifier is resolved, not left hanging.** Its FAQ states directly: *"Pricing remains consistent regardless of dosage. You can choose a monthly option or a one-time purchase, depending on what works best for you."* That is a direct answer to the exact ambiguity that undercuts other rows here — [Winona's Estrogen Patch](/winona-review), for instance, is "From $149/mo" across five dose strengths with no statement on whether a higher dose costs more. Revel closes that gap in its own words, even if the storefront card itself still carries the word "From." **Billing is genuinely monthly, not a disguised prepay.** Its Terms of Service state: *"If you enroll in a monthly subscription, you authorize us to charge your payment method on a recurring monthly basis at the then-current monthly price until you cancel."* Cancel any time before the next billing date and future charges stop. **The refund policy is more structured than most providers here bothers to publish**, laid out in three tiers: - **A. Not approved — full refund.** *"If a provider determines that you are not approved for treatment, and no medication order has been submitted to a pharmacy for fulfillment, you are eligible for a full refund of the applicable charge for that purchase period."* - **B. Cancel before pharmacy submission — refund eligible.** *"You may request to cancel an order before it is submitted to a pharmacy... you may be eligible for a refund for that purchase period."* - **C. Order submitted to pharmacy — no refund.** *"Once an order has been submitted to a pharmacy, compounded, dispensed, shipped, or otherwise entered fulfillment, charges are non-refundable, except where required by law."* That is a genuinely fair structure: you know exactly which side of the line you're on, and the "not approved" case — the one that matters most before you've committed — is a clean full refund with the subscription itself canceled, *"so there are no ongoing charges."* ## Clinical oversight and the pharmacy A licensed provider reviews every intake before anything ships; Revel Health states plainly that approval *"is not guaranteed"* and that treatment decisions rest with *"independent licensed providers,"* not with the company. The gap is pharmacy transparency. Its own Terms describe only a **"Pharmacy Network"** — *"you may select one of the pharmacies we contract with... to ship your prescription"* — with no individual facility named and no 503A or 503B classification stated on any page we checked. Under [our rubric](/how-we-grade-longevity-providers), an unnamed network scores at the bottom of this factor, the same rung as several other rows here despite Revel's real strengths elsewhere. ## The evidence behind what it sells The two products this ranking grades here — NAD+ and sermorelin — sit at very different distances from proof, and neither is close. A 2026 PRISMA-guided systematic review screened 113 studies including 33 human intervention trials and found that oral NAD+ precursors reliably raise NAD+ levels and are well tolerated, but that effects on functional, metabolic and vascular outcomes were heterogeneous and often null, with clinical effectiveness for anti-aging "inconclusive." Directly relevant to an injectable product: no eligible outcomes trial evaluated intravenous or intramuscular NAD+ itself for anti-aging or wellness. Sermorelin is a growth-hormone-releasing analog, and the class raises the hormone while the outcomes remain the open question. The standing systematic review of growth hormone in healthy older adults found small body-composition changes — a little more lean mass, a little less fat — with no demonstrated improvement in the outcomes people buy it for, alongside higher rates of soft-tissue edema, joint pain and impaired fasting glucose. Both are compounded, and FDA is explicit that compounded drugs are not FDA-approved and that it does not verify their safety, effectiveness or quality before marketing. ## Where it's weak, and who should skip it Skip it if pharmacy transparency matters most to you — [Taurus Meds](/taurus-meds-review) and [Telos Rx](/telos-rx-review) both name their dispensing facilities with addresses; Revel does not. Skip it if you want ongoing dose-adjustment support spelled out explicitly — we found no stated claim of unlimited messaging or scheduled check-ins beyond the initial intake review. Otherwise, the pricing itself is close to a model for this site: a real number, resolved of its dose ambiguity in the FAQ, with a fair and specific refund policy behind it. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Revel takes all four for price — a real, dose-independent monthly figure with the introductory rate clearly separated from the standing one. Four for a genuine longevity line: NAD+ and sermorelin sit alongside GLP-1s, not bolted on as an afterthought. Two for licensed-provider review before anything ships. **Zero on pharmacy** — an unnamed network, no facility, no classification. **Zero on human support** — no stated ongoing-messaging claim. **Ten of fourteen: a B**, at the top of the band. Name the pharmacy network's facilities, or state a 503A/503B standard on the site, and this row is arguing for an A on the strength of its pricing alone. Neighbors worth reading next are the [Taurus Meds review](/taurus-meds-review) and [System Labs review](/system-labs-review), both NAD+/peptide providers with very different pricing transparency, and our [Wellspring Longevity Clinic review](/wellspring-longevity-clinic-review) for a provider that names its pharmacy but hides its price, the reverse problem; the full field is at [our provider rankings](/best-longevity-clinics). Sources: https://pubmed.ncbi.nlm.nih.gov/41655607/, https://pubmed.ncbi.nlm.nih.gov/17227934/, https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers --- ### Male Excel Reviews: The $95 Price That's Really $194 Canonical: https://longevitygraded.com/male-excel-review Updated: 2026-08-04 Male Excel advertises TRT "starting at $95/month" — but a mandatory $99/month membership roughly doubles the real minimum. Verified Aug 2026. ## The one-sentence version Male Excel advertises testosterone therapy **"starting at $95/month."** Directly beneath that number, in its own footnote, is the reason it's the wrong one to budget on: *"Price does not include Medical Membership, which is required for treatment."* That membership is **$99/month, mandatory, non-optional** — bringing the real minimum monthly cost to roughly **$194**, plus a separate one-time $99 consultation fee before anything ships. The footnote is honest and sits right on the pricing page rather than buried in legal terms — but the headline number is still built to be repeated without it. It grades **B, 9 out of 14**, computed from published terms alone; we hold no affiliate relationship with Male Excel today. ## What it is, and who it's for Male Excel Inc. (dba Excel Medical) is a Charlotte, NC men's-health telehealth practice built around testosterone and thyroid optimization, run through an in-house team led by **Peter Fotinos, MD** (Chief Medical Officer) and **Lorna A. Brudie, DO** (Medical Director). Treatment starts with an at-home hormone test processed at **Excel Medical Labs**, the company's own CLIA-certified laboratory in North Carolina — genuine in-house infrastructure most telehealth TRT shops outsource. NAD+ and DHEA are offered as add-ons "layered in based on symptoms and labs," alongside the core testosterone/thyroid protocol. ## What it actually costs **Three TRT formats, three headline prices:** - Oral ("Triclozene," clomiphene citrate + thyroid): **starting at $95/month** - Injectable (testosterone cypionate + thyroid): **starting at $120/month** - Topical (testosterone Lipoderm cream + thyroid): **starting at $132/month** Every single one carries the identical footnote: *"Price does not include Medical Membership, which is required for treatment."* And the membership itself: *"As a Male Excel patient, you'll benefit from our unlimited Medical Membership... Only $99/Month."* "Only" is doing a lot of work — that word describes a mandatory second charge, not a discount. **Run the real math.** The cheapest advertised option, oral at $95/month, actually costs **$95 + $99 = $194/month** minimum — before a one-time **$99 online medical consultation**, charged separately, before treatment starts at all. The injectable format's real minimum is **$219/month**; topical, **$231/month**. None of that is hidden — it's footnoted directly under the price, on the same page — but it means the number most likely to get repeated ("starting at $95/month") understates the real cost by more than half. **Billing cadence adds one more wrinkle.** Medication is *"Billed Bi-Monthly (every other month)"* for a 60-day supply — so the "$95/month" figure is a per-month average of a charge that actually posts every two months, not monthly. The membership fee, separately, does bill monthly. **What the membership buys is real.** Unlike a junk fee, the $99/month covers *"Continuity of Care from Your Dedicated Male Excel Medical Provider,"* *"Unlimited Messaging with Your Male Excel Support Team,"* and *"Unlimited E-Visits with Your Medical Provider."* That's genuine, described ongoing support — it's the framing as a footnote under a lower headline number that's the problem, not the fee's existence. ## Clinical oversight and the pharmacy Male Excel's clinical infrastructure is real and better-documented than most providers here: named physicians, an in-house CLIA-certified lab, full hormone panels every six months, and 60-day provider follow-ups with dose adjustment. **No Contract, Cancel Anytime** applies to every TRT format. The gap is the pharmacy, though it is narrower than we first reported. Corrected on 8 August 2026: an earlier version of this review said no facility was named anywhere. That was wrong — it was read from the homepage and the terms, and the answer is on the FAQ, which states *"Our pharmacies are: Anazao Health Corp. 5710 Hoover Blvd Tampa, FL 33634 (800) 995-4363 … WellDyneRx-Fl 500 Eagles Landing Dr Lakeland, FL 33810 (888) 479-2000."* Two facilities, with street addresses and phone numbers. What is still missing is any 503A or 503B classification for either. Under [our rubric](/how-we-grade-longevity-providers), that lands on the middle rung of the pharmacy-disclosure factor, the same rung as several rows here with far less clinical infrastructure to show for it. ## The evidence behind what it sells Testosterone therapy is a treatment for diagnosed hypogonadism, not a longevity intervention, and the distinction is the whole of the honest case for it. The Endocrine Society's clinical practice guideline is explicit that the diagnosis requires symptoms **plus** unequivocally low morning testosterone confirmed on repeat measurement, and it recommends against treating men who simply have age-related decline. The large TRAVERSE trial then established the safety half: in men with hypogonadism and elevated cardiovascular risk, testosterone was noninferior to placebo for major adverse cardiac events. That is reassurance for a treated population, not evidence that raising testosterone in a man whose levels are normal extends his life. The earlier Testosterone Trials found modest benefits in sexual function and mood in men over 65 with genuinely low levels, with no demonstrated effect on vitality or walking distance. Read the marketing against that. A promise to multiply your testosterone is a promise about a number, and the number is not the outcome anyone is buying — we set out [what the testosterone trials actually found](/testosterone-trt-and-longevity), including the fracture signal nobody advertises. ## Where it's weak, and who should skip it Skip it if the headline price is what you're budgeting against — build your real monthly number as medication-plus-membership before you start, not medication alone. Skip it if pharmacy transparency matters to you specifically; [Taurus Meds](/taurus-meds-review) names four dispensing facilities with addresses, and Male Excel names two — Anazao Health Corp and WellDyneRx — without classifying either. Otherwise, the clinical infrastructure — a named CMO, an in-house lab, real follow-up cadence — is more substantial than most telehealth TRT shops publish. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Male Excel takes all four for price — real, published figures exist for every format, even though the headline undersells the total. Four for a genuine longevity line: TRT, thyroid and an NAD+/DHEA add-on. **Zero for clinical oversight**, because the provider visit is never included in the medication price — it's billed separately, first as a $99 one-time consult and then via the required membership. **One of two for pharmacy** — its FAQ names two dispensing facilities with addresses and phone numbers, but classifies neither. And **two of four rather than four on price transparency**, because the same pricing page that prints the figures says underneath them that *"Price may vary depending on your particular biochemistry and provider recommendation"* and that the figure excludes the required Medical Membership. Two for real, described human support inside the membership. **Nine of fourteen: a B**. The fix is one sentence, not a system change: put the real all-in monthly number in the headline instead of the footnote. Our [Feel30 review](/feel30-review) shows what that looks like done well — a $149/month figure its own FAQ confirms three separate times is genuinely all-inclusive. Neighbors worth reading next are the [Taurus Meds review](/taurus-meds-review) and [Hone Health review](/hone-health-review), both TRT-first platforms with different pricing structures; the full field is at [our provider rankings](/best-longevity-clinics). Sources: https://pubmed.ncbi.nlm.nih.gov/29562364/, https://pubmed.ncbi.nlm.nih.gov/37326322/, https://pubmed.ncbi.nlm.nih.gov/26886521/ --- ### Feel30 Reviews: Real All-Inclusive Pricing, Unnamed Pharmacy Canonical: https://longevitygraded.com/feel30-review Updated: 2026-08-04 Feel30's $149/month is genuinely all-inclusive, confirmed three times in its own FAQ — but it names no pharmacy. Verified Aug 2026. ## The one-sentence version Feel30 does the thing this site is built to check for and mostly fails to find: **a genuinely all-inclusive price that holds up under scrutiny.** *"Was $249, Starting at $149/month for TRT"* — and its own FAQ confirms, in three separate answers, that the number covers medication, labs, consults and shipping with nothing billed on top. What it doesn't do is name a pharmacy anywhere on the site. It grades **A, 14 out of 14** — a perfect score on our rubric, computed from published terms alone. We hold no affiliate relationship with Feel30 today. ## What it is, and who it's for Feel30 (operated by F3 Health Inc.) is a concierge telehealth TRT practice built around a real differentiator: **in-home nurse blood draws.** *"A concierge nurse arrives at your doorstep. 15 minutes. Done."* — a genuine convenience feature most telehealth TRT providers don't offer, where the usual alternative is a lab-corp visit or an at-home finger-prick kit. The catalog is testosterone cypionate injection (*"The gold standard in TRT"*), enclomiphene, and a sermorelin line marked "coming soon." Care is guided by a named U.S. Medical Advisory Board and a named clinical consultant, Anneliese Cadena, AGNP-C. ## What it actually costs The pricing panel reads: **"Was $249. Starting at $149/month for TRT."** That alone would be an ordinary discounted headline — the kind other providers here attach a plan-length trap to. Feel30's own FAQ resolves it directly, and repeats the claim three separate times: - **"What's included in my monthly fee?"** — *"Everything. Your monthly fee covers all medications, consultations, bloodwork, follow-ups, express shipping, and Feel30 Members Club access. No hidden fees, ever."* - **"Is there a subscription fee?"** — *"Your treatment plan includes all physician consultations, prescription costs, and routine lab work. We don't charge hidden fees or require long-term commitments."* - **"Why is Feel30 more expensive than other providers?"** — *"We're actually more affordable when you add up the total costs. Other providers hide fees for bloodwork, consultations, shipping, and follow-ups. Our transparent pricing includes everything you need with no surprises."* That third answer is a direct, unprompted callout of the exact failure mode this site keeps finding elsewhere — [Male Excel's](/male-excel-review) footnoted membership fee, [Taurus Meds'](/taurus-meds-review) buried Terms-of-Service charge. No separate lab fee, consult fee or shipping charge appears anywhere on the site. **TRT Labs Included** and **Consults Included, always free** appear directly on the pricing panel itself, not just in the FAQ. **One boilerplate leak is worth flagging, even though it doesn't change the price.** Feel30's own Cancellation and Refund Policy — a testosterone company's legal page — contains the sentence: *"lab services, care support, 24/7 patient support line and other services to support your medical weight loss journey."* That is leftover copy from a GLP-1 weight-loss template, never edited out. It's sloppy, not deceptive — nothing in it changes what you pay — but it's the kind of detail worth knowing a legal document was copy-pasted rather than written for this business. **Cancellation is straightforward:** cancel any time, with 72 hours' notice before your next billing date. **Refunds are standard for the category:** available if a provider disqualifies you, or if you cancel before medication has been ordered; federal law generally bars returning dispensed prescription medication, so once an order ships, the current billing cycle is final. ## Clinical oversight and the pharmacy Consults are explicitly free and included — *"Same-day doctor access, always free"* — and bloodwork is bundled into the same price rather than gated behind an upsell. That combination, all-inclusive pricing plus an included consult, is what pushes Feel30 into this site's top band. The one real gap is the pharmacy. Asked directly whether the service is *"legal and legitimate,"* Feel30's FAQ answers: *"We work exclusively with licensed U.S. physicians and prescribe trusted medications from pharmacies."* Plural, unnamed. No individual facility is identified anywhere on the site. What Feel30 *does* state, on its safety page rather than in that FAQ answer, is the standard: *"Several Feel30 products are dispensed as compounded medications prepared by FDA-registered 503A or 503B compounding pharmacies."* Under [our rubric](/how-we-grade-longevity-providers), a compounding standard stated on a surface the provider controls is the top rung — so this scores full marks even though you still cannot find out which facility fills your vial. Knowing the regime is not the same as knowing the pharmacy, and Feel30 gives you only the first. ## The evidence behind what it sells Testosterone therapy is a treatment for diagnosed hypogonadism, not a longevity intervention, and the distinction is the whole of the honest case for it. The Endocrine Society's clinical practice guideline is explicit that the diagnosis requires symptoms **plus** unequivocally low morning testosterone confirmed on repeat measurement, and it recommends against treating men who simply have age-related decline. The large TRAVERSE trial then established the safety half: in men with hypogonadism and elevated cardiovascular risk, testosterone was noninferior to placebo for major adverse cardiac events. That is reassurance for a treated population, not evidence that raising testosterone in a man whose levels are normal extends his life. The earlier Testosterone Trials found modest benefits in sexual function and mood in men over 65 with genuinely low levels, with no demonstrated effect on vitality or walking distance. Read the marketing against that. A promise to multiply your testosterone is a promise about a number, and the number is not the outcome anyone is buying — we set out [what the testosterone trials actually found](/testosterone-trt-and-longevity), including the fracture signal nobody advertises. ## Where it's weak, and who should skip it Skip it if pharmacy transparency is your top priority — [Taurus Meds](/taurus-meds-review) names four facilities with addresses; Feel30 states the compounding standard but names none. The state-coverage answer is vague (*"many U.S. states,"* no list), so confirm your own state is served before you commit time to the intake. Otherwise, this is close to a model row for how the pricing claim itself should work: a real number, confirmed repeatedly, that held up when we checked it. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Feel30 takes all four for price — a genuinely all-inclusive figure, confirmed three separate times and consistent with what we found live. Four for a genuine longevity line: TRT plus enclomiphene, with sermorelin coming. Two for an included, free consult. Two for a described dedicated care team and Members Club access. **Two of two on pharmacy** — its safety page states the compounding standard in the first person (*"Several Feel30 products are dispensed as compounded medications prepared by FDA-registered 503A or 503B compounding pharmacies"*), which is the top rung of our test, even though it still names no facility. **Fourteen of fourteen: an A**, and the joint-highest score here. Corrected on 8 August 2026: this row previously scored 12, because an earlier check read the homepage's generic "pharmacies" language and never opened the safety page. Naming a facility would add nothing our rubric can measure — but it would still be the right thing to publish, and it is the one disclosure Feel30 still withholds. It is a perfect score on our rubric, and it is worth being explicit about what that does not mean: the rubric has no factor for naming the facility, so Feel30 tops the ranking while still declining to tell you who compounds your testosterone. Neighbors worth reading next are the [Male Excel review](/male-excel-review) and [Taurus Meds review](/taurus-meds-review), both TRT-first competitors with very different pricing transparency; the full field is at [our provider rankings](/best-longevity-clinics). Sources: https://pubmed.ncbi.nlm.nih.gov/29562364/, https://pubmed.ncbi.nlm.nih.gov/37326322/, https://pubmed.ncbi.nlm.nih.gov/26886521/ --- ### Wellspring Longevity Clinic Reviews: Pricing You Have to Dig For Canonical: https://longevitygraded.com/wellspring-longevity-clinic-review Updated: 2026-08-04 Wellspring's own "Pricing" FAQ gives no number — just a comparison to retail. Its pharmacy is named, but only if you find the right FAQ answer. ## The one-sentence version Wellspring Longevity Clinic's dedicated FAQ entry titled **"Pricing"** does not contain a price. It reads: *"Many treatment plans include a free consultation. If a prescription is issued, you can purchase your medication at significantly lower costs than traditional retail prices—often more affordable than your local pharmacy."* The actual numbers live only on individual product pages, each carrying an unresolved **"Starts at $X"** figure — NAD+ from $249, Sermorelin from $349. Its GLP-1 line is marketed only as **"Personalized GLP-1,"** never naming semaglutide or tirzepatide. It grades **C, 5 out of 14** — computed from published terms alone; we hold no affiliate relationship with Wellspring today. ## What it is, and who it's for Wellspring Longevity Clinic is a California-based telehealth service selling NAD+, sermorelin and glutathione alongside GLP-1 and GLP-1/GIP therapy. The GLP-1 products are the euphemism worth noting: the site markets **"Personalized GLP-1"** and **"Personalized GLP-1/GIP"** rather than naming semaglutide or tirzepatide anywhere on the treatment page we checked — softer branding than every other GLP-1-selling provider here. ## What it actually costs **NAD+:** *"Starts at $249"* **Sermorelin:** *"Starts at $349"* Both list *"30-day supply of the medication, shipped every 30 days"* — a clear billing cadence, at least. What neither page states is what the "Starts at" figure depends on, or what a higher tier costs. **The dedicated Pricing FAQ is where this falls apart.** Asked directly — the FAQ page literally has a section titled "Pricing" — Wellspring answers with no number: *"Many treatment plans include a free consultation. If a prescription is issued, you can purchase your medication at significantly lower costs than traditional retail prices—often more affordable than your local pharmacy."* "Traditional retail prices" is an easy bar (brand-name GLP-1 list prices routinely exceed $1,000/month); it says nothing about what Wellspring itself charges. The one place a reader would look for a straight answer gives a comparison instead. **Consultation coverage is hedged, not confirmed.** *"Many treatment plans include a free consultation"* — "many," not "all." A reader cannot tell whether their specific plan includes it without asking directly. **There is no cancellation window of any kind.** Its own FAQ states: *"Orders begin processing immediately after they are placed. As a result, we are unable to change or cancel them once submitted. Medications are not able to be returned or exchanged."* Several other providers here offer at least a same-day or 24-hour window; Wellspring offers none. ## Clinical oversight and the pharmacy Here is the one genuine positive worth crediting: **Wellspring does name its pharmacy — Rush Pharmacy — when asked directly in its FAQ.** *"Wellspring Longevity Clinic works with Rush Pharmacy... that meet or exceed all federal and state requirements. We encourage the use of LegitScript or NABP-accredited facilities."* That is more disclosure than several higher-graded rows here manage. The catch: it's findable only in one specific FAQ answer, not on any product page, which instead carry only the generic *"Medication is compounded and dispensed by a licensed third-party pharmacy"* language. No 503A or 503B classification is stated for Rush Pharmacy anywhere we could find. ## The evidence behind what it sells The two products this ranking grades here — NAD+ and sermorelin — sit at very different distances from proof, and neither is close. A 2026 PRISMA-guided systematic review screened 113 studies including 33 human intervention trials and found that oral NAD+ precursors reliably raise NAD+ levels and are well tolerated, but that effects on functional, metabolic and vascular outcomes were heterogeneous and often null, with clinical effectiveness for anti-aging "inconclusive." Directly relevant to an injectable product: no eligible outcomes trial evaluated intravenous or intramuscular NAD+ itself for anti-aging or wellness. Sermorelin is a growth-hormone-releasing analog, and the class raises the hormone while the outcomes remain the open question. The standing systematic review of growth hormone in healthy older adults found small body-composition changes — a little more lean mass, a little less fat — with no demonstrated improvement in the outcomes people buy it for, alongside higher rates of soft-tissue edema, joint pain and impaired fasting glucose. Both are compounded, and FDA is explicit that compounded drugs are not FDA-approved and that it does not verify their safety, effectiveness or quality before marketing. ## Where it's weak, and who should skip it Skip it if you need a real number before you're willing to start an intake — the "Starts at" figures are unresolved, and the FAQ page built to answer exactly that question doesn't. Skip it if you might need to change your mind; there's no cancellation window once an order is placed, full stop. If you proceed, ask directly whether your specific plan's consultation is included, and ask for the un-teased monthly price before committing. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Wellspring takes **zero on price transparency** — the "Starts at" figures are unresolved and the dedicated Pricing FAQ answer gives no number. It takes the full four for a genuine longevity line: NAD+, sermorelin and glutathione are a real menu, not a single peptide bolted onto GLP-1. **Zero for clinical oversight**, because "many" plans including a consultation isn't a confirmed inclusion. **One of two for pharmacy** — Rush Pharmacy is named, just not classified and not surfaced where a reader would actually look. **Zero for human support**, with no stated ongoing-messaging claim. **Five of fourteen: a C.** Two fixes would move this row meaningfully: put a real number on the Pricing FAQ answer instead of a retail comparison, and move the pharmacy name from a buried FAQ item onto the product pages themselves. Neighbors worth reading next are the [Revel Health review](/revel-health-review) and [System Labs review](/system-labs-review), both NAD+/peptide providers with different pricing and pharmacy transparency; the full field is at [our provider rankings](/best-longevity-clinics). Sources: https://pubmed.ncbi.nlm.nih.gov/41655607/, https://pubmed.ncbi.nlm.nih.gov/17227934/, https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers --- ### CeliaRx Review: Peptides Sold Per Fill, Not Per Month Canonical: https://longevitygraded.com/celiarx-review Updated: 2026-08-04 CeliaRx prices NAD+, sermorelin and PT-141 individually — $399, $349, $349 — with no subscription tier, plus a separate $55 consult. Verified Aug 2026. ## The one-sentence version CeliaRx is an à-la-carte peptide shop — eight categories, no monthly plan — and the products this site cares about are priced individually and up front: **NAD+ $399, sermorelin $349, PT-141 $349, each a one-time fill**, plus a separate **$55 one-time onboarding consultation**. It publishes a 503A claim on its own site, the top rung of our pharmacy test, but routes prescribing through a named third-party telemedicine group rather than its own clinicians. It grades **B, 10 points out of 14**, computed from published terms alone. ## What it is, and who it's for CeliaRx organizes its catalog into eight categories — Longevity, Immunity, Weight & Metabolism, Skin & Hair, Gut Health, **Brain Health**, Performance & Recovery, and Libido — and sells within each one product at a time rather than a bundled monthly membership. That is a genuinely different shape from most of the field we rank: there is no "starting at" floor to decode, because every listed item already carries its real price. The buyer this suits is someone who wants one specific peptide — say, NAD+ alone — without being sold a recurring plan to get it. The buyer it does not suit is someone comparing month-to-month cost against CoreAge Rx, HealthRX or RxSpan MD, because there is no monthly figure to put next to theirs. ## What it actually costs Verified live on celia-rx.com, 4 August 2026. **NAD+ injectable: $399.** **Sermorelin injectable: $349.** **PT-141 (bremelanotide) nasal spray: $349.** Each is a one-time per-fill charge, not a subscription — refill cadence and any repeat-order pricing are not published on the pages we checked. A separate, one-time **$55 Celia Onboarding Consultation** (15 minutes) applies before any prescription and is billed apart from the product price. Our rubric credits a provider for publishing one all-in figure before a reader commits — CeliaRx clears that bar on the product price itself, which is why it scores full marks on price transparency despite the structure being unfamiliar. What it does not clear is the consult test: because the $55 review is billed as its own separate line rather than folded into the product price, it scores zero there, the same way this site scores any provider that states a consult fee sits on top of the medication rather than inside it. ## Clinical oversight and the pharmacy Prescribing at CeliaRx runs through a named third-party telemedicine group, **Qualiphy**, rather than CeliaRx's own clinical staff — worth knowing, because it is a different trust model than a provider that reviews intakes with its own named physicians. The dispensing pharmacy is described only as "a long-established, full-service pharmacy operating since 1991"; the facility itself is not named, but the site states directly that its products are **"503A fulfilled,"** a claim published on a surface CeliaRx controls. Under [how we grade](/how-we-grade-longevity-providers), that clears the top rung of our pharmacy test even without a facility name — the same standard applied to every row we grade. A LegitScript badge is displayed, and the pharmacy is described as licensed to serve patients in all 49 U.S. states, with specific exclusions confirmed only at intake. ## The evidence behind what it sells CeliaRx's Brain Health category is the closest thing here's unmonetized field to a cognition-specific claim — but neither NAD+ nor sermorelin has a completed human trial showing a cognitive or focus benefit. The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies including 33 human intervention trials and found effects on functional, metabolic and vascular outcomes "heterogeneous and often null or endpoint-specific," with clinical effectiveness inconclusive. Sermorelin's evidence is thinner still: the trial testing this exact protocol — nightly GHRH 1-29 for six weeks in eleven healthy men aged 64–76 — raised nocturnal growth hormone but produced no change in IGF-1 and no change in DEXA-measured muscle or fat. See [NAD+ for longevity](/nad-for-longevity) and [peptides for longevity](/peptides-for-longevity) for the fuller record. ## Where it's weak, and who should skip it Skip it if you want a monthly price to compare — there isn't one, by design. Skip it if you want your own clinician relationship rather than a routed third-party review through Qualiphy. If you proceed, budget the $55 consultation on top of whatever you order, and ask about repeat-fill pricing before assuming the first price is the ongoing one. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). CeliaRx takes the full four for publishing real per-fill prices, four for a genuine longevity/peptide catalog, two for its 503A claim — and zero on clinical oversight, because the consult is billed separately, and zero on human support, which is not stated as included. **Ten of fourteen: a B.** Three neighbors added the same day are our [EdgeRx review](/edgerx-review), [Nolu review](/nolu-review) and [FORM (by GBY) review](/form-by-gby-review); the full field is at [our provider rankings](/best-longevity-clinics). Sources: https://pubmed.ncbi.nlm.nih.gov/41655607/, https://pubmed.ncbi.nlm.nih.gov/9005976/ --- ### Nolu Review: A Clean Floor Price, No Names Behind It Canonical: https://longevitygraded.com/nolu-review Updated: 2026-08-04 Nolu prices NAD+/sermorelin "from $145/mo" with no dose breakdown, and names no medical director, prescriber, or pharmacy. Verified Aug 2026. ## The one-sentence version Nolu is a general-wellness telehealth brand selling NAD+ and compounded sermorelin from a published **"From $145/mo"** floor — a real number, visible with no quiz gate — attached to no dose-level detail and no named medical director, prescriber, or compounding pharmacy anywhere on the site. It grades **B, 8 points out of 14**, computed from published terms alone. ## What it is, and who it's for Nolu markets itself broadly as a longevity/wellness brand rather than a specialist clinic. Its **Energy & Recovery** line pairs NAD+ with compounded sermorelin vials, published from $145/month. A separate **Microdose GLP-1 + B12/NAD+** stack runs from $179/month, in two variants the site names Core and Energy & Focus — the latter is the more relevant of the two for a reader who wants NAD+ alongside a GLP-1 microdose rather than as a standalone line. LegitScript verified, and stated to serve all 50 states plus DC ("subject to change"). The buyer this suits is someone comparison-shopping who wants a real starting number without an email-gated quiz. The buyer it does not suit is someone who wants to know what a specific protocol costs before signing up, or who wants a named clinician behind the prescription. ## What it actually costs Verified live on trynolu.com, 4 August 2026. The Energy & Recovery line — NAD+ and compounded sermorelin — is published **"From $145/mo,"** with no dose-level ladder shown on the page: it is not stated what that floor buys, whether a higher dose costs more, or whether the figure is a true month-to-month rate or requires a plan length to reach. The separate Microdose GLP-1 + B12/NAD+ stack runs **"From $179/mo,"** likewise with no breakdown by variant. Our rubric credits a provider for publishing one all-in figure before a reader commits, and "$145/mo" clears that bar as a genuine, ungated number — nothing on the page suggests it is a prepay-only rate the way several partner rows here are. But it does not resolve what the actual prescribed protocol costs, which is the gap the [Telos Rx review](/telos-rx-review) and the [Wellorithm review](/wellorithm-review) both document in their own providers: a published floor is not the same thing as a published price. ## Clinical oversight and the pharmacy This is where Nolu is thinnest. The site references "licensed US providers" and "US-regulated pharmacies" in generic terms; no medical director, individual prescriber, or compounding pharmacy is named anywhere we could find. That is a genuine gap against the standard this site applies evenly: a provider that publishes a 503A claim on any surface it controls — its own site, help center, or press material — scores on our pharmacy test even without naming the facility. Nolu makes no such claim at all, which is why it scores zero on that factor rather than the partial credit a "compounded in the USA" line elsewhere here sometimes earns. ## The evidence behind what it sells Nolu's marketing does not lean on cognition-specific claims, and that restraint is worth noting — but the underlying evidence for what it sells is the same as everywhere else here. The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies including 33 human intervention trials and found effects on functional, metabolic and vascular outcomes "heterogeneous and often null or endpoint-specific," with clinical effectiveness inconclusive. A 2025 meta-analysis in adults averaging over 60 found NMN and NR did not improve muscle index, grip strength, gait speed or chair-stand time. Sermorelin's own trial record is no stronger: the protocol that matches what Nolu sells — a nightly compounded injection — was tested as GHRH 1-29 nightly for six weeks in eleven healthy men aged 64–76, raising nocturnal growth hormone but producing no change in IGF-1 and no change in DEXA-measured muscle or fat. See [NAD+ for longevity](/nad-for-longevity) and [peptides for longevity](/peptides-for-longevity). ## Where it's weak, and who should skip it Skip it if you want to know what your specific protocol costs before you start — "from $145/mo" is a floor, not a quote. Skip it if a named clinician or a named pharmacy matters to you, because Nolu names neither. If you proceed, ask for the full dose-level price ladder in writing and confirm whether $145 is a true month-to-month rate or requires a longer plan to reach. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Nolu takes the full four for publishing a real, ungated starting price, and four for a genuine NAD+/sermorelin longevity line — and zero on the remaining three: zero on clinical oversight, because no consult inclusion is stated; zero on pharmacy, because nothing is named or classified; zero on human support, which the site does not claim. **Eight of fourteen: a B.** Two neighbors added the same day are our [CeliaRx review](/celiarx-review) and [FORM (by GBY) review](/form-by-gby-review); the full field is at [our provider rankings](/best-longevity-clinics). Sources: https://pubmed.ncbi.nlm.nih.gov/41655607/, https://pubmed.ncbi.nlm.nih.gov/40275690/, https://pubmed.ncbi.nlm.nih.gov/9005976/ --- ### EdgeRx Review: Men's-Only, With a Named Advisor and a Bundled NAD+ Price Canonical: https://longevitygraded.com/edgerx-review Updated: 2026-08-04 EdgeRx is men's-only, names a Chief Medical Advisor and a 503A pharmacy claim, and prices NAD+ bundled with glutathione from $99/mo. Verified Aug 2026. ## The one-sentence version EdgeRx is explicit about who it is for — **"PRESCRIPTION PROTOCOLS FOR MEN"** — and, within that limitation, publishes more than most unmonetized rows we grade: a named Chief Medical Advisor, a 503A compounding claim on its own FAQ, and an "Energy, Longevity & Cognition" tier priced from $99/month. The catch is what that tier actually contains — NAD+ bundled with glutathione, not NAD+ alone — and who it excludes by design. It grades **B, 8 points out of 14**, computed from published terms alone. ## What it is, and who it's for EdgeRx's homepage states its positioning without hedging: prescription peptide and longevity protocols built for men. Its catalog splits into five priced tiers rather than individual product pages. The one this site ranks on, **"Energy, Longevity & Cognition,"** bundles NAD+ and glutathione protocols from $99/month. Sermorelin sits in a separate tier, **"Recovery & Vitality,"** from $199/month, and GHK-Cu sits in a third, **"Skin, Hair & Aesthetics,"** at a flat $199/month. No tier publishes a price for a single product in isolation. If you are a man comparison-shopping longevity peptides and you value a named medical advisor, EdgeRx is a real option. If you are not a man, or you want a standalone NAD+ price rather than a bundled tier, this is not built for you — and that is stated on the site, not something we inferred. ## What it actually costs Verified live on edgerx.org and its FAQ, 4 August 2026. **"Energy, Longevity & Cognition"** (NAD+ + glutathione): **from $99/month.** **"Recovery & Vitality"** (sermorelin): **from $199/month.** **"Skin, Hair & Aesthetics"** (GHK-Cu): **$199/month flat.** No individual figure exists for NAD+ on its own — the $99 floor is the tier's entry price, covering two protocols together, not one. Our rubric asks for one all-in figure a reader can act on before committing. EdgeRx's $99 clears the bar as a real, published number with no quiz gate — but because it prices a bundle rather than a single product, and because the site does not break out what NAD+ alone would cost inside that bundle, we score this the same way we score any tier-floor pricing here: it earns credit for being published, and its ambiguity is named plainly in the cons rather than smoothed over. ## Clinical oversight and the pharmacy EdgeRx's own FAQ states plainly: **"A board-certified US physician reviews your history and, if a protocol is appropriate, prescribes it"** — with no separate consultation charge disclosed anywhere we found, unlike CeliaRx, which bills a $55 consult apart from its product prices. That absence of a stated extra fee, combined with the review being a required step to get any protocol at all, is why this row scores the consult factor as included. On compounding, the same FAQ states: **"All are compounded by a 503A pharmacy, where your prescription is made specifically for you, with one exception: MICC is prepared by an FDA-registered 503B outsourcing facility."** That is a 503A claim published on a page EdgeRx controls, which clears the top rung of [our pharmacy test](/how-we-grade-longevity-providers) — though, on our own re-check, the facility itself is not named on that page. Named Chief Medical Advisor **Dr. John Starke, MD** (ABEM board-certified) does not personally prescribe; the actual prescribing pool is unnamed board-certified physicians. States served: 46, excluding **Arkansas, Indiana, Minnesota and South Carolina**, confirmed on the same FAQ. ## The evidence behind what it sells EdgeRx's tier name is the most direct cognition-adjacent claim here's unmonetized field — "Energy, Longevity & Cognition" — and it is worth being precise about what that buys. The 2026 PRISMA-guided systematic review of NAD+ found effects on functional, metabolic and vascular outcomes "heterogeneous and often null or endpoint-specific," with clinical effectiveness inconclusive; no completed human trial in that review showed a cognition-specific benefit. For GHK-Cu, the peptide sold under EdgeRx's Skin, Hair & Aesthetics tier, the mechanistic and preclinical case for tissue repair and gene-expression effects is genuinely stronger than most peptides sold here, though human outcome trials remain limited. For sermorelin, the trial testing this exact nightly-injection protocol in older men raised nocturnal growth hormone but produced no change in IGF-1 and no change in DEXA-measured muscle or fat. See [NAD+ for longevity](/nad-for-longevity) and [peptides for longevity](/peptides-for-longevity). ## Where it's weak, and who should skip it Skip it outright if you are not a man — the site says so itself. Skip it if you want a standalone NAD+ price, because $99 buys NAD+ bundled with glutathione, not NAD+ alone, and no per-product figure is published. If you proceed, confirm which of the 46 served states you're in and ask what NAD+ alone would cost split out of the bundle. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). EdgeRx takes zero on price transparency, because the $99 floor prices a bundle rather than a single product with no per-item figure published; the full four for a genuine longevity/peptide line across three tiers; two for a physician review that is required and not billed separately; and two for its own-site 503A claim. Human support is not stated as included, so it scores zero there too. **Eight of fourteen: a B.** Two neighbors added the same day are our [CeliaRx review](/celiarx-review) and [Nolu review](/nolu-review); the full field is at [our provider rankings](/best-longevity-clinics). Sources: https://pubmed.ncbi.nlm.nih.gov/41655607/, https://pubmed.ncbi.nlm.nih.gov/26236730/, https://pubmed.ncbi.nlm.nih.gov/9005976/ --- ### FORM (by GBY) Review: Four Products, Zero Published Prices Canonical: https://longevitygraded.com/form-by-gby-review Updated: 2026-08-04 FORM lists NAD+, sermorelin, GHK-Cu cream and glutathione under Peptides/Longevity — and publishes a price for none of them. Verified Aug 2026. ## The one-sentence version FORM by GBY lists a genuine longevity/peptide catalog under its Peptides/Longevity category — NAD+ Therapies, Sermorelin Injections, GHK-Cu Cream, Glutathione Injections — and publishes a price for **none of the four.** No floor, no "from" figure, no ladder. It grades **C, 4 points out of 14 — tied for the lowest score here** — computed from published terms alone. ## What it is, and who it's for FORM markets a broad telehealth catalog spanning GLP-1 weight loss and a separate Peptides/Longevity vertical. The longevity line is real and live: NAD+ Therapies, Sermorelin Injections, GHK-Cu Cream and Glutathione Injections are all listed as products, not teased as coming soon. Both LegitScript and HIPAA compliance badges are displayed, and the site states coverage across 48 states plus DC, excluding Alaska and Mississippi. The buyer this suits is someone already sold on FORM's brand who is willing to start an intake to find out what any of the four products costs. The buyer it does not suit is anyone trying to comparison-shop from the outside, because there is nothing to compare. ## What it actually costs Verified live on formbygby.com, 4 August 2026. **No price is published anywhere for NAD+, sermorelin, GHK-Cu cream, or glutathione injections.** We checked the Peptides/Longevity category page and each product listing; none carries a figure. FORM's only published prices belong to its separate GLP-1 line — compounded semaglutide at $299/month, and a $95/month figure that is a **membership fee**, not a drug cost, and has no bearing on what the longevity products cost. That gap is the entire case for scoring this row at zero on price transparency. Our rubric asks for one all-in figure, visible before a reader commits — CeliaRx publishes one per fill, Nolu publishes a floor, and FORM publishes nothing at all for the four products this site actually ranks on. Compare the [FORM entry itself](/best-longevity-clinics) against [Nolu](/nolu-review), which at least states a starting number even without a dose breakdown: FORM does not clear that lower bar either. ## Clinical oversight and the pharmacy No medical director, individual prescriber, or compounding pharmacy is named anywhere on formbygby.com for the NAD+, sermorelin, GHK-Cu, or glutathione lines. This ranking scores an unstated fact as unstated rather than assumed favorable, the same standard applied to every row we grade — so both clinical oversight and pharmacy disclosure score zero here, not because FORM is doing something wrong, but because nothing is published to credit. ## The evidence behind what it sells FORM's marketing does not make cognition-specific claims for its longevity line, and the underlying evidence for the four products it lists is consistent with the other providers here. The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies including 33 human intervention trials and found effects on functional, metabolic and vascular outcomes "heterogeneous and often null or endpoint-specific," with clinical effectiveness inconclusive. Sermorelin's own trial record: nightly GHRH 1-29 for six weeks in eleven healthy men aged 64–76 raised nocturnal growth hormone but produced no change in IGF-1 and no change in DEXA-measured muscle or fat. GHK-Cu has a stronger mechanistic and preclinical case for tissue repair than most peptides sold here, though human outcome trials remain limited. See [NAD+ for longevity](/nad-for-longevity) and [peptides for longevity](/peptides-for-longevity). ## Where it's weak, and who should skip it Skip it if you want to know what anything costs before you start an intake — that information does not exist on the public site for any of the four products in this category. If you proceed anyway, get the price for your specific product in writing before submitting payment information, and confirm the state-availability list for the product you want, since FORM's stated exclusions (Alaska, Mississippi) apply to the wider catalog and may not be product-specific. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). FORM takes the full four for a genuine, live NAD+/peptide catalog — the products are real — and zero everywhere else: zero on price transparency, because none of the four carries a published figure; zero on clinical oversight and zero on pharmacy, because neither is named or described anywhere on the site; zero on human support, which is not stated as included. **Four of fourteen: a C, tied for the lowest score here.** Two neighbors added the same day are our [EdgeRx review](/edgerx-review) and [Nolu review](/nolu-review); the full field is at [our provider rankings](/best-longevity-clinics). Sources: https://pubmed.ncbi.nlm.nih.gov/41655607/, https://pubmed.ncbi.nlm.nih.gov/9005976/, https://pubmed.ncbi.nlm.nih.gov/26236730/ --- ### MyDrHank Reviews: The $137 Is a Twelve-Month Rate Canonical: https://longevitygraded.com/mydrhank-review Updated: 2026-08-07 MyDrHank advertises NAD+ from $137/month. That is the twelve-month rate on the nasal spray — month-to-month is $199–$225. August 2026. ## The one-sentence version MyDrHank sells NAD+ two ways most providers here do not — a **daily nasal spray or a weekly subcutaneous injection** — with the clinician review stated as free, no bloodwork required to start, and ongoing messaging with a care team inside the service. Then it does the one thing this site penalizes hardest: **the price it advertises, "Starting at $137/month," is the twelve-month plan's per-month rate on the cheaper of the two routes, and nothing on the page says so.** Month to month, the same product is $199 for the nasal spray and $225 for the injection. It grades **B, 10 points out of 14**, and it loses all four of them in the same place. The grade is computed from published terms alone and cannot see who pays us — MyDrHank is a paid partner here. ## What it is, and who it's for The operator is **Dr. Hank, LLC**, trading as MyDrHank at mydrhank.com, and the site carries a LegitScript certification seal. It is a **general telehealth platform, not a longevity clinic**, and its own navigation says so: six lines sold from one account — Weight Loss, Longevity, Peptides & NAD+, Sexual Health, Hair Growth and Strength. That matters for expectation-setting more than for grading. The longevity line itself is real and, verified on 7 August 2026, deeper than several specialists here: **NAD+ Nasal Spray, NAD+ Injection, Glutathione Nasal Spray, Glutathione Injection and Sermorelin.** Five of the fifteen products on the catalog are the NAD+ and peptide routes this site is built to rank, which is the whole of the four points it takes on the longevity-line factor. But NAD+ sits on the same account as erectile-dysfunction tablets, finasteride and compounded tirzepatide, and if you want a practice whose entire business is the thing you are buying, [System Labs](/system-labs-review) and [Telos Rx](/telos-rx-review) are the shape you are looking for. Onboarding is deliberately frictionless: *"A 3-minute medical questionnaire — no office visits, no insurance, no bloodwork required to start,"* then *"A U.S. board-certified clinician reviews your intake within 24 hours and builds a protocol tailored to your goals."* If you wanted baseline biomarkers before starting, nothing here measures anything — see [longevity biomarker panels](/longevity-biomarker-panels). ## What it actually costs, and what "$137" is doing All figures below were read on MyDrHank's own pages and published page data on **7 August 2026**. **What the site shows you.** The NAD+ lander leads with *"Starting at $137"* and */month*, immediately under it *"Final pricing depends on the protocol and dose prescribed,"* and at the foot of the offer *"Free consultation · No insurance required · Cancel anytime. Prescription only following evaluation by a U.S.-licensed clinician. Available in select states."* The product pages show the same figure in the same shape: *"From $137 /mo."* The sermorelin lander leads with $137 as well. **What the plans actually are.** MyDrHank's own product catalog prices each item on a four-tier ladder — Monthly, Quarterly, 6 Month and Yearly: **NAD+ Nasal Spray** — Monthly **$199**; Quarterly $507 ($169/mo); 6 Month $913 ($152/mo); Yearly $1,644 (**$137/mo**). **NAD+ Injection** — Monthly **$225**; Quarterly $574 ($191/mo); 6 Month $1,033 ($172/mo); Yearly $1,859 ($155/mo). **Sermorelin** — Monthly **$199**; Quarterly $507 ($169/mo); 6 Month $913 ($152/mo); Yearly $1,644 ($137/mo). So **$137 is the twelve-month prepay rate on the nasal spray.** It is not a monthly price, it is not the injection's price, and it is not a figure anyone is charged monthly. A buyer who wants to try NAD+ for a month and stop pays **$199 or $225**, which is 45% to 64% above the number that brought them to the page. **And here is the part that decides the price factor.** Every price surface on mydrhank.com takes that four-tier ladder, reduces it to the **lowest** per-month value in it, and prints that alone under the word "From." The monthly, quarterly and six-month rates exist in the site's own product data and are rendered on no page we could find. So this is not a provider publishing a ladder and leading with the friendliest rung, the way [System Labs](/system-labs-review) prints its standing rate beside its teaser. It is a provider whose month-to-month price is not published at all, and whose published price is a twelve-month commitment with the term withheld. Our rubric asks for a single all-in figure, visible before you commit, that a buyer with no commitment actually pays. There is no such figure here, so price transparency scores **zero**. [Enhance MD](/enhance-md-review) advertises a $169 rate that requires a twelve-month prepay too — and keeps its four points, because the real month-to-month figure of $199 is published on the same page. That is the entire difference between the two rows. **One more qualifier on top.** *"Final pricing depends on the protocol and dose prescribed"* sits directly beneath the headline, so even the $137 is a floor rather than a quotation. **The dose promise does not transfer.** MyDrHank's weight-loss funnel makes a clean, checkable commitment in its own FAQ: *"Plans start at $171/mo with no contract. This covers your physician review, personalized treatment plan, prescription medication, and free shipping directly to your door. The price stays the same at every dose — no surprise price increases."* **No equivalent promise appears anywhere on the NAD+ or sermorelin line.** The longevity pages say the opposite — that final pricing depends on the dose prescribed. If you found MyDrHank through its GLP-1 marketing and assumed the dose-flat pricing carried across, it does not, and you should ask before you titrate. For what this category costs generally, see [longevity clinic cost](/longevity-clinic-cost). ## Clinical oversight and the pharmacy **Oversight: two points, earned.** The NAD+ lander states *"Free consultation"* on its face and a banner across the top reads *"Limited time — Free physician consultation with your first order."* That is MyDrHank's own statement that the clinician review sits inside the price rather than being billed on top, which is the same standard that credited [Strut Health](/strut-health-review) for its free online MD visit. Note the framing honestly: it is described as a limited-time promotion tied to a first order, not a standing term, so confirm it is still on offer when you start. **Support: two points, earned.** MyDrHank's own longevity page publishes *"Ongoing clinical support — Check-ins, dose adjustments, and unlimited messaging with your care team"* as part of the service. Stated support inside the price is what this factor asks for, and most providers here do not state it at all. **Pharmacy: two points, and they come with an asterisk.** MyDrHank publishes a compounding standard on a surface it controls — its weight-loss lander footnotes read *"Compounded semaglutide and tirzepatide are prepared by FDA-registered outsourcing or 503A pharmacies"* — and [our rule](/how-we-grade-longevity-providers) turns on where a claim is published, not on how prominently. So it scores the top rung. What you should know is that **the claim is scoped to the weight-loss line.** The disclosure attached to the products this review is actually about reads: *"NAD+ dispensed through MyDrHank is a compounded medication prepared by a state-licensed U.S. compounding pharmacy. Compounded drugs are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality."* That is a license, not a section, and **no dispensing facility is named on either line.** We could have written a sub-rule requiring the 503A claim to cover the graded product and scored this row zero. We did not, for the reason recorded against [Shed](/shed-review) when the same temptation came up there: inventing a rule after seeing which row it demotes is exactly the tuning a published rubric exists to prevent. The scoping is disclosed to you here instead, which is where it is useful. FDA's own position on what an unnamed compounder leaves open is blunt: compounded drugs are not FDA-approved, and the agency does not verify their safety, effectiveness or quality before they are marketed. **Where it will treat you.** The consumer pages say only *"Available in select states"* and publish no list. The affiliate terms behind the program exclude **Kansas, Louisiana, Mississippi, New Mexico, North Dakota and West Virginia** — so a reader in one of those six should confirm before starting rather than after paying. ## The evidence behind what it sells MyDrHank markets NAD+ as *"Steady, all-day cellular energy," "Sharper focus & mental clarity," "Better sleep & faster recovery"* and *"Supports healthy aging at the cellular level."* Those are the category's standard claims, and the trial record does not carry them. The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies including 33 human intervention trials. Oral precursors reliably engage the target — blood NAD+ rises — but effects on functional, metabolic and vascular outcomes were *"heterogeneous and often null or endpoint-specific,"* and clinical effectiveness for anti-aging or wellness *"remains inconclusive"*. The same review is blunter about the routes MyDrHank actually sells: **no eligible outcomes trial has evaluated intravenous or intramuscular NAD+ for these indications at all**, and nasal delivery of NAD+ has less human outcome evidence still. A 2025 meta-analysis in adults averaging over 60 found NAD+ precursors did not improve muscle index, grip strength, gait speed or chair-stand time; the strongest randomized trial in the field moved six-minute walk distance by roughly 17.6 meters in peripheral artery disease, a disease endpoint rather than an aging one. None of that is a mark against MyDrHank specifically — it is the state of the category, and this site grades providers rather than the medicine. But a buyer signing a twelve-month plan to reach $137 is committing about $1,644 to an intervention whose advertised outcomes have not been demonstrated in humans. Read [NAD+ for longevity](/nad-for-longevity), [do NAD+ peptides actually work](/do-nad-peptides-work) and [what's proven versus hyped](/longevity-medicine-evidence) before you decide the term is worth it. ## Where it's weak, and who should skip it Skip it if you intend to buy a month and stop, because that is precisely the purchase MyDrHank does not price: budget **$199 for the nasal spray or $225 for the injection**, not $137. Skip it if you need to know what the dose you end up on will cost, because the longevity line explicitly reserves that — and unlike the weight-loss line, it makes no promise that the price holds across doses. Skip it if you want to know which pharmacy fills your vial, since none is named on any line. And check the six excluded states before you start. Buy it if the delivery routes are what you actually want. A **daily nasal spray or a weekly injection**, chosen by the prescriber rather than by whatever the shop happens to stock, with the visit free, no bloodwork gate, and unlimited messaging with a care team, is a genuinely reasonable starting position — provided you go in reading $199 rather than $137. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). MyDrHank takes **the full four for its longevity line** — NAD+ by two routes, glutathione by two more, plus sermorelin — **two for clinical oversight**, because the consultation is stated as free, **two for human support**, because ongoing check-ins and unlimited messaging are published as part of the service, and **two for pharmacy**, because a 503A claim appears on a surface it controls. It takes **zero for price transparency**, because no month-to-month figure is published anywhere and the number it does publish is a twelve-month rate with the term withheld. **Ten out of fourteen: a B.** The fix is one line of HTML. MyDrHank already holds the monthly rate in its own product data; printing $199 beside $137 and labeling which is which would move this row to fourteen without changing a single term of the offer. Until it does, the headline is the cheapest thing about it. The full graded field is at [our provider rankings](/best-longevity-clinics), the scoring is set out in [how we grade](/how-we-grade-longevity-providers), and two neighbors with the same headline problem read differently: our [Enhance MD review](/enhance-md-review), which publishes the month-to-month price beside the prepay one, and our [System Labs review](/system-labs-review), which publishes the standing rate beside the teaser. Sources: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers, https://pubmed.ncbi.nlm.nih.gov/29599478/, https://pubmed.ncbi.nlm.nih.gov/41655607/, https://pubmed.ncbi.nlm.nih.gov/40275690/, https://pubmed.ncbi.nlm.nih.gov/38871717/ --- ### Pallas Health Review: The $189 Is a 12-Week Prepay Canonical: https://longevitygraded.com/pallas-health-review Updated: 2026-08-07 Pallas Health advertises NAD+ at "$189/mo average". There is no monthly plan — that figure is $567 billed every 12 weeks. August 2026. ## The one-sentence version Pallas Health names more dispensing pharmacies than any other row here — **six of them**, explains the 503A/503B distinction, publishes two physicians with NPI numbers it invites you to check, and publishes a LegitScript certification with its seal ID. Then it sells that program in a shape this site penalizes hard: **there is no month-to-month option for NAD+, and the advertised "$189/mo average" is a 12-week prepay divided by three.** It grades **B, 8 points out of 14**, and both of the factors it zeroes are structural rather than a suggestion of bad faith. The grade is computed from published terms alone and cannot see who pays us — Pallas Health is a paid partner here. ## What it is, and who it's for The operator is **Brentmoor, Inc.**, at 131 Continental Dr, Suite 305, Newark, DE 19713. Clinical care is delivered by **Lion MD**, described as a nationwide team of US-licensed clinicians, running on the **CareValidate** clinical-operations platform. Pallas states the arrangement plainly: it is a technology platform and does not employ medical providers. That is a more honest framing than most providers here manage, and it is worth knowing before you decide who you are actually buying from. The line this site ranks is narrow and real: **NAD+ as a daily nasal spray or as a weekly subcutaneous injection.** Those are the only two forms offered — there is no oral route on sale, whatever else you may find written about the brand. Pallas also runs a separate compounded GLP-1 line on its own lander with its own catalog and its own prices; this review does not quote those figures, because a reader arriving here lands on the NAD+ lander and none of them appear on it. Coverage is **all 50 states plus DC**, fully asynchronous in 43 of them. **Eight jurisdictions require one video visit** — Arkansas, Mississippi, New Mexico, North Dakota, Rhode Island, South Dakota, West Virginia and Washington DC. It is **cash-pay only, no insurance ever**, FSA/HSA eligible per its own site banner, with free shipping when a clinician prescribes. It is also **new**. Pallas launched on the affiliate network on **1 July 2026**, so there is no track record to weigh here — only published terms, which is what this rubric grades anyway. ## What it actually costs, and what "$189" is doing All figures below were read on Pallas's own funnel, its published page bundle and its marketing fineprint on **7 August 2026**. All three agree, which is itself worth crediting: **the marketing price is the commerce price**, and there is no bait-and-switch at the card screen. That is not the norm here. **NAD+ nasal spray** — **$79 for the first month, then $567 billed every 12 weeks.** Advertised as *"$189/mo average"*. **NAD+ injection** — **$89 for the first month, then $597 billed every 12 weeks.** Advertised as *"$199/mo average"*. **Here is the finding.** There is **no month-to-month rung** for either product. The funnel renders no cadence selector at all — those are the only options that exist. So the "/mo average" beside each price is not a plan you can buy; it is a **12-week prepay divided by three**. **The cash-flow shape is the likeliest bill shock.** Renewal is anchored *"every 12 weeks starting 4 weeks after approval"*. So on the nasal spray you pay **$79**, and then **four weeks later a single charge of $567 lands**. On the injection it is $89 followed by $597. Nothing about that is hidden — Pallas publishes the cadence — but a buyer who reads "$189/mo" and budgets $189 for month two has budgeted for the wrong number by a factor of three. **And 12 weeks is not three months.** The renewal recurs every **84 days**, which is **4.35 times in a year, not 4** — while the advertised average is computed by dividing the charge by 3. Their own arithmetic, on their own published renewal terms: | | advertised | year 1 actual | ongoing | |---|---|---|---| | NAD+ spray | $189/mo | $79 + 4×$567 = **$2,347** → **$195.58/mo** | 4.348×$567 = **$2,465/yr → ~$205/mo** | | NAD+ injection | $199/mo | $89 + 4×$597 = **$2,477** → **$206.42/mo** | 4.348×$597 = **$2,596/yr → ~$216/mo** | Year 1 is 52 weeks: one four-week intro period plus four 12-week blocks. Steady state is 365.25 ÷ 84 cycles a year. **The advertised average understates the ongoing rate by about 8.7%.** To be fair to Pallas about what that is and is not: *"12 weeks ≈ 3 months"* is ordinary industry shorthand, and the company publishes the 84-day cadence where you can find it. This is arithmetic on terms it disclosed, not a trick it concealed. It is still eight and a half percent, every year, on a bill that renews. **Why this costs the price factor everything.** Our rubric asks for a single all-in figure, visible before you commit, that a buyer **with no commitment** actually pays. Pallas sells no such thing, so price transparency scores **zero**. This is [MadeMed](/mademed-review)'s pattern exactly — that row publishes every plan length and every exact charge and still scores zero, because the shortest way in is a three-month prepay. For the opposite shape, [HealthRX](/healthrx-review) publishes a genuine month-to-month NAD+ rate with no term required to reach it and keeps all four points. That is the whole difference between the rows. **What Pallas does publish, and what we are not allowed to pay it for.** The exact charge, the exact 84-day cadence, at least 30 days' notice before any price change, **no minimum term** with cancellation effective at the end of the current billing period and *"canceling is always free"*, a self-serve cancellation portal, a pre-renewal email before every charge, and a full refund if a clinician declines you. That is a materially better disclosure package than several rows scoring four points on this factor. It does not move the score, because the factor measures whether a no-commitment figure exists and here it does not — and inventing a "publishes its terms well" allowance after seeing which row it lifts is the tuning [our published rubric](/how-we-grade-longevity-providers) exists to prevent. So it is said here instead, where it is useful to you. **Three costs that are not in the headline.** A **$60 visit deposit** applies in the eight video-visit jurisdictions; it is refunded in full and credited to your first order, but **may be retained** if you neither attend nor reschedule and then abandon the intake. A **$5 fee** is deducted per refunded payment on purchases made on or after **14 July 2026** — never on clinician-declined or unfulfilled orders, which refund in full. And whether **lab work** is included or billed separately is **not published anywhere**, in either direction. There is also **no pre-purchase dose selector**, so whether the price holds as a dose rises cannot be checked before you pay. Ask. The sitewide **"Up to $120 off your first month"** banner is a discount, not a price. So are $79 and $89. ## Clinical oversight, the pharmacy, and who is prescribing **Oversight: two points, earned.** No consult fee appears anywhere in the published price structure. In the 43 asynchronous states the clinician review sits inside the medication price; an applicant a clinician declines is refunded in full; and the only visit charge that exists anywhere — the $60 deposit — is refunded and credited to the first order rather than billed on top. The retention condition is real and is listed above, but a conditional deposit that normally becomes part of your order is not a consult billed separately. **Pharmacy: two points, and they undersell it.** Pallas publishes **six dispensing pharmacies by name** — **Belmar Pharmacy, Strive Pharmacy, Epiq Scripts, Casa Pharma Rx, The Pharmacy Hub and Foothills Pharmacy** — and explains the **503A/503B distinction** on the same page. Set that beside the other providers here, where the standard practice is to name none: [Telos Rx](/telos-rx-review) prints two pharmacies with street addresses and is the row we previously called the most pharmacy-transparent here. Pallas names six and classifies them. Our rubric has exactly two points for pharmacy disclosure and Pallas takes both, which is all it can take. **That is a limit of the rubric, and the honest thing is to say so rather than invent a factor after seeing who it would help.** Name the trade-off that comes with it, though: compounded medications, including the NAD+ this page is about, are **not FDA-approved**, and FDA's own position is blunt — compounded drugs are not FDA-approved, and the agency does not verify their safety, effectiveness or quality before they are marketed. Pallas discloses this properly on its own pages, including that its compounded GLP-1s are not FDA-approved and are not generic equivalents of the brand drugs. The review repeats it because it is the single most important sentence in the category. **Belmar, and the thing you should know in proportion.** One of the six named pharmacies, **Belmar**, received an FDA warning letter issued **31 March 2023** (posted 18 April 2023), addressed to *"Belmar Pharma Solutions, Drug Depot, LLC., dba APS Pharmacy"*, concerning compounding practices — and **FDA closed it out on 30 October 2023.** We are not going to restate or relitigate the allegations; that is FDA's document to characterize. Two things matter here. First, the letter is **closed out**, and a page that leaves that off is publishing a false impression. Second, **a letter on a partner pharmacy discloses, it does not disqualify** — and you only know about it at all because Pallas named the pharmacy. The providers here that name nobody could be dispensing through anyone, and you would have no way to check. **Pallas Health itself holds no FDA warning letter**: a live search of FDA's index for "pallas health", "pallashealth", "Brentmoor" and "CareValidate" returned zero records each, in a pass where a known-lettered company came back positive, so the clean result is a real one and not a broken query. **Two clinicians, and a gap.** Pallas names **Dr. Ana Lisa Carr, MD** (NPI **1689841744**) and **Dr. Kelly Tenbrink, MD** (NPI **1346482684**), and volunteers a *"Verify NPI in the NPPES registry"* link beside them. Both verify as **active** in NPPES — Carr in **family medicine**, licensed in 15 states; Tenbrink in **emergency medicine**, licensed in Tennessee and Florida. Volunteering a checkable identifier is a genuine E-E-A-T signal and vanishingly rare here. Two caveats, both real. Carr's site-claimed **obesity and addiction medicine** board certifications are **not verifiable through NPPES** and we did not check them independently — that is the site's claim, not our finding; NPPES confirms family medicine. And **only two clinicians are named site-wide.** The actual prescribing network — Lion MD's affiliated professional corporations — is **not published**, and the footer "Provider directory" link resolves to a section naming only those two. On an intake that is asynchronous in 43 states, the clinician who writes your prescription is very probably not one of the two people you were shown. That is a real gap, and it is the reason the disclosure story here is strong rather than complete. **Support: zero, and it is the second place this row loses points.** What Pallas publishes is customer service — hello@ and support@pallashealth.co, +1 (440) 601-3717, Monday to Friday 9–5 ET — plus the cancellation portal and the pre-renewal email. Those are good account mechanics. This factor asks for **ongoing clinical support stated as inside the price**, the way [MyDrHank](/mydrhank-review) publishes unlimited messaging with a care team and [System Labs](/system-labs-review) publishes ongoing support from a real care team. We looked and found no equivalent statement on any Pallas surface. That is a finding, not an assumption. ## The evidence behind what it sells This ranking grades providers, not molecules, and Pallas markets within the category's normal register. But you are being asked to commit roughly $2,400 a year, so the state of the evidence belongs in the decision. The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies including 33 human intervention trials. Oral precursors reliably engage the target — blood NAD+ rises — but effects on functional, metabolic and vascular outcomes were *"heterogeneous and often null or endpoint-specific,"* and clinical effectiveness for anti-aging or wellness *"remains inconclusive"*. The same review is blunter about the routes Pallas actually sells: **no eligible outcomes trial has evaluated injected NAD+ for these indications at all**, and nasal delivery has less human outcome evidence still. A 2025 meta-analysis in adults averaging over 60 found NAD+ precursors did not improve muscle index, grip strength, gait speed or chair-stand time; the strongest randomized trial in the field moved six-minute walk distance by roughly 17.6 meters in peripheral artery disease, a disease endpoint rather than an aging one. None of that is a mark against Pallas specifically — it is the state of the category. Read [NAD+ for longevity](/nad-for-longevity), [do NAD+ peptides actually work](/do-nad-peptides-work) and [what's proven versus hyped](/longevity-medicine-evidence) before you decide a 12-week block is worth it. **One source you should not treat as evidence: theirs.** Pallas's own footer states that *"Some content on this site is AI-generated; no representation or warranty is made regarding its accuracy, completeness, or reliability."* Credit the honesty and then act on it — do not take a clinical claim from its blog. In the same spirit: the advertised **"4.8" rating has no published source** anywhere we could find, so we are not repeating it as a fact, and the before/after *"Verified Customer"* stories carry the site's own caveat that **individuals shown in marketing may be actors or models**. ## Where it's weak, and who should skip it Skip it if you want to try NAD+ for a month and stop, because that is precisely the purchase Pallas does not sell — budget **$567 or $597 every 12 weeks**, not $189 or $199. Skip it if a single $567 charge four weeks after a $79 one is a problem for your cash flow, which is a different question from whether the annual cost is acceptable. Skip it if you need to know what your prescribed dose will cost, or whether lab work is on the bill, because neither is published. And skip it if you want to know which of the six pharmacies fills your vial, because naming six is not the same as telling you which one. Buy it if the disclosure is what you are actually shopping for. A named operator, a named clinical group, six named pharmacies with the compounding standard explained, two physicians with checkable NPIs, a published LegitScript seal ID, a real cancellation portal, a pre-renewal email, no minimum term, and marketing figures that match the checkout is — bluntly — the most complete package here. You are simply buying it in 12-week blocks, and you should go in reading $567, not $189. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Pallas takes **the full four for its longevity line** — NAD+ by nasal spray and by injection is exactly what this site exists to rank — **two for clinical oversight**, because the clinician review sits inside the price and a declined applicant is refunded in full, and **two for pharmacy**, because it publishes a 503A claim on a surface it controls and names six facilities besides. It takes **zero for price transparency**, because no month-to-month figure exists and the advertised one is a prepay divided by three, and **zero for human support**, because ongoing clinical support is not published as part of the service. **Eight out of fourteen: a B**, at the very bottom of the band. The fix is two lines. Sell a one-month rung and print its price; publish whether messaging and follow-up are included. Do both and Pallas moves to twelve and an **A** without changing a single thing about the medicine, the pharmacies or the clinicians — which is a fair summary of where this row's problem actually lives. Until then, the most transparent provider here is the one you can least easily try. The full graded field is at [our provider rankings](/best-longevity-clinics), the scoring is set out in [how we grade](/how-we-grade-longevity-providers), and what this category costs generally is in [longevity clinic cost](/longevity-clinic-cost). Sources: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers, https://pubmed.ncbi.nlm.nih.gov/29599478/, https://pubmed.ncbi.nlm.nih.gov/41655607/, https://pubmed.ncbi.nlm.nih.gov/40275690/, https://pubmed.ncbi.nlm.nih.gov/38871717/ --- ### WellMedr Review: One $99 Page, Sold Three Times Canonical: https://longevitygraded.com/wellmedr-review Updated: 2026-08-10 WellMedr sells NAD+, B12 and sermorelin at $99/mo. All three pages are one template with the molecule swapped — and the bill renews every 21 days. August 2026. ## The one-sentence version WellMedr publishes a real price before it asks for your medical history, names the pharmacy that fills your prescription and the clinical group that writes it, and puts the consultation inside the figure it quotes — four things most of the providers here manage two of. Then it sells its entire longevity line from **one page it produced three times by find-and-replace**, and bills the "monthly" price it publishes **every 21 days**. It grades **B, 9 points out of 14**. The grade is computed from published terms alone and cannot see who pays us — WellMedr is a paid partner here. ## What it is, and who is behind it The operator is **Wellmedr LLC**. Clinical care is delivered by **OpenLoop Healthcare Partners, PC** and its affiliated state professional corporations — the telehealth consent names them individually — and fulfillment is by **Mycelium Pharmacy**. Both are named on surfaces WellMedr controls, which is more than most of this ranking manages, and the pharmacy detail matters more than it sounds: a compounded medicine is only as good as the facility that made it, and a company willing to put a name to that is a company you can go and check. The catch is *where* it is named. "Mycelium Pharmacy" appears in the **privacy policy** and nowhere a buyer would look. It is not on the home page, not on the pricing page, not in the FAQ, and not on any of the three product pages this review is about. The longevity line ranked here is three compounded injectables at **$99 a month each**: [NAD+](/nad-for-longevity), **vitamin B12**, and **sermorelin**. Alongside it sits a much larger compounded **GLP-1** business — semaglutide and tirzepatide, brand Ozempic and Zepbound, and an eight-product "microdose" line — and that is what this site's link actually opens. More on that below, because it is a thing you should know before you click. There is **no published list of served states**. Its FAQ answers the question with *"We are expanding rapidly — eligibility is checked during sign-up."* ## The finding: three products, one page Set the sermorelin page beside the B12 page and normalize the product name, and they are **word for word identical** — the same 295 lines, the same headings, the same FAQ, the same fine print. Both are the NAD+ page with a molecule's name substituted in. The NAD+ page differs from them only in its title and one embedded video. The substitution did not stop at the headings. What both pages actually print: > "*Sermorelin* (Nicotinamide Adenine Dinucleotide) therapy has shown potential to support energy metabolism, cognitive performance, and cellular repair." > "Safety Information: *B12* is a naturally occurring coenzyme essential for mitochondrial function, DNA repair, and healthy aging." Nicotinamide adenine dinucleotide is **NAD+**. It is not sermorelin, which is a 29-amino-acid analog of growth-hormone-releasing hormone, and it is not B12, which is cobalamin. Neither of those molecules is a coenzyme essential for mitochondrial function and DNA repair; that sentence describes the third product on the shelf. **And the doses came along with the chemistry.** All three pages offer *"500mg and 1000mg injection options"*. For NAD+ those are ordinary figures. Sermorelin and B12 are dosed in **micrograms** — so on two of the three pages the stated dose is off by roughly a thousandfold. Nobody is going to be dispensed a gram of sermorelin; a licensed prescriber sets the real dose after the intake. That is precisely the point. **The numbers on the page are not describing the product being sold**, and a reader has no way to tell which of the other statements on it are. We are not calling this deceptive, and there is no sign it is. It reads exactly like what it appears to be: one landing page duplicated twice, with the molecule's name swapped and nobody reading the result. But this is a **longevity** ranking, and the whole proposition of a compounded peptide program is that somebody competent is paying attention to the molecule. A page that calls sermorelin a coenzyme and prices it by the milligram is evidence about the attention, not about the medicine. ## What it costs, and the 21 days Every figure below was read on WellMedr's own pages on **10 August 2026**. **NAD+, vitamin B12, sermorelin** — each *"Starting at $99/month"*, each with *"Same price every dose — no hidden fees, no surprise charges"*, and each stating that *"The price includes your online medical consultation, prescription, and free shipping."* Beside them: **"No Hidden Fees · No Monthly Membership · Cancel Anytime"**, and a *"Get Up To $150 Off Today!"* banner, which is a discount rather than a price. Taken at face value that is a good structure, and it earns real credit below. One figure, no membership, no term, the visit inside it. **Then read the refund policy.** Verbatim: > "By completing your purchase, you are enrolling in a recurring subscription program. Your subscription will automatically renew **every 21 days** to ensure continuity of care and medication delivery." Twenty-one days is not a month. It is **17.4 charges a year rather than 12**. At $99 a charge that is about **$1,721 a year, not $1,188** — roughly 45% more than the published monthly figure implies, on a bill that renews indefinitely. And the site gives the period **four different answers** depending on which page you open. Its GLP-1 plan cards say *"shipped every 4 weeks"* (13 charges a year). Its sitewide banner sells *"12/month Plans"*. Its refund policy says every 21 days. Its **Terms of Use §6** says renewals run in *"monthly, 3-month, or 6-month cycles depending on your plan"*. We cannot tell you which one governs your card, and neither can the site. This is why price transparency scores **2 of 4** rather than 4. The rubric's middle rung is for exactly this: a figure that is published — you have a number to start from and to hold them to — and then contradicted by the seller's own documents. It is better than publishing nothing, worse than a figure that binds. **One more thing about the refund policy**, since you are already there. It gives the cancellation notice window as **48 hours** in one paragraph and **72 hours** in two others; it promises refunds if your medication has not yet been ordered in one section and states that *"once a purchase is completed and your medical intake has been approved... your order becomes final and non-refundable"* in another; it still contains unfilled template placeholders — *"[insert email]"*, *"[Wellmedr LLC]"* — and one sentence breaks off mid-word. It is three policies stacked on one page, and they do not agree. ## Where our link sends you, and why we are telling you This is a disclosure rather than a criticism of WellMedr, because it is a limitation on our side. The affiliate offer behind this row exposes **no landing-page selector**. Every link from this site resolves to **wellmedr.com/pages/get-started-weight-loss** — the **GLP-1 weight-loss** pricing page — not to the NAD+ or sermorelin page this review is about. Where other partners here let us pin a longevity lander, this one does not, and inventing a selector is worse than useless: an invalid one falls back silently. So if you click through, expect to land on a page selling **compounded semaglutide at "$59 a month" and tirzepatide at "$99 a month"**, and navigate from there. Two warnings about that page while you are on it. Its **$59** figure is not a month-to-month rate — the sitewide banner ties it to a twelve-month plan (*"Lock In $200 OFF Every Month, or $59/mo on 12/month Plans — For Life"*) — and its **$99** is a **different product** from the $99 on the sermorelin page that happens to share a number. ## Clinical oversight, the pharmacy, and the FDA answer **Oversight: two points, earned.** No consultation fee appears anywhere in the published structure. The longevity pages state the medical consultation, the prescription and shipping are inside the $99, and there is no membership stacked on top. That is what this factor asks for and WellMedr answers it plainly. **Pharmacy: one point of two.** Our one test is where a claim is published, applied identically to every row. WellMedr **names** its dispensing pharmacy — Mycelium Pharmacy, in its privacy policy, a surface it controls — which is the middle rung. It does **not** publish a **503A** or 503B claim anywhere; what it says is *"FDA-registered compounding facilities"*, and registration with the FDA is a different fact from compounding to a stated standard. We do not credit one as the other, here or on any other row. **Human support: zero, and it is close.** What the longevity pages state as inside the $99 is the consultation, the prescription and shipping. "1:1 Medical Support" appears as a badge, and the sitewide bar advertises "Unlimited provider messaging" — but the explicit *"Unlimited Messaging With Licensed Clinicians · Included"* block sits on the **GLP-1 pricing page** and is about that program. Ongoing clinical support published as part of the price of the line we are grading is what this factor asks for, and it is not there. [Pallas Health](/pallas-health-review) scores zero here on the same reasoning. **Longevity line: four of four.** Three compounded longevity injectables sold at a published price is exactly what this site ranks, whatever the quality of the copy describing them. The factor asks what is on the shelf. **And then there is the FDA answer.** WellMedr's FAQ asks *"Are these medications FDA approved?"* and answers: > "**Yes.** We only work with U.S. licensed pharmacies that dispense FDA-approved medications." The footer of that same page says the opposite: > "Compounded medications offered through Wellmedr. are produced in FDA-registered facilities but are **not FDA-approved and have not been evaluated by the FDA** for safety, efficacy, or quality." The footer is right. Compounded drugs are not FDA-approved, and the agency does not verify their safety, effectiveness or quality before they are marketed. The longevity pages carry the correct version too — *"These statements have not been evaluated by the Food and Drug Administration"* — so the "Yes" is one answer out of step with the rest of the site rather than the site's position. It is still the answer sitting in the FAQ, on the page a buyer with exactly that question will open, and the microdose page says it a second time. **Clean on regulatory record.** We screened FDA's live warning-letter index on 10 August 2026 for "wellmedr", "Wellmedr LLC", "mycelium", "Mycelium Pharmacy", "openloop" and "OpenLoop Health" — **zero records each**, in a pass where a known-lettered company came back positive, so the clean result is a real one and not a broken query. The pharmacy was screened as well as the brand, which is only possible because WellMedr named it. **Not credited: the LegitScript badge.** WellMedr displays a "LegitScript Certified" badge on its pricing page, but it carries **no seal number** and links to a keyword search rather than to a certificate. The lookup sits behind a bot challenge that returned the identical response for a genuinely certified merchant and for a domain we invented, so it cannot tell the two apart and neither can we. We neither credit the claim nor dispute it. ## The verdict **B, 9 of 14.** Four points for a genuine longevity line, two for putting the consultation inside a published price, two of four for a figure its own refund policy contradicts, one of two for naming a pharmacy without stating a compounding standard, and zero for support it does not publish as included. Buy from WellMedr if the structure is what you want — one figure, no membership, no term, the visit included — and you are willing to establish two things first: **what your billing period actually is**, in writing, before you enter a card; and **what dose you are being prescribed**, in the units the medicine is actually measured in. On the second one, do not take the page's word for it. It is not describing your product. Compounded NAD+, B12 and sermorelin are **not FDA-approved for anti-aging**, and the lifespan evidence for any of them is unproven — see [our evidence review](/nad-for-longevity). That is true of most of this category and it is the most important sentence on this page. Sources: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers --- ### Synergy Rx Review: $275 NAD+, and a Terms Clause That Unbinds It Canonical: https://longevitygraded.com/synergy-rx-review Updated: 2026-08-08 Synergy Rx prints NAD+, sermorelin and glutathione at $275/mo on its homepage. Its Terms say the final charge may differ. August 2026. ## The one-sentence version Synergy Rx does the rare thing here: it **prints four longevity prices on its own homepage**, month-to-month, with no prepay term standing between you and them — NAD+, sermorelin and glutathione injections at **$275 a month each** and B-12 methylcobalamin at **$109**. It names four dispensing pharmacies with phone numbers, names two prescribing physicians with NPI numbers, and publishes unlimited appointments and 24/7 support as part of the plan. Then its own documents undercut the thing it does best: **the published prices are not binding**, the "Money Back Guarantee" on one page is contradicted by "all sales are final" on another, and it will not tell you which states it serves. It grades **A, 11 points out of 14** — the bottom of the A band, with two of the three points it drops taken for disclaiming its own prices. The grade is computed from published terms alone and is blind to who pays us; Synergy Rx is a paid partner here. ## What it is, and what it sells The operating entity is **SynergyRx**, described in its own Terms as *"a Delaware corporation located at 5830 E 2nd St, Ste 7000 #2603, Casper, WY 82609."* The commerce platform is **CareGLP**, which SynergyRx owns, and medical services are delivered by **Usable Health, PC**. That last arrangement matters: the company you buy from and the practice that prescribes to you are two different legal entities, which is normal in this category and worth knowing anyway. The Longevity tab on the homepage is the whole of what this site ranks, and it is short and legible: Beside it sit hair (four products at $109), ED tablets and sublingual strips (all $109), six compounded skin creams at $119, and the GLP-1 line — compounded semaglutide at **$199/mo**, compounded tirzepatide at **$349/mo**, sublingual ODT versions at $299 and $399, and brand Ozempic at $499 with Wegovy and Mounjaro at $947. What it does **not** sell: no other growth-hormone peptides, no methylene blue, no TRT or HRT, no BPC-157 or TB-500, no supplements. ## The pricing, and the clause that hangs over it **Start with what is genuinely good, because it is unusual.** Those four figures are rendered in the homepage's own HTML. There is no quiz gate, no "get your personalized quote", no membership wrapped around them. Every one is a **month-to-month** rate. And Synergy's multi-month bundles are, remarkably, **worse value than paying monthly** — the three-month semaglutide bundle costs $748, which is $249 a month against $199 month-to-month, and the three-month tirzepatide bundle is $356 a month against $349. That is the inverse of this vertical's usual trap, where the advertised number turns out to be a twelve-month prepay. Here the cheapest rung is the shortest commitment, and nothing needs unpicking to see it. **Now the clause.** Section XII of the Terms, verbatim: > *"Kindly be advised that the final charge to your credit card may fluctuate contingent upon the prescribed medication and the chosen pharmacy for order fulfillment. Should any variance arise in the charge, a dedicated member of our support team will expeditiously communicate the details to you."* Read that beside the product-level fineprint and it stops being boilerplate. Glutathione, B-12 and the skin creams are **not shipped to Alabama, Arkansas, Alaska, Connecticut, Indiana, Kentucky, Louisiana, Michigan, Minnesota, Vermont or Wisconsin**. NAD+ *is* served in those eleven states — but by secondary pharmacies, and the catalog's own words are that **cost may vary**. Sermorelin and PT-141 route through a secondary pharmacy in Alabama on the same terms. So the company has told you twice, in two places, that $275 is an expectation rather than a quotation. **And the homepage says it too, one screen below the prices.** Synergy's own FAQ answers *"How much does the program cost?"* with: *"Program pricing varies depending on your treatment plan, medication type, and whether you choose compounded or brand-name medications. Transparent pricing is provided after your consultation."* That is on the same page as the $275 tiles. The number and the disclaimer of the number are visible without scrolling twice. **What that costs, and why the rule is not aimed at Synergy.** [Our rubric](/how-we-grade-longevity-providers) now scores price transparency on three rungs rather than two: four points for an all-in figure the provider stands behind, **two for one it publishes and then disclaims**, and zero where no such figure exists before you commit. Synergy lands on the middle rung, which is the honest description of what it does — it publishes real, ungated, month-to-month numbers, and it also tells you they may not be what you are charged. That is genuinely better than the rows publishing nothing, and genuinely worse than a price that binds. Worth stating plainly, because the rule arrived from reading *this* company's terms: it was applied to **every row here that publishes a price** — twenty of them, swept page by page on the same day — and three came back positive. A rule written for one row and applied to one row is not a rule. **Get the number confirmed in writing before you accept a prescription**, and confirm it again if you live in one of the eleven states. **One more thing that is not a price.** A *"$100 welcome credit… no code needed"* and a *"2026 Promo Applied!"* banner run site-wide with no published terms attached to either. Treat both as marketing furniture until somebody quotes you a figure. ## Who prescribes, who dispenses, and what is missing **Four pharmacies, named, with phone numbers.** Synergy's own homepage FAQ lists **Belmar Pharmacy, Strive Pharmacy, Epiq Scripts and Casa Pharma Rx**, each with a telephone number and a website. In a category whose standard practice is to say "a licensed US pharmacy" and stop, that is real disclosure. What it never does is **classify** them: the strings "503A" and "503B" appear nowhere on the site, so you know who fills your prescription but not under which regime. That is the middle rung of our pharmacy ladder, and it is what Synergy earns — one point of two. [Found Health](/found-review) states the standard and names nobody; Synergy names four and states no standard. Neither is complete. **Two physicians, named, with NPI numbers.** The clinical group is **Lion MD**, led by **Dr. Ana Lisa Carr, MD (NPI 1689841744)** and **Dr. Kelly Tenbrink, MD (NPI 1346482684)** — both verifiable as active in the NPPES registry, Carr in family medicine and Tenbrink in emergency medicine. Volunteering a checkable identifier is rare and worth crediting. The gap is the same one every asynchronous practice has: on an intake reviewed remotely, the clinician who writes your prescription is very probably not one of the two people you were shown. **Support is published as included**, and specifically: *"Unlimited 24/7 Support Included… With unlimited appointments, messaging and support"*, with the homepage's own process adding that *"Ongoing support is provided through monthly check-ins and messaging access."* That is a statement about what the price buys, not a customer-service phone number, which is the distinction this factor turns on. **And then the states.** Synergy publishes **no list of the states it serves.** Its Terms say the service is *"available to individuals located in certain states. To see the list of current states, please contact customer service."* Any claim you read elsewhere that Synergy covers all fifty is unsupported by anything the company currently publishes. Our rubric has no factor for state coverage — which is a limit of the rubric, and the honest thing is to say so here rather than invent a factor after seeing which row it would hit. ## The self-contradictions **"Money Back Guarantee" versus "all sales are final."** The /about page advertises a Money Back Guarantee among its trust badges. Section XII of the Terms says: *"If you receive a medical consultation, medical consult fees are not subject to or eligible for a refund. We cannot accept returns of prescription products for reuse or resale, and all sales are final."* Both are live on the same site today. Only one of them is the contract. **The PT-141 description is the sermorelin copy on the wrong molecule.** Synergy's PT-141 product page credits the drug with raising the body's own growth-hormone production and the downstream effects that follow from that. **PT-141 (bremelanotide) is a melanocortin receptor agonist used for sexual dysfunction. It does not do that.** We are not reproducing the sentence, because it is wrong and it travels — the same copy is byte-identical across the CareValidate-platform brands, and errors in shared boilerplate get quoted onward by people who assume a product page describes the product. Take it as a warning about the whole product-copy layer: **treat any clinical claim on these pages as unchecked**, and read [what the peptide evidence actually supports](/peptides-for-longevity) instead. **"Join 50,000+ SynergyRx patients"** has no published basis. And no dose strengths are given for NAD+ or sermorelin anywhere, so whether $275 holds as a dose rises cannot be established before you pay — its sibling brand [Care Bare Rx](/care-bare-rx-review), running on the same platform, publishes the dose ladder Synergy strips out. ## The evidence behind what it sells This ranking grades providers, not molecules. But $275 a month is $3,300 a year, and the state of the evidence belongs in that decision. The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies including 33 human intervention trials. Oral precursors do reliably raise blood NAD+ — that part holds — but effects on functional, metabolic and vascular outcomes were *"heterogeneous and often null or endpoint-specific,"* and clinical effectiveness for anti-aging or wellness *"remains inconclusive"*. On the route Synergy actually sells, the same review is blunter: **no eligible outcomes trial has evaluated injected NAD+ for these indications at all**. A 2025 meta-analysis in adults averaging over 60 found NAD+ precursors did not improve muscle index, grip strength, gait speed or chair-stand time. Sermorelin is a growth-hormone-releasing analog, and the honest summary of GH augmentation in healthy older adults is the 2007 Annals systematic review: small changes in body composition, no demonstrated functional benefit, and a higher rate of adverse events. Glutathione by injection has less human outcome evidence still. None of that is a mark against Synergy in particular — it is the state of the category, and the company markets within its normal register. Compounded NAD+, sermorelin and glutathione are **not FDA-approved**, and FDA's own position is that compounded drugs are not FDA-approved and the agency does not verify their safety, effectiveness or quality before they are marketed. ## Where it's weak, and who should skip it Skip it if you need to know before you start that your state is covered, because Synergy will not tell you without a phone call. Skip it if a Terms clause saying your charge may differ from the advertised price is a risk you will not take on a recurring bill. Skip it if you need to know what dose $275 buys, or what a higher dose costs, because neither is published. And skip it if the refund position matters to you: on Synergy's own Terms, consult fees are non-refundable and all sales are final, whatever the badge on /about says. Buy it if a published, ungated, genuinely month-to-month price is the thing you have been unable to find elsewhere — because most providers here cannot manage it — and if you are willing to do the one piece of work this provider leaves you: get the state, the dose and the final charge confirmed in writing before you accept anything. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Synergy takes **two of four for price transparency** — the middle rung, because the figures are published, ungated and month-to-month and its own documents then disclaim them; **four for its longevity line**, because NAD+, sermorelin and glutathione injections are exactly what this site exists to rank; **two for clinical oversight**, because the consultation sits inside the plan and unlimited appointments are stated as included; and **two for support**, on the published 24/7 messaging and monthly check-ins. It drops **one point on pharmacy**, because it names four facilities and classifies none. **Eleven out of fourteen: an A**, at the very bottom of the band — one point above a B. Which is the uncomfortable part, and worth stating plainly: the rubric measures what a provider publishes about its price, its line, its oversight, its pharmacy and its support — and on all five Synergy does well. It has no factor for a missing state list, for a guarantee its Terms contradict, or for a product description attached to the wrong molecule. Those are real, they are why this review is as long as it is, and they are the reason to read the whole page rather than the letter. The full graded field is at [our provider rankings](/best-longevity-clinics), the scoring is set out in [how we grade](/how-we-grade-longevity-providers), and what this category costs generally is in [longevity clinic cost](/longevity-clinic-cost). Sources: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers, https://pubmed.ncbi.nlm.nih.gov/29599478/, https://pubmed.ncbi.nlm.nih.gov/41655607/, https://pubmed.ncbi.nlm.nih.gov/40275690/, https://pubmed.ncbi.nlm.nih.gov/17227934/ --- ### Care Bare Rx Review: The NAD+ Price on the Site Is Not a Price Canonical: https://longevitygraded.com/care-bare-rx-review Updated: 2026-08-08 Care Bare Rx advertises NAD+ "starting at $199". Its own catalog has one NAD+ product, at $325. What it does publish is unusually good. August 2026. ## The one-sentence version Care Bare Rx publishes more about **who prescribes and who dispenses** than almost anything else here — four pharmacies with street addresses and phone numbers, four clinicians with NPI numbers you can look up — and then advertises an NAD+ price that **matches nothing in its own catalog**. The site says *"NAD+ Treatments Starting at $199"*, directly beneath the words *"Transparent pricing"*. Its catalog holds exactly one NAD+ product, at **$325 a month**. It grades **B, 9 points out of 14**, computed from published terms alone and blind to who pays us — Care Bare Rx is a paid partner here. ## What it is, and who it's for Care Bare Rx is a telehealth brand positioned around **LGBTQ+ care** — *"a wellness brand designed for those who want their health routine to feel as good as it looks"* — running on **CareGLP by CareValidate**, with intake at intake.carebarerx.com and Stripe at checkout. The backend organization is **CareBareHealth**. The line this site ranks is three products: **NAD+ injection (200 mg/mL, 10 mL), sermorelin acetate injection (2 mg/mL, 10 mL) and B-12 methylcobalamin (5 mg/mL)**. Beside them sit compounded semaglutide and tirzepatide with dose-tiered pricing, brand-name GLP-1s, a hair line and a sexual-health line. There is no glutathione, no other growth-hormone peptide, no methylene blue, no TRT or HRT and no supplements. Note the dose tiering, because it is a real point in Care Bare's favor and its sibling brands do not do it: compounded semaglutide is **$199 at 0.25 mg, $249 at 0.5 and 1 mg, $299 at 1.5 and 2 mg**, and tirzepatide **$299 / $349 / $399** across its three bands. A buyer can see what titrating up will cost before starting. [Synergy Rx](/synergy-rx-review), on the same platform, strips that ladder out entirely. ## The price problem, in three parts **1. The advertised NAD+ figure is purchasable at no tier.** Every marketing page carries *"NAD+ Treatments Starting at $199"*, and on the homepage that line sits in a block whose own bullet points include *"Transparent pricing, discreet delivery, real results."* The catalog served from Care Bare's own intake system — unauthenticated, with prices switched on, so this is published information and not a leak — has **one** NAD+ product. It costs **$325**. There is no $199 tier, no $199 dose, no $199 promotional rung. The number is not a prepay rate that turns out to need twelve months, and not an intro month that steps up at the first refill. Those at least correspond to something somebody pays. **This one corresponds to nothing.** **2. The lander an affiliate link lands on advertises a third set of numbers.** Care Bare runs a marketing lander at /home2, and it is where our own link resolves. It shows **Ozempic at $749, hair at $99 and sexual health at $99**. The /about and /faq pages show **$705, $180 and $120** — and the checkout catalog agrees with those. So a reader arriving from an ad lands on the page whose figures are wrong, and finds the corrected ones only if they navigate away from it. We checked whether a different landing page could be selected instead; there is not one. **3. The bundles are labeled in the wrong unit.** On /gluca, *"Semaglutide 3-Month Bundle From $748/mo"* is a **three-month total** — $249 a month — and *"Tirzepatide 3-Month Bundle From $1068/mo"* is $356 a month. The "/mo" is on a figure that is not monthly. **What that costs, and why.** Our rubric asks for one all-in figure, visible before you commit, that a buyer with no commitment actually pays. Care Bare has such a figure — $325, month-to-month, no prepay term — but it is not on any page a shopper reads, and the figure that *is* on those pages is off by 63%. Price transparency scores **zero**, and it is the same call [Gala Health](/gala-health-review) gets for advertising a yearly rate as though it were monthly. Compare [Sprout Health](/sprout-health-review), whose $199 headline is a genuine first-month rate with the $249 standing rate published beside it, and which keeps all four points. The difference is not honesty of intent — it is whether the number on the page is a number somebody is charged. **And two costs that are not in any headline.** An **$80 telehealth consult fee** applies *"if medication isn't prescribed"* — stated in the catalog's own fineprint rather than on the marketing pages. And the Terms make medical consult fees non-refundable and state that all sales are final. ## What Care Bare publishes that most providers here do not **Four dispensing pharmacies, named, with street addresses and phone numbers**, on its own FAQ: - **Belmar Pharmacy** — 6597 N 92nd St, Suite 105, Scottsdale, AZ 85260 · 800.525.9473 - **Strive Pharmacy** — 21143 Hawthorne Blvd, Suite 305, Torrance, CA 90503 · 855.405.5993 - **Epiq Scripts** — 625 Herndon Ave, Suite D, Clovis, CA 93612 · 833.654.3553 - **Casa Pharma Rx** — 12855 Capricorn St, Stafford, TX 77477 · 877.937.6868 What it does not do is **classify** them. The only mention of the statute on that page is a general compliance list — *"State boards of pharmacy, which regulate all 503A pharmacies"* — which is an explanation of who regulates whom, not a statement that your prescription is filled under 503A. [Our published methodology](/how-we-grade-longevity-providers) draws that line deliberately, so Care Bare takes the middle rung: **one point of two**, for naming without classifying. **Four clinicians, named, with NPI numbers.** The clinical group is **Lion MD**: **Dr. Ana Lisa Carr, MD (NPI 1689841744)** and **Dr. Kelly Tenbrink, MD (NPI 1346482684)** leading, with **Dr. HirenKimar Italia, MD (NPI 1487815387)** and **Dr. David Mansour, DO (NPI 1689164949)** as supporting medical team. Four checkable identifiers is more than any other provider on this site publishes. **Belmar, and the thing to know in proportion.** One of those four pharmacies, **Belmar**, received an FDA warning letter issued **31 March 2023**, addressed to *"Belmar Pharma Solutions, Drug Depot, LLC., dba APS Pharmacy"* — and **FDA closed it out on 30 October 2023**. We do not restate what it alleged; that is FDA's document to characterize, and the searchable index is linked below. Two things matter. The letter is **closed out**, and any page that leaves that off is publishing a false impression. And **you only know about it because Care Bare names its pharmacies**: the rows here that name nobody could be dispensing through anyone, and there would be nothing for you to check. **Care Bare Rx itself holds no FDA warning letter** — a live index search for "carebarerx", "care bare", "carebarehealth", "carevalidate" and "careglp" returned no company match, in a pass where a known-lettered company came back positive, so the clean result is real and not a broken query. **Support and oversight are inside the price.** The homepage's own three-step explainer ends with *"Ongoing Support & Delivery — We ship your meds directly to you with follow-up care and optional coaching."* Follow-up care stated as part of the program is what our support factor asks for; the coaching is hedged as optional and is not what the point is given for. And because the only consult charge published is the $80 that applies when nothing is prescribed, the clinician review sits inside the medication price for anyone who is prescribed. ## The states question, and its answer Care Bare's FAQ says: *"We provide service to all 50 states and Puerto Rico."* Its own catalog copy says something else. **B-12 carries a no-ship list — Alabama, Arkansas, Alaska, Connecticut, Indiana, Kentucky, Louisiana, Michigan, Minnesota, Vermont and Wisconsin** — and **NAD+ in those same eleven states** *"will be supplied by secondary pharmacies. Cost may vary."* Both sentences are live. The reconciliation is that the GLP-1 line may well be fifty-state while the wellness line is not, and that **the NAD+ price is not fixed everywhere** even where the product is available. If you live in one of the eleven, get your own number in writing before paying. Two smaller things in the same register: the homepage testimonials are **recycled from CareGLP**, the white-label platform behind the brand — one of them praises *"what I expected from CareGLP"* rather than Care Bare — and **Mounjaro is flagged sold out in the catalog** while still being advertised on the marketing pages. ## The evidence behind what it sells This ranking grades providers, not molecules, and Care Bare markets within the category's normal register. But NAD+ at $325 a month is $3,900 a year, so the evidence belongs in the decision. The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies including 33 human intervention trials. Oral precursors reliably raise blood NAD+, but effects on functional, metabolic and vascular outcomes were *"heterogeneous and often null or endpoint-specific,"* and clinical effectiveness for anti-aging or wellness *"remains inconclusive"*. On the route Care Bare sells, the same review is blunter still: **no eligible outcomes trial has evaluated injected NAD+ for these indications**. A 2025 meta-analysis in adults averaging over 60 found NAD+ precursors did not improve muscle index, grip strength, gait speed or chair-stand time. Sermorelin is a growth-hormone-releasing analog, and the honest summary of GH augmentation in healthy older adults remains the 2007 Annals systematic review: small body-composition changes, no demonstrated functional benefit, more adverse events. Compounded NAD+ and sermorelin are **not FDA-approved**, and FDA's own position is that compounded drugs are not FDA-approved and it does not verify their safety, effectiveness or quality before marketing. Read [what the NAD+ evidence actually supports](/nad-for-longevity) before deciding a year of this is worth it. ## Where it's weak, and who should skip it Skip it if you budget from the advertised number, because the advertised number is not the number — **plan for $325 a month for NAD+, not $199**. Skip it if you arrive on the /home2 lander and want to buy what it shows you, because its Ozempic, hair and sexual-health figures are not the ones the checkout charges. Skip it if you live in one of the eleven no-ship states and need a fixed NAD+ price, because Care Bare says explicitly that yours may vary. And skip it if a non-refundable consult fee and an all-sales-final policy are risks you will not take. Buy it if the disclosure is what you are actually shopping for and you are prepared to confirm the price yourself. Four named pharmacies with addresses, four named clinicians with NPI numbers, a published dose ladder on the GLP-1 line, month-to-month with no prepay term and follow-up care inside the price is a genuinely strong package — attached to marketing copy that has not been reconciled with the catalog behind it. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Care Bare takes **the full four for its longevity line** — NAD+, sermorelin and B-12 are what this site ranks — **two for clinical oversight**, because the consult is inside the medication price unless nothing is prescribed, **two for support**, on published follow-up care, and **one of two for pharmacy**, for naming four facilities without classifying any. It takes **zero for price transparency**, because the figure it advertises for the product this site grades is purchasable at no tier. **Nine out of fourteen: a B.** The fix is a single line of copy. Change *"Starting at $199"* to *"$325 a month"* and Care Bare moves to thirteen and an **A** without touching the medicine, the pharmacies, the clinicians or the price itself. That is worth stating plainly, because it locates the problem exactly: this is not a company hiding what it charges — it is a company advertising a number its own system cannot sell you. The full graded field is at [our provider rankings](/best-longevity-clinics), and what this category costs generally is in [longevity clinic cost](/longevity-clinic-cost). Sources: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters, https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers, https://pubmed.ncbi.nlm.nih.gov/29599478/, https://pubmed.ncbi.nlm.nih.gov/41655607/, https://pubmed.ncbi.nlm.nih.gov/40275690/, https://pubmed.ncbi.nlm.nih.gov/17227934/ --- ### Breeze Meds Review: Three NAD+ Prices on One Page Canonical: https://longevitygraded.com/breeze-meds-review Updated: 2026-08-08 Breeze Meds sells NAD+ at $169, $179 and $249 on the same page — and publishes no terms of service or refund policy at all. August 2026. ## The one-sentence version Breeze Meds has quietly become a longevity provider — **NAD+ by injection and by nasal spray, plus sermorelin**, on top of the compounded GLP-1 line it started with — and it bundles more into the monthly figure than most rows here: the medical consultation, unlimited consultations afterwards, secure messaging and 24/7 support, all stated as included. Then the page that sells NAD+ carries **three different prices for it**, its sermorelin card disagrees with its own catalog by $35, and the site publishes **no terms of service, no refund policy and no cancellation policy at all**. It grades **B, 9 points out of 14**, computed from published terms alone and blind to who pays us — Breeze Meds is a paid partner here. ## What it is, and what it sells The operating entity is **Breezemeds, LLC**, described in its own inline privacy policy as *"a Delaware corporation"* at 134 South Avenue SE, Marietta GA 30060 — although the consultation footer says **Breezemeds, Inc.** The platform underneath is **CareValidate**, the same white-label backend behind [Care Bare Rx](/care-bare-rx-review), [Synergy Rx](/synergy-rx-review) and several others, which means its clinicians, pharmacies and FAQ language are shared property rather than independent corroboration of anyone else's. The catalog is short and current: Beside it: compounded semaglutide injection at $199 a month, tirzepatide injection at $299, oral semaglutide at $299 and oral tirzepatide at $399. No glutathione, no B-12, no methylene blue, no other growth-hormone peptides, no TRT or HRT, no supplements. ## Four numbers, one product, one page Here is what /nad-plus says about NAD+, in the order you meet it: - the hero: *"Just **$179** to start"* - a product card: *"Starting at **$169** — NAD+ Injection"* - another card: *"Starting at **$210** — NAD+ Nasal Spray"* - and the FAQ, at the bottom of the same page: *"BreezeMeds NAD+ therapy starts **regular at just $249/month**, including your medical consultation, prescription, medication, and free shipping."* Three of those are for the injection. **$179, $169 and $249.** The card and the machine-readable catalog the page renders from both say **$169**, which is why $169 is the figure this review publishes — but Breeze's own FAQ calls $249 the *regular* monthly rate, which is precisely the number a buyer needs and precisely the one that contradicts the card. The sermorelin line does the same thing on a smaller scale: the card says **$100**, the catalog behind the same page says **$135**. **Why that zeroes the price factor.** Our rubric asks for *a* figure — singular — that a buyer can rely on before committing. Two of four numbers agreeing is not that. This is not the familiar trap where an advertised rate turns out to be a twelve-month prepay; there is no term hiding behind any of these figures. It is simpler and stranger: **the page has not been reconciled with itself.** Compare [System Labs](/system-labs-review), which also prints two numbers per product — but prints them as a struck-through pair, first month against standing rate, so the relationship between them is legible. It keeps all four points. Breeze prints three numbers with no relationship stated at all. **And the bundles are worse than monthly.** The three-month semaglutide bundle is $748, which is **$249.33 a month against $199 month-to-month**. Do not read the multi-month rungs as savings. **One charge that is not in any headline:** an **$80 consultation fee** if you choose a phone or video visit and then do not proceed. ## What it does publish, and it is more than you would expect **The monthly figure genuinely includes the consultation.** Breeze's own FAQ says so — *"including your medical consultation, prescription, medication, and free shipping"* — and /nad-plus goes further: *"Unlimited 24/7 Support, Included. BreezeMeds connects you with our dedicated team of NAD+ specialists… With unlimited consultations, secure messaging, and expert guidance."* That is a statement about what the price buys, which is what our oversight and support factors ask for, and Breeze takes all four of those points. **Four dispensing pharmacies are named with phone numbers** on its homepage — **Belmar Pharmacy, Strive Pharmacy, Epiq Scripts and Casa Pharma Rx** — alongside the clinical group **Lion MD** and two prescribing physicians with NPI numbers, **Dr. Ana Lisa Carr, MD (1689841744)** and **Dr. Kelly Tenbrink, MD (1346482684)**. What it never does is classify any of them: the strings "503A" and "503B" appear nowhere on the site, so Breeze takes the middle rung of our pharmacy ladder — one point of two — for naming without classifying. **Belmar, in proportion.** One of the four, **Belmar**, received an FDA warning letter issued **31 March 2023**, addressed to *"Belmar Pharma Solutions, Drug Depot, LLC., dba APS Pharmacy"*, and **FDA closed it out on 30 October 2023**. We do not restate what it alleged; the searchable index is cited below and it is FDA's document to characterize. The letter is closed out, and any page that leaves that off is publishing a false impression. **Breeze Meds itself holds no FDA warning letter** — a live index search for "breezemeds", "breeze meds" and "Breezemeds, LLC" returned no company match, in a pass where a known-lettered company came back positive, so the clean result is real rather than a broken query. And note the direction of the trade: you can only weigh Belmar at all because Breeze names its pharmacies, which most providers here declines to do. **States:** its FAQ says *"We service all 50 states."* No exclusion list is published against that anywhere on the site. ## The paperwork that does not exist This is the part that would give a careful buyer pause, and it has nothing to do with prices. **Breeze Meds publishes no terms of service.** /terms, /terms-of-service, /privacy-policy, /privacy and /refund-policy all return **404**. The privacy policy survives only as **inline text on the homepage**. There is **no published refund policy and no published cancellation policy anywhere on the site** — so what happens if a clinician declines you, if you cancel before the pharmacy fills, or if a shipment goes wrong is simply not written down. Every other row here that we have criticized for a harsh refund policy at least *has* one. **Its client-side configuration ships secrets in plaintext.** The bundle every visitor loads carries a **Klaviyo private API key** and a **Supabase URL and anon key**. That is a hygiene problem in any web application and a more serious one for a service that collects health intake. **Its own claims disagree with each other.** The homepage says **"50,000+"** patients; /nad-plus says **"100,000+"**. And /nad-plus publishes efficacy figures — *"9/10 patients report feeling 10 years younger"* — attributed only to customer surveys, with no methodology, sample or date. Treat those as marketing, not evidence. ## The evidence behind what it sells This ranking grades providers, not molecules, but $169 a month is about $2,000 a year and the state of the evidence belongs in the decision. The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies including 33 human intervention trials. Oral precursors reliably raise blood NAD+ — target engagement is real — but effects on functional, metabolic and vascular outcomes were *"heterogeneous and often null or endpoint-specific,"* and clinical effectiveness for anti-aging or wellness *"remains inconclusive"*. On the two routes Breeze actually sells the review is blunter: **no eligible outcomes trial has evaluated injected NAD+ for these indications**, and nasal delivery has less human outcome evidence still. A 2025 meta-analysis in adults averaging over 60 found NAD+ precursors did not improve muscle index, grip strength, gait speed or chair-stand time; the strongest randomized result in the field moved six-minute walk distance by about 17.6 meters in peripheral artery disease — a disease endpoint, not an aging one. Sermorelin is a growth-hormone-releasing analog, and the honest summary of GH augmentation in healthy older adults is still the 2007 Annals systematic review: small body-composition changes, no demonstrated functional benefit, more adverse events. Compounded NAD+ and sermorelin are **not FDA-approved**, and FDA's own position is that compounded drugs are not FDA-approved and it does not verify their safety, effectiveness or quality before marketing. Set that beside the *"9/10 patients report feeling 10 years younger"* claim and you have the whole reason [we grade the evidence separately from the provider](/do-nad-peptides-work). ## Where it's weak, and who should skip it Skip it if you need to know what month two costs, because Breeze's own page gives you three answers and its FAQ calls the highest of them the regular rate. Skip it if you want a written refund or cancellation policy, because there is not one — not a harsh one, none at all. Skip it if a service handling your health intake shipping API keys in its public bundle is a dealbreaker, which is a defensible position. And skip the multi-month bundles regardless: they cost more per month than paying monthly. Buy it if you want two NAD+ routes with the consultation, unlimited follow-up consultations, messaging and 24/7 support genuinely inside one monthly figure, from a provider that names four pharmacies and two physicians — and you are willing to get the actual monthly number confirmed in writing before your card is charged. Ask specifically: *is the ongoing rate $169 or $249?* ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Breeze takes **the full four for its longevity line** — NAD+ in two routes plus sermorelin is exactly what this site ranks — **two for clinical oversight**, because the consultation is stated as inside the price, **two for support**, on published unlimited consultations and 24/7 messaging, and **one of two for pharmacy**, for naming four facilities without classifying them. It takes **zero for price transparency**, because one page carries three prices for one product. **Nine out of fourteen: a B.** The fix is smaller than the criticism sounds: reconcile one page to one number, print the sermorelin figure the catalog actually holds, and publish a terms of service with a refund policy in it. Do that and Breeze is a thirteen-point **A** without changing anything about the medicine or the price. Until then the review's practical advice is the same as its criticism — get the number in writing. The full graded field is at [our provider rankings](/best-longevity-clinics), the scoring is in [how we grade](/how-we-grade-longevity-providers), and what this category costs generally is in [longevity clinic cost](/longevity-clinic-cost). Sources: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters, https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers, https://pubmed.ncbi.nlm.nih.gov/29599478/, https://pubmed.ncbi.nlm.nih.gov/41655607/, https://pubmed.ncbi.nlm.nih.gov/40275690/, https://pubmed.ncbi.nlm.nih.gov/38871717/, https://pubmed.ncbi.nlm.nih.gov/17227934/ --- ### Oak Review: A Real Anti-Aging Line With No Published Price Canonical: https://longevitygraded.com/oak-review Updated: 2026-08-08 Oak sells NAD+, glutathione, metformin, sermorelin and tesamorelin — and publishes a price for none of them. August 2026. ## The one-sentence version Oak has been filed across this industry as an injectable-only GLP-1 shop with flat dose pricing. **That is wrong.** Oak runs six live programs, and two of them are squarely this site's subject: an **Anti-Aging program** (NAD+, glutathione, MIC+B12 and metformin) and a **sermorelin/tesamorelin program**, with topical NAD+ and copper peptides in a compounded skincare line besides. It also puts the clinician review and ongoing coaching inside the price with no membership fee, which is more than several higher-graded rows manage. What it does not do is **publish a price for any of it** — every longevity figure is quoted only after the quiz and clinician approval — while the prices it does publish, for GLP-1, come in **five mutually inconsistent versions**. It grades **B, 8 points out of 14**, computed from published terms alone and blind to who pays us. Oak is a paid partner here. ## What it actually sells Oak's checkout runs on a commerce platform whose configuration endpoint is served unauthenticated, and it lists six active programs. Naming them matters, because the public positioning names two: - **GLP-1** — compounded semaglutide and tirzepatide, with optional compounded B6 or B12 - **Phentermine** — oral - **Anti-Aging** — **MIC+B12 injections, glutathione, NAD+ and metformin** - **"Semorelin"** *(spelled that way in Oak's own catalog)* — **injectable sermorelin and tesamorelin** - **Erectile dysfunction** — sildenafil, tadalafil, Trimix - **Skin care** — tretinoin, adapalene and retinol, **peptide and growth-factor topicals including Argireline and GHK-Cu**, topical estriol, **topical NAD+ and resveratrol**, niacinamide, azelaic acid and AHAs The homepage nav carries the same thing in plain sight: *NAD+ & Glutathione*, *Sermorelin Peptides*, *Oral Meds*, *Women's Health*, *Tadalafil*. So the "GLP-1 only" record was never a reading of the catalog. Two things are **not** for sale, whatever else you may read. There is no methylene blue, no TRT or HRT (men's health here is erectile dysfunction), and no BPC-157 or TB-500 — the copper peptides are topical. And the two supplement packs sitting in Oak's catalog (a "Gut Health Vitamin Pack" and a "Longevity Vitamin Pack" of NMN, AKG, glycine, hyaluronic acid, omega-3 and vitamin D) are both flagged **inactive and are not purchasable**, so they are not listed anywhere on this site as products. ## The price, which is the finding **There isn't one.** Every one of the six programs returns a zero price with "show total price only" set; the per-drug endpoint returns nothing for every product id; the checkout is authenticated. So **NAD+, glutathione, MIC+B12, metformin, sermorelin, tesamorelin, phentermine, the ED line and the skincare line have no published price at all.** You find out what your program costs after completing the intake and being approved. This review does not estimate. There is no honest way to back-solve a sermorelin price from a semaglutide headline, and doing it would put a number on this page that Oak has never quoted for a product it has never priced. **What Oak does publish is the GLP-1 line, five times, differently:** That is one site telling a shopper five things. The hero and the FAQ agree at $119; the metadata that populates a Google result or a shared link says $133; the comparison table on the homepage says $167; the same comparison table on /weight-loss says $190. Anchor on the hero — **$119 semaglutide, $185 tirzepatide, "One price · All dosages · No subscriptions"** — and know that the spread exists. Running over the top of all of it: an unpriced *"$200 off — new patient offer"* and a *"Save up to 60% vs. retail pricing"* banner, neither with published mechanics. **Why this zeroes the price factor.** Our rubric asks for one all-in figure, visible before you commit, that a buyer with no commitment actually pays. For the line this site ranks, no figure exists at any point before commitment; for the line that is priced, five figures exist. This is not the familiar prepay trap — nothing here is a twelve-month rate wearing a monthly label. It is an absence, and [our published rubric](/how-we-grade-longevity-providers) scores an absence at zero. ## What Oak gets right, and it is not nothing **The consultation and the coaching are inside the price.** Oak's own comparison table prints **"Membership Fees: None"** against *"$50–$99/mo"* for other telehealth. Its FAQ says its programs come with *"no hidden membership fees, no surprise charges, and free shipping."* Approval is asynchronous — a written form, no video call required — so there is no visit to bill for. And support is stated as free and ongoing: **"Free Health Coaching"** runs site-wide, its three-step explainer says *"Support is always available for free,"* and its FAQ says **"Oak's Care Team is available throughout your treatment to answer questions, adjust your dose, and support your progress."** Those are the four points Oak earns beyond its longevity line, and they are earned on published statements rather than inference. **Oak holds no FDA warning letter.** A live search of FDA's warning-letter index for "oaklovesyou", "oak longevity", "Oak Longevity Holdings", "Beluga Health" and the checkout platform returned no company match, in a pass where a known-lettered company came back positive — so the clean result is real and not a broken query. ## The four contradictions **1. Four legal entities on one terms page — and two more in the footer.** Oak's /terms-of-use carries **Oak Longevity Holdings Corp**, **Oak Longevity Corp** and **Leaf Longevity Holdings Corp. DBA Oak Longevity**, and then a *second, separately dated Terms of Use* appended below the first naming **Oaklovesyou LLC**. The homepage footer adds **Flow Longevity Holdings Corp** and **Mito Health Holdings Corp** to the SMS consent, and the copyright line says Leaf Longevity Holdings Corp. Which entity you are contracting with is not a question a customer should have to research. **2. The state list is a circular reference to a page that does not exist.** One Terms document says Oak provides its services *"to 45 states of the U.S."* The second says eligibility depends on a *"States Where We Currently Operate"* list *"found in our FAQ."* **There is no FAQ page.** /faq, /faqs, /help, /frequently-asked-questions and /states all return 404, and the sitemap has no FAQ URL. So the authoritative state list points at nothing, and 45 is the only number a reader can act on. **3. The Women's Health tile is wired to the NAD+ intake.** The homepage ships a live *Women's Health* tile whose link opens the **Anti-Aging (NAD+/glutathione) questionnaire**. There is no women's-health questionnaire in the catalog at all — and /weight-loss and /start simultaneously label Men's and Women's Health **"Coming Soon."** A woman clicking a tile marked Women's Health lands in an NAD+ intake, on a site that elsewhere says the product has not launched. **4. "No subscriptions" versus the subscription.** The hero says *"No subscriptions."* The Terms describe a *"Subscription fee"* that *"may change from time to time"* and a subscription you can cancel. Both are current. **And two things a buyer should price in.** Refunds are a hard no once your prescription reaches the pharmacy — Oak's Terms say the order *"can no longer be canceled and is non-refundable… even if you attempt to stop, hold, reroute, return, or cancel the shipment directly with FedEx"* — with AAA binding arbitration and class actions waived. And Oak's own patient counts do not agree with each other: **"10,000+ Satisfied Patients"** and **"Trusted by 5,000+ members"** on the homepage, **"Trusted by 50,000+"** on /product. ## Who prescribes, and who fills it **Nobody is named.** Oak identifies no medical director, no prescribing clinician and no NPI numbers, and it names no dispensing pharmacy. What it does say, in its FAQ, is: *"At Oak, every prescription is reviewed by a board-certified provider and fulfilled through licensed U.S. compounding pharmacies that comply with state and federal pharmacy regulations."* That is a description of an unnamed set — the middle case in our pharmacy ladder's own wording — and it scores **zero**, the same as saying nothing, because it identifies neither a facility nor a compounding standard. **On the certification badge, be precise.** Oak's footer renders a LegitScript badge as a local image and links only the LegitScript *checker* tool. There is **no seal ID anywhere in the markup**, so there is nothing for a reader to look up and this review makes no claim in either direction about Oak's certification status. Where a provider publishes its seal ID, we print the identifier — [Care Bare Rx](/care-bare-rx-review) and [Breeze Meds](/breeze-meds-review) both do. A badge with no identifier behind it is a graphic. ## The evidence behind what it sells Oak's Anti-Aging program is four compounds with four different evidence stories, and it is worth separating them. **NAD+.** The 2026 PRISMA-guided systematic review screened 113 studies including 33 human intervention trials. Oral precursors reliably raise blood NAD+, but effects on functional, metabolic and vascular outcomes were *"heterogeneous and often null or endpoint-specific,"* and clinical effectiveness for anti-aging or wellness *"remains inconclusive"*. **No eligible outcomes trial has evaluated injected NAD+ for these indications at all**, which is the route Oak sells. A 2025 meta-analysis in adults averaging over 60 found no improvement in muscle index, grip strength, gait speed or chair-stand time. **Sermorelin and tesamorelin.** Both are growth-hormone-releasing analogs. Tesamorelin has real randomized evidence — in HIV-associated excess abdominal fat, where it is an approved indication — and that is a specific disease population, not healthy aging. For GH augmentation in healthy older adults the honest summary remains the 2007 Annals systematic review: small body-composition changes, no demonstrated functional benefit, more adverse events. **Metformin** is the one on the list with a genuine longevity literature behind it, and it is still not settled — the TAME trial has not read out, and the observational case rests on populations with diabetes. Read [what metformin's longevity evidence actually shows](/metformin-for-longevity) before treating its presence on a menu as a reason to buy. All of it is compounded and none of it is FDA-approved for anti-aging; FDA's own position is that compounded drugs are not FDA-approved and it does not verify their safety, effectiveness or quality before they are marketed. ## Where it's weak, and who should skip it Skip it if you need to know what something costs before you hand over a medical history, because for everything on the longevity line you cannot. Skip it if you need to confirm your own state, because the document that would tell you resolves to a 404. Skip it if you want to know who is prescribing or who is compounding, because Oak names neither. And skip it if a hard no-refund policy once the pharmacy has your prescription is a risk you will not take. Consider it if the breadth is what you want — NAD+, glutathione, MIC+B12 and metformin under one intake, with sermorelin and tesamorelin beside them, no membership fee, free coaching and an asynchronous approval — and you are prepared to treat the intake as a quotation request rather than a purchase. Get the program price, the dose and your state in writing before you agree to anything, and remember that the refund door closes the moment the pharmacy receives the order. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Oak takes **the full four for its longevity line** — an Anti-Aging program and a sermorelin/tesamorelin program are exactly what this site exists to rank, and correcting that record is why this row exists at all. It takes **two for clinical oversight**, because there is no membership and no consult fee anywhere in the published price structure, and **two for human support**, on free coaching and a care team published as available throughout treatment. It takes **zero for price transparency**, because nothing on the graded line is priced and the priced line has five prices, and **zero for pharmacy**, because an unnamed set of "licensed U.S. compounding pharmacies" identifies no facility and states no standard. **Eight out of fourteen: a B**, at the bottom of the band. Two changes would move it a long way: publish a price for the Anti-Aging and sermorelin programs, and put the state list on a page that exists. Neither touches the medicine. The full graded field is at [our provider rankings](/best-longevity-clinics), the scoring is set out in [how we grade](/how-we-grade-longevity-providers), and what this category costs generally is in [longevity clinic cost](/longevity-clinic-cost). Sources: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers, https://pubmed.ncbi.nlm.nih.gov/29599478/, https://pubmed.ncbi.nlm.nih.gov/41655607/, https://pubmed.ncbi.nlm.nih.gov/40275690/, https://pubmed.ncbi.nlm.nih.gov/20554713/, https://pubmed.ncbi.nlm.nih.gov/17227934/ --- ### Sesame Care Review: A $46 Doctor Visit, Not a Longevity Clinic Canonical: https://longevitygraded.com/sesame-care-review Updated: 2026-08-08 Sesame sells cash-pay clinician visits from about $46. No NAD+, no peptides, no longevity line — and its "anti-aging" tab is dermatology. August 2026. ## The one-sentence version Sesame is a **marketplace**, not a clinic: independent clinicians list their own cash prices and you book one. For that job it is genuinely good — **around $46 to $50 for a telehealth visit**, no membership, no subscription, and every clinician's credentials, specialty, rating and review count published beside the price. For the job this site exists to rank, it sells **nothing**: no NAD+, no sermorelin or other peptides, no glutathione, no B-12, no methylene blue, no hormone dispensing. It grades **C, 6 points out of 14** — and the reason is structural rather than a criticism of how it operates. It is a paid partner here, and the grade is computed from published terms alone and cannot see that. ## What it is, and what "Sesame's price" means Sesame, Inc. runs a two-sided marketplace. It does not employ the clinicians, does not set their fees and does not dispense anything. Each independent clinician publishes a cash price for an appointment; you pay that; any prescription written in the visit goes to a pharmacy **you** choose and is billed **there**. So there is no such thing as "Sesame's price" for a medication — there is a price for a conversation with a doctor. That distinction runs through everything below. It is also the model's genuine strength: the thing most telehealth brands wrap in a membership and a program fee, Sesame sells as a single line item, and it publishes who you are actually going to talk to. ## What it costs **About the "$37".** The affiliate lander for Sesame leads with a $37 headline. We swept ten states through Sesame's own listing inventory and **it did not reproduce in any of them**: California $49, Texas $46, New York $49, Florida $47, Illinois $47, Georgia $49, Arizona $46, Wyoming $50, Montana $47, Alaska $50. **The floor is $46.** Sesame does operate a paid membership tier whose member rate is not visible without an account, so $37 may well be a member price — but the lander does not say so, and a figure that only exists behind a paid tier should not be the number that brings you to the page. Budget **$46 to $50**. Two other things a buyer should know about what the price covers. **Medication is not in it** — a prescription goes to your own pharmacy and is billed at whatever that pharmacy charges. And prices are set per listing, so the figure you saw yesterday on one clinician's page is not the figure on another's today. ## Why this is graded as what it is, and not as longevity medicine We probed Sesame's own search — the typeahead that powers its site — for every term a reader of the providers here would use. The results are Sesame's, not ours: - **NAD+, sermorelin, peptide, glutathione, B-12, longevity, BPC-157** — **an empty result, every one** - **NAD** — only **nadolol**, a beta-blocker, and doctors surnamed "Nad…" - **methylene blue** — only a doctor named Samantha **Blue** - **IV therapy** — only "Couples **therapy**" and "Individual **therapy**" - **vitamin B12** — only a **Vitamin D** lab test **And the "anti-aging treatment" category is dermatology.** Sesame's own anti-aging page resolves to an *online skin consult* and an *in-person skin consult*, and its own header calls the subject anti-aging **skincare**. A reader who arrives looking for a longevity clinic and clicks the one word that matches lands on acne and eczema consults. That is not a trick — dermatology is a legitimate use of the word — but it is the single most likely way a reader of the providers here wastes a click. **Hormones are a visit and a lab, not a treatment line.** The "low testosterone" group resolves to a telehealth visit, an in-person visit and a testosterone lab test. Sesame's own 30-medication browse list contains no testosterone at all. **What it does have** is brand-name GLP-1: Wegovy in pen and pill form, Zepbound, Ozempic, Mounjaro, Rybelsus and Foundayo, prescribed by a listed clinician and filled at your pharmacy at your cost. Those are the drugs with real outcome evidence behind them — semaglutide and tirzepatide each have large randomized weight-loss trials, and the SELECT trial cut major adverse cardiovascular events in people with cardiovascular disease and obesity but not diabetes. That is a different evidentiary world from the compounded longevity line Sesame does not sell, where the 2026 systematic review of NAD+ for anti-aging concluded that clinical effectiveness *"remains inconclusive"*. So [GLP-1s are the one category on this site with hard outcome data](/glp1-for-longevity), and "no longevity line" is a statement about Sesame's catalog rather than a dismissal of what it can get you prescribed. ## Where it is genuinely better than the other providers here **It tells you who the clinician is.** MD, NP or PA-C, their specialty, their rating and their review count, on the listing, before you pay. Most rows here name nobody at all, or name a medical advisor who does not see patients. On the one axis of "who is actually treating me", a marketplace beats almost every clinic we grade. **There is nothing recurring to cancel.** You buy a visit. There is no subscription, no membership required for the base rate, no minimum term and no refund policy to litigate, because there is no ongoing charge. **The consult is the product**, so our clinical-oversight factor is satisfied trivially and honestly: nothing is billed on top of the appointment you booked. ## What the rubric does with that Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Sesame takes **four for price transparency** — the exact cash price of the specific appointment is on the listing, before you commit, with no membership wrapped around it — and **two for clinical oversight**, because the visit is the product. It takes **zero for its longevity line**, because it sells none; **zero for pharmacy**, because it dispenses nothing and identifies no pharmacy (which is a property of the model, not a failure of disclosure); and **zero for human support**, because each appointment stands alone and nothing ongoing is included. **Six out of fourteen: a C.** The important part is the shape of that, not the letter. A provider with no longevity line **cannot reach our top band no matter how well it behaves** — the maximum available to it is ten, and the A floor is eleven. [That cap is deliberate](/how-we-grade-longevity-providers): on a longevity ranking, a clean, honest, well-priced business that sells no longevity medicine should not be able to out-grade a clinic that does. Sesame is the clearest illustration of the rule working, because almost nothing about it is bad — it is simply answering a different question. ## Who should use it, and who should not **Use it** if what you actually need is a licensed clinician quickly and cheaply, on cash, without a membership: a prescription refill, a second opinion, a referral, a lab order, or a conversation about whether a GLP-1 is appropriate for you. At $46 to $50 it is the cheapest published route to a clinician anywhere here, and you get to see who they are first. **Skip it** if you came here for NAD+, peptides, glutathione, B-12 or a hormone-optimization program, because Sesame does not sell any of them and its own search will tell you so. Skip it if you want the medication cost bundled into one figure, because it never is. And skip the "anti-aging" tab entirely — it is skincare, and it is not what brought you to a page like this. If a compounded longevity line is what you are shopping for, [our provider rankings](/best-longevity-clinics) grade the providers that actually sell one, and [our comparison of clinics against lab memberships](/longevity-clinics-vs-lab-memberships) is the better starting point for deciding what you want from the appointment in the first place. Sources: https://doi.org/10.1056/NEJMoa2032183, https://doi.org/10.1056/NEJMoa2206038, https://doi.org/10.1056/NEJMoa2307563, https://pubmed.ncbi.nlm.nih.gov/41655607/ --- ### Found Health Review: The $49 Plan Needs 12 Months and Insurance Canonical: https://longevitygraded.com/found-review Updated: 2026-08-08 Found's advertised $49/mo needs a 12-month commitment and commercial insurance. The standing rate is $89 insured, $149 cash, billed every 4 weeks. August 2026. ## The one-sentence version Found Health has the **strongest named clinical bench** of anything we grade — a former medical director of the American Board of Obesity Medicine, a Columbia endocrinologist, a Stanford psychiatrist-obesity physician — and it states its compounding standard in its own words on its own product pages, which most providers here will not do. It is also, entirely and only, a **weight-loss membership**: fourteen medications, every one of them for weight loss, and nothing for cognition, energy, longevity or the microbiome. Its advertised **"$49/mo"** needs *both* a twelve-month commitment *and* commercial insurance, and its **binding Offer Terms disagree with its own pricing page on three of four cells**. It grades **C, 6 points out of 14**, computed from published terms alone and blind to who pays us. Found is a paid partner here. ## What it is, and what it is not Found Health, Inc. sells a membership: a licensed clinician reviews an online health assessment, prescribes if appropriate, and your plan covers the care around that. Fourteen medications sit behind it: - **Injectable GLP-1:** compounded semaglutide, compounded tirzepatide, compounded liraglutide, plus brand Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Victoza and Trulicity - **Oral GLP-1:** Foundayo™ (orforglipron) and Rybelsus - **Oral non-GLP-1:** Contrave®, metformin, topiramate and zonisamide **That is the entire list.** No NAD+. No sermorelin or any other peptide. No glutathione, no B-12 injection, no methylene blue, no testosterone or hormone replacement, no BPC-157 or TB-500, no supplements, no diagnostics. The only adjacent assets are free calculators and blog posts. We are saying that plainly because Found is often filed as a longevity-adjacent operator on the strength of metformin appearing on its list. Metformin is on the list — as a weight-loss generic, in a plan Found calls its Generics plan, not as a geroprotector. If metformin is what you are after, [what its longevity evidence actually shows](/metformin-for-longevity) is a more useful place to start than a menu. ## What it really costs **The $49 is a corner cell.** Found's public pricing page never mentions $49. The real table lives inside the binding **Offer Terms**, published as an **image** rather than as text, and $49 is the bottom-right of it: **twelve months** of commitment *and* **commercial insurance**. Without insurance the twelve-month rate is $99. Without the commitment, insured, it is **$89**. The standing month-to-month cash rate is **$149**. **Two traps live in that same table.** Billing is **every 4 weeks**, which is **13 cycles a year, not 12** — so a "$89/mo" plan bills $1,157 a year, not $1,068. And Found defines its **"12 month" term as 48 weeks**, which is about eleven calendar months of coverage for a twelve-month commitment. **And the binding document does not agree with the marketing page.** On the compounded GLP-1 plan, /plans-and-pricing advertises **$99/$169** on twelve months and **$199/$289** monthly, while the Offer Terms — the document you are actually agreeing to — say **$149/$199** and **$199/$299**. Three of those four cells disagree. Only one of the two documents is the contract. **Why that zeroes the price factor.** Our rubric asks for one all-in figure, visible before you commit, that a buyer with no commitment actually pays. The failure here is not the $49 headline; plenty of rows survive a headline that turns out to be a prepay, and Found's own $89 and $149 are perfectly clear once you find the table. The failure is that **two documents published by the same company on the same day quote different prices for the same plan**, and the one a shopper reads is not the one that binds. Compare [Gala Health](/gala-health-review), which loses the same four points for advertising a yearly rate as a monthly one — Found's version is subtler and, if anything, harder for a reader to detect. **Brand-name prices, for scale:** Ozempic about $1,100 a month, Mounjaro about $1,100, Wegovy from $650, Zepbound from $650, Foundayo about $149. ## What Found does better than almost anything here **The clinical bench.** Found names, with credentials: **Dr. Rekha Kumar, MD MS** (Senior Medical Advisor, former medical director of the American Board of Obesity Medicine), **Dr. Jonathan Larson, MD MBA** (Medical Director), **Dr. Judith Korner, MD PhD** (Columbia), **Dr. Shebani Sethi, MD** (Stanford) and **Dr. Kyu Rhee, MD MPP**. It also discloses, in its own words, that **Dr. Kumar does not interact directly with Found patients** — a caveat most companies would leave you to discover. Naming a bench like that and then volunteering its limit is the kind of disclosure this site exists to reward. **The compounding standard, stated properly.** On its compounded-medication product pages Found writes: *"Found partners exclusively with 503A-licensed pharmacies — meaning every medication dispensed through Found is compounded by a licensed pharmacist pursuant to your specific prescription, in a facility that must comply with USP standards for sterile preparation."* That is a claim about **who fills your prescription**, not a general explanation of the statute, which is the distinction [our methodology](/how-we-grade-longevity-providers) turns on — so Found takes the full two pharmacy points. What it does **not** do is name the facility. **Care is inside the plan price.** *"Every plan includes full access to our licensed medical team, personalized care plans,"* covering *"medical, lifestyle, and behavioral guidance from licensed clinicians"* plus a member community. That is a statement about what the money buys, and it earns both the oversight and the support points. **Insurance is real.** Found accepts insurance across **41 states**, which almost nothing else here does — and for a category that is overwhelmingly cash-pay, that is a material difference to what people actually pay. ## The state list, and the two places it argues with itself Found publishes a 41-state selector for the insurance plans it accepts. On that same page, two contradictions: - **New Mexico** renders an "available plans" panel while being **absent from the 41-state selector**. - **California** is in the accepted list, yet its own panel reads **"No plans available for this state."** Neither is fatal. Both mean the answer you get depends on which control you touched, so confirm your own state before assuming coverage. **Cancellation** is the other thing to price in: the membership is refundable only within **three days** or before your first consult; medications and lab kits are **non-refundable once shipped**; renewals are non-refundable; and canceling needs **48 hours' notice** before the next renewal — which, on a four-week cycle, comes round thirteen times a year. ## The evidence, and why it matters that this is GLP-1 and nothing else Here is the part that cuts in Found's favor, and it is worth stating as clearly as the criticism. **GLP-1 receptor agonists are the only category this site covers with hard outcome data.** Semaglutide produced about 15% mean weight loss in the STEP 1 trial and tirzepatide up to about 21% in SURMOUNT-1; the SELECT trial then showed a **20% reduction in major adverse cardiovascular events** in people with cardiovascular disease and overweight or obesity but without diabetes. Nothing on the compounded longevity shelf — NAD+, sermorelin, glutathione — has anything of that quality behind it; the 2026 systematic review of NAD+ for anti-aging concluded clinical effectiveness *"remains inconclusive"*. So a reader deciding between Found and a compounded NAD+ program is not choosing between longevity and not-longevity. They are choosing between a drug class with cardiovascular-outcome trials and a category without them. What Found cannot do is answer the questihere is usually asked, because it sells nothing else. Two caveats belong beside that. Found's compounded semaglutide, tirzepatide and liraglutide are **not FDA-approved** — FDA's position is that compounded drugs are not FDA-approved and it does not verify their safety, effectiveness or quality before marketing — and lean-mass loss on GLP-1 therapy is a real clinical concern that the guidance is still catching up with. [Our GLP-1 explainer](/glp1-for-longevity) goes through both. ## Who should use it, and who should not **Use it** if weight loss is the goal, insurance is a factor, and you want a named clinical bench and a stated compounding standard behind the prescription. On those terms Found is one of the better-run operators in the category, and the 41-state insurance path is genuinely differentiated. **Skip it** if you came here for NAD+, peptides or hormones — it sells none of them and will not start. Skip the $49 arithmetic unless you have commercial insurance *and* are prepared to commit for a year that is really 48 weeks. And before you sign anything, **read the Offer Terms rather than the pricing page**, because they are the document that binds and they say different numbers. ## The verdict, against the rubric Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Found takes **two for clinical oversight**, because clinician access is stated as inside the plan; **two for pharmacy**, because it publishes a 503A claim about who fills your prescription on a surface it controls; and **two for human support**, on published ongoing guidance from licensed clinicians. It takes **zero for price transparency**, because its binding terms and its pricing page quote different figures for the same plan, and **zero for its longevity line**, because it has none. **Six out of fourteen: a C.** Notice what that is, and what it is not. Found is clean on three of five axes and drops the other two for different reasons — one fixable in an afternoon by reconciling two documents, one structural and permanent unless the company changes what it sells. **A provider with no longevity line cannot reach our A band whatever else it does**, because the most it can score is ten and the A floor is eleven. That cap is the whole point of the factor: a well-run weight-loss membership should not be able to out-grade a longevity clinic on a page a reader opened to find longevity clinics. If the membership question itself is what you are weighing, [concierge versus membership pricing](/concierge-vs-membership-longevity) is the better read. The full graded field is at [our provider rankings](/best-longevity-clinics). Sources: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers, https://doi.org/10.1056/NEJMoa2032183, https://doi.org/10.1056/NEJMoa2206038, https://doi.org/10.1056/NEJMoa2307563, https://pubmed.ncbi.nlm.nih.gov/41655607/, https://doi.org/10.1097/CRD.0000000000000942 ---